PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Laser-controlled cells	SCIENCE			English	Article																		Halfon MS, 1997, P NATL ACAD SCI USA, V94, P6255, DOI 10.1073/pnas.94.12.6255; Harris J, 1996, DEVELOPMENT, V122, P3117; STRINGHAM EG, 1993, J EXP ZOOL, V266, P227, DOI 10.1002/jez.1402660309	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					975	975						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281076				2022-12-28	WOS:A1997XQ98500047
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Selecting the needle	SCIENCE			English	Article																		KETNER G, 1994, P NATL ACAD SCI USA, V91, P6186, DOI 10.1073/pnas.91.13.6186; LARIONOV V, 1997, P NATL ACAD SCI USA, V97, P7384	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					975	975						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281076				2022-12-28	WOS:A1997XQ98500048
J	Yew, PR; Kirschner, MW				Yew, PR; Kirschner, MW			Proteolysis and DNA replication: The CDC34 requirement in the Xenopus egg cell cycle	SCIENCE			English	Article							UBIQUITIN-CONJUGATING ENZYME; LICENSING FACTOR; YEAST; TRANSITION; INITIATION; EXTRACTS; PROTEIN; COMPONENT; CLONING; EMBRYOS	The cell division cycle gene, CDC34, is required for ubiquitin-mediated degradation of G(1) regulators and cell cycle progression through the transition from G(1) to S phase in budding yeast. A CDC34 requirement for S phase onset in higher eukaryotes has not been established, Studies of the simple embryonic cell cycle of Xenopus laevis eggs demonstrated that Cdc34p in a large molecular size complex was required in the initiation of DNA replication, Cdc34p appears to regulate the initiation function of Cdk2-cyclin E, perhaps through the degradation of the Xenopus cdk inhibitor, Xic1.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Harlow E., 1988, ANTIBODIES LAB MANUA; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; SATOH N, 1977, DEV GROWTH DIFFER, V19, P111; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; YEW PR, UNPUB	29	61	63	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1672	1676		10.1126/science.277.5332.1672	http://dx.doi.org/10.1126/science.277.5332.1672			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287222				2022-12-28	WOS:A1997XV68400053
J	Resnick, MD; Bearman, PS; Blum, RW; Bauman, KE; Harris, KM; Jones, J; Tabor, J; Beuhring, T; Sieving, RE; Shew, M; Ireland, M; Bearinger, LH; Udry, JR				Resnick, MD; Bearman, PS; Blum, RW; Bauman, KE; Harris, KM; Jones, J; Tabor, J; Beuhring, T; Sieving, RE; Shew, M; Ireland, M; Bearinger, LH; Udry, JR			Protecting adolescents from harm - Findings from the National Longitudinal Study on Adolescent Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-USE; RISK; RESILIENCE; COMPETENCE; CHILDREN; VULNERABILITY; CHILDHOOD; BEHAVIORS; ADULTHOOD; AMERICA	Context.-The main threats to adolescents' health are the risk behaviors they choose, How their social context shapes their behaviors is poorly understood. Objective.-To identify risk and protective factors at the family, school, and individual levels as they relate to 4 domains of adolescent health and morbidity: emotional health, violence, substance use, and sexuality. Design.-Cross-sectional analysis of interview data from the National Longitudinal Study of Adolescent Health. Participants.-A total of 12 118 adolescents in grades 7 through 12 drawn from an initial national school survey of 90 118 adolescents from 80 high schools plus their feeder middle schools. Setting.-The interview was completed in the subject's home. Main Outcome Measures.-Eight areas were assessed: emotional distress; suicidal thoughts and behaviors; violence; use of 3 substances (cigarettes, alcohol, marijuana); and 2 types of sexual behaviors (age of sexual debut and pregnancy history), Independent variables included measures of family context, school context, and individual characteristics. Results.-Parent-family connectedness and perceived school connectedness were protective against every health risk behavior measure except history of pregnancy, Conversely, ease of access to guns at home was associated with suicidality (grades 9-12: P<.001) and violence (grades 7-8: P<.001; grades 9-12: P<.001). Access to substances in the home was associated with use of cigarettes (P<.001), alcohol (P<.001), and marijuana (P<.001) among all students. Working 20 or more hours a week was associated with emotional distress of high school students (P<.01), cigarette use (P<.001), alcohol use (P<.001), and marijuana use (P<.001). Appearing ''older than most'' in class was associated with emotional distress and suicidal thoughts and behaviors among high school students (P<.001); it was also associated with substance use and an earlier age of sexual debut among both junior and senior high students, Repeating a grade in school was associated with emotional distress among students in junior high (P<.001) and high school (P<.01) and with tobacco use among junior high students (P<.001). On the other hand, parental expectations regarding school achievement were associated with lower levels of health risk behaviors; parental disapproval of early sexual debut was associated with a later age of onset of intercourse (P<.001). Conclusions.-Family and school contexts as well as individual characteristics are associated with health and risky behaviors in adolescents. The results should assist health and social service providers, educators, and others in taking the first steps to diminish risk factors and enhance protective factors for our young people.	UNIV N CAROLINA, CAROLINA POPULAT CTR, CHAPEL HILL, NC USA	University of North Carolina; University of North Carolina Chapel Hill	Resnick, MD (corresponding author), UNIV MINNESOTA, ADOLESCENT HLTH PROGRAM, BOX 721, 420 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.		Fahimifar, Sepideh/M-5303-2019	bearman, peter/0000-0002-3745-3164	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD031921] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD31921] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*A GUTTM I, 1994, SEX AM TEEN; *AE CAS FDN, 1997, KIDS COUNT DAT BOOK; ALLEN JP, 1990, PSYCHIAT CLIN N AM, V13, P455; American Medical Association, 1994, GUID AD PREV SERV; BACHMAN JG, 1993, DEV PSYCHOL, V29, P220, DOI 10.1037/0012-1649.29.2.220; Bearman P.S, 1997, NATL LONGITUDINAL ST; Blum RW, 1996, AM J PUBLIC HEALTH, V86, P1767, DOI 10.2105/AJPH.86.12.1767; BROOKSGUNN J, 1983, GIRLS PUBERTY BIOL P; Byrd RS, 1996, ARCH PEDIAT ADOL MED, V150, P470, DOI 10.1001/archpedi.1996.02170300024006; *CDCP, 1992, MMWR-MORBID MORTAL W, V40, P885; *CDCP, 1992, MMWR-MORBID MORTAL W, V43, P213; *CDCP, 1993, PUBLIC HLTH REP, V108, P1; *CDCP, 1993, MORT TRENDS CAUS DEA; *CDCP, 1991, MMWR-MORBID MORTAL W, V39, P929; *CDCP, 1995, MON SER, V1; *CHILDR DEF FUND, 1997, STAT AM CHILDR YB 19; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DRYFOOS JG, 1994, FULL SERVICE SCH REV, P1; FUCHS VR, 1992, SCIENCE, V255, P41, DOI 10.1126/science.1553531; GARMEZY N, 1984, CHILD DEV, V55, P97, DOI 10.1111/j.1467-8624.1984.tb00276.x; GARMEZY N, 1991, AM BEHAV SCI, V34, P416, DOI 10.1177/0002764291034004003; Greenberger Ellen., 1986, TEENAGERS WORK PSYCH; HAUSER ST, 1985, FAM RELAT, V34, P99, DOI 10.2307/583762; HAWKINS J, 1992, COMMUNITIES CARE ACT, P8; HAWKINS JD, 1992, PSYCHOL BULL, V112, P64, DOI 10.1037/0033-2909.112.1.64; Hechinger F M, 1992, FATEFUL CHOICES HLTH; HEWLETT S, 1991, BOUGH BREAKS COST NE, P90; IRWIN C, 1996, HLTH CARE REFORM OPP, V86, P513; JESSOR R, 1977, PROBLEM BEHAVIOR PSY; Johnston LD, 1996, NATL SURVEY RESULTS, P1; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; KAYSER B, 1973, SOCIOL METHOD RES, V1, P298; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; KOOP CE, 1994, JAMA-J AM MED ASSOC, V271, P1404; KOOP CE, 1994, JAMA-J AM MED ASSOC, V268, P3074; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; LOOKER ED, 1989, SOCIOL EDUC, V62, P257, DOI 10.2307/2112830; LUTHAR SS, 1991, AM J ORTHOPSYCHIAT, V61, P6, DOI 10.1037/h0079218; MCANARNEY E, 1994, BRIGHT FUTURES GUIDE, P196; MCBRIDE CM, 1995, J SCHOOL HEALTH, V65, P63, DOI 10.1111/j.1746-1561.1995.tb03347.x; MCLOYD VC, 1990, CHILD DEV, V61, P311, DOI 10.1111/j.1467-8624.1990.tb02781.x; Millstein S. G., 1993, PROMOTING HLTH ADOLE; *NAT RES COUNC COM, 1993, LOS GEN AD HIGH RISK, P64; PERRY C, 1994, PREVENTING TOBACCO U, P5; Perry CL., 1993, PROMOTING HLTH ADOLE, P73; PETERSON AC, 1985, J YOUTH ADOLESCENCE, V3, P47; QUINTON D, 1988, PARENTAL BREAKDOWN M; Radke-Yarrow M, 1990, DEV PSYCHOPATHOL, V2, P349, DOI 10.1017/S0954579400005770; RESNICK MD, 1993, J PAEDIATR CHILD H, V29, pS3, DOI 10.1111/j.1440-1754.1993.tb02257.x; RESNICK MD, 1994, PEDIATRICS, V94, P907; RICHALET JP, 1988, INT J SPORTS MED, V9, P157, DOI 10.1055/s-2007-1024997; RUTTER M, 1987, AM J ORTHOPSYCHIAT, V57, P316, DOI 10.1111/j.1939-0025.1987.tb03541.x; RUTTER M, 1993, J ADOLESCENT HEALTH, V14, P626, DOI 10.1016/1054-139X(93)90196-V; SAMEROFF JA, 1985, RISK PROTECTIVE FACT, P52; Sells CW, 1996, AM J PUBLIC HEALTH, V86, P513, DOI 10.2105/AJPH.86.4.513; STEINBERG L, 1996, CLASSROOM WHY SCH RE, P62; WERNER EE, 1989, SCI AM, V260, P106, DOI 10.1038/scientificamerican0489-106; WERNER EE, 1989, AM J ORTHOPSYCHIAT, V59, P72, DOI 10.1111/j.1939-0025.1989.tb01636.x	58	2880	2904	20	539	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					823	832		10.1001/jama.278.10.823	http://dx.doi.org/10.1001/jama.278.10.823			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU552	9293990	Green Submitted			2022-12-28	WOS:A1997XU55200037
J	Adams, MA; Dolan, P				Adams, MA; Dolan, P			Could sudden increases in physical activity cause degeneration of intervertebral discs?	LANCET			English	Article							LUMBAR SPINE; EXERCISE; STRENGTH; PAIN	Epidemiological studies link high repetitive loading of the lower back with degeneration of intervertebral discs, and experiments on cadaver spines confirm that repetitive mechanical loading can disrupt the lumbar discs in a manner characteristic of ''degeneration''. But why do living discs not just strengthen in response to this stimulus, as other musculo-skeletal tissues do? Our hypothesis proposes that the low metabolic rate of lumbar discs (the largest avascular structures in the body) prevents them from keeping pace with adaptive remodelling changes in adjacent tissues, so that large and abrupt increases in a person's level of physical activity may leave the lumbar discs the weak link in a strengthening and heavily loaded spine. Recent laboratory investigations support the hypothesis, but clinical evidence Is required to relate recent disc degeneration with recent increases in physical activity, and so test the hypothesis.			Adams, MA (corresponding author), UNIV BRISTOL, DEPT ANAT, SOUTHWELL ST, BRISTOL BS2 8EJ, AVON, ENGLAND.		Adams, Michael A/C-9875-2009	Adams, Michael A/0000-0003-0435-8651; Dolan, Patricia/0000-0001-8561-675X				ADAMS MA, 1982, SPINE, V7, P184, DOI 10.1097/00007632-198205000-00002; ADAMS MA, 1985, SPINE, V10, P524, DOI 10.1097/00007632-198507000-00006; ADAMS MA, 1994, CLIN BIOMECH, V9, P5, DOI 10.1016/0268-0033(94)90052-3; ADAMS MA, 1995, INT SOC STUD LUMB SP; Battie MC, 1995, SPINE, V20, P2601, DOI 10.1097/00007632-199512150-00001; BAYLISS MT, 1988, SPINE, V13, P972, DOI 10.1097/00007632-198809000-00003; Boos N, 1995, SPINE, V20, P2613, DOI 10.1097/00007632-199512150-00002; DOLAN P, 1994, J BIOMECH, V27, P1237, DOI 10.1016/0021-9290(94)90277-1; GRANHED H, 1987, SPINE, V12, P146, DOI 10.1097/00007632-198703000-00010; Green T P, 1993, Eur Spine J, V2, P209, DOI 10.1007/BF00299448; Ishihara H, 1996, J APPL PHYSIOL, V80, P839, DOI 10.1152/jappl.1996.80.3.839; JONES HH, 1977, J BONE JOINT SURG AM, V59, P204, DOI 10.2106/00004623-197759020-00012; KELSEY J L, 1984, Journal of Orthopaedic Research, V2, P61, DOI 10.1002/jor.1100020110; LANYON LE, 1982, J BIOMECH, V15, P141, DOI 10.1016/0021-9290(82)90246-9; MAROUDAS A, 1975, J ANAT, V120, P113; McNally D.S., 1996, BONE JOINT SURG BR, V78, P965, DOI [10.1302/0301-620X.78B6.0780965, DOI 10.1302/0301-620X.78B6.0780965]; MOFFETT JAK, 1993, INT J NURS STUD, V30, P197, DOI 10.1016/0020-7489(93)90031-O; MONETA GB, 1994, SPINE, V19, P1968, DOI 10.1097/00007632-199409000-00018; NEUMANN P, 1993, SPINE, V18, P637, DOI 10.1097/00007632-199304000-00017; OSTI OL, 1990, SPINE, V15, P762, DOI 10.1097/00007632-199008010-00005; PORTER RW, 1989, SPINE, V14, P201, DOI 10.1097/00007632-198902000-00009; VASCONCELOS D, 1973, EPILEPSIA, V14, P323, DOI 10.1111/j.1528-1157.1973.tb03967.x; VIDEMAN T, 1995, SPINE, V20, P699, DOI 10.1097/00007632-199503150-00011	23	35	37	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	1997	350	9079					734	735		10.1016/S0140-6736(97)03021-3	http://dx.doi.org/10.1016/S0140-6736(97)03021-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291918				2022-12-28	WOS:A1997XU97700045
J	Levi, F; Zidani, R; Misset, JL				Levi, F; Zidani, R; Misset, JL			Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer	LANCET			English	Article							QUALITY-OF-LIFE; LIVER METASTASES; PHASE-II; INFUSION FLUOROURACIL; CIRCADIAN-RHYTHM; VENOUS INFUSION; BONE-MARROW; CHEMOTHERAPY; 5-FLUOROURACIL; MODULATION	Background The efficacy of chemotherapy may be affected by circadian rhythms. Therefore, we tested chronomodulated infusion (administered to coincide with relevant circadian rhythms) of oxaliplatin, fluorouracil, and folinic acid compared with a constant-rate infusion method. The combination of three drugs was delivered for 5-day courses with 16-day intervals. Methods We expected chronotherapy to increase objective response rate by 20% compared with constant-rate infusion. We tested this effect in a randomised multicentre trial involving patients with previously untreated metastases from colorectal cancer who were enrolled at nine institutions in three countries. 93 patients were asssigned chronotherapy and 93 were assigned constant-rate infusion via multichannel programmable ambulatory pumps. The trial was interrupted when a significant difference in main outcome was reached. All data were analysed by intention to treat. Findings On enrolment, we found significant imbalances in two characteristics-abdominal gland or bone metastases (constant-rate infusion two patients, chronotherapy ten patients) and relapse from surgically treated metastases (constant-rate infusion seven patients, chronotherapy 22 patients). An objective response was obtained in 47 (51%) of the chronotherapy group, and in 27 (29%) of the constant-rate group (difference 21.5% [95% CI 13.7-31.2], p=0003). Chronotherapy reduced five-fold the rate of severe mucosal toxicity (14% vs 76%, p<0.0001) and halved that of functional impairment from peripheral sensitive neuropathy (16% vs 31%, difference 15.0% [9.5-25.7], p<0.01). Median time to treatment failure was 6.4 months on chronotherapy and 4.9 months on constant-rate infusion (p=0.006), and 24% of the patients from the constant-rate infusion group received chronotherapy after failure. With a minimum follow-up of 3 years, median survival times and 3-year survival were similar in both groups (15.9 vs 16.9 months and 22% vs 21%, respectively). Interpretation Chronotherapy was significantly less toxic and more effective than constant-rate infusion. The results support the concept of temporal selectivity of cancer chemotherapy.			Levi, F (corresponding author), HOP PAUL BROUSSE,14 AVE PAUL VAILLANT COUTURIER,F-94807 VILLEJUIF,FRANCE.							ALLENMERSH TG, 1994, LANCET, V344, P1255, DOI 10.1016/S0140-6736(94)90750-1; BertheaultCvitkovic F, 1996, J CLIN ONCOL, V14, P2950, DOI 10.1200/JCO.1996.14.11.2950; Bismuth H, 1996, ANN SURG, V224, P509, DOI 10.1097/00000658-199610000-00009; BOUGHATTAS NA, 1989, CANCER RES, V49, P3362; BUYSE M, IN PRESS BIOMETRICS; CAUSSANEL JP, 1990, J NATL CANCER I, V82, P1046, DOI 10.1093/jnci/82.12.1046; Cohen AM, 1993, CANC PRINCIPLES PRAC, P929; GLIMELIUS B, 1994, CANCER, V73, P556, DOI 10.1002/1097-0142(19940201)73:3<556::AID-CNCR2820730310>3.0.CO;2-8; Hansen RM, 1996, J NATL CANCER I, V88, P668, DOI 10.1093/jnci/88.10.668; HARRIS BE, 1990, CANCER RES, V50, P197; HILL M, 1995, J CLIN ONCOL, V13, P2317, DOI 10.1200/JCO.1995.13.9.2317; HRYNIUK WM, 1987, SEMIN ONCOL, V14, P3; LEICHMAN CG, 1995, J CLIN ONCOL, V13, P1303, DOI 10.1200/JCO.1995.13.6.1303; LEVI F, 1992, CANCER, V69, P893, DOI 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X; LEVI F, 1993, EUR J CANCER, V29A, P1280, DOI 10.1016/0959-8049(93)90073-O; Levi F, 1997, HDB EXPT PHARM PHYSL, P299; LEVI F, 1997, P 33 ANN M AM SOC CL; LEVI FA, 1994, JNCI-J NATL CANCER I, V86, P1608, DOI 10.1093/jnci/86.21.1608; Levi Francis, 1996, Current Opinion in Oncology, V8, P334; Machover D, 1996, ANN ONCOL, V7, P95; METZGER G, 1994, CLIN PHARMACOL THER, V56, P190, DOI 10.1038/clpt.1994.123; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; SMAALAND R, 1991, BLOOD, V77, P2603; SMAALAND R, 1992, BRIT J CANCER, V66, P39, DOI 10.1038/bjc.1992.213; STANGL R, 1994, LANCET, V343, P1405, DOI 10.1016/S0140-6736(94)92529-1	28	516	545	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					681	686		10.1016/S0140-6736(97)03358-8	http://dx.doi.org/10.1016/S0140-6736(97)03358-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291901				2022-12-28	WOS:A1997XU97700007
J	Sundberg, K; Bang, J; SmidtJensen, S; Brocks, V; Lundsteen, C; Parner, J; Keiding, N; Philip, J				Sundberg, K; Bang, J; SmidtJensen, S; Brocks, V; Lundsteen, C; Parner, J; Keiding, N; Philip, J			Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling	LANCET			English	Article							FOLLOW-UP; GESTATION; TRIMESTER; TRIAL	Background Several cohort studies have shown the feasibility of early amniocentesis (between 11 and 13 weeks of gestation) as an alternative to chorionic villus sampling (CVS) for karyotyping, but the only completed randomised study of fetal safety showed a significant fetal-loss risk related to first-trimester amniocentesis. We assessed fetal safety in early amniocentesis and CVS. Methods We assessed early amniocentesis at 11-13 weeks' gestational age compared with the fetal risk associated with CVS at 10-12 weeks. 1160 pregnant women were randomly assigned one procedure (581 early amniocentesis, 579 CVS) after a baseline ultrasound examination at 10 weeks' gestation and were followed up until birth. Total fetal loss and neonatal morbidity were the primary outcome measures. Sampling success and pregnancy complications were secondary outcomes. We used a filter to increase the cell yield in the early amniotic-fluid samples. CVS was transabdominal. Findings We found a significantly increased occurrence of talipes equinovarus in the early amniocentesis group (p<0.01), the risk of which was associated with sampling at the earliest gestational ages and with temporary leakage of amniotic fluid after sampling. Therefore, the trial was stopped early, which reduced the power of the safety study, 48% (27) of fetuses in the CVS group and 5.4% (30) in the early amniocentesis group were lost after randomisation (p=0.66). More detailed survival analysis did not show any significant differences in fetal loss rates. Leakage of amniotic fluid after sampling occurred significantly more frequently after early amniocentesis than after CVS (p<0.001), but we found no other major differences in pregnancy complications. Significantly more CVS than early amniocentesis procedures were repeated or railed to produce a karyotype (p<0.01). Interpretation Even though the numbers were small, we found an association between early amniocentesis and talipes equinovarus. We believe this association to be true, since it supports a trend in a similar randomised study. Our results show that early amniocentesis, when done with the filter technique, is associated with an abortion risk similar to CVS, although the limited size of our study population reduced the strength of this conclusion.	NATL UNIV HOSP, JULIANE MARIE CTR, DEPT CLIN GENET, COPENHAGEN, DENMARK; NATL UNIV HOSP, JULIANE MARIE CTR, ULTRASOUND CLIN, COPENHAGEN, DENMARK; UNIV COPENHAGEN, DEPT BIOSTAT, DK-1168 COPENHAGEN, DENMARK	University of Copenhagen								BRYNDORF T, 1994, LANCET, V343, P802, DOI 10.1016/S0140-6736(94)91885-6; BRYNE DL, 1994, FETAL MAT MED REV, V6, P203; Cox DR., 1989, ANAL BINARY DATA; CRANDALL BF, 1994, PRENATAL DIAG, V14, P913, DOI 10.1002/pd.1970141004; ELEJALDE BR, 1990, AM J MED GENET, V35, P188, DOI 10.1002/ajmg.1320350210; FEDRICK J, 1978, BRIT J OBSTET GYNAEC, V85, P1, DOI 10.1111/j.1471-0528.1978.tb15816.x; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FRYDMAN H, 1994, J ROY STAT SOC B MET, V56, P71; GIORLANDINO C, 1994, PRENATAL DIAG, V14, P803, DOI 10.1002/pd.1970140907; HANSON FW, 1992, AM J OBSTET GYNECOL, V166, P1707, DOI 10.1016/0002-9378(92)91560-W; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; HENRY GP, 1992, J REPROD MED, V37, P396; HOSMER DW, 1989, APPL LOGISTIC REGRES; JACKSON LG, 1992, NEW ENGL J MED, V327, P594, DOI 10.1056/NEJM199208273270903; Johnson JAM, 1996, FETAL DIAGN THER, V11, P85, DOI 10.1159/000264285; JORGENSEN FS, 1995, PRENATAL DIAG, V15, P621; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEDBETTER DH, 1992, PRENATAL DIAG, V12, P317, DOI 10.1002/pd.1970120503; NICOLAIDES K, 1994, LANCET, V344, P435, DOI 10.1016/S0140-6736(94)91769-8; PENSO CA, 1990, OBSTET GYNECOL, V76, P1032; SMIDTJENSEN S, 1992, LANCET, V340, P1237, DOI 10.1016/0140-6736(92)92946-D; Snijders RJ, 1996, ULTRASOUND MARKERS F; Sundberg K, 1996, PRENATAL DIAG, V16, P1121, DOI 10.1002/(SICI)1097-0223(199612)16:12<1121::AID-PD6>3.0.CO;2-Z; SUNDBERG K, 1995, J ULTRAS MED, V14, P585; SUNDBERG K, 1995, J PERINAT MED, V23, P149; TABOR A, 1986, LANCET, V1, P1287; TABOR A, 1988, DAN MED B; Thayer B, 1990, Birth Defects Orig Artic Ser, V26, P58; THOMPSON PJ, 1992, BRIT J OBSTET GYNAEC, V99, P479, DOI 10.1111/j.1471-0528.1992.tb13785.x; TURNBULL BW, 1976, J R STAT SOC B, V38, P290	30	117	122	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	1997	350	9079					697	703		10.1016/S0140-6736(97)02449-5	http://dx.doi.org/10.1016/S0140-6736(97)02449-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291904				2022-12-28	WOS:A1997XU97700010
J	Peng, CY; Graves, PR; Thoma, RS; Wu, ZQ; Shaw, AS; PiwnicaWorms, H				Peng, CY; Graves, PR; Thoma, RS; Wu, ZQ; Shaw, AS; PiwnicaWorms, H			Mitotic and G(2) checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216	SCIENCE			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE CONTROL; FISSION YEAST; KINASE; IDENTIFICATION; PATHWAY; ROLES	Human Cdc25C is a dual-specificity protein phosphatase that controls entry into mitosis by dephosphorylating the protein kinase Cdc2. Throughout interphase, but not in mitosis, Cdc25C was phosphorylated on serine-216 and bound to members of the highly conserved and ubiquitously expressed family of 14-3-3 proteins. A mutation preventing phosphorylation of serine-216 abrogated 14-3-3 binding. Conditional overexpression of this mutant perturbed mitotic timing and allowed cells to escape the G(2) checkpoint arrest induced by either unreplicated DNA or radiation-induced damage. Chk1, a fission yeast kinase involved in the DNA damage checkpoint response, phosphorylated Cdc25C in vitro on serine-216. These results indicate that serine-216 phosphorylation and 14-3-3 binding negatively regulate Cdc25C and identify Cdc25C as a potential target of checkpoint control in human cells.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; HARVARD UNIV,SCH MED,COMM VIROL,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)			Piwnica-Worms, Helen/C-5214-2012		NIAID NIH HHS [AI34094] Funding Source: Medline; NIGMS NIH HHS [GM47017, GM18428] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047017, F32GM018428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITLEN A, 1996, TRENDS CELL BIOL, V6, P341; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAVES PR, UNPUB; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng C., UNPUB; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; THOMA R, UNPUB; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	23	1186	1247	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1501	1505		10.1126/science.277.5331.1501	http://dx.doi.org/10.1126/science.277.5331.1501			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278512				2022-12-28	WOS:A1997XV42900039
J	Henningsen, U; Schliwa, M				Henningsen, U; Schliwa, M			Reversal in the direction of movement of a molecular motor	NATURE			English	Article							MICROTUBULE MOTOR; CRYSTAL-STRUCTURE; NCD PROTEIN; KINESIN; DROSOPHILA; DOMAINS; SEGREGATION	Kinesin and non-claret disjunctional (ncd) are molecular motors of the kinesin superfamily that move in opposite directions along microtubules. The molecular basis underlying the direction of movement is unclear, although it is thought to be an intrinsic property of the motor domain, a conserved region about 330 amino acids in length(1-3). The motor domain is found at the amino terminus in conventional kinesins, but at the carboxy terminus in ncd(4,5). Here we report on a chimaera composed of the motor domain of the minus-end-directed kinesin of Neurospora crassa(6). The bacterially expressed fusion protein was tested in motility assays using polarity-marked microtubules(7). Surprisingly, the chimaera moved towards the plus end, demonstrating that the polarity of force generation of the ncd motor domain has been reversed. This finding indicates that the domain organization, particularly the position of the motor domain, is of fundamental importance for the polarity of force production. It also demonstrates that the direction of microtubule movement is not controlled solely by the motor domain(8).	UNIV MUNICH, ADOLF BUTENANDT INST ZELLBIOL, D-80336 MUNICH, GERMANY	University of Munich								AMAL I, 1996, CURR BIOL, V6, P1265; Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HYMAN AA, 1991, J CELL SCI, P125; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MARKS DL, 1994, J CELL SCI, V107, P2417; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TABOR S, 1990, CURRENT PROTOCOLS MO; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0	22	182	184	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					93	96		10.1038/38022	http://dx.doi.org/10.1038/38022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288974				2022-12-28	WOS:A1997XU59600052
J	Liu, RH; Orgel, LE				Liu, RH; Orgel, LE			Oxidative acylation using thioacids	NATURE			English	Article							CONDENSATION	Several important prebiotic reactions, including the coupling of amino acids into polypeptides by the formation of amide linkages, involve acylation. Theae reactions present a challenge to the understanding of prebiotic synthesis. Condensation reactions relying on dehydrating agents are either inefficient in aqueous solution(1,2) or require strongly acidic conditions and high temperatures(3). Activated amino acids such as thioester derivatives have therefore been suggested as likely substrates for prebiotic peptide synthesis(4-7). Here we propose a closely related route to amide bond formation involving oxidative acylation by thioacids. We find that phenylalanine, leucine and phenylphosphate are acylated efficiently in aqueous solution by thioacetic acid and oxidizing agent, From a prebiotic point of view, oxidative acylation has the advantage of proceeding efficiently in solution and under mild conditions. We anticipate that oxidative acylation should prove to be a general method for activating carboxylic acids, including amino acids.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	Salk Institute								BRATERMAN PS, 1983, NATURE, V303, P163, DOI 10.1038/303163a0; BUTLER EA, 1958, ANAL CHEM, V30, P1379, DOI 10.1021/ac60140a027; Cefola M., 1962, TALANTA, V9, P537, DOI DOI 10.1016/0039-9140(62)80125-8; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; de Duve C, 1991, BLUEPRINT CELL NATUR; FERRIS J P, 1987, P29; HAWKER JR, 1981, J MOL EVOL, V17, P285, DOI 10.1007/BF01795750; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; HULSHOF J, 1976, ORIGINS LIFE EVOL B, V7, P197, DOI 10.1007/BF00926938; KELLER M, 1994, NATURE, V368, P836, DOI 10.1038/368836a0; Liu CF, 1996, TETRAHEDRON LETT, V37, P933, DOI 10.1016/0040-4039(95)02394-1; ROSENTHAL D, 1957, J AM CHEM SOC, V79, P2684, DOI 10.1021/ja01568a007; SHEEHAN JC, 1952, J AM CHEM SOC, V74, P4726, DOI 10.1021/ja01138a528; SMITH PAS, 1965, CHEM OPEN CHAIN ORGA, P165; WEBER AL, 1981, J MOL EVOL, V18, P24, DOI 10.1007/BF01733208; WEBER AL, 1979, J MOL EVOL, V13, P193, DOI 10.1007/BF01739479; Whittet DCB, 1997, ORIGINS LIFE EVOL B, V27, P249, DOI 10.1023/A:1006534500363; WIELAND T, 1988, ROOTS OF MODERN BIOCHEMISTRY, P213	18	71	73	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					52	54		10.1038/37944	http://dx.doi.org/10.1038/37944			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288964				2022-12-28	WOS:A1997XU59600040
J	Srivastava, TN; Payment, MF				Srivastava, TN; Payment, MF			Paradoxical embolism - Thrombus in transit through a patent foramen ovale	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Srivastava, TN (corresponding author), VET AFFAIRS MED CTR,JACKSON,MS 39216, USA.								0	53	58	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					681	681		10.1056/NEJM199709043371005	http://dx.doi.org/10.1056/NEJM199709043371005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU349	9278465				2022-12-28	WOS:A1997XU34900005
J	Smith, CAD; Harrison, DJ				Smith, CAD; Harrison, DJ			Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema	LANCET			English	Article							ALPHA-1-ANTITRYPSIN DEFICIENCY; CIGARETTE-SMOKING; LUNG-DISEASE; EXPRESSION; INHIBITOR; ELASTASE; CANCER; MODEL; LIVER	Background The first-pass metabolism of foreign compounds in the lung is an mechanism against whether polymorphisms in the gene for microsomal epoxide hydrolase (mEPHX), an enzyme involved in this protective process, had any bearing on individual susceptibility to the development of chronic obstructive pulmonary disease (COPD) and emphysema. Methods We designed PCR-based genotyping assays to detect variant forms of mEPHX that confer slow and fast activity. We used these assays to screen 203 blood-donor controls and groups of patients with asthma (n=57), lung cancer (n=50), COPD (n=68), and emphysema (n=94), who were attending specialised clinics in Edinburgh, UK. Findings The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]). The odds ratios for homozygous slow activity versus all other phenotypes were 4.1 (95% CI 1.8-9.7) for COPD and 5.0 (2.3-10.9) for emphysema. Interpretation Genetic polymorphisms in xenobiotic enzymes may have a role in individual susceptibility to oxidant-related lung disease. Epoxide derivatives of cigarette-smoke components may be the cause of some of the lung damage characteristic of these diseases.	UNIV EDINBURGH, DEPT PATHOL, EDINBURGH, MIDLOTHIAN, SCOTLAND	University of Edinburgh								AARON J, 1985, AM REV RESPIR DIS, V132, P417; BARTSCH H, 1992, ENVIRON HEALTH PERSP, V98, P119, DOI 10.2307/3431257; CANTLAY AM, 1994, THORAX, V49, P1010, DOI 10.1136/thx.49.10.1010; CANTLAY AM, 1995, J CLIN PATHOL-CL MOL, V48, pM210; CARP H, 1982, P NATL ACAD SCI-BIOL, V79, P2041, DOI 10.1073/pnas.79.6.2041; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; COX DW, 1988, AM REV RESPIR DIS, V137, P371, DOI 10.1164/ajrccm/137.2.371; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; EVANS MD, 1994, AM J PHYSIOL, V266, pL593, DOI 10.1152/ajplung.1994.266.6.L593; FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; GARVER RI, 1986, NEW ENGL J MED, V314, P762, DOI 10.1056/NEJM198603203141207; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; Hoffmann D., 1990, CHEM CARCINOGENESIS, P63, DOI [10.1007/978-3-642-74775-5_3, DOI 10.1007/978-3-642-74775-5_3]; KALSHEKER NA, 1987, BRIT MED J, V294, P1511, DOI 10.1136/bmj.294.6586.1511; MARTORANA PA, 1993, LAB INVEST, V68, P233; MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384; MORGAN K, 1992, EUR J CLIN INVEST, V22, P134, DOI 10.1111/j.1365-2362.1992.tb01946.x; OGUSHI F, 1991, J CLIN INVEST, V87, P1060, DOI 10.1172/JCI115066; OMIECINSKI CJ, 1993, PHARMACOGENETICS, V3, P150, DOI 10.1097/00008571-199306000-00005; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; SMITH CAD, 1994, EUR J CANCER, V30A, P1921, DOI 10.1016/0959-8049(94)00382-F; TETLEY TD, 1993, THORAX, V48, P560, DOI 10.1136/thx.48.5.560; TINGLE MD, 1993, BIOCHEM PHARMACOL, V46, P1529, DOI 10.1016/0006-2952(93)90319-R	24	335	360	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					630	633		10.1016/S0140-6736(96)08061-0	http://dx.doi.org/10.1016/S0140-6736(96)08061-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288046				2022-12-28	WOS:A1997XU28300011
J	Wilcken, DEL				Wilcken, DEL			MTHFR 677C->T mutation, folate intake, neural-tube defect, and risk of cardiovascular disease	LANCET			English	Editorial Material							METHYLENETETRAHYDROFOLATE REDUCTASE; VASCULAR-DISEASE; HOMOCYSTEINE				Wilcken, DEL (corresponding author), UNIV NEW S WALES,DEPT CARDIOVASC MED,SYDNEY,NSW 2036,AUSTRALIA.							BOCKXMEER FM, 1997, CIRCULATION, V95, P21; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Fowler B, 1997, J INHERIT METAB DIS, V20, P270, DOI 10.1023/A:1005369109055; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; KANG SS, 1991, AM J HUM GENET, V48, P536; Ma J, 1996, CIRCULATION, V94, P2410, DOI 10.1161/01.CIR.94.10.2410; Molloy AM, 1997, LANCET, V349, P1591, DOI 10.1016/S0140-6736(96)12049-3; SMITHELLS RW, 1980, LANCET, V1, P339; vanderPut NMJ, 1997, QJM-MON J ASSOC PHYS, V90, P111, DOI 10.1093/qjmed/90.2.111; Wilcken DEL, 1996, ARTERIOSCL THROM VAS, V16, P878, DOI 10.1161/01.ATV.16.7.878	10	47	48	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					603	604		10.1016/S0140-6736(05)63320-X	http://dx.doi.org/10.1016/S0140-6736(05)63320-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288038				2022-12-28	WOS:A1997XU28300003
J	Barsky, AJ; Delbanco, TL				Barsky, AJ; Delbanco, TL			A 37-year-old man with multiple somatic complaints	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; SOMATIZATION DISORDER; PSYCHIATRIC-DISORDERS; ANXIETY DISORDERS; MEDICAL-CARE; SYMPTOMS; THERAPY; HYPOCHONDRIASIS; MANAGEMENT; HEALTH		BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD MED SCH, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								BARSKY AJ, 1983, AM J PSYCHIAT, V140, P273; Barsky AJ, 1996, PSYCHOSOMATICS, V37, P48, DOI 10.1016/S0033-3182(96)71598-0; BARSKY AJ, 1992, PSYCHOSOMATICS, V33, P28, DOI 10.1016/S0033-3182(92)72018-0; BARSKY AJ, 1990, BRIT J PSYCHIAT, V157, P404, DOI 10.1192/bjp.157.3.404; BARSKY AJ, 1991, J GEN INTERN MED, V6, P413, DOI 10.1007/BF02598162; BASS C, 1993, BRIT J PSYCHIAT, V162, P472, DOI 10.1192/bjp.162.4.472; BASS C, 1990, SOMATIZATION PHYSICA; BRIDGES KW, 1985, J PSYCHOSOM RES, V29, P563, DOI 10.1016/0022-3999(85)90064-9; BROWN FW, 1990, PSYCHOSOM MED, V52, P445, DOI 10.1097/00006842-199007000-00006; BUCKELEW SP, 1989, AM J PHYS MED REHAB, V68, P37, DOI 10.1097/00002060-198902000-00010; CASSEM NH, 1991, MASSACHUSETTS GEN HO, P131; CAUDILL M, 1995, PSYCHOSOM MED, V57, P234; CRAIG TKJ, 1993, BRIT J PSYCHIAT, V163, P579, DOI 10.1192/bjp.163.5.579; Deale A, 1997, AM J PSYCHIAT, V154, P408; DEGRUY F, 1987, J FAM PRACTICE, V25, P45; DEGUIRE S, 1992, AM J CARDIOL, V70, P673, DOI 10.1016/0002-9149(92)90211-G; DWORKIN SF, 1990, ARCH GEN PSYCHIAT, V47, P239; ESCOBAR JI, 1987, AM J PUBLIC HEALTH, V77, P837, DOI 10.2105/AJPH.77.7.837; FINK P, 1992, PSYCHOL MED, V22, P173, DOI 10.1017/S0033291700032827; FINK P, 1992, J PSYCHOSOM RES, V36, P439, DOI 10.1016/0022-3999(92)90004-L; FORD CV, 1983, SOMATIZING DISORDERS; FORD P, 1983, J PSYCHOSOM RES; KATON W, 1984, COMPR PSYCHIAT, V25, P208, DOI 10.1016/0010-440X(84)90009-9; KATON W, 1991, AM J PSYCHIAT, V148, P34; Kellner R., 1986, SOMATIZATION HYPOCHO; KIRMAYER LJ, 1993, AM J PSYCHIAT, V150, P734; Kroenke K, 1994, Arch Fam Med, V3, P774; KROENKE K, 1989, AM J MED, V86, P262, DOI 10.1016/0002-9343(89)90293-3; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; LIPOWSKI ZJ, 1986, CAN MED ASSOC J, V135, P609; MARTIN PR, 1989, BRIT J CLIN PSYCHOL, V28, P347, DOI 10.1111/j.2044-8260.1989.tb00839.x; MECHANIC D, 1978, J HUM STRESS, V4, P26, DOI 10.1080/0097840X.1978.10545983; ORMEL J, 1990, PSYCHOL MED, V20, P909, DOI 10.1017/S0033291700036606; OXMAN TE, 1983, J FAM PRACTICE, V17, P439; PENNEBAKER JW, 1983, J PERS, V51, P468, DOI 10.1111/j.1467-6494.1983.tb00341.x; PENNEBAKER JW, 1991, CURRENT CONCEPTS SOM, P24; PENNEBAKER JW, 1982, PSYCHOL PHYSICAL SYM; PILOWSKY I, 1987, J PSYCHOSOM RES, V31, P177, DOI 10.1016/0022-3999(87)90074-2; ROBBINS PR, 1974, J PERS ASSESS, V38, P578, DOI 10.1080/00223891.1974.10120020; RUSSO J, 1994, PSYCHOSOMATICS, V35, P546, DOI 10.1016/S0033-3182(94)71723-0; SALKOVSKIS PM, 1989, COGNITIVE BEHAV THER, P235; SHARPE M, 1992, J PSYCHOSOM RES, V36, P515, DOI 10.1016/0022-3999(92)90037-3; Sharpe M, 1995, TREATMENT OF FUNCTIONAL SOMATIC SYMPTOMS, P122; SIMON G, 1995, AM J PSYCHIAT, V152, P352; SMITH GR, 1986, ARCH INTERN MED, V146, P69, DOI 10.1001/archinte.146.1.69; SPECKENS AEM, 1995, BRIT MED J, V311, P1328, DOI 10.1136/bmj.311.7016.1328; STRAIN JJ, 1994, PSYCHOSOMATICS, V35, P253, DOI 10.1016/S0033-3182(94)71773-4; SWARTZ M, 1986, AM J PSYCHIAT, V143, P1403; VANDERGAAG J, 1978, MED CARE, V16, P299, DOI 10.1097/00005650-197804000-00003; vanDulmen AM, 1996, PSYCHOSOM MED, V58, P508, DOI 10.1097/00006842-199609000-00013; WARWICK HMC, 1988, BRIT J PSYCHIAT, V152, P239, DOI 10.1192/bjp.152.2.239; ZOCCOLILLO MS, 1986, SOUTHERN MED J, V79, P532, DOI 10.1097/00007611-198605000-00004	53	12	12	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					673	679		10.1001/jama.278.8.673	http://dx.doi.org/10.1001/jama.278.8.673			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR547	9272901				2022-12-28	WOS:A1997XR54700042
J	Thiru, Y; Bateman, DN; Coulthard, MG				Thiru, Y; Bateman, DN; Coulthard, MG			Successful breast feeding while mother was taking cyclosporin	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY				Thiru, Y (corresponding author), ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							[Anonymous], 1994, LANCET, V344, P1239; COCKBURN I, 1989, TRANSPLANT P, V21, P3730; DERFLER K, 1988, CLIN NEPHROL, V29, P96; FLECHNER SM, 1985, AM J KIDNEY DIS, V5, P60, DOI 10.1016/S0272-6386(85)80138-4; ROGAN WJ, 1993, EARLY HUM DEV, V31, P181, DOI 10.1016/0378-3782(93)90194-Y	5	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					463	463		10.1136/bmj.315.7106.463	http://dx.doi.org/10.1136/bmj.315.7106.463			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284666	Green Published			2022-12-28	WOS:A1997XT71400021
J	Grady, RM; Teng, HB; Nichol, MC; Cunningham, JC; Wilkinson, RS; Sanes, JR				Grady, RM; Teng, HB; Nichol, MC; Cunningham, JC; Wilkinson, RS; Sanes, JR			Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy	CELL			English	Article							MDX MOUSE MUSCLE; NEUROMUSCULAR-JUNCTION; GLYCOPROTEIN COMPLEX; AGRIN RECEPTOR; PROTEIN; FIBERS; CELLS; REGENERATION; LOCALIZATION; ASSOCIATION	Dystrophin is a cytoskeletal protein of muscle fibers; its toss in humans leads to Duchenne muscular dystrophy, an inevitably fatal wasting of skeletal and cardiac muscle. mdx mice also lack dystrophin, but are only mildly dystrophic. Utrophin, a homolog of dystrophin, is confined to the postsynaptic membrane at skeletal neuromuscular junctions and has been implicated in synaptic development. However, mice lacking utrophin show only subtle neuromuscular defects. Here, we asked whether the mild phenotypes of the two single mutants reflect compensation between the two proteins. Synaptic development was qualitatively normal in double mutants, but dystrophy was severe and closely resembled that seen in Duchenne. Thus, utrophin attenuates the effects of dystrophin deficiency, and the double mutant may provide a useful model for studies of pathogenesis and therapy.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	Grady, RM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110, USA.		Wilkinson, Robert/F-5408-2012					AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Amalfitano A, 1996, MUSCLE NERVE, V19, P1549, DOI 10.1002/(SICI)1097-4598(199612)19:12<1549::AID-MUS4>3.0.CO;2-A; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BELL CD, 1968, J NEUROL SCI, V7, P529, DOI 10.1016/0022-510X(68)90058-0; Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRIDGES LR, 1986, J NEUROL SCI, V72, P147, DOI 10.1016/0022-510X(86)90003-1; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; DECONINCK AE, 1997, IN PRESS CELL, V90, P717; Deconinck N, 1996, P NATL ACAD SCI USA, V93, P3570, DOI 10.1073/pnas.93.8.3570; DIMARIO JX, 1991, DEV BIOL, V148, P314, DOI 10.1016/0012-1606(91)90340-9; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; Engel AG, 1994, MYOLOGY, P1769; Engel AG, 1994, MYOLOGY, pP1133; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FRANKEL KA, 1976, HUM PATHOL, V7, P375, DOI 10.1016/S0046-8177(76)80053-6; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Gillis JM, 1996, ACTA PHYSIOL SCAND, V156, P397, DOI 10.1046/j.1365-201X.1996.201000.x; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; KARPATI G, 1988, MUSCLE NERVE, V11, P795, DOI 10.1002/mus.880110802; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; LICHTMAN JW, 1987, J PHYSIOL-LONDON, V393, P355, DOI 10.1113/jphysiol.1987.sp016827; LYONS PR, 1991, J NEUROCYTOL, V20, P969, DOI 10.1007/BF01187915; MASTAGLIA FL, 1975, J NEUROL SCI, V25, P227, DOI 10.1016/0022-510X(75)90143-4; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCGEACHIE JK, 1993, J NEUROL SCI, V119, P169, DOI 10.1016/0022-510X(93)90130-Q; MENKE A, 1995, J CELL SCI, V108, P727; Mora M, 1996, DEV BRAIN RES, V91, P70, DOI 10.1016/0165-3806(95)00169-7; MUKOYAMA M, 1987, J NEUROL SCI, V81, P155, DOI 10.1016/0022-510X(87)90092-X; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; ODA T, 1993, J PEDIATR ORTHOPED, V13, P478, DOI 10.1097/01241398-199307000-00012; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PETROF BJ, 1993, AM J PHYSIOL, V265, pC834; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; Quinlivan RM, 1996, NEUROMUSCULAR DISORD, V6, P237, DOI 10.1016/0960-8966(96)00007-7; REISER PJ, 1988, DEV BIOL, V129, P400, DOI 10.1016/0012-1606(88)90387-9; REZVANI M, 1995, J APPL PHYSIOL, V78, P961, DOI 10.1152/jappl.1995.78.3.961; SANES JR, 1995, DEV BIOL, V6, P163; SARTORE S, 1982, NATURE, V298, P294, DOI 10.1038/298294a0; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; THIMAN N, 1991, J CELL BIOL, V115, P1695; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; WAKAI S, 1988, J NEUROL SCI, V84, P167, DOI 10.1016/0022-510X(88)90122-0; WILKINSON RS, 1992, J PHYSIOL-LONDON, V448, P413, DOI 10.1113/jphysiol.1992.sp019049	63	516	530	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					729	738		10.1016/S0092-8674(00)80533-4	http://dx.doi.org/10.1016/S0092-8674(00)80533-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288752	Bronze			2022-12-28	WOS:A1997XT06600016
J	Ichikawa, A; Kinoshita, T; Watanabe, T; Kato, H; Nagai, H; Tsushita, K; Saito, H; Hotta, T				Ichikawa, A; Kinoshita, T; Watanabe, T; Kato, H; Nagai, H; Tsushita, K; Saito, H; Hotta, T			Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; TUMOR SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; COMBINATION CHEMOTHERAPY; DISEASE PROGRESSION; MALIGNANT-LYMPHOMA; DELETIONS; REGIMEN; MARKER; CARCINOMAS	Background Mutations of the p53 gene are associated with a poor prognosis in several types of cancer. We investigated the prognostic importance of p53 mutations in patients with aggressive B-cell lymphoma. Methods We examined the relation between the presence or absence of a detectable p53 mutation in lymphoma cells and the response to chemotherapy and overall survival in 102 previously untreated patients with aggressive B-cell lymphoma. Mutations of the p53 gene were identified by polymerase-chain-reaction-mediated analysis of single-strand conformation polymorphisms and by direct sequencing. Results Of 102 cases of aggressive B-cell lymphoma, 22 (22 percent) involved p53 mutations. The rate of complete remission was significantly lower in patients with a tumor carrying a p53 mutation (6 of 22 patients, 27 percent) than in those with the wild-type p53 gene (61 of 80 patients, 76 percent) (P<0.001). Overall survival was significantly lower among patients with p53 mutations than among those with the wild-type p53 gene; the Kaplan-Meier estimates of survival at five years were 16 percent and 64 percent, respectively (P<0.001). Multivariate analysis incorporating prognostic factors from the international prognostic index demonstrated that p53 mutations had independent effects on the rates of complete remission and survival. When we categorized patients according to the international prognostic index, we found no effect of p53 mutations in patients in the groups at high-intermediate and high risk. However, these mutations were significantly associated (P<0.001) with low rates of complete remission (33 percent vs. 91 percent) and survival (27 percent vs. 81 percent at five years) in the groups at low and low-intermediate risk. Conclusions Mutations of the p53 gene are associated with a poor prognosis in patients with aggressive B-cell lymphoma. (C) 1997, Massachusetts Medical Society.	NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 1, NAGOYA, AICHI 466, JAPAN	Nagoya University	Ichikawa, A (corresponding author), GIFU PREFECTURAL TAJIMI HOSP, DEPT HEMATOL ONCOL, MAEHATA CHO, TAJIMI, JAPAN.			Watanabe, Takashi/0000-0002-9015-5246				Armitage P., 2001, STAT METHODS MED RES; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CARBONE PP, 1971, CANCER RES, V31, P1860; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COIFFIER B, 1991, J CLIN ONCOL, V9, P211, DOI 10.1200/JCO.1991.9.2.211; COIFFIER B, 1989, BLOOD, V74, P558; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1970, ANAL BINARY DATA; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FISHER RI, 1981, BLOOD, V58, P45; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; ICHIKAWA A, 1992, BLOOD, V79, P2701; JAGANNATH S, 1986, J CLIN ONCOL, V4, P859, DOI 10.1200/JCO.1986.4.6.859; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; LAURENCE J, 1982, ANN INTERN MED, V97, P190, DOI 10.7326/0003-4819-97-2-190; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LISTER, 1990, J CLIN ONCOL, V8, P1602; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKELVEY EM, 1976, CANCER, V38, P1484, DOI 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PUI CH, 1987, BLOOD, V70, P624; RODRIGUEZ V, 1977, BLOOD, V49, P325; ROSENBERG SA, 1982, CANCER, V49, P2112; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; SCHOUTEN HC, 1990, BLOOD, V75, P1841; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P128, DOI 10.1200/JCO.1988.6.1.128; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SOUSSI T, 1990, ONCOGENE, V5, P945; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VOSE JM, 1988, J CLIN ONCOL, V6, P1838, DOI 10.1200/JCO.1988.6.12.1838; Wilson WH, 1997, BLOOD, V89, P601, DOI 10.1182/blood.V89.2.601	48	231	237	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					529	534		10.1056/NEJM199708213370804	http://dx.doi.org/10.1056/NEJM199708213370804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262496				2022-12-28	WOS:A1997XR54800004
J	Rainville, P; Duncan, GH; Price, DD; Carrier, B; Bushnell, MC				Rainville, P; Duncan, GH; Price, DD; Carrier, B; Bushnell, MC			Pain affect encoded in human anterior cingulate but not somatosensory cortex	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; CORTICAL AFFERENTS; MONKEY; RESPONSES	Recent evidence demonstrating multiple regions of human cerebral cortex activated by pain has prompted speculation about their individual contributions to this complex experience. To differentiate cortical areas involved in pain affect, hypnotic suggestions were used to alter selectively the unpleasantness of noxious stimuli, without changing the perceived intensity. Positron emission tomography revealed significant changes in pain-evoked activity within anterior cingulate cortex, consistent with the encoding of perceived unpleasantness, whereas primary somatosensory cortex activation was unaltered. These findings provide direct experimental evidence in humans linking frontal-lobe limbic activity with pain affect, as originally suggested by early clinical lesion studies.	UNIV MONTREAL, CTR RECH SCI NEUROL, MONTREAL, PQ H3C 3J7, CANADA; MONTREAL NEUROL INST, MCCONNELL BRAIN IMAGING CTR, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT ANESTHESIOL, MONTREAL, PQ H3A 1A1, CANADA	Universite de Montreal; McGill University; McGill University			Price, Donald D./A-3094-2008; Rainville, Pierre/M-5480-2015	Price, Donald D./0000-0002-8971-7184; Rainville, Pierre/0000-0001-9801-757X				BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; COGHILL RC, 1994, J NEUROSCI, V14, P4095; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; CORBETTA M, 1991, J NEUROSCI, V11, P2383; Craig A. D., 1996, Society for Neuroscience Abstracts, V22, P111; Dostrovsky J. O., 1996, Society for Neuroscience Abstracts, V22, P111; Fields H. L., 1987, PAIN; FOLTZ EL, 1962, J NEUROSURG, V19, P89, DOI 10.3171/jns.1962.19.2.0089; FOLTZ EL, 1968, INT J NEUROL, V6, P353; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P323, DOI 10.1002/cne.902520304; GINGOLD SI, 1991, J COMP NEUROL, V308, P467, DOI 10.1002/cne.903080312; Hurt R W, 1974, Clin Neurosurg, V21, P334; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; KENSHALO DR, 1988, BRAIN RES, V454, P378, DOI 10.1016/0006-8993(88)90841-4; KIERNAN BD, 1995, PAIN, V60, P39, DOI 10.1016/0304-3959(94)00134-Z; MELZACK R, 1968, P423; Morin C., 1994, Society for Neuroscience Abstracts, V20, P127; MUFSON EJ, 1982, J COMP NEUROL, V212, P23, DOI 10.1002/cne.902120103; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; Paus T, 1996, CEREB CORTEX, V6, P207, DOI 10.1093/cercor/6.2.207; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; Price DD, 1988, PSYCHOL NEURAL MECH; RAINVILLE P, 1992, SOMATOSENS MOT RES, V9, P265, DOI 10.3109/08990229209144776; Rainville P., 1996, Society for Neuroscience Abstracts, V22, P117; RAUSELL E, 1991, J NEUROSCI, V11, P226; SIKES RW, 1992, J NEUROPHYSIOL, V68, P1720, DOI 10.1152/jn.1992.68.5.1720; STEVENS RT, 1993, BRAIN RES, V631, P241, DOI 10.1016/0006-8993(93)91541-Y; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; VOGT BA, 1979, SCIENCE, V204, P205, DOI 10.1126/science.107587; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; [No title captured]; [No title captured]; [No title captured]	38	1770	1815	0	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	1997	277	5328					968	971		10.1126/science.277.5328.968	http://dx.doi.org/10.1126/science.277.5328.968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252330				2022-12-28	WOS:A1997XQ98500045
J	Chen, HW; Lin, RJ; Schiltz, RL; Chakravarti, D; Nash, A; Nagy, L; Privalsky, ML; Nakatani, Y; Evans, RM				Chen, HW; Lin, RJ; Schiltz, RL; Chakravarti, D; Nash, A; Nagy, L; Privalsky, ML; Nakatani, Y; Evans, RM			Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300	CELL			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTION FACTOR TFIIB; DEPENDENT TRANSACTIVATION; CO-REPRESSOR; PROTEIN CBP; DOMAIN; SUPERFAMILY; NUCLEOSOME; MEDIATE; BINDING	We report here the identification of a novel cofactor, ACTR, that directly binds nuclear receptors and stimulates their transcriptional activities in a hormone-dependent fashion. ACTR also recruits two other nuclear factors, CBP and P/CAF, and thus plays a central role in creating a multisubunit coactivator complex. In addition, and unexpectedly, we show that purified ACTR is a potent histone acetyltransferase and appears to define a distinct evolutionary branch to this recently described family. Thus, hormonal activation by nuclear receptors involves the mutual recruitment of at least three classes of histone acetyltransferases that may act cooperatively as an enzymatic unit to reverse the effects of histone cleacetylase shown to be part of the nuclear receptor corepressor complex.	HOWARD HUGHES MED INST,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,SCH MED,GRAD PROGRAM MOL PATHOL,LA JOLLA,CA 92037; NICHHD,LAB MOL GROWTH REGULAT,NATL INST HLTH,BETHESDA,MD 20892; UNIV CALIF DAVIS,MICROBIOL SECT,DIV BIOL SCI,DAVIS,CA 95616	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Davis			Evans, Ronald/AAF-4001-2019; Nagy, Laszlo/A-3814-2008	Evans, Ronald/0000-0002-9986-5965; Nagy, Laszlo/0000-0001-6653-2155; Lin, Richard/0000-0002-0834-7880; Chakravarti, Debabrata/0000-0001-8446-8599	NICHD NIH HHS [HD27183] Funding Source: Medline; NIGMS NIH HHS [GM26444] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026444, R01GM026444] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; ING NH, 1992, J BIOL CHEM, V267, P17617; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANKNECHT R, 1996, CURR BIOL, V6, P951; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; SOEL W, 1995, MOL ENDOCRINOL, V9, P72; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	59	1238	1267	2	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					569	580		10.1016/S0092-8674(00)80516-4	http://dx.doi.org/10.1016/S0092-8674(00)80516-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267036	Bronze			2022-12-28	WOS:A1997XQ06300020
J	Tang, AH; Neufeld, TP; Kwan, E; Rubin, GM				Tang, AH; Neufeld, TP; Kwan, E; Rubin, GM			PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-dependent mechanism	CELL			English	Article							DROSOPHILA EYE DEVELOPMENT; ETS DOMAIN PROTEIN; TYROSINE KINASE; EXPRESSION PATTERN; ECTOPIC EXPRESSION; SEGMENTATION GENE; FUSHI-TARAZU; TRAMTRACK; SEVENLESS; UBIQUITIN	We show that Tramtrack (TTK88) expression represses neuronal fate determination in the developing Drosophila eye. Phyllopod (PHYL) acts to antagonize this repression by a mechanism that requires Seven In Absentia (SINA) and is associated with decreased TTK88 protein levels, but not reduced ttk88 gene transcription or mRNA stability. We present evidence that SINA, PHYL, and TTK88 physically interact and that SINA interacts genetically and physically with UBCD1, a component of the ubiquitin-dependent protein degradation pathway. Our results suggest a model in which activation of the Sevenless receptor tyrosine kinase induces PHYL expression, which then acts with SINA to target the transcriptional repressor TTK88 for degradation, thereby promoting R7 cell fate specification.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley			Tang, Amy/L-3226-2016	Tang, Amy/0000-0002-5772-2878; Neufeld, Thomas/0000-0001-5659-4811; Rubin, Gerald/0000-0001-8762-8703				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BROWN JL, 1993, DEVELOPMENT, V117, P45; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTHEW RW, 1994, P NATL ACAD SCI USA, V91, P11689, DOI 10.1073/pnas.91.24.11689; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson Barry, 1993, P1327; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Huang YZ, 1996, DEVELOPMENT, V122, P3207; Kauffmann RC, 1996, GENE DEV, V10, P2167, DOI 10.1101/gad.10.17.2167; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; READ D, 1992, MECH DEVELOP, V38, P183, DOI 10.1016/0925-4773(92)90052-L; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREIER M, 1992, EMBO J, V11, P367, DOI 10.1002/j.1460-2075.1992.tb05059.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff Tanya, 1993, P1277; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; XU T, 1993, DEVELOPMENT, V117, P1223; Yamamoto D, 1996, ROUX ARCH DEV BIOL, V205, P215, DOI 10.1007/BF00365799; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	65	198	201	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					459	467		10.1016/S0092-8674(00)80506-1	http://dx.doi.org/10.1016/S0092-8674(00)80506-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267026	Bronze			2022-12-28	WOS:A1997XQ06300010
J	Tousoulis, D; Davies, G; Tentolouris, C; Crake, T; Toutouzas, P				Tousoulis, D; Davies, G; Tentolouris, C; Crake, T; Toutouzas, P			Coronary stenosis dilatation induced by L-arginine	LANCET			English	Article									UNIV ATHENS,SCH MED,HIPPOKRAT HOSP,CARDIOL UNIT,GR-11527 ATHENS,GREECE	Athens Medical School; Hippokration General Hospital; National & Kapodistrian University of Athens	Tousoulis, D (corresponding author), HAMMERSMITH HOSP,CARDIOL UNIT,LONDON W12 0NN,ENGLAND.							Aji W, 1997, CIRCULATION, V95, P430; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; Taddei S, 1996, CIRCULATION, V94, P1298, DOI 10.1161/01.CIR.94.6.1298	5	54	54	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1812	1813		10.1016/S0140-6736(05)61692-3	http://dx.doi.org/10.1016/S0140-6736(05)61692-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269220				2022-12-28	WOS:A1997XF73500016
J	Moore, M; Onorato, IM; McCray, E; Castro, KG				Moore, M; Onorato, IM; McCray, E; Castro, KG			Trends in drug-resistant tuberculosis in the United States, 1993-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION	Context.-With the resurgence of tuberculosis (TB) disease in the late 1980s and early 1990s in the United States, multidrug-resistant (MDR) TB emerged as a serious challenge to TB control. In response, the Centers for Disease Control and Prevention in 1993 added drug susceptibility test results to the information collected for the national surveillance system to monitor trends in drug resistance. Objective.-To determine the extent of drug-resistant tuberculosis (TB) in the United States. Design.-Descriptive analysis or TB surveillance data. Study Population.-Patients reported to the national TB surveillance system as confirmed TB cases with culture-positive disease from 1993 through 1996 by the 50 states, New York City, and the District of Columbia (DC). Main Outcome Measure.-Percentage of case patients with culture-positive disease whose isolates are resistant to specific anti-TB drugs. Results.-Overall resistance to at least isoniazid was 8.4%; rifampin, 3.0%; both isoniazid and rifampin (ie, MDR TB), 2.2%; pyrazinamide, 3.0%; streptomycin, 6.2%; and ethambutol hydrochloride, 2.2%. Rates of resistance were significantly higher for case patients with a prior TB episode. Among those without prior TB, isoniazid resistance of 4% or more was found in 41 states, New York City, and DC. A total of 1457 MDR TB cases were reported from 42 states, New York City, and DC; however, 38% were reported from New York City. Rates of isoniazid and streptomycin resistance were higher for cases among US-born compared with foreign-born patients, but rates of rifampin resistance and MDR TB were similar. Among US-born patients, resistance to first-line drugs, particularly rifampin mono-resistance, was significantly higher among those with human immunodeficiency virus (HIV) infection. Conclusions.-Compared with recent US surveys in 1991 and 1992, isoniazid resistance has remained relatively stable. In addition, the percentage of MDR TB has decreased, although the national trend was significantly influenced by the marked decrease in New York City. Foreign-born and HIV-positive patients and those with prior TB have higher rates of resistance. The widespread extent of isoniazid resistance confirms the need for drug susceptibility testing to guide optimal treatment of patients with culture-positive disease.			Moore, M (corresponding author), CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,NATL CTR HIV STD & TB PREVENT,MAILSTOP E-10,ATLANTA,GA 30333, USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				*AM THOR SOC, 1994, AM J RESP CRIT CARE, V149, P1359; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; Bloch AB, 1996, PUBLIC HEALTH REP, V111, P26; BLOCH AB, 1994, AM LUNG ASS AM THOR; Bradford WZ, 1996, LANCET, V348, P928, DOI 10.1016/S0140-6736(96)03027-9; BURWEN DR, 1995, ARCH INTERN MED, V155, P1281, DOI 10.1001/archinte.155.12.1281; *CDC, 1983, MMWR-MORBID MORTAL W, V32, P521; *CDC, 1981, MMWR-MORBID MORTAL W, V30, P273; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P587; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; DOSTER B, 1976, AM REV RESPIR DIS, V113, P419; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FRIEDEN TB, 1993, NEW ENGL J MED, V528, P521; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; KOPANOFF DE, 1978, AM REV RESPIR DIS, V118, P835; LASZLO A, 1994, B WORLD HEALTH ORGAN, V72, P603; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1995, AM J RESP CRIT CARE, V152, P1067, DOI 10.1164/ajrccm.152.3.7663785; RIDZON R, 1996, AM J RESP CRIT CARE, V153, pA493; RILEY LW, 1989, AM REV RESPIR DIS, V139, P1282, DOI 10.1164/ajrccm/139.5.1282; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; WHITNEY CG, 1996, AM J RESP CRIT CARE, V153, pA492	28	129	132	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					833	837		10.1001/jama.278.10.833	http://dx.doi.org/10.1001/jama.278.10.833			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU552	9293991				2022-12-28	WOS:A1997XU55200038
J	Minkoff, H; Bauer, T; Joyce, T				Minkoff, H; Bauer, T; Joyce, T			Welfare reform and the obstetrical care of immigrants and their newborns	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMPACT		NATL BUR ECON RES,NEW YORK,NY 10017	National Bureau of Economic Research	Minkoff, H (corresponding author), SUNY HLTH SCI CTR,BOX 24,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							*ASS AM MED COLL, 1997, AAMC FACT SHEET, V1; BATES AS, 1994, JAMA-J AM MED ASSOC, V272, P1105, DOI 10.1001/jama.272.14.1105; BUESCHER PA, 1991, AM J PUBLIC HEALTH, V81, P1625, DOI 10.2105/AJPH.81.12.1625; CHAVEZ LR, 1986, WOMEN HEALTH, V11, P3, DOI 10.1300/J013v11n02_02; *DEP HLTH SERV, 1997, MED CAL FUND DEL 199; Halfon N, 1997, JAMA-J AM MED ASSOC, V277, P636, DOI 10.1001/jama.277.8.636; *MARCH DIM BIRTH D, 1995, FACTS MED PREGN WOM; Minkoff H, 1997, NEW ENGL J MED, V336, P1392, DOI 10.1056/NEJM199705083361916; *NAT GOV ASS, 1996, STAT MED COV PREGN W; Reichman NE, 1996, J HEALTH ECON, V15, P455, DOI 10.1016/S0167-6296(96)00491-2; SINGH S, 1994, FAM PLANN PERSPECT, V26, P31, DOI 10.2307/2136094	11	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					705	707		10.1056/NEJM199709043371011	http://dx.doi.org/10.1056/NEJM199709043371011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU349	9278471				2022-12-28	WOS:A1997XU34900011
J	Roth, AE; Peranson, E				Roth, AE; Peranson, E			The effects of the change in the NRMP Matching algorithm	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL EXPERIMENT; MARKET; REEXAMINATION; ORGANIZATION; PHYSICIANS	Context.-Following 2 years of heated controversy about the resident match, the National Resident Matching Program (NRMP) recently voted to replace the existing matching algorithm with a newly designed applicant-proposing algorithm. Objective.-To design an applicant-proposing algorithm for the match and compare it with the existing NRMP algorithm to determine how many applicants and residency programs could be expected to receive better or worse matches from the 2 algorithms, how the different algorithms influence the opportunity for strategic behavior, and what advice can be given to participants. Design.-Computational experiments compared the newly designed applicant-proposing algorithm with the existing NRMP algorithm on the rank order lists (ROLs) submitted by all applicants and residency programs in the 1987 and 1993 through 1996 NRMP matches. Results.-Differences in the matchings produced by the 2 algorithms are small: fewer than 1 in 1000 applicants would have received a different match. Most (but not all) of the few applicants who are matched to different positions by the 2 algorithms do better when the applicant-proposing algorithm is used; the opposite is true for programs, Opportunities for profitable strategic behavior are very rare for both applicants and programs under either algorithm. With either algorithm, both applicants and programs can be advised that trying to get a preferred match by behaving strategically is far more likely to harm than to help them. Conclusions.-The existing NRMP algorithm and the newly designed applicant-proposing algorithm perform similarly, Both algorithms make it sensible for applicants and residency programs to arrange their ROLs based solely on their preferences for possible matches, The choice of algorithms will systematically affect the matches of only a small group of applicants (<0.1%), The NRMP's recent decision to use the applicant-proposing algorithm starting in 1998 reflects a judgment about the impact of this difference on applicants and programs.	NATL MATCHING SERV INC,TORONTO,ON,CANADA		Roth, AE (corresponding author), UNIV PITTSBURGH,DEPT ECON,PITTSBURGH,PA 15260, USA.		annie, annie/N-4756-2014	Roth, Alvin/0000-0002-8834-6481				Aldershof B, 1996, DISCRETE APPL MATH, V68, P203, DOI 10.1016/0166-218X(96)89151-7; *AM MED ASS MED ST, 1997, AM MED ASS MED STUD; *AM MED STUD ASS P, 1997, REP HOSP BIAS NRMP; GALE D, 1962, AM MATH MON, V69, P9, DOI 10.2307/2312726; PERANSON E, 1995, ACAD MED, V70, P490; PERANSON E, 1995, ACAD MED, V70, P477, DOI 10.1097/00001888-199506000-00008; ROTH A, 1996, EVALUATION CURRENT N; Roth A E, 1996, JAMA, V275, P1054, DOI 10.1001/jama.275.13.1054; Roth A.E., 1990, 2 SIDED MATCHING STU, V18; Roth A. E., 1996, REPORT DESIGN TESTIN; ROTH AE, 1994, AM ECON REV, V84, P992; ROTH AE, 1991, AM ECON REV, V81, P415; ROTH AE, 1984, J POLIT ECON, V92, P991, DOI 10.1086/261272; ROTH AE, 1990, SCIENCE, V250, P1524, DOI 10.1126/science.2274783; ROTH AE, 1990, ECONOMETRICA, V58, P1475, DOI 10.2307/2938326; SONMEZ T, IN PRESS J EC THEORY; WILLIAMS KJ, 1995, ACAD MED, V70, P485; WILLIAMS KJ, 1995, ACAD MED, V70, P470, DOI 10.1097/00001888-199506000-00007	18	56	57	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					729	732		10.1001/jama.278.9.729	http://dx.doi.org/10.1001/jama.278.9.729			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XT709	9286832				2022-12-28	WOS:A1997XT70900025
J	Clever, LH				Clever, LH			Obtain informed consent before publishing information about patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Clever, LH (corresponding author), WESTERN JOURNAL MED, 221 MAIN ST, 3RD FLOOR, SAN FRANCISCO, CA 94105 USA.							Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; [Anonymous], 1992, ANN INTERN MED, V117, P947; COURT C, 1995, BRIT MED J, V311, P1245, DOI 10.1136/bmj.311.7015.1245; *INT COMM MED J ED, 1997, W J MED, V166, P72; *INT COMM MED J ED, 1995, BRIT MED J, V302, P1272; International Committee of Medical Journal Editors, 1995, BMJ, V311, P1272; Katz J, 1996, JAMA-J AM MED ASSOC, V276, P1662, DOI 10.1001/jama.276.20.1662; Nightingale S L, 1997, J Int Assoc Physicians AIDS Care, V3, P24; *NUR DOCT TRIAL RE, 1996, JAMA-J AM MED ASSOC, V276, P1617; PARKIN JR, 1993, BRIT J PSYCHIAT, V162, P246, DOI 10.1192/bjp.162.2.246; SLUE WE, 1989, NEW ENGL J MED, V321, P550, DOI 10.1056/NEJM198908243210823; Smith R, 1996, BRIT MED J, V313, P16, DOI 10.1136/bmj.313.7048.16; *UN DEP PUBL INF, 1949, UN DECL HUM RIGHTS; Veatch RM, 1997, NEW ENGL J MED, V336, P869, DOI 10.1056/NEJM199703203361209; WILKINSON G, 1995, BRIT J PSYCHIAT, V166, P555, DOI 10.1192/bjp.166.5.555; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	16	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					628	629		10.1001/jama.278.8.628	http://dx.doi.org/10.1001/jama.278.8.628			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272884				2022-12-28	WOS:A1997XR54700018
J	Snider, DE				Snider, DE			Patient consent for publication and the health of the public	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUBERCULOSIS				Snider, DE (corresponding author), CTR DIS CONTROL & PREVENT,MAILSTOP D-50,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.							[Anonymous], 1997, JAMA, V277, P927; BAYER R, 1986, MILBANK Q, V64, P168, DOI 10.2307/3350046; CLIFFT MA, 1986, B MENNINGER CLIN, V50, P511; COLVINRHODES LM, 1978, HASTINGS CENT RE AUG, P21; COURT C, 1995, BRIT MED J, V311, P1245, DOI 10.1136/bmj.311.7015.1245; Evans N, 1996, GEOGRAPHY, V81, P225; International Committee of Medical Journal Editors, 1995, BMJ, V311, P1272; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; LAROSSA R, 1981, J MARRIAGE FAM, V43, P303, DOI 10.2307/351382; LUNDGREN R, 1987, TUBERCLE, V68, P147, DOI 10.1016/0041-3879(87)90032-8; MURRAY J, 1982, JAMA-J AM MED ASSOC, V248, P3093, DOI 10.1001/jama.1982.03330230015007; MURRAY JC, 1984, CLIN RES, V32, P404; Perr I N, 1983, Bull Am Acad Psychiatry Law, V11, P207; Sieverts S, 1978, Hastings Cent Rep, V8, P4, DOI 10.2307/3561459; SMITH R, 1995, BRIT MED J, V311, P1240, DOI 10.1136/bmj.311.7015.1240; Smith R, 1996, BRIT MED J, V313, P16, DOI 10.1136/bmj.313.7048.16; Vollmann J, 1996, BRIT MED J, V312, P578, DOI 10.1136/bmj.312.7030.578b; WEISS BD, 1982, JAMA-J AM MED ASSOC, V247, P2695, DOI 10.1001/jama.247.19.2695; WILKINS D, 1994, MED J AUSTRALIA, V160, P395, DOI 10.5694/j.1326-5377.1994.tb138261.x	19	25	25	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					624	626		10.1001/jama.278.8.624	http://dx.doi.org/10.1001/jama.278.8.624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR547	9272883				2022-12-28	WOS:A1997XR54700017
J	Christo, GG; Balasubramaniam, R				Christo, GG; Balasubramaniam, R			Advertising adversities - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							PHARMACEUTICAL ADVERTISEMENTS; MEDICAL JOURNALS											FLETCHER RH, 1992, ANN INTERN MED, V116, P951, DOI 10.7326/0003-4819-116-11-951; GORSKI TN, 1990, JAMA-J AM MED ASSOC, V263, P2177, DOI 10.1001/jama.1990.03440160039016; HERXHEIMER A, 1990, BRIT MED J, V300, P307, DOI 10.1136/bmj.300.6720.307; MOSER RH, 1977, ANN INTERN MED, V87, P114, DOI 10.7326/0003-4819-87-1-114; RELMAN AS, 1979, NEW ENGL J MED, V301, P999, DOI 10.1056/NEJM197911013011811; WADE VA, 1989, LANCET, V334, P1261; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; 1994, BRIT MED J, V308, P1692; 1894, JAMA-J AM MED ASSOC, V22, P958; 1993, PEDIATRICS, V92, P610	10	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					460	460		10.1136/bmj.315.7106.460	http://dx.doi.org/10.1136/bmj.315.7106.460			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284663	Green Published			2022-12-28	WOS:A1997XT71400018
J	Beltramo, M; Stella, N; Calignano, A; Lin, SY; Makriyannis, A; Piomelli, D				Beltramo, M; Stella, N; Calignano, A; Lin, SY; Makriyannis, A; Piomelli, D			Functional role of high-affinity anandamide transport, as revealed by selective inhibition	SCIENCE			English	Article							CANNABINOID RECEPTOR AGONIST; PHARMACOLOGICAL ACTIVITY; BRAIN CONSTITUENT; RAT-BRAIN; INVOLVEMENT; NEURONS; IDENTIFICATION; LOCALIZATION; PROTEIN; BINDING	Anandamide, an endogenous ligand for central cannabinoid receptors, is released from neurons on depolarization and rapidly inactivated. Anandamide inactivation is not completely understood, but it may occur by transport into cells or by enzymatic hydrolysis. The compound N-(4-hydroxyphenyl)arachidonylamide (AM404) was shown to inhibit high-affinity anandamide accumulation in rat neurons and astrocytes in vitro, an indication that this accumulation resulted from carrier-mediated transport. Although AM404 did not activate cannabinoid receptors or inhibit anandamide hydrolysis, it enhanced receptor-mediated anandamide responses in vitro and in vivo, The data indicate that carrier-mediated transport may be essential for termination of,the biological effects of anandamide, and may represent a potential drug target.	INST NEUROSCI,SAN DIEGO,CA 92121; UNIV NAPLES,SCH PHARM,I-80131 NAPLES,ITALY; UNIV CONNECTICUT,SCH PHARM,STORRS,CT 06269	University of Naples Federico II; University of Connecticut				CALIGNANO, Antonio/0000-0002-1742-3179				Barker Eric L., 1995, P321; Beltramo M, 1997, FEBS LETT, V403, P263, DOI 10.1016/S0014-5793(97)00061-6; BELTRAMO M, UNPUB; BITO LZ, 1976, J PHYSIOL-LONDON, V256, P257, DOI 10.1113/jphysiol.1976.sp011324; BITO LZ, 1975, NATURE, V256, P1234; Bojesen IN, 1996, ACTA PHYSIOL SCAND, V156, P501, DOI 10.1046/j.1365-201X.1996.456173000.x; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEWEY WL, 1986, PHARMACOL REV, V38, P151; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; Jung M, 1997, J NEUROCHEM, V68, P402; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Khanolkar AD, 1996, J MED CHEM, V39, P4515, DOI 10.1021/jm960152y; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; KUSTER JE, 1993, J PHARMACOL EXP THER, V264, P1352; MAKI R, 1994, J NEUROSCI, V14, P6754; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MECHOULAM R, 1994, BIOCHEM PHARMACOL, V48, P1537, DOI 10.1016/0006-2952(94)90197-X; PORRECA F, 1984, J PHARMACOL EXP THER, V230, P341; PREZEAU L, 1992, P NATL ACAD SCI USA, V89, P8040, DOI 10.1073/pnas.89.17.8040; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; STEIN WD, 1990, CHANNELS PUMPS INTRO, P53; STELLA N, 1995, J NEUROSCI, V15, P3307; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823	35	652	688	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1094	1097		10.1126/science.277.5329.1094	http://dx.doi.org/10.1126/science.277.5329.1094			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262477	Green Submitted			2022-12-28	WOS:A1997XT03300034
J	Matsunami, H; Buck, LB				Matsunami, H; Buck, LB			A multigene family encoding a diverse array of putative pheromone receptors in mammals	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; OLFACTORY EPITHELIUM; VOMERONASAL SYSTEM; ODORANT RECEPTORS; GENE-EXPRESSION; NEURONS; ORGANIZATION; TRANSDUCTION; INFORMATION; PROTEINS	The vomeronasal organ of mammals is an olfactory sensory structure that detects pheromones. It contains two subsets of sensory neurons that differentially express G alpha(o) and G alpha(i2). By comparing gene expression in single neurons, we identified a novel multigene family that codes for a diverse array of candidate pheromone receptors (VRs) expressed by the G alpha(o)(+) subset. Different VRs are expressed by different neurons, but those neurons are interspersed, suggesting a distributed mode of sensory coding. Chromosome mapping experiments suggest an evolutionary connection between genes encoding VRs and receptors for volatile odorants. However, a dramatically different structure for VRs and the existence of variant VR mRNA forms indicate that there are diverse strategies to detect functionally distinct sensory stimuli.			Matsunami, H (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROBIOL,BOSTON,MA 02115, USA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; AXEL R, 1995, SCI AM, V273, P154, DOI 10.1038/scientificamerican1095-154; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Berghard A, 1996, P NATL ACAD SCI USA, V93, P2365, DOI 10.1073/pnas.93.6.2365; Berghard A, 1996, J NEUROSCI, V16, P909; BRADY G, 1993, METHOD ENZYMOL, V225, P611; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BUCK LB, 1987, CELL, V51, P127, DOI 10.1016/0092-8674(87)90017-1; BUCK LB, 1995, CELL, V83, P349, DOI 10.1016/0092-8674(95)90110-8; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Firestein S, 1992, Curr Opin Neurobiol, V2, P444, DOI 10.1016/0959-4388(92)90178-N; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; Jia CP, 1996, BRAIN RES, V719, P117, DOI 10.1016/0006-8993(96)00110-2; KARLSON P, 1959, NATURE, V183, P55, DOI 10.1038/183055a0; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NOVOTNY M, 1990, CHEM SIGNAL, V5, P1; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RONNETT GV, 1992, TRENDS NEUROSCI, V15, P508, DOI 10.1016/0166-2236(92)90104-G; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; Segaloff D L, 1992, Oxf Rev Reprod Biol, V14, P141; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SINGER AG, 1991, J STEROID BIOCHEM, V39, P627, DOI 10.1016/0960-0760(91)90261-3; Sorensen PW, 1996, CHEM SENSES, V21, P245, DOI 10.1093/chemse/21.2.245; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Vogt R.G., 1987, P385; WILSON EO, 1963, SCI AM, V208, P100, DOI 10.1038/scientificamerican0563-100; Wu YM, 1996, BIOCHEM BIOPH RES CO, V220, P900, DOI 10.1006/bbrc.1996.0503; Wysocki C.J., 1987, P125	55	550	569	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					775	784		10.1016/S0092-8674(00)80537-1	http://dx.doi.org/10.1016/S0092-8674(00)80537-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288756	Bronze			2022-12-28	WOS:A1997XT06600020
J	Spitzer, NC; Sejnowski, TJ				Spitzer, NC; Sejnowski, TJ			Computational biology - Biological information processing: Bits of progress	SCIENCE			English	Editorial Material							MECHANISM		UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	University of California System; University of California San Diego; Howard Hughes Medical Institute; Salk Institute	Spitzer, NC (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Sejnowski, Terrence/AAV-5558-2021	Spitzer, Nicholas/0000-0002-3523-1103				ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERRIDGE MJ, 1979, J EXP BIOL, V81, P217; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Bezrukov SM, 1997, NATURE, V385, P319, DOI 10.1038/385319a0; BRABANT G, 1997, INT C BIOL INF PROC; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hartwell L, 1997, NATURE, V387, P855, DOI 10.1038/43072; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Prank K, 1996, BIOPHYS J, V70, P2540, DOI 10.1016/S0006-3495(96)79825-9; REINITZ J, 1995, MECH DEVELOP, V49, P133, DOI 10.1016/0925-4773(94)00310-J; Rieke F., 1997, SPIKES EXPLORING NEU	15	16	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1060	1061		10.1126/science.277.5329.1060	http://dx.doi.org/10.1126/science.277.5329.1060			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9289851				2022-12-28	WOS:A1997XT03300023
J	Kalkwarf, HJ; Specker, BL; Bianchi, DC; Ranz, J; Ho, M				Kalkwarf, HJ; Specker, BL; Bianchi, DC; Ranz, J; Ho, M			The effect of calcium supplementation on bone density during lactation and after weaning	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINERAL DENSITY; POSTMENOPAUSAL WOMEN; MASS; RECOVERY; MILK; HISTORY; MOTHERS; SPINE	Background Women may lose bone during lactation because of calcium lost in breast milk. We studied whether calcium supplementation prevents bone loss during lactation or augments bone gain after weaning. Methods We conducted two randomized, placebo-controlled trials of calcium supplementation (1 g per day) in postpartum women. In one trial (the study of lactation), 97 lactating and 99 nonlactating women were enrolled a mean (+/-SD) of 16+/-2 days post partum. In the second trial (the study of weaning), 95 lactating women who weaned their infants in the 2 months after enrollment and 92 nonlactating women were enrolled 5.6+/-0.8 months post partum. The bone density of the total body, lumbar spine, and forearm was measured at enrollment and after three and six months. Results The bone density of the lumbar spine decreased by 4.2 percent in the lactating women receiving calcium and by 4.9 percent in those receiving placebo and increased by 2.2 and 0.4 percent, respectively, in the nonlactating women (P<0.001 for the effect of lactation; P=0.01 for the effect of calcium). After weaning, the bone density of the lumbar spine increased by 5.9 percent in the lactating women receiving calcium and by 4.4 percent in those receiving placebo; it increased by 2.5 and 1.6 percent, respectively, in the nonlactating women (P<0.001 for the effects of lactation and calcium). There was no effect of either lactation or calcium supplementation on bone density in the forearm, and there was no effect of calcium supplementation on the calcium concentration in breast milk. Conclusions Calcium supplementation does not prevent bone loss during lactation and only slightly enhances the gain in bone density after weaning. (C) 1997, Massachusetts Medical Society.	CHILDRENS HOSP, MED CTR, DEPT PEDIAT, CINCINNATI, OH 45229 USA	Cincinnati Children's Hospital Medical Center				Specker, Bonny/0000-0003-4759-9957	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR008084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041366] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR 08084] Funding Source: Medline; NIAMS NIH HHS [R01 AR41366] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Affinito P, 1996, J CLIN ENDOCR METAB, V81, P2314, DOI 10.1210/jc.81.6.2314; CROSS NA, 1995, J BONE MINER RES, V10, P1312; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; DOBNIG H, 1995, J CLIN ENDOCR METAB, V80, P3699, DOI 10.1210/jc.80.12.3699; FELDBLUM PJ, 1992, EPIDEMIOLOGY, V3, P527, DOI 10.1097/00001648-199211000-00012; FOX KM, 1993, J BONE MINER RES, V8, P901; HAYSLIP CC, 1989, OBSTET GYNECOL, V73, P588; HOPKINSON J, 1995, FASEB J, V9, pA85; HRESHCHYSHYN MM, 1988, AM J OBSTET GYNECOL, V159, P318, DOI 10.1016/S0002-9378(88)80075-9; KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029-7844(95)00083-4; Kalkwarf HJ, 1996, AM J CLIN NUTR, V63, P526, DOI 10.1093/ajcn/63.4.526; KARRA MV, 1988, AM J CLIN NUTR, V47, P642, DOI 10.1093/ajcn/47.4.642; KENT GN, 1990, J BONE MINER RES, V5, P361, DOI 10.1002/jbmr.5650050409; KOETTING CA, 1988, AM J CLIN NUTR, V48, P1479, DOI 10.1093/ajcn/48.6.1479; KRITZSILVERSTEIN D, 1992, AM J EPIDEMIOL, V136, P1052, DOI 10.1093/oxfordjournals.aje.a116570; Lippuner K, 1996, J BONE MINER RES, V11, P1394; LISSNER L, 1991, CALCIFIED TISSUE INT, V48, P319, DOI 10.1007/BF02556151; Lopez JM, 1996, OSTEOPOROSIS INT, V6, P153, DOI 10.1007/BF01623940; MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P76, DOI 10.1007/BF01623377; MOSER PB, 1988, AM J CLIN NUTR, V47, P735, DOI 10.1093/ajcn/47.4.735; PRENTICE A, 1995, AM J CLIN NUTR, V62, P58, DOI 10.1093/ajcn/62.1.58; Sinigaglia L, 1996, J REPROD MED, V41, P439; SOWERS M, 1993, JAMA-J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130; Sowers MF, 1996, JAMA-J AM MED ASSOC, V276, P549, DOI 10.1001/jama.276.7.549; WALKER ARP, 1972, CLIN SCI, V42, P189, DOI 10.1042/cs0420189; WARDLAW GM, 1986, AM J CLIN NUTR, V44, P1002; WARDLAW GM, 1986, AM J CLIN NUTR, V44, P283, DOI 10.1093/ajcn/44.2.283	27	193	194	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					523	528		10.1056/NEJM199708213370803	http://dx.doi.org/10.1056/NEJM199708213370803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262495				2022-12-28	WOS:A1997XR54800003
J	Rivara, FP; Grossman, DC; Cummings, P				Rivara, FP; Grossman, DC; Cummings, P			Injury prevention .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHILD PEDESTRIAN INJURY; HELMET-USE-LAW; UNITED-STATES; MOTORCYCLE CRASHES; PUBLIC-POLICY; ALCOHOL-ABUSE; TRAUMA; RISK; INTERVENTIONS; FATALITIES		UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Rivara, FP (corresponding author), UNIV WASHINGTON,HARBORVIEW INJURY PREVENT & RES CTR,BOX 359960,325 9TH AVE,SEATTLE,WA 98104, USA.							BAKER SP, 1974, AM J PUBLIC HEALTH, V64, P318, DOI 10.2105/AJPH.64.4.318; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BERGER LR, 1984, PEDIATRICS, V74, P16; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BRADDOCK M, 1991, PEDIATRICS, V88, P1242; BREWER RD, 1994, NEW ENGL J MED, V331, P513, DOI 10.1056/NEJM199408253310806; Christoffel KK, 1996, PEDIATRICS, V97, P33; CHRISTOPHERSEN ER, 1982, PEDIATRICS, V70, P21; COTE TR, 1992, PEDIATRICS, V89, P1216; CRAIG GR, 1983, INJURY, V15, P163, DOI 10.1016/0020-1383(83)90005-0; Deery HA, 1996, ADDICTION, V91, P815, DOI 10.1046/j.1360-0443.1996.9168158.x; EVANS L, 1992, AM J PUBLIC HEALTH, V82, P1105, DOI 10.2105/AJPH.82.8.1105; EVANS L, 1990, ACCIDENT ANAL PREV, V22, P167, DOI 10.1016/0001-4575(90)90067-U; EVANS L, 1988, ACCIDENT ANAL PREV, V20, P447, DOI 10.1016/0001-4575(88)90043-7; FERGUSSON DM, 1982, PEDIATRICS, V69, P515; FLEMING NS, 1992, MED CARE, V30, P832, DOI 10.1097/00005650-199209000-00007; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; HADDON W, 1972, J TRAUM, V12, P193, DOI 10.1097/00005373-197203000-00002; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; HADDON W, 1961, J CHRON DIS, V14, P655, DOI 10.1016/0021-9681(61)90122-9; Henry MC, 1996, ANN EMERG MED, V28, P627, DOI 10.1016/S0196-0644(96)70085-9; HILLMAN M, 1991, ONE FALSE MOVE STUDY; Hingson R, 1996, AM J PUBLIC HEALTH, V86, P791, DOI 10.2105/AJPH.86.6.791; HOGUE CC, 1982, J AM GERIATR SOC, V30, P183, DOI 10.1111/j.1532-5415.1982.tb01302.x; HOXIE RE, 1994, J AM GERIATR SOC, V42, P241, DOI 10.1111/j.1532-5415.1994.tb01745.x; HUNT DK, 1995, AM J MED, V98, P343, DOI 10.1016/S0002-9343(99)80312-X; *INS I HIGHW SAF, 1996, STATUS REPORT INS I, V31; JOHNSON RM, 1995, J TRAUMA, V38, P876, DOI 10.1097/00005373-199506000-00008; Johnson SW, 1996, 808338 DOT HS; JOHNSTON C, 1994, PEDIATRICS, V93, P960; Kahane CJ, 1996, 808470 DOT HS; KARLSON TA, 1992, CRIT REV ENV CONTR, V22, P195, DOI 10.1080/10643389209388436; KELSEY SL, 1986, CALDMVRSS86106; KENDRICK D, 1993, ARCH DIS CHILD, V68, P669, DOI 10.1136/adc.68.5.669; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; KRAUS JF, 1995, J NEUROTRAUM, V12, P873, DOI 10.1089/neu.1995.12.873; LI GH, 1994, ACCIDENT ANAL PREV, V26, P543, DOI 10.1016/0001-4575(94)90045-0; MACKAY M, 1987, ADV TRAUMA, V2, P21; MUELLEMAN RL, 1992, ANN EMERG MED, V21, P266, DOI 10.1016/S0196-0644(05)80886-8; *NAT COMM INJ PREV, 1989, INJ PREV M CHALL, P115; *NAT CTR HLTH STAT, 1993, DHHS PHS; *NAT HIGHW TRAFF S, 1996, EFF OCC PROT SYST TH; *NAT HIGHW TRAFF S, 1995, TRAFF SAF FACTS 1995; *NAT RES COUNC, 1985, INJ AM CONT PUBL HLT; ORSAY E, 1995, ANN EMERG MED, V26, P455, DOI 10.1016/S0196-0644(95)70114-1; PEEK C, 1994, J TRAUMA, V37, P358; PERSSON J, 1989, ALCOHOL, V6, P403, DOI 10.1016/0741-8329(89)90011-6; PLESS IB, 1989, J PEDIATR-US, V115, P932, DOI 10.1016/S0022-3476(89)80745-0; *PREV SERV TASK FO, 1996, GUID CLIN PREV SERV, P651; Rice DP, 1989, COST INJURY US REPOR; RIVARA FP, 1985, PEDIATRICS, V76, P375; RIVARA FP, 1990, AM J DIS CHILD, V144, P692, DOI 10.1001/archpedi.1990.02150300090023; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; RIVARA FP, 1989, J TRAUMA, V29, P462, DOI 10.1097/00005373-198904000-00008; RIVARA FP, 1994, PEDIATRICS, V93, P567; ROBERTS I, 1994, NEW ZEAL MED J, V107, P331; ROBERTS I, 1995, BRIT MED J, V310, P91, DOI 10.1136/bmj.310.6972.91; ROBERTS I, 1994, AUST J PUBLIC HEALTH, V18, P209; Robertson L.S., 1983, INJURIES CAUSES CONT; Rowland J, 1996, AM J PUBLIC HEALTH, V86, P41, DOI 10.2105/AJPH.86.1.41; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; STEVENSON MR, 1995, INT J EPIDEMIOL, V24, P957, DOI 10.1093/ije/24.5.957; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC, 1996, EPIDEMIOLOGY SPORTS, P98; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Waller JA., 1985, INJURY CONTROL GUIDE; ZADOR PL, 1985, AM J PUBLIC HEALTH, V75, P543, DOI 10.2105/AJPH.75.5.543; 1991, MMWR-MORBID MORTAL W, V40, P600	70	131	141	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					543	548		10.1056/NEJM199708213370807	http://dx.doi.org/10.1056/NEJM199708213370807			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR548	9262499				2022-12-28	WOS:A1997XR54800007
J	Xu, ZH; Horwich, AL; Sigler, PB				Xu, ZH; Horwich, AL; Sigler, PB			The crystal structure of the asymmetric GroEL-GroES-(ADP)(7) chaperonin complex	NATURE			English	Article							ESCHERICHIA-COLI; GROEL; PROTEIN; BINDING; RELEASE; COOPERATIVITY; POLYPEPTIDE; AGGREGATION; HYDROLYSIS; MICROSCOPY	Chaperonins assist protein folding with the consumption of ATP. They exist as multi-subunit protein assemblies comprising rings of subunits stacked back to back. in Escherichia coli, asymmetric Intermediates of GroEL are formed with the co-chaperonin GroES and nucleotides bound only to one of the seven-subunit rings (the cis ring) and not to the opposing ring (the trans ring). The structure of the GroEL-GroES-(ADP), complex reveals how large en bloc movements of the cis ring's intermediate and apical domains enable bound GroES to stabilize a foiling chamber with ADP confined to the cis ring. Elevation and twist of the apical domains double the volume of the central cavity anal bury hydrophobic peptide-binding residues in the interface with GroES, as well as between GroEL subunits, leaving a hydrophilic cavity lining that is conducive to protein folding. An inward tilt of the cis equatorial domain causes an outward tilt in the trans ring that opposes the binding of a second GroES. When combined with new functional results, this negative allosteric mechanism suggests a model for an ATP-driven folding cycle that requires a double toroid.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR MOL MED,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University; Yale University								Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; ELLIS RJ, 1996, CHAPERONINS; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1992, FEBS LETT, V310, P99; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; LAMBRIGHT DG, 1994, NATURE, V369, P921; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIN S, 1995, J BIOL CHEM, V270, P1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; Thiyagarajan P, 1996, STRUCTURE, V4, P79, DOI 10.1016/S0969-2126(96)00011-1; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; TRUNGER AT, 1993, X PLOR VERSION 3 1 M; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; ZEILSTRARYALLS J, 1994, J BACTERIOL, V176, P6558, DOI 10.1128/JB.176.21.6558-6565.1994	59	989	1019	3	115	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					741	750		10.1038/41944	http://dx.doi.org/10.1038/41944			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285585				2022-12-28	WOS:A1997XR66700042
J	Bastian, LA; Piscitelli, JT				Bastian, LA; Piscitelli, JT			Is this patient pregnant? Can you reliably rule in or rule out early pregnancy by clinical examination?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TESTS; RELIABILITY	This review addresses a common problem facing the clinician: ''When treating or evaluating a woman of childbearing years, what is the value of historical or physical examination features in determining the probability of early pregnancy?'' We focus on the clinical examination findings that may help the clinician rule in or rule out early pregnancy. Generally accepted indicators of pregnancy include amenorrhea, morning sickness, tender or tingling breasts, and, after 8 weeks' gestational age, an enlarged uterus with a soft cervix. We reviewed the value tie, sensitivity and specificity) of these indicators, as well as home pregnancy test results, as predictors of the diagnosis of early pregnancy. The available evidence suggests that some historical features, when absent, are fair but not reliable for ruling out pregnancy. When diagnosing early pregnancy, the clinician should not rely on the clinical examination or a home pregnancy test-a laboratory test should be requested.	DUKE UNIV, MED CTR, DEPT INTERNAL MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT OBSTET & GYNECOL, DURHAM, NC 27710 USA; VET AFFAIRS MED CTR, WOMEN VET COMPREHENS HLTH CTR, DURHAM, NC 27705 USA	Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bastian, LA (corresponding author), VET AFFAIRS MED CTR, CTR HLTH SERV RES PRIMARY CARE, MAIL CODE 152, 508 FULTON ST, DURHAM, NC 27705 USA.							Bachmann G A, 1984, J Med Soc N J, V81, P857; BATES B, 1995, GUIDE PHYSICAL EXAMI; CAIOLA S M, 1992, American Pharmacy, V32, P57; CHADWICK JR, 1987, T AM GYNECOL SOC 188, V11, P399; Cunningham FG, 1997, WILIAMS OBSTET, V20th; DAVIAUD J, 1993, CLIN CHEM, V39, P53; DOSHI ML, 1986, AM J PUBLIC HEALTH, V76, P512, DOI 10.2105/AJPH.76.5.512; HIBBARD BM, 1971, BRIT MED J, V1, P593, DOI 10.1136/bmj.1.5749.593; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P1334; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; JENG LL, 1991, BIRTH-ISS PERINAT C, V18, P11, DOI 10.1111/j.1523-536X.1991.tb00046.x; LATMAN N S, 1989, Biomedical Instrumentation and Technology, V23, P144; MCDONALD E, 1908, AM J OBSTET DIS WOME, V57, P323; MEEKS GR, 1995, J REPROD MED, V40, P194; OCONNOR RE, 1993, AM J EMERG MED, V11, P434, DOI 10.1016/0735-6757(93)90186-F; RAMOSKA EA, 1989, ANN EMERG MED, V18, P48, DOI 10.1016/S0196-0644(89)80310-5; Robinson E T, 1977, J R Coll Gen Pract, V27, P335; SCOTT JR, 1994, DANFORTHS OBSTET GYN; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; STENGEL CL, 1994, ANN EMERG MED, V24, P697, DOI 10.1016/S0196-0644(94)70280-2; STOKES M, 1995, CATEGORICAL DATA ANA; Zabin LS, 1996, JAMA-J AM MED ASSOC, V275, P113, DOI 10.1001/jama.275.2.113	22	17	18	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					586	591		10.1001/jama.278.7.586	http://dx.doi.org/10.1001/jama.278.7.586			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268281				2022-12-28	WOS:A1997XQ98600034
J	Lowy, A; Willis, D; Abrams, K				Lowy, A; Willis, D; Abrams, K			Is histological examination of tissue removed by general practitioners always necessary? Before and after comparison of detection rates of serious skin lesions	BRITISH MEDICAL JOURNAL			English	Article							MINOR SURGERY; 1990 CONTRACT; GUIDELINES; BIOPSIES	Objectives: To examine whether histological examination of all tissue removed by general practitioners in minor surgery increases the rate of detection of clinically important skin lesions, and to assess the impact of such a policy on pathologists' workload. Design: Before and after comparison. Setting: Stratified random sample of 257 general practitioner partnerships from the catchment areas of 19 English pathology laboratories. Subjects: Tissue removed in minor surgery by general practitioners during the control period (September 1992 to February 1993) and intervention period (September 1993 to February 1994). Intervention: General practitioners referred to their local pathology laboratory all solid tissue removed in all minor surgery, irrespective of their previous policy. Main outcome measures: Numbers of specimens referred for histology by general practitioners during intervention and control periods; numbers of primary malignant melanomas, non-melanoma malignancies, premalignant lesions, and benign lesions. Results: 257/330 partnerships participated (response rate 78%). During the intervention period 5723 specimens were sent, compared with 4430 during the control period. The referral rate increased by an estimated 1.34 specimens per 1000 patient years (95% confidence interval 0.93 to 1.76, P<0.001). General practitioners sent 204 specimens that were malignant (including 16 malignant melanomas) in the control period and 188 that were malignant (including 15 malignant melanomas) during the intervention period (change in total number of malignancies, -1.0 per 100 000 patient years (-5.9 to 3.8, non-significant). Conclusions: The intervention was associated dth a substantial increase in laboratory workload, all of which was accounted for by increases in non-serious lesions. This observation should be taken into account when considering the merits of a policy requiring histological examination in every case.	GREENWOOD INST CHILD HLTH,LEICESTER LE3 0QU,LEICS,ENGLAND	University of Leicester	Lowy, A (corresponding author), UNIV LEICESTER,FAC MED,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 6TP,LEICS,ENGLAND.		Abrams, Keith/AAA-2557-2020	Abrams, Keith/0000-0002-7557-1567				BRIGGS M, 1984, BRIT MED J, V288, P983; BROOKS SC, 1981, BRIT MED J, V282, P607, DOI 10.1136/bmj.282.6264.607; COX NH, 1992, BRIT MED J, V304, P93, DOI 10.1136/bmj.304.6819.93; *DEP HLTH SCOTT HO, 1989, GEN PRACT NAT HLTH S; *GEN MED SERV COMM, 1996, MIN SURG GEN PRACT G; HILLAN KJ, 1991, BRIT MED J, V303, P1180, DOI 10.1136/bmj.303.6811.1180; LOWY A, 1994, BRIT J GEN PRACT, V44, P364; LOWY A, 1993, BRIT MED J, V307, P413, DOI 10.1136/bmj.307.6901.413; LOWY A, 1993, BRIT J GEN PRACT, V43, P478; MACKIE RM, 1992, BRIT MED J, V304, P1012, DOI 10.1136/bmj.304.6833.1012; MCWILLIAM LJ, 1991, BRIT MED J, V303, P1177, DOI 10.1136/bmj.303.6811.1177; OCATHAIN A, 1992, BRIT J GEN PRACT, V42, P13; OSHEA JP, 1992, ASS CLIN PATHOLOGIST; PARASKEVOPOULOS JA, 1988, J ROY SOC MED, V81, P583, DOI 10.1177/014107688808101010; *ROYAL COLL PATH, 1972, MED SCI STAFF NAT HL; SHORROCK K, 1993, J CLIN PATHOL, V46, P989, DOI 10.1136/jcp.46.11.989; SLATER D, 1990, BRIT MED J, V300, P1074, DOI 10.1136/bmj.300.6731.1074; STEPHENSON T, 1992, BRIT J HOSP MED, V48, P10; WHIMSTER WF, 1991, BRIT MED J, V303, P1149, DOI 10.1136/bmj.303.6811.1149; WILLIAMS RB, 1991, BRIT MED J, V303, P1179, DOI 10.1136/bmj.303.6811.1179	20	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					406	408		10.1136/bmj.315.7105.406	http://dx.doi.org/10.1136/bmj.315.7105.406			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277607	Green Submitted, Green Published			2022-12-28	WOS:A1997XR54900023
J	Palda, VA; Detsky, AS; Thibault, GE; Feussner, JR; Audet, AMJ; Freisinger, GC; Kent, DL; Marton, KI; Whyte, JJ; Winters, PL				Palda, VA; Detsky, AS; Thibault, GE; Feussner, JR; Audet, AMJ; Freisinger, GC; Kent, DL; Marton, KI; Whyte, JJ; Winters, PL			Clinical guideline .1. Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery	ANNALS OF INTERNAL MEDICINE			English	Article											Palda, VA (corresponding author), ST MICHAELS HOSP, 30 BOND ST, 4-151, TORONTO, ON M5B 1W8, CANADA.							CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Vanzetto G, 1996, AM J CARDIOL, V77, P143, DOI 10.1016/S0002-9149(96)90585-8	5	165	171	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					309	312		10.7326/0003-4819-127-4-199708150-00012	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265433				2022-12-28	WOS:A1997XR26600012
J	Little, P; Gould, C; Williamson, I; Warner, G; Gantley, M; Kinmonth, AL				Little, P; Gould, C; Williamson, I; Warner, G; Gantley, M; Kinmonth, AL			Reattendance and complications in a randomised trial of prescribing strategies for sore throat: the medicalising effect of prescribing antibiotics	BRITISH MEDICAL JOURNAL			English	Article							STREPTOCOCCAL PHARYNGITIS; DIAGNOSIS	Objective: To assess the medicalising effect of prescribing antibiotics for sore throat Setting: 11 general practices in England. Design: Randomised trial of three approaches to sore throat: a 10 day prescription of antibiotics, no antibiotics, or a delayed prescription if the sore throat had not started to settle after three days. Patients: 716 patients aged 4 and over with sore throat and an abnormal physical sign: 84% had tonsillitis or pharyngitis. Outcome measures: Number and rate of patients making a first return with sore throat, pharyngitis, or tonsillitis. Early returns (within two weeks) and complications (otitis media, sinusitis, quinsy). Outcomes were documented in 675 subjects (94%). Results: Mean follow up time was similar (antibiotic group 1.07 years, other two groups 1.03 years). More of those initially prescribed antibiotics initially returned to the surgery with sore throat (38% v 27%, adjusted hazard ratio for return 1.39, 95% confidence interval 1.03 to 1.89). Antibiotics prescribed for sore throat during the previous year had an additional effect (hazard ratio 1.69, 1.20 to 2.37). Longer duration of illness (> 5 days) was associated with increased return within six weeks (hazard ratio 2.90, 1.70 to 4.92). Prior attendance with upper respiratory conditions was also associated with increased reattendance. There was no difference between groups in early return (13/238 (5.5%) v 27/437 (6%)), or complications (2/236 (0.8%) v 3/434 (0.7%)). Conclusions: Complications and early return resulting from no or delayed prescribing of antibiotics for sore throat are rare. Both current and previous prescribing for sore throat increase reattendance. To avoid medicalising a self limiting illness doctors should avoid antibiotics or offer a delayed prescription for most patients with sore throat.	NIGHTINGALE SURG,ROMSEY SO16 5ST,HANTS,ENGLAND		Little, P (corresponding author), UNIV SOUTHAMPTON,FAC HLTH MED & BIOL SCI,ALDERMOOR HLTH CTR,SOUTHAMPTON SO16 5ST,HANTS,ENGLAND.			Little, Paul/0000-0003-3664-1873	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BREESE BB, 1977, AM J DIS CHILD, V131, P514, DOI 10.1001/archpedi.1977.02120180028003; Centor R M, 1981, Med Decis Making, V1, P239, DOI 10.1177/0272989X8100100304; CHANCELLOR AHB, 1965, ANN GEN PRACT, V10, P88; DELMAR C, 1992, MED J AUSTRALIA, V156, P572, DOI 10.5694/j.1326-5377.1992.tb121422.x; DELMAR C, 1992, MED J AUSTRALIA, V156, P644, DOI 10.5694/j.1326-5377.1992.tb121463.x; HERZ MJ, 1988, FAM PRACT, V5, P196, DOI 10.1093/fampra/5.3.196; Little P, 1996, FAM PRACT, V13, P317, DOI 10.1093/fampra/13.3.317; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Office of Population Censuses and Surveys, 1994, MORB STAT GEN PRACT; SCAMBLER G, 1991, SOCIOLOGY APPL MED, P33; SHULMAN ST, 1994, PEDIATR INFECT DIS J, V13, P1, DOI 10.1097/00006454-199401000-00002; 1995, DRUGS THERAPEUTICS B, V33, P9	12	289	297	12	23	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					350	352						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270458				2022-12-28	WOS:A1997XQ86400023
J	Ginsburg, J				Ginsburg, J			Unanswered questions in carcinoma of the testis	LANCET			English	Editorial Material									UCL, SCH MED, LONDON NW3 2QG, ENGLAND	University of London; University College London; UCL Medical School	Ginsburg, J (corresponding author), ROYAL FREE HOSP, JOINT UNIV DEPT MED, POND ST, LONDON NW3 2QG, ENGLAND.							BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298	1	7	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1785	1786		10.1016/S0140-6736(05)61688-1	http://dx.doi.org/10.1016/S0140-6736(05)61688-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269209				2022-12-28	WOS:A1997XF73500005
J	Wang, PH				Wang, PH			When should ACE inhibitors be given to normotensive patients with IDDM	LANCET			English	Editorial Material							DISEASE				Wang, PH (corresponding author), UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92697, USA.							*DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y	5	20	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1782	1783		10.1016/S0140-6736(97)22025-8	http://dx.doi.org/10.1016/S0140-6736(97)22025-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269206				2022-12-28	WOS:A1997XF73500002
J	Genbacev, O; Zhou, Y; Ludlow, JW; Fisher, SJ				Genbacev, O; Zhou, Y; Ludlow, JW; Fisher, SJ			Regulation of human placental development by oxygen tension	SCIENCE			English	Article							CYTOTROPHOBLASTS; EXPRESSION; TROPHOBLAST; INVASION; PROTEINS; TUMORS; CELLS	Cytotrophoblasts, specialized placental cells, proliferate early in pregnancy and then differentiate into tumor-like cells that establish blood flow to the placenta by invading the uterus and its vasculature. In this study, cytotrophoblasts cultured under hypoxic conditions (2 percent oxygen), mimicking the environment near the uterine surface before 10 weeks of gestation, continued proliferating and differentiated poorly. When cultured in 20 percent oxygen, mimicking the environment near uterine arterioles, the cells stopped proliferating and differentiated normally. Thus, oxygen tension determines whether cytotrophoblasts proliferate or invade, thereby regulating placental growth and cellular architecture.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV ROCHESTER,CTR CANC,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14642	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Rochester					NCI NIH HHS [CA 56904] Funding Source: Medline; NICHD NIH HHS [HD30367] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD030367] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Boyd J D, 1967, J Obstet Gynaecol Br Commonw, V74, P161; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAMSKY CH, 1994, DEVELOPMENT, V120, P3657; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; Fisher S J, 1993, Semin Cell Biol, V4, P183, DOI 10.1006/scel.1993.1022; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; GENBACEV O, 1992, PLACENTA, V13, P439, DOI 10.1016/0143-4004(92)90051-T; Genbacev O, 1996, J CLIN INVEST, V97, P540, DOI 10.1172/JCI118447; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hertig A.T., 1942, ANAT REC, V82, P420; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KURMAN RJ, 1984, INT J GYNECOL PATHOL, V3, P101, DOI 10.1097/00004347-198403010-00009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; MCMASTER MT, 1995, J IMMUNOL, V154, P3771; RODESCH F, 1992, OBSTET GYNECOL, V80, P283; SCHWARTING R, 1993, LAB INVEST, V68, P597; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316	22	691	738	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1669	1672		10.1126/science.277.5332.1669	http://dx.doi.org/10.1126/science.277.5332.1669			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287221				2022-12-28	WOS:A1997XV68400052
J	Gulick, RM; Mellors, JW; Havlir, D; Eron, JJ; Gonzalez, C; McMahon, D; Richman, DD; Valentine, FT; Jonas, L; Meibohm, A; Emini, EA; Chodakewitz, JA				Gulick, RM; Mellors, JW; Havlir, D; Eron, JJ; Gonzalez, C; McMahon, D; Richman, DD; Valentine, FT; Jonas, L; Meibohm, A; Emini, EA; Chodakewitz, JA			Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	XIth International Conference on AIDS	JUL 07-13, 1996	VANCOUVER, CANADA				TYPE-1 PROTEASE INHIBITOR; HIV-1 RNA LEVELS; CUBIC MILLIMETER; RESISTANCE; PLASMA; RITONAVIR; AIDS; ZALCITABINE; PROGRESSION; MUTATION	Background The new protease inhibitors are potent inhibitors of the human immunodeficiency virus (HIV), and in combination with other antiretroviral drugs they may be able to cause profound and sustained suppression of HIV replication. Methods In this double-blind study, 97 HIV-infected patients who had received zidovudine treatment for at least 6 months and had 50 to 400 CD4 cells per cubic millimeter and at least 20,000 copies of HIV RNA per milliliter were randomly assigned to one of three treatments for up to 52 weeks: 800 mg of indinavir every eight hours; 200 mg of zidovudine every eight hours combined with 150 mg of lamivudine twice daily; or all three drugs. The patients were followed to monitor the occurrence of adverse events and changes in viral load and CD4 cell counts. Results The decrease in HIV RNA over the first 24 weeks was greater in the three-drug group than in the other groups (P < 0.001 for each comparison). RNA levels decreased to less than 500 copies per milliliter at week 24 in 28 of 31 patients in the three-drug group (90 percent), 12 of 28 patients in the indinavir group (43 percent), and none of 30 patients in the zidovudine-lamivudine group. The increase in CD4 cell counts over the first 24 weeks was greater in the two groups receiving indinavir than in the zidoviadine-lamivudine group (P less than or equal to 0.01 for each comparison). The changes in the viral load and the CD4 cell count persisted for up to 52 weeks. All the regimens were generally well tolerated. Conclusions In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year. (C) 1997, Massachuselts Medical Society.	UNIV PITTSBURGH, PITTSBURGH, PA USA; VET AFFAIRS MED CTR, PITTSBURGH, PA USA; UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; MERCK RES LABS, W POINT, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill; Merck & Company	Gulick, RM (corresponding author), NYU MED CTR, SCH MED, DEPT MED, 550 1ST AVE, NEW YORK, NY 10016 USA.			Valentine, Fred/0000-0002-6046-5913	NIAID NIH HHS [N01-AI-27670, P30-AI-27742, U01-AI-27665] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027665, U01AI027670, P30AI027742] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; BUCKTON KE, 1967, NATURE, V214, P470, DOI 10.1038/214470a0; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; CRIXIVAN, 1997, PHYSICIANS DESK REFE, P1670; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DAWSON JD, 1991, J ACQ IMMUN DEF SYND, V4, P667; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056; Kuritzkes DR, 1996, AIDS, V10, P975, DOI 10.1097/00002030-199610090-00007; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MELLORS J, 1995, 35 INT C ANT AG CHEM, P235; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; STASZEWSKI S, 1996, 11 INT C AIDS VANC B, P21; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; [No title captured]	32	1530	1577	1	50	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					734	739		10.1056/NEJM199709113371102	http://dx.doi.org/10.1056/NEJM199709113371102			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287228	Green Submitted			2022-12-28	WOS:A1997XV17400002
J	Chen, X; Weisberg, E; Fridmacher, V; Watanabe, M; Naco, G; Whitman, M				Chen, X; Weisberg, E; Fridmacher, V; Watanabe, M; Naco, G; Whitman, M			Smad4 and FAST-1 in the assembly of activin-responsive factor	NATURE			English	Article							MESODERM INDUCTION; MAD PROTEINS; BETA; RECEPTORS; FAMILY	Members of the TGF-beta superfamily of signalling molecules work by activating transmembrane receptors with phosphorylating activity (serine-threonine kinase receptors)(1); these in turn phosphorylate and activate(2) SMADs(3,4), a class of signal transducers. Activins are growth factors that act primarily through Smad2(5-7), possibly in partnership with Smad4, which forms heteromeric complexes with different ligand-specific SMADs after activation(8,9). In frog embryos, Smad2 participates in an activin-responsive factor (ARF), which then binds to a promoter element of the Mix.2 gene(10). The principal DNA-binding component of ARF is FAST-1 (ref. 11), a transcription factor with a novel winged-helix structure. We now report that Smad4 is present in ARF, and that FAST-1, Smad4 and Smad2 co-immunoprecipitate in a ligand-regulated fashion. We have mapped the site of interaction between FAST-1 and Smad2/Smad4 to a novel carboxyterminal domain of FAST-1, and find that overexpression of this domain specifically inhibits activin signalling. In a yeast two-hybrid assay,the FAST-1 carboxy terminus interacts with Smad2 but not Smad4. Deletion mutants of the FAST-1 carboxy terminus that still participate in ligand-regulated Smad2 binding no longer associated with Smad4 or ARF. These results indicate that Smad4 stabilizes a ligand-stimulated Smad2-FAST-1 complex as an active DNA-binding factor.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								Bartel P. L., 1993, CELLULAR INTERACTION, P153; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	17	484	500	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					85	89		10.1038/38008	http://dx.doi.org/10.1038/38008			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288972				2022-12-28	WOS:A1997XU59600050
J	GomisRuth, FX; Maskos, K; Betz, M; Bergner, A; Huber, R; Suzuki, K; Yoshida, N; Nagase, H; Brew, K; Bourenkov, GP; Bartunik, H; Bode, W				GomisRuth, FX; Maskos, K; Betz, M; Bergner, A; Huber, R; Suzuki, K; Yoshida, N; Nagase, H; Brew, K; Bourenkov, GP; Bartunik, H; Bode, W			Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1	NATURE			English	Article							HUMAN-TISSUE INHIBITOR; CATALYTIC DOMAIN; TERMINAL DOMAIN; 3-DIMENSIONAL STRUCTURE; COLLAGENASES; HYDROXAMATE; SUPERFAMILY; ACTIVATION; ASTACINS; PROTEIN	Matrix metalloproteinases (MMPs) are zinc endopeptidases that are required for the degradation of extracellular matrix components during normal embryo development, morphogenesis and tissue remodelling(1). Their proteolytic activities are precisely regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs)(1-5). Disruption of this balance results in diseases such as arthritis, atherosclerosis, tumour growth and metastasis(1,2). Here we report the crystal structure of an MMP-TIMP complex formed between the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1. TIMP-1, a 184-residue protein(5), has the shape of an elongated, contiguous wedge. With its long edge, consisting of five different chain regions, it occupies the entire length of the active-site cleft of MMP-3. The central disulphide-linked segments Cys 1-Thr 2-Cys 3-Val 4 and Ser 68-Val 69 bind to either side of the catalytic zinc. Cys 1 bidentally coordinates this zinc, and the Thr-2 side chain extends into the large specificity pocket of MMP-3. This unusual architecture of the interface between MMP-3 and TIMP-1 suggests new possibilities for designing TIMP variants and synthetic MMP inhibitors with potential therapeutic applications.	MAX PLANCK INST BIOCHEM,ABT STRUKTURFORSCH,D-82152 MARTINSRIED,GERMANY; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOL BIOL,KANSAS CITY,KS 66160; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOL BIOL,MIAMI,FL 33101; DESY,AG PROT DYNAM MPG ASMB,D-22603 HAMBURG,GERMANY	Max Planck Society; University of Kansas; University of Kansas Medical Center; University of Miami; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Brew, Keith/W-1643-2019; Brew, Keith/A-6746-2009; Bourenkov, Gleb P/C-7794-2017	Brew, Keith/0000-0003-1306-1032; Bourenkov, Gleb P/0000-0002-2617-5920; Bergner, Andreas/0000-0002-5843-4325; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; Brunger AT, 1991, CURR OPIN STRUC BIOL, V1, P1016, DOI 10.1016/0959-440X(91)90100-8; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; COWTAN K, 1994, JOINT CCP4 ESF EACBM, V31; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nagase H, 1996, ZINC METALLOPROTEASE, P153; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1996, DENZO FILM PROCESSIN; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; ROUSSEL A, 1989, TURBO FRODO SILICON; STOCKER W, 1995, PROTEIN SCI, V4, P823; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK E, 1994, AM J RESP CRIT CARE, V150, P5165; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; [No title captured]	30	480	495	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					77	81		10.1038/37995	http://dx.doi.org/10.1038/37995			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288970				2022-12-28	WOS:A1997XU59600048
J	Simonneau, G; Sors, H; Charbonnier, B; Page, Y; Laaban, JP; Azarian, R; Laurent, M; Hirsch, JL; Ferrari, E; Bosson, JL; Mottier, D; Beau, B				Simonneau, G; Sors, H; Charbonnier, B; Page, Y; Laaban, JP; Azarian, R; Laurent, M; Hirsch, JL; Ferrari, E; Bosson, JL; Mottier, D; Beau, B			A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP VENOUS THROMBOSIS; RANDOMIZED TRIAL; VEIN THROMBOSIS; METAANALYSIS; PERFUSION; THERAPY; HOME	Background Low-molecular-weight heparin appears to be at least as effective and safe as standard, unfractionated heparin for the treatment of deep-vein thrombosis, but only limited data are available on the use of low-molecular-weight heparin to treat acute symptomatic pulmonary embolism. Methods We randomly assigned 612 patients with symptomatic pulmonary embolism who did not require thrombolytic therapy or embolectomy to either subcutaneous low-molecular-weight heparin (tinzaparin) given once daily in a fixed dose or adjusted-dose, intravenous unfractionated heparin. Oral anticoagulant therapy was begun between the first and the third day and was given for at least three months. We compared the treatments at day 8 and day 90 with respect to a combined end point of recurrent thromboembolism, major bleeding, and death. Results In the first eight days of treatment, 9 of 308 patients assigned to receive unfractionated heparin (2.9 percent) reached at least one of the end points, as compared with 9 of 304 patients assigned to low-molecular-weight heparin (3.0 percent; absolute difference, 0.1 percentage point; 95 percent confidence interval, -2.7 to 2.6). By day 90, 22 patients assigned to unfractionated heparin (7.1 percent) and 18 patients assigned to low-molecular-weight heparin (5.9 percent) had reached at least one end point (P=0.54; absolute difference, 1.2 percentage points; 95 percent confidence interval, -2.7 to 5.1). The risk of major bleeding was similar in the two treatment groups throughout the study. Conclusions Under the conditions of this study, initial subcutaneous therapy with the low-molecular-weight heparin tinzaparin appeared to be as effective and safe as intravenous unfractionated heparin in patients with acute pulmonary embolism. (C) 1997, Massachusetts Medical Society.	HOP LAENNEC, F-75340 PARIS, FRANCE; HOP TROUSSEAU, TOURS, FRANCE; HOP BELLEVUE, ST ETIENNE, FRANCE; HOP HOTEL DIEU, PARIS, FRANCE; HOP ANDRE MIGNOT, VERSAILLES, FRANCE; HOP HOTEL DIEU, RENNES, FRANCE; HOP HENRI DUFFAUT, AVIGNON, FRANCE; HOP LOUIS PASTEUR, F-06002 NICE, FRANCE; HOP UNIV GRENOBLE, GRENOBLE, FRANCE; HOP CAVALE BLANCHE, BREST, FRANCE; LEO PHARMACEUT PROD, St Quentin en Yvelines, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; CHU Tours; CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier de Versailles; CHU Rennes; CHU Nice; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Brest; Universite de Bretagne Occidentale	Simonneau, G (corresponding author), HOP ANTOINE BECLERE, SERV PNEUMOL & REANIMAT, 157 RUE PORTE TRIVAUX, F-92141 CLAMART, FRANCE.		bosson, jean-luc/AAP-5163-2020; Simonneau, Gerald/ABE-6614-2020	bosson, jean-luc/0000-0003-0967-6026; 				BARRITT DW, 1960, LANCET, V1, P1309; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; HIRSH J, 1992, BLOOD, V79, P1; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; HYERS TM, 1995, CHEST, V108, pS335, DOI 10.1378/chest.108.4_Supplement.335S; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Meyer G, 1995, THROMB HAEMOSTASIS, V74, P1432; MEYER G, 1990, EUR J NUCL MED, V17, P315, DOI 10.1007/BF01268022; MONREAL M, 1989, CHEST, V95, P976, DOI 10.1378/chest.95.5.976; Siragusa S, 1996, AM J MED, V100, P269, DOI 10.1016/S0002-9343(97)89484-3; STEIN PD, 1994, ANN INTERN MED, V121, P313, DOI 10.7326/0003-4819-121-5-199409010-00001; The urokinase pulmonary embolism trial, 1973, CIRCULATION, V47, pII1; THERY C, 1992, CIRCULATION, V85, P1380, DOI 10.1161/01.CIR.85.4.1380; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753	18	626	641	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					663	669		10.1056/NEJM199709043371002	http://dx.doi.org/10.1056/NEJM199709043371002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU349	9278462				2022-12-28	WOS:A1997XU34900002
J	Weitz, JI				Weitz, JI			Low-molecular-weight heparins	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DEEP-VEIN THROMBOSIS; SPINAL-CORD INJURY; TOTAL HIP-REPLACEMENT; LOW-DOSE HEPARIN; FACTOR PATHWAY INHIBITOR; ACUTE ISCHEMIC STROKE; UNFRACTIONATED HEPARIN; VENOUS THROMBOSIS; STANDARD HEPARIN; INDUCED THROMBOCYTOPENIA		MCMASTER UNIV, HAMILTON, ON, CANADA	McMaster University	Weitz, JI (corresponding author), HAMILTON CIV HOSP, RES CTR, 711 CONCESS ST, HAMILTON, ON L8V 1C3, CANADA.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				ABILDGAARD U, 1991, HAEMOSTASIS, V21, P254; AMIRAL J, 1995, THROMB HAEMOSTASIS, V73, P21; ANDERSON DR, 1993, ANN INTERN MED, V119, P1105, DOI 10.7326/0003-4819-119-11-199312010-00008; BARA L, 1985, THROMB RES, V39, P631, DOI 10.1016/0049-3848(85)90244-0; Bara L, 1988, Acta Chir Scand Suppl, V543, P65; BARROWCLIFFE TW, 1984, THROMB RES, V34, P125, DOI 10.1016/0049-3848(84)90069-0; Barsotti J, 1990, J Orthop Trauma, V4, P371, DOI 10.1097/00005131-199012000-00001; BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; BEGUIN S, 1989, THROMB HAEMOSTASIS, V61, P30; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; BERGQVIST D, 1993, SEMIN THROMB HEMOST, V19, P147; BJORNSSON TD, 1982, CLIN PHARMACOL THER, V31, P104, DOI 10.1038/clpt.1982.16; BLAJCHMAN MA, 1989, ANN NY ACAD SCI, V556, P245; BONEU B, 1993, BLOOD COAGUL FIBRIN, V4, pS21; Braunwald E, 1997, J AM COLL CARDIOL, V29, P1474; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; CADROY Y, 1991, THROMB RES, V63, P385, DOI 10.1016/0049-3848(91)90141-I; Cairns JA, 1996, CIRCULATION, V94, P1553, DOI 10.1161/01.CIR.94.7.1553; CARTER CJ, 1982, BLOOD, V59, P1239; CHONG BH, 1989, BLOOD, V73, P1592; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DAHAN R, 1986, HAEMOSTASIS, V16, P159; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DECHAVANNE M, 1989, HAEMOSTASIS, V19, P5; DEROMEUF C, 1993, THROMB HAEMOSTASIS, V69, P436; EDMONDSON, 1994, LANCET, V344, P1307; EDMONDSON RA, 1994, LANCET, V344, P914, DOI 10.1016/S0140-6736(94)92269-1; FAREED J, 1988, HAEMOSTASIS, V18, P3; FAREED J, 1988, HAEMOSTASIS, V18, pA389; FAXON DP, 1994, CIRCULATION, V90, P908, DOI 10.1161/01.CIR.90.2.908; FORESTIER F, 1984, THROMB RES, V34, P557, DOI 10.1016/0049-3848(84)90260-3; FRIEDMAN RJ, 1994, J BONE JOINT SURG AM, V76A, P1174; FRISBIE JH, 1981, PARAPLEGIA, V19, P343, DOI 10.1038/sc.1981.65; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; *GERM HIP ARTHR TR, 1992, ARCH ORTHOP TRAUMA S, V111, P110; GREEN D, 1990, ANN INTERN MED, V113, P571, DOI 10.7326/0003-4819-113-8-571; GREEN D, 1982, PARAPLEGIA, V20, P227, DOI 10.1038/sc.1982.41; GREEN D, 1988, JAMA-J AM MED ASSOC, V260, P1255, DOI 10.1001/jama.260.9.1255; GREEN D, 1994, CHEST SA, V102, pS649; GURFINKEL EP, 1995, J AM COLL CARDIOL, V26, P313, DOI 10.1016/0735-1097(95)80001-W; Hamulyak K, 1995, THROMB HAEMOSTASIS, V74, P1428; HANDELAND GF, 1990, EUR J CLIN PHARMACOL, V39, P107, DOI 10.1007/BF00280041; HARENBERG J, 1990, THROMB RES, V59, P639, DOI 10.1016/0049-3848(90)90422-9; HARENBERG J, 1990, SEMIN THROMB HEMOST, V16, P12; Heit JA, 1997, THROMB HAEMOSTASIS, V77, P32; HIRSH J, 1976, CIRCULATION, V53, P691, DOI 10.1161/01.CIR.53.4.691; HOLST J, 1994, BLOOD COAGUL FIBRIN, V5, P795, DOI 10.1097/00001721-199410000-00018; HORELLOU MH, 1984, THROMB HAEMOSTASIS, V51, P134; HORNE MK, 1990, BRIT J HAEMATOL, V74, P306, DOI 10.1111/j.1365-2141.1990.tb02588.x; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; IMPERIALE TF, 1995, JAMA-J AM MED ASSOC, V273, P288; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KAKKAR VV, 1993, LANCET, V341, P259, DOI 10.1016/0140-6736(93)92614-Y; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Klein W., 1996, European Heart Journal, V17, P306; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Lane D. A., 1989, HEPARIN CHEM BIOL PR, P363; Leclerc JR, 1996, ANN INTERN MED, V124, P619, DOI 10.7326/0003-4819-124-7-199604010-00001; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; LEROY J, 1985, SEMIN THROMB HEMOST, V11, P326, DOI 10.1055/s-2007-1004387; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Marder VJ., 1994, HEMOSTASIS THROMBOSI, P837; MATZSCH T, 1987, THROMB HAEMOSTASIS, V57, P97; MELISSARI E, 1992, THROMB HAEMOSTASIS, V68, P652; MENZIN J, 1995, ARCH INTERN MED, V155, P757, DOI 10.1001/archinte.155.7.757; MERLI GJ, 1992, PARAPLEGIA, V30, P558, DOI 10.1038/sc.1992.115; MONREAL M, 1994, THROMB HAEMOSTASIS, V71, P7; MOSKOVITZ PA, 1978, J BONE JOINT SURG AM, V60, P1065, DOI 10.2106/00004623-197860080-00008; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OBRIEN BJ, 1994, CAN MED ASSOC J, V150, P1083; OFOSU FA, 1989, BIOCHEM J, V257, P143, DOI 10.1042/bj2570143; PINI M, 1994, THROMB HAEMOSTASIS, V72, P191; POWERS PJ, 1989, ARCH INTERN MED, V149, P771, DOI 10.1001/archinte.149.4.771; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; PRINS MH, 1989, HAEMOSTASIS, V19, P245; SALZMAN EW, 1980, J CLIN INVEST, V65, P64, DOI 10.1172/JCI109661; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SANDSET PM, 1990, SEMIN THROMB HEMOST, V16, P25; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; Siragusa S, 1996, AM J MED, V100, P269, DOI 10.1016/S0002-9343(97)89484-3; SOBEL M, 1991, J CLIN INVEST, V87, P1787, DOI 10.1172/JCI115198; SPIRO TE, 1994, BLOOD, V84, pA246; SPIRO TE, 1994, ANN INTERN MED, V121, P81, DOI 10.7326/0003-4819-121-2-199407150-00001; tenCate JW, 1997, NEW ENGL J MED, V337, P657; TORHOLM C, 1991, J BONE JOINT SURG BR, V73, P434, DOI 10.1302/0301-620X.73B3.1670445; TURPIE AGG, 1991, THROMB HAEMOSTASIS, V65, P753; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; VANRYNMCKENNA J, 1990, THROMB HAEMOSTASIS, V63, P271; VITOUX JF, 1986, THROMB HAEMOSTASIS, V55, P37; Wallentin L, 1996, LANCET, V347, P561; WARING WP, 1991, PARAPLEGIA, V29, P8, DOI 10.1038/sc.1991.2; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; YOUNG E, 1994, THROMB HAEMOSTASIS, V71, P300; YOUNG E, 1993, THROMB HAEMOSTASIS, V70, P625; YOUNG E, 1992, THROMB HAEMOSTASIS, V67, P639	103	1144	1184	1	93	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					688	698		10.1056/NEJM199709043371007	http://dx.doi.org/10.1056/NEJM199709043371007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU349	9278467				2022-12-28	WOS:A1997XU34900007
J	Dunn, MR; Miller, RS				Dunn, MR; Miller, RS			US graduate medical education, 1996-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN WORKFORCE	Workforce planners continue to be concerned that unlimited growth in graduate medical education (GME)-principally fueled by unrestrained federal support-will lead to a physician surplus. Because of this concern, in 1996 six major professional organizations called for a reduction in Medicare support of GME to bring residency training programs into more rational alignment with population needs. As of July 1, 1997, no final action had been taken by Congress to limit GME funding, although extensive discussions are under way. Even without governmental restrictions, the American Medical Association's annual survey of GME programs showed a reduction in the numbers of first-year residents in most major specialties and subspecialties. Minor reductions were initially noticed last year; now, the decreases are significant. Nearly all the specialties that had difficulty placing their graduates for 2 consecutive years also reported at least 10% fewer first-year residents than in 1994. More importantly, disciplines without employment difficulties also reported downsizing. The overall effect of these first-year reductions is easily masked by the addition of programs in new disciplines and some residents staying in the GME system longer. Entry-level reductions appear to be broader and more extensive than can be explained by market forces alone.			Dunn, MR (corresponding author), AMER MED ASSOC,DIV GRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							Barzansky B, 1996, JAMA-J AM MED ASSOC, V276, P714, DOI 10.1001/jama.276.9.714; BILBERGER AB, 1988, HLTH AFF MILLWOOD S, P121; *COUNC GRAD MED ED, 1994, 4 REP REC IMPR ACC H; Dunn MR, 1996, JAMA-J AM MED ASSOC, V276, P710, DOI 10.1001/jama.276.9.710; *I MED, 1996, NAT PHYS WORKF OPT B; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; Miller RS, 1997, JAMA-J AM MED ASSOC, V277, P1699, DOI 10.1001/jama.277.21.1699; MITKA M, 1997, AM MED NEWS, V40, P5; MITKA M, 1997, AM MED NEWS     0224, V40, P1; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; *NAT RES MATCH PRO, 1997, NRMP DAT; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; RANDOLPH L, 1996, PHYSICIAN CHARACTERI; SEIFER SD, 1995, JAMA-J AM MED ASSOC, V274, P685, DOI 10.1001/jama.274.9.685	14	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					750	754		10.1001/jama.278.9.750	http://dx.doi.org/10.1001/jama.278.9.750			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286836				2022-12-28	WOS:A1997XT70900029
J	AgerholmLarsen, B; TybjaergHansen, A; FrikkeSchmidt, R; Gronholdt, MLM; Jensen, G; Nordestgaard, BG				AgerholmLarsen, B; TybjaergHansen, A; FrikkeSchmidt, R; Gronholdt, MLM; Jensen, G; Nordestgaard, BG			ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article						polymorphism (genetics); peptidyl-dipeptidase A; cerebrovascular disorders; cerebral ischemia; cerebral ischemia, transient	ANGIOTENSIN-CONVERTING-ENZYME; INSERTION DELETION POLYMORPHISM; MYOCARDIAL-INFARCTION; STROKE; JAPANESE	Background: Researchers have suggested that the deletional allele of the ACE (angiotensin-converting enzyme) gene insertion-deletion polymorphism is a potent risk factor for myocardial infarction. This association could not be confirmed in the Copenhagen City Heart Study, in which 10 150 persons were studied. The ACE gene polymorphism has also recently been suggested as a potent risk factor for ischemic cerebrovascular disease. Objective: To investigate the association between ACE gene polymorphism and ischemic cerebrovascular disease. Design: Two case-referent studies and a cross-sectional study. Setting: University hospital in Copenhagen, Denmark. Participants: Case-referent study 1: 35 women and 38 men who developed ischemic cerebrovascular disease before 50 years of age compared with 1454 women and 1737 men from a general population sample. Case-referent study 2: 82 women and 137 men with ischemic cerebrovascular disease and carotid stenosis greater than 40% compared with 4273 women and 3091 men from the general population sample. Cross-sectional study of the general population sample: 67 women and 93 men with ischemic cerebrovascular disease compared with 4077 women and 3156 men without such disease. Measurements: Genotype; age; body mass index; smoking habits; levels of lipids, lipoproteins, apolipoproteins, and fibrinogen; and diagnosis of hypertension, diabetes mellitus, and ischemic cerebrovascular disease. Results: Odds ratios for ischemic cerebrovascular disease by ACE genotype classes were not significantly different from 1.0 in women or men in any of the three studies, separately or combined. In a logistic regression analysis that controlled for age and conventional cardiovascular risk factors, odds ratios in either sex still did not significantly differ from 1.0 in any study, separately or combined. Conclusion: In two case-referent studies, a cross-sectional study, and the three studies combined, no statistically significant difference was found in the development of ischemic cerebrovascular disease between genotype classes of the ACE gene polymorphism in women or men.	HERLEV UNIV HOSP, DEPT CLIN BIOCHEM, DK-2730 HERLEV, DENMARK; UNIV COPENHAGEN, NATL HOSP, DEPT VASC SURG, DK-2100 COPENHAGEN, DENMARK; UNIV COPENHAGEN, COPENHAGEN, DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; University of Copenhagen			Nordestgaard, Borge Gronne/ABF-1310-2020	Frikke-Schmidt, Ruth/0000-0003-4084-5027				AgerholmLarsen B, 1997, CIRCULATION, V95, P2358, DOI 10.1161/01.CIR.95.10.2358; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Catto A, 1996, STROKE, V27, P435, DOI 10.1161/01.STR.27.3.435; ERDOS EG, 1987, LAB INVEST, V56, P345; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; Kario K, 1996, CIRCULATION, V93, P1630, DOI 10.1161/01.CIR.93.9.1630; LACHURIE ML, 1995, CIRCULATION, V91, P2933, DOI 10.1161/01.CIR.91.12.2933; LEE EJD, 1994, BRIT J CLIN PHARMACO, V37, P212, DOI 10.1111/j.1365-2125.1994.tb04264.x; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; Margaglione M, 1996, ARTERIOSCL THROM VAS, V16, P304, DOI 10.1161/01.ATV.16.2.304; MARKUS HS, 1995, STROKE, V26, P1329, DOI 10.1161/01.STR.26.8.1329; NAKAI K, 1994, CIRCULATION, V90, P2199, DOI 10.1161/01.CIR.90.5.2199; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708; *SPSS WIND, 1993, ADV STAT, P1; *SPSS WIND, 1993, BAS SYST US GUID; TALMUD P, 1991, ATHEROSCLEROSIS, V89, P137, DOI 10.1016/0021-9150(91)90053-6; TIRET L, 1992, AM J HUM GENET, V51, P197; Winkelmann BR, 1996, ANN INTERN MED, V125, P19, DOI 10.7326/0003-4819-125-1-199607010-00004; 1989, SCAND J SOC MED S, V41, P1	22	53	54	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					346	+		10.7326/0003-4819-127-5-199709010-00002	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273825				2022-12-28	WOS:A1997XU10000002
J	BoltonMaggs, PHB; Moon, I				BoltonMaggs, PHB; Moon, I			Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines	LANCET			English	Article							LONG-TERM FOLLOW; THERAPY	Background Guidelines for management of acute immune thrombocytopenic purpura (ITP) in childhood were published in 1992. Regional audit in 1995 showed substantial variation in clinical practice not related to clinical differences in patient groups, which indicated a need for national audit. Methods Individuals aged from birth to their 16th birthday newly presenting with ITP were identified over 14 months by regular mailing of paediatricians and haematologists for case notification. Information was obtained from follow-up by a detailed questionnaire. Findings ITP was clinically mild and benign in 323 (76%) of 427 cases, including 181 (70%) of 260 cases with platelet counts below 10x10(9)/L. There were no deaths or intracranial haemorrhages. There was a substantial discrepancy between clinical practice and published guidelines: many children were admitted to hospital and received treatment unnecessarily; there was overuse of intravenous immunoglobulin (IVIg) as first-line therapy (94 children); children received steroids without marrow examination; and there was inappropriate use of platelet transfusions (41 with mild or moderate disease). Interpretation Our results indicate a need for change in practice.			BoltonMaggs, PHB (corresponding author), ALDER HEY CHILDRENS HOSP,DEPT HAEMATOL,LIVERPOOL L12 2AP,MERSEYSIDE,ENGLAND.							BLANCHERRE VS, 1985, ROYAL SOC MED INT C, V84, P71; BLANCHETTE VS, 1993, J PEDIATR-US, V123, P989, DOI 10.1016/S0022-3476(05)80400-7; BOLTONMAGGS PHB, 1995, THROMB HAEMOSTASIS, V73, P1069; BUCHANAN GR, 1987, EUR J PEDIATR, V146, P107, DOI 10.1007/BF02343213; Buchanan GR, 1997, BLOOD, V89, P1464, DOI 10.1182/blood.V89.4.1464; CHESSELLS J, 1989, ARCH DIS CHILD, V64, P1326, DOI 10.1136/adc.64.9.1326; DUHEM C, 1994, CLIN EXP IMMUNOL, V97, P79; EDEN OB, 1992, ARCH DIS CHILD, V67, P1056, DOI 10.1136/adc.67.8.1056; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; HALPERIN DS, 1988, AM J DIS CHILD, V142, P508, DOI 10.1001/archpedi.1988.02150050046027; LILLEYMAN JS, 1994, ARCH DIS CHILD, V71, P251, DOI 10.1136/adc.71.3.251; MCELFRESH AE, 1975, J PEDIATR-US, V87, P160, DOI 10.1016/S0022-3476(75)80110-7; REID MM, 1992, ACTA PAEDIATR, V81, P1052, DOI 10.1111/j.1651-2227.1992.tb12175.x; REID MM, 1995, ARCH DIS CHILD, V72, P125, DOI 10.1136/adc.72.2.125; SEKUL EA, 1994, ANN INTERN MED, V121, P259, DOI 10.7326/0003-4819-121-4-199408150-00004; TAMARY H, 1994, ACTA PAEDIATR, V83, P931, DOI 10.1111/j.1651-2227.1994.tb13175.x; WALKER RW, 1984, ARCH DIS CHILD, V59, P316, DOI 10.1136/adc.59.4.316	17	149	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					620	623		10.1016/S0140-6736(97)04143-3	http://dx.doi.org/10.1016/S0140-6736(97)04143-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288044				2022-12-28	WOS:A1997XU28300009
J	Schroll, M				Schroll, M			Effects of systematic geriatric assessment	LANCET			English	Editorial Material											Schroll, M (corresponding author), UNIV COPENHAGEN,DEPT GERIATR MED,KOMMUNEHOSP,DK-1399 COPENHAGEN,DENMARK.							CHALLIS DJ, 1996, ASSESSMENT CONTINUIN; Fries BE, 1997, J AM GERIATR SOC, V45, P994, DOI 10.1111/j.1532-5415.1997.tb02972.x; Hawes C., 1997, J AM GERIATR SOC, V45, P997; Mor V, 1997, J AM GERIATR SOC, V45, P1002, DOI 10.1111/j.1532-5415.1997.tb02973.x; Morris JN, 1997, J AM GERIATR SOC, V45, P1011, DOI 10.1111/j.1532-5415.1997.tb02974.x; Morris JN, 1997, J AM GERIATR SOC, V45, P1017, DOI 10.1111/j.1532-5415.1997.tb02975.x; Phillips CD, 1997, J AM GERIATR SOC, V45, P986, DOI 10.1111/j.1532-5415.1997.tb02971.x; 1997, AGE AGEING S2, V26	8	5	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					604	605		10.1016/S0140-6736(05)63321-1	http://dx.doi.org/10.1016/S0140-6736(05)63321-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU283	9288039				2022-12-28	WOS:A1997XU28300004
J	vantHof, AWJ; Liem, A; deBoer, MJ; Zijlstra, F				vantHof, AWJ; Liem, A; deBoer, MJ; Zijlstra, F			Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction	LANCET			English	Article							LEFT-VENTRICULAR FUNCTION; PRIMARY CORONARY ANGIOPLASTY; INTRAVENOUS STREPTOKINASE; SUCCESSFUL THROMBOLYSIS; RANDOMIZED TRIAL; ARTERY PATENCY; SIZE; PREDICTOR; ELEVATION; INTERVENTION	Background A simple clinical method to stratify risk for patients who have had successful reperfusion therapy after myocardial infarction is attractive since it facilitates the tailoring of therapy. Methods We investigated the clinical value of the 12-lead electrocardiogram (EGG), in 403 patients after successful reperfusion therapy by primary coronary angioplasty, in relation to infarct size measured by enzyme activity, left-ventricular function, and clinical outcome. ECGs were analysed to find the extent of the ST-segment-elevation resolution 1 h after reperfusion therapy. Findings A normalised ST segment was seen in 51% of patients, a partly normalised ST segment in 34%, and 15% had no ST-segment-elevation resolution. Enzymatic infarct size and ejection fraction were related to the extent of the early resolution of the ST segment. The relative risk of death among patients with no resolution compared with patients with a normalised ST segment was 8.7 (95% CI 3.7-20.1), and that among patients with partial resolution compared with patients with a normalised ST segment was 3.6 (1.6-8.3). Interpretation Our findings suggest that ECG patterns reflect the effectiveness of myocardial reperfusion. Patients for whom reperfusion therapy by primary angioplasty was successful and who had normalised ST segments had limited damage to the myocardium and an excellent outlook during follow-up. Patients with persistent ST elevation after reperfusion therapy may need additional interventions since they have more extensive myocardial damage and have a higher mortality rate.	ZIEKENHUIS WEEZENLANDEN, DEPT CARDIOL, NL-8011 JW ZWOLLE, NETHERLANDS				de Boer, M.J./H-8014-2014					BARBASH GI, 1990, BRIT HEART J, V64, P241; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CLEMMENSEN P, 1990, AM J CARDIOL, V66, P1407, DOI 10.1016/0002-9149(90)90524-5; COX DR, 1972, J R STAT SOC B, V34, P187; DEBOER MJ, 1994, CIRCULATION, V90, P753, DOI 10.1161/01.CIR.90.2.753; DEBOER MJ, 1995, EUR HEART J, V16, P1347, DOI 10.1093/oxfordjournals.eurheartj.a060741; DEZWAAN C, 1988, BRIT HEART J, V59, P175; FERRARI R, 1995, AM J CARDIOL, V76, pB17; *FIBR THER TRIAL F, 1994, LANCET, V43, P311; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HASCHE ET, 1995, CIRCULATION, V92, P710, DOI 10.1161/01.CIR.92.4.710; Hashimoto A, 1996, AM J CARDIOL, V77, P25, DOI 10.1016/S0002-9149(97)89129-1; HERMENS WT, 1992, LANCET, V340, P1297, DOI 10.1016/0140-6736(92)93003-6; Iliceto S, 1996, AM J CARDIOL, V77, P441, DOI 10.1016/S0002-9149(97)89334-4; ITO H, 1992, CIRCULATION, V85, P1699, DOI 10.1161/01.CIR.85.5.1699; Ito H, 1996, CIRCULATION, V93, P223, DOI 10.1161/01.CIR.93.2.223; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klootwijk P, 1996, EUR HEART J, V17, P689; MAES A, 1995, CIRCULATION, V92, P2072, DOI 10.1161/01.CIR.92.8.2072; MAURI F, 1994, J AM COLL CARDIOL, V24, P600, DOI 10.1016/0735-1097(94)90003-5; OHMAN EM, 1994, CIRCULATION, V90, P792, DOI 10.1161/01.CIR.90.2.792; Raitt MH, 1996, CIRCULATION, V93, P48, DOI 10.1161/01.CIR.93.1.48; RENTROP KP, 1995, J AM COLL CARDIOL, V25, pS1; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P203; SCHRODER R, 1994, J AM COLL CARDIOL, V24, P384, DOI 10.1016/0735-1097(94)90292-5; VANDERLAARSE A, 1986, AM HEART J, V112, P672, DOI 10.1016/0002-8703(86)90460-6; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WONG PHC, 1994, CATHETER CARDIO DIAG, V33, P39, DOI 10.1002/ccd.1810330111; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	32	478	484	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					615	619		10.1016/S0140-6736(96)07120-6	http://dx.doi.org/10.1016/S0140-6736(96)07120-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288043				2022-12-28	WOS:A1997XU28300008
J	Wardlaw, JM; Warlow, CP; Counsell, C				Wardlaw, JM; Warlow, CP; Counsell, C			Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke	LANCET			English	Article							ACUTE ISCHEMIC STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; STREPTOKINASE; TRIALS; INFARCTION	Background Recent trials of thrombolytic therapy in acute ischaemic stroke have given apparently conflicting results. Only one trial, the National Institute of Neurological Disorders and Stroke trial of tissue plasminogen activator (tPA), suggested that thrombolysis was definitely beneficial, To make sense of these results, we have done a systematic review of all available randomised trials of thrombolysis in acute ischaemic stroke. Methods From all available completed randomised trials of thrombolytic therapy compared with control in acute ischaemic stroke (with prerandomisation CT), we checked tabular data on deaths during roughly the first 2 weeks, deaths from all causes and functional outcome (disability) at the end of the trial follow-up period, and early symptomatic and fatal intracranial haemorrhages. Findings 12 trials included 3435 patients, of whom 694 (20%) were dead and 1001 (39%) of 2567 were functionally dependent at the end of follow-up (duration of follow-up varied between trials, but the longest was 6 months). 214 (6%) of the 3435 patients had early symptomatic or fatal intracranial haemorrhages. Thrombolytic therapy was associated with a significant excess of early deaths (91 per 1000 patients treated [95% CI 54-134]), and total deaths (37 per 1000 [20-83]), but there was nevertheless a significant reduction in the number of patients in the combined outcome of dead or dependent (65 fewer per 1000 patients treated [28-107]). There was a substantial and significant excess of symptomatic and fatal intracranial haemorrhages with thrombolysis-which was similar in all recent trials-of about 70 extra symptomatic intracranial haemorrhages per 1000 patients treated (of which 51 per 1000 were fatal), In the cohort of patients randomised within 3 h of stroke, there was a significant reduction in the number of patients who were dead or dependent al the end of follow-up (141 fewer dead or dependent per 1000 patients treated [75-206] and a non-significant increase in the number dead (nine per 1000 treated [-39 to 70]). There was significant heterogeneity between the trials for total deaths at the end of follow-up, which may be partly explained by differences in the use of antithrombotic drugs within the first 24 h of thrombolysis; the variation in severity of strokes included: the time window to thrombolytic treatment; and the dose of thrombolytic drug used. There were no direct comparisons of tPA with streptokinase or urokinase: much of the poor outcome in the streptokinase-treated patients might be explained by the inclusion of more severe strokes, greater use of antithrombotic drugs, higher doses, and the longer time to treatment compared with the trials that used tPA. Interpretation Thrombolysis requires further testing in large randomised trials because the risks seem substantial, and the benefit uncertain. The time window for effective treatment remains unclear. There is no objective evidence to suggest that tPA is safer than streptokinase; the apparent hazards and benefits may be similar when differences in trial design and baseline variables are accounted for.	UNIV EDINBURGH, DEPT CLIN NEUROSCI, EDINBURGH, MIDLOTHIAN, SCOTLAND	University of Edinburgh			Hernandez, María/GYU-3543-2022; Wardlaw, Joanna M/Y-3456-2019	Wardlaw, Joanna M/0000-0002-9812-6642	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abe T, 1986, Folia Haematol Int Mag Klin Morphol Blutforsch, V113, P122; Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Araki G., 1985, CLIN EVAL, V13, P659; Bogousslavsky J, 1996, CEREBROVASC DIS, V6, P315; CANDELISE L, 1995, LANCET, V346, P1509; DAVIS SM, 1996, CEREBROVASC DIS, V6, P188; DELZOPPO G, 1996, CEREBROVASC DIS, V6, P184; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; *EMS BRIDG TRIAL I, 1996, CEREBROVASC DIS, V6, P184; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; Hommel M, 1996, NEW ENGL J MED, V335, P145; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; *MAST IT INV, 1996, CEREBROVASC DIS, V6, P183; MEYER JS, 1963, NEUROLOGY, V13, P927, DOI 10.1212/WNL.13.11.927; MEYER JS, 1964, JAMA-J AM MED ASSOC, V189, P373; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; MORRIS AD, 1995, QJM-MON J ASSOC PHYS, V88, P727; MOTTO C, 1996, CEREBROVASC DIS, V6, P129; Muir KW, 1996, LANCET, V347, P391, DOI 10.1016/S0140-6736(96)90568-1; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Naito I., 1981, BLOOD VESSELS, V12, P321, DOI 10.2491/jjsth1970.12.321; OHTOMO E, 1985, CLIN EVAL, V15, P711; PANG SQ, 1993, CHIN J NEUROL PSYCHI, V26, P229; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; Sandercock P, 1997, LANCET, V349, P1569; SHAHAR E, 1995, LANCET, V345, P578, DOI 10.1016/S0140-6736(95)90484-0; Sharp SJ, 1996, BRIT MED J, V313, P735; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; SUSSMAN BJ, 1958, JAMA-J AM MED ASSOC, V167, P1705, DOI 10.1001/jama.1958.02990310011002; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205; WARDLAW JM, 1994, J NEUROL NEUROSUR PS, V57, P255, DOI 10.1136/jnnp.57.2.255; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; WARDLAW JM, 1997, STROKE MODULE COCHRA; XIANG WH, 1995, P 4 CHIN STROK C CHE, P149; XIANG ZY, 1995, P 4 CHIN STROK C CHE, P44; Yamaguchi T., 1993, THROMBOLYTIC THERAPY, P59	40	218	230	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					607	614		10.1016/S0140-6736(97)03022-5	http://dx.doi.org/10.1016/S0140-6736(97)03022-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288042				2022-12-28	WOS:A1997XU28300007
J	Hoet, P; Graf, MLM; Bourdi, M; Pohl, LR; Duray, PH; Chen, WQ; Peter, RM; Nelson, SD; Verlinden, N; Lison, D				Hoet, P; Graf, MLM; Bourdi, M; Pohl, LR; Duray, PH; Chen, WQ; Peter, RM; Nelson, SD; Verlinden, N; Lison, D			Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons	LANCET			English	Article							HALOTHANE-ASSOCIATED HEPATITIS; ANTIBODIES; HEPATOTOXICITY; 1,1-DICHLORO-2,2,2-TRIFLUOROETHANE; HEPATOCYTES; METABOLISM; EXPOSURE; HCFC-123; SERA	Background Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs). Limited studies in animals indicate potential hepatotoxicity of some of these compounds. We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC, 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124). All nine exposed workers were affected to various degrees. Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane. We aimed to test whether HCFCs 123 and 124 can result in serious liver disease. Methods For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done. The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome-P450 2E1 (P450 2E1) and P58 protein disulphide isomerase isoform (P58). Findings The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis). Trifluoroacetyl-adducted proteins were detected in surviving hepatocytes. Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers. Interpretation Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population. Although the exact mechanism of hepatotoxicity of these agents is not known, the results suggest that trifluoroacetyl-altered liver proteins are involved. In view of the potentially widespread use of these compounds, there is an urgent need to develop safer alternatives.	NHLBI,MOL & CELLULAR TOXICOL SECT,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892; NCI,DEPT PATHOL,NIH,BETHESDA,MD 20892; JOHNS HOPKINS MED INST,DEPT ANESTHESIOL & CRIT CARE MED,BALTIMORE,MD 21205; UNIV WASHINGTON,SCH PHARM,DEPT MED CHEM,SEATTLE,WA 98195	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine; University of Washington; University of Washington Seattle	Hoet, P (corresponding author), UNIV CATHOLIQUE LOUVAIN,FAC MED,IND TOXICOL & OCCUPAT MED UNIT,CLOS CHAPELLE AUX CHAMPS 30-54,B-1200 BRUSSELS,BELGIUM.		Lison, Dominique/A-8985-2010	Lison, Dominique/0000-0001-6557-2518	NIGMS NIH HHS [GM 32165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032165] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bourdi M, 1996, CHEM RES TOXICOL, V9, P1159, DOI 10.1021/tx960083q; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Dekant W, 1996, ENVIRON HEALTH PERSP, V104, P75, DOI 10.2307/3432698; Eliasson E, 1996, MOL PHARMACOL, V50, P573; HARRIS JW, 1992, CHEM RES TOXICOL, V5, P720, DOI 10.1021/tx00029a020; KENNA JG, 1988, J PHARMACOL EXP THER, V245, P1103; KENNA JG, 1987, J PHARMACOL EXP THER, V242, P733; LIND RC, 1995, TOXICOL APPL PHARM, V134, P175, DOI 10.1006/taap.1995.1182; MARIT GB, 1994, TOXICOL PATHOL, V22, P404, DOI 10.1177/019262339402200406; MARTIN JL, 1992, ANESTH ANALG, V74, P605; MARTIN JL, 1993, BIOCHEM PHARMACOL, V46, P1247, DOI 10.1016/0006-2952(93)90474-B; RUSCH GM, 1994, FUND APPL TOXICOL, V23, P169, DOI 10.1006/faat.1994.1095; SATOH H, 1985, J PHARMACOL EXP THER, V233, P857; URBAN G, 1994, CHEM RES TOXICOL, V7, P170, DOI 10.1021/tx00038a009; VERGANI D, 1980, NEW ENGL J MED, V303, P66, DOI 10.1056/NEJM198007103030202; WHO, 1992, ENV HLTH CRIT, V139; YIN HQ, 1995, P NATL ACAD SCI USA, V92, P11076, DOI 10.1073/pnas.92.24.11076	17	62	68	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					556	559		10.1016/S0140-6736(97)03094-8	http://dx.doi.org/10.1016/S0140-6736(97)03094-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284778	hybrid			2022-12-28	WOS:A1997XT22100011
J	Herrada, G; Dulac, C				Herrada, G; Dulac, C			A novel family of putative pheromone receptors in mammals with a topographically organized and sexually dimorphic distribution	CELL			English	Article							ACCESSORY OLFACTORY-BULB; VOMERONASAL SYSTEM; DIFFERENTIAL LOCALIZATION; CA2+-SENSING RECEPTOR; GLUTAMATE RECEPTOR; G-PROTEINS; EXPRESSION; EPITHELIUM; RAT; BINDING	Mammals have retained two functionally and anatomically independent collections of olfactory neurons located in the main olfactory epithelium and in the vomeronasal organ (VNO). Pheromones activate the VNO in order to elicit fixed action behaviors and neuroendocrine changes involved in animal reproduction and aggression. Differential screening of cDNA libraries constructed from individual rat VNO neurons has led to the isolation of a novel family of similar to 100 genes encoding seven transmembrane receptors with sequence similarity with Ca2+-sensing and metabotropic glutamate receptors. These genes are likely to encode a novel family of pheromone receptors. Patterns of receptor gene expression suggest that the VNO is organized into discrete and sexually dimorphic functional units that may permit segregation of pheromone signals leading to specific arrays of behaviors and neuroendocrine responses.			Herrada, G (corresponding author), HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOL BIOL,CAMBRIDGE,MA 02138, USA.			Dulac, Catherine/0000-0001-5024-5418				Berghard A, 1996, J NEUROSCI, V16, P909; Berliner DL, 1996, J STEROID BIOCHEM, V58, P259, DOI 10.1016/0960-0760(96)00062-3; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HENZEL WJ, 1988, J BIOL CHEM, V263, P16682; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; Humphrey T, 1940, J COMP NEUROL, V73, P431, DOI 10.1002/cne.900730305; ICHIKAWA M, 1994, DEV BRAIN RES, V78, P1, DOI 10.1016/0165-3806(94)90002-7; IMAMURA K, 1985, BRAIN RES, V328, P362, DOI 10.1016/0006-8993(85)91050-9; JACOBSON L, 1811, ANN MUS HIST NAT PAR, V18, P412; JIANG XC, 1990, J BIOL CHEM, V265, P8736; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LIMAN ER, 1996, NEUROBIOLOGY, V6, P487; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MELROSE DR, 1971, BRIT VET J, V127, P497, DOI 10.1016/S0007-1935(17)37337-2; MENZIES RA, 1992, PHYSIOL BEHAV, V52, P741, DOI 10.1016/0031-9384(92)90408-T; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1987, BRAIN RES, V408, P215, DOI 10.1016/0006-8993(87)90375-1; MURPHY MR, 1970, SCIENCE, V167, P302, DOI 10.1126/science.167.3916.302; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Rasmussen LEL, 1996, NATURE, V379, P684, DOI 10.1038/379684a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHELLER RH, 1982, CELL, V28, P707, DOI 10.1016/0092-8674(82)90050-2; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SHINOHARA H, 1992, ACTA ANAT, V144, P167; SINGER AG, 1986, J BIOL CHEM, V261, P3323; SORENSEN PW, 1988, BIOL REPROD, V39, P1039, DOI 10.1095/biolreprod39.5.1039; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4348; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILSON E, 1963, PHEROMONES SCI AM, V5, P2; WYSOCKI CJ, 1989, NEURAL CONTROL REPRO, P545	47	559	581	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					763	773		10.1016/S0092-8674(00)80536-X	http://dx.doi.org/10.1016/S0092-8674(00)80536-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288755	Bronze			2022-12-28	WOS:A1997XT06600019
J	Smith, MW; Dean, M; Carrington, M; Winkler, C; Huttley, GA; Lomb, DA; Goedert, JJ; OBrien, TR; Jacobson, LP; Kaslow, R; Buchbinder, S; Vittinghoff, E; Vlahov, D; Hoots, K; Hilgartner, MW; OBrien, SJ				Smith, MW; Dean, M; Carrington, M; Winkler, C; Huttley, GA; Lomb, DA; Goedert, JJ; OBrien, TR; Jacobson, LP; Kaslow, R; Buchbinder, S; Vittinghoff, E; Vlahov, D; Hoots, K; Hilgartner, MW; OBrien, SJ			Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MULTICENTER AIDS COHORT; IN-VITRO; CELLS; HEMOPHILIA	The critical role of chemokine receptors (CCR5 and CXCR4) in human immunodeficiency virus-type 1 (HIV-1) infection and pathogenesis prompted a search for polymorphisms in other chemokine receptor genes that mediate HIV-1 disease progression, A mutation (CCR2-64I) within the first transmembrane region of the CCR2 chemokine and HIV-1 receptor gene is described that occurred at an allele frequency of 10 to 15 percent among Caucasians and African Americans. Genetic association analysis of five acquired immunodeficiency syndrome (AIDS) cohorts (3003 patients) revealed that although CCR2-64I exerts no influence on the incidence of HIV-1 infection, HIV-1-infected individuals carrying the CCR2-64I allele progressed to AIDS 2 to 4 years later than individuals homozygous for the common allele. Because CCR2-64I occurs invariably on a CCR5-+-bearing chromosomal haplotype, the independent effects of CCR5-Delta 32 (which also delays AIDS onset) and CCR2-64I were determined. An estimated 38 to 45 percent of AIDS patients whose disease progresses rapidly (less than 3 years until onset of AIDS symptoms after HIV-1 exposure) can be attributed to their CCR2-+/+ or CCR5-+/+ genotype, whereas the survival of 28 to 29 percent of long-term survivors, who avoid AIDS for 16 years or more, can be explained by a mutant genotype for CCR2 or CCR5.	NCI,VIRAL EPIDEMIOL BRANCH,BETHESDA,MD 20892; NCI,SCI APPLICAT INT CORP FREDERICK,FREDERICK,MD 21702; NCI,LAB GENOM DIVERS,FREDERICK,MD 21702; JOHNS HOPKINS MED INST,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; UNIV ALABAMA,DEPT EPIDEMIOL,BIRMINGHAM,AL 35294; DEPT PUBL HLTH,AIDS OFF,SAN FRANCISCO,CA 94102; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT INTERNAL MED,HOUSTON,TX 77030; CORNELL UNIV,MED CTR,NEW YORK HOSP,DIV PEDIAT HEMATOL & ONCOL,NEW YORK,NY 10021	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas System; Cornell University; NewYork-Presbyterian Hospital			Smith, Michael/B-5341-2012; OBRIEN, STEPHEN/ABD-1346-2020; Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Huttley, Gavin A/G-5169-2015	Dean, Michael C/0000-0003-2234-0631; Huttley, Gavin A/0000-0001-7224-2074; Jacobson, Lisa P./0000-0003-1722-6826; OBRIEN, STEPHEN/0000-0001-7857-0757				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; *CDC, 1987, MORB MORT WKLY RE S1, V36; *CDC, 1992, MORB MORT WKLY REP, V41; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cohen J, 1997, SCIENCE, V275, P1261, DOI 10.1126/science.275.5304.1261; COLLMAN R, 1992, J VIROL, V66, P7515; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CONNER RI, 1993, J VIROL, V68, P4400; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Detels R, 1996, AIDS, V10, P102, DOI 10.1097/00002030-199601000-00016; DITTMAR MT, 1997, NATURE, V385, P496; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRADE JMR, IN PRESS J CLIN INVE; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HILGARTNER MW, 1993, AM J PEDIAT HEMATOL, V15, P208; Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; Koot M, 1996, J INFECT DIS, V173, P349, DOI 10.1093/infdis/173.2.349; KRONER BL, 1995, AIDS, V9, P275, DOI 10.1097/00002030-199509030-00009; LEDERMAN MM, 1995, J INFECT DIS, V172, P228, DOI 10.1093/infdis/172.1.228; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUI KJ, 1988, SCIENCE, V240, P1333, DOI 10.1126/science.3163848; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; RAAS MTL, 1992, J INFECT DIS, V165, P427; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; *SAS I, PROP HAZ REGR SAS RE; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; STEPHENS J, UNPUB; Theodorou I, 1997, LANCET, V349, P1219; Unutmaz D, 1997, P NATL ACAD SCI USA, V94, P1615, DOI 10.1073/pnas.94.5.1615; VLAHOV D, 1991, NIDA RES MONOGRAPH S, V103; Wang J., COMMUNICATION; Weiss RA, 1996, SCIENCE, V272, P1885, DOI 10.1126/science.272.5270.1885; Wilkinson D, 1996, CURR BIOL, V6, P1051, DOI 10.1016/S0960-9822(02)70661-1; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; ZHAO T, 1993, SCIENCE, V261, P1179; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	63	756	806	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					959	965		10.1126/science.277.5328.959	http://dx.doi.org/10.1126/science.277.5328.959			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252328				2022-12-28	WOS:A1997XQ98500043
J	Shankaran, S; Papile, LA; Wright, LL; Ehrenkranz, RA; Mele, L; Lemons, JA; Korones, SB; Stevenson, DK; Donovan, EF; Stoll, BJ; Fanaroff, AA; Oh, W				Shankaran, S; Papile, LA; Wright, LL; Ehrenkranz, RA; Mele, L; Lemons, JA; Korones, SB; Stevenson, DK; Donovan, EF; Stoll, BJ; Fanaroff, AA; Oh, W			The effect of antenatal phenobarbital therapy on neonatal intracranial hemorrhage in preterm infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH-WEIGHT INFANTS; INTRAVENTRICULAR HEMORRHAGE; INTRACEREBRAL HEMORRHAGE; PREVENTION; NEWBORN; TRIAL; LESS	Background The administration of phenobarbital to pregnant women before delivery has been thought to decrease the frequency of intracranial hemorrhage in preterm infants. To evaluate this potential neuroprotective therapy further, we determined the effect of antenatal administration of phenobarbital on the frequency of neonatal intracranial hemorrhage and early death. Methods We studied 610 women who were 24 to 33 weeks pregnant and who were expected to deliver their infants within 24 hours. The women were randomly assigned to receive either phenobarbital (10 mg per kilogram of body weight) or placebo intravenously, followed by maintenance doses until delivery or 34 weeks of gestation. The infants born to these women underwent cranial ultrasonography to detect the presence of intracranial hemorrhage. Results There were 309 women in the phenobarbital group and 301 in the placebo group. A total of 247 women (80 percent) in the phenobarbital group and 235 (78 percent) in the placebo group delivered within 24 hours after infusion of the study drug or administration of the last maintenance dose, Intracranial hemorrhage or early death occurred in 83 of the 344 infants born to the women in the phenobarbital group (24 percent) and in 74 of the 324 born to the women in the placebo group (23 percent; risk ratio for the infants in the phenobarbital group, 1.1; 95 percent confidence interval, 0.8 to 1.4), Among infants born before 34 weeks' gestation in whom ultrasonographic studies were performed, intracranial hemorrhage was diagnosed in 70 of 311 infants in the phenobarbital group (23 percent) and 64 of 279 in the placebo group (23 percent; risk ratio, 1.0; 95 percent confidence interval, 0.8 to 1.4). Conclusions Antenatal administration of phenobarbital does not decrease the risk of intracranial hemorrhage or early death in preterm infants. (C) 1997, Massachusetts Medical Society.	WAYNE STATE UNIV,DETROIT,MI; NICHHD,BETHESDA,MD 20892; YALE UNIV,NEW HAVEN,CT; GEORGE WASHINGTON UNIV,CTR BIOSTAT,ROCKVILLE,MD; INDIANA UNIV,INDIANAPOLIS,IN 46204; UNIV TENNESSEE,MEMPHIS,TN; STANFORD UNIV,PALO ALTO,CA 94304; UNIV CINCINNATI,CINCINNATI,OH; EMORY UNIV,ATLANTA,GA 30322; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; BROWN UNIV,WOMEN & INFANTS HOSP,PROVIDENCE,RI; HARVARD UNIV,BOSTON,MA 02115; UNIV ARKANSAS,LITTLE ROCK,AR 72204; UNIV MICHIGAN,ANN ARBOR,MI 48109	Wayne State University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Yale University; George Washington University; Indiana University System; Indiana University-Purdue University Indianapolis; University of Tennessee System; University of Tennessee Health Science Center; Stanford University; University System of Ohio; University of Cincinnati; Emory University; Case Western Reserve University; Brown University; Women & Infants Hospital Rhode Island; Harvard University; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; University of Michigan System; University of Michigan					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027871, U10HD021385] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD027881] Funding Source: NIH RePORTER; NICHD NIH HHS [U10 HD27881, U10 HD21385, U10 HD27871] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		De Carolis S, 1988, Fetal Ther, V3, P224; GODDARDFINEGOLD J, 1987, PEDIATRICS, V79, P901; Horbar Jeffrey D., 1992, P562; KAEMPF JW, 1990, J PEDIATR-US, V117, P933, DOI 10.1016/S0022-3476(05)80141-6; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lan KKG, 1982, COMMUN STATIST C, V1, P207, DOI DOI 10.1080/07474948208836014; MENT LR, 1994, PEDIATRICS, V93, P543; MERCER BM, 1995, LANCET, V346, P1271, DOI 10.1016/S0140-6736(95)91868-X; MERCER BM, 1996, LANCET, V347, P410; MORALES WJ, 1986, OBSTET GYNECOL, V68, P295, DOI 10.1097/00006250-198609000-00001; *NIH, 1994, NIH CONSENSUS STATE, V12, P1; PANETH N, 1993, AM J EPIDEMIOL, V137, P1167, DOI 10.1093/oxfordjournals.aje.a116619; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; SHANKARAN S, 1986, DEV PHARMACOL THERAP, V9, P171, DOI 10.1159/000457089; Shankaran S, 1996, PEDIATRICS, V97, P644; SHANKARAN S, 1986, AM J OBSTET GYNECOL, V154, P53, DOI 10.1016/0002-9378(86)90392-3; Shankaran S, 1996, ARCH PEDIAT ADOL MED, V150, P491, DOI 10.1001/archpedi.1996.02170300045009; SHAVER DC, 1992, OBSTET GYNECOL, V80, P831; THORP JA, 1995, OBSTET GYNECOL, V86, P1, DOI 10.1016/0029-7844(95)00091-5; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; WEI LJ, 1989, CONTROL CLIN TRIALS, V10, pA126; WIMBERLEY PD, 1982, ACTA PAEDIATR SCAND, V71, P537, DOI 10.1111/j.1651-2227.1982.tb09471.x	22	37	40	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					466	471		10.1056/NEJM199708143370705	http://dx.doi.org/10.1056/NEJM199708143370705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250849				2022-12-28	WOS:A1997XQ49900005
J	Speller, V; Learmonth, A; Harrison, D				Speller, V; Learmonth, A; Harrison, D			The search for evidence of effective health promotion	BRITISH MEDICAL JOURNAL			English	Article							EDUCATION; INTERVENTIONS		N DURHAM COMMUNITY HLTH CARE TRUST,CTR HLTH,DURHAM DH3 3UR,ENGLAND; SHAROE GREEN HOSP,LANCASHIRE HLTH PROMOT UNIT,PRESTON PR2 8DU,LANCS,ENGLAND		Speller, V (corresponding author), WESSEX INST HLTH RES & DEV,WINCHESTER SO22 5DH,HANTS,ENGLAND.							Black N, 1996, BRIT MED J, V312, P1215; *CENTR SYDN AR HLT, 1994, PROGR MAN GUID HLTH; Clandinin DJ., 1994, HDB QUALITATIVE RES, P413; *DEP HLTH, 1992, HLTH NAT; EBRAHIM S, 1996, HLTH PROMOTION OLDER; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FOUNTAIN J, 1993, INTERPRETING FIELD A, P145; Grossman R, 1993, HLTH PROMOTION ORG D; HEATHER N, 1995, ALCOHOL ALCOHOLISM, V30, P287; HERITAGE J, 1992, TALK WORK, P59; LIMB L, 1996, HLTH SERVICES J 1114, P8; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; *NHS CTR REV DISS, 1996, EFFECTIVE HLTH CARE, V2, P5; *NHS CTR REV DISS, 1993, EFFECTIVE HLTH CARE, V7; *NHS CTR REV DISS, 1996, EFFECTIVE HLTH CARE, V2, P4; OAKLEY A, 1995, BRIT MED J, V310, P158, DOI 10.1136/bmj.310.6973.158; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Tannahill A, 1985, Health Educ J, V44, P167, DOI 10.1177/001789698504400402; Taylor A., 1993, WOMEN DRUG USERS ETH; TOWNER E, 1996, HLTH PROMOTION CHILD; VEEN CA, 1994, INSTRUMENT ANAL EFFE; World Health Organization, 1986, OTT CHART PRINC HLTH; 1996, HLTH SERVICES J 1114, P25; 1994, LANCET, V343, P429	24	89	92	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					361	363						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270462				2022-12-28	WOS:A1997XQ86400027
J	Gerber, JK; Gogel, E; Berger, C; Wallisch, M; Muller, F; Grummt, I; Grummt, F				Gerber, JK; Gogel, E; Berger, C; Wallisch, M; Muller, F; Grummt, I; Grummt, F			Termination of mammalian rDNA replication: Polar arrest of replication fork movement by transcription termination factor TTF-I	CELL			English	Article							RIBOSOMAL-RNA GENES; BACILLUS-SUBTILIS CHROMOSOME; SIMIAN VIRUS-40 DNA; POLYMERASE-I; 3' END; SACCHAROMYCES-CEREVISIAE; TERMINUS REGION; BINDING DOMAIN; SEQUENCES; ORGANIZATION	A replication fork barrier (RFB) al the 3' end of eukaryotic ribosomal RNA genes blocks bidirectional fork progression and limits DNA replication to the same direction as transcription. We have reproduced the RFB in vitro in HeLa cell extracts using 3' terminal murine rDNA fused to an SV40 origin-based vector. The RFB is polar and modularly organized, requiring both the Sal box transcription terminator and specific flanking sequences. Mutations within the terminator element, depletion of the RNA polymerase I-specific transcription termination factor TTF-I, or deletion of the termination domain of TTF-I abolishes RFB activity. Thus, the same factor that blocks elongating RNA polymerase I prevents head-on collision between the DNA replication apparatus and the transcription machinery.	UNIV WURZBURG,INST BIOCHEM,D-97074 WURZBURG,GERMANY; GERMAN CANC RES CTR,DIV MOL BIOL CELL 2,D-69120 HEIDELBERG,GERMANY; INST MOL BIOTECHNOL,DIV BIOCHEM,D-07745 JENA,GERMANY	University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)				Wallisch, Michael/0000-0002-7133-795X				BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BARTSCH I, 1988, MOL CELL BIOL, V8, P3891, DOI 10.1128/MCB.8.9.3891; BARTSCH I, 1987, MOL CELL BIOL, V7, P2521, DOI 10.1128/MCB.7.7.2521; Bastia D., 1996, DNA REPLICATION EUKA, P177; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; Ermakova OV, 1996, J BIOL CHEM, V271, P33009, DOI 10.1074/jbc.271.51.33009; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; EVERS R, 1995, P NATL ACAD SCI USA, V92, P5827, DOI 10.1073/pnas.92.13.5827; Gogel E, 1996, CHROMOSOMA, V104, P511, DOI 10.1007/BF00352115; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; GRUMMT I, 1986, CELL, V45, P837, DOI 10.1016/0092-8674(86)90558-1; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HOSS A, 1990, J VIROL, V64, P4799; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KERMEKCHIEV MB, 1987, NUCLEIC ACIDS RES, V15, P4131, DOI 10.1093/nar/15.10.4131; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; KUHN A, 1988, EMBO J, V7, P1497, DOI 10.1002/j.1460-2075.1988.tb02968.x; LABHART P, 1987, MOL CELL BIOL, V7, P1900, DOI 10.1128/MCB.7.5.1900; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; LUCCHINI R, 1994, MOL CELL BIOL, V14, P318, DOI 10.1128/MCB.14.1.318; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; PFLEIDERER C, 1990, NUCLEIC ACIDS RES, V18, P4727, DOI 10.1093/nar/18.16.4727; REEDER RH, 1994, MOL MICROBIOL, V12, P11, DOI 10.1111/j.1365-2958.1994.tb00989.x; Sander EE, 1996, NUCLEIC ACIDS RES, V24, P3677, DOI 10.1093/nar/24.19.3677; SANDER EE, 1997, NUCLEIC ACIDS RES, V25, P3677; SMID A, 1992, J MOL BIOL, V227, P635, DOI 10.1016/0022-2836(92)90213-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	43	100	103	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					559	567		10.1016/S0092-8674(00)80515-2	http://dx.doi.org/10.1016/S0092-8674(00)80515-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267035	Bronze			2022-12-28	WOS:A1997XQ06300019
J	Hanson, PI; Roth, R; Morisaki, H; Jahn, R; Heuser, JE				Hanson, PI; Roth, R; Morisaki, H; Jahn, R; Heuser, JE			Structure and conformational changes in NSF and its membrane receptor complexes visualized by quick-freeze/deep-etch electron microscopy	CELL			English	Article							SENSITIVE FUSION PROTEIN; VESICLE FUSION; VESICULAR TRANSPORT; ESCHERICHIA-COLI; CLPAP PROTEASE; GENE-PRODUCT; IN-VITRO; YEAST; MECHANISM; BINDING	Using quick-freeze/deep-etch electron microscopy of recombinant proteins adsorbed to mica, we show that NSF, the oligomeric ATPase involved in membrane fusion, is a hollow 10 x 16 nm cylinder whose conformation depends upon nucleotide binding. Depleted of nucleotide, NSF converts to a ''splayed'' protease-sensitive conformation that reveals its subunit composition. NSF's synaptic membrane substrate, the ternary SNARE complex containing syntaxin, SNAP-25, and synaptobrevin, is a 4 x 14 nm rod with a ''tail'' at one end, corresponding to the N-terminus of syntaxin. Using epitope tags, antibodies, and maltose-binding protein markers, we find that syntaxin and synaptobrevin are aligned in parallel in the complex, with their membrane anchors located at the same end of the rod. This SNARE rod binds with alpha-SNAP to one end of the NSF cylinder to form an asymmetric ''20S'' complex. Together, these images suggest how NSF could dissociate the SNARE complex and how association and dissociation of the complex could be related to membrane fusion.	HOWARD HUGHES MED INST, BOYER CTR MOL MED, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute	Hanson, PI (corresponding author), YALE UNIV, DEPT PHARMACOL, ROOM 247, 295 CONGRESS AVE, NEW HAVEN, CT 06510 USA.		Hanson, Phyllis/E-9420-2012; Heuser, John/H-5940-2012	Jahn, Reinhard/0000-0003-1542-3498	NIGMS NIH HHS [GM-29647] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; RAND RP, 1986, ANNU REV PHYSIOL, V48, P201; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHELLER RH, 1995, NEURON, V14, P893; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SINGH SK, 1994, J BIOL CHEM, V269, P29537; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILLIAMS RC, 1946, J APPL PHYS, V17, P23, DOI 10.1063/1.1707630; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	49	653	669	2	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					523	535		10.1016/S0092-8674(00)80512-7	http://dx.doi.org/10.1016/S0092-8674(00)80512-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267032	hybrid			2022-12-28	WOS:A1997XQ06300016
J	Dolan, RJ; Fletcher, PC				Dolan, RJ; Fletcher, PC			Dissociating prefrontal and hippocampal function in episodic memory encoding	NATURE			English	Article							AMNESIA; ACTIVATION; RETRIEVAL	Human lesion data indicate that an intact left hippocampal formation is necessary for auditory-verbal memory(1). By contrast, functional neuroimaging has highlighted the role of the left prefrontal cortex(2-4) but has generally failed to reveal the predicted left hippocampal activation. Here we describe an experiment involving learning category-exemplar word pairs (such as 'dog...boxer') in which we manipulate the novelty of either individual elements or the entire category-exemplar pairing. We demonstrate both left medial temporal (including hippocampal) and left prefrontal activation and show that these activations are dissociable with respect to encoding demands. Left prefrontal activation is maximal with a change in category-exemplar pairings, whereas medial temporal activation is sensitive to the overall degree of novelty. Thus, left prefrontal cortex is sensitive to processes required to establish meaningful connections between a category and its exemplar, a process maximized when a previously formed connection is changed. Conversely, the left medial temporal activation reflects processes that register the overall novelty of the presented material. Our results provide striking evidence of functionally dissociable roles for the prefrontal cortex and hippocampal formation during learning of auditory-verbal material.	ROYAL FREE HOSP,SCH MED,LONDON NW3,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Dolan, RJ (corresponding author), INST NEUROL,WELLCOME DEPT COGNIT NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND.		Fletcher, Paul/F-5380-2011	Fletcher, Paul/0000-0001-8257-1517; Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACK FW, 1976, J CLIN PSYCHOL, V32, P366, DOI 10.1002/1097-4679(197604)32:2<366::AID-JCLP2270320234>3.0.CO;2-F; DIMSDALE H, 1964, NEUROPSYCHOLOGIA, V1, P287, DOI 10.1016/0028-3932(64)90022-3; FAHY FL, 1993, EXP BRAIN RES, V96, P457; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V13, P1305; GRADY CL, 1994, J NEUROSCI, V14, P1450, DOI 10.1523/JNEUROSCI.14-03-01450.1994; Grafman, 1989, HDB NEUROPSYCHOLOGY, P91; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; Halgren Eric, 1995, P1137; JETTER W, 1986, CORTEX, V22, P229, DOI 10.1016/S0010-9452(86)80047-8; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; LI L, 1993, J NEUROPHYSIOL, V69, P1918, DOI 10.1152/jn.1993.69.6.1918; Martin A, 1996, NATURE, V379, P649, DOI 10.1038/379649a0; MOSCOVITCH M, 1982, MULTIPLE DISSOCIATIO, P337; NYBERG J, 1996, P NATL ACAD SCI USA, V93, P11280; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SCHACTER DL, 1987, PSYCHOBIOLOGY, V15, P21; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SHIMAMURA AP, 1995, J COGNITIVE NEUROSCI, V7, P144, DOI 10.1162/jocn.1995.7.2.144; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; ZATORRE RJ, 1983, BRAIN COGNITION, V2, P331, DOI 10.1016/0278-2626(83)90017-9; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	29	328	329	2	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					582	585		10.1038/41561	http://dx.doi.org/10.1038/41561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252188	Bronze, Green Submitted			2022-12-28	WOS:A1997XP72200049
J	Egger, E; ZellwegerZahner, T; Schneider, M; Junker, C; Lengeler, C; Antes, G				Egger, E; ZellwegerZahner, T; Schneider, M; Junker, C; Lengeler, C; Antes, G			Language bias in randomised controlled trials published in English and German	LANCET			English	Article							PUBLICATION BIAS; CLINICAL-TRIALS; GINKGO-BILOBA; HOMEOPATHT; COHORT	Background Some randomised controlled trials (RCTs) done in German-speaking Europe are published in international English-language journals and others in national German-language journals. We assessed whether authors are more likely to report trials with statistically significant results in English than in German. Methods We studied pairs of RCT reports, matched for first author and time of publication, with one report published in German and the other in English. Pairs were identified from reports fround in a manual search of five leading German-language journals and from reports published by the same authors in English found on Medline. Quality of methods and reporting were assessed with two different scales by two investigators who were unaware of authors' identities, affiliations, and other characteristics of trial reports. Main study endpoints were selected by two investigators who were unaware of trial results. Our main outcome was the number of pairs of studies in which the levels of significance (shown by p values) were discordant. Findings 62 eligible pairs of reports were identified but 19 (31%) were excluded because they were duplicate publications. A further three pairs (5%) were excluded because no p values were given. The remaining 40 pairs were analysed. Design characteristics and quality features were similar for reports in both languages. Only 35% of German-language articles, compared with 62% of English-language articles, reported significant (p<0.05) differences in the main endpoint between study and control groups (p=0.002 by McNemar's test). Logistic regression showed that the only characteristic that predicted publication in an English-language journal was a significant result. The odds ratio for publication of trials with significant results in English was 3.75 (95% CI 1.25-11.3). Interpretation Authors were more likely to publish RCTs in an English-language journal if the results were statistically significant. English language bias may, therefore, be introduced in reviews and meta-analyses if they include only trials reported in English. The effort of the Cochrane Collaboration to identify as many controlled trials as possible, through the manual search of many medical journals published in different languages will help to reduce such bias.	UNIV BERN, DEPT SOCIAL & PREVENT MED, BERN, SWITZERLAND; SWISS TROP INST, DEPT EPIDEMIOL & PUBL HLTH, CH-4002 BASEL, SWITZERLAND; UNIV FREIBURG, DEPT MED BIOMETRY & MED INFORMAT, FREIBURG, GERMANY	University of Bern; University of Basel; Swiss Tropical & Public Health Institute; University of Freiburg	Egger, E (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, CANYNGE HALL, BRISTOL BS8 2PR, AVON, ENGLAND.			Egger, Matthias/0000-0001-7462-5132				[Anonymous], 1991, NEW ENGL J MED, V324, P424; [Anonymous], 1995, LANCET, V346, P785; BAYERDORFFER E, 1987, DEUT MED WOCHENSCHR, V112, P1407, DOI 10.1055/s-2008-1068260; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; *COCHR CONTR TRIAL, 1997, COCHR LIB CDROM ONL; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger M, 1996, LANCET, V347, P1047, DOI 10.1016/S0140-6736(96)90188-9; EGGER M, 1997, IN PRESS BMJ; FLAMM J, 1988, WIEN KLIN WOCHENSCHR, V100, P589; GANTEN D, 1995, J MOL MED-JMM, V73, P1; GASEL B, 1990, ANN INTERN MED, V112, P70; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; *I SCI INF, 1995, SCI CIT IND J CIT RE; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JURINCICWINKLER CD, 1994, WIEN KLIN WOCHENSCHR, V106, P455; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KLEIJNEN J, 1992, PHARM WEEKBLAD, V14, P316, DOI 10.1007/BF01977620; KLEIJNEN J, 1992, LANCET, V340, P1136, DOI 10.1016/0140-6736(92)93158-J; LEMMEL EM, 1988, DEUT MED WOCHENSCHR, V113, P172, DOI 10.1055/s-2008-1067614; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; SIMES RJ, 1987, STAT MED, V6, P11, DOI 10.1002/sim.4780060104; ZOLLNER N, 1992, CLIN INVESTIGATOR, V70, P1, DOI 10.1007/BF00422929; 1984, DIABETOLOGIA, V25, pA4; 1992, LANCET, V340, P1131	32	663	671	2	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 2	1997	350	9074					326	329		10.1016/S0140-6736(97)02419-7	http://dx.doi.org/10.1016/S0140-6736(97)02419-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251637				2022-12-28	WOS:A1997XP24200010
J	Gerada, C; Ashworth, M				Gerada, C; Ashworth, M			Addiction and dependence .1. Illicit drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Review																		CHICK J, 1994, SEMINARS ALCOHOL DRU; *DEP HLTH, 1991, DRUG MIS DEP GUID CL; Russell J, 1993, GUIDELINES PREVENTIO; Williams H, 1996, BRIT J CLIN PRACT, V50, P94; WILLIAMS H, 1996, PREVENTION MENTAL IL, P223; 1997, DRUG THER B, V35, P18	6	35	35	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 2	1997	315	7103					297	300		10.1136/bmj.315.7103.297	http://dx.doi.org/10.1136/bmj.315.7103.297			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274553	Green Published			2022-12-28	WOS:A1997XP75000028
J	Kroman, N; Jensen, MB; Melbye, M; Wohlfahrt, J; Mouridsen, HT				Kroman, N; Jensen, MB; Melbye, M; Wohlfahrt, J; Mouridsen, HT			Should women be advised against pregnancy after breast-cancer treatment?	LANCET			English	Article							SUBSEQUENT; MASTECTOMY; PROGNOSIS; CARCINOMA; SURVIVAL	Background Oestrogen is an established growth factor in breast cancer. There has, therefore, been much discussion about whether women should be advised against becoming pregnant after breast-cancer treatment because of a possible negative prognostic effect from the high oestrogen concentrations associated with pregnancy. Methods We studied 5725 women with primary breast cancer. Information on these women was obtained from the Danish Breast Cancer Cooperative Group. Since 1977 this group has collected population-based data on tumour characteristics, treatment regimens, and follow-up status of Danish women with breast cancer. Details of reproductive history were obtained from The Danish Civil Registration System, the National Birth Registry, and the National Induced Abortion registry. We estimated the relative risk of death among women who became pregnant after breast-cancer treatment compared with women who had not become pregnant. Findings 5725 women with primary breast cancer aged 45 years or younger at the time of diagnosis were followed up for 35067 patient-years. Among these, 113 women became pregnant after treatment of breast cancer. Women who had a full-term pregnancy after breast-cancer treatment had a non-significantly reduced risk of death (relative risk 0.55 [95% CI 0.28-1.06]) compared with women who had had no full-term pregnancy after adjustment for age at diagnosis, stage of disease (tumour size, axillary nodal status, and histological grading), and reproductive history before diagnosis. The effect was also not significantly modified by age at diagnosis, tumour size, nodal status, or reproductive history before diagnosis of breast cancer. Neither miscarriages nor induced abortions after breast-cancer treatment influenced the prognosis. Interpretation We found no evidence that a pregnancy after breast-cancer treatment increased the risk of a poor methods outcome.	STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL RES,DK-2300 COPENHAGEN S,DENMARK; RIGSHOSP,DANISH BREAST CANC COOPERAT GRP,DK-2100 COPENHAGEN,DENMARK	Aarhus University; Statens Serum Institut; Danish Breast Cancer Cooperative Group (DBCG); Rigshospitalet; University of Copenhagen				melbye, mads/0000-0001-8264-6785				ANDERSEN KW, 1988, ACTA ONCOL, V27, P627, DOI 10.3109/02841868809091763; Applewhite R R, 1973, Am Surg, V39, P101; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Beatson GW, 1896, LANCET, V2, P162, DOI DOI 10.1016/S0140-6736(01)72384-7; Clark R M, 1989, Clin Oncol (R Coll Radiol), V1, P11, DOI 10.1016/S0936-6555(89)80004-4; COOPER DR, 1970, ANN SURG, V171, P429, DOI 10.1097/00000658-197003000-00017; *DANM STAT, 1996, STAT 10 YEAR REV; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; GREENBERG ER, 1985, BRIT J CANCER, V51, P691, DOI 10.1038/bjc.1985.104; GUINEE VF, 1994, LANCET, V343, P1587; HARVEY JC, 1981, SURG GYNECOL OBSTET, V153, P723; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; KING RM, 1985, SURG GYNECOL OBSTET, V160, P228; Kroman N, 1994, Eur J Surg Oncol, V20, P430; KROMAN N, IN PRESS BMJ; LETHABY AE, 1996, ONT J CANC, V67, P751; Malamos NA, 1996, ONCOLOGY, V53, P471; Melbye M, 1997, NEW ENGL J MED, V336, P81, DOI 10.1056/NEJM199701093360201; NUGENT P, 1985, ARCH SURG-CHICAGO, V120, P1221; Petrek J A, 1994, J Natl Cancer Inst Monogr, P113; RISSANEN PM, 1969, ACTA RADIOL THER PHY, V8, P415, DOI 10.3109/02841866909134468; SANKILA R, 1994, AM J OBSTET GYNECOL, V170, P818, DOI 10.1016/S0002-9378(94)70290-X; Schouten LJ, 1997, BREAST CANCER RES TR, V43, P217, DOI 10.1023/A:1005790531122; Storm H H, 1991, IARC Sci Publ, P220; Westergaard T, 1997, BMJ-BRIT MED J, V314, P775, DOI 10.1136/bmj.314.7083.775	25	111	115	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					319	322		10.1016/S0140-6736(97)03052-3	http://dx.doi.org/10.1016/S0140-6736(97)03052-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251635				2022-12-28	WOS:A1997XP24200008
J	Weed, LL				Weed, LL			New connections between medical knowledge and patient care	BRITISH MEDICAL JOURNAL			English	Article											Weed, LL (corresponding author), PKC CORP,1 MILL ST,BOX A-8,BURLINGTON,VT 05401, USA.							DAWES R, 1988, RATIONAL CHOICE UNCE, P202; DAWES R, 1988, RATIONAL CHOICE UNCE, P143; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Logan RL, 1996, LANCET, V347, P595, DOI 10.1016/S0140-6736(96)91284-2; MILLAY EST, 1988, COLLECTED SONNETS, P140; NORMAN GR, 1988, MED EDUC, V22, P279, DOI 10.1111/j.1365-2923.1988.tb00754.x; Weber P. S., 2001, KNOWLEDGE COUPLING N, V37, P227; WEED L L, 1964, Ir J Med Sci, V462, P271; WEED LL, 1968, NEW ENGL J MED, V278, P652, DOI 10.1056/NEJM196803212781204; WEED LL, 1968, NEW ENGL J MED, V278, P593, DOI 10.1056/NEJM196803142781105; WEED LL, 1985, MT SINAI J MED, V52, P94; WEED LL, 1981, NEW ENGL J MED, V304, P903, DOI 10.1056/NEJM198104093041511; WEED LL, 1991, KNOWLEDGE COUPLING N, P8; WEED LL, 1975, RECENT TRENDS MED ED; WEED LL, 1994, FEDERATION B, V81, P149; WEED LL, 1995, FED B, V82, P24; Weed LL, 1969, MED RECORDS MED ED P; Whitehead Alfred North, 1911, INTRO MATH, P61	18	84	88	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					231	235		10.1136/bmj.315.7102.231	http://dx.doi.org/10.1136/bmj.315.7102.231			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	9253272	Green Published			2022-12-28	WOS:A1997XN51700028
J	Khardori, R; Taraben, A; Taylor, GJ; Falcone, M				Khardori, R; Taraben, A; Taylor, GJ; Falcone, M			Growth hormone in end-stage heart failure	LANCET			English	Letter									SO ILLINOIS UNIV,SCH MED,DEPT INTERNAL MED,DIV CARDIOL,SPRINGFIELD,IL 62794	Southern Illinois University System; Southern Illinois University	Khardori, R (corresponding author), SO ILLINOIS UNIV,SCH MED,DEPT INTERNAL MED,DIV ENDOCRINOL,SPRINGFIELD,IL 62794, USA.							Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; FRUSTACI A, 1996, NEW ENGL J MED, V335, P642; LopezVelasco R, 1997, J CLIN ENDOCR METAB, V82, P1047, DOI 10.1210/jc.82.4.1047; ODriscoll JG, 1997, LANCET, V349, P1068, DOI 10.1016/S0140-6736(05)62290-8; Volterrani M, 1997, LANCET, V349, P1067, DOI 10.1016/S0140-6736(97)24015-8	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1842	1842		10.1016/S0140-6736(05)61729-1	http://dx.doi.org/10.1016/S0140-6736(05)61729-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269241				2022-12-28	WOS:A1997XF73500058
J	Bunn, HF				Bunn, HF			Mechanisms of disease - Pathogenesis and treatment of sickle cell disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FETAL HEMOGLOBIN PRODUCTION; BONE-MARROW TRANSPLANTATION; GLOBIN GENE-EXPRESSION; RED-BLOOD-CELLS; ERYTHROCYTE ADHERENCE; SODIUM-BUTYRATE; WATER-CONTENT; K+ TRANSPORT; F PRODUCTION; S GELATION		HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV HEMATOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School								ABRAHAM DJ, 1983, P NATL ACAD SCI-BIOL, V80, P324, DOI 10.1073/pnas.80.2.324; al-Khatti A, 1988, Trans Assoc Am Physicians, V101, P54; ASAKURA T, 1994, P NATL ACAD SCI USA, V91, P12589, DOI 10.1073/pnas.91.26.12589; BALLAS SK, 1989, AM J HEMATOL, V32, P104, DOI 10.1002/ajh.2830320206; BARABINO GA, 1987, BLOOD, V70, P152; BENESCH RE, 1982, NATURE, V299, P231, DOI 10.1038/299231a0; Bridges KR, 1996, BLOOD, V88, P4701, DOI 10.1182/blood.V88.12.4701.bloodjournal88124701; BRITTAIN HA, 1993, BLOOD, V81, P2137; BRUGNARA C, 1985, J CLIN INVEST, V75, P1608, DOI 10.1172/JCI111867; BRUGNARA C, 1986, SCIENCE, V232, P388, DOI 10.1126/science.3961486; BRUGNARA C, 1987, BLOOD, V70, P1810; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; CANESSA M, 1986, FEBS LETT, V200, P197, DOI 10.1016/0014-5793(86)80538-5; CERAMI A, 1971, P NATL ACAD SCI USA, V68, P1180, DOI 10.1073/pnas.68.6.1180; CHARACHE S, 1992, BLOOD, V79, P2555; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; CHARACHE S, 1987, BLOOD, V69, P109; Charache S, 1996, MEDICINE, V75, P300, DOI 10.1097/00005792-199611000-00002; CONSTANTOULAKIS P, 1989, BLOOD, V74, P1963; DEFRANCESCHI L, 1994, J CLIN INVEST, V93, P1670, DOI 10.1172/JCI117149; DEFRANCESCHI L, IN PRESS J CLIN INVE; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; Dover G J, 1983, Prog Clin Biol Res, V134, P475; DOVER GJ, 1986, BLOOD, V67, P735; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; EATON WA, 1987, BLOOD, V70, P1245; FABRY ME, 1991, HEMATOL ONCOL CLIN N, V5, P375, DOI 10.1016/S0889-8588(18)30421-0; Ferster A, 1996, BLOOD, V88, P1960, DOI 10.1182/blood.V88.6.1960.bloodjournal8861960; GEE BE, 1995, BLOOD, V85, P268, DOI 10.1182/blood.V85.1.268.bloodjournal851268; GOLDBERG MA, 1990, NEW ENGL J MED, V323, P366, DOI 10.1056/NEJM199008093230602; HEBBEL RP, 1991, BLOOD, V77, P214; HEBBEL RP, 1980, J CLIN INVEST, V65, P154, DOI 10.1172/JCI109646; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; Hillery CA, 1996, BLOOD, V87, P4879, DOI 10.1182/blood.V87.11.4879.bloodjournal87114879; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; HOFRICHTER J, 1976, P NATL ACAD SCI USA, V73, P3035, DOI 10.1073/pnas.73.9.3035; HOOVER R, 1979, BLOOD, V54, P872; Joneckis CC, 1996, BLOOD, V87, P4862, DOI 10.1182/blood.V87.11.4862.bloodjournal87114862; Kasschau MR, 1996, BLOOD, V87, P771, DOI 10.1182/blood.V87.2.771.bloodjournal872771; Kaul DK, 1995, J CLIN INVEST, V96, P2845, DOI 10.1172/JCI118355; KAUL DK, 1993, BLOOD, V81, P2429; Kumar A, 1996, BLOOD, V88, P4348; LEW VL, 1991, J CLIN INVEST, V87, P100, DOI 10.1172/JCI114958; LEW VL, 1985, NATURE, V315, P586, DOI 10.1038/315586a0; LEY TJ, 1983, BLOOD, V62, P370; LIAKOPOULOU E, 1995, BLOOD, V86, P3227; LITTLE JA, 1995, BLOOD, V85, P1712, DOI 10.1182/blood.V85.7.1712.bloodjournal8571712; MOZZARELLI A, 1987, SCIENCE, V237, P500, DOI 10.1126/science.3603036; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NAGEL RL, 1993, BLOOD, V81, P9; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; NOGUCHI CT, 1980, P NATL ACAD SCI-BIOL, V77, P5487, DOI 10.1073/pnas.77.9.5487; NOGUCHI CT, 1983, J CLIN INVEST, V72, P846, DOI 10.1172/JCI111055; OLIVIERI O, 1992, BLOOD, V79, P793; ORRINGER EP, 1991, BLOOD, V78, P212; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PERRINE SP, 1989, BLOOD, V74, P454; PERRINE SP, 1988, P NATL ACAD SCI USA, V85, P8540, DOI 10.1073/pnas.85.22.8540; PERRINE SP, 1985, NEW ENGL J MED, V312, P334, DOI 10.1056/NEJM198502073120602; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; Platt OS, 1996, NEW ENGL J MED, V335, P426, DOI 10.1056/NEJM199608083350609; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; RODGERS GP, 1993, NEW ENGL J MED, V328, P73, DOI 10.1056/NEJM199301143280201; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; ROSA RM, 1980, NEW ENGL J MED, V303, P1138, DOI 10.1056/NEJM198011133032002; SHER GD, 1995, NEW ENGL J MED, V332, P1606, DOI 10.1056/NEJM199506153322404; STAMATOYANNOPOULOS G, 1994, BLOOD, V84, P3198, DOI 10.1182/blood.V84.9.3198.bloodjournal8493198; SUGIHARA K, 1992, BLOOD, V80, P2634; SWERLICK RA, 1993, BLOOD, V82, P1891; WALDER JA, 1979, BIOCHEMISTRY-US, V18, P4265, DOI 10.1021/bi00587a001; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601	73	683	708	0	102	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					762	769		10.1056/NEJM199709113371107	http://dx.doi.org/10.1056/NEJM199709113371107			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287233				2022-12-28	WOS:A1997XV17400007
J	Conte, JE				Conte, JE			A novel approach to preventing insect-borne diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTHROPOD VECTOR COMPETENCE				Conte, JE (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							BEARD CB, 1993, PARASITOL TODAY, V9, P179, DOI 10.1016/0169-4758(93)90142-3; BEARD CB, 1992, AM J TROP MED HYG, V46, P195, DOI 10.4269/ajtmh.1992.46.195; Durvasula RV, 1997, P NATL ACAD SCI USA, V94, P3274, DOI 10.1073/pnas.94.7.3274; Richards F. F., 1993, ASM News (Washington), V59, P509; Ward E S, 1993, Adv Pharmacol, V24, P1, DOI 10.1016/S1054-3589(08)60931-X	5	11	11	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					785	786		10.1056/NEJM199709113371112	http://dx.doi.org/10.1056/NEJM199709113371112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287238				2022-12-28	WOS:A1997XV17400012
J	Hillman, BJ				Hillman, BJ			Medical imaging in the 21st century	LANCET			English	Article							PHYSICIAN WORKFORCE; ACADEMIC RADIOLOGY; COSTS	Imaging has been one of the success stories of 20th century medicine but is now under pressure from tight healthcare budgets and from professional competition. The 21st century will need a very different type of radiologist, one trained not just in imaging but also in more basic disciplines and in informatics. Research in radiology will need more attention than hitherto, and the imager of tomorrow will have to defend his or her specialty against the charge of ''expensive high technology'' and adapt, by taking a more market oriented approach to the added value that the specialty provides.	UNIV VIRGINIA, HLTH SCI CTR, CHARLOTTESVILLE, VA 22908 USA	University of Virginia	Hillman, BJ (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT RADIOL, CHARLOTTESVILLE, VA 22908 USA.							Goodman DC, 1996, JAMA-J AM MED ASSOC, V276, P1811, DOI 10.1001/jama.276.22.1811; HILLMAN BJ, 1992, MED INN CR, V3, P133; HILLMAN BJ, 1992, RADIOLOGY, V182, P315, DOI 10.1148/radiology.182.2.1732942; HILLMAN BJ, 1990, INVEST RADIOL, V25, P587, DOI 10.1097/00004424-199005000-00020; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; HILLMAN BJ, 1989, INVEST RADIOL, V24, P842, DOI 10.1097/00004424-198911000-00002; HILLMAN BJ, 1992, JAMA-J AM MED ASSOC, V268, P2050, DOI 10.1001/jama.268.15.2050; HILLMAN BJ, 1994, RADIOLOGY, V193, P307, DOI 10.1148/radiology.193.2.7972731; HOLMAN BL, 1990, RADIOLOGY, V176, P329, DOI 10.1148/radiology.176.2.2367648; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; SUNSHINE JH, 1993, AM J ROENTGENOL, V161, P419, DOI 10.2214/ajr.161.2.8333388; SWEDLOW A, 1992, NEW ENGL J MED, V327, P1502, DOI 10.1056/NEJM199211193272107; TARLOV AR, 1995, JAMA-J AM MED ASSOC, V274, P1558, DOI 10.1001/jama.274.19.1558; VIRAPONGSE C, 1990, RADIOLOGY, V175, P247, DOI 10.1148/radiology.175.1.2315489	15	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					731	733		10.1016/S0140-6736(97)04570-4	http://dx.doi.org/10.1016/S0140-6736(97)04570-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291917				2022-12-28	WOS:A1997XU97700044
J	Blattner, FR; Plunkett, G; Bloch, CA; Perna, NT; Burland, V; Riley, M; ColladoVides, J; Glasner, JD; Rode, CK; Mayhew, GF; Gregor, J; Davis, NW; Kirkpatrick, HA; Goeden, MA; Rose, DJ; Mau, B; Shao, Y				Blattner, FR; Plunkett, G; Bloch, CA; Perna, NT; Burland, V; Riley, M; ColladoVides, J; Glasner, JD; Rode, CK; Mayhew, GF; Gregor, J; Davis, NW; Kirkpatrick, HA; Goeden, MA; Rose, DJ; Mau, B; Shao, Y			The complete genome sequence of Escherichia coli K-12	SCIENCE			English	Review							SINGLE-STRANDED-DNA; CODON USAGE; SALMONELLA-TYPHIMURIUM; MYCOPLASMA-GENITALIUM; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; BINDING-PROTEIN; FLAGELLAR HOOK; REGION; REPLICATION	The 4,639,221-base pair sequence of Escherichia coli K-12 is presented. Of 4288 protein-coding genes annotated, 38 percent have no attributed function. Comparison with five other sequenced microbes reveals ubiquitous as well as narrowly distributed gene families; many families of similar genes within E. coli are also evident. The largest family of paralogous proteins contains 80 ABC transporters. The genome as a whole is strikingly organized with respect to the local direction of replication; guanines, oigonucleotides possibly related to replication and recombination, and most genes are so oriented. The genome also contains insertion sequence (IS) elements, phage remnants, and many other patches of unusual composition indicating genome plasticity through horizontal transfer.	UNIV MICHIGAN, SCH MED, DEPT PEDIAT, ANN ARBOR, MI 48105 USA; FMC BIOPROD, ROCKLAND, ME 04841 USA; MARINE BIOL LABS, WOODS HOLE, MA 02543 USA; UNIV NACL AUTONOMA MEXICO, CTR INVEST FIJAC NITROGENO, CUERNAVACA 62100, MORELOS, MEXICO	University of Michigan System; University of Michigan; Marine Biological Laboratory - Woods Hole; Universidad Nacional Autonoma de Mexico	Blattner, FR (corresponding author), UNIV WISCONSIN, GENET LAB, 445 HENRY MALL, MADISON, WI 53706 USA.		Mayhew, George F/B-4042-2016; Riley, Monica/E-1427-2011; Plunkett, Guy/B-8058-2009; Riley, Andrew/F-3526-2013	Mayhew, George F/0000-0003-0609-6018; Plunkett, Guy/0000-0003-1422-469X; Perna, Nicole/0000-0001-8208-0929; Riley, Andrew/0000-0001-9003-3540; Collado-Vides, Julio/0000-0001-8780-7664	NCRR NIH HHS [S10 RR10379] Funding Source: Medline; NHGRI NIH HHS [P01 HG01428] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010379] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG001428] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ABDULLAH KM, 1991, J BACTERIOL, V173, P5597, DOI 10.1128/jb.173.18.5597-5603.1991; Aiba H, 1996, DNA Res, V3, P363, DOI 10.1093/dnares/3.6.363; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bachellier S, 1996, CELLULAR MOL BIOL, VII, P2012; BACHMANN BJ, 1996, CELLULAR MOL BIOL, V2, P2460; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; BHAGWAT AS, 1992, NUCLEIC ACIDS RES, V20, P1663, DOI 10.1093/nar/20.7.1663; BLAISDELL BE, 1993, J MOL BIOL, V229, P833, DOI 10.1006/jmbi.1993.1090; BLATTNER FR, 1983, SCIENCE, V222, P719, DOI 10.1126/science.222.4625.719; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; Bloch CA, 1996, BIOCHEM BIOPH RES CO, V223, P104, DOI 10.1006/bbrc.1996.0853; BLOCH CA, UNPUB; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BREWER BJ, 1990, BACTERIAL CHROMOSOME, P61; BUGG TDH, 1993, BIOCHIM BIOPHYS ACTA, V1202, P258, DOI 10.1016/0167-4838(93)90013-H; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; BURLAND V, 1993, NUCLEIC ACIDS RES, V21, P3385, DOI 10.1093/nar/21.15.3385; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; BURLAND V, 1995, NUCLEIC ACIDS RES, V23, P2105, DOI 10.1093/nar/23.12.2105; Burland V, 1996, BIOTECHNIQUES, V21, P142; BURLINGAME RP, 1986, J BACTERIOL, V168, P55, DOI 10.1128/jb.168.1.55-64.1986; CAMPBELL AM, 1996, CELLULAR MOL BIOL, V2, P2041; CARDON LR, 1993, NUCLEIC ACIDS RES, V21, P3875, DOI 10.1093/nar/21.16.3875; CHUANG SE, 1993, J BACTERIOL, V175, P2026, DOI 10.1128/JB.175.7.2026-2036.1993; DANIELS DL, 1990, BACTERIAL CHROMOSOME, P43; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DANIELS DL, 1982, COLD SPRING HARB SYM, V47, P1009; DEONIER RC, 1996, CELLULAR MOL BIOL, V2, P2000; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRANCOIS V, 1989, MOL MICROBIOL, V3, P995, DOI 10.1111/j.1365-2958.1989.tb00250.x; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GRALLA JD, 1996, CELLULAR MOL BIOL, V1, P1232; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HILL TM, 1996, CELLULAR MOL BIOL, V2, P1602; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HLASA H, 1989, GENE, V84, P9; HOMMA M, 1990, J MOL BIOL, V213, P819, DOI 10.1016/S0022-2836(05)80266-9; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; Itoh T, 1996, DNA Res, V3, P379, DOI 10.1093/dnares/3.6.379; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; Kaneko T, 1996, DNA Res, V3, P109; KARLIN S, 1994, ANNU REV MICROBIOL, V48, P619, DOI 10.1146/annurev.mi.48.100194.003155; Karp PD, 1997, NUCLEIC ACIDS RES, V25, P43, DOI 10.1093/nar/25.1.43; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOFOID E, COMMUNICATION; KUTSUKAKE K, 1994, GENE, V143, P49; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LABEDAN B, 1995, MOL BIOL EVOL, V12, P980; LAWTHER RP, 1982, J BACTERIOL, V149, P294, DOI 10.1128/JB.149.1.294-298.1982; LIM DB, 1992, MOL MICROBIOL, V6, P3531, DOI 10.1111/j.1365-2958.1992.tb01788.x; LINDSEY DF, 1992, J BACTERIOL, V174, P3834, DOI 10.1128/JB.174.11.3834-3835.1992; LIU D, 1994, MICROBIOL-UK, V140, P49, DOI 10.1099/13500872-140-1-49; Lobry JR, 1996, SCIENCE, V272, P745, DOI 10.1126/science.272.5262.745; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LU Y, 1992, J BIOL CHEM, V267, P24848; MACNAB RM, 1996, CELLULAR MOL BIOL, V2, P123; MATSUTANI S, 1993, GENE, V127, P111; MCCLELLAND M, 1992, NATURE, V355, P595; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; MEDIGUE C, 1991, MOL MICROBIOL, V5, P2629, DOI 10.1111/j.1365-2958.1991.tb01972.x; MERKL R, 1992, NUCLEIC ACIDS RES, V20, P1657, DOI 10.1093/nar/20.7.1657; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; NAKATA A, 1989, J BACTERIOL, V171, P3553, DOI 10.1128/jb.171.6.3553-3556.1989; NEIDHARDT FC, 1996, CELLULAR MOL BIOL, V2, P1; NEIDHARDT FC, 1996, CELLULAR MOL BIOL; OHNISHI K, 1994, J BACTERIOL, V176, P2272, DOI 10.1128/JB.176.8.2272-2281.1994; Ohno S., 1970, EVOLUTION GENE DUPLI; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Oshima T, 1996, DNA Res, V3, P137, DOI 10.1093/dnares/3.3.137; PERNA NT, 1995, J MOL EVOL, V41, P353, DOI 10.1007/BF01215182; PERRIN A, 1993, EMBO J, V12, P2939, DOI 10.1002/j.1460-2075.1993.tb05956.x; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; POSFAI G, 1994, NUCLEIC ACIDS RES, V22, P2392, DOI 10.1093/nar/22.12.2392; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; Riley M, 1997, NUCLEIC ACIDS RES, V25, P51, DOI 10.1093/nar/25.1.51; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; RILEY M, 1997, J MOL BIOL, V269, P1; RILEY M, 1996, CELLULAR MOL BIOL, V2, P2118; RODE CK, 1995, GENE, V166, P1, DOI 10.1016/0378-1119(95)00630-5; Rosenblueth DA, 1996, COMPUT APPL BIOSCI, V12, P415; SACERDOT C, 1982, EMBO J, V1, P311, DOI 10.1002/j.1460-2075.1982.tb01166.x; SALYERS AA, 1994, BACTERIOL PATHOGENES; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SCHULTZ DW, 1981, J MOL BIOL, V146, P275, DOI 10.1016/0022-2836(81)90388-0; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; Spence EL, 1996, J BACTERIOL, V178, P5249, DOI 10.1128/jb.178.17.5249-5256.1996; STAHL F, 1995, J HERED, V86, P327, DOI 10.1093/oxfordjournals.jhered.a111599; SWART JR, 1993, J BIOL CHEM, V268, P12970; TAN HM, 1993, GENE, V130, P33, DOI 10.1016/0378-1119(93)90343-2; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; VANVLIET F, 1988, ANN INST PASTEUR MIC, V139, P493, DOI 10.1016/0769-2609(88)90111-1; WANG TCV, 1994, BIOCHEM BIOPH RES CO, V198, P844, DOI 10.1006/bbrc.1994.1120; WANG TCV, 1992, BIOCHEM BIOPH RES CO, V184, P1496, DOI 10.1016/S0006-291X(05)80052-X; WU CI, 1987, NATURE, V327, P169, DOI 10.1038/327169a0; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; YODA KY, 1988, NUCLEIC ACIDS RES, V16, P6531, DOI 10.1093/nar/16.14.6531; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305	105	5762	10589	23	781	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	1997	277	5331					1453	+		10.1126/science.277.5331.1453	http://dx.doi.org/10.1126/science.277.5331.1453			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278503				2022-12-28	WOS:A1997XV42900030
J	Furnari, B; Rhind, N; Russell, P				Furnari, B; Rhind, N; Russell, P			Cdc25 mitotic inducer targeted by Chk1 DNA damage checkpoint kinase	SCIENCE			English	Article							WEE1 PROTEIN-KINASE; FISSION YEAST; NEGATIVE REGULATION; FEEDBACK CONTROLS; MITOSIS; PHOSPHORYLATION; PATHWAY; ARREST	Arrest of the cell cycle at the G(2) checkpoint, induced by DNA damage, requires inhibitory phosphorylation of the kinase Cdc2 in both fission yeast and human cells. The kinase Wee1 and the phosphatase Cdc25, which regulate Cdc2 phosphorylation, were evaluated as targets of Chk1, a kinase essential for the checkpoint. Fission yeast cdc2-3w Delta cdc25 cells, which express activated Cdc2 and lack Cdc25, were responsive to Wee1 but insensitive to Chk1 and irradiation. Expression of large amounts of Chk1 produced the same phenotype as did loss of the cdc25 gene in cdc2-3w cells. Cdc25 associated with Chk1 in vivo and was phosphorylated when copurified in Chk1 complexes. These findings identify Cdc25, but not Wee1, as a target of the DNA damage checkpoint.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute				Rhind, Nicholas/0000-0003-1758-7736				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FEILOTTER H, 1991, GENETICS, V127, P309; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FUMARI B, UNPUB; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHELDRICK KS, 1993, BIOESSAYS, V15, P775, DOI 10.1002/bies.950151202; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0	29	468	480	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	1997	277	5331					1495	1497		10.1126/science.277.5331.1495	http://dx.doi.org/10.1126/science.277.5331.1495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278510				2022-12-28	WOS:A1997XV42900037
J	Jones, GRN				Jones, GRN			Are CS sprays safe?	LANCET			English	Editorial Material																		ABDO K, 1990, NIH PUBL; BHATTACHARYA ST, 1993, ANAESTHESIA, V48, P896, DOI 10.1111/j.1365-2044.1993.tb07424.x; GIBBONS S, 1996, POLICE REV      0216, P4; HELLREICH A, 1967, 4075 EDGW ARS; HIMSWORTH H, 1971, CMND4775; Himsworth H., 1969, CMND4173; PARNEIXSPAKE A, 1993, ARCH DERMATOL, V129, P913, DOI 10.1001/archderm.1993.01680280103029	7	6	6	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					605	606		10.1016/S0140-6736(05)63322-3	http://dx.doi.org/10.1016/S0140-6736(05)63322-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288040				2022-12-28	WOS:A1997XU28300005
J	Riccio, A; Pierchala, BA; Ciarallo, CL; Ginty, DD				Riccio, A; Pierchala, BA; Ciarallo, CL; Ginty, DD			An NGF-TrkA-mediated retrograde signal to transcription factor CREB in sympathetic neurons	SCIENCE			English	Article							NERVE GROWTH-FACTOR; AXONAL-TRANSPORT; LOCAL-CONTROL; TYROSINE KINASE; PROTEIN-KINASE; PHOSPHORYLATION; TRANSDUCTION; RECEPTORS; CULTURES; K252A	Nerve growth factor (NGF) is a neurotrophic factor secreted by cells that are the targets of innervation of sympathetic and some sensory neurons. However, the mechanism by which the NGF signal is propagated from the axon terminal to the cell body, which can be more than 1 meter away, to influence biochemical events critical for growth and survival of neurons has remained unclear. An NGF-mediated signal transmitted from the terminals and distal axons of cultured rat sympathetic neurons to their nuclei regulated phosphorylation of the transcription factor CREB (cyclic adenosine monophosphate response element-binding protein). Internalization of NGF and its receptor tyrosine kinase TrkA, and their transport to the cell body, were required for transmission of this signal. The tyrosine kinase activity of TrkA was required to maintain it in an autophosphorylated state upon its arrival in the cell body and for propagation of the signal to CREB within neuronal nuclei. Thus, an NGF-TrkA complex is a messenger that delivers the NGF signal from axon terminals to cell bodies of sympathetic neurons.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA	Johns Hopkins University								BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERG MM, 1992, J BIOL CHEM, V267, P13; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; CAMPENOT RB, 1977, P NATL ACAD SCI USA, V74, P4516, DOI 10.1073/pnas.74.10.4516; CAMPENOT RB, 1994, J NEUROBIOL, V25, P599, DOI 10.1002/neu.480250603; CAMPENOT RB, 1982, DEV BIOL, V93, P1, DOI 10.1016/0012-1606(82)90232-9; CLAUDE P, 1982, J NEUROSCI, V2, P431; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; EHLERS MD, 1995, J CELL BIOL, V130, P149, DOI 10.1083/jcb.130.1.149; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Grimes ML, 1996, J NEUROSCI, V16, P7950; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HENDRY IA, 1974, BRAIN RES, V68, P103, DOI 10.1016/0006-8993(74)90536-8; JOHANSON SO, 1995, BRAIN RES, V690, P55, DOI 10.1016/0006-8993(95)00587-G; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KORSCHING S, 1983, NEUROSCI LETT, V39, P1, DOI 10.1016/0304-3940(83)90155-6; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; MAYO RA, 1993, PHARMACOL THERAPEUT, V65, P93; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RICCIO A, UNPUB; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; TAPLEY P, 1992, ONCOGENE, V7, P371; Ure DR, 1997, J NEUROSCI, V17, P1282	32	352	365	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	1997	277	5329					1097	1100		10.1126/science.277.5329.1097	http://dx.doi.org/10.1126/science.277.5329.1097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262478				2022-12-28	WOS:A1997XT03300035
J	Tanaka, TU; Knapp, D; Nasmyth, K				Tanaka, TU; Knapp, D; Nasmyth, K			Loading of an Mcm protein onto DNA replication origins is regulated by Cdc6p and CDKs	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; RECOGNITION COMPLEX; S-PHASE; XENOPUS; INITIATION; CHROMATIN; BINDING; KINASE; PHOSPHORYLATION	In eukaryotic cells, firing of DNA replication origins normally does not recur until after M phase. This characteristic is thought to be due to the properties of ''initiation'' proteins like Ore, Cdc6, and Mcms. Using formaldehyde cross-linking, we show that Cdc6p and Mcm7p associate specifically with replication origins during G1 but not during G2 in S. cerevisiae. Mcm7p's association with origins depends on Cdc6p. Ectopic expression of Cdc6p enables it to associate with origins during G2, but this fails to recruit Mcm7p. Our data suggest that the loading of Mcm proteins onto origins is regulated by two mechanisms: first, by Cdc6p occupancy, and second, by S-and M-CDKs, whose activity during S, G2, and M phases prevents Mcm loading.			Tanaka, TU (corresponding author), RES INST MOL PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.		Knapp, Dunja/N-2180-2017; Tanaka, Tomoyuki U/A-4775-2008	Knapp, Dunja/0000-0002-7533-2208; Nasmyth, Kim/0000-0001-7030-4403; Tanaka, Tomoyuki/0000-0002-9886-5947				BLOW JJ, 1996, EUKARYOTIC DNA REPLI, P143; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; Lei M, 1996, MOL CELL BIOL, V16, P5081; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; NASMYTH K, 1996, DNA REPLICATION EUKA, P331; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TOYN JH, 1995, MOL CELL BIOL, V15, P5312; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	36	431	437	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					649	660		10.1016/S0092-8674(00)80526-7	http://dx.doi.org/10.1016/S0092-8674(00)80526-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288745	Bronze			2022-12-28	WOS:A1997XT06600009
J	Tomioka, N; Fujino, K				Tomioka, N; Fujino, K			Natural (Mg,Fe)SiO3-ilmenite and -perovskite in the Tenham meteorite	SCIENCE			English	Article							PHASES; MGSIO3	The minerals (Mg, Fe)SiO3-ilmenite and -perovskite were identified in the shock-induced veins in the Tenham chondritic meteorite. Both phases are inferred to have transformed from pyroxene at high pressures and temperatures by shock metamorphism. Columnar-shaped ilmenite grains, one of two types of morphologies, have a topotaxial relationship with neighboring pyroxene grains, indicating shear transformation. Granular-shaped perovskite grains showed a diffraction pattern consistent with orthorhombic perovskite, but these grains were not stable under the electron beam irradiation and became amorphous. The higher iron concentration in both phases compared with those experimentally reported may suggest their metastable transition from enstatite because of shock compression.			Tomioka, N (corresponding author), HOKKAIDO UNIV,GRAD SCH SCI,DIV EARTH & PLANETARY SCI,SAPPORO,HOKKAIDO 060,JAPAN.		Tomioka, Naotaka/AID-3472-2022; Tomioka, Naotaka/B-1888-2011	Tomioka, Naotaka/0000-0001-5725-9513				BINNS RA, 1969, NATURE, V221, P943, DOI 10.1038/221943a0; Chen M, 1996, SCIENCE, V271, P1570, DOI 10.1126/science.271.5255.1570; Coleman LC, 1977, CAN MINERAL, V15, P97; Fei YW, 1996, J GEOPHYS RES-SOL EA, V101, P11525, DOI 10.1029/96JB00408; FUJINO K, 1996, P US JAP SEM MAU HI; ITO E, 1989, J GEOPHYS RES-SOLID, V94, P10637, DOI 10.1029/JB094iB08p10637; Ito E., 1977, HIGH PRESSURE RES, P193; Ito E., 1982, HIGH PRESSURE RES GE, P405; KATO T, 1985, NATURE, V316, P803, DOI 10.1038/316803a0; LIU L, 1975, GEOPHYS RES LETT, V2, P417, DOI 10.1029/GL002i010p00417; LIU LG, 1976, EARTH PLANET SC LETT, V31, P200, DOI 10.1016/0012-821X(76)90212-0; MASON B, 1968, SCIENCE, V160, P66, DOI 10.1126/science.160.3823.66; MORI H, 1985, LUNAR PLANET SCI, V16, P579; PRICE GD, 1979, CONTRIB MINERAL PETR, V71, P211, DOI 10.1007/BF00375437; PRICE GD, 1983, CAN MINERAL, V21, P29; PUTNIS A, 1979, NATURE, V280, P217, DOI 10.1038/280217a0; Sawamoto H., 1987, HIGH PRESSURE RES MI, P209; Stu┬ffler D., 1972, FORTSCHRITTE MINERAL, V49, P50; VANSCHMUS WR, 1967, GEOCHIM COSMOCHIM AC, V31, P747, DOI 10.1016/S0016-7037(67)80030-9	19	112	117	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1084	1086		10.1126/science.277.5329.1084	http://dx.doi.org/10.1126/science.277.5329.1084			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262473				2022-12-28	WOS:A1997XT03300030
J	Dixon, AK				Dixon, AK			Evidence-based diagnostic radiology	LANCET			English	Article; Proceedings Paper	1995 Kemp Memorial Lecture on Evidence Based Radiology	1995	UNIV OXFORD, OXFORD, ENGLAND		UNIV OXFORD		COMPUTED-TOMOGRAPHY; QUALITY	The radiological community has a long track record of self-examination, starting well before evidence-based medicine came of age. It had to produce such evidence to prove the need for and win funds for its expensive gadgets. The assessment of new tests is easier than proving the value of well-established ones, and in scrutinising the evidence base for an imaging technique a balance must be struck between apparent (eg, diagnostic) benefit and real benefit to the patient. And even when there is a wealth of good evidence healthy debate continues. So radiology may be ahead of some other disciplines in considering the evidence for its daily practice. For example, where is the evidence for the routine clinical examination-and might the radiologist with a chest X-ray and abdominal ultrasound do better?			Dixon, AK (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT RADIOL, CAMBRIDGE CB2 2QQ, ENGLAND.							Bearcroft PW, 1997, CLIN RADIOL, V52, P345, DOI 10.1016/S0009-9260(97)80128-6; COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; DallaPalma L, 1997, EUR RADIOL, V7, P147; DELACEY G, 1979, BRIT MED J, V1, P1597, DOI 10.1136/bmj.1.6178.1597; DIXON AK, 1981, LANCET, V1, P1199; DIXON AK, 1985, CLIN RADIOL, V36, P287, DOI 10.1016/S0009-9260(85)80066-0; DIXON AK, 1991, BRIT MED J, V302, P79, DOI 10.1136/bmj.302.6768.79; FINEBERG HV, 1977, JAMA-J AM MED ASSOC, V238, P224, DOI 10.1001/jama.238.3.224; FRY IK, 1984, BRIT J RADIOL, V57, P765, DOI 10.1259/0007-1285-57-681-765; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; HILLMAN BJ, 1994, RADIOLOGY, V193, P307, DOI 10.1148/radiology.193.2.7972731; Hunink MGM, 1996, EUR RADIOL, V6, P615; LAUBENBERGER R, 1995, MAGNET RESON MED, V33, P18, DOI 10.1002/mrm.1910330104; LEUNG DPY, 1992, CLIN RADIOL, V46, P279, DOI 10.1016/S0009-9260(05)80171-0; MACKENZIE R, 1994, QUAL LIFE RES, V3, P29, DOI 10.1007/BF00647846; MACKENZIE R, 1995, CLIN RADIOL, V50, P513, DOI 10.1016/S0009-9260(05)83184-8; Mackenzie R, 1996, CLIN RADIOL, V51, P245, DOI 10.1016/S0009-9260(96)80340-0; MACVICAR D, 1993, CLIN RADIOL, V47, P149, DOI 10.1016/S0009-9260(05)81152-3; NHS Executive, 1996, CLIN GUID US CLIN GU; RITTON PD, 1996, BR J RADIOL S, V69, P160; ROBERTS CJ, 1992, CLIN RADIOL, V45, P365, DOI 10.1016/S0009-9260(05)80991-2; *ROYAL COLL RAD, 1995, MAK BEST US DEP CLIN; SACKETT DL, 1997, EVIDENCE BASED MED; SEIDENWURM D, 1994, RADIOLOGY, V190, P21, DOI 10.1148/radiology.190.1.8259407; Simel DL, 1997, JAMA-J AM MED ASSOC, V277, P572, DOI 10.1001/jama.277.7.572; TEASDALE GM, 1989, BRIT MED J, V299, P349, DOI 10.1136/bmj.299.6695.349; vanRossum AB, 1996, RADIOLOGY, V201, P467, DOI 10.1148/radiology.201.2.8888242; Webb JAW, 1997, CLIN RADIOL, V52, P167, DOI 10.1016/S0009-9260(97)80269-3; White PM, 1997, CLIN RADIOL, V52, P124, DOI 10.1016/S0009-9260(97)80105-5; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003; [No title captured]	31	56	59	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	1997	350	9076					509	512		10.1016/S0140-6736(97)06100-X	http://dx.doi.org/10.1016/S0140-6736(97)06100-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XR135	9274596				2022-12-28	WOS:A1997XR13500041
J	Fraser, FC				Fraser, FC			Trinucleotide repeats not the only cause of anticipation	LANCET			English	Editorial Material											Fraser, FC (corresponding author), MCGILL UNIV,CTR HUMAN GENET,MONTREAL,PQ H3A 1B1,CANADA.							CROW TJ, 1991, EUR ARCH PSY CLIN N, V240, P314, DOI 10.1007/BF02279759; Horwitz M, 1996, AM J HUM GENET, V59, P990; McInnis MG, 1996, AM J HUM GENET, V59, P973; Paterson AD, 1996, AM J HUM GENET, V59, P264; PENROSE LS, 1948, ANN EUGENIC, V14, P125; Petronis A., 1996, American Journal of Human Genetics, V59, pA186; Polito JMII, 1996, LANCET, V347, P798, DOI 10.1016/S0140-6736(96)90870-3; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636	8	44	45	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					459	460		10.1016/S0140-6736(05)63077-2	http://dx.doi.org/10.1016/S0140-6736(05)63077-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274580				2022-12-28	WOS:A1997XR13500006
J	Gore, SM; Bingham, S; Day, NE				Gore, SM; Bingham, S; Day, NE			Age related dietary exposure to meat products from British dietary surveys of teenagers and adults in the 1980s and 1990s	BRITISH MEDICAL JOURNAL			English	Article									MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB2 2SR,ENGLAND		Gore, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; *COUNC ROYAL SOC, 1997, UPD BSE, P1; Gregory J., 1990, DIETARY NUTR SURVEY; Ministry of Agriculture Fisheries and Food, 1991, 50 YEARS NAT FOOD SU; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					404	405		10.1136/bmj.315.7105.404	http://dx.doi.org/10.1136/bmj.315.7105.404			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277606	Green Published			2022-12-28	WOS:A1997XR54900022
J	Maggiorini, M; Bartsch, P; Oelz, O				Maggiorini, M; Bartsch, P; Oelz, O			Association between raised body temperature and acute mountain sickness: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							PULMONARY-EDEMA; HIGH-ALTITUDE		UNIV CLIN MED,HEIDELBERG,GERMANY; STADTSPITAL TRIEMLI,DEPT MED,ZURICH,SWITZERLAND	Triemli Hospital	Maggiorini, M (corresponding author), UNIV ZURICH HOSP,DEPT MED,CH-8091 ZURICH,SWITZERLAND.			Maggiorini, Marco/0000-0001-8180-2117				HOUSTON CS, 1987, GOING HIGHER STORY M; Kleger GR, 1996, J APPL PHYSIOL, V81, P1917, DOI 10.1152/jappl.1996.81.5.1917; MAGGIORINI M, 1990, BRIT MED J, V301, P853, DOI 10.1136/bmj.301.6756.853; SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605, DOI 10.1152/jappl.1988.64.6.2605; VOCK P, 1989, RADIOLOGY, V170, P661, DOI 10.1148/radiology.170.3.2916019	5	19	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					403	404		10.1136/bmj.315.7105.403	http://dx.doi.org/10.1136/bmj.315.7105.403			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277605	Green Published			2022-12-28	WOS:A1997XR54900021
J	Maki, DG; Stolz, SM; Wheeler, S; Mermel, LA				Maki, DG; Stolz, SM; Wheeler, S; Mermel, LA			Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							SILVER SULFADIAZINE CREAM; NOSOCOMIAL INFECTIONS; POVIDONE-IODINE; INTENSIVE-CARE; RISK-FACTORS; BURN WOUNDS; TOPICAL USE; CHLORHEXIDINE; SEPSIS; DEVICES	Background: Bloodstream infection related to shortterm use of noncuffed central venous catheters is a common and serious problem, Technologic innovations to reduce the risk for these infections are needed. Objective: To determine 1) the efficacy of a novel antiseptic catheter in preventing central venous catheter-related infection, 2) patient tolerance of this catheter, and 3) the sources of bloodstream infection originating from noncuffed, multilumen central venous catheters. Design: Randomized, controlled clinical trial. Setting: Medical-surgical intensive care unit of a 450-bed university hospital. Participants: 158 adults scheduled to receive a central venous catheter; 403 catheters were studied. Intervention: Participants received either a standard triple-lumen polyurethane catheter or a catheter that was indistinguishable from the standard catheter and was impregnated with chlorhexidine and silver sulfadiazine. Measurements: Catheters were studied for colonization and catheter-related bloodstream infection at removal; local and systemic effects of catheters were assessed. The origin of each catheter-associated bloodstream infection was sought by culturing all potential sources (skin, catheter segments, hubs, and infusate) and confirmed by restriction-fragment DNA subtyping. Results: Antiseptic catheters were less likely to be colonized at removal than control catheters (13.5 compared with 24.1 colonized catheters per 100 catheters; relative risk, 0.56 [95% CI, 0.36 to 0.89], P = 0.005) and were nearly fivefold less likely to produce bloodstream infection (1.0 compared with 4.7 infections per 100 catheters; 1.6 compared with 7.6 infections per 1000 catheter-days; relative risk, 0.21 [CI, 0.03 to 0.95]; P = 0.03). In the control group, 8 catheter-related bloodstream infections were caused by Staphylococcus aureus, gram-negative bacilli, enterococci, or Candida species; no infections with these organisms occurred in the antiseptic catheter group (P = 0.003). No adverse effects from the antiseptic catheter were seen, and none of the 122 isolates obtained from infected catheters in either group showed in vitro resistance to chlorhexidine-silver sulfadiazine. Cost-benefit analysis indicated that the antiseptic catheter should prove cost-beneficial if an institution's rate of catheter-related bacteremia with noncuffed central venous catheters is at least 3 infections per 1000 catheter-days). Conclusions: The chlorhexidine-silver sulfadiazine catheter is well tolerated, reduces the incidence of catheter-related infection, extends the time that noncuffed central venous catheters can be safely left in place for the short term, and should allow cost savings.	UNIV WISCONSIN, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Madison	Maki, DG (corresponding author), UNIV WISCONSIN, HOSP & CLIN, H4-574, MADISON, WI 53792 USA.		Mermel, Leonard/Z-1475-2019					ALVARADO CJ, 1991, AM J MED, V91, pS272, DOI 10.1016/0002-9343(91)90381-7; ALY R, 1976, APPL ENVIRON MICROB, V31, P931, DOI 10.1128/AEM.31.6.931-935.1976; AOYAMA H, 1990, BURNS, V16, P163, DOI 10.1016/0305-4179(90)90030-Z; BALL AJ, 1987, J UROLOGY, V138, P491, DOI 10.1016/S0022-5347(17)43237-X; BOZZETTI F, 1983, ANN SURG, V198, P48, DOI 10.1097/00000658-198307000-00009; CARR HS, 1973, ANTIMICROB AGENTS CH, V4, P585, DOI 10.1128/AAC.4.5.585; Case DE, 1976, SPECIAL PROBLEMS CHE, P367; CHRISTENSEN KK, 1985, EUR J OBSTET GYN R B, V19, P231, DOI 10.1016/0028-2243(85)90034-6; CLARKE AM, 1975, MED J AUSTRALIA, V1, P413, DOI 10.5694/j.1326-5377.1975.tb140346.x; COBB DK, 1992, NEW ENGL J MED, V327, P1062, DOI 10.1056/NEJM199210083271505; COLLIGNON PJ, 1984, MED J AUSTRALIA, V141, P345, DOI 10.5694/j.1326-5377.1984.tb132802.x; COWEN J, 1979, ARCH DIS CHILD, V54, P379, DOI 10.1136/adc.54.5.379; CROSFILL M, 1969, BRIT J SURG, V56, P906, DOI 10.1002/bjs.1800561209; DEGREEF H, 1985, CONTACT DERMATITIS, V12, P33, DOI 10.1111/j.1600-0536.1985.tb01036.x; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; EYER S, 1990, CRIT CARE MED, V18, P1073, DOI 10.1097/00003246-199010000-00005; FABBRI L, 1982, DIALYSIS TRANSPLANT, V11, P483; FRENEY J, 1988, ANTIMICROB AGENTS CH, V32, P873, DOI 10.1128/AAC.32.6.873; Fuller F W, 1988, J Burn Care Rehabil, V9, P606, DOI 10.1097/00004630-198811000-00006; Gardner JF, 1983, DISINFECTION STERILI, P251; GATELL JM, 1988, REV INFECT DIS, V10, P203; GREGORY JA, 1985, AM SURGEON, V51, P534; GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258; HAGLEY MT, 1992, CRIT CARE MED, V20, P1426, DOI 10.1097/00003246-199210000-00011; HOFFMANN S, 1984, SCAND J PLAST RECONS, V18, P119, DOI 10.3109/02844318409057413; INMAN RJ, 1984, BURNS, V11, P35, DOI 10.1016/0305-4179(84)90159-1; KAHAN A, 1983, J INFECTION, V7, P256, DOI 10.1016/S0163-4453(83)97196-7; KAMAL GD, 1991, JAMA-J AM MED ASSOC, V265, P2364, DOI 10.1001/jama.265.18.2364; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOO DS, 1989, BURNS, V15, P193; KULICK MI, 1985, ANN PLAS SURG, V14, P407, DOI 10.1097/00000637-198505000-00003; LENNETTE EH, 1980, MANUAL CLIN MICROBIO; LEVIN A, 1991, KIDNEY INT, V40, P934, DOI 10.1038/ki.1991.297; LOE H, 1973, J PERIODONTAL RES, P5; LOWBURY EJL, 1973, BMJ-BRIT MED J, V1, P510, DOI 10.1136/bmj.1.5852.510; Maki Dennis G., 1994, P155; MAKI DG, 1981, AM J MED, V70, P719, DOI 10.1016/0002-9343(81)90603-3; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1991, ANN INTERN MED, V114, P845, DOI 10.7326/0003-4819-114-10-845; MAKI DG, 1989, ARCH INTERN MED, V149, P30, DOI 10.1001/archinte.149.1.30; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1982, 22ND INT C ANT AG CH, P699; MARRIE TJ, 1981, APPL ENVIRON MICROB, V42, P1093, DOI 10.1128/AEM.42.6.1093-1102.1981; MERMEL LA, 1991, AM J MED, V91, pS197, DOI 10.1016/0002-9343(91)90369-9; MERMEL LA, 1993, J INFECT DIS, V167, P920, DOI 10.1093/infdis/167.4.920; MICHEL LA, 1988, INT SURG, V73, P180; OBRIEN MS, 1984, DEVIANT BEHAV, V5, P141, DOI 10.1080/01639625.1984.9967638; OKANO M, 1989, ARCH DERMATOL, V125, P50, DOI 10.1001/archderm.125.1.50; ONEILL J, 1982, CURR THER RES CLIN E, V31, P485; Pearson ML, 1996, INFECT CONT HOSP EP, V17, P438; PETERS G, 1981, ZBL BAKT MIK HYG B, V173, P293; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; PITTET D, 1995, JAMA-J AM MED ASSOC, V91, P1819; QUESNEL LB, 1978, J APPL BACTERIOL, V45, P397, DOI 10.1111/j.1365-2672.1978.tb04241.x; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Raad I, 1995, 35 INT C ANT AG CHEM; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; REYNOLDS NJ, 1990, CONTACT DERMATITIS, V22, P103, DOI 10.1111/j.1600-0536.1990.tb01526.x; SAWHNEY CP, 1989, BURNS, V15, P403, DOI 10.1016/0305-4179(89)90110-1; SHERERTZ RJ, 1993, J INFECT DIS, V167, P98, DOI 10.1093/infdis/167.1.98; SNEDECOR GW, 1978, STATISTICAL METHODS, P593; SNYDER RH, 1988, ANN SURG, V208, P651, DOI 10.1097/00000658-198811000-00018; STICKLER DJ, 1983, BRIT J CLIN PRACT, V25, P23; TROOSKIN SZ, 1985, SURGERY, V97, P547; VALSECCHI R, 1986, CONTACT DERMATITIS, V15, P45, DOI 10.1111/j.1600-0536.1986.tb01268.x; VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865; VELEZ LA, 1992, 32 INT C ANT AG CHEM, P1164	68	544	582	0	42	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					257	+		10.7326/0003-4819-127-4-199708150-00001	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265424				2022-12-28	WOS:A1997XR26600003
J	Mindel, S				Mindel, S			Role of imager in developing world	LANCET			English	Article							ULTRASOUND	Medical imaging in the developing world is done by radiologists trained in the west or in the western manner, Yet they have go practise the specialty with equipment that is unreliable, poorly maintained, and difficult to repair, Developing countries face economic hardship, and the scarcity of radiologists and of imaging equipment is likely to continue. If used as the first, and very often the only, imaging technique, ultrasound has great advantages In such settings. Medical schools in the developing world and WHO should support training programmes in clinical ultrasound, a skill that could be offered to all doctors, not just radiologist.										AGENANT DMA, 1988, TROP GEOR MED, V40, P85; COCKERHAM WC, 1992, MED SOCIOLOGY, P300; de Geus A, 1993, Trop Geogr Med, V45, P97; ELTAHIR MI, 1992, BRIT J RADIOL, V65, P390, DOI 10.1259/0007-1285-65-773-390; HONDA H, 1992, GASTROINTEST RADIOL, V17, P255; LEYS C, 1997, GUARDIAN LONDON 0215; MINDEL S, 1992, S AFR MED J, V81, P446; MINDEL S, IN PRESS IMAGING TRO; NITTAYARAMPHONG S, 1994, HEALTH POLICY PLANN, V9, P31; PALMER PES, 1993, TROP GEOG MED, V45, P100; SPENCER JA, 1990, BRIT J RADIOL, V63, P369, DOI 10.1259/0007-1285-63-749-369; WEINBERGER E, 1990, AM J ROENTGENOL, V155, P347, DOI 10.2214/ajr.155.2.2115266	12	57	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					426	429		10.1016/S0140-6736(97)03340-0	http://dx.doi.org/10.1016/S0140-6736(97)03340-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259668				2022-12-28	WOS:A1997XQ24800044
J	Ewalt, KL; Hendrick, JP; Houry, WA; Hartl, FU				Ewalt, KL; Hendrick, JP; Houry, WA; Hartl, FU			In vivo observation of polypeptide flux through the bacterial chaperonin system	CELL			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; REACTION CYCLE; ATPASE CYCLE; IN-VIVO; GROEL; EXPRESSION; RHODANESE; BINDING	The quantitative contribution of chaperonin GroEL to protein folding in E. coli was analyzed. A diverse set of newly synthesized polypeptides, predominantly between 10-55 kDa, interacts with GroEL, accounting for 10%-15% of all cytoplasmic protein under normal growth conditions, and for 30% or more upon exposure to heat stress. Most proteins leave GroEL rapidly within 10-30 s. We distinguish three classes of substrate proteins: (I) proteins with a chaperonin-independent folding pathway; (II) proteins, more than 50% of total, with an intermediate chaperonin dependence for which normally only a small fraction transits GroEL; and (III) a set of highly chaperonin-dependent proteins, many of which dissociate slowly from GroEL and probably require sequestration of aggregation-sensitive intermediates within the GroEL cavity for successful folding.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MAX PLANCK INST BIOCHEM,DEPT CELLULAR BIOCHEM,D-82152 MARTINSRIED,GERMANY	Memorial Sloan Kettering Cancer Center; Max Planck Society	Ewalt, KL (corresponding author), MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021, USA.		Hartl, F. Ulrich/Y-8206-2019					Ausubel FM, 1992, CURRENT PROTOCOLS MO; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLANAGAN JM, 1992, P NATL ACAD SCI USA, V89, P748, DOI 10.1073/pnas.89.2.748; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hagenmaier S, 1997, J BACTERIOL, V179, P2073, DOI 10.1128/jb.179.6.2073-2076.1997; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOHFELD J, 1995, CELL, V83, P589; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KIM HB, 1991, BIOCHEM INT, V25, P381; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MARTIN J, 1997, P NATL ACAD SCI USA, V94, P14107; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	49	280	286	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					491	500		10.1016/S0092-8674(00)80509-7	http://dx.doi.org/10.1016/S0092-8674(00)80509-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267029	Bronze			2022-12-28	WOS:A1997XQ06300013
J	Casson, IF; Clarke, CA; Howard, CV; McKendrick, O; Pennycook, S; Pharoah, POD; Platt, MJ; Stanisstreet, M; vanVelszen, D; Walkinshaw, S				Casson, IF; Clarke, CA; Howard, CV; McKendrick, O; Pennycook, S; Pharoah, POD; Platt, MJ; Stanisstreet, M; vanVelszen, D; Walkinshaw, S			Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-ANOMALIES; SPONTANEOUS-ABORTION; MELLITUS; CARE	Objective: To monitor pregnancies in women with pre-existent insulin dependent diabetes for pregnancy loss, congenital malformations, and fetal growth in a geographically defined area of north west England. Design: Population cohort study. Setting: 10 maternity units in Cheshire, Lancashire, and Merseyside which had no regional guidelines for the management of pregnancy in diabetic women. Subjects: 462 pregnancies in 355 women with insulin dependent diabetes from the 10 centres over five years (1990-4 inclusive). Main outcome measures: Numbers and rates of miscarriages, stillbirths, and neonatal and postneonatal deaths; prevalence of congenital malformations; birth weight in relation to gestational age. Results: Among 462 pregnancies, 351 (76%) resulted in a liveborn infant, 78 (17%) aborted spontaneously, nine (2%) resulted in stillbirth, and 24 (5%) were terminated. Of the terminations, nine were for congenital malformation. The stillbirth rate was 25.0/1000 total births (95% confidence interval 8.9 to 41.1) compared with a population rate of 5.0/1000, and infant mortality was 19.9/1000 live births (5.3 to 34.6) compared with 6.8/1000. The prevalence of congenital malformations was 94.0/1000 live births (63.5 to 124.5) compared with 9.7/1000 in the general population. When corrected for gestational age, mean birth weight in the sample was 1.3 standard deviations greater than that of infants of non-diabetic mothers. Infants with congenital malformations weighed less than those without. Conclusion: In an unselected population the infants of women with pre-existent insulin dependent diabetes mellitus have a 10-fold greater risk of a congenital malformation and a fivefold greater risk of being stillborn than infants in the general population. Further improvements in the management of pregnancy in diabetic women are needed if target of die St Vincent declaration of 1989 is to be met.	BROADGREEN HOSP,LIVERPOOL L14 3LD,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,SCH BIOL SCI,LIVERPOOL L69 38X,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; LIVERPOOL WOMENS HOSP,LIVERPOOL L8 7SS,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3GB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool			Platt, MJ/K-4588-2012	Platt, MJ/0000-0002-9372-9575; Howard, Charles Vyvyan/0000-0002-6151-3446				Albert TJ, 1996, AM J OBSTET GYNECOL, V174, P1424, DOI 10.1016/S0002-9378(96)70583-5; CORDERO L, 1993, CLIN PERINATOL, V20, P635, DOI 10.1016/S0095-5108(18)30390-7; Diabet Control Complications Trial Res Grp, 1996, AM J OBSTET GYNECOL, V174, P1343; DOLK H, 1991, DESCRIPTIVE EUROCAT; DUNLOP DC, 1996, DIABETIC MED, V13, pS44; HAWTHORNE GC, 1996, DIABET MED S3, V13, pS44; KITZMILLER JL, 1991, JAMA-J AM MED ASSOC, V265, P731, DOI 10.1001/jama.265.6.731; LANDON MB, 1987, AM J OBSTET GYNECOL, V156, P1089, DOI 10.1016/0002-9378(87)90116-5; Landon MB, 1995, MED DISORDERS PREGNA, P63; LOWRY C, 1986, DIABETIC MED, V3, P458; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; *N W REG HLTH AUTH, 1995, HLTH N W ENGL COMM D; *NW REG HLTH AUTH, 1995, N W REG 1994 PUBL HL; OATS JN, 1995, BAILLIERE CLIN OB GY, V9, P481, DOI 10.1016/S0950-3552(05)80376-1; *OFF NAT STAT, 1996, POP TRENDS 84; *OFF POP CENS SURV, 1982, INF PER MORT SOC BIO; *OFF POP CENS SURV, 1992, INF PER MORT SOC BIO; *OFF POP CENS SURV, 1992, BRITH STAT; *OFF POP CENS SURV, 1992, CONG MALF STAT; ROSENN B, 1994, OBSTET GYNECOL, V84, P515; *SCOTT HLTH SERV C, 1991, BIRTHW HEAD CIRC LEN; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; WEATHERALL JAC, 1978, POPUL TRENDS, V11, P27; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; ZAR JH, 1984, BIOSTAT ANAL, P386	26	368	374	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					275	278		10.1136/bmj.315.7103.275	http://dx.doi.org/10.1136/bmj.315.7103.275			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274545	Green Published			2022-12-28	WOS:A1997XP75000019
J	Swerlick, RA; Lawley, TJ				Swerlick, RA; Lawley, TJ			Hypersensitivity vasculitis - not always benign?	LANCET			English	Editorial Material											Swerlick, RA (corresponding author), EMORY UNIV,SCH MED,DEPT DERMATOL,ATLANTA,GA 30345, USA.		Swerlick, Robert/AAY-1998-2020	Swerlick, Robert/0000-0002-9802-4144				EKENSTAM AE, 1984, ARCH DERMATOL, V120, P484; MartinezTaboada VM, 1997, AM J MED, V102, P186; TancredeBohin E, 1997, ARCH DERMATOL, V133, P438, DOI 10.1001/archderm.133.4.438; WINKELMANN RK, 1964, MEDICINE, V43, P59, DOI 10.1097/00005792-196401000-00003; WISNIESKI JJ, 1995, MEDICINE, V74, P24, DOI 10.1097/00005792-199501000-00003	5	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					306	307		10.1016/S0140-6736(05)63383-1	http://dx.doi.org/10.1016/S0140-6736(05)63383-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251631				2022-12-28	WOS:A1997XP24200004
J	Otis, TS; Kavanaugh, MP; Jahr, CE				Otis, TS; Kavanaugh, MP; Jahr, CE			Postsynaptic glutamate transport at the climbing fiber Purkinje cell synapse	SCIENCE			English	Article							GATED CHLORIDE CHANNEL; GLIAL-CELLS; RAT-BRAIN; CONDUCTANCE; TRANSMITTER; SALAMANDER; TRANSMISSION; RECEPTOR; RELEASE; NEURONS	The role of postsynaptic, neuronal glutamate transporters in terminating signals at central excitatory synapses is not known. Stimulation of a climbing fiber input to cerebellar Purkinje cells was shown to generate an anionic current mediated by glutamate transporters. The kinetics of transporter currents were resolved by pulses of glutamate to outside-out membrane patches from Purkinje cells. Comparison of synaptic transporter currents to transporter currents expressed in Xenopus oocytes suggests that postsynaptic uptake at the climbing fiber synapse removes at least 22 percent of released glutamate. These neuronal transporter currents arise from synchronous activation of transporters that greatly outnumber activated AMPA receptors.			Otis, TS (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,L 474,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.				NINDS NIH HHS [NS33270, NS21419] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033270, R01NS021419] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; Billups B, 1996, J NEUROSCI, V16, P6722; BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Diamond JS, 1997, J NEUROSCI, V17, P4672; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; GRANT GB, 1995, J NEUROSCI, V15, P3852; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; Kataoka Y, 1996, J NEUROPHYSIOL, V76, P1870, DOI 10.1152/jn.1996.76.3.1870; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2262; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Muller T, 1995, INT REV NEUROBIOL, V38, P341, DOI 10.1016/S0074-7742(08)60530-9; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PICAUD SA, 1995, J NEUROPHYSIOL, V74, P1760, DOI 10.1152/jn.1995.74.4.1760; RIVAROS N, 1986, BRAIN RES, V386, P405; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; Takahashi M, 1996, J PHYSIOL-LONDON, V497, P523, DOI 10.1113/jphysiol.1996.sp021785; TAKAHASHI M, 1995, J NEUROSCI, V15, P5693; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; TRAYNELIS SF, 1993, NEURON, V11, P279, DOI 10.1016/0896-6273(93)90184-S; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WYLLIE DJA, 1993, J PHYSIOL-LONDON, V463, P193, DOI 10.1113/jphysiol.1993.sp019591; Yamada K, 1996, NEUROREPORT, V7, P2013, DOI 10.1097/00001756-199608120-00032; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	34	153	156	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1515	1518		10.1126/science.277.5331.1515	http://dx.doi.org/10.1126/science.277.5331.1515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278516				2022-12-28	WOS:A1997XV42900043
J	Presley, JF; Cole, NB; Schroer, TA; Hirschberg, K; Zaal, KJM; LippincottSchwartz, J				Presley, JF; Cole, NB; Schroer, TA; Hirschberg, K; Zaal, KJM; LippincottSchwartz, J			ER-to-Golgi transport visualized in living cells	NATURE			English	Article							GREEN-FLUORESCENT PROTEIN; ENDOPLASMIC-RETICULUM; VIRAL GLYCOPROTEIN; BETA-COP; COMPLEX; COMPARTMENT; VIRUS; ORGANIZATION; MEMBRANES; SURFACE	Newly synthesized proteins that leave the endoplasmic reticulum (ER) are funnelled through the Golgi complex before being sorted for transport to their different final destinations. Traditional approaches have elucidated the biochemical requirements for such transport(1-3) and have established a role for transport intermediates(4-8). New techniques for tagging proteins fluorescently(9,10) have made it possible to follow the complete life history of single transport intermediates in living cells, including their formation, path and velocity en route to the Golgi complex. We have now visualized ER-to-Golgi transport using the viral. glycoprotein ts045 VSVG tagged with green fluorescent protein (VSVG-GFP). Upon export from the ER, VSVG-GFP became concentrated in many differently shaped, rapidly forming pre-Golgi structures, which translocated inwards towards the Golgi complex along microtubules by using the microtubule minus-end-directed motor complex of dynein/dynactin. No loss of fluorescent material from pre-Golgi structures occurred during their translocation to the Golgi complex and they frequently stretched into tubular shapes. Together, our results indicate that these pre-Golgi carrier structures moving unidirectionally along microtubule tracks are responsible for transporting VSVG-GFP through the cytoplasm to the Golgi complex. This contrasts with the traditional focus on small vesicles as the primary vehicles for ER-to-Golgi transport.	NICHHD, CELL BIOL & METAB BRANCH, NICHHD, NIH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Johns Hopkins University			Hirschberg, Koret/AAF-4566-2019	Schroer, Trina/0000-0002-5065-1835	NIGMS NIH HHS [R01 GM044589] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Burkhardt J. K., 1995, Molecular Biology of the Cell, V6, p266A; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; SARASTE J, 1991, J CELL SCI, V100, P415; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429	31	940	960	1	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					81	85		10.1038/38001	http://dx.doi.org/10.1038/38001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288971				2022-12-28	WOS:A1997XU59600049
J	tenCate, JW; Buller, HR; Gent, M; Hirsh, J; Prins, MH; Baildon, R; Lensing, AWA; Anderson, DR; vanBeek, EJR; Fiesinger, JN; Tijssen, JGP; vanBarneveld, A; Eimers, LT; Graafsma, YP; Hettiarachchi, R; Hutten, B; Redekop, K; Haley, S; LIberale, L; Finch, T; Whittaker, S; Wilkinson, L; Prandoni, P; Villalta, S; Girolami, B; Bagatella, P; Rossi, L; Girolami, A; Piovella, F; Barone, M; Beltrametti, C; Serafini, S; Siragusa, S; Ascari, E; Kovacs, MJ; Morrow, B; Kovacs, J; Kuijer, PMM; Koopman, MMW; Jagt, H; Weitz, J; Kearon, C; Biagioni, L; Haas, S; Lossner, F; Spengel, FA; Berger, M; Demers, C; Poulin, J; vanderMeer, J; Que, GTH; Smid, WM; Robinson, KS; Boyle, E; Leclerc, JR; StJacques, B; Finkenbine, S; Gallus, AS; Cohlan, D; Rich, C; Brandjes, DPM; Hoefnagel, CA; deRijk, M; Turkstra, F; Desjardins, L; CoteDesjardins, J; Couture, L; Ruel, M; Villenueve, J; Geerts, WH; Jay, RM; Code, EKI; Turpie, AGG; Johnson, J; Nguyen, P; Cusson, JR; Roy, S; Wells, PS; Bormanis, J; Goudie, D; Cruickshank, M; vonLewinski, M; Monreal, M; Sahuquillo, JC; Lafoz, E; Simonneau, G; Parent, F; Jagot, J; Douketis, JD; Kinnon, K; Ginsberg, JS; BrillEdwards, P; Donovan, D; Ockelford, PA; Kassis, J; Bornais, S; Planchon, B; ElKouri, D; Pistorius, MA; Escribano, M; Garrido, G; Chesterman, CN; Chong, BH; Pritchard, S; Cade, JF; Bynon, T; Stanford, J; Brien, WM; Palmer, B; Faivre, R; Petiteau, B; Manucci, PM; Moia, M; Bucciarelli, P				tenCate, JW; Buller, HR; Gent, M; Hirsh, J; Prins, MH; Baildon, R; Lensing, AWA; Anderson, DR; vanBeek, EJR; Fiesinger, JN; Tijssen, JGP; vanBarneveld, A; Eimers, LT; Graafsma, YP; Hettiarachchi, R; Hutten, B; Redekop, K; Haley, S; LIberale, L; Finch, T; Whittaker, S; Wilkinson, L; Prandoni, P; Villalta, S; Girolami, B; Bagatella, P; Rossi, L; Girolami, A; Piovella, F; Barone, M; Beltrametti, C; Serafini, S; Siragusa, S; Ascari, E; Kovacs, MJ; Morrow, B; Kovacs, J; Kuijer, PMM; Koopman, MMW; Jagt, H; Weitz, J; Kearon, C; Biagioni, L; Haas, S; Lossner, F; Spengel, FA; Berger, M; Demers, C; Poulin, J; vanderMeer, J; Que, GTH; Smid, WM; Robinson, KS; Boyle, E; Leclerc, JR; StJacques, B; Finkenbine, S; Gallus, AS; Cohlan, D; Rich, C; Brandjes, DPM; Hoefnagel, CA; deRijk, M; Turkstra, F; Desjardins, L; CoteDesjardins, J; Couture, L; Ruel, M; Villenueve, J; Geerts, WH; Jay, RM; Code, EKI; Turpie, AGG; Johnson, J; Nguyen, P; Cusson, JR; Roy, S; Wells, PS; Bormanis, J; Goudie, D; Cruickshank, M; vonLewinski, M; Monreal, M; Sahuquillo, JC; Lafoz, E; Simonneau, G; Parent, F; Jagot, J; Douketis, JD; Kinnon, K; Ginsberg, JS; BrillEdwards, P; Donovan, D; Ockelford, PA; Kassis, J; Bornais, S; Planchon, B; ElKouri, D; Pistorius, MA; Escribano, M; Garrido, G; Chesterman, CN; Chong, BH; Pritchard, S; Cade, JF; Bynon, T; Stanford, J; Brien, WM; Palmer, B; Faivre, R; Petiteau, B; Manucci, PM; Moia, M; Bucciarelli, P			Low-molecular-weight heparin in the treatment of patients with venous thromboembolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; INTRAVENOUS UNFRACTIONATED HEPARIN; SUSPECTED PULMONARY-EMBOLISM; INITIAL TREATMENT; STANDARD HEPARIN; METAANALYSIS; MANAGEMENT; HOME; VENOGRAPHY	Background Low-molecular-weight heparin is known to be safe and effective for the initial Treatment of patients with proximal deep-vein thrombosis. However, its application to patients with pulmonary embolism or previous episodes of thromboembolism has not been studied. Methods We randomly assigned 1021 patients with symptomatic venous thromboembolism to fixed-dose, subcutaneous low-molecular-weight heparin (reviparin sodium) or adjusted-dose, intravenous unfractionated heparin. Oral anticoagulant therapy with a coumarin derivative was started concomitantly and continued for 12 weeks, Approximately one third of the patients had associated pulmonary embolism, The outcome events studied over the 12 weeks were symptomatic recurrent venous thromboembolism, major bleeding, and death. We sought to determine whether low-molecular-weight heparin is at least equivalent to unfractionated heparin in patients with venous thromboembolism. Results Twenty-seven of the 510 patients assigned to low-molecular-weight heparin (5.3 percent) had recurrent thromboembolic events, as compared with 25 of the 511 patients assigned to unfractionated heparin (4.9 percent). The difference of 0.4 percentage point indicates that the two therapies have equivalent value according to our predetermined definition of equivalence. Sixteen patients assigned to low-molecular-weight heparin (3.1 percent) and 12 patients assigned to unfractionated heparin (2.3 percent) had episodes of major bleeding (P=0.63), and the mortality rates in the two groups were 7.1 percent and 7.6 percent, respectively (P=0.89). Conclusions Fixed-dose, subcutaneous low-molecular-weight heparin is as effective and safe as adjusted-dose, intravenous unfractionated heparin for the initial management of venous thromboembolism, regardless of whether the patient has pulmonary embolism or a history of venous thromboembolism. (C) 1997, Massachusetts Medical Society.	HAMILTON CIV HOSP,RES CTR,HAMILTON,ON,CANADA; INST MED SEMEIOT,PADUA,ITALY; POLICLIN SAN MATTEO,I-27100 PAVIA,ITALY; VICTORIA HOSP,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,LONDON,ON,CANADA; HAMILTON CIV HOSP,HENDERSON GEN DIV,HAMILTON,ON,CANADA; STADT KRANKENHAUS MUNCHEN BOGENHAUSEN,MED POLIKLIN,MUNICH,GERMANY; HOP ST SACREMENT,QUEBEC CITY,PQ,CANADA; UNIV GRONINGEN HOSP,GRONINGEN,NETHERLANDS; VICTORIA GEN HOSP,HALIFAX,NS B3H 2Y9,CANADA; MONTREAL GEN HOSP,MONTREAL,PQ H3G 1A4,CANADA; FLINDERS MED CTR,ADELAIDE,SA,AUSTRALIA; SLOTERVAARE HOSP,AMSTERDAM,NETHERLANDS; CHU LAVAL,QUEBEC CITY,PQ G1V 4G2,CANADA; SUNNYBROOK HLTH SCI CTR,TORONTO,ON M4N 3M5,CANADA; HAMILTON CIV HOSP,HAMILTON GEN DIV,HAMILTON,ON,CANADA; HOP HOTEL DIEU,MONTREAL,PQ,CANADA; OTTAWA CIVIC HOSP,OTTAWA,ON K1Y 4E9,CANADA; UNIV HOSP LONDON,LONDON,ON,CANADA; HOSP GERMANS TRIAS & PUJOL,BARCELONA,SPAIN; HOP ANTOINE BECLERE,CLAMART,FRANCE; ST JOSEPHS HOSP,HAMILTON,ON,CANADA; MCMASTER UNIV,MED CTR,HAMILTON,ON,CANADA; AUCKLAND HOSP,AUCKLAND,NEW ZEALAND; HOP MAISON NEUVE ROSEMONT,MONTREAL,PQ H1T 2M4,CANADA; CHU HOTEL DIEU,NANTES,FRANCE; HOSP 12 OCTUBRE,E-28041 MADRID,SPAIN; PRINCE WALES HOSP,SYDNEY,NSW,AUSTRALIA; ROYAL MELBOURNE HOSP,MELBOURNE,FL; ST JOSEPHS HLTH CTR,LONDON,ON,CANADA; ST VINCENTS CLIN,BESANCON,FRANCE; MAGGIORE HOSP,HEMOPHILIA & THROMBOSIS CTR A BIANCHI BONOMI,MILAN,ITALY	McMaster University; IRCCS Fondazione San Matteo; University of Victoria; Western University (University of Western Ontario); Western University (University of Western Ontario); McMaster University; Munchen Klinik; Laval University; University of Groningen; Dalhousie University; University of Victoria; McGill University; Flinders Medical Centre; Slotervaart Hospital; Laval University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; McMaster University; Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute; Western University (University of Western Ontario); Hospital Germans Trias i Pujol; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; McGill University; McMaster University; McMaster University; Auckland City Hospital; Universite de Montreal; Nantes Universite; CHU de Nantes; Hospital Universitario 12 de Octubre; Western University (University of Western Ontario); IRCCS Ca Granda Ospedale Maggiore Policlinico	tenCate, JW (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,MEIBERGDREEF 9,NL-1105 AZ AMSTERDAM,NETHERLANDS.		Douketis, James/AAO-5659-2021; Redekop, Ken/AAA-2423-2020; Chong, Beng/AAE-2617-2019; Weitz, Jeffrey/AAD-1929-2019; ginsberg, jeffrey s/ABC-1065-2020; Boyle, Eleanor/G-4567-2016; Bucciarelli, Paolo/J-1907-2015; Bucciarelli, Paolo/AAB-5024-2019; Smid, Willem Martin/AFT-8623-2022; Moia, Marco/J-2888-2015; Piovella, Franco/AAM-8305-2020; Kovacs, Michael/G-3315-2011; Chong, Beng/AAM-9010-2021; Simonneau, Gerald/ABE-6614-2020	Weitz, Jeffrey/0000-0002-1092-7550; Boyle, Eleanor/0000-0002-9012-9128; Bucciarelli, Paolo/0000-0003-0877-365X; Bucciarelli, Paolo/0000-0003-0877-365X; Smid, Willem Martin/0000-0001-8487-0043; Moia, Marco/0000-0002-7041-7755; Gallus, Alexander/0000-0001-7347-9989				ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; CLARK S, 1995, LANCET, V346, P113, DOI 10.1016/S0140-6736(95)92133-8; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; KIERKEGAARD A, 1980, ACTA CHIR SCAND, V146, P267; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; KRUIT WHJ, 1991, J INTERN MED, V230, P333, DOI 10.1111/j.1365-2796.1991.tb00453.x; LAGERSTEDT CI, 1985, LANCET, V2, P515; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; Schafer AI, 1996, NEW ENGL J MED, V334, P724, DOI 10.1056/NEJM199603143341110; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; Siragusa S, 1996, AM J MED, V100, P269, DOI 10.1016/S0002-9343(97)89484-3; VANBEEK EJR, 1996, TXB VASCULAR MED, P471	24	642	648	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					657	662						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU349	9280815				2022-12-28	WOS:A1997XU34900001
J	Ferguson, JR				Ferguson, JR			Biomedical research and insider trading	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Ferguson, JR (corresponding author), SONNENSCHEIN NATH & ROSENTHAL,CHICAGO,IL 60606, USA.							BISHOP J, 1995, WALL STREET J   0613, pB3; *COR THER INC, 1995, WALL STREET J   0615, pB7; JOHANNES I, 1996, WALL STREET J   0829, pB1; NEWMAN A, 1994, WALL STREET J   0520, pR16; ROUSH W, 1995, SCIENCE, V269, P627, DOI 10.1126/science.7624787; STIPP D, 1994, WALL STREET J   0728, pB11; TURNER R, 1994, WALL STREET J   0314, pB4; WALDHOLZ M, 1988, WALL STREET J   0218, P25; WALDHOLZ M, 1988, WALL STREET J   0218, P1; 1997, NY TIMES        0411, pD4; 1996, WALL STREET J   0816, pB4; 1996, NY TIMES        1019, pA39; 1996, NY TIMES        1231, pD3	13	9	9	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					631	634		10.1056/NEJM199708283370910	http://dx.doi.org/10.1056/NEJM199708283370910			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271488				2022-12-28	WOS:A1997XT39400010
J	Dorman, PJ; Slattery, J; Farrell, B; Dennis, MS; Sandercock, PAG				Dorman, PJ; Slattery, J; Farrell, B; Dennis, MS; Sandercock, PAG			A randomised comparison of the EuroQol and short form-36 after stroke	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE				Dorman, PJ (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,NEUROSCI TRIALS UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				Fallowfield L, 1996, LANCET, V348, P421, DOI 10.1016/S0140-6736(05)64534-5; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124	4	84	86	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					461	461		10.1136/bmj.315.7106.461	http://dx.doi.org/10.1136/bmj.315.7106.461			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284664	Green Published			2022-12-28	WOS:A1997XT71400019
J	Eickbush, TH				Eickbush, TH			Telomerase and retrotransposons: Which came first?	SCIENCE			English	Editorial Material							REVERSE-TRANSCRIPTASE; RNA; SEQUENCES				Eickbush, TH (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.							BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; COUNTER CM, IN PRESS P NATL ACAD; Eickbush Thomas H., 1994, P121; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; LEVIS RW, 1993, CELL, V75, P1; LINDNER J, 1997, SCIENCE, V276, P561; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6	15	157	170	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					911	912		10.1126/science.277.5328.911	http://dx.doi.org/10.1126/science.277.5328.911			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281073				2022-12-28	WOS:A1997XQ98500029
J	Leon, DA; Chenet, L; Shkolnikov, VM; Zakharov, S; Shapiro, J; Rakhmanova, G; Vassin, S; McKee, M				Leon, DA; Chenet, L; Shkolnikov, VM; Zakharov, S; Shapiro, J; Rakhmanova, G; Vassin, S; McKee, M			Huge variation in Russian mortality rates 1984-94: Artefact, alcohol, or what?	LANCET			English	Article							SUDDEN CARDIAC DEATH; INTEMPERANCE; TUBERCULOSIS; DISEASE; STROKE; MEN	Background According to published data, between 1984 and 1994 mortality rates in Russia initially underwent a rapid decline followed by an even steeper increase. In 1994, male life expectancy at birth was 57.6 years, having fallen by 6.2 years since 1990, There has been concern that such striking fluctuations in mortality are an artefact, although, among other factors, alcohol consumption has been implicated. Methods We analysed the age-specific and cause-specific patterns of mortality decrease and increase by use of data from a newly reconstructed mortality series for Russia so that we could examine the plausibility of various ex planations for the mortality trends. Findings All major causes of death, with the exception of neoplasms, showed declines in mortality between 1984 and 1987 and increases between 1987 and 1994, In relative terms, these tended to be largest for the age-group 40-50 years; surprisingly, they were of the same magnitude among women and men, The largest declines and subsequent increases in proportional terms were observed for alcohol-related deaths and accidents and violence. However, pronounced effects were also seen for deaths from infections, circulatory disease, and respiratory disease. No substantial variations were seen for neoplasms. Interpretation The stability of mortality from neoplasms in contrast to other causes over the period 1984-94 largely precludes the possibility that the changes in life expectancy are mainly an artefact, particularly one due to underestimation of the population. Although factors such as nutrition and health services may be involved, the evidence is that substantial changes in alcohol consumption over the period could plausibly explain the main features of the mortality fluctuations observed, These results provide a major challenge to public health in Russia and to our understanding of the determinants of alcohol consumption and its role in explaining mortality patterns within and between many other countries.	CTR DEMOG & HUMAN ECOL, MOSCOW, RUSSIA; UNIV LONDON GOLDSMITHS COLL, LONDON SE14 6NW, ENGLAND	University of London; Goldsmiths University London	Leon, DA (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, EUROPEAN CTR HLTH SOC TRANSIT, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Shkolnikov, Vladimir/D-2986-2017; McKee, Marc D/E-2187-2011; Zakharov, Sergei V/K-4797-2015; Leon, David A/G-2195-2010; Mckee, Martin/E-6673-2018; Vasin, Sergey/I-2897-2015	Shkolnikov, Vladimir/0000-0003-2259-5423; McKee, Marc D/0000-0001-8349-965X; Zakharov, Sergei V/0000-0002-1653-4264; Leon, David A/0000-0001-9747-1762; Mckee, Martin/0000-0002-0121-9683; Vasin, Sergei/0000-0003-3647-9247				ANDERSON CS, 1993, MED J AUSTRALIA, V158, P85, DOI 10.5694/j.1326-5377.1993.tb137529.x; ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; BEDNIY MS, 1980, ANAL MED DEMOGRAFICH; BURNS DN, 1994, LANCET, V343, P1445, DOI 10.1016/S0140-6736(94)92576-3; CASSILETH BR, 1995, JAMA-J AM MED ASSOC, V273, P1569, DOI 10.1001/jama.273.20.1569; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FEIGIN VL, 1995, MAYO CLIN PROC, V70, P847; Ginter E, 1996, INT J VITAM NUTR RES, V66, P183; *GOSK, 1996, DEM EZH ROSS DEMOGRA; *INT AG RES CANC, 1989, IARC MON EV CARC RIS, V44; LITHELL H, 1987, BRIT MED J, V294, P1456, DOI 10.1136/bmj.294.6585.1456; Lopez A., 1992, GEOGRAPHICAL ENV EPI, P37; Macfarlane GJ, 1996, J EPIDEMIOL COMMUN H, V50, P636, DOI 10.1136/jech.50.6.636; MESLE F, 1992, EUR J POPUL, V8, P281, DOI 10.1007/BF01796624; MESLE F, 1996, TENDANCES RECENTES M; MESLE F, 1996, POPULATION, V3, P773; MESLE F, 1995, REV ETUDES COMP ES 4, P9; NELSON S, 1995, ALCOHOL CLIN EXP RES, V19, P17, DOI 10.1111/j.1530-0277.1995.tb01467.x; NEMTSOV A, 1996, NASELENIYE OBSHCHEES, V10, P1; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; POPKIN BM, 1996, AM J PUBLIC HEALTH, V86, P35; ROSENGREN A, 1987, ACTA MED SCAND, V222, P201; RYAN M, 1995, BRIT MED J, V310, P646; SCHMIDT W, 1981, CANCER-AM CANCER SOC, V47, P1031, DOI 10.1002/1097-0142(19810301)47:5<1031::AID-CNCR2820470534>3.0.CO;2-C; SHANMUGAN M, 1996, RES MONOGRAPH NATL I, V31, P159; Shkolnikov V. M., 1997, PREMATURE DEATH NEW, P239; Shkolnikov VM, 1996, RAND CONF PROC, P113; UNICEF, 1994, 2 UNICEF; VANGIJN J, 1993, HLTH ISSUES RELATED, P43; VIKHERT AM, 1986, J AM COLL CARDIOL, V8, pA3, DOI 10.1016/S0735-1097(86)80023-7; WANNAMETHEE G, 1992, BRIT HEART J, V68, P443; WATSON RR, 1994, ALCOHOL ALCOHOLISM, V29, P131; Yuan JM, 1997, BRIT MED J, V314, P18, DOI 10.1136/bmj.314.7073.18; ZOHOORI N, 1996, MONITORING HLTH COND	34	566	591	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					383	388		10.1016/S0140-6736(97)03360-6	http://dx.doi.org/10.1016/S0140-6736(97)03360-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259651				2022-12-28	WOS:A1997XQ24800007
J	Hawthorne, G; Robson, S; Ryall, EA; Sen, D; Roberts, SH; Platt, MPW				Hawthorne, G; Robson, S; Ryall, EA; Sen, D; Roberts, SH; Platt, MPW			Prospective population based survey of outcome of pregnancy in diabetic women: results of the northern diabetic pregnancy audit, 1994	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-ANOMALIES; PRECONCEPTION CARE	Objective: To determine whether the St Vincent declaration (1989) target of diabetic pregnancy outcome approximating non-diabetic pregnancy outcome is near to being achieved. Design: Prospective collection of population based information on pregnancies in women with diabetes from all participating hospitals. Setting: District general and teaching hospitals of the former Northern region. Subjects: 111 diabetic women booking with pregnancy during 1 January to 31 December 1994. Main outcome measures: Diabetic control, perinatal mortality rate, fetal abnormality rate. Results: The perinatal mortality rate was 48/1000 for diabetic pregnancies compared with 8.9/1000 for the background population (odds ratio 5.38; 95% confidence interval 2.27 to 12.70) and the neonatal mortality rate was 59/1000 compared with 3.9/1000 (15.0; 6.77 to 33.10). Two late neonatal deaths were due to congenital heart defects. Six per cent of all fetal losses (6/109 cases) were due to major malformations. The congenital malformation rate was 83/1000 compared with 21.3/1000 (3.76; 2.00 to 7.06) in the background population. Conclusion: Diabetic pregnancy remains a high risk state with perinatal mortality and fetal malformation rates much higher than in the background population.	UNIV NEWCASTLE UPON TYNE, ROYAL VICTORIA INFIRM, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; N TEES GEN HOSP, STOCKTON ON TEES TS19 8PE, ENGLAND; N TYNESIDE HOSP, DIABET RESOURCE CTR, N SHIELDS NE29 8NH, TYNE & WEAR, ENGLAND	Newcastle University - UK; University Hospital of North Tees	Hawthorne, G (corresponding author), HARTLEPOOL GEN HOSP, HARTLEPOOL TS24 9AH, CLEVELAND, ENGLAND.		Platt, Martin Ward/D-4008-2014	Platt, Martin Ward/0000-0003-0536-5749				Diabetes care and research in Europe, 1990, DIABETIC MED, V7, P360; ELIXHAUSER A, 1993, DIABETES CARE, V16, P1146, DOI 10.2337/diacare.16.8.1146; GREGORY R, 1992, J ROY COLL PHYS LOND, V26, P162; KITZMILLER JL, 1991, JAMA-J AM MED ASSOC, V265, P731, DOI 10.1001/jama.265.6.731; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MORRIS JA, 1989, STAT CONFIDENCE, P50; *N REG HLTH AUTH, 1995, REG FET ABN SURV PRO; *NO REG HLTH AUTH, 1995, COLL SURV PER LAT NE; RENWICK M, 1992, ARCH DIS CHILD-FETAL, V67, P770; ROSENN B, 1991, OBSTET GYNECOL, V77, P846; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; TIN W, IN PRESS BR J OBSTET; TRAUB AI, 1987, BRIT J OBSTET GYNAEC, V94, P957, DOI 10.1111/j.1471-0528.1987.tb02269.x	14	157	160	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					279	281		10.1136/bmj.315.7103.279	http://dx.doi.org/10.1136/bmj.315.7103.279			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274546	Green Published			2022-12-28	WOS:A1997XP75000020
J	Sanchez, JL; Taylor, DN				Sanchez, JL; Taylor, DN			Cholera	LANCET			English	Article							NORTH-AMERICAN VOLUNTEERS; VIBRIO-CHOLERAE; EPIDEMIC CHOLERA; UNITED-STATES; O139 BENGAL; VACCINE; TRANSMISSION; BANGLADESH; LIVE; EFFICACY		WALTER REED ARMY MED CTR, WALTER REED ARMY INST RES, DIV COMMUNICABLE DIS & IMMUNOL, WASHINGTON, DC 20307 USA; USN, MED RES INST DETACHMENT, LIMA, PERU	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center	Sanchez, JL (corresponding author), USA, MED RES UNIT BRAZIL, APO, AA 34030 USA.							ALBERT MJ, 1993, LANCET, V342, P387, DOI 10.1016/0140-6736(93)92811-7; [Anonymous], 1995, Lancet, V345, P339; [Anonymous], 1978, LANCET, V2, P300; Barua Dhiman, 1992, P329; BATTACHARYA SK, 1993, J INFECTION, V33, P560; BEGUE RE, 1994, AM J TROP MED HYG, V51, P585, DOI 10.4269/ajtmh.1994.51.585; BENEDITOSILVA AA, 1990, PROG CLIN BIOL RES, V341, P89; Bennish Michael L., 1994, P229; BESSER RE, 1994, JAMA-J AM MED ASSOC, V272, P1203, DOI 10.1001/jama.272.15.1203; Brown V, 1997, LANCET, V349, P212, DOI 10.1016/S0140-6736(05)60959-2; CASH RA, 1974, J INFECT DIS, V129, P45, DOI 10.1093/infdis/129.1.45; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P104; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1989, J INFECT DIS, V159, P770, DOI 10.1093/infdis/159.4.770; Colwell Rita R., 1994, P117; COSTER TS, 1995, LANCET, V345, P949, DOI 10.1016/S0140-6736(95)90698-3; DALSGAARD A, 1995, LANCET, V345, P1637, DOI 10.1016/S0140-6736(95)90142-6; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; Dhar U, 1996, T ROY SOC TROP MED H, V90, P402, DOI 10.1016/S0035-9203(96)90522-2; DIZON JJ, 1967, B WORLD HEALTH ORGAN, V37, P737; Feachem R G, 1982, Trop Dis Bull, V79, P1; FEELEY JC, 1980, CHOLERA RELATED DIAR, P204; GANGAROSA EJ, 1974, CHOLERA, P381; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; GLASS RI, 1983, NEW ENGL J MED, V308, P1389, DOI 10.1056/NEJM198306093082304; GLASS RI, 1985, AM J EPIDEMIOL, V121, P791, DOI 10.1093/oxfordjournals.aje.a114050; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; Glass Roger I., 1992, P129; GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101; GOTUZZO E, 1995, CLIN INFECT DIS, V20, P1485, DOI 10.1093/clinids/20.6.1485; HALL RH, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92839-L; Holmgren J., 1994, P415; ISLAM MS, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92840-P; Joo I., 1974, CHOLERA, P333; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; KENNER JR, 1995, J INFECT DIS, V172, P1126, DOI 10.1093/infdis/172.4.1126; Khan WA, 1996, LANCET, V348, P296, DOI 10.1016/S0140-6736(96)01180-4; KOLVIN JL, 1982, J HYG-CAMBRIDGE, V89, P243, DOI 10.1017/S0022172400070777; LACEY SW, 1995, CLIN INFECT DIS, V20, P1409, DOI 10.1093/clinids/20.5.1409; Le vine MM, 1981, ACUTE ENTERIC INFECT, P443; Levine MM, 1997, LANCET, V349, P220, DOI 10.1016/S0140-6736(97)22004-0; Levine Myron M., 1994, P395; Maggi P, 1996, LANCET, V348, P1446, DOI 10.1016/S0140-6736(04)70088-4; MAHALANABIS D, 1994, EPIDEMIOL INFECT, V112, P463, DOI 10.1017/S0950268800051165; McLaughlin James C., 1995, P465; MHALU FS, 1979, LANCET, V1, P345; Mitra R, 1996, LANCET, V348, P1181, DOI 10.1016/S0140-6736(05)65326-3; MORRIS JG, 1995, J INFECT DIS, V171, P903, DOI 10.1093/infdis/171.4.903; Morris JG, 1996, J INFECT DIS, V174, P1364, DOI 10.1093/infdis/174.6.1364; MORRIS JG, 1994, VIBRIO CHOLERAE CHOL, P95; NAIR GB, 1994, J INFECT DIS, V169, P1029, DOI 10.1093/infdis/169.5.1029; POLLITZER R, 1959, WHO MONOGR, V43; POPOVIC T, 1995, J INFECT DIS, V171, P122, DOI 10.1093/infdis/171.1.122; RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5; Sack R B, 1996, Curr Clin Top Infect Dis, V16, P172; SAKAZAKI R, 1971, JPN J MED SCI BIOL, V24, P93, DOI 10.7883/yoken1952.24.93; SANCHEZ JL, 1993, J INFECT DIS, V167, P1446, DOI 10.1093/infdis/167.6.1446; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; SANCHEZ JL, 1994, P 43 ANN AM SOC TROP; SCAS C, 1996, INT J INFECT DIS, V1, P37; SHCARS P, 1994, ANN TROP MED PARASIT, V88, P109; SIDDIQUE AK, 1995, LANCET, V345, P359, DOI 10.1016/S0140-6736(95)90344-5; SNYDER JD, 1982, JAMA-J AM MED ASSOC, V247, P2268, DOI 10.1001/jama.1982.03320410050031; SWERDLOW DL, 1993, LANCET, V342, P382, DOI 10.1016/0140-6736(93)92806-5; SWERDLOW DL, 1992, LANCET, V340, P28, DOI 10.1016/0140-6736(92)92432-F; SWERDLOW DL, 1992, JAMA-J AM MED ASSOC, V267, P1495, DOI 10.1001/jama.267.11.1495; TACKET CO, 1992, J INFECT DIS, V166, P837, DOI 10.1093/infdis/166.4.837; TACKET CO, 1994, P 30 JOINT C US JAP, P142; Tauxe Robert, 1994, P321; TAUXE RV, 1995, EMERG INFECT DIS, V1, P141, DOI 10.3201/eid0104.950408; TAYLOR DN, 1994, J INFECT DIS, V170, P1518, DOI 10.1093/infdis/170.6.1518; Taylor DN, 1996, CLIN INFECT DIS, V22, P1108, DOI 10.1093/clinids/22.6.1108; Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7; vanLoon FPL, 1996, VACCINE, V14, P162, DOI 10.1016/0264-410X(95)00122-H; VANLOON FPL, 1990, J CLIN EPIDEMIOL, V43, P1361, DOI 10.1016/0895-4356(90)90103-V; WALDOR MK, 1994, INFECT IMMUN, V62, P72, DOI 10.1128/IAI.62.1.72-78.1994; WALDOR MK, 1994, P 30 JOINT C CHOL RE, P148; WEBER JT, 1994, ARCH INTERN MED, V154, P551, DOI 10.1001/archinte.154.5.551; Wittlinger, 1995, J Travel Med, V2, P154, DOI 10.1111/j.1708-8305.1995.tb00643.x; World Health Organization, 1995, CDRGPV951 WHO; YAMAMOTO T, 1995, ANTIMICROB AGENTS CH, V39, P241, DOI 10.1128/AAC.39.1.241	81	45	47	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	1997	349	9068					1825	1830		10.1016/S0140-6736(97)04486-3	http://dx.doi.org/10.1016/S0140-6736(97)04486-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269227				2022-12-28	WOS:A1997XF73500043
J	Villard, J; LisowskaGrospierre, B; vandenElsen, P; Fischer, A; Reith, W; Mach, B				Villard, J; LisowskaGrospierre, B; vandenElsen, P; Fischer, A; Reith, W; Mach, B			Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BARE LYMPHOCYTE SYNDROME; BINDING-PROTEIN; COOPERATIVE BINDING; X-BOX; COMPLEMENTATION; EXPRESSION; IMMUNODEFICIENCY; INDUCTION; PROMOTERS; REQUIRES	Background Major-histocompatibility - complex (MHC) class II deficiency is an autosomal recessive primary immunodeficiency disease in which MHC class II molecules are absent, It is a genetically heterogeneous disease of gene regulation resulting from defects in several transactivating genes that regulate the expression of MHC class II genes, The mutations responsible for MHC class II deficiency are classified according to complementation group (a group in which the phenotype remains uncorrected in pairwise fusions of cells), There are three known complementation groups (A, B, and C). Methods To elucidate the genetic defect in patients with MHC class II deficiency that was not classified genetically, we performed direct complementation assays with the three genes known to regulate the expression of MHC class II genes, CIITA, RFX5, and RFXAP, and the relevant mutations were identified in each patient. Results Mutations in the RFXAP gene were found in three patients from unrelated families, and the resulting defect was classified as belonging to a novel complementation group (D), Transfection with the wild-type RFXAP gene restored the expression of MHC class II molecules in the patients' cells. Conclusions Mutations in a novel MHC class II transactivating factor, RFXAP, can cause MHC class II deficiency. These mutations abolish the expression of MHC class II genes and lead to the same clinical picture of immunodeficiency as in patients with mutations in the other two MHC class II regulatory genes. (C) 1997, Massachusetts Medical Society.	UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,LOUIS JEANTET LAB MOL GENET,CH-1211 GENEVA 4,SWITZERLAND; HOP NECKER ENFANTS MALAD,INSERM,U429,PARIS,FRANCE; LEIDEN UNIV HOSP,DEPT IMMMUNOHEMATOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,BLOOD BANK,LEIDEN,NETHERLANDS	University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)								AMALDI I, 1989, J IMMUNOL, V142, P999; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; CHENG YSE, 1986, J INTERFERON RES, V6, P417, DOI 10.1089/jir.1986.6.417; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GRISCELLI C, 1993, NEW CONCEPTS IMMUNOD, P177; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HAUBER I, 1995, J EXP MED, V181, P1411, DOI 10.1084/jem.181.4.1411; KLEIN C, 1995, BLOOD, V85, P580; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LISOWSKAGROSPIERRE B, 1994, HUM MOL GENET, V3, P953, DOI 10.1093/hmg/3.6.953; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; PEIJNENBURG A, 1995, IMMUNOGENETICS, V41, P287, DOI 10.1007/BF00172153; REITH W, 1994, J BIOL CHEM, V269, P20020; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; SEIDL C, 1992, J IMMUNOL, V148, P1576; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TOURAINE JL, 1981, HUM IMMUNOL, V2, P147, DOI 10.1016/0198-8859(81)90061-6; TOURAINE JL, 1978, J PEDIATR-US, V93, P47, DOI 10.1016/S0022-3476(78)80598-8; VILLARD J, IN PRESS HUM MUTAT; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10934, DOI 10.1093/nar/16.22.10934; WOLF HM, 1995, NEW ENGL J MED, V332, P86, DOI 10.1056/NEJM199501123320204	30	57	59	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					748	753		10.1056/NEJM199709113371104	http://dx.doi.org/10.1056/NEJM199709113371104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287230				2022-12-28	WOS:A1997XV17400004
J	Ferris, LE; Norton, PG; Dunn, EV; Gort, EH; Degani, N				Ferris, LE; Norton, PG; Dunn, EV; Gort, EH; Degani, N			Guidelines for managing domestic abuse when male and female partners are patients of the same physician	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY VIOLENCE; PSYCHIATRIC-INPATIENTS; BATTERED WOMEN; EMERGENCY; RISK; DANGEROUSNESS; RECOGNITION; PREVALENCE; MANAGEMENT; BEHAVIORS	Objective.-To provide clinical guidelines for primary care physicians who are dealing with domestic abuse and who have both the abused woman and her partner as patients. Participants.-A 15 member expert panel with members having experience in family practice, gynecology, emergency medicine, medical ethics, nursing, psychology, law, and social work; an 11-member consulting group with members representing medicine, consumers, police, psychology, social work, and nursing; and participants from focus groups including 48 previously abused women and 10 previously abusive men. Members of the expert panel and the consulting group were recruited by the research team, Focus group members were recruited through the agencies from which they were receiving services. Evidence.-Available research information, and opinions of the expert panel, the consulting group, and the focus group participants. Consensus Process.-Scoring of 144 clinical scenarios was performed by the expert panel using a modified Delphi technique involving 4 iterations, Scenarios were rated in terms of best practice for primary care physicians dealing with suspected and confirmed cases of physical abuse, Consulting group members and focus group participants then commented on the panel's results. Final guidelines were approved by the panel and the consulting group, with comments reserved in the guidelines for information from focus group participants. Conclusions.-It is not a conflict of interest for the physician to deal with abuse of the female partner when both partners are patients. Both patients have a right to autonomy, confidentiality, honesty, and quality care. Patients should be dealt with independently, thereby facilitating assessment of the magnitude and severity of the victim's injuries. Physicians should not discuss the possibility of domestic abuse with the male partner without the prior consent of the abused female partner. Joint counseling is generally inadvisable and should be attempted only when the violence has ended, provided both partners give independent consent and the physician has adequate training and skills to deal with the situation without escalating the violence. if the physician feels unable to deal effectively with either patient because of the dual relationship, referral to another qualified physician is preferred.	UNITED ARAB EMIRATES UNIV,DEPT FAMILY MED,AL AIN,U ARAB EMIRATES; SUNNYBROOK HLTH SCI CTR,CLIN EPIDEMIOL UNIT,N YORK,ON,CANADA; SUNNYBROOK HLTH SCI CTR,DEPT FAMILY & COMMUNITY MED,N YORK,ON,CANADA; SUNNYBROOK HLTH SCI CTR,PRIMARY CARE RES UNIT,N YORK,ON,CANADA; INST CLIN EVALUAT SCI,N YORK,ON,CANADA	United Arab Emirates University; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center	Ferris, LE (corresponding author), UNIV TORONTO,FAC MED,DEPT PUBL HLTH SCI,MCMURRICH BLDG,TORONTO,ON M5S 1A8,CANADA.							ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; ALPERT EJ, 1995, ANN INTERN MED, V123, P774, DOI 10.7326/0003-4819-123-10-199511150-00006; *AM MED ASS, 1992, DIAGN TREATM GUID CH; American Medical Association, 1992, DIAGN TREATM GUID DO; APTER A, 1993, ACTA PSYCHIAT SCAND, V87, P1, DOI 10.1111/j.1600-0447.1993.tb03321.x; APTER A, 1991, AM J PSYCHIAT, V148, P883; ASNIS GM, 1994, HOSP COMMUNITY PSYCH, V45, P127; BECK JC, 1991, AM J PSYCHIAT, V148, P1562; BINDER RL, 1988, AM J PSYCHIAT, V145, P728; BISHOP J, 1992, CAN J PSYCHIAT, V37, P458, DOI 10.1177/070674379203700702; BOWKER LH, 1987, WOMEN HEALTH, V12, P25, DOI 10.1300/J013v12n01_03; BROWN JB, 1993, J FAM PRACTICE, V36, P185; Burge S K, 1989, Fam Med, V21, P368; CONVIC A, 1989, CURRENT APPROACHES P; CONVIT A, 1988, HOSP COMMUNITY PSYCH, V39, P429; *COUNC SCI AFF, 1992, JAMA-J AM MED ASSOC, V267, P3184; ELSE LT, 1993, HOSP COMMUNITY PSYCH, V44, P54; Ferris LE, 1997, CAN MED ASSOC J, V156, P1015; FERRIS LE, 1995, STUDY EXAMINE DUAL R; FERRIS LE, IN PRESS CAN J PSYCH; GHENT WR, 1985, CAN MED ASSOC J, V132, P541; GONDOLF EW, 1990, HOSP COMMUNITY PSYCH, V41, P191; Hart B., 1988, FEMINIST PERSPECTIVE, P234; HART SD, 1994, VIOLENCE MENTAL DISO, P81; HART SD, 1992, J PERSONAL DISORD, V7, P328; HERBERT CP, 1991, CAN FAM PHYSICIAN, V37, P385; Hill M N, 1991, Int J Technol Assess Health Care, V7, P30; Hoffman B. F., 1988, CANADIAN J COMMUNITY, V7, P53; JAFFE P, 1986, CAN J PSYCHIAT, V31, P625, DOI 10.1177/070674378603100705; Jaffe P.G., 1990, CHILDREN BATTERED WO; LENT B, 1986, CAN FAM PHYSICIAN, V32, P547; LIDZ CW, 1993, JAMA-J AM MED ASSOC, V269, P1007, DOI 10.1001/jama.269.8.1007; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; MCNIEL DE, 1995, AM J PSYCHIAT, V152, P901; MCNIEL DE, 1994, HOSP COMMUNITY PSYCH, V45, P133; MCNIEL DE, 1994, VIOLENCE MENTAL DISO, P183; MEHTA P, 1988, AM FAM PHYSICIAN, V37, P193; Neidig PM., 1986, MODIFIED CONFLICT TA; NOVELLO AC, 1992, JAMA-J AM MED ASSOC, V267, P3132, DOI 10.1001/jama.267.23.3132; *ONT MED ASS CO, 1986, ONT MED REV REP WIF; *ONT MED ASS COMM, 1991, SPOUS ASS CRIM JUST; ROSSI AM, 1986, J NERV MENT DIS, V174, P154, DOI 10.1097/00005053-198603000-00005; SASSETTI MR, 1993, PRIMARY CARE, V20, P289; SAUNDERS DG, 1992, AM J ORTHOPSYCHIAT, V62, P264, DOI 10.1037/h0079333; SEGAL SP, 1988, ARCH GEN PSYCHIAT, V45, P753; Sonkin D. J., 1985, MALE BATTERER TREATM; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; Swanson J. W., 1994, VIOLENCE MENTAL DISO, P101, DOI DOI 10.1371/JOURNAL.PMED.1000120; Taylor PJ, 1994, VIOLENCE MENTAL DISO, P161; TEPLIN LA, 1994, AM PSYCHOL, V49, P335, DOI 10.1037/0003-066X.49.4.335; TRUTE B, 1988, CAN J COMMUNITY MENT, V7, P61; *URB RUR SYST ASS, 1980, DOM VIOL PROGR NAT A; VIKEN RM, 1982, POSTGRAD MED, V71, P115, DOI 10.1080/00325481.1982.11716067; Widiger T. A., 1994, VIOLENCE MENTAL DISO, P203; WILCOXEN M, 1981, ASSAULTED WOMEN HDB; WOLFE DA, 1985, J CONSULT CLIN PSYCH, V53, P657, DOI 10.1037/0022-006X.53.5.657	57	25	25	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					851	857		10.1001/jama.278.10.851	http://dx.doi.org/10.1001/jama.278.10.851			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU552	9293995				2022-12-28	WOS:A1997XU55200042
J	Zenilman, JM				Zenilman, JM			Typhoid fever	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIDRUG-RESISTANT SALMONELLA; VI CAPSULAR POLYSACCHARIDE; UNITED-STATES; NEW-YORK; OUTBREAK; VACCINE; INFECTIONS				Zenilman, JM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,ROSS RES BLDG,ROOM 1159,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.							ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; ALAM MN, 1995, AM J TROP MED HYG, V53, P306, DOI 10.4269/ajtmh.1995.53.306; BIRKHEAD GS, 1993, J INFECT DIS, V167, P1228, DOI 10.1093/infdis/167.5.1228; BUTLER T, 1991, REV INFECT DIS, V13, P85; *CDC, 1990, MMWR-MORBID MORTAL W, V39, P749; *CDCP, 1991, MMWR-MORBID MORTAL W, V43, P1; Centers for Disease Control and Prevention (CDC), 1994, MMWR-MORBID MORTAL W, V43, P805; Centers for Disease Control and Prevention (CDC), 1994, MMWR-MORBID MORTAL W, V43, P689; CHILDS CG, COMMUNICATION; COTE TR, 1995, J COMMUN HEALTH, V20, P451, DOI 10.1007/BF02277062; CUSHING H, 1940, LIFE W OSLER, P379; DAMIAN RF, 1994, GINECOL OBSTET MEX, V62, P362; Felix A, 1934, LANCET, V2, P186; GERMANIER R, 1975, J INFECT DIS, V141, P553; Jagadish K, 1994, Indian Pediatr, V31, P807; KLOTZ SA, 1984, ARCH INTERN MED, V144, P533, DOI 10.1001/archinte.144.3.533; KLUGMAN KP, 1987, LANCET, V2, P1165; LEVINE MM, 1987, LANCET, V1, P1049; LEVINE MM, 1994, VACCINES, P597; LIN FYC, 1988, J CLIN MICROBIOL, V26, P1194, DOI 10.1128/JCM.26.6.1194-1197.1988; MATHIEU JJ, 1994, ARCH INTERN MED, V154, P1713, DOI 10.1001/archinte.154.15.1713; Miller S.I., 1995, PRINCIPLES PRACTICE, P2013; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; NOLAN CM, 1978, JAMA-J AM MED ASSOC, V239, P2352, DOI 10.1001/jama.239.22.2352; OSLER W, 1900, J HOPKINS HOSP REP, V8, P421; PLOTKIN SA, 1995, ARCH INTERN MED, V155, P2293, DOI 10.1001/archinte.155.21.2293; RAO PS, 1993, AM J TROP MED HYG, V48, P108, DOI 10.4269/ajtmh.1993.48.108; RYAN CA, 1989, REV INFECT DIS, V11, P1; RYAN CA, 1987, JAMA-J AM MED ASSOC, V258, P3269, DOI 10.1001/jama.258.22.3269; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; STUART BM, 1946, ARCH INTERN MED, V78, P629, DOI 10.1001/archinte.1946.00220060002001; WAHDAN MH, 1982, J INFECT DIS, V145, P292, DOI 10.1093/infdis/145.3.292	32	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					847	850		10.1001/jama.278.10.847	http://dx.doi.org/10.1001/jama.278.10.847			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU552	9293994				2022-12-28	WOS:A1997XU55200041
J	DawsonHughes, B; Harris, SS; Krall, EA; Dallal, GE				DawsonHughes, B; Harris, SS; Krall, EA; Dallal, GE			Effect of calcium and vitamin D supplementation on bone, density in men and women 65 years of age or older	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; CONTROLLED TRIAL; MINERAL DENSITY; ELDERLY WOMEN; DOUBLE-BLIND; FRACTURES; OSTEOPOROSIS; ABSORPTION; PROTEIN; ASSAY	Background Inadequate dietary intake of calcium and vitamin D may contribute to the high prevalence of osteoporosis among older persons. Methods We studied the effects of three years of dietary supplementation with calcium and vitamin D on bone mineral density, biochemical measures of bone metabolism and the incidence of nonvertebral fractures in 176 men and 213 women 65 years of age or older who were living at home. They received either 500 mg of calcium plus 700 IU of vitamin D-3 (cholecalciferol) per day or placebo. Bone mineral density was measured by dual-energy x-ray absorptiometry, blood and urine were analyzed every six months, and cases of nonvertebral fracture were ascertained by means of interviews and verified with use of hospital records. Results The mean (+/-SD) changes in bone mineral density in the calcium-vitamin D and placebo groups were as follows: femoral neck, +0.50+/-4.80 and -0.70+/-5.03 percent, respectively (P=0.02); spine, +2.12+/-4.06 and +1.22+/-4.25 percent (P=0.04); and total body, +0.06+/-1.83 and -1.09+/-1.71 percent (P< 0.001). The difference between the calcium-vitamin D and placebo groups was significant at all skeletal sites after, one year, but it was significant only for total-body bone mineral density in the second and third years. Of 37 subjects who had nonvertebral fractures, 26 were in the placebo group and 11 were in the calcium-vitamin D group (P=0.02). Conclusions In men and women 65 years of age or older who are living in the community, dietary supplementation with calcium and vitamin D moderately reduced bone loss measured in the femoral neck, spine, and total body over the three-year study period and reduced the incidence of nonvertebral fractures. (C) 1997, Massachusetts Medical Society.			DawsonHughes, B (corresponding author), TUFTS UNIV,USDA,JEAN MAYER HUMAN NUTR RES CTR,711 WASHINGTON ST,BOSTON,MA 02111, USA.			Kaye, Elizabeth/0000-0001-7529-2501	NIA NIH HHS [AG10353] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG010353] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALOIA JF, 1994, ANN INTERN MED, V120, P97, DOI 10.7326/0003-4819-120-2-199401150-00001; BARRAGRY JM, 1978, CLIN SCI MOL MED, V55, P213, DOI 10.1042/cs0550213; BULLAMORE JR, 1970, LANCET, V2, P535; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHEVALLEY T, 1994, OSTEOPOROSIS INT, V4, P245, DOI 10.1007/BF01623348; DAWSONHUGHES B, 1995, AM J CLIN NUTR, V61, P1140, DOI 10.1093/ajcn/61.5.1140; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DELMAS PD, 1993, J BONE MINER RES, V8, P643; ELDERS PJM, 1991, J CLIN ENDOCR METAB, V73, P533, DOI 10.1210/jcem-73-3-533; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; EPSTEIN S, 1984, LANCET, V1, P307; FROST HM, 1973, ORTHOPEDIC LECT, V3, P28; GREENSPAN SL, 1994, J BONE MINER RES, V9, P1959, DOI 10.1002/jbmr.5650091216; HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497; JONES G, 1994, BRIT MED J, V309, P691, DOI 10.1136/bmj.309.6956.691; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052; ORWOLL ES, 1990, ANN INTERN MED, V112, P29, DOI 10.7326/0003-4819-112-1-29; PREECE MA, 1974, CLIN CHIM ACTA, V54, P235, DOI 10.1016/0009-8981(74)90241-1; PRINCE R, 1995, J BONE MINER RES, V10, P1068, DOI 10.1002/jbmr.5650100711; Recker RR, 1996, J BONE MINER RES, V11, P1961; REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002-9343(99)80310-6; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; SMITH KT, 1987, CALCIFIED TISSUE INT, V41, P351, DOI 10.1007/BF02556676; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4	31	1538	1595	1	96	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					670	676		10.1056/NEJM199709043371003	http://dx.doi.org/10.1056/NEJM199709043371003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU349	9278463	Bronze			2022-12-28	WOS:A1997XU34900003
J	Melzer, D; Ely, M; Brayne, C				Melzer, D; Ely, M; Brayne, C			Cognitive impairment in elderly people: population based estimate of the future in England, Scotland, and Wales	BRITISH MEDICAL JOURNAL			English	Article											Melzer, D (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,CAMBRIDGE CB2 2SR,ENGLAND.		Brayne, Carol/AAA-4285-2020	Brayne, Carol/0000-0001-5307-663X; Melzer, David/0000-0002-0170-3838				ELY M, 1996, RES POLICY PLANNING, V14, P13; *GOV STAT SERV, 1993, OPCS NAT POP PROJ GR; *HOUS COMM HLTH CO, 1996, LONG TERM CAR FUT PR; Martin J., 1988, PREVALENCE DISABILIT; Wattis JP, 1996, INT J GERIATR PSYCH, V11, P163	5	56	57	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					462	462		10.1136/bmj.315.7106.462	http://dx.doi.org/10.1136/bmj.315.7106.462			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XT714	9284665	Green Published			2022-12-28	WOS:A1997XT71400020
J	Cooper, GW; Thiemens, MH; Jackson, TL; Chang, S				Cooper, GW; Thiemens, MH; Jackson, TL; Chang, S			Sulfur and hydrogen isotope anomalies in meteorite sulfonic acids	SCIENCE			English	Article							MURCHISON METEORITE; CARBONACEOUS CHONDRITES; HYDROCARBONS; MONOSULFIDE; CHEMISTRY; OZONE	Intramolecular carbon, hydrogen, and sulfur isotope ratios were measured on a homologous series of organic sulfonic acids discovered in the Murchison meteorite. Mass independent sulfur isotope fractionations were observed along with high deuterium/hydrogen ratios. The deuterium enrichments indicate formation of the hydrocarbon portion of these compounds in a low-temperature environment that is consistent with that of interstellar clouds. Sulfur-33 enrichments observed in methanesulfonic acid could have resulted from gas-phase ultraviolet irradiation of a precursor, carbon disulfide, The source of the sulfonic acid precursors may have been the reactive interstellar molecule carbon monosulfide.	NASA, AMES RES CTR, MOFFETT FIELD, CA 94035 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of California System; University of California San Diego	Cooper, GW (corresponding author), SETI INST, MS 239-4, MOFFETT FIELD, CA 94035 USA.							BOHN RB, 1992, J AM CHEM SOC, V114, P6452, DOI 10.1021/ja00042a024; BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; COLEMAN ML, 1978, ANAL CHEM, V50, P1594, DOI 10.1021/ac50033a056; Colman JJ, 1996, SCIENCE, V273, P774, DOI 10.1126/science.273.5276.774; Cooper G. W., 1995, LPS, VXXVI, P281; COOPER GW, 1995, GEOCHIM COSMOCHIM AC, V59, P1003, DOI 10.1016/0016-7037(95)00018-6; COOPER GW, 1992, GEOCHIM COSMOCHIM AC, V56, P4109, DOI 10.1016/0016-7037(92)90023-C; COOPER GW, 1995, METEORITICS, V30, P500; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; DESORGO M, 1965, CAN J CHEMISTRY, V43, P1886; EPSTEIN S, 1987, NATURE, V326, P477, DOI 10.1038/326477a0; GAO X, 1993, GEOCHIM COSMOCHIM AC, V57, P3159, DOI 10.1016/0016-7037(93)90300-L; Gao X., 1991, GEOCHIM COSMOCHIM AC, V55, P2671, DOI DOI 10.1016/0016-7037(91)90381-E; HAYES JM, 1968, GEOCHIM COSMOCHIM AC, V32, P239, DOI 10.1016/S0016-7037(68)80006-7; HEIDENREICH JE, 1986, J CHEM PHYS, V84, P2129, DOI 10.1063/1.450373; HOGG MAP, 1958, J CHEM SOC, P4196; KLABUNDE KJ, 1989, PHOSPHORUS SULFUR, V43, P47, DOI 10.1080/10426508908040278; MAUERSBERGER K, 1993, GEOPHYS RES LETT, V20, P1031, DOI 10.1029/93GL01080; MOLTZEN EK, 1988, CHEM REV, V88, P391, DOI 10.1021/cr00084a003; STEUDEL R, 1966, Z NATURFORSCH B, V218, P1106; STUDIER MH, 1972, GEOCHIM COSMOCHIM AC, V36, P189; THIEMENS MH, 1994, METEORITICS, V29, P540; THIEMENS MH, 1995, LUNAR PLANET SCI, V26, P1405; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WHITE CM, 1974, THESIS U N DAKOTA GR; Xu X.Y, UNPUB; YUEN G, 1984, NATURE, V307, P252, DOI 10.1038/307252a0	27	69	70	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1072	1074		10.1126/science.277.5329.1072	http://dx.doi.org/10.1126/science.277.5329.1072			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262469	Green Submitted			2022-12-28	WOS:A1997XT03300026
J	Korolev, S; Hsieh, J; Gauss, GH; Lohman, TM; Waksman, G				Korolev, S; Hsieh, J; Gauss, GH; Lohman, TM; Waksman, G			Major domain swiveling revealed by the crystal structures of complexes of E-coli Rep helicase bound to single-stranded DNA and ADP	CELL			English	Article							ADENINE-NUCLEOTIDE BINDING; XERODERMA-PIGMENTOSUM; INDUCED DIMERIZATION; KINETIC MECHANISM; EXCISION-REPAIR; UVRD PROTEINS; SEQUENCE; MONOMER; HYDROLYSIS; PROGRAM	Crystal structures of binary and ternary complexes of the E. coli Rep helicase bound to single-stranded (ss) DNA or ssDNA and ADP were determined to a resolution of 3.0 Angstrom and 3.2 Angstrom, respectively. The asymmetric unit in the crystals contains two Rep monomers differing from each other by a large reorientation of one of the domains, corresponding to a swiveling of 130 degrees about a hinge region. Such domain movements are sufficiently large to suggest that these may be coupled to translocation of the Rep dimer along DNA. The ssDNA binding site involves the helicase motifs la, Iii, and V, whereas the ADP binding site involves helicase motifs I and IV. Residues in motifs II and VI may function to transduce the allosteric effects of nucleotides on DNA binding. These structures represent the first view of a DNA helicase bound to DNA.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOL BIOPHYS, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Korolev, Sergey/ABA-7517-2020	Korolev, Sergey/0000-0001-9313-7126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948, R01GM054033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54033, R01 GM045948] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Bjornson KP, 1996, BIOCHEMISTRY-US, V35, P2268, DOI 10.1021/bi9522763; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1996, NATURE, V379, P621; LANE HED, 1974, J BACTERIOL, V120, P805, DOI 10.1128/JB.120.2.805-814.1974; LANE HED, 1975, J MOL BIOL, V97, P99; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1993, J BIOL CHEM, V268, P20386; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Wong I, 1997, BIOCHEMISTRY-US, V36, P3115, DOI 10.1021/bi9621977; Wong I, 1996, P NATL ACAD SCI USA, V93, P10051, DOI 10.1073/pnas.93.19.10051; Wong I, 1996, BIOCHEMISTRY-US, V35, P5726, DOI 10.1021/bi952959i; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	49	431	450	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					635	647		10.1016/S0092-8674(00)80525-5	http://dx.doi.org/10.1016/S0092-8674(00)80525-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288744	Bronze			2022-12-28	WOS:A1997XT06600008
J	Luo, JM; Sladek, R; Bader, JA; Matthyssen, A; Rossant, J; Giguere, V				Luo, JM; Sladek, R; Bader, JA; Matthyssen, A; Rossant, J; Giguere, V			Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta	NATURE			English	Article							STEM-CELLS; MICE; IDENTIFICATION; TROPHOBLAST; PROTEIN; GENES	Classical endocrine studies have shown that steroid hormones are required for the maintenance of pregnancy and placental viability. The oestrogen-receptor-related receptor beta (ERR-beta) is an orphan member of the superfamily of nuclear hormone receptors(1) Although ERR-beta is homologous to the oestrogen receptor and binds the oestrogen response element(2), it is not activated by oestrogens'. Expression of ERR-beta during embryogenesis defines a subset of extra-embryonic ectoderm that subsequently forms the dome of the chorion, suggesting that ERR-beta may be involved in early placental development. Homozygous mutant embryos generated by targeted disruption of the Estrrb gene have severely impaired placental formation, and die at 10.5 days post-coitum. The mutants display abnormal chorion development associated with an overabundance of trophoblast giant cells and a severe deficiency of diploid trophoblast. The phenotype can be rescued by aggregation of Estrrb mutant embryos with tetraploid wildtype cells, which contribute exclusively to extra-embryonic tissues. Our results indicate that ERR-beta has an important role in early placentation, and suggest that an inductive signal originating from or modified by the chorion is required for normal trophoblast proliferation and differentiation.	ROYAL VICTORIA HOSP,MOL ONCOL GRP,MONTREAL,PQ H3A 1A1,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1A8,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; Royal Victoria Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; McGill University; McGill University			Sladek, Robert/R-2391-2019	Sladek, Robert/0000-0002-2730-1204; Giguere, Vincent/0000-0001-9567-3694				COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; FINNERTY H, 1993, ONCOGENE, V8, P2293; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; ILGREN EB, 1983, PLACENTA, V4, P307, DOI 10.1016/S0143-4004(83)80010-1; ILGREN EB, 1981, J EMBRYOL EXP MORPH, V62, P183; Kaufman M.H., 1992, ATLAS MOUSE DEV; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; LINZER DIH, 1985, P NATL ACAD SCI USA, V82, P4356, DOI 10.1073/pnas.82.13.4356; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; PARAMITHIOTIS E, 1994, EUR J IMMUNOL, V24, P458, DOI 10.1002/eji.1830240229; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; ROSSANT J, 1981, J EMBRYOL EXP MORPH, V62, P217; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Speroff L, 1994, CLIN GYNECOLOGIC END, V5th; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Yen S. S. C., 1991, REPROD ENDOCRINOLOGY	23	321	333	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					778	782		10.1038/42022	http://dx.doi.org/10.1038/42022			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285590	Bronze			2022-12-28	WOS:A1997XR66700052
J	Palsboll, PJ; Allen, J; Berube, M; Clapham, PJ; Feddersen, TP; Hammond, PS; Hudson, RR; Jorgensen, H; Katona, S; Larsen, AH; Larsen, F; Lien, J; Mattila, DK; Sigurjonsson, J; Sears, R; Smith, T; Sponer, R; Stevick, P; Oien, N				Palsboll, PJ; Allen, J; Berube, M; Clapham, PJ; Feddersen, TP; Hammond, PS; Hudson, RR; Jorgensen, H; Katona, S; Larsen, AH; Larsen, F; Lien, J; Mattila, DK; Sigurjonsson, J; Sears, R; Smith, T; Sponer, R; Stevick, P; Oien, N			Genetic tagging of humpback whales	NATURE			English	Article							MEGAPTERA-NOVAEANGLIAE; SIMPLE SEQUENCES; DNA; POPULATION; MAINE; GULF	The ability to recognize individual animals has substantially increased our knowledge of the biology and behaviour of many taxa(1). However, not all species lend themselves to this approach, either because of insufficient phenotypic variation or because tag attachment is not feasible. The use of genetic markers ('tags') represents a viable alternative to traditional methods of individual recognition, as they are permanent and exist in all individuals. We tested the use of genetic markers as the primary means of identifying individuals in a study of humpback whales in the North Atlantic Ocean. Analysis of six microsatellite loci(2,3) among 3,060 skin samples collected throughout this ocean allowed the unequivocal identification of individuals. Analysis of 692 'recaptures', identified by their genotype, revealed individual local and migratory movements of up to 10,000 km, limited exchange among summer feeding grounds, and mixing in winter breeding areas, and also allowed the first estimates of animal abundance based solely on genotypic data. Our study demonstrates that genetic tagging is not only feasible, but generates data (for example, on sex) that can be valuable when interpreting-the results of tagging experiments.	COLL ATLANTIC,BAR HARBOR,ME 04609; DEPT NAT RESOURCES SCI,ST ANNE BELLEVUE,PQ H9X 3V9,CANADA; CTR COASTAL STUDIES,PROVINCETOWN,MA 02657; UNIV ST ANDREWS,SEA MAMMAL RES UNIT,ST ANDREWS KY16 9LB,FIFE,SCOTLAND; UNIV CALIF IRVINE,DEPT ECOL & EVOLUTIONARY BIOL,IRVINE,CA 92697; GREENLAND INST NAT RESOURCES,NUUK 3900,GREENLAND; MEM UNIV NEWFOUNDLAND,WHALE RES GRP,ST JOHNS,NF A1B 3X9,CANADA; MARINE RES INST,IS-121 REYKJAVIK,ICELAND; MINGAN ISL CETACEAN STUDY INC,ST LAMBERT,PQ J4P 1T3,CANADA; NATL MARINE FISHERIES SERV,NE FISHERIES SCI CTR,WOODS HOLE,MA 02543; INST MARINE RES,N-5024 BERGEN,NORWAY	University of St Andrews; University of California System; University of California Irvine; Greenland Institute of Natural Resources; Memorial University Newfoundland; Marine & Freshwater Research Institute (MFRI); National Oceanic Atmospheric Admin (NOAA) - USA; Institute of Marine Research - Norway	Palsboll, PJ (corresponding author), DEPT POPULAT BIOL,UNIV PK 15,DK-2100 COPENHAGEN,DENMARK.		Palsboll, Per J/G-6988-2011; Palsbøll, Per J/L-3494-2013	Palsboll, Per J/0000-0002-4198-7599; Palsbøll, Per J/0000-0002-4198-7599; Berube, Martine/0000-0002-1831-2657; Larsen, Finn/0000-0001-6498-9012				AMOS B, 1993, SCIENCE, V260, P670, DOI 10.1126/science.8480176; [Anonymous], 1982, ESTIMATION ANIMAL AB; Barlow J, 1997, ECOLOGY, V78, P535; Berube M, 1996, MOL ECOL, V5, P283; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P1065, DOI 10.1139/z93-142; CLAPHAM PJ, 1993, MAR MAMMAL SCI, V9, P213, DOI 10.1111/j.1748-7692.1993.tb00448.x; Clapham PJ, 1997, P ROY SOC B-BIOL SCI, V264, P95, DOI 10.1098/rspb.1997.0014; CLAPHAM PJ, 1995, MAR MAMMAL SCI, V11, P227, DOI 10.1111/j.1748-7692.1995.tb00520.x; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P440, DOI 10.1139/z93-063; CONSTABLE JJ, 1995, NATURE, V373, P393, DOI 10.1038/373393a0; GERLOFF U, 1995, MOL ECOL, V4, P515, DOI 10.1111/j.1365-294X.1995.tb00247.x; Hammond PS, 1990, REPORT INT WHALING C, P440; Katona S.K., 1981, Polar Record, V20, P439; KATONA S. K., 1990, REPORT INT WHALING C, P295; LAMBERTSEN RH, 1987, J MAMMAL, V68, P443, DOI 10.2307/1381495; LARSEN AH, 1996, P R SOC LOND B, V263, P611; Maniatis T., 1982, MOL CLONING; MATTILA DK, 1989, CAN J ZOOL, V67, P281, DOI 10.1139/z89-041; MORIN PA, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P63; PAETKAU D, 1994, MOL ECOL, V3, P489, DOI 10.1111/j.1365-294X.1994.tb00127.x; Palsboll P.J., 1991, Reports of the International Whaling Commission Special Issue, P71; PALSBOLL PJ, 1995, MAR ECOL PROG SER, V116, P1, DOI 10.3354/meps116001; PALSBOLL PJ, IN PRESS MOL ECOL; ROY MS, 1994, MOL BIOL EVOL, V11, P553; STEVICK PT, IN PRESS MAR MAMM SC; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEBER JL, 1989, AM J HUM GENET, V44, P388	28	209	227	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					767	769		10.1038/42005	http://dx.doi.org/10.1038/42005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285587	Green Submitted, Bronze			2022-12-28	WOS:A1997XR66700049
J	FrasureSmith, N; Lesperance, F; Prince, RH; Verrier, P; Garber, RA; Juneau, M; Wolfson, C; Bourassa, MG				FrasureSmith, N; Lesperance, F; Prince, RH; Verrier, P; Garber, RA; Juneau, M; Wolfson, C; Bourassa, MG			Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction	LANCET			English	Article							STRESS-MONITORING-PROGRAM; SUDDEN CARDIAC DEATH; MORTALITY; DISEASE; WOMEN; CORONARY; IMPACT; GENDER	Background Increases in life stress have been linked to poor prognosis after myocardial infarction (MI). Previous research suggested that a programme of monthly screening for psychological distress, combined with supportive and educational home nursing interventions for distressed patients, may improve post-MI survival among men. Our study assessed this approach for both men and women. We aimed to find out whether the programme would reduce 1-year cardiac mortality for women and men. Methods We carried out a randomised, controlled trial of 1376 post-MI patients (903 men, 473 women) assigned to the intervention programme (n=692) or usual care (n=684) for 1 year. All patients completed a baseline interview that included assessment of depression and anxiety. Survivors were also interviewed at 1 year. Findings The programme had no overall survival impact. Preplanned analyses showed higher cardiac (9.4 vs 5.0%, p=0.064) and all-cause mortality (10.3 vs 5.4%, p=0.051) among women in the intervention group. There was no evidence of either benefit or harm among men (cardiac mortality 2.4 vs 2.5%, p=0.94; all-cause mortality 3.1 vs 3.1%, p=0.93). The programme's impact on depression and anxiety among survivors was small. Interpretation Our results do not warrant the routine implementation of programmes that involve psychological-distress screening and home nursing intervention for patients recovering from MI. The poorer overall outcome for women, and the possible harmful impact of the intervention on women, underline the need for further research and the inclusion of adequate numbers of women in future post-MI trials.	MCGILL UNIV,DEPT PSYCHIAT,MONTREAL,PQ,CANADA; MCGILL UNIV,SCH NURSING,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA; UNIV MONTREAL,DEPT PSYCHIAT,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL,PQ H3C 3J7,CANADA	McGill University; McGill University; McGill University; Universite de Montreal; Universite de Montreal	FrasureSmith, N (corresponding author), MONTREAL HEART INST,RES CTR,5000 BELANGER E,MONTREAL,PQ H1T 1C8,CANADA.		Lesperance, Francois/C-4716-2015	Lesperance, Francois/0000-0003-4604-2823; Bourassa, Martial G./0000-0002-4439-8650	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047330] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47330-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLUMENTHAL JA, 1987, PSYCHOSOM MED, V49, P331, DOI 10.1097/00006842-198707000-00002; CAIRNS JA, 1989, CAN J CARDIOL, V5, P239; CONNOLLY SJ, 1989, CIRCULATION S4, V80, P47; CROWN S, 1983, BRIT J PSYCHIAT, V143, P436, DOI 10.1192/bjp.143.5.436; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRASURESMITH N, 1989, PSYCHOSOM MED, V51, P485, DOI 10.1097/00006842-198909000-00002; FRASURESMITH N, 1985, PSYCHOSOM MED, V47, P431, DOI 10.1097/00006842-198509000-00003; FREEDMAN LS, 1995, CONTROL CLIN TRIALS, V16, P277, DOI 10.1016/0197-2456(95)00048-8; GARFIELD SL, 1992, HIST PSYCHOTHERAPY C, P335; Goldberg DP, 1972, ASSESSMENT PSYCHIAT; Gorkin L, 1996, CONTROL CLIN TRIALS, V17, P46, DOI 10.1016/0197-2456(95)00089-5; Jones DA, 1996, BRIT MED J, V313, P1517, DOI 10.1136/bmj.313.7071.1517; KAMARCK T, 1991, PSYCHOL BULL, V109, P42, DOI 10.1037/0033-2909.109.1.42; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; Lesperance F, 1996, LANCET, V347, P414, DOI 10.1016/S0140-6736(96)90004-5; MCGEE HM, 1992, BRIT MED J, V305, P283, DOI 10.1136/bmj.305.6848.283-a; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Meinert CL., 1986, CLIN TRIALS DESIGN C; NATHANSON CA, 1975, SOC SCI MED, V9, P57, DOI 10.1016/0037-7856(75)90094-3; POWELL LH, 1989, PSYCHOSOM MED, V51, P479, DOI 10.1097/00006842-198909000-00001; PRATT CM, 1986, AM J CARDIOL, V58, P906, DOI 10.1016/S0002-9149(86)80008-X; RAHE RH, 1974, ARCH INTERN MED, V133, P221, DOI 10.1001/archinte.133.2.221; Rouleau JL, 1996, J AM COLL CARDIOL, V27, P1119, DOI 10.1016/0735-1097(95)00599-4; SPIELBERGER CD, 1983, HLTH PSYCHOL INDIVID; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; VERBRUGGE LM, 1989, J HEALTH SOC BEHAV, V30, P282, DOI 10.2307/2136961; VERRIER RL, 1992, PACE, V15, P1387	29	334	335	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					473	479		10.1016/S0140-6736(97)02142-9	http://dx.doi.org/10.1016/S0140-6736(97)02142-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR135	9274583				2022-12-28	WOS:A1997XR13500009
J	Grol, R				Grol, R			Personal paper: Beliefs and evidence in changing clinical practice	BRITISH MEDICAL JOURNAL			English	Article							IMPLEMENTATION; GUIDELINES; TRIALS		UNIV MAASTRICHT,CTR QUAL CARE RES,NL-6500 HB NIJMEGEN,NETHERLANDS	Maastricht University; Radboud University Nijmegen	Grol, R (corresponding author), UNIV NIJMEGEN,CTR QUAL CARE RES,POSTBOX 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		Grol, Richard/C-8523-2013					ALBANESE MA, 1993, ACAD MED, V68, P52, DOI 10.1097/00001888-199301000-00012; BANDURA A, 1986, SOCIAL F THOUGHT ACT; Batalden P B, 1993, Jt Comm J Qual Improv, V19, P424; BERO LA, 1995, IMPLEMENTING FINDING; BERWICK D, 1992, QUALITY HLTH CARE S, pS2; Berwick DM, 1996, BRIT MED J, V312, P619, DOI 10.1136/bmj.312.7031.619; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DIETRICH AJ, 1992, BRIT MED J, V304, P687, DOI 10.1136/bmj.304.6828.687; FIELD M, 1992, GUIELINES CLIN PRACT; Freemantle N, 1995, Qual Health Care, V4, P45, DOI 10.1136/qshc.4.1.45; Green LW., 1980, HLTH ED PLANNING DIA, V1; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; GROL R, 1995, J FAM PRACTICE, V40, P435; Grol R, 1992, Qual Health Care, V1, P184, DOI 10.1136/qshc.1.3.184; Grol R, 1996, QUAL HEALTH CARE, V5, P235, DOI 10.1136/qshc.5.4.235; Grol R, 1995, QUALITY IMPROVEMENT; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; Kanouse DE, 1995, HEALTH POLICY, V34, P167, DOI 10.1016/0168-8510(95)00760-1; Kotler P, 1989, SOCIAL MARKETING STR; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; Mittman B S, 1992, QRB Qual Rev Bull, V18, P413; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PERVIN LA, 1970, PERSONALITY; Robertson N, 1996, QUAL HEALTH CARE, V5, P51, DOI 10.1136/qshc.5.1.51; Rogers EM., 1983, DIFFUSION INNOVATION; SMITH R, 1995, BRIT MED J, V311, P961; SMITH R, 1987, BRIT MED J, V295, P1335, DOI 10.1136/bmj.295.6609.1335; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549	30	571	577	2	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					418	421		10.1136/bmj.315.7105.418	http://dx.doi.org/10.1136/bmj.315.7105.418			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277610	Green Published			2022-12-28	WOS:A1997XR54900028
J	Sampson, RJ; Raudenbush, SW; Earls, F				Sampson, RJ; Raudenbush, SW; Earls, F			Neighborhoods and violent crime: A multilevel study of collective efficacy	SCIENCE			English	Article							SOCIAL-DISORGANIZATION; COMMUNITY ATTACHMENT; MASS SOCIETY; MODELS; COEFFICIENTS	It is hypothesized that collective efficacy, defined as social cohesion among neighbors combined with their willingness to intervene on behalf of the common good, is linked to reduced violence. This hypothesis was tested on a 1995 survey of 8782 residents of 343 neighborhoods in Chicago, Illinois. Multilevel analyses showed that a measure of collective efficacy yields a high between-neighborhood reliability and is negatively associated with variations in violence, when individual-level characteristics, measurement error, and prior violence are controlled. Associations of concentrated disadvantage and residential instability with violence are largely mediated by collective efficacy.	MICHIGAN STATE UNIV,COLL EDUC,E LANSING,MI 48824; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Michigan State University; Harvard University; Harvard T.H. Chan School of Public Health	Sampson, RJ (corresponding author), UNIV CHICAGO,DEPT SOCIOL,CHICAGO,IL 60637, USA.		Sampson, Robert J./AAB-7369-2020					ALLISON PD, 1995, AM J SOCIOL, V100, P1294, DOI 10.1086/230639; [Anonymous], 1986, CRIMINAL CAREERS CAR; BANDURA A, 1986, SOCIAL F THOUGHT ACT; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; BROOKSGUNN J, 1993, AM J SOCIOL, V99, P353, DOI 10.1086/230268; BURSIK RJ, 1988, CRIMINOLOGY, V26, P519, DOI 10.1111/j.1745-9125.1988.tb00854.x; CLOGG CC, 1995, AM J SOCIOL, V100, P1261, DOI 10.1086/230638; Coleman JS., 1990, FDN SOCIAL THEORY; COOK T, IN PRESS NEIGHBORHOO, V2; Elliott DS, 1996, J RES CRIME DELINQ, V33, P389, DOI 10.1177/0022427896033004002; FURSTENBERG FF, IN PRESS URBAN FAMIL, pCH7; HACKER J, 1974, SOC PROBL, V21, P358; KAISER HF, 1995, PSYCHOMETRIKA, V30, P1; KASARDA JD, 1974, AM SOCIOL REV, V39, P328, DOI 10.2307/2094293; Kornhauser R.R., 1978, SOCIAL SOURCES DELIN; LAND KC, 1990, AM J SOCIOL, V95, P922, DOI 10.1086/229381; LINDLEY DV, 1972, J ROY STAT SOC B, V34, P1; Logan John., 2007, URBAN FORTUNES POLIT; MACCOBY EE, 1958, J SOC ISSUES, V14, P38, DOI 10.1111/j.1540-4560.1958.tb01415.x; MASSEY DS, 1993, AM APARTHELD SEGREGA; MAYER SE, 1989, SCIENCE, V243, P1441, DOI 10.1126/science.243.4897.1441; Putnam R.D., 1994, MAKING DEMOCRACY WOR, DOI DOI 10.2307/206637; RAUDENBUSH SW, 1991, J EDUC STAT, V16, P295, DOI 10.2307/1165105; RAUDENBUSH SW, 1993, POSTERIOR MODELS APP; REISS AJ, 1993, UNDERSTANDING PREVEN, P18; ROWAN B, 1991, AM J EDUC, V99, P238, DOI 10.1086/443980; Sampson R.J., 1994, UNDERSTANDING PREVEN, V3, P1; SAMPSON RJ, 1989, AM J SOCIOL, V94, P774, DOI 10.1086/229068; SAMPSON RJ, 1988, AM SOCIOL REV, V53, P766, DOI 10.2307/2095822; SAMPSON RK, UNPUB; SHAW C, 1969, JUVENILE DELINQUENCY, P176; SHORT J, 1997, POVERTY ETHNICITY VI; Short Jr James F., 1965, GROUP PROCESS GANG D; Skogan W.G., 1990, DISORDER DECLINE CRI; TAYLOR R, 1983, J RES CRIME DELINQ, V21, P303; Thrasher Frederic, 1927, GANG STUDY 1 313 GAN; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025; Wilson R., 1987, TRULY DISADVANTAGED; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	39	6894	6974	22	651	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					918	924		10.1126/science.277.5328.918	http://dx.doi.org/10.1126/science.277.5328.918			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XQ985	9252316				2022-12-28	WOS:A1997XQ98500031
J	Ledent, C; Vaugeois, JM; Schiffmann, SN; Pedrazzini, T; ElYacoubi, M; Vanderhaeghen, JJ; Costentin, J; Heath, JK; Vassart, G; Parmentier, M				Ledent, C; Vaugeois, JM; Schiffmann, SN; Pedrazzini, T; ElYacoubi, M; Vanderhaeghen, JJ; Costentin, J; Heath, JK; Vassart, G; Parmentier, M			Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A(2a) receptor	NATURE			English	Article							GENE-EXPRESSION; CAFFEINE; RAT; STRIATUM; AGONISTS; CLONING; NEURONS; BRAIN	Adenosine is released from metabolically active cells by facilitated diffusion, and is generated extracellularly by degradation of released ATP. It is a potent biological mediator that modulates the activity of numerous cell types, including various neuronal populations, platelets, neutrophils and mast cells, and smooth muscle cells in bronchi and vasculatue. Most of these effects help to protect cells and tissues during stress conditions such as ischaemia. Adenosine mediates its effects through four receptor subtypes: the A(1), A(2a), A(2b) and A(3) receptors(1). The A(2a) receptor (A(2a)R)(2,3) is abundant in basal ganglia, vasculature and platelets, and stimulates adenylyl cyclase. It is a major target of caffeine, the most widely used psychoactive drug(4). Here we investigate the role of the A(2a) receptor by disrupting the gene in mice. Here found that A(2a)R-knockout (A(2a)R(-/-)) mice were viable and bred normally. Their exploratory activity was reduced, whereas caffeine, which normally stimulates exploratory behaviour, became a depressant of exploratory activity. Knockout animals scored higher in anxiety tests, and male mice were much more aggressive towards intruders. The response of A(2a)R(-/-) mice to acute pain stimuli was slower. Blood pressure and heart rate were increased, as well as platelet aggregation. The specific A(2a) agonist CGS 21680 lost its biological activity in all systems tested.	FREE UNIV BRUSSELS, IRIBHN, LAB RECH NEUROPEPTIDES, B-1070 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, SERV GENET MED, B-1070 BRUSSELS, BELGIUM; FAC MED & PHARM, IFRMP,UNITE NEUROPSYCHOPHARMACOL EXPT,CNRS, UPRESA 6036, F-76803 ST ETIENNE DU ROUVRAY, FRANCE; UNIV LAUSANNE, SCH MED, DIV HYPERTENS, CH-1011 LAUSANNE, SWITZERLAND; UNIV OXFORD, DEPT BIOCHEM, CRC GROWTH FACTORS, OXFORD OX1 3QU, ENGLAND	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); University of Lausanne; University of Oxford				Parmentier, Marc/0000-0001-8081-4685; Schiffmann, Serge/0000-0002-0118-9816; Vaugeois, Jean-Marie/0000-0001-8296-672X; EL YACOUBI, Malika/0000-0002-1010-9179				BALK JH, 1995, NATURE, V377, P424; COSTENTIN J, 1986, EUR J PHARMACOL, V123, P37, DOI 10.1016/0014-2999(86)90684-9; CRISTALLI G, 1994, N-S ARCH PHARMACOL, V349, P644, DOI 10.1007/PL00004904; DELANDER GE, 1994, J PHARMACOL EXP THER, V268, P943; DIONISOTTI S, 1992, N-S ARCH PHARMACOL, V346, P673; FILE SE, 1988, PHARMACOL BIOCHEM BE, V30, P809, DOI 10.1016/0091-3057(88)90104-9; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x; FURLONG TJ, 1992, MOL BRAIN RES, V15, P62, DOI 10.1016/0169-328X(92)90152-2; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; HOPKER VH, 1995, NEUROREPORT, V6, P1153; JAIN N, 1995, BRIT J PHARMACOL, V116, P2127, DOI 10.1111/j.1476-5381.1995.tb16421.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MCQUEEN DS, 1986, BRIT J PHARMACOL, V88, P615, DOI 10.1111/j.1476-5381.1986.tb10242.x; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIKODIJEVIC O, 1993, PHARMACOL BIOCHEM BE, V44, P199, DOI 10.1016/0091-3057(93)90299-9; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6; PALMOUR RM, 1989, LIFE SCI, V44, P1293, DOI 10.1016/0024-3205(89)90367-6; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SAWYNOK J, 1993, PHARMACOL REV, V45, P43; SCHIFFMANN SN, 1992, J COMP NEUROL, V317, P117, DOI 10.1002/cne.903170202; SCHIFFMANN SN, 1993, J NEUROSCI, V13, P1080; SWEENEY MI, 1987, EUR J PHARMACOL, V141, P169, DOI 10.1016/0014-2999(87)90428-6; Varani K, 1996, BRIT J PHARMACOL, V117, P1693, DOI 10.1111/j.1476-5381.1996.tb15341.x; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WORST W, 1993, GENE TARGETING PRACT, P33	28	721	748	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	1997	388	6643					674	678		10.1038/41771	http://dx.doi.org/10.1038/41771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262401	Bronze			2022-12-28	WOS:A1997XQ86300049
J	Jones, KV				Jones, KV			Screening babies for vesicoureteric reflux	LANCET			English	Editorial Material							INFECTION				Jones, KV (corresponding author), CARDIFF ROYAL INFIRM,DEPT CHILD HLTH,CARDIFF CF2 1SZ,S GLAM,WALES.							[Anonymous], 1978, Lancet, V1, P889; [Anonymous], 1987, Br Med J (Clin Res Ed), V295, P237; HODSON C J, 1959, Proc R Soc Med, V52, P669; *INT REFL STUD CHI, 1992, PEDIATR NEPHROL, V6, P223; SMELLIE JM, 1994, BRIT MED J, V308, P1193, DOI 10.1136/bmj.308.6938.1193; vanderVoort J, 1997, FAM PRACT, V14, P44, DOI 10.1093/fampra/14.1.44; WINBERG J, 1975, KIDNEY INT, V8, pS101	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					380	380		10.1016/S0140-6736(05)64129-3	http://dx.doi.org/10.1016/S0140-6736(05)64129-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259648				2022-12-28	WOS:A1997XQ24800004
J	Davies, SW; Turmaine, M; Cozens, BA; DiFiglia, M; Sharp, AH; Ross, CA; Scherzinger, E; Wanker, EE; Mangiarini, L; Bates, GP				Davies, SW; Turmaine, M; Cozens, BA; DiFiglia, M; Sharp, AH; Ross, CA; Scherzinger, E; Wanker, EE; Mangiarini, L; Bates, GP			Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation	CELL			English	Article							DISEASE GENE HOMOLOG; IT15 PROTEIN PRODUCT; HUNTINGTONS-DISEASE; EMBRYONIC LETHALITY; CAUDATE-NUCLEUS; BRAIN; EXPRESSION; LOCALIZATION; REPEAT; EXPANSION	Huntington's disease (HD) is one of an increasing number of human neurodegenerative disorders caused by a CAG/polyglutamine-repeat expansion. The mutation occurs in a gene of unknown function that is expressed in a wide range of tissues. The molecular mechanism responsible for the delayed onset, selective pattern of neuropathology, and cell death observed in HD has not been described. We have observed that mice transgenic for exon 1 of the human Ho gene carrying (GAG)(115) to (CAG)(156) repeat expansions develop pronounced neuronal intranuclear inclusions, containing the proteins huntingtin and ubiquitin, prior to developing a neurological phenotype. The appearance in transgenic mice of these inclusions, followed by characteristic morphological change within neuronal nuclei, is strikingly similar to nuclear abnormalities observed in biopsy material from HD patients.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114; JOHNS HOPKINS UNIV,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOL GENET,LONDON SE1 9RT,ENGLAND; MAX PLANCK INST MOL GENET,BERLIN,DAHLEM,GERMANY	Harvard University; Harvard Medical School; Massachusetts General Hospital; Johns Hopkins University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Max Planck Society	Davies, SW (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Bates, Gillian P/E-1146-2012; Ross, Christopher A/H-8395-2013	Bates, Gillian P/0000-0002-4041-6305; Wanker, Erich/0000-0001-8072-1630	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALZHEIMER A, 1911, Z GES NEUROL PSYCH, V3, P566; [Anonymous], ADV NEUROL; ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; BATES GP, 1997, IN PRESS HUM MOL GEN; Bhide PG, 1996, J NEUROSCI, V16, P5523; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruyn GW, 1987, ACTA NEUROPATHOL, V5, P21; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DELAMONTE SM, 1988, J NEUROPATH EXP NEUR, V47, P516, DOI 10.1097/00005072-198809000-00003; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Ebling FJP, 1996, BRAIN RES BULL, V41, P257, DOI 10.1016/S0361-9230(96)00192-X; FORNO LS, 1979, ADV NEUROL, V23, P95; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HADREEN JC, 1995, J NEUROPATHOL EXP NE, V54, P105; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22; Hollen KM, 1997, MOL BRAIN RES, V47, P31, DOI 10.1016/S0169-328X(97)00034-X; *HUNT DIS COLL RES, 1993, CELL, V72, P971; IDE K, 1995, BIOCHEM BIOPH RES CO, V209, P1119, DOI 10.1006/bbrc.1995.1613; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; KEMP JM, 1971, PHILOS T R SOC B, V262, P383, DOI 10.1098/rstb.1971.0102; KOSINSKI CM, 1997, IN PRESS EXP NEUROL; KOWALL NW, 1987, TRENDS NEUROSCI, V10, P24, DOI 10.1016/0166-2236(87)90120-2; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; LOWE J, 1989, NEUROSCI LETT, V105, P7, DOI 10.1016/0304-3940(89)90003-7; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MYERS RH, 1991, J NEUROPATH EXP NEUR, V50, P729, DOI 10.1097/00005072-199111000-00005; MYERS RH, 1988, NEUROLOGY, V38, P341, DOI 10.1212/WNL.38.3.341; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; Peters A., 1991, FINE STRUCTURE NERVO; ROOS RAC, 1983, J NEUROL SCI, V61, P37, DOI 10.1016/0022-510X(83)90053-9; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHILLING G, 1995, HUM MOL GENET, V4, P1365, DOI 10.1093/hmg/4.8.1365; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3952, DOI 10.1073/pnas.87.10.3952; TELLEZNAGEL I, 1974, J NEUROCYTOL, V3, P308; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	55	1812	1871	2	69	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					537	548		10.1016/S0092-8674(00)80513-9	http://dx.doi.org/10.1016/S0092-8674(00)80513-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267033	hybrid			2022-12-28	WOS:A1997XQ06300017
J	Boers, M; Verhoeven, AC; Markusse, HM; vandeLaar, MAFJ; Westhovens, R; vanDenderen, JC; vanZeben, D; Dijkmans, BAC; Peeters, AJ; Jacobs, P; vandenBrink, HR; Schouten, HJA; vanderHeijde, DMFM; Boonen, A; vanderLinden, S				Boers, M; Verhoeven, AC; Markusse, HM; vandeLaar, MAFJ; Westhovens, R; vanDenderen, JC; vanZeben, D; Dijkmans, BAC; Peeters, AJ; Jacobs, P; vandenBrink, HR; Schouten, HJA; vanderHeijde, DMFM; Boonen, A; vanderLinden, S			Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis	LANCET			English	Article							ANTIRHEUMATIC DRUGS; DISEASE-ACTIVITY; CLINICAL-TRIALS; THERAPY; CLASSIFICATION; IMPROVEMENT; COMBINATION; DISABILITY; CRITERIA	Background The value of intensive combination therapy in early rheumatoid arthritis is unproven. In a multicentre, double-blind, randomised trial (COBRA), we compared the combination of sulphasalazine (2 g/day), methotrexate (7.5 mg/week), and prednisolone (initially 60 mg/day, tapered in 6 weekly steps to 7.5 mg/day) with sulphasalazine alone. Methods 155 patients with early rheumatoid arthritis (median duration 4 months) were randomly assigned combined treatment (76) or sulphasalazine alone (79). Prednisolone and methotrexate were tapered and stopped after 28 and 40 weeks, respectively. The main outcomes were the pooled index (a weighted change score of live disease activity measures) and the Sharp/Van der Heijde radiographic damage score in hands and feet. Independent health-care professionals assessed the main outcomes without knowledge of treatment allocation. Findings At week 28, the mean pooled index was 1.4 (95% CI 1.2-1.6) in the combined treatment group and 0.8 (0.6-1.0) in the sulphasalazine group (p<0.0001). At this time, 55 (72%) and 39 (49%) patients, respectively, were improved according to American College of Rheumatology criteria. The clinical difference between the groups decreased and was no longer significant after prednisolone was stopped, and there were no further changes after methotrexate was stopped. At 28 weeks, the radiographic damage score had increased by a median of 1 (range 0-28) in the combined-therapy group and 4 (0-44) in the sulphasalazine group (p<0.0001). The increases at week 56 (2 [0-43] vs 6 [0-54], p=0.004), and at week 80 (4 [0-80] vs 12 [0-72], p=0.01) were also significant. Further analysis suggests that combined therapy immediately suppressed damage progression, whereas sulphasalazine did so less effectively and with a lag of 6 to 12 months. There were fewer withdrawals in the combined therapy than the sulphasalazine group (6 [8%] vs 23 [29%]), and they occurred later. Interpretation This combined-therapy regimen offers additional disease control over and above that of sulphasalazine alone that persists for up to a year after corticosteroids are stopped. Although confirmatory studies and long-term follow-up are needed, this approach may prove useful in the treatment of early rheumatoid arthritis.	UNIV HOSP, MAASTRICHT, NETHERLANDS; ZUIDERZIEKENHUIS, ROTTERDAM, NETHERLANDS; MED SPECTRUM TWENTE, ENSCHEDE, NETHERLANDS; TWENTEBORG HOSP, ENSCHEDE, NETHERLANDS; CATHOLIC UNIV LEUVEN, PELLENBERG HOSP, B-3000 LOUVAIN, BELGIUM; JAN VAN BREEMEN INST, AMSTERDAM, NETHERLANDS; BRONOVO HOSP, THE HAGUE, NETHERLANDS; UNIV HOSP, LEIDEN, NETHERLANDS; REINIER DE GRAAF GASTHUIS, DELFT, NETHERLANDS; ST LAURENTIUS HOSP, ROERMOND, NETHERLANDS; MED CTR ALKMAAR, ALKMAAR, NETHERLANDS	Maastricht University; Medical Spectrum Twente; KU Leuven; Haaglanden Medical Center; Bronovo Hospital; Reinier de Graaf Hospital; Medical Center Of Alkmaar								ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P1093, DOI 10.1002/anr.1780320907; [Anonymous], 1959, ANN RHEUM DIS, V18, P173; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BOERS M, 1994, J RHEUMATOL, V21, P86; Ciconelli RM, 1996, BRIT J RHEUMATOL, V35, P150; DEANDRADE J R, 1965, Arthritis Rheum, V8, P302; Dougados M., 1996, Arthritis and Rheumatism, V39, pS103; EDMONDS JP, 1993, ARTHRITIS RHEUM, V36, P336, DOI 10.1002/art.1780360308; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; FRIES JF, 1993, ARTHRITIS RHEUM, V36, P297, DOI 10.1002/art.1780360303; Haagsma C., 1995, Arthritis and Rheumatism, V38, pS368; HAAGSMA CJ, 1994, BRIT J RHEUMATOL, V33, P1049; HARRIS ED, 1993, TXB RHEUMATOLOGY, P912; JONES E, 1991, J RHEUMATOL, V18, P1313; Kirwan John, 1996, Arthritis and Rheumatism, V39, pS218; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415; Morrison E, 1996, BRIT J RHEUMATOL, V35, P2; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; PINALS RS, 1981, ARTHRITIS RHEUM, V24, P1308, DOI 10.1002/art.1780241012; Saag KG, 1996, ARTHRITIS RHEUM-US, V39, P1818, DOI 10.1002/art.1780391107; Schouten HJA, 1995, BIOMETRICS, V51, P1529, DOI 10.2307/2533283; SIEGERT CEH, 1984, CLIN RHEUMATOL, V3, P305, DOI 10.1007/BF02032335; SMYTHE HA, 1977, J RHEUMATOL, V4, P144; TUGWELL P, 1987, J RHEUMATOL, V14, P446; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; TUGWELL P, 1994, RHEUMATOID ARTHRITIS, P357; vanderHeide A, 1996, ANN INTERN MED, V124, P699, DOI 10.7326/0003-4819-124-8-199604150-00001; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; VANDERHEIJDE DMFM, 1990, ANN RHEUM DIS, V49, P916, DOI 10.1136/ard.49.11.916; VANGESTEL AM, 1995, BRIT J RHEUMATOL, V34, P347; VANSCHAARDENBURG D, 1995, ARTHRITIS RHEUM, V38, P334; VANZEBEN D, 1993, J RHEUMATOL, V20, P1288; VEER GV, 1992, EUR J CLIN CHEM CLIN, V30, P301; WEUSTEN BLAM, 1993, SEMIN ARTHRITIS RHEU, V23, P183, DOI 10.1016/S0049-0172(05)80039-3	35	873	890	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 2	1997	350	9074					309	318		10.1016/S0140-6736(97)01300-7	http://dx.doi.org/10.1016/S0140-6736(97)01300-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251634				2022-12-28	WOS:A1997XP24200007
J	Iyo, M; Namba, H; Fukushi, K; Shinotoh, H; Nagatsuka, S; Suhara, T; Sudo, Y; Suzuki, K; Irie, T				Iyo, M; Namba, H; Fukushi, K; Shinotoh, H; Nagatsuka, S; Suhara, T; Sudo, Y; Suzuki, K; Irie, T			Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease	LANCET			English	Article							COMPUTED-TOMOGRAPHY; IN-VIVO; DEMENTIA; DEFICITS; RECEPTORS; SEVERITY	Background Acetylcholinesterase activity, a marker for degeneration of the central cholinergic system, has consistently been reported, in necropsy brain studies, to be reduced in the cerebral cortex of patients with Alzheimer's disease. We have shown regional acetylcholinesterase activity in vivo in rodent and primate brains with radioactive acetylcholine analogues. In the present study, we used one of the analogues to map acetylcholinesterase activity in the brains of living people. Methods Positron emission tomography (PET) and a radiolabelled acetylcholine analogue with high hydrolytic specificity to acetylcholinesterase [C-11]N-methyl-4-piperidyl acetate (MP4A), was used in eight elderly healthy controls and five patients with Alzheimer's disease who had mild dementia. All participants were given an intravenous injection of [C-11]MP4A and then sequential patterns of radioactivity in various brain regions were obtained by PET. Time courses of [C-11]MP4A concentration in arterial blood were also measured to obtain an input function. A three-compartment model was used to estimate regional acetylcholinesterase activity in the brain. Findings The estimated acetylcholinesterase distribution in the brain of the control participants agreed with the acetylcholinesterase distribution at necropsy. All patients with Alzheimer's disease had multiple cortical regions with a reduced estimated acetylcholinesterase activity in comparison with control participants. The reduction was more pronounced in the parietotemporal cortex, with an average reduction rate of 31% in temporal and 38% in parietal cortex, and less pronounced in other cortical lesions (19% in frontal, 24% in occipital, and 20% in sensorimotor cortex), Each patient was found to have at least two cortical regions with significantly reduced acetylcholinesterase activity. Interpretation The method we describe for non-invasive in-vivo detection of regional acetylcholinesterase changes in the living human brain that is feasible for biochemical assessment of Alzheimer's disease.	NATL INST RADIOL SCI,DIV CLIN RES,INAGE KU,CHIBA 263,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST MENTAL HLTH,CHIBA,JAPAN; CHIBA CANC CTR HOSP,DIV NEUROL SURG,CHIBA,JAPAN; CHIBA UNIV,SCH MED,DEPT NEUROL,CHIBA 280,JAPAN; DAIICHI PURE CHEM CO LTD,TOKAI RES LABS,IBARAKI,OSAKA,JAPAN	National Institutes for Quantum Science & Technology; National Center for Neurology & Psychiatry - Japan; Chiba Cancer Center; Chiba University; Sekisui Chemical Co Ltd								Arai H, 1984, Rinsho Shinkeigaku, V24, P1128; ATACK JR, 1986, J NEUROCHEM, V47, P263; BIERER LM, 1995, J NEUROCHEM, V64, P749; CARLSSON A, 1987, GERONTOLOGY, V33, P159, DOI 10.1159/000212870; DAVIES P, 1976, LANCET, V2, P1403; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEWEY SL, 1990, SYNAPSE, V5, P213, DOI 10.1002/syn.890050307; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOTTFRIES CG, 1985, PSYCHOPHARMACOLOGY, V86, P245, DOI 10.1007/BF00432208; HAMBA H, 1996, ANN NUCL MED, V10, P161; HANSEN LA, 1988, NEUROLOGY, V38, P48, DOI 10.1212/WNL.38.1.48; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Irie T, 1996, J NUCL MED, V37, P649; IRIE T, 1994, NUCL MED BIOL, V21, P801, DOI 10.1016/0969-8051(94)90159-7; JAGUST WJ, 1987, ARCH NEUROL-CHICAGO, V44, P258, DOI 10.1001/archneur.1987.00520150014011; JOHNSON KA, 1987, ARCH NEUROL-CHICAGO, V44, P165, DOI 10.1001/archneur.1987.00520140035014; LASSEN NA, 1988, J CEREBR BLOOD F MET, V8, pS13, DOI 10.1038/jcbfm.1988.28; MARTIN EM, 1987, NEUROLOGY, V37, P1201, DOI 10.1212/WNL.37.7.1201; MCKHANN G, 1984, NEUROLOGY, V35, P939; NAMBA H, 1994, BRAIN RES, V667, P278, DOI 10.1016/0006-8993(94)91507-5; Pappata S, 1996, J NEUROCHEM, V67, P876; PERRY EK, 1978, BRIT MED J, V2, P1427; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; SIMS NR, 1983, J NEUROCHEM, V40, P503, DOI 10.1111/j.1471-4159.1983.tb11311.x; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; WALDEMAR G, 1994, J NEUROL NEUROSUR PS, V57, P285, DOI 10.1136/jnnp.57.3.285; WEINBERGER DR, 1991, ARCH NEUROL-CHICAGO, V48, P169, DOI 10.1001/archneur.1991.00530140061018; WILCOCK GK, 1982, J NEUROL SCI, V57, P407, DOI 10.1016/0022-510X(82)90045-4	28	201	207	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1805	1809		10.1016/S0140-6736(96)09124-6	http://dx.doi.org/10.1016/S0140-6736(96)09124-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269216				2022-12-28	WOS:A1997XF73500012
J	Carelli, S; Ceriotti, A; Cabibbo, A; Fassina, G; Ruvo, M; Sitia, R				Carelli, S; Ceriotti, A; Cabibbo, A; Fassina, G; Ruvo, M; Sitia, R			Cysteine and glutathione secretion in response to protein disulfide bond formation in the ER	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; XENOPUS-OOCYTES; TYROSINE KINASE; MESSENGER-RNA; NITRIC-OXIDE; RETENTION; TEMPERATURE; TRANSLATION; ISOMERASE; TRANSPORT	Protein folding in the endoplasmic reticulum(ER) often involves the formation of disulfide bonds, The oxidizing conditions required within this organelle were shown to be maintained through the release of small thiols, mainly cysteine and glutathione, Thiol secretion was stimulated when proteins rich in disulfide bonds were translocated into the ER, and secretion was prevented by the inhibition of protein synthesis, Endogenously generated cysteine and glutathione counteracted thiol-mediated retention in the ER and altered the extracellular redox, The secretion of thiols might link disulfide bond formation in the ER to intra-and intercellular redox signaling.	IST SCI SAN RAFFAELE, DIBIT, MILAN, ITALY; CNR, IST BIOSINTESI VEGETALI, I-20133 MILAN, ITALY; TECNOGEN, Piana Monte Verna, CE, ITALY	Vita-Salute San Raffaele University; Consiglio Nazionale delle Ricerche (CNR)			Fassina, Giorgio/I-7127-2012; Sitia, Roberto/AAB-5005-2019; Ceriotti, Aldo/A-1448-2016	Fassina, Giorgio/0000-0003-1845-2657; Sitia, Roberto/0000-0001-7086-4152; Ceriotti, Aldo/0000-0002-8230-8863				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERRIDGE MV, 1976, CELL, V8, P283, DOI 10.1016/0092-8674(76)90012-X; Carelli S, 1997, EUR J IMMUNOL, V27, P1283, DOI 10.1002/eji.1830270533; CARELLI S, UNPUB; Ceriotti A, 1995, Methods Mol Biol, V37, P151; CERIOTTI A, 1991, EUR J BIOCHEM, V202, P959, DOI 10.1111/j.1432-1033.1991.tb16456.x; CERIOTTI A, 1989, J CELL BIOL, V109, P1439, DOI 10.1083/jcb.109.4.1439; Collesi C, 1996, MOL CELL BIOL, V16, P5518; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; HWANG C, 1992, THESIS MIT; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI [10.1002/RCM.1290020802, DOI 10.1002/RCM.1290020802, 10.1002/rcm.1290020802]; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; ZOPPE M, COMMUNICATION	31	79	81	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1681	1684		10.1126/science.277.5332.1681	http://dx.doi.org/10.1126/science.277.5332.1681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287224				2022-12-28	WOS:A1997XV68400055
J	Counsell, C				Counsell, C			Formulating questions and locating primary studies for inclusion in systematic reviews	ANNALS OF INTERNAL MEDICINE			English	Article							PUBLICATION BIAS; CLINICAL-TRIALS; MEDICAL LITERATURE; USERS GUIDES; MYOCARDIAL-INFARCTION; IDENTIFYING RELEVANT; RANDOMIZED TRIALS; META-ANALYSIS; METAANALYSIS; ARTICLE	Much time and effort are spent on designing primary research studies. Similar care must be given to planning systematic reviews. The review should be based on an important, well-focused question that is relevant to patient care. By formulating the question properly, the criteria that primary studies must meet to be included in the review become clear. These criteria, which comprise the types of persons involved, exposure, control group, outcomes, and study designs of interest, can then be refined so that they are clinically relevant, sensible, and workable. Inclusion criteria that are too narrow will limit the amount of data in the review, thereby increasing the risk for chance results and making the review less useful for the reader. Reviews should include studies whose designs offer the least biased answer to the question being asked. To maximize available data and reduce the risk for bias, as many relevant studies as possible need to be identified, regardless of publication status or language. Multiple overlapping search strategies should therefore be used and must be carefully planned. Strategies include searching the many electronic databases available (after careful consideration of which terms to enter), manually searching journals and conference proceedings, searching bibliographies of articles, searching existing registers of studies, and contacting companies or researchers. The time taken to formulate the question adequately and develop appropriate searches will increase the chance of producing a high-quality, meaningful review.			Counsell, C (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, BRAMWELL DOTT BLDG, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BERLIN JA, 1995, AM J EPIDEMIOL, V142, P383, DOI 10.1093/oxfordjournals.aje.a117645; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; *COCHR CONTR TRIAL, 1996, COCHR LIB; *COCHR CTR, 1995, J HAND SEARCH MAN BA; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; COUNSELL C, 1995, BRIT MED J, V310, P126, DOI 10.1136/bmj.310.6972.126; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; CROWLEY P, 1996, PREGNANCY CHILDBIRTH; DESILVA RA, 1981, LANCET, V2, P855; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; DICKERSIN K, 1996, COCHRANE COLLABORATI; Donaldson M, 1992, SETTING PRIORITIES H; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; EASTERBROOK PJ, 1992, STAT MED, V11, P345, DOI 10.1002/sim.4780110307; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Eddy D M, 1989, Int J Technol Assess Health Care, V5, P485; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Glass G.V., 1981, META ANAL SOCIAL RES; GOODARE H, 1995, BMJ-BRIT MED J, V310, P1277, DOI 10.1136/bmj.310.6990.1277; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JADAD AR, 1993, BMJ-BRIT MED J, V307, P66, DOI 10.1136/bmj.307.6895.66-a; JADAD AR, 1993, ONLINE J CURR CLIN T, V33, P3973; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; LARA ME, 1990, NATL PRIORITIES ASSE; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; Mumford CJ, 1996, QJM-MON J ASSOC PHYS, V89, P1; NEWCOMBE RG, 1987, BRIT MED J, V295, P656, DOI 10.1136/bmj.295.6599.656; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1249; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; SACKETT D, 1996, COCHRANE LIB; SCHERER RW, 1994, JAMA-J AM MED ASSOC, V272, P158, DOI 10.1001/jama.272.2.158; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SIMES RJ, 1987, STAT MED, V6, P11, DOI 10.1002/sim.4780060104; Smith R, 1996, BRIT MED J, V313, P1062; *STAND GROUP HLTH, 1994, 1994 DEP HLTH; TSUTANI K, 1994, P 2 INT COCHR C HAM; WILLINGER M, 1994, PEDIATRICS, V93, P814; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; 1991, LANCET, V338, P244; 1995, FUNDAM CLIN PHARM, V9, P384	57	293	299	2	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					380	387		10.7326/0003-4819-127-5-199709010-00008	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273830				2022-12-28	WOS:A1997XU10000007
J	Woo, KS; Robinson, JTC; Chook, P; Adams, MR; Yip, G; Mai, ZJ; Lam, CWK; Sorensen, KE; Deanfield, JE; Celermajer, DS				Woo, KS; Robinson, JTC; Chook, P; Adams, MR; Yip, G; Mai, ZJ; Lam, CWK; Sorensen, KE; Deanfield, JE; Celermajer, DS			Differences in the effect of cigarette smoking on endothelial function in Chinese and white adults	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTHY-YOUNG ADULTS; PASSIVE SMOKING; ATHEROSCLEROSIS; EPIDEMIOLOGY; DYSFUNCTION; DISEASE	Background: The prevalence of coronary artery disease in southern China is approximately one fifth that in ''westernized'' countries, even though approximately 70% of Chinese men smoke cigarettes and Chinese women have substantial passive exposure to cigarette smoke. Objectives: Endothelial dysfunction is an early event in atherosclerosis and occurs in young white active and passive smokers; we compared endothelial physiology in healthy young Chinese and white smokers and nonsmokers. Patients: 144 healthy adults who were 16 to 45 years of age: 72 Chinese persons in a village in southern China and 72 white persons in Australia and England who were matched for exposure to cigarette smoke. Each ethnic group comprised 36 controls (lifelong nonsmokers with no regular exposure to cigarette smoke; 16 men and 20 women) and 36 active or passive smokers (15 men and 21 women). Measurements: Arterial endothelial function was tested with high-resolution external vascular ultrasonography, and brachial artery diameter was measured at rest, after flow increase (which causes endothelium-dependent dilatation), and after administration of sublingual nitroglycerin (an endothelium-independent dilator). Results: Endothelium-dependent dilatation was similar in Chinese (7.9%) and white (8.4%) nonsmokers (P > 0.2). Among white persons, endothelium-dependent dilatation was lower in active or passive smokers (3.9%) than in nonsmokers (8.4%) (P < 0.001). Among Chinese persons, dilatation was not significantly lower in active or passive smokers (7.3%) than in nonsmokers (7.9%) (P > 0.2). Dilatation was higher in Chinese active or passive smokers (7.3%) than in white active or passive smokers (3.9%) (P < 0.001). Dilatation responses to nitroglycerin were similar in all groups (P = 0.17). Conclusion: Young Chinese adults have less evidence of arterial endothelial dysfunction than young white adults with similar direct or indirect exposure to cigarette smoke.	ROYAL PRINCE ALFRED HOSP, DEPT CARDIOL, CAMPERDOWN, NSW 2050, AUSTRALIA; PAN YU CTY HOSP, PAN YU, PEOPLES R CHINA; GREAT ORMOND ST HOSP CHILDREN, CARDIOTHORAC UNIT, LONDON WC1N 3JH, ENGLAND; HEART RES INST, SYDNEY, NSW, AUSTRALIA; CHINESE UNIV HONG KONG, HONG KONG, HONG KONG	University of Sydney; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Sydney; Heart Research Institute; Chinese University of Hong Kong			Deanfield, John E/C-5178-2008; YIP, Gabriel/A-8837-2008	YIP, Gabriel/0000-0002-3859-7194; Deanfield, John/0000-0001-8806-6052				Adams MR, 1996, J VASC INVEST, V2, P146; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; Cook NC, 1996, J NUTR BIOCHEM, V7, P66, DOI 10.1016/0955-2863(95)00168-9; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Heitzer T, 1996, CIRCULATION, V93, P1346, DOI 10.1161/01.CIR.93.7.1346; *HLTH BEN SMOK CES, 1990, 9084161917 DHHS CDC; HOLBROOK JH, 1984, CIRCULATION, V70, P1114; HONORE EK, 1995, CIRCULATION S1, V92, P1; PITTILO RM, 1984, BRIT J HAEMATOL, V58, P627, DOI 10.1111/j.1365-2141.1984.tb06109.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SORENSEN KE, 1995, BRIT HEART J, V74, P247; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; WENG XZ, 1988, CHINESE MED J-PEKING, V101, P371; WENG XZ, 1987, CHINESE MED J-PEKING, V100, P886; WOO KS, 1989, INT J CARDIOL, V24, P83, DOI 10.1016/0167-5273(89)90045-4	17	42	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					372	375		10.7326/0003-4819-127-5-199709010-00006	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273828				2022-12-28	WOS:A1997XU10000005
J	Fitzpatrick, DC; Batra, R; Stanford, TR; Kuwada, S				Fitzpatrick, DC; Batra, R; Stanford, TR; Kuwada, S			A neuronal population code for sound localization	NATURE			English	Article							INFERIOR COLLICULUS; UNANESTHETIZED RABBIT; BINAURAL INTERACTION; CHANGING FREQUENCY; INTERAURAL DELAYS; INFORMATION; DIRECTION; MOVEMENT	The accuracy with which listeners can locate sounds is much greater than the spatial sensitivity of single neurons(1-3). The broad spatial tuning of auditory neurons indicates that a code based on the responses of ensembles of neurons, a population code, must be used to determine the position of a sound in space, Here we show that the tuning of neurons to the most potent localization cue, the interaural time difference in low-frequency signals (< similar to 2 kHz; refs 4, 5), becomes sharper as the information ascends through the auditory system, We also show that this sharper tuning increases the efficiency of the population code, in the sense that fewer neurons are required to achieve a given acuity.			Fitzpatrick, DC (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT ANAT, FARMINGTON, CT 06030 USA.		Fitzpatrick, Douglas/AFT-2814-2022	Fitzpatrick, Douglas/0000-0001-8099-7194; Stanford, Terrence/0000-0003-0759-5599				BATRA R, 1989, J NEUROPHYSIOL, V61, P257, DOI 10.1152/jn.1989.61.2.257; BATRA R, IN PRESS J NEUROPHYS; BLAUERT J, 1982, SPATIAL HEARING; BRUGGE JF, 1997, BINAURAL SPATIAL HEA, P447; CAPUANO U, 1981, J COMP NEUROL, V196, P13, DOI 10.1002/cne.901960103; DYE RH, 1990, J ACOUST SOC AM, V88, P2159, DOI 10.1121/1.400113; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Green D. M., 1966, SIGNAL DETECTION THE, V1; HAFTER ER, 1975, J ACOUST SOC AM, V57, P181, DOI 10.1121/1.380412; HEFFNER H, 1980, J ACOUST SOC AM, V68, P1584, DOI 10.1121/1.385213; Heller LM, 1996, J ACOUST SOC AM, V99, P3632, DOI 10.1121/1.414961; Hinton G. E., 1986, FOUNDATIONS, V1, P77; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KUWADA S, 1987, J NEUROPHYSIOL, V57, P1338, DOI 10.1152/jn.1987.57.5.1338; KUWADA S, 1997, BINAURAL SPATIAL HEA, P399; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; LI L, 1992, J NEUROSCI, V12, P4530; Mills A. W., 1958, J ACOUST SOC AM, V65, P991; PERROTT DR, 1984, J ACOUST SOC AM, V75, P1201, DOI 10.1121/1.390771; RUMMELHART DE, 1986, PARALLEL DISTRIBUTED, V2, P77; Salinas E, 1994, J Comput Neurosci, V1, P89, DOI 10.1007/BF00962720; STANFORD TR, 1992, J NEUROSCI, V12, P3200, DOI 10.1523/JNEUROSCI.12-08-03200.1992; STERN RM, 1992, ADV BIOSCI, V83, P547; STERN RM, 1978, J ACOUST SOC AM, V64, P127, DOI 10.1121/1.381978; THEUNISSEN FE, 1991, J NEUROPHYSIOL, V66, P1690, DOI 10.1152/jn.1991.66.5.1690; TRAHIOTIS C, 1990, J ACOUST SOC AM, V87, P810, DOI 10.1121/1.398892; VANGISBERGEN JAM, 1987, NEUROSCIENCE, V21, P541, DOI 10.1016/0306-4522(87)90140-0; WIGHTMAN FL, 1992, J ACOUST SOC AM, V91, P1648, DOI 10.1121/1.402445; YIN TCT, 1983, J NEUROPHYSIOL, V50, P1020, DOI 10.1152/jn.1983.50.4.1020	30	131	133	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					871	874		10.1038/42246	http://dx.doi.org/10.1038/42246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278047	Bronze			2022-12-28	WOS:A1997XT75400048
J	Gu, W; Roeder, RG				Gu, W; Roeder, RG			Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain	CELL			English	Article							NUCLEAR-PROTEIN CBP; TRANSCRIPTIONAL ACTIVATION; SUPPRESSION; COACTIVATOR; GROWTH; LOOP; SITE; TRANSFORMATION; EXPRESSION; INHIBITOR	The tumor suppressor p53 exerts antiproliferation effects through its ability to function as a sequence-specific DNA-binding transcription factor. Here, we demonstrate that p53 can be modified by acetylation both in vivo and in vitro. Remarkably, the site of p53 that is acetylated by its coactivator, p300, resides in a C-terminal domain known to be critical for the regulation of p53 DNA binding. Furthermore, the acetylation of p53 can dramatically stimulate its sequence-specific DNA-binding activity, possibly as a result of an acetylation-induced conformational change. These observations clearly indicate a novel pathway for p53 activation and, importantly, provide an example of an acetylation-mediated change in the function of a nonhistone regulatory protein. These results have significant implications regarding the molecular mechanisms of various acetyltransferase-containing transcriptional coactivators whose primary targets have been presumed to be histones.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University								Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Buckley AR, 1996, CELL GROWTH DIFFER, V7, P1713; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Chresta CM, 1996, NAT MED, V2, P745, DOI 10.1038/nm0796-745; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; FISCELLA M, 1994, ONCOGENE, V9, P3249; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MIYASHITA T, 1995, CELL, V80, P293; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shaw P, 1996, ONCOGENE, V12, P921; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SOUSSI T, 1990, ONCOGENE, V5, P945; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	83	2110	2194	1	128	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					595	606		10.1016/S0092-8674(00)80521-8	http://dx.doi.org/10.1016/S0092-8674(00)80521-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288740	Bronze			2022-12-28	WOS:A1997XT06600004
J	Creamer, P; Hochberg, MC				Creamer, P; Hochberg, MC			Osteoarthritis	LANCET			English	Article							SYMPTOMATIC KNEE OSTEOARTHRITIS; MEDICAL-MANAGEMENT; OSTEO-ARTHRITIS; SELF-MANAGEMENT; RISK-FACTORS; HIP; GUIDELINES; CLASSIFICATION; PROGRESSION; SYNOVITIS		UNIV MARYLAND,DEPT MED,DIV CLIN IMMUNOL & RHEUMATOL,SCH MED,BALTIMORE,MD 21201; MARYLAND VET AFFAIRS HLTH CARE SYST,CTR GERIATR RES EDUC & CLIN,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; Geriatric Research Education & Clinical Center								ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ALTMAN RD, 1991, SEMIN ARTHRITIS RHEU, V20, P40, DOI 10.1016/0049-0172(91)90026-V; *AM COLL RHEUM AD, 1996, ARTHRITIS RHEUM, V39, P723; AMIN AR, 1995, J EXP MED, V182, P2097, DOI 10.1084/jem.182.6.2097; BALDWIN CT, 1995, AM J HUM GENET, V56, P692; Belcher C, 1996, ANN RHEUM DIS, V55, P230, DOI 10.1136/ard.55.4.230; Bellamy N, 1996, ARTHRITIS RHEUM, V39, P357, DOI 10.1002/art.1780390302; BELLAMY N, 1977, J RHEUMATOL, V24, P799; BRANDT KD, 1995, J RHEUMATOL, V22, P149; BRANDT KD, 1995, ANN INTERN MED, V122, P874, DOI 10.7326/0003-4819-122-11-199506010-00011; BRANDT KD, 1994, ANN NY ACAD SCI, V732, P199, DOI 10.1111/j.1749-6632.1994.tb24735.x; BRANDT KD, 1996, DRUGS, V52, P1; BRUNE K, 1997, RHEUMATOLOGY, V11, P3; Caron JP, 1996, ARTHRITIS RHEUM, V39, P1535, DOI 10.1002/art.1780390914; Cicuttini FM, 1996, J CLIN PATHOL, V49, P617, DOI 10.1136/jcp.49.8.617; COOPER C, 1994, J RHEUMATOL, V21, P307; CREAMER P, 1997, BR J RHEUMATOL, V37, P726; CREAMER P, 1997, IN PRESS ANN RHEUM D; DAVIS MA, 1992, J RHEUMATOL, V19, P1943; Dequeker J, 1996, BRIT J RHEUMATOL, V35, P813; DIEPPE P, 1993, ANN RHEUM DIS, V52, P557, DOI 10.1136/ard.52.8.557; Dieppe PA, 1997, OSTEOARTHR CARTILAGE, V5, P87, DOI 10.1016/S1063-4584(97)80002-7; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FAM AG, 1995, ARTHRITIS RHEUM-US, V38, P201, DOI 10.1002/art.1780380208; Felson DT, 1997, ARTHRITIS RHEUM, V40, P728, DOI 10.1002/art.1780400420; FELSON DT, 1992, ANN INTERN MED, V116, P535, DOI 10.7326/0003-4819-116-7-535; FELSON DT, 1994, J RHEUMATOL, V21, P181; HAMERMAN D, 1997, OSTEOARTHRITIS PUBLI; HARAOUI B, 1991, ARTHRITIS RHEUM, V34, P153, DOI 10.1002/art.1780340205; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Hochberg M C, 1996, Arthritis Care Res, V9, P170, DOI 10.1002/1529-0131(199606)9:3<170::AID-ANR1790090304>3.0.CO;2-K; Hochberg M.C., 1997, OSTEOARTHRITIS PUBLI, P169; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; Hochberg MC, 1996, ANN RHEUM DIS, V55, P685, DOI 10.1136/ard.55.9.685; HORTON W, 1996, ARTHRITIS RHEUM, V39, P167; Jonsson H, 1996, ANN RHEUM DIS, V55, P540, DOI 10.1136/ard.55.8.540; Keefe FJ, 1996, ARTHRIT CARE RES, V9, P279, DOI 10.1002/1529-0131(199608)9:4<279::AID-ANR1790090413>3.0.CO;2-6; Kraus VB, 1997, MED CLIN N AM, V81, P85, DOI 10.1016/S0025-7125(05)70506-X; KUETTNER KE, 1995, OSTEOARTHRITIC DISOR; LEDINGHAM J, 1995, ANN RHEUM DIS, V54, P53, DOI 10.1136/ard.54.1.53; LINDBLAD S, 1987, ARTHRITIS RHEUM, V30, P1081, DOI 10.1002/art.1780301001; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; LOUGHLIN J, 1994, BRIT J RHEUMATOL, V33, P1103; MADSEN OR, 1996, CLIN RHEUMATOL, V14, P308; Mansell JP, 1997, BRIT J RHEUMATOL, V36, P16; Marok R, 1996, ARTHRITIS RHEUM, V39, P583, DOI 10.1002/art.1780390407; MARTIN K, 1996, ARTHRITIS RHEUM, V39, P225; MOSKOWITZ RW, 1993, RHEUM DIS CLIN N A, V19, P523; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; Nevitt MC, 1996, ANN RHEUM DIS, V55, P673, DOI 10.1136/ard.55.9.673; NEVITT MC, 1995, ARTHRITIS RHEUM-US, V38, P907, DOI 10.1002/art.1780380706; Nguyen M, 1997, BRIT J RHEUMATOL, V36, P77; PELLETIER JP, 1995, J RHEUMATOL, V22, P1; Preidler KW, 1996, RADIOL CLIN N AM, V34, P259; PUETT DW, 1994, ANN INTERN MED, V121, P133, DOI 10.7326/0003-4819-121-2-199407150-00010; Roivainen A, 1996, BRIT J RHEUMATOL, V35, P933; Ryan Maria E., 1996, Current Opinion in Rheumatology, V8, P238, DOI 10.1097/00002281-199605000-00013; Schilke JM, 1996, NURS RES, V45, P68, DOI 10.1097/00006199-199603000-00002; SCHUMACHER HR, 1995, J RHEUMATOL, V20, P101; Scott DL, 1996, BRIT J RHEUMATOL, V35, P6; SCOTT DL, 1993, J ROY COLL PHYS LOND, V27, P391; SILMAN AJ, 1993, EPIDEMIOLOGY RHEUMAT, P257; Spangler RS, 1996, SEMIN ARTHRITIS RHEU, V26, P435, DOI 10.1016/S0049-0172(96)80024-2; Spector TD, 1996, BRIT MED J, V312, P940; Spector TD, 1997, ARTHRITIS RHEUM, V40, P723, DOI 10.1002/art.1780400419; SPECTOR TD, 1994, ANN RHEUM DIS, V53, P43; STAR VL, 1994, RHEUM DIS CLIN N AM, V20, P561; Towheed TE, 1997, SEMIN ARTHRITIS RHEU, V26, P755, DOI 10.1016/S0049-0172(97)80043-1; TOWHEED TE, 1997, J RHEUMATOL, V24, P549; Wada M, 1996, BRIT J RHEUMATOL, V35, P560; Watson PJ, 1996, ARTHRITIS RHEUM, V39, P1327, DOI 10.1002/art.1780390810; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; 1996, ANN RHEUM DIS, V55, P651	75	380	417	1	25	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					503	509		10.1016/S0140-6736(97)07226-7	http://dx.doi.org/10.1016/S0140-6736(97)07226-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274595				2022-12-28	WOS:A1997XR13500040
J	Averof, M; Patel, NH				Averof, M; Patel, NH			Crustacean appendage evolution associated with changes in Hox gene expression	NATURE			English	Article							BODY PLANS; ULTRABITHORAX; MORPHOLOGY; ANTIBODY; INSECT	Homeotic (Hox) genes specify the differential identity of segments along the body axis of insects. Changes in the segmental organization of arthropod bodies may therefore be driven by changes in the function of Hox genes(1-3), but so far this has been difficult to demonstrate. We shaw here that changes in the expression pattern of the Hox genes Ubx and AbdA in different crustaceans correlate well with the modification of their anterior thoracic limbs into feeding appendages (maxillipeds). Our observations provide direct evidence that major morphological changes in arthropod body plans are associated with changes in Hox gene regulation. They suggest that homeotic changes(1,4) may play a role in the normal process of adaptive evolutionary change.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND	Howard Hughes Medical Institute; University of Chicago				Patel, Nipam/0000-0003-4328-654X; Averof, Michalis/0000-0002-6803-7251	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1995, PHILOS T R SOC B, V349, P313, DOI 10.1098/rstb.1995.0119; AKAM M, 1988, DEVELOPMENT, V104, P123; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; Averof M, 1996, SEMIN CELL DEV BIOL, V7, P539, DOI 10.1006/scdb.1996.0068; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BRIGGS DEG, 1978, PHILOS T ROY SOC B, V281, P439, DOI 10.1098/rstb.1978.0005; Brusca R.C., 1990, INVERTEBRATES, P1; BURKE AC, 1995, DEVELOPMENT, V121, P333; CALMAN WT, 1909, CRUSTACEA; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; GAUNT SJ, 1994, INT J DEV BIOL, V38, P549; GIESBRECHT W, 1931, HANDWORTERBUCH NATUR, P800; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; LEWIS EB, 1978, NATURE, V276, P567; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MULLER KJ, 1988, FOSSILS STRATA, V23, P1; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PATEL NH, 1989, DEVELOPMENT, V107, P201; Raff R. A., 1991, EMBRYOS GENES EVOLUT; Salser SJ, 1996, DEVELOPMENT, V122, P1651; Schram F.R., 1986, CRUSTACEA; WAGNER GP, 1989, ANNU REV ECOL SYST, V20, P51, DOI 10.1146/annurev.es.20.110189.000411; Walossek Dieter, 1993, Fossils and Strata, V32, P1	26	269	274	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					682	686		10.1038/41786	http://dx.doi.org/10.1038/41786			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262403	Bronze			2022-12-28	WOS:A1997XQ86300051
J	Fass, D; Blacklow, S; Kim, PS; Berger, JM				Fass, D; Blacklow, S; Kim, PS; Berger, JM			Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module	NATURE			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CYSTEINE-RICH REPEAT; 3-DIMENSIONAL STRUCTURE; APOLIPOPROTEIN-E; BINDING DOMAIN; PROTEIN; MODELS; ERRORS; MAPS	The low-density lipoprotein receptor (LDLR) is responsible for the uptake of cholesterol-containing lipoprotein particles into cells(1,2). The amino-terminal region of LDLR, which consists of seven tandemly repeated, similar to 40-amino-acid, cysteine-rich modules (LDL-A modules), mediates binding to lipoproteins(3,4). LDL-A modules are biologically ubiquitous domains, found in over 100 proteins in the sequence database(5). The structure of ligand-binding repeat 5 (LR5) of the LDLR, determined to 1.7 Angstrom resolution by X-ray crystallography and presented here, contains a calcium ion coordinated by acidic residues that lie at the carboxy-terminal end of the domain and are conserved among LDL-A modules. Naturally occurring point mutations found in patients with the disease familial hypercholesterolaemia(6) alter residues that directly coordinate Ca2+ or that serve as scaffolding residues of LR5.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02142; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute								ABBADI A, 1991, J AM CHEM SOC, V113, P2729, DOI 10.1021/ja00007a056; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, X PLOR VERSION 3 1 S; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; ESSER V, 1988, J BIOL CHEM, V263, P13282; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JI ZS, 1994, J BIOL CHEM, V269, P2764; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUSSELL DW, 1989, J BIOL CHEM, V264, P21782; *SERC DAR LAB, 1979, 4 SERC DAR LAB; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	27	296	307	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					691	693		10.1038/41798	http://dx.doi.org/10.1038/41798			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262405	Bronze			2022-12-28	WOS:A1997XQ86300053
J	Shubin, N; Tabin, C; Carroll, S				Shubin, N; Tabin, C; Carroll, S			Fossils, genes and the evolution of animal limbs	NATURE			English	Review							DROSOPHILA IMAGINAL DISKS; DISTAL-LESS GENE; HOX GENES; PATTERN-FORMATION; ARTHROPOD PHYLOGENY; WING DEVELOPMENT; VERTEBRATE LIMB; TETRAPOD LIMBS; HOMEOTIC GENES; SONIC-HEDGEHOG	The morphological and functional evolution of appendages has played a crucial role in the adaptive radiation of tetrapods, arthropods and winged insects. The origin and diversification of fins, wings and other structures, long a focus of palaeontology, can now be approached through developmental genetics, Modifications of appendage number and architecture in each phylum ave correlated with regulatory changes in specific patterning genes. Although their respective evolutionary histories are unique, vertebrate, insect anal other animal appendages are organized by a similar genetic regulatory system that may have been established in a common ancestor.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV WISCONSIN,MOL BIOL LAB,MADISON,WI 53706	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Shubin, N (corresponding author), UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104, USA.							AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; Averof M, 1997, NATURE, V385, P627, DOI 10.1038/385627a0; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Beckers J, 1996, DEV BIOL, V180, P543, DOI 10.1006/dbio.1996.0327; Bolker JA, 1996, BIOESSAYS, V18, P489, DOI 10.1002/bies.950180611; BOORE JL, 1995, NATURE, V376, P163, DOI 10.1038/376163a0; BUDD G, 1993, NATURE, V364, P709, DOI 10.1038/364709a0; Budd GE, 1996, LETHAIA, V29, P1, DOI 10.1111/j.1502-3931.1996.tb01831.x; CAPDEVILA J, 1994, EMBO J, V6, P715; CAPECCHI MR, 1996, ANN NY ACAD SCI, V97, P34; Carroll RL, 1988, VERTEBRATE PALEONTOL; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHEN JY, 1994, SCIENCE, V264, P1304, DOI 10.1126/science.264.5163.1304; COATES MI, 1994, DEVELOPMENT, P169; Coates MI, 1996, T ROY SOC EDIN-EARTH, V87, P363, DOI 10.1017/S0263593300006787; COATES MI, 1995, CURR BIOL, V5, P844, DOI 10.1016/S0960-9822(95)00169-2; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; Davis AP, 1996, DEVELOPMENT, V122, P1175; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Favier B, 1996, DEVELOPMENT, V122, P449; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; FromentalRamain C, 1996, DEVELOPMENT, V122, P461; GAUTHIER JA, 1986, MEM CALIF ACAD SCI, V8, P1; Gerard Matthieu, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P985; GIBSON G, 1988, DEVELOPMENT, V102, P657; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; GREER A, 1980, J HERPETOL, V24, P142; GREGORY WILLIAM K., 1941, ANN NEW YORK ACAD SCI, V42, P273, DOI 10.1111/j.1749-6632.1941.tb55396.x; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HOLDER N, 1983, J THEOR BIOL, V104, P451, DOI 10.1016/0022-5193(83)90117-0; Holmgren N., 1939, Acta Zoologica Stockholm, V20, P89; HOLMGREN NILS, 1933, ACT ZOOL, V14, P185; HOU HX, 1995, GEOL FORENING FORHAN, V117, P163; HOU XG, 1995, ZOOL J LINN SOC-LOND, V114, P3, DOI 10.1006/zjls.1995.0014; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; JARVIK E, 1980, STRUCTURE EVOLUTION, V1; Jarvik Erik, 1996, Fossils and Strata, V40, P1; JERAM AJ, 1990, SCIENCE, V250, P658, DOI 10.1126/science.250.4981.658; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KUKALOVAPECK J, 1991, INSECTS AUSTR; LANDE R, 1978, EVOLUTION, V32, P73, DOI 10.1111/j.1558-5646.1978.tb01099.x; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LEBEDEV OA, 1995, ZOOL J LINN SOC-LOND, V113, P302; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MacFadden B.J., 1992, FOSSIL HORSES; MACKEM S, 1993, PROG CLIN BIOL RES, V383, P21; MANTON SM, 1964, MANDIBULAR MECH EVOL, V247; MARDEN JH, 1994, SCIENCE, V266, P427, DOI 10.1126/science.266.5184.427; Marigo V, 1996, DEVELOPMENT, V122, P1225; MORSE ES, 1872, ANN LYC NAT HIST NY, V10, P141; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; MULLER GB, 1991, ANNU REV ECOL SYST, V22, P229, DOI 10.1146/annurev.es.22.110191.001305; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Panganiban G, 1997, P NATL ACAD SCI USA, V94, P5162, DOI 10.1073/pnas.94.10.5162; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PETERSON RL, 1994, MECH DEVELOP, V47, P253, DOI 10.1016/0925-4773(94)90043-4; Popadic A, 1996, NATURE, V380, P395, DOI 10.1038/380395a0; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; Raff R.A., 1996, SHAPE LIFE; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; ROTH VL, 1991, J EVOLUTION BIOL, V4, P167, DOI 10.1046/j.1420-9101.1991.4020167.x; SANICOLA M, 1995, GENETICS, V139, P745; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SHUBIN N, 1995, EVOL BIOL, V28, P39; SHUBIN N, 1995, EVOLUTION, V49, P874, DOI 10.1111/j.1558-5646.1995.tb02323.x; SHUBIN NH, 1986, EVOLUTIONARY BIOL, V20, P318; SIMONETTA AM, 1991, EARLY EVOLUTION META, P189; Snodgrass RE, 1935, PRINCIPLES INSECT MO; Sordino P, 1996, TRENDS ECOL EVOL, V11, P114, DOI 10.1016/0169-5347(96)81089-5; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; SPREICHER S, 1994, DEVELOPMENT, V120, P535; STRUHL G, 1981, NATURE, V292, P635, DOI 10.1038/292635a0; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TABIN C, 1993, NATURE, V361, P692, DOI 10.1038/361692a0; TABIN CJ, 1992, DEVELOPMENT, V116, P289; Tickle C, 1996, DEV GENET, V19, P1, DOI 10.1002/(SICI)1520-6408(1996)19:1&lt;1::AID-DVG1&gt;3.0.CO;2-D; TODT WL, 1984, J EMBRYOL EXP MORPH, V80, P21; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; Vorobyeva E, 1996, EVOL BIOL, V29, P263; WAGNER GP, 1989, EVOLUTION, V43, P1157, DOI 10.1111/j.1558-5646.1989.tb02566.x; WALL NA, 1995, MECH DEVELOP, V53, P383, DOI 10.1016/0925-4773(95)00453-X; Watson D. M. S., 1913, Anatomischer Anzeiger, V44; WHEELER WC, 1993, CLADISTICS, V9, P1, DOI 10.1111/j.1096-0031.1993.tb00207.x; WIGGLESW.VB, 1973, NATURE, V246, P127, DOI 10.1038/246127a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	115	558	574	5	221	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					639	648		10.1038/41710	http://dx.doi.org/10.1038/41710			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262397				2022-12-28	WOS:A1997XQ86300039
J	Leger, J; LevyMarchal, C; Bloch, J; Pinet, A; Chevenne, D; Porquet, D; Collin, D; Czernichow, P				Leger, J; LevyMarchal, C; Bloch, J; Pinet, A; Chevenne, D; Porquet, D; Collin, D; Czernichow, P			Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY HEART-DISEASE; LOW-BIRTH-WEIGHT; BLOOD-PRESSURE; ADULT LIFE; FETAL GROWTH; INFANT GROWTH; CARDIOVASCULAR-DISEASE; INTRAUTERINE GROWTH; CHILDREN	Objective: To investigate whether the association between low birth weight and increased risk of developing impaired glucose tolerance, insulin resistance, hypertriglyceridaemia, and hypertension in middle age is apparent by the age of 20 in people born small for gestational age, Design: Regional cohort study. Setting: Maternity registry, Haguenau, France, Subjects: 236 full term singleton babies born small for gestational age (birth weight or length, or both, below third centile) during 1971-8 and 281 with normal birth weight (between 25th and 75th centile). All subjects were contacted and evaluated at a mean (SD) age of 20.6 (2.1) years. Main outcome measures: Adult height; concentrations of glucose, insulin, and proinsulin during an oral glucose tolerance test; lipid and fibrinogen concentrations; and blood pressure, Results: After sex and target height were adjusted for, subjects who had been born small for gestational age were significantly shorter at age 20 than those with a normal birth weight (men 4.5 cm shorter (95% confidence interval 6.0 to 3.0 cm); women 3.94 cm shorter (5.2 to 2.7 cm)), After sex and body mass index were adjusted for, mean plasma glucose concentration 30 minutes after a glucose load, fasting insulin concentration (in women), and insulin and proinsulin concentrations 30 and 120 minutes after a glucose load were significantly higher in subjects who had been born small for gestational age than in those with a normal birth weight Mean lipid and fibrinogen concentrations and blood pressure were not different between the two groups. Conclusions: Intrauterine growth retardation has long term consequences such as reduced final height Raised insulin and proinsulin concentrations are present in young adults born small for gestational age and could be markers of early changes in insulin sensitivity.	HOP ROBERT DEBRE,INSERM,CJF 9313,F-75019 PARIS,FRANCE; HOP ROBERT DEBRE,DEPT BIOCHEM,F-75019 PARIS,FRANCE; CTR HOSP HAGUENAU,MATERN UNIT,HAGUENAU,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Leger, J (corresponding author), HOP ROBERT DEBRE,ENDOCRINOL & DIABET UNIT,F-75019 PARIS,FRANCE.							BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1989, BRIT MED J, V298, P567; CHEVENNE D, 1994, CLIN CHEM, V40, P754; CHEVENNE D, 1995, ANN BIOL CLIN-PARIS, V53, P3; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; deZegher F, 1996, J CLIN ENDOCR METAB, V81, P1887, DOI 10.1210/jc.81.5.1887; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HAFFNER SM, 1994, J CLIN ENDOCR METAB, V79, P1806, DOI 10.1210/jc.79.6.1806; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HOKKENKOELEGA ACS, 1995, PEDIATR RES, V38, P267, DOI 10.1203/00006450-199508000-00022; Job JC, 1996, PEDIATR RES, V39, P354, DOI 10.1203/00006450-199602000-00027; KARLBERG J, 1995, PEDIATR RES, V38, P733, DOI 10.1203/00006450-199511000-00017; KRAMER MS, 1990, PEDIATRICS, V86, P707; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; LESAGE C, 1991, J PEDIATR-US, V119, P29, DOI 10.1016/S0022-3476(05)81034-0; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; MILLER HC, 1971, PEDIATRICS, V48, P511; NILSEN ST, 1984, ACTA PAEDIATR SCAND, V73, P168, DOI 10.1111/j.1651-2227.1984.tb09923.x; PAPIERNIK E, 1985, PEDIATRICS, V76, P154; PAZ I, 1993, AM J DIS CHILD, V47, P337; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P592; PHILLIPS DIW, 1994, DIABETIC MED, V11, P286, DOI 10.1111/j.1464-5491.1994.tb00273.x; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; Sheu W, 1996, J CLIN ENDOCR METAB, V81, P1156; TANNER JM, 1970, ARCH DIS CHILD, V45, P755, DOI 10.1136/adc.45.244.755; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; WALKER J, 1989, J CLIN ENDOCR METAB, V69, P253, DOI 10.1210/jcem-69-2-253; WESTWOOD M, 1983, PEDIATRICS, V71, P376; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	51	290	296	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					341	347						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270455				2022-12-28	WOS:A1997XQ86400020
J	Silverman, M				Silverman, M			BCG vaccination and atopy - unfinished business?	LANCET			English	Editorial Material							MEASLES				Silverman, M (corresponding author), UNIV LEICESTER,DEPT CHILD HLTH,LEICESTER LE2 7LX,LEICS,ENGLAND.							Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Sander B, 1995, IMMUNOLOGY, V86, P512; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; WARD BJ, 1993, CLIN IMMUNOL IMMUNOP, V67, P171, DOI 10.1006/clin.1993.1061	7	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					380	381		10.1016/S0140-6736(05)64130-X	http://dx.doi.org/10.1016/S0140-6736(05)64130-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259649				2022-12-28	WOS:A1997XQ24800005
J	VargaWeisz, PD; Wilm, M; Bonte, E; Dumas, K; Mann, M; Becker, PB				VargaWeisz, PD; Wilm, M; Bonte, E; Dumas, K; Mann, M; Becker, PB			Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II	NATURE			English	Article							PROMOTER IN-VITRO; CELL-FREE SYSTEM; TRANSCRIPTION FACTOR; DROSOPHILA EMBRYOS; ATP; IDENTIFICATION; INVOLVEMENT; DISRUPTION; MICROSCOPY; BINDING	Repressive chromatin structures need to be unravelled to allow DNA-binding proteins access to their target sequences. This de-repression constitutes an important point at which transcription and presumably other nuclear processes can be regulated(1,2). Energy-consuming enzyme complexes that facilitate the interaction of transcription factors with chromatin by modifying nucleosome structure are involved in this regulation(3-5). One such factor, nucleosome-remodelling factor (NURF), has been isolated from Drosophila embryo extracts(4,6,7), We have now identified a chromatin-accessibility complex (CHRAC) which uses energy to increase the general accessibility of DNA in chromatin. However, unlike other known chromatin remodelling factors, CHRAC can also function during chromatin assembly: it uses ATP to convert irregular chromatin into a regular array of nucleosomes with even spacing. CHRAC combines enzymes that modulate nucleosome structure and DNA topology. Using mass spectrometry, we identified two of the five CHRAC subunits as the ATPase ISWI, which is also part of NURF6,8, and topoisomerase II, The presence of ISWI in different contexts suggests that chromatin remodelling machines have a modular nature and that ISWI has a central role in different chromatin remodelling reactions.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Varga-Weisz, Patrick/0000-0001-7409-8686; Wilm, Matthias/0000-0002-5461-6834; Becker, Peter/0000-0001-7186-0372				ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BUCHENAU P, 1993, J CELL SCI, V104, P1175; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHEN GL, 1984, J BIOL CHEM, V259, P3560; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; POLJAK L, 1995, TRENDS CELL BIOL, V5, P348, DOI 10.1016/S0962-8924(00)89068-6; SANDALTZOPOULOS R, 1995, NUCLEIC ACIDS RES, V23, P2479, DOI 10.1093/nar/23.13.2479; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	29	424	429	2	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					598	602		10.1038/41587	http://dx.doi.org/10.1038/41587			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252192	Bronze			2022-12-28	WOS:A1997XP72200053
J	Jones, AL; Hayes, PC; Proudfoot, AT; Vale, JA; Prescott, LF				Jones, AL; Hayes, PC; Proudfoot, AT; Vale, JA; Prescott, LF			Controversies in management - Should methionine be added to every paracetamol tablet? No: The risks are not well enough known	BRITISH MEDICAL JOURNAL			English	Article							SERUM TOTAL HOMOCYSTEINE; ORAL METHIONINE; ACETAMINOPHEN OVERDOSE; NITROGEN; DISEASE; INJURY; MEN		ROYAL INFIRM EDINBURGH NHS,SCOTTISH LIVER TRANSPLANT UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; CITY HOSP NHS TRUST,W MIDLANDS POISON UNIT,NATL POISONS INFORMAT SERV,BIRMINGHAM CTR,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND; WESTERN GEN HOSP,PHARMACOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,RES CTR,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Jones, AL (corresponding author), ROYAL INFIRM EDINBURGH NHS,SCOTTISH POISONS INFORMAT BUR,EDINBURGH CTR,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.		Vale, Allister/AAA-9216-2019					ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOND GR, 1995, PHARMACOECONOMICS, V8, P177, DOI 10.2165/00019053-199508030-00001; BREILLOT F, 1986, ANTICANCER RES, V76, P629; CHO ES, 1979, J NUTR, V109, P1086, DOI 10.1093/jn/109.6.1086; COHEN SM, 1974, BIOL PSYCHIAT, V8, P209; CONNOR H, 1978, POSTGRAD MED J, V54, P318, DOI 10.1136/pgmj.54.631.318; CROME P, 1976, LANCET, V2, P829; GATTONUMPHRESS TL, 1993, HOSP PRACT, V28, P83, DOI 10.1080/21548331.1993.11442926; GUO HY, 1993, CANCER RES, V53, P5676; HAMLYN AN, 1981, J INT MED RES, V9, P226, DOI 10.1177/030006058100900314; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; HAWTON K, 1992, BRIT MED J, V304, P1409, DOI 10.1136/bmj.304.6839.1409; LEMANN J, 1956, J CLIN INVEST, V38, P2215; LITOVITZ TL, 1995, AM J EMERG MED, V13, P551, DOI 10.1016/0735-6757(95)90171-X; MACLEAN AEM, 1975, BIOCHEM PHARMACOL, V24, P37; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; MCLEAN AEM, 1974, LANCET, V1, P729; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; PHEAR EA, 1956, CLIN SCI, V15, P93; PRESCOTT LF, 1976, LANCET, V2, P109; PRINTEN KJ, 1979, AM J CLIN NUTR, V32, P1200, DOI 10.1093/ajcn/32.6.1200; SKOGLUND LA, 1992, GEN PHARMACOL, V23, P155, DOI 10.1016/0306-3623(92)90002-2; SPOONER JB, 1993, PHARM J, V250, P706; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; TAI J, 1994, P NATL ACAD SCI USA, V91, P6369; UELAND PM, 1992, ATHEROSCLEROTIC CARD, P1832; VALE JA, 1981, ARCH INTERN MED, V141, P394, DOI 10.1001/archinte.141.3.394; VALE JA, 1954, HUM TOXICOL, V3, P135; ZEZULKA AY, 1976, J NUTR, V106, P1286, DOI 10.1093/jn/106.9.1286	31	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					301	303		10.1136/bmj.315.7103.301	http://dx.doi.org/10.1136/bmj.315.7103.301			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274554	Green Published			2022-12-28	WOS:A1997XP75000029
J	Hemmings, BA				Hemmings, BA			Update: Signal transduction - PtdIns(3,4,5)P-3 gets its message across	SCIENCE			English	Editorial Material											Hemmings, BA (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.							Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; JAMES SR, 1996, J BIOCH, V315, P709; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648	11	77	89	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					534	534		10.1126/science.277.5325.534	http://dx.doi.org/10.1126/science.277.5325.534			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9254423				2022-12-28	WOS:A1997XM86700042
J	Bebb, G; Glickman, B; Gelmon, K; Gatti, R				Bebb, G; Glickman, B; Gelmon, K; Gatti, R			''AT risk'' for breast cancer	LANCET			English	Editorial Material							ATAXIA-TELANGIECTASIA		UNIV VICTORIA,CTR ENVIRONM HLTH,VICTORIA,BC,CANADA; UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90024	University of Victoria; University of California System; University of California Los Angeles	Bebb, G (corresponding author), BRITISH COLUMBIA CANC AGCY,DEPT ADV THERAPEUT,VANCOUVER,BC V5Z 4E6,CANADA.							Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; EASTON DF, 1995, BRIT J CANCER, V72, P805; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; KASTAN MB, 1992, CELL, V74, P353; KIRSCH IR, 1994, INT J RADIAT BIOL, V66, pS97, DOI 10.1080/09553009414551921; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Telatar M, 1996, AM J HUM GENET, V59, P40; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1784	1785		10.1016/S0140-6736(05)61687-X	http://dx.doi.org/10.1016/S0140-6736(05)61687-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269208				2022-12-28	WOS:A1997XF73500004
J	Chaturvedi, N; Stevenson, J; Fuller, JH; Rottiers, R; Ferriss, B; Karamanos, B; Kofinis, A; Petrou, C; IonescuTirgovisite, C; Iosif, C; Tamas, G; Bibok, G; Kerenyi, Z; KisGombos, P; Toth, J; Grealy, G; Priem, H; Koivisto, V; Tuominen, J; Kostamo, E; IdziorWalus, B; Solnica, B; GalickaLatalie, D; Michel, G; Keipes, M; Giuliani, A; Herode, A; Santeusanio, F; Bueti, A; Bistoni, S; Cagini; Navalesi, R; Penno, G; Nannipieri, M; Rizzo, L; Miccoli, R; Ghirlanda, G; Cotroneo, P; Manto, A; Minella, A; Saponara, C; Ward, J; Plater, M; Ibrahim, S; Ibbotson, S; Mody, C; Papazoglou, N; Manes, C; Soulis, K; Voukias, M; Muggeo, M; Cacciatori, V; Gemma, ML; Dellera, A; Castellarin, A; Irsigler, K; Abrahamian, H; Gurdet, C; Willinger, C; Nelstrop, A; Feben, C; Walford, S; McLelland, V; Hughes, S; Metelko, Z; Roglic, G; Pepeonik, ZR; Stephenson, J; Viberti, GC; Sjolie, AK; Holloway, J; Milne, M; Webb, D; Bulpitt, C; Fletcher, A; Shipley, M; John, G; Newman, DJ				Chaturvedi, N; Stevenson, J; Fuller, JH; Rottiers, R; Ferriss, B; Karamanos, B; Kofinis, A; Petrou, C; IonescuTirgovisite, C; Iosif, C; Tamas, G; Bibok, G; Kerenyi, Z; KisGombos, P; Toth, J; Grealy, G; Priem, H; Koivisto, V; Tuominen, J; Kostamo, E; IdziorWalus, B; Solnica, B; GalickaLatalie, D; Michel, G; Keipes, M; Giuliani, A; Herode, A; Santeusanio, F; Bueti, A; Bistoni, S; Cagini; Navalesi, R; Penno, G; Nannipieri, M; Rizzo, L; Miccoli, R; Ghirlanda, G; Cotroneo, P; Manto, A; Minella, A; Saponara, C; Ward, J; Plater, M; Ibrahim, S; Ibbotson, S; Mody, C; Papazoglou, N; Manes, C; Soulis, K; Voukias, M; Muggeo, M; Cacciatori, V; Gemma, ML; Dellera, A; Castellarin, A; Irsigler, K; Abrahamian, H; Gurdet, C; Willinger, C; Nelstrop, A; Feben, C; Walford, S; McLelland, V; Hughes, S; Metelko, Z; Roglic, G; Pepeonik, ZR; Stephenson, J; Viberti, GC; Sjolie, AK; Holloway, J; Milne, M; Webb, D; Bulpitt, C; Fletcher, A; Shipley, M; John, G; Newman, DJ			Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria	LANCET			English	Article							ANGIOTENSIN-CONVERTING ENZYME; CLINICAL-TRIALS; NEPHROPATHY; INHIBITION; CAPTOPRIL; MELLITUS; HYPERTENSION; PROGRESSION; PROTEINURIA; SENSITIVITY	Background Renal disease in people with insulin-dependent diabetes (IDDM) continues to pose a major health threat. Inhibitors of angiotensin-converting enzyme (ACE) slow the decline of renal function in advanced renal disease, but their effects at earlier stages are unclear, and the degree of albuminuria at which treatment should start is not known. Methods We carried out a randomised, double-blind, placebo-controlled trial of the ACE inhibitor lisinopril in 530 men and women with IDDM aged 20-59 years with normoalbuminuria or microalbuminuria. Patients were recruited from 18 European centres, and were not on medication for hypertension. Resting blood pressure at entry was at least 75 and no more than 90 mm Hg diastolic, and no more than 155 mm Hg systolic. Urinary albumin excretion rate (AER) was centrally assessed by means of two overnight urine collections at baseline, 6, 12, 18, and 24 months. Findings There were no differences in baseline characteristics by treatment group; mean AER was 8.0 mu g/min in both groups; and prevalence of microalbuminuria was 13% and 17% in the placebo and lisinopril groups, respectively. On intention-to-treat analysis at 2 years, AER was 2.2 mu g/min lower in the lisinopril than in the placebo group, a percentage difference of 18.8% (95% CI 2.0-3.27, p=0.03), adjusted for baseline AER and centre, absolute difference 2 2 mu g/min. In people with normoalbuminuria, the treatment difference was 1.0 mu g/min (12.7% [-2.9 to 26.0], p=0.1). In those with microalbuminuria, however, the treatment difference was 34.2 mu g/min (49.7% [-14.5 to 77.9], p=0.1; for interaction, p=0.04). For patients who completed 24 months on the trial, the final treatment difference in AER was 38.5 mu g/min in those with microalbuminuria at baseline (p=0.001), and 0.23 mu g/min in those with narmoalbuminuria at baseline (p=0.6). There was no treatment difference in hypoglycaemic events or in metabolic control as assessed by glycated haemoglobin. Interpretation Lisinopril slows the progression of renal disease in normotensive IDDM patients with little or no albuminuria, though greatest effect was in those with microalbuminuria (AER greater than or equal to 20 mu g/min). Our results show that lisinopril does not increase the risk of hypoglycaemic events in IDDM.	HIPPOKRATION HOSP, ATHENS, GREECE; CLIN DIABET NUTR & METAB DIS, BUCHAREST, ROMANIA; SEMMELWEIS UNIV MED, H-1085 BUDAPEST, HUNGARY; SZENT IMRE TEACHING HOSP, BUDAPEST, HUNGARY; CORK UNIV HOSP, CORK, IRELAND; UNIV HOSP GENT, GHENT, BELGIUM; HELSINKI UNIV HOSP, HELSINKI, FINLAND; KRAKOW TECH UNIV, SCH MED, KRAKOW, POLAND; CTR HOSP LUXEMBOURG, LUXEMBOURG, LUXEMBOURG; INST MED INTERNA & SCI ENDOCRINE & METAB, PERUGIA, ITALY; UNIV PISA, INST MED CLIN 2, I-56100 PISA, ITALY; UNIV CATTOLICA SACRO CUORE, ROME, ITALY; ROYAL HALLAMSHIRE HOSP, SHEFFIELD, ENGLAND; AGIOS PAVLOS GEN HOSP, THESSALONIKI, GREECE; OSPED CIVILE, VERONA, ITALY; HOSP VIENNA LAINZ, VIENNA, AUSTRIA; WATFORD DIST GEN HOSP, WATFORD, ENGLAND; NEW CROSS HOSP, WOLVERHAMPTON, ENGLAND; VUK VRHOVAK INST DIABET, ZAGREB, CROATIA; HAMMERSMITH HOSP, LONDON, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; ROYAL LONDON HOSP, LONDON E1 1BB, ENGLAND	Hippokration General Hospital; Semmelweis University; University College Cork; Ghent University; Ghent University Hospital; University of Helsinki; Helsinki University Central Hospital; Cracow University of Technology; Luxembourg Hospital Center; University of Pisa; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Sheffield; Watford General Hospital; New Cross Hospital; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Barts Health NHS Trust; Royal London Hospital	Chaturvedi, N (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Nannipieri, Monica/AAA-1464-2019	Nannipieri, Monica/0000-0003-1346-2813				Boner G, 1996, DIABETOLOGIA, V39, P587; DONNELLY R, 1992, J CARDIOVASC PHARM, V20, P38; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; HERINGS RMC, 1995, LANCET, V345, P1195, DOI 10.1016/S0140-6736(95)91988-0; JOHN GW, 1933, CLIN CHEM, V39, P663; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; LAFFEL LMB, 1995, AM J MED, V99, P497, DOI 10.1016/S0002-9343(99)80226-5; LAIRD NM, 1990, CONTROL CLIN TRIALS, V11, P405, DOI 10.1016/0197-2456(90)90018-W; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MEDCALF EA, 1990, CLIN CHEM, V36, P446; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MIMRAN A, 1988, DIABETES CARE, V11, P850, DOI 10.2337/diacare.11.10.850; MOGENSEN CE, 1976, SCAND J CLIN LAB INV, V36, P383, DOI 10.3109/00365517609055274; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; PAOLISSO G, 1992, J HUM HYPERTENS, V6, P175; PASSA P, 1987, DIABETES CARE, V10, P200, DOI 10.2337/diacare.10.2.200; PEDERSEN MM, 1988, DIABETIC MED, V5, P562, DOI 10.1111/j.1464-5491.1988.tb01052.x; PETRIE J, 1995, LANCET, V346, P583, DOI 10.1016/S0140-6736(95)91425-0; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; STEPHENSON J, 1994, DIABETOLOGIA, V37, P278, DOI 10.1007/BF00398055; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1982, LANCET, V1, P1430; Wang SL, 1996, DIABETES CARE, V19, P305, DOI 10.2337/diacare.19.4.305; WIEGMANN TB, 1992, DIABETES, V41, P62, DOI 10.2337/diabetes.41.1.62	27	412	422	0	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1787	1792		10.1016/S0140-6736(96)10244-0	http://dx.doi.org/10.1016/S0140-6736(96)10244-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269212				2022-12-28	WOS:A1997XF73500008
J	Hudson, LD; Martin, TR				Hudson, LD; Martin, TR			Predicting ARDS: Problems and prospects	LANCET			English	Editorial Material							RESPIRATORY-DISTRESS SYNDROME		UNIV WASHINGTON,SCH MED,SEATTLE,WA 98104	University of Washington; University of Washington Seattle	Hudson, LD (corresponding author), SEATTLE VA MED CTR,HARBORVIEW MED CTR,SECT PULM CRIT CARE MED,SEATTLE,WA 98104, USA.							Connelly KG, 1997, AM J RESP CRIT CARE, V155, P21, DOI 10.1164/ajrccm.155.1.9001283; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593; HAMMERSCHMIDT DE, 1980, LANCET, V1, P947; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; MOSS M, 1995, AM J RESP CRIT CARE, V151, P15, DOI 10.1164/ajrccm.151.1.7812545; PITTET JF, IN PRESS AM J RESP C; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1783	1783		10.1016/S0140-6736(05)61686-8	http://dx.doi.org/10.1016/S0140-6736(05)61686-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269207				2022-12-28	WOS:A1997XF73500003
J	Velzeboer, SCJM; Frenkel, J; deWolff, FA				Velzeboer, SCJM; Frenkel, J; deWolff, FA			A hypertensive toddler	LANCET			English	Article							MERCURY		LEIDEN UNIV, MED CTR, DEPT PEDIAT, NL-2300 RA LEIDEN, NETHERLANDS; LEIDEN UNIV, MED CTR, DEPT HUMAN TOXICOL, TOXICOL LAB, NL-2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Velzeboer, SCJM (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, DEPT PEDIAT, POB 22700, NL-1100 DE AMSTERDAM, NETHERLANDS.							CLOAREC S, 1995, ARCH PEDIATRIE, V2, P43, DOI 10.1016/0929-693X(96)89808-3; HENNINGSSON C, 1993, J PEDIATR-US, V122, P252, DOI 10.1016/S0022-3476(06)80125-3; VONMUHLENDAHL KE, 1990, LANCET, V336, P1578; WARKANY J, 1951, AMA AM J DIS CHILD, V81, P335, DOI 10.1001/archpedi.1951.02040030345004; WARKANY J, 1948, LANCET, V254, P829	5	18	19	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	1997	349	9068					1810	1810		10.1016/S0140-6736(97)04265-7	http://dx.doi.org/10.1016/S0140-6736(97)04265-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269217	Green Submitted			2022-12-28	WOS:A1997XF73500013
J	Darnell, JE				Darnell, JE			STATs and gene regulation	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; DNA-BINDING; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; INTERFERON-GAMMA; ALPHA-INTERFERON; C-FOS; SERINE PHOSPHORYLATION	STATs (signal transducers and activators of transcription) are a family of latent cytoplasmic proteins that are activated to participate in gene control when cells encounter various extracellular polypeptides. Biochemical and molecular genetic explorations have defined a single tyrosine phosphorylation site and, in a dimeric partner molecule, an Src homology 2 (SH2) phosphotyrosine-binding domain, a DNA interaction domain, and a number of protein-protein interaction domains (with receptors, other transcription factors, the transcription machinery, and perhaps a tyrosine phosphatase), Mouse genetics experiments have defined crucial roles for each known mammalian STAT, The discovery of a STAT in Drosophila, and most recently in Dictyostelium discoideum, implies an ancient evolutionary origin for this dual-function set of proteins.			Darnell, JE (corresponding author), ROCKEFELLER UNIV,MOL CELL BIOL LAB,NEW YORK,NY 10021, USA.		Yang, Chen/G-1379-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034420, R01AI032489, R01AI034420] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34420, AI32489] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; CALDENHOVEN C, 1996, J BIOL CHEM, V271, P31221; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Cho SS, 1996, J IMMUNOL, V157, P4781; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Duncan SA, 1997, DEV DYNAM, V208, P190, DOI 10.1002/(SICI)1097-0177(199702)208:2<190::AID-AJA6>3.0.CO;2-D; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUYER NB, 1995, J IMMUNOL, V155, P3472; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HELM MH, 1995, SCIENCE, V267, P1347; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; HORVATH CM, UNPUB; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KAYNE RS, 1995, CURR OPIN GENE DEV, V5, P38; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEMMON MA, 1993, TRENDS BIOCHEM SCI, V18, P459; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pennisi E, 1997, SCIENCE, V275, P155, DOI 10.1126/science.275.5297.155; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3929; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER C, COMMUNICATION; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TRIER M, 1994, CELL, V78, P787; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VAISSE C, UNPUB; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YAN R, UNPUB; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu X. R., UNPUB; 1996, TRENDS BIOCH SCI	99	3160	3289	5	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1630	1635		10.1126/science.277.5332.1630	http://dx.doi.org/10.1126/science.277.5332.1630			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287210				2022-12-28	WOS:A1997XV68400041
J	Rutgeerts, P; Rauws, E; Wara, P; Swain, P; Hoos, A; Solleder, E; Halttunen, J; Dobrilla, G; Richter, G; Prassler, R				Rutgeerts, P; Rauws, E; Wara, P; Swain, P; Hoos, A; Solleder, E; Halttunen, J; Dobrilla, G; Richter, G; Prassler, R			Randomised trial of single and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding peptic ulcer	LANCET			English	Article							UPPER GASTROINTESTINAL HEMORRHAGE; ENDOSCOPIC INJECTION; THERAPY; HEMOSTASIS; SCLEROTHERAPY; EPINEPHRINE; NECROSIS; THROMBIN	Background Although injection treatments for ulcer haemostasis seem to be effective, recurrent bleeding remains a serious problem. Large randomised clinical trials are required to show differences between treatment modalities for gastrointestinal bleeding. The aim of this study was to compare the safety and efficacy of repeated endoscopic injection of fibrin glue (FG) with that of single endoscopic injection of polidocanol in the prevention of recurrent bleeding. Methods 854 patients with active gastroduodenal bleeding (spurting, oozing), or ulcers with a visible non-bleeding vessel, were randomly assigned one of three endoscopic treatments: single application of polidocanol 1%, single application of FG, or daily repeated application of FG until the visible vessel had disappeared. All patients were pretreated with local injection of epinephrine (1/10 000), and had daily repeat endoscopies until the vessel observed at initial endoscopy was no longer visible. Findings Recurrent bleeding rates among the 790 patients in whom the rates could be assessed were 58 (22.8%) of 254 in the polidocranol group, 51 (19.2%) of 266 in the FG-single group, and 41 (15.2%) of 270 in the FG-repeated group. The difference between FG-repeated treatment and polidocanol was significant (p=0.036). Treatment failed, making other treatments (including surgery) necessary, in 34 (13.0%) of 261 in the polidocanol group, 34 (12.4%) of 274 in the FG-single group, and 21 (7.7%) of 274 in the FG-repeated group. The difference between FG-repeated treatment and polidocanol was significant (p=0.046). The 30-day-mortality rates were low in all three treatment groups (polidocanol 4.7%, FG-single treatment 5.3%, FG-repeated treatment 4.3%), The safety profiles of the three treatment strategies were similar. Interpretation Repeated injection with FG glue is significantly more effective than injection with polidocanol 1% in the treatment of bleeding from gastroduodenal ulcers.	UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL,NL-1105 AZ AMSTERDAM,NETHERLANDS; AARHUS UNIV HOSP,DEPT SURG,DK-8000 AARHUS,DENMARK; ROYAL LONDON HOSP,DEPT GASTROENTEROL,LONDON,ENGLAND; CENTEON PHARMA GMBH,MARBURG,GERMANY; UNIV HELSINKI,CENT HOSP,DEPT SURG 2,HELSINKI,FINLAND; GEN REG HOSP,DEPT GASTROENTEROL,BOLZANO,ITALY; ZENT KLINIKUM,MED KLIN,AUGSBURG,GERMANY; KLINIKUM,MED KLIN,MINDEN,GERMANY	University of Amsterdam; Academic Medical Center Amsterdam; Aarhus University; Barts Health NHS Trust; Royal London Hospital; University of Helsinki; Helsinki University Central Hospital	Rutgeerts, P (corresponding author), UNIV HOSP GASTHUISBERG,DEPT GASTROENTEROL,HERESTR 49,B-3000 LOUVAIN,BELGIUM.							BALANZO J, 1988, ENDOSCOPY, V20, P289, DOI 10.1055/s-2007-1013023; BALANZO J, 1990, ENDOSCOPY, V22, P157, DOI 10.1055/s-2007-1012828; BERG PL, 1994, ENDOSCOPY, V26, P528, DOI 10.1055/s-2007-1009028; CAPELLI J, 1993, ENDOSCOPY, V25, P431; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; CUTLER JA, 1981, DIGEST DIS SCI, V26, pS90, DOI 10.1007/BF01300814; EIMILLER A, 1990, BIOMED PROG, V2, P24; FLEISCHER D, 1983, GASTROENTEROLOGY, V84, P538; FRIEDRICHS O, 1994, ENDOSKOPIE HEUTE, V1, P16; GILBERT DA, 1981, GASTROINTEST ENDOSC, V27, P94; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; GOLDBERG PA, 1993, J CLIN GASTROENTEROL, V16, P136, DOI 10.1097/00004836-199303000-00011; Kubba AK, 1996, GASTROENTEROLOGY, V111, P623, DOI 10.1053/gast.1996.v111.pm8780566; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; LANGMAN MJS, 1985, GUT, V26, P217, DOI 10.1136/gut.26.3.217; LEVY J, 1991, LANCET, V337, P504, DOI 10.1016/0140-6736(91)93452-F; LONGSTRETH GF, 1995, AM J GASTROENTEROL, V90, P861; LOPERFIDO S, 1990, ENDOSCOPY, V22, P285, DOI 10.1055/s-2007-1010728; MEISSNER K, 1993, ENDOSCOPY, V25, P185, DOI 10.1055/s-2007-1010282; RANDALL GM, 1989, GASTROENTEROLOGY, V96, P1274, DOI 10.1016/S0016-5085(89)80014-9; ROCKALL TA, 1995, BRIT MED J, V311, P222, DOI 10.1136/bmj.311.6999.222; RUTGEERTS P, 1989, GASTROENTEROLOGY, V97, P610, DOI 10.1016/0016-5085(89)90632-X; RUZKOWSKI CJ, 1991, GASTROINTESTINAL CLI, V1, P303; SAEED Z, 1995, GASTROINTEST ENDOSC, V40, P293; SALM R, 1994, TECHNIK FIBRINKLEBUN, P153; SICKMULLER B, 1990, EG GCP NOTE GUIDANCE; Silvertstein FE, 1981, GASTROINTEST ENDOSC, V27, P73, DOI DOI 10.1016/S0016-5107(81)73155-9]; STOREY DW, 1989, JAMA-J AM MED ASSOC, V262, P1369; Strohm W. D., 1994, DMW (Deutsche Medizinische Wochenschrift), V119, P249, DOI 10.1055/s-2008-1058686; SWAIN CP, 1986, GASTROENTEROLOGY, V90, P595, DOI 10.1016/0016-5085(86)91113-3; VandeMierop F, 1996, ENDOSCOPY, V28, P54, DOI 10.1055/s-2007-1005418; VILLANUEVA C, 1994, GASTROINTEST ENDOSC, V40, P34, DOI 10.1016/S0016-5107(94)70006-0; WARA P, 1985, GASTROENTEROLOGY, V88, P1209, DOI 10.1016/S0016-5085(85)80081-0	33	135	138	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					692	696		10.1016/S0140-6736(97)03233-9	http://dx.doi.org/10.1016/S0140-6736(97)03233-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291903				2022-12-28	WOS:A1997XU97700009
J	Richards, B; Zhang, H; Phear, G; Meuth, M				Richards, B; Zhang, H; Phear, G; Meuth, M			Conditional mutator phenotypes in hMSH2-deficient tumor cell lines	SCIENCE			English	Article							MISMATCH REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY; COLON-CANCER; COLORECTAL TUMORIGENESIS; GENETIC INSTABILITY; HPRT LOCUS; MUTATIONS; PROTEIN; ACCUMULATION; DEFECTS	Two human tumor cell lines that are deficient in the mismatch repair protein hMSH2 show little or no increase in mutation rate relative to that of a mismatch repair-proficient cell line when the cells are maintained in culture conditions allowing rapid growth. However, mutations accumulate at a high rate in these cells when they are maintained at high density. Thus the mutator phenotype of some mismatch repair-deficient cell lines is conditional and strongly depends on growth conditions. These observations have implications for tumor development because they suggest that mutations may accumulate in tumor cells when growth is limited.	UNIV UTAH,ECCLES INST HUMAN GENET,DEPT ONCOL SCI,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES INST HUMAN GENET,DEPT RADIAT ONCOL,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah				Zhang, Hong/0000-0002-3930-6731; Richards, Burt/0000-0003-1789-2335	NCI NIH HHS [R01-CA-62244, T32-CA-09602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602, R01CA062244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; BAKER RM, 1974, CELL, V1, P9, DOI 10.1016/0092-8674(74)90149-4; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6063; BRANCH P, 1995, CANCER RES, V55, P2304; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; delaChapelle A, 1995, ANNU REV GENET, V29, P329, DOI 10.1146/annurev.ge.29.120195.001553; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FREEDMAN RS, 1978, CANCER, V42, P2352, DOI 10.1002/1097-0142(197811)42:5<2352::AID-CNCR2820420536>3.0.CO;2-#; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; Luria SE, 1943, GENETICS, V28, P491; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marra G, 1996, ONCOGENE, V13, P2189; Meyers M, 1997, CANCER RES, V57, P206; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reynolds TY, 1996, CANCER RES, V56, P5754; RICHARDS BS, UNPUB; RISINGER JI, 1995, CANCER RES, V55, P5664; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STRAUSS BS, 1992, CANCER RES, V52, P249	38	85	91	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1523	1526		10.1126/science.277.5331.1523	http://dx.doi.org/10.1126/science.277.5331.1523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278518				2022-12-28	WOS:A1997XV42900045
J	Ruggiu, M; Speed, R; Taggart, M; McKay, SJ; Kilanowski, F; Saunders, P; Dorin, J; Cooke, HJ				Ruggiu, M; Speed, R; Taggart, M; McKay, SJ; Kilanowski, F; Saunders, P; Dorin, J; Cooke, HJ			The mouse Dazla gene encodes a cytoplasmic protein essential for gametogenesis	NATURE			English	Article							Y-CHROMOSOME; AUTOSOMAL GENE; ZONA PELLUCIDA; AZOOSPERMIA; HOMOLOG; SPERMATOGENESIS; DELETIONS; CANDIDATE; OOCYTES; HUMANS	RBM and DAZ/SPGY are two families of genes located on the Y chromosome that encode proteins containing RNA-binding motifs, and both have been described as candidate human spermatogenesis genes(1,2). Transmission of deletions from father to son has been observed in the case of DAZ(3-5), but neither gene family has been shown to be essential for spermatogenesis in human males. The DAZ/SPGY genes are particularly amenable to a knockout approach, as they are found on the Y chromosome in Old World primates and apes(6), but in other mammals, they are represented only by an autosomal gene, DAZLA(7-10), which is also present in Old World primates and apes. It has also been shown that a Dazla homologue is essential for spermatogenesis in Drosophila(11). Here we show that Dazla protein is cytoplasmic in male and female germ cells, unlike the nuclear RBM protein(12) Disruption of the Dazla gene leads to loss of germ cells and complete absence of gamete production, demonstrating that Dazla is essential for the differentiation of germ cells.	WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; MRC, REPROD BIOL UNIT, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND	University of Edinburgh			Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380; Ruggiu, Matteo/0000-0002-6404-1210	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1980, P NATL ACAD SCI-BIOL, V77, P1029, DOI 10.1073/pnas.77.2.1029; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; Frojdman K, 1993, SERTOLI CELL, P87; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Nakahori Y, 1996, HORM RES, V46, P20, DOI 10.1159/000185175; Niederberger C, 1997, MAMM GENOME, V8, P277, DOI 10.1007/s003359900409; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; Reijo R, 1996, GENOMICS, V35, P346, DOI 10.1006/geno.1996.0366; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; SEARLE AG, 1974, MUTAT RES, V22, P63, DOI 10.1016/0027-5107(74)90009-8; Shan ZH, 1996, HUM MOL GENET, V5, P2005, DOI 10.1093/hmg/5.12.2005; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; Yen PH, 1996, HUM MOL GENET, V5, P2013, DOI 10.1093/hmg/5.12.2013	17	498	523	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					73	77		10.1038/37987	http://dx.doi.org/10.1038/37987			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288969				2022-12-28	WOS:A1997XU59600047
J	Rivara, FP; Grossman, DC; Cummings, P				Rivara, FP; Grossman, DC; Cummings, P			Medical progress - Injury prevention .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WATER BURN PREVENTION; RISK FACTOR; HIP-FRACTURES; UNITED-STATES; GUN OWNERSHIP; SCALD BURNS; SUICIDE; CHILDREN; ANTIDEPRESSANTS; COMMUNITY		UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Rivara, FP (corresponding author), UNIV WASHINGTON,HARBORVIEW INJURY PREVENT & RES CTR,BOX 359960,325 9TH AVE,SEATTLE,WA 98104, USA.				PHS HHS [R49/CCR002570] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Asher K N, 1995, Inj Prev, V1, P228, DOI 10.1136/ip.1.4.228; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BEASLEY CM, 1991, BRIT MED J, V303, P968; Blumstein A, 1995, NATL I JUSTICE J, V229, P2; BOTKIN JR, 1988, JAMA-J AM MED ASSOC, V260, P226, DOI 10.1001/jama.260.2.226; BRENNER RA, 1994, JAMA-J AM MED ASSOC, V271, P1606, DOI 10.1001/jama.271.20.1606; CANTOR CH, 1995, MED J AUSTRALIA, V162, P583, DOI 10.5694/j.1326-5377.1995.tb138547.x; CHAPUY MC, 1995, AGING-CLIN EXP RES, V7, P164, DOI 10.1007/BF03324331; CLARKE A, 1979, PEDIATRICS, V63, P687; COBB N, 1991, JAMA-J AM MED ASSOC, V266, P659, DOI 10.1001/jama.266.5.659; Cook PJ, 1995, J CRIM LAW CRIM, V86, P59, DOI 10.2307/1144000; Denno DM, 1996, ARCH PEDIAT ADOL MED, V150, P927, DOI 10.1001/archpedi.1996.02170340041008; EDWARDS JG, 1995, BRIT MED J, V310, P205, DOI 10.1136/bmj.310.6974.205; ELBERG JJ, 1987, BURNS, V13, P391, DOI 10.1016/0305-4179(87)90130-6; ERBAUGH SJ, 1986, PERCEPT MOTOR SKILL, V62, P439, DOI 10.2466/pms.1986.62.2.439; ERDMANN TC, 1991, PEDIATRICS, V88, P572; FELDMAN KW, 1978, PEDIATRICS, V62, P1; FERGUSSON DM, 1984, NEW ZEAL MED J, V97, P777; GAMBLE CL, 1995, GERIATRICS, V50, P39; GORMAN RL, 1985, PEDIATRICS, V75, P14; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Hammond J, 1993, J Burn Care Rehabil, V14, P473, DOI 10.1097/00004630-199307000-00016; HAUGHT K, 1995, PEDIATRICS, V96, P649; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; HENRY JA, 1995, BRIT MED J, V310, P911; HENRY JA, 1995, BRIT MED J, V310, P221, DOI 10.1136/bmj.310.6974.221; HOWLAND J, 1988, ACCIDENT ANAL PREV, V20, P19, DOI 10.1016/0001-4575(88)90011-5; HOWLAND J, 1993, JAMA-J AM MED ASSOC, V270, P91, DOI 10.1001/jama.270.1.91; *INT WORK PART SWI, 1988, PRESCH DROWN PRIV SW; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; JACKSON JA, 1992, AM J MED SCI, V304, P4, DOI 10.1097/00000441-199207000-00003; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; KAPLAN MS, 1994, GERONTOLOGIST, V34, P59, DOI 10.1093/geront/34.1.59; KATCHER ML, 1987, AM J PUBLIC HEALTH, V77, P1195, DOI 10.2105/AJPH.77.9.1195; KATCHER ML, 1989, PEDIATRICS, V83, P766; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KREITMAN N, 1976, BRIT J PREV SOC MED, V30, P86; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LAWSON GR, 1983, BRIT MED J, V287, P15, DOI 10.1136/bmj.287.6384.15; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; Mallonee S, 1996, NEW ENGL J MED, V335, P27, DOI 10.1056/NEJM199607043350106; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; MCLOUGHLIN E, 1985, AM J PUBLIC HEALTH, V75, P858, DOI 10.2105/AJPH.75.8.858; MCLOUGHLIN E, 1982, AM J PUBLIC HEALTH, V72, P241, DOI 10.2105/AJPH.72.3.241; MEUNIER PJ, 1994, OSTEOPOROSIS INT, V4, P71; MILLER TR, 1995, PEDIATRICS, V96, P1; MILLINER N, 1980, MED J AUSTRALIA, V2, P510; *NAT TRANSP SAF BO, 1993, NTSBSS9301; NOLAN L, 1988, J AM GERIATR SOC, V36, P142, DOI 10.1111/j.1532-5415.1988.tb01785.x; Paganini-Hill A, 1991, Epidemiology, V2, P16; PEARN JH, 1979, AM J PUBLIC HEALTH, V69, P450, DOI 10.2105/AJPH.69.5.450; Present P, 1987, CHILD DROWNING STUDY; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; QUAN L, 1989, PEDIATRICS, V83, P1035; RAY WA, 1989, LANCET, V1, P687; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; SMITH GS, 1994, 122 ANN M AM PUBL HL, P323; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; SPEECHLEY M, 1991, J AM GERIATR SOC, V39, P46, DOI 10.1111/j.1532-5415.1991.tb05905.x; *STAT DEP, 1995, ACC FACTS; STOCKWELL RA, 1993, PERSONAL FLOTATION D; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; TEUTSCH S M, 1992, Morbidity and Mortality Weekly Report, V41, P1; THAPA PB, 1995, AM J EPIDEMIOL, V142, P202, DOI 10.1093/oxfordjournals.aje.a117619; TINETTI ME, 1993, J AM GERIATR SOC, V41, P315, DOI 10.1111/j.1532-5415.1993.tb06710.x; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; WALTON WW, 1982, PEDIATRICS, V69, P363; Weinstein MC, 1990, J GEN INTERN MED S, V5, pS89; WINTEMUTE GJ, 1987, AM J PUBLIC HEALTH, V77, P830, DOI 10.2105/AJPH.77.7.830; WINTEMUTE GJ, 1990, AM J DIS CHILD, V144, P663, DOI 10.1001/archpedi.1990.02150300061018; WYSOWSKI DK, 1993, PUBLIC HEALTH REP, V108, P565; YTTERSTAD B, 1995, BURNS, V21, P259, DOI 10.1016/0305-4179(94)00003-G; 1993, MMWR-MORBID MORTAL W, V42, P681; 1996, MMWR-MORBID MORTAL W, V45, P460; 1993, MMWR-MORBID MORTAL W, V42, P675	78	72	75	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					613	618		10.1056/NEJM199708283370907	http://dx.doi.org/10.1056/NEJM199708283370907			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XT394	9271485				2022-12-28	WOS:A1997XT39400007
J	Egger, G; Swinburn, B				Egger, G; Swinburn, B			An ''ecological'' approach to the obesity pandemic	BRITISH MEDICAL JOURNAL			English	Article							DIETARY-FAT INTAKE; BODY-COMPOSITION; WOMEN; WEIGHT; EPIDEMIOLOGY		DEAKIN UNIV,SCH HUMAN MOVEMENT,MELBOURNE,VIC,AUSTRALIA; UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND 1,NEW ZEALAND	Deakin University; University of Auckland								BOURDIN M, 1993, EUR J APPL PHYSIOL O, V66, P439, DOI 10.1007/BF00599618; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; FLATT JP, 1988, DIABETES METAB REV, V4, P571, DOI 10.1002/dmr.5610040603; FRISCH RE, 1994, P NUTR SOC, V53, P113, DOI 10.1079/PNS19940015; GLASSER GA, 1995, SPORTS MED DIGES MAR, P5; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; HAWKS SR, 1994, J HLTH ED, V25, P147; HEITMANN BL, 1995, AM J CLIN NUTR, V61, P1213, DOI 10.1093/ajcn/61.6.1213; JAMES WPT, 1992, INT J OBESITY, V16, pS23; JAMES WPT, 1995, INT J OBESITY, V19, pS37; KATAHN M, 1990, ANN NY ACAD SCI, V602, P189, DOI 10.1111/j.1749-6632.1990.tb22739.x; Kickbusch I., 1989, HLTH PROMOTION, V4, P265, DOI DOI 10.1093/HEAPR0/4.4.265; LIEBEL RL, 1995, NEW ENGL J MED, V332, P621; LISSNER L, 1995, EUR J CLIN NUTR, V49, P79; LYON XH, 1995, INT J OBESITY, V19, P260; MAGNUS P, 1994, MED J AUSTRALIA, V161, P519; PRENTICE AM, 1991, P NUTR SOC, V50, P441, DOI 10.1079/PNS19910055; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; PREWITT TE, 1991, AM J CLIN NUTR, V54, P304, DOI 10.1093/ajcn/54.2.304; RAYUSSIN E, 1992, OBESITY THEORY THERA, P97; REBUFFESCRIVE M, 1985, J CLIN INVEST, V75, P1973, DOI 10.1172/JCI111914; Rose G., 1992, STRATEGY PREVENTIVE; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; STUBBS RJ, 1995, INT J OBESITY, V19, pS11; SWINBURN B, 1993, AM J CLIN NUTR S, V57; TUTEN C, 1995, OBES RES, V3, P313, DOI 10.1002/j.1550-8528.1995.tb00156.x; WESTSTRATE JA, 1995, INT J OBESITY, V19, pS38; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	571	573	1	44	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					477	480		10.1136/bmj.315.7106.477	http://dx.doi.org/10.1136/bmj.315.7106.477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284671	Green Published			2022-12-28	WOS:A1997XT71400026
J	Whiteman, MC; Deary, IJ; Lee, AJ; Fowkes, FGR				Whiteman, MC; Deary, IJ; Lee, AJ; Fowkes, FGR			Submissiveness and protection from coronary heart disease in the general population: Edinburgh Artery Study	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; WESTERN-COLLABORATIVE-GROUP; A BEHAVIOR; PATTERN; PERSONALITY; HOSTILITY	Background Type A behaviour and, more specifically, hostility and anger have been associated with increased risk of coronary heart disease (CHD). But less attention has been paid to other features of personality. Our aim was to assess whether a submissiveness trait, which is independent of hostility, was related to future risk of CHD in the general population. Methods The Edinburgh Artery Study is a cohort study of a random sample of 809 men and 783 women aged 55 to 74 years, At the baseline examination in 1988, we administered the Bedford-Foulds Personality Deviance Scales. The participants were followed up for 5 years for cardiovascular events. Criteria to define events were adapted from the American Heart Association. Events were ascertained from the Information and Statistics Division of the Scottish Office Home and Health Department, general practitioners, the UK National Health Service Central Register, annual questionnaires to the participants, and the second examination at the end of follow-up. Findings During follow-up, 57 (7.0%) men and 28 (3.6%) women had non-fatal myocardial infarctions; 25 (3.1%) men and 8 (1.0%) women had fatal myocardial infarctions; and 48 (5.9%) men and 41 (5.2%) women developed angina pectoris. We found that mean submissiveness scores were significantly higher in men and women who did not have a non-fatal myocardial infarction than in those who did (18.88 [SE 0.15] vs 17.70 [0.40], p=0.023 in men; 20.76 [0.17] vs 18.18 [0.86], p=0.002 in women). In multiple logistic-regression models, submissiveness remained independently associated with risk of myocardial infarction in women only; a decreased risk of both non-fatal myocardial infarction (relative risk 0.59 [95% Cl 0.40-0.85]) and, to a lesser extent, total myocardial infarction (0.69 [0.27-0.96]), was associated with an increase of 1 SD in submissiveness. Interpretation The personality trait of submissiveness may be protective against non-fatal myocardial infarction, particularly in women. A better understanding is required of the complicated effects of personality on CHD development.	UNIV EDINBURGH,DEPT PSYCHOL,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIPHERAL VASC DIS,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				[Anonymous], 1990, PERSONALITY ADULTHOO; BAREFOOT JC, 1995, AM J EPIDEMIOL, V142, P477, DOI 10.1093/oxfordjournals.aje.a117663; BEDFORD A, 1978, PERSONALITY DEVIANCE; BOOTHKEWLEY S, 1987, PSYCHOL BULL, V101, P343, DOI 10.1037/0033-2909.101.3.343; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; Brunner E, 1997, BMJ-BRIT MED J, V314, P1472, DOI 10.1136/bmj.314.7092.1472; CASE RB, 1985, NEW ENGL J MED, V312, P737, DOI 10.1056/NEJM198503213121201; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cook WW, 1954, J APPL PSYCHOL, V38, P414, DOI 10.1037/h0060667; DEARY IJ, 1995, PERS INDIV DIFFER, V19, P275, DOI 10.1016/0191-8869(95)00061-A; DEARY IJ, 1994, PSYCHOSOM MED, V56, P197, DOI 10.1097/00006842-199405000-00004; DEMBROSKI TM, 1987, J PERS, V55, P211, DOI 10.1111/j.1467-6494.1987.tb00435.x; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRIEDMAN M, 1996, BEHAV ITS DIAGNOSIS; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; HAYNES SG, 1980, AM J EPIDEMIOL, V111, P37, DOI 10.1093/oxfordjournals.aje.a112873; HECKER MHL, 1988, PSYCHOSOM MED, V50, P153, DOI 10.1097/00006842-198803000-00005; Houston BK, 1997, PSYCHOSOM MED, V59, P5, DOI 10.1097/00006842-199701000-00002; JOHNSTON DW, 1993, J R SOC MED, V86, P409; Kaplan JR, 1996, PSYCHOSOM MED, V58, P598, DOI 10.1097/00006842-199611000-00008; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; MATTHEWS KA, 1982, PSYCHOL BULL, V91, P293; MILLER TQ, 1991, PSYCHOL BULL, V110, P469, DOI 10.1037/0033-2909.110.3.469; Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322; Prineas R., 1982, MINNESOTA CODE MANUA; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSENMAN RH, 1975, JAMA-J AM MED ASSOC, V233, P872, DOI 10.1001/jama.233.8.872; Sapolsky RM, 1995, ANN NY ACAD SCI, V771, P626, DOI 10.1111/j.1749-6632.1995.tb44715.x; SHEKELLE RB, 1985, AM J EPIDEMIOL, V122, P559, DOI 10.1093/oxfordjournals.aje.a114135; SHEKELLE RB, 1985, AM J CARDIOL, V56, P221; SHIVELY CA, 1994, ARTERIOSCLER THROMB, V14, P721, DOI 10.1161/01.ATV.14.5.721; Stone SV, 1990, PERSONALITY DIS, P178; Whitehead M, 1992, INEQUALITIES HLTH BL	33	42	43	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					541	545		10.1016/S0140-6736(96)03141-8	http://dx.doi.org/10.1016/S0140-6736(96)03141-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284775				2022-12-28	WOS:A1997XT22100008
J	Brown, ZA; Selke, S; Zeh, J; Kopelman, J; Maslow, A; Ashley, RL; Watts, DH; Berry, S; Herd, M; Corey, L				Brown, ZA; Selke, S; Zeh, J; Kopelman, J; Maslow, A; Ashley, RL; Watts, DH; Berry, S; Herd, M; Corey, L			The acquisition of herpes simplex virus during pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENITAL HERPES; GLYCOPROTEIN-G; TYPE-2 INFECTION; NEONATAL HERPES; HIGH-PREVALENCE; ANTIBODIES; EPIDEMIOLOGY; IMMUNOBLOT; DIAGNOSIS; DELIVERY	Background The acquisition of genital herpes during pregnancy has been associated with spontaneous abortion, prematurity, and congenital and neonatal herpes. The frequency of seroconversion, maternal symptoms of the disease, and the timing of its greatest effect on the outcome of pregnancy have not been systematically studied. Methods We studied 7046 pregnant women whom serologic tests showed to be at risk for herpes simplex virus (HSV) infection. Serum samples obtained at the first prenatal visit, at approximately 16 and 24 weeks, and during labor were tested for antibodies to HSV types 1 and 2 (HSV-1 and HSV-2) by the Western blot assay, and the results were correlated with the occurrence of antenatal genital infections. Results Ninety-four of the women became seropositive for HSV; 34 of the 94 women (36 percent) had symptoms consistent with herpes infection. Women who were initially seronegative for both HSV-1 and HSV-2 had an estimated chance of seroconversion for either virus of 3.7 percent; those who were initially seropositive only for HSV-1 had an estimated chance of HSV-2 seroconversion of 1.7 percent; and those who were initially HSV-2-seropositive had an estimated chance of zero for acquiring HSV-1 infection. Among the 60 of the 94 pregnancies for which the time of acquisition of HSV infection was known, 30 percent of the infections occurred in the first trimester, 30 percent in the second, and 40 percent in the third. HSV seroconversion completed by the time of labor was not associated with an increase in neonatal morbidity or with any cases of congenital herpes infection. However, among the infants born to nine women who acquired genital HSV infection shortly before labor, neonatal HSV infection occurred in four infants, of whom one died. Conclusions Two percent or more of susceptible women acquire HSV infection during pregnancy. Acquisition of infection with seroconversion completed before labor does not appear to affect the outcome of pregnancy, but infection acquired near the time of labor is associated with neonatal herpes and perinatal morbidity. (C) 1997, Massachusetts Medical Society.	UNIV WASHINGTON,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT STAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; MADIGAN ARMY MED CTR,DEPT OBSTET & GYNECOL,TACOMA,WA 98431	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Madigan Army Medical Center	Brown, ZA (corresponding author), UNIV WASHINGTON,DEPT OBSTET & GYNECOL,BOX 356460,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1982, JACKKNIFE BOOTSTRAP; ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1995, CLINICAL MANAGEMENT OF HERPES VIRUSES, P137; ASHLEY RL, 1993, GENITOURIN MED, V69, P174; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; Brown ZA, 1996, OBSTET GYNECOL, V87, P483, DOI 10.1016/0029-7844(95)00457-2; BROWN ZA, 1987, NEW ENGL J MED, V317, P1246, DOI 10.1056/NEJM198711123172002; COREY L, 1988, LANCET, V1, P1; COREY L, 1994, SEX TRANSM DIS, V21, pS38; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; DESCHRYVER A, 1990, B WORLD HEALTH ORGAN, V68, P639; Edgington E. S., 1980, RANDOMIZATION TESTS; Iams JD, 1996, OBSTET NORMAL PROBLE, P743; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; PEPE F, 1987, Clinical and Experimental Obstetrics and Gynecology, V14, P60; PROBER CG, 1992, CLIN INFECT DIS, V15, P1031, DOI 10.1093/clind/15.6.1031; PROBER CG, 1988, NEW ENGL J MED, V318, P887, DOI 10.1056/NEJM198804073181404; ROSS JDC, 1993, GENITOURIN MED, V69, P381; SAFRIN S, 1992, J CLIN MICROBIOL, V30, P1312, DOI 10.1128/JCM.30.5.1312-1314.1992; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; TAYAL SC, 1994, INT J STD AIDS, V5, P359, DOI 10.1177/095646249400500514; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; WHITLEY R, 1991, NEW ENGL J MED, V324, P450, DOI 10.1056/NEJM199102143240704; WHITLEY RJ, 1994, P NATL ACAD SCI USA, V91, P2441, DOI 10.1073/pnas.91.7.2441	27	500	511	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					509	515		10.1056/NEJM199708213370801	http://dx.doi.org/10.1056/NEJM199708213370801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262493				2022-12-28	WOS:A1997XR54800001
J	Gore, SM				Gore, SM			Age related exposure of patients to the agent of BSE should not be downplayed - Commentary	BRITISH MEDICAL JOURNAL			English	Article											Gore, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							ALPEROVITCH A, 1996, B EPIDEMIOL HEBDOM, V48, P207; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; GORE SM, 1995, BRIT MED J, V311, P1416, DOI 10.1136/bmj.311.7017.1416a; GORE SM, 1996, SCI PARLIAMENT, V53, P2; Gregory J., 1990, DIETARY NUTR SURVEY; Will RG, 1997, LANCET, V349, P847, DOI 10.1016/S0140-6736(97)24012-2	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					395	396		10.1136/bmj.315.7105.395	http://dx.doi.org/10.1136/bmj.315.7105.395			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277602	Green Published			2022-12-28	WOS:A1997XR54900018
J	Jentsch, JD; Redmond, DE; Elsworth, JD; Taylor, JR; Youngren, KD; Roth, RH				Jentsch, JD; Redmond, DE; Elsworth, JD; Taylor, JR; Youngren, KD; Roth, RH			Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine	SCIENCE			English	Article							PREFRONTAL CORTEX; CINGULATE CORTEX; WORKING MEMORY; MOTOR DEFICITS; SCHIZOPHRENIA; CLOZAPINE; ACTIVATION; MPTP; AMPHETAMINE; DISEASE	The effects of the psychotomimetic drug phencyclidine on the neurochemistry and function of the prefrontal cortex in vervet monkeys were investigated, Monkeys treated with phencyclidine twice a day for 14 days displayed performance deficits on a task that was sensitive to prefrontal cortex function; the deficits were ameliorated by the atypical antipsychotic drug clozapine, Repeated exposure to phencyclidine caused a reduction in both basal and evoked dopamine utilization in the dorsolateral prefrontal cortex, a brain region that has long been associated with cognitive function, Behavioral deficits and decreased dopamine utilization remained after phencyclidine treatment was stopped, an indication that these effects were not simply due to direct drug effects. The data suggest that repeated administration of phencyclidine in monkeys may be useful for studying psychiatric disorders associated with cognitive dysfunction and dopamine hypofunction in the prefrontal cortex, particularly schizophrenia.	YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT USA; YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT USA; YALE UNIV, SCH MED, DEPT NEUROSURG, NEW HAVEN, CT USA; YALE UNIV, SCH MED, INTERDEPT NEUROSCI PROGRAM, NEW HAVEN, CT USA	Yale University; Yale University; Yale University; Yale University; Yale University					NIMH NIH HHS [RSA K05-MH00643, MH44866, MH14092] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000643, R01MH014092, R37MH014092, P50MH044866] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGRIST B, 1982, PSYCHOPHARMACOLOGY, V78, P128, DOI 10.1007/BF00432248; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Bunney Blynn Garland, 1995, P1205; CARLIN AS, 1979, AM J DRUG ALCOHOL AB, V6, P273, DOI 10.3109/00952997909001717; COSGROVE J, 1991, J CLIN PSYCHOL, V47, P159, DOI 10.1002/1097-4679(199101)47:1<159::AID-JCLP2270470125>3.0.CO;2-O; Daniel D G, 1989, J Neuropsychiatry Clin Neurosci, V1, P377; DANIEL DG, 1991, J NEUROSCI, V11, P1907; DAVIS KL, 1991, AM J PSYCHIAT, V148, P11; DEUTCH AY, 1992, J NEURAL TRANSM-GEN, P61; DIAMOND A, 1989, BEHAV NEUROSCI, V103, P526, DOI 10.1037/0735-7044.103.3.526; Diamond A, 1988, THOUGHT LANGUAGE, P337; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; ELSWORTH JD, 1990, NEUROSCI LETT, V114, P316, DOI 10.1016/0304-3940(90)90583-U; FEY ET, 1951, J CONSULT PSYCHOL, V15, P311; FREEDMAN M, 1986, BEHAV NEUROSCI, V100, P337, DOI 10.1037/0735-7044.100.3.337; GOLDBERG TE, 1993, BRIT J PSYCHIAT, V162, P43, DOI 10.1192/bjp.162.1.43; GOLDBERG TE, 1994, J CLIN PSYCHIAT, V55, P88; Goldberg Terry E., 1995, P1245; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1; HERTZMAN M, 1990, AM J PSYCHIAT, V147, P255; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Jentsch JD, 1997, J NEUROSCI, V17, P1769; Jentsch JD, 1997, NEUROPSYCHOPHARMACOL, V17, P92, DOI 10.1016/S0893-133X(97)00034-1; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KARLSSON P, 1995, PSYCHOPHARMACOLOGY, V121, P309, DOI 10.1007/BF02246068; KLONOFF H, 1970, J NERV MENT DIS, V150, P291, DOI 10.1097/00005053-197004000-00004; LEE MA, 1994, J CLIN PSYCHIAT, V55, P82; LEVIN S, 1984, J PSYCHIATR RES, V18, P27, DOI 10.1016/0022-3956(84)90046-3; LEWIS JE, 1986, PHENCYCLIDINE UPDATE, P66; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; Murphy BL, 1997, NEUROPSYCHOPHARMACOL, V16, P433, DOI 10.1016/S0893-133X(97)00019-5; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; RIDLEY RM, 1993, NEUROSCIENCE, V52, P595, DOI 10.1016/0306-4522(93)90409-9; ROBBINS TW, 1990, SCHIZOPHRENIA BULL, V16, P391, DOI 10.1093/schbul/16.3.391; SALETU B, 1987, PHARMACOPSYCHIATRY, V20, P12, DOI 10.1055/s-2007-1017125; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SHALLICE T, 1991, PSYCHOL MED, V21, P661, DOI 10.1017/S0033291700022303; TAYLOR JR, 1990, BEHAV NEUROSCI, V104, P564, DOI 10.1037/0735-7044.104.4.564; TAYLOR JR, 1990, BRAIN, V113, P617, DOI 10.1093/brain/113.3.617; WEINBERGER DR, 1988, ARCH GEN PSYCHIAT, V45, P609; WU JC, 1991, PSYCHOPHARMACOLOGIA, V11, P47; Young K. A., 1995, Society for Neuroscience Abstracts, V21, P1705; YOUNGREN KD, 1994, NEUROSCI LETT, V165, P41, DOI 10.1016/0304-3940(94)90704-8	45	324	345	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					953	955		10.1126/science.277.5328.953	http://dx.doi.org/10.1126/science.277.5328.953			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XQ985	9252326				2022-12-28	WOS:A1997XQ98500041
J	Martin, TG; Somberg, KA; Meng, YG; Cohen, RL; Heid, CA; deSauvage, FJ; Shuman, MA				Martin, TG; Somberg, KA; Meng, YG; Cohen, RL; Heid, CA; deSauvage, FJ; Shuman, MA			Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							C-MPL LIGAND; THROMBOCYTOPENIA	Background: Thrombocytopenia is a common manifestation of cirrhosis. Objectives: To determine plasma thrombopoietin levels in cirrhotic patients with thrombocytopenia, monitor those levels before and after orthotopic liver transplantation, and compare thrombopoietin messenger RNA (mRNA) levels in liver samples from cirrhotic patients and controls. Design: A cross-sectional study of patients with cirrhosis, including a small subset of patients who had orthotopic liver transplantation. Setting: University-affiliate hospital. Patients: 44 patients with cirrhosis, including 17 patients who had orthotopic liver transplantation. Intervention: Orthotopic liver transplantation. Measurements: Plasma thrombopoietin levels in all patients, platelet counts in all patients, and thrombopoietin mRNA levels in liver samples from nine patients with cirrhosis and eight controls. Results: Thrombopoietin levels were undetectable in 39 of 44 patients with cirrhosis. In 16 of 17 patients, the levels became detectable after liver transplantation. Thrombopoietin mRNA levels were decreased in liver samples from patients with cirrhosis compared with controls (P = 0.0103). Conclusions: The low thrombopoietin levels in cirrhotic patients with thrombocytopenia and the increased levels after orthotopic liver transplantation suggest that impaired production of thrombopoietin may contribute to thrombocytopenia associated with cirrhosis.	GENENTECH INC, BIOANALYT TECHNOL DEPT, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MOL ONCOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Martin, TG (corresponding author), UNIV CALIF SAN FRANCISCO, MED CTR, DIV HEMATOL, BOX 1270, PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584	NHLBI NIH HHS [HL54476] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054476] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez OA, 1996, AM J GASTROENTEROL, V91, P134; ASTER RH, 1966, J CLIN INVEST, V45, P645, DOI 10.1172/JCI105380; CRANE C, 1962, SURG GYNECOL OBSTET, V115, P12; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; FERRARA J, 1979, SURGERY, V86, P570; HARKER LA, 1969, J CLIN INVEST, V48, P963, DOI 10.1172/JCI106077; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KAUSHANSKY K, 1995, THROMB HAEMOSTASIS, V74, P521; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; LOK S, 1994, STEM CELLS, V12, P586, DOI 10.1002/stem.5530120606; MCALLISTER E, 1995, AM SURGEON, V61, P129; Meng YG, 1996, BRIT J HAEMATOL, V95, P535, DOI 10.1046/j.1365-2141.1996.d01-1933.x; Sanyal AJ, 1996, HEPATOLOGY, V23, P32, DOI 10.1002/hep.510230105; TOGHILL PJ, 1977, J CLIN PATHOL, V30, P367, DOI 10.1136/jcp.30.4.367	15	136	137	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					285	288		10.7326/0003-4819-127-4-199708150-00005	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265428				2022-12-28	WOS:A1997XR26600007
J	Danesh, J; Collins, R; Peto, R				Danesh, J; Collins, R; Peto, R			Chronic infections and coronary heart disease: is there a link?	LANCET			English	Review							CHLAMYDIA-PNEUMONIAE TWAR; HELICOBACTER-PYLORI INFECTION; CARDIOVASCULAR RISK-FACTORS; ARTERIAL FATTY STREAKS; SMOOTH-MUSCLE CELLS; CYTOMEGALO-VIRUS; NUCLEIC-ACIDS; ATHEROSCLEROSIS; ASSOCIATION; PLAQUES	A large number of studies have reported on associations of human coronary heart disease (CHD) and certain persistent bacterial and viral infections. We review the epidemiological and clinical evidence on CHD and Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus (CMV), as well as possible mechanisms. The association between CHD and H pylori may be accounted for by residual confounding from risk factors. Although the association between C pneumoniae and CHD is stronger, the sequence of infection and disease is uncertain. As regards CMV, a limited number of patients with classic atherosclerotic coronary artery disease have been studied. Further studies are needed to these uncertainties.	UNIV OXFORD,RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,EPIDEMIOL STUDIES UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	Danesh, J (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,CLIN TRIAL SERV UNIT,OXFORD OX2 6HE,ENGLAND.							Beck J, 1996, J PERIODONTOL, V67, P1123, DOI 10.1902/jop.1996.67.10s.1123; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; BIRNIE D, 1996, HEART, V75, P64; Blasi F, 1996, J CLIN MICROBIOL, V34, P2766, DOI 10.1128/JCM.34.11.2766-2769.1996; BRUGGEMAN CA, 1991, PROGR MED VIROLOGY, P1; CAMPBELL LA, 1995, J INFECT DIS, V172, P585, DOI 10.1093/infdis/172.2.585; CAMPBELL LA, 1996, P 3 EUR SOC CHLAM RE, V3, P106; CHEN R, 1995, NATL MED J CHINA, V75, P592; COLINJONES DG, 1992, GUT, V33, P1280, DOI 10.1136/gut.33.9.1280; CUNNINGHAM A, 1996, P 3 EUR SOC CHLAM RE, V3, P106; Epstein SE, 1996, LANCET, V348, pS13, DOI 10.1016/S0140-6736(96)98005-8; FABRICANT CG, 1978, J EXP MED, V148, P335, DOI 10.1084/jem.148.1.335; FERNANDO S, 1994, J MED VIROL, V42, P396, DOI 10.1002/jmv.1890420412; Gaydos CA, 1996, INFECT IMMUN, V64, P1614, DOI 10.1128/IAI.64.5.1614-1620.1996; GILL EA, 1992, CURR OPIN INFECT DIS, V5, P381, DOI 10.1097/00001432-199206000-00012; GONZALEZVALENCI.G, 1996, HELICOBACTER, V1, P1; GRAYSTON JT, 1995, CIRCULATION, V92, P3397, DOI 10.1161/01.CIR.92.12.3397; GUILIZIA JM, 1995, AM J PATHOL, V147, P461; GYORKEY F, 1984, EXP MOL PATHOL, V40, P328, DOI 10.1016/0014-4800(84)90050-9; HAVLIK RJ, 1989, ARTERIOSCLEROSIS, V9, P877, DOI 10.1161/01.ATV.9.6.877; HENDRIX MGR, 1989, AM J PATHOL, V134, P1151; HENDRIX MGR, 1990, AM J PATHOL, V136, P23; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; JUVONEN J, 1996, P 3 EUR SOC CHLAM RE, V3, P221; Kaner RJ, 1996, ATHEROSCLEROSIS CORO, P569; KOL A, 1995, CIRCULATION, V91, P1910, DOI 10.1161/01.CIR.91.7.1910; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1993, ARTERIOSCLER THROMB, V13, P1501, DOI 10.1161/01.ATV.13.10.1501; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; LARSSON PA, 1991, INT J CANCER, V49, P14, DOI 10.1002/ijc.2910490104; LEINONEN M, 1993, EUR HEART J, V14, P57; MALATY HM, 1994, ANN INTERN MED, V120, P982, DOI 10.7326/0003-4819-120-12-199406150-00002; MELNICK JL, 1983, LANCET, V2, P644; MELNICK JL, 1994, J MED VIROL, V42, P170, DOI 10.1002/jmv.1890420213; Mendall MA, 1996, BRIT MED J, V312, P1061; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; MURRAY LJ, 1995, BRIT HEART J, V74, P497; NDAWULA EM, 1994, EUR J CLIN MICROBIOL, V13, P621, DOI 10.1007/BF01971319; Niemela S, 1996, HEART, V75, P573, DOI 10.1136/hrt.75.6.573; Nieto FJ, 1996, CIRCULATION, V94, P922, DOI 10.1161/01.CIR.94.5.922; Ong G, 1996, J CLIN PATHOL, V49, P102, DOI 10.1136/jcp.49.2.102; ONG G, 1996, 3 E EUR SOC CHLAM RE, V3, P222; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Pauletto P, 1996, STROKE, V27, P1669, DOI 10.1161/01.STR.27.9.1669; PERRIE BL, 1988, PROG MED VIROL, V35, P21; PETRIE BL, 1987, J INFECT DIS, V155, P158, DOI 10.1093/infdis/155.1.158; PUOLAKKAINEN M, 1993, J CLIN MICROBIOL, V31, P2212, DOI 10.1128/JCM.31.8.2212-2214.1993; Ramirez JA, 1996, ANN INTERN MED, V125, P979, DOI 10.7326/0003-4819-125-12-199612150-00008; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Scragg RKR, 1996, J EPIDEMIOL COMMUN H, V50, P578, DOI 10.1136/jech.50.5.578; SHOR A, 1992, S AFR MED J, V82, P158; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Speizer, 1976, NATURAL HIST CHRONIC, P218; SUNT JJY, 1996, HEART, V76, P305; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X; WANG SP, 1984, 1983 INT S MED VIR, P87; Weiss SM, 1996, J INFECT DIS, V173, P957, DOI 10.1093/infdis/173.4.957; WU TC, 1992, AM J PATHOL, V140, P739; Xu QB, 1996, MOL MED TODAY, V2, P372, DOI 10.1016/S1357-4310(96)10034-4; YAMASHIROYA HM, 1988, AM J PATHOL, V130, P71	62	1009	1062	1	38	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					430	436		10.1016/S0140-6736(97)03079-1	http://dx.doi.org/10.1016/S0140-6736(97)03079-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259669				2022-12-28	WOS:A1997XQ24800045
J	Emery, P				Emery, P			Rheumatoid arthritis: Not yet curable with early intensive therapy	LANCET			English	Editorial Material											Emery, P (corresponding author), UNIV LEEDS,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.		emery, paul/B-3560-2013					EMERY P, 1995, ANN RHEUM DIS, V54, P944, DOI 10.1136/ard.54.12.944; GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140-6736(94)91049-9; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; MCGONAGLE D, 1997, BR J RHEUMATOL S1, V36, P230; Morrison E, 1996, BRIT J RHEUMATOL, V35, P2; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; tenWolde S, 1996, LANCET, V347, P347, DOI 10.1016/S0140-6736(96)90535-8; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; VANLEEUWEN MA, 1993, BR J RHEUMATOL S3, V32, P3	9	25	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					304	305		10.1016/S0140-6736(97)22031-3	http://dx.doi.org/10.1016/S0140-6736(97)22031-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251629				2022-12-28	WOS:A1997XP24200002
J	Greenhalgh, T				Greenhalgh, T			How to read a paper - Assessing the methodological quality of published papers	BRITISH MEDICAL JOURNAL			English	Article											Greenhalgh, T (corresponding author), UCL, SCH MED, ROYAL FREE HOSP, WHITTINGTON HOSP, DEPT PRIMARY CARE & POPULAT, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				Altman DG, 1991, PRACTICAL STAT MED R, P456; Bero LA, 1996, INT J TECHNOL ASSESS, V12, P209, DOI 10.1017/S0266462300009582; BOWIE C, 1990, LANCET, V335, P397, DOI 10.1016/0140-6736(90)90220-Y; BRENNAN P, 1994, BRIT MED J, V309, P727, DOI 10.1136/bmj.309.6956.727; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; DUNNING M, 1997, C NORTH 22 23 MAY 19; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GREENHALGH T, 1997, READ PAPER BASICS EV, P87; KNIPSCHILD P, 1995, SYSTEMATIC REV, P9; MACKIRE M, 1993, EPIDEMIOL REV, V15, P328; MACMAHON S, 1993, J VASC MED BIOL, V4, P265; Rose G, 1994, EPIDEMIOLOGY UNINITI; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P19; Stewart LA, 1996, INT J TECHNOL ASSESS, V12, P264, DOI 10.1017/S0266462300009612	15	124	128	1	112	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					305	308		10.1136/bmj.315.7103.305	http://dx.doi.org/10.1136/bmj.315.7103.305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274555	Green Published			2022-12-28	WOS:A1997XP75000031
J	Kledal, TN; Rosenkilde, MM; Coulin, F; Simmons, G; Johnsen, AH; Alouani, S; Power, CA; Luttichau, HR; Gerstoft, J; Clapham, PR; ClarkLewis, I; Wells, TNC; Schwartz, TW				Kledal, TN; Rosenkilde, MM; Coulin, F; Simmons, G; Johnsen, AH; Alouani, S; Power, CA; Luttichau, HR; Gerstoft, J; Clapham, PR; ClarkLewis, I; Wells, TNC; Schwartz, TW			A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus	SCIENCE			English	Article							PROTEIN-COUPLED RECEPTOR; DNA-SEQUENCES; MOLECULAR MIMICRY; INTERLEUKIN-8; RANTES; GENES; CHEMOATTRACTANT; EXPRESSION; PATHWAYS; CLONING	Kaposi's sarcoma-associated herpesvirus encodes a chemokine called vMIP-II, This protein displayed a broader spectrum of receptor activities than any mammalian chemokine as it bound with high affinity to a number of both CC and CXC chemokine receptors, Binding of vMIP-II, however, was not associated with the normal, rapid mobilization of calcium from intracellular stores; instead, it blocked calcium mobilization induced by endogenous chemokines, In freshly isolated human monocytes the virally encoded vMIP-II acted as a potent and efficient antagonist of chemotaxis induced by chemokines. Because vMIP-II could inhibit cell entry of human immunodeficiency virus (HIV) mediated through CCR3 and CCR5 as well as CXCR4, this protein may serve as a lead for development of broad-spectrum anti-HIV agents.	GLAXO WELLCOME RES & DEV LTD,GENEVA BIOMED RES INST,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND; UNIV COPENHAGEN,PANUM INST,MOL PHARMACOL LAB,INST PHARMACOL,DK-2200 COPENHAGEN,DENMARK; RIGSHOSP,DEPT INFECT DIS,DK-2100 COPENHAGEN,DENMARK; INST CANC RES,CHESTER BEATTY LABS,SECT VIROL,LONDON SW3 6JB,ENGLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA	GlaxoSmithKline; University of Copenhagen; Rigshospitalet; University of Copenhagen; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of British Columbia			Simmons, Graham/G-3523-2012	Simmons, Graham/0000-0002-9615-7023; Wells, Timothy/0000-0001-9796-847X; Luttichau, Hans Rudolf/0000-0002-5428-4075; Schwartz, Thue W./0000-0002-0261-6904; Rosenkilde, Mette Marie/0000-0001-9600-3254				AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; AKRANITAKIS L, 1997, NATURE, V385, P347; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P1043; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1989, J BIOL CHEM, V264, P18907; Damaj BB, 1996, J BIOL CHEM, V271, P20540, DOI 10.1074/jbc.271.34.20540; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DRAJIC T, 1996, NATURE, V381, P667; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FINCHAM NJ, 1988, J IMMUNOL, V140, P4294; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; JUNG YK, 1992, MOL ENDOCRINOL, V6, P2027, DOI 10.1210/me.6.12.2027; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; LustiNarasimhan M, 1996, J BIOL CHEM, V271, P3148, DOI 10.1074/jbc.271.6.3148; MacDonald MR, 1997, J VIROL, V71, P1671, DOI 10.1128/JVI.71.2.1671-1678.1997; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Power CA, 1996, TRENDS PHARMACOL SCI, V17, P209, DOI 10.1016/0165-6147(96)10019-5; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Weiss RA, 1996, NAT MED, V2, P277, DOI 10.1038/nm0396-277; WULFF BS, 1993, MOL CELL ENDOCRINOL, V91, P135, DOI 10.1016/0303-7207(93)90265-L; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641	37	402	444	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1656	1659		10.1126/science.277.5332.1656	http://dx.doi.org/10.1126/science.277.5332.1656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287217				2022-12-28	WOS:A1997XV68400048
J	Engels, EA; Spitz, MR				Engels, EA; Spitz, MR			PACE-setting research	LANCET			English	Editorial Material									UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EPIDEMIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Engels, EA (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN CARE RES,BOSTON,MA 02111, USA.							Charlton BG, 1997, QJM-MON J ASSOC PHYS, V90, P147, DOI 10.1093/qjmed/90.2.147; Donne John., 1624, DEVOTIONS EMERGENT O; PROCTOR SJ, 1995, LEUKEMIA, V9, P1246; PROCTOR SJ, 1993, LEUKEMIA, V7, P1911; ROSENBERG L, 1994, AM J EPIDEMIOL, V140, P771; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, V1, P77	6	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					677	678		10.1016/S0140-6736(05)63506-4	http://dx.doi.org/10.1016/S0140-6736(05)63506-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291897				2022-12-28	WOS:A1997XU97700003
J	Billings, JA; Block, S				Billings, JA; Block, S			Palliative care in undergraduate medical education - Status report and future directions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	1995 Annual Meeting of the Association-of-Canadian-Medical-Colleges / Association-of-Canadian-Teaching-Hospitals / Canadian-Association-for-Medical-Education	MAY 02, 1995	QUEBEC CITY, CANADA	Assoc Canadian Med Coll, Assoc Canadian Teaching Hosp, Canadian Assoc Med Educ			DEATH EDUCATION; STUDENTS; COMMUNICATION; PATIENT; SCHOOLS; SKILLS	Objective.-To describe the status of palliative care education in the under-graduate medical curriculum and to offer recommendations for improvement. Data Sources.-Review of literature on palliative care and of recently submitted grants on medical education for end-of-life care. Study Selection.-English-language reports of educational programs targeted toward medical students were examined, as well as surveys of medical schools. Data Extraction.-Studies were reviewed by the authors to assess the quality of the educational program, evaluation methodology, and conclusions. From over 9000 citations on palliative care and related topics that were retrieved from MEDLINE searches from 1980 through 1995, and from reviewing 14 palliative care journals published from 1985 through 1996, 310 articles were identified that addressed medical education for end-of-life care, and 180 were carefully examined. Data Synthesis.-While nearly all medical schools offer some formal teaching about end-of-life care, there is considerable evidence that current training is inadequate, most strikingly in the clinical years. Teaching about palliative care is received favorably by students, positively influences student attitudes, and enhances communication skills. However, curricular offerings are not well integrated; the major teaching format is the lecture; formal teaching is predominantly preclinical; clinical experiences are mostly elective; there is little attention to home care, hospice, and nursing home care; role models are few; and students are not encouraged to examine their personal reactions to these clinical experiences. Conclusions.-The increasing attention to palliative care education has created major opportunities for improving education about care at the end of life. Educational programs should be rigorously evaluated to identify best educational practices.	HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DIV PSYCHIAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, HARVARD PILGRIM HLTH CARE, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital	Billings, JA (corresponding author), MASSACHUSETTS GEN HOSP, PALLIAT CARE SERV, FOUNDERS HOUSE 600, 55 FRUIT ST, BOSTON, MA 02114 USA.		Van den Block, Lieve/D-1247-2011	Van den Block, Lieve/0000-0002-7770-348X	NATIONAL CANCER INSTITUTE [R25CA066818] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AD HOC COMM CANC, 1992, J CLIN ONCOL, V10, P1830; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; ANDERSON JL, 1982, MED EDUC, V16, P202, DOI 10.1111/j.1365-2923.1982.tb01249.x; [Anonymous], 1995, J Am Geriatr Soc, V43, P577; ARTISS KL, 1973, NEW ENGL J MED, V288, P1210, DOI 10.1056/NEJM197306072882305; BARTON D, 1972, J MED EDUC, V47, P945; BARTON D, 1972, J MED EDUC, V47, P169; BARTON D, 1975, OMEGA, V6, P243; BELANI CP, 1994, SUPPORT CARE CANCER, V2, P50, DOI 10.1007/BF00355239; Benoliel J Q, 1988, J Palliat Care, V4, P41; BERTMAN SL, 1985, MED EDUC, V19, P374, DOI 10.1111/j.1365-2923.1985.tb01340.x; BERTMAN SL, 1982, DEATH ED HLTH CARE P, P95; Billings J A, 1993, Hosp J, V9, P69, DOI 10.1300/J011v09n01_06; BILLINGS JA, 1985, J MED EDUC, V60, P855; BILLINGS JA, 1989, CLIN ENCOUNTER GUIDE; BLANCHARD CG, 1981, CANCER, V47, P2756, DOI 10.1002/1097-0142(19810601)47:11<2756::AID-CNCR2820471135>3.0.CO;2-G; BLANK LL, 1995, WESTERN J MED, V163, P297; BLOCH S, 1981, ED MED STUDENT THANA, P129; Block SD, 1996, ACAD PSYCHIATR, V20, P65, DOI 10.1007/BF03341552; BLOCK SD, 1997, HARVARD MED ALUMNI B, V70, P37; BLOCK SD, 1994, NEW PATHWAYS MED ED, P114; CALMAN KC, 1989, EDINBURGH S PAIN CON, P175; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSELL EJ, 1985, TALKING PATIENTS, V1; CASSELL EJ, 1985, TALKING PATIENTS, V2; CASSEM NH, 1978, HARVARD GUIDE MODERN; Cassileth B R, 1989, J Cancer Educ, V4, P261; CASSILETH BR, 1979, J MED EDUC, V54, P797; DICKINSON GE, 1976, J MED EDUC, V51, P134; DICKINSON GE, 1985, J MED EDUC, V60, P942; DIMAGGIO JR, 1993, GEN HOSP PSYCHIAT, V15, P166, DOI 10.1016/0163-8343(93)90120-D; DOYLE D, 1993, OXFORD TXB PALLIATIV, P3; DOYLE D, 1986, TERMINAL CARE, P207; DURLAK JA, 1991, DEATH STUD, V15, P39, DOI 10.1080/07481189108252408; DURLAK JA, 1979, OMEGA-J DEATH DYING, V9, P57, DOI 10.2190/1BQ0-HLTL-WL45-4QUV; EVANS BJ, 1991, MED EDUC, V25, P517, DOI 10.1111/j.1365-2923.1991.tb00105.x; FIELD MJ, 1992, APPROACHING DEATH IM; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; Garvin D. A., 1991, ED JUDGMENT ARTISTRY, P3; Goldberg R, 1987, J Cancer Educ, V2, P159; GOODELL BW, 1982, DEATH EDUC, V5, P363; GROSSMAN SA, 1985, J MED EDUC, V60, P552; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; HOLLEMAN WL, 1994, TEACH LEARN MED, V6, P260; IRWIN WG, 1989, MED EDUC, V23, P387, DOI 10.1111/j.1365-2923.1989.tb01565.x; Itano J K, 1991, J Cancer Educ, V6, P219; Jacox A, 1994, AHCPR PUBLICATION; Kassirer JP, 1996, NEW ENGL J MED, V335, P507, DOI 10.1056/NEJM199608153350709; Kaye J M, 1991, J Cancer Educ, V6, P21; KITCHEN AD, 1986, J MED EDUC, V61, P760; KITCHEN AD, 1988, THANATOLOGY CURRICUL, P3; Kleinman A., 1988, ILLNESS NARRATIVES; Knight C F, 1992, Am J Hosp Palliat Care, V9, P23, DOI 10.1177/104990919200900104; KNOTT JE, 1982, THANATOPICS MANUAL S; Kubler-Ross E., 1969, DEATH DYING; LATTANZI ME, 1983, HOSPICE CARE PRINCIP, P223; LINN BS, 1982, J MED EDUC, V57, P684; LISTON EH, 1973, J MED EDUC, V48, P577; LOCKARD BE, 1989, DEATH STUD, V13, P137, DOI 10.1080/07481188908252291; MacDonald N, 1993, J Cancer Educ, V8, P197; MacLeod R D, 1993, Hosp J, V9, P55, DOI 10.1300/J011v09n01_05; Maguire P, 1996, EUR J CANCER, V32A, P1486, DOI 10.1016/0959-8049(96)00059-7; MARKS SC, 1980, J MED EDUC, V55, P48; MARTIN RW, 1989, ACAD MED, V64, P413, DOI 10.1097/00001888-198907000-00018; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; MASON C, 1986, MED EDUC, V20, P342, DOI 10.1111/j.1365-2923.1986.tb01377.x; MATHEW LM, 1983, J MED EDUC, V58, P772; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; McGrath PA, 1996, J PAIN SYMPTOM MANAG, V12, P87, DOI 10.1016/0885-3924(96)00099-1; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; Mishler EG, 1984, DISCOURSE MED DIALEC; OLIN HS, 1972, J MED EDUC, V47, P564; *PALL ONC ED SECT, 1996, J CANCER EDUC, V11, P7; Plumb J D, 1992, Am J Hosp Palliat Care, V9, P32, DOI 10.1177/104990919200900311; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V12, P93, DOI 10.1016/0885-3924(96)00078-4; Qvarnstrom U, 1988, J Palliat Care, V4, P38; RAPPAPORT W, 1993, SURGERY, V113, P163; REULER JB, 1994, WESTERN J MED, V160, P335; SACK WH, 1984, PEDIATRICS, V73, P676; SANKAR A, 1985, J MED EDUC, V60, P308; SAUNDERS C, 1969, DEATH DYING, P59; Schmidt HG, 1996, ACAD MED, V71, P658, DOI 10.1097/00001888-199606000-00021; SCHMIDT HG, 1983, MED EDUC, V17, P11, DOI 10.1111/j.1365-2923.1983.tb01086.x; SCITOVSKY AA, 1994, MILBANK Q, V72, P561, DOI 10.2307/3350356; SMITH MD, 1980, J MED EDUC, V55, P844; Stedeford A, 1989, J Cancer Educ, V4, P103; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; Weissman D E, 1993, J Cancer Educ, V8, P191; WHITE LP, 1964, ANN NY ACAD SCI, V164, P822; WOLRAICH M, 1984, J MED EDUC, V59, P751; *WORK PART ASS PAL, 1992, ASS PALL MED GREAT B; YOUNG R, 1981, J MED EDUC, V56, P341	95	232	240	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					733	738		10.1001/jama.278.9.733	http://dx.doi.org/10.1001/jama.278.9.733			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XT709	9286833				2022-12-28	WOS:A1997XT70900026
J	Alarcon, GS; Kremer, JM; Macaluso, M; Weinblatt, ME; Cannon, GW; Palmer, WR; StClair, EW; Sundy, JS; Alexander, RW; Smith, GJW; Axiotis, CA				Alarcon, GS; Kremer, JM; Macaluso, M; Weinblatt, ME; Cannon, GW; Palmer, WR; StClair, EW; Sundy, JS; Alexander, RW; Smith, GJW; Axiotis, CA			Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis - A multicenter, case-control study	ANNALS OF INTERNAL MEDICINE			English	Article						methotrexate; arthritis, rheumatoid; lung diseases; diabetes mellitus; age factors	LOW-DOSE METHOTREXATE; FOLIC-ACID SUPPLEMENTATION; PLACEBO-CONTROLLED TRIAL; DISEASE-ACTIVITY SCORE; LONG-TERM TREATMENT; GOLD TOXICITY; BRONCHOALVEOLAR LAVAGE; INDUCED PNEUMONITIS; PULSE METHOTREXATE; CLINICAL-PRACTICE	Background: Toxicity limits the use of methotrexate. Objective: To identify risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. Design: Case-control study. Setting: One private and five academic rheumatology practices. Participants: Methotrexate recipients with rheumatoid arthritis with and without lung injury. Measurements: Potential risk factors examined were sociodemographic and lifestyle characteristics, medical history, clinical and ancillary features and treatment of rheumatoid arthritis before methotrexate therapy, and characteristics of methotrexate therapy. Cases of lung injury were defined according to the modified criteria of Searles and McKendry. Results: Ninety-four percent of the study participants were white, and 67% were women. Case-patients (n = 29) were older than controls (n = 82) (61.5 compared with 54.5 years of age). The strongest predictors of lung injury, after adjustment for other variables, were older age (odds ratio [OR], 5.1 [95% CI, 1.2 to 21.1]), diabetes (OR, 35.6 [CI, 1.3 to infinity]), rheumatoid pleuropulmonary involvement (OR, 7.1 [CI, 1.1 to 45.4]), previous use of disease-modifying anti-rheumatic drugs (OR, 5.6 [CI, 1.2 to 27.0]), and hypoalbuminemia (OR, 19.5 [CI, 3.5 to 109.7]). Previous use of disease-modifying antirheumatic drugs and hypoalbuminemia had very large attributable risks. Conclusion: Knowledge of the risk factors that predispose patients with rheumatoid arthritis to the toxic effects of methotrexate on the lung may provide a rationale for monitoring high-risk patients and may facilitate their management.	ALBANY MED COLL, DIV RHEUMATOL, ALBANY, NY 12208 USA; UNIV ALABAMA, MIH SCH PUBL HLTH 106, BIRMINGHAM, AL 35294 USA; UNIV UTAH, SCH MED, SALT LAKE CITY, UT USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; COLUMBUS HOSP, DEPT PATHOL, GREAT FALLS, MT 59405 USA; KINGS CTY HOSP, DEPT PATHOL ANAT, BROOKLYN, NY 11203 USA; INTERNAL MED ASSOCIATES, OMAHA, NE USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84148 USA	Albany Medical College; University of Alabama System; University of Alabama Birmingham; Utah System of Higher Education; University of Utah; Duke University; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Alarcon, GS (corresponding author), UNIV ALABAMA, BIRMINGHAM STN, MEB 615, 1813 6TH AVE S, BIRMINGHAM, AL 35294 USA.		Macaluso, Maurizio/J-2076-2015	Macaluso, Maurizio/0000-0002-2977-9690				AGLAS F, 1995, ARTHRITIS RHEUM, V38, P291, DOI 10.1002/art.1780380222; ALARCON GS, 1985, ARTHRITIS RHEUM, V28, P236, DOI 10.1002/art.1780280224; ALARCON GS, 1989, ARTHRITIS RHEUM, V32, P671, DOI 10.1002/anr.1780320603; ALARCON GS, 1986, RHEUMATOL INT, V6, P13, DOI 10.1007/BF00270659; ALARCON GS, 1989, J RHEUMATOL, V16, P1007; ANAYA JM, 1995, SEMIN ARTHRITIS RHEU, V24, P242, DOI 10.1016/S0049-0172(95)80034-4; BANNWARTH B, 1994, DRUGS, V47, P25, DOI 10.2165/00003495-199447010-00003; BARGER BO, 1984, ARTHRITIS RHEUM, V27, P601, DOI 10.1002/art.1780270601; BARRERA P, 1994, ANN RHEUM DIS, V53, P479, DOI 10.1136/ard.53.7.479; BUCHBINDER R, 1993, J RHEUMATOL, V20, P639; BUCKLEY LM, 1990, J RHEUMATOL, V17, P1158; BUNCH TW, 1984, ARTHRITIS RHEUM, V27, P267, DOI 10.1002/art.1780270304; CANNON GW, 1983, ARTHRITIS RHEUM, V26, P1269, DOI 10.1002/art.1780261015; CARROLL GJ, 1994, J RHEUMATOL, V21, P51; CARSON CW, 1987, SEMIN ARTHRITIS RHEU, V16, P186, DOI 10.1016/0049-0172(87)90021-7; CLARK P, 1993, ANN INTERN MED, V119, P1067, DOI 10.7326/0003-4819-119-11-199312010-00002; CLARYSSE AM, 1969, J AMER MED ASSOC, V209, P1861, DOI 10.1001/jama.209.12.1861; CLERC D, 1991, ANN RHEUM DIS, V48, P247; COLLINS D, 1994, J RHEUMATOL, V21, P1220; COOK NJ, 1992, ANN RHEUM DIS, V51, P272, DOI 10.1136/ard.51.2.272; CORNELISSEN JJ, 1991, ANN RHEUM DIS, V50, P642, DOI 10.1136/ard.50.9.642; ELSASSER S, 1989, AM REV RESPIR DIS, V140, P1089, DOI 10.1164/ajrccm/140.4.1089; ENGELBRECHT JA, 1983, ARTHRITIS RHEUM, V26, P1275, DOI 10.1002/art.1780261016; ERICKSON AR, 1995, ARTHRITIS RHEUM, V38, P1115, DOI 10.1002/art.1780380814; ESDAILE JM, 1995, AM J MED, V98, P156; FRIES JF, 1991, J RHEUMATOL, V18, P6; FRIES JF, 1990, J RHEUMATOL, V17, P12; FURST DE, 1990, J RHEUMATOL, V17, P1628; GISPEN JG, 1987, J RHEUMATOL, V14, P74; GOLDEN MR, 1995, J RHEUMATOL, V22, P1043; HILLIQUIN P, 1991, Revue de Pneumologie Clinique, V47, P179; HOSMER DW, 1991, AM J PUBLIC HEALTH, V81, P1630, DOI 10.2105/AJPH.81.12.1630; HOSMER DW, 1989, APPL LOGISTIC REGRES; KREMER JM, 1992, ARTHRITIS RHEUM, V35, P138, DOI 10.1002/art.1780350203; KREMER JM, 1994, ARTHRITIS RHEUM-US, V37, P316, DOI 10.1002/art.1780370304; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; LAW KF, 1993, J RHEUMATOL, V20, P872; LEDUC D, 1993, CHEST, V104, P1620, DOI 10.1378/chest.104.5.1620; LEIGH JP, 1994, SOC SCI MED, V38, P575, DOI 10.1016/0277-9536(94)90254-2; LIANG MH, 1984, ARTHRITIS RHEUM, V27, P522, DOI 10.1002/art.1780270507; LOUIE S, 1986, THORAX, V41, P703, DOI 10.1136/thx.41.9.703; LYNGBERG KK, 1994, ARCH PHYS MED REHAB, V75, P1189, DOI 10.1016/0003-9993(94)90003-5; MALLYA RK, 1982, J RHEUMATOL, V9, P224; MCKENDRY RJR, 1993, J RHEUMATOL, V20, P1850; MORGAN SL, 1993, J RHEUMATOL, V20, P929; MORGAN SL, 1990, ARTHRITIS RHEUM-US, V33, P9, DOI 10.1002/art.1780330102; MORGAN SL, 1994, ANN INTERN MED, V121, P833, DOI 10.7326/0003-4819-121-11-199412010-00002; NYFORS A, 1978, DAN MED BULL, V25, P208; OREILLY S, 1994, TUBERCLE LUNG DIS, V75, P153, DOI 10.1016/0962-8479(94)90046-9; PERRUQUET JL, 1983, ARTHRITIS RHEUM, V26, P1291, DOI 10.1002/art.1780261021; PINCUS T, 1986, J RHEUMATOL, V13, P841; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P38; Sandoval DM, 1995, BRIT J RHEUMATOL, V34, P49; SCHERAK O, 1993, J RHEUMATOL, V20, P944; SEARLES G, 1987, J RHEUMATOL, V14, P1164; SHIROKY JB, 1993, ARTHRITIS RHEUM, V36, P795, DOI 10.1002/art.1780360609; SITUNAYAKE RD, 1987, ANN RHEUM DIS, V46, P177, DOI 10.1136/ard.46.3.177; SOSTMAN HD, 1976, MEDICINE, V55, P371, DOI 10.1097/00005792-197609000-00002; STCLAIR EW, 1985, ARCH INTERN MED, V145, P2035, DOI 10.1001/archinte.145.11.2035; STENGER AAME, 1994, SCAND J RHEUMATOL, V23, P51, DOI 10.3109/03009749409102137; TERKELTAUB R, 1984, J RHEUMATOL, V11, P147; TISHLER M, 1988, ARTHRITIS RHEUM, V31, P906, DOI 10.1002/art.1780310712; TRENKWALDER P, 1992, CLIN INVESTIGATOR, V70, P951; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; VANDERHEIJDE DMFM, 1990, ANN RHEUM DIS, V49, P916, DOI 10.1136/ard.49.11.916; VANDERHEIJDE DMFM, 1993, J RHEUMATOL, V20, P579; VANSCHAARDENBURG D, 1993, J RHEUMATOL, V20, P45; WALKER AM, 1993, ARTHRITIS RHEUM, V36, P329, DOI 10.1002/art.1780360307; WEINBLATT ME, 1990, J RHEUMATOL, V17, P33; WILLKENS RF, 1990, SEMIN ARTHRITIS RHEU, V20, P76, DOI 10.1016/0049-0172(90)90020-G; WOLLNER A, 1991, THORAX, V46, P205, DOI 10.1136/thx.46.3.205; WOOLEY PH, 1980, NEW ENGL J MED, V303, P300, DOI 10.1056/NEJM198008073030602; Wyss E, 1994, Schweiz Rundsch Med Prax, V83, P449	73	207	215	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					356	+		10.7326/0003-4819-127-5-199709010-00003	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273826				2022-12-28	WOS:A1997XU10000003
J	Jeong, B; Bae, YH; Lee, DS; Kim, SW				Jeong, B; Bae, YH; Lee, DS; Kim, SW			Biodegradable block copolymers as injectable drug-delivery systems	NATURE			English	Article							CONTROLLED RELEASE; MEMBRANE; PH	Polymers that display a physicochemical response to stimuli are widely explored as potential drug-delivery systems(1-4), Stimuli studied to date include chemical substances and changes in temperature, pH and electric field, Homopolymers or copolymers of N-isopropylacrylamide(5,6) and poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (known as poloxamers)(7) are typical examples of thermosensitive polymers, but their use in drug delivery is problematic because they are toxic and nonbiodegradable, Biodegradable polymers used for drug delivery to date have mostly been in the form of injectable microspheres or implant systems, which require complicated fabrication processes using organic solvents(8). Such systems have the disadvantage that the use of organic solvents can cause denaturation when protein drugs are to be encapsulated. Furthermore, the solid form requires surgical insertion, which often results in tissue irritation and damage, Here we report the synthesis of a thermosensitive, biodegradable hydrogel consisting of blocks of poly(ethylene oxide) and poly(L-lactic acid), Aqueous solutions of these copolymers exhibit temperature-dependent reversible gel-sol transitions, The hydrogel can be loaded with bioactive molecules in an aqueous phase at an elevated temperature (around 45 degrees C), where they form a sol. In this form, the polymer is injectable. On subcutaneous injection and subsequent rapid cooling to body temperature, the loaded copolymer forms a gel that can act as a sustained-release matrix for drugs.	UNIV UTAH, CCCD PHARMACEUT, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah			Kang, Bo Kyung/F-6726-2015; LEE, DOO SUNG/D-3363-2011; Jeong, Byeongmoon/AAB-1570-2021	Jeong, Byeongmoon/0000-0001-9582-1343				ALEXANDRIDIS P, 1994, MACROMOLECULES, V27, P2414, DOI 10.1021/ma00087a009; BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; ISHIHARA K, 1984, J APPL POLYM SCI, V29, P211, DOI 10.1002/app.1984.070290119; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; MALSTOM M, 1992, MACROMOLECULES, V25, P5440; MORITZ AR, 1947, AM J PATHOL, V23, P695; Ronneberger B, 1996, J BIOMED MATER RES, V30, P31; THOMAS JL, 1995, J AM CHEM SOC, V117, P2949, DOI 10.1021/ja00115a039; Wout Z G, 1992, J Parenter Sci Technol, V46, P192; YOUXIN L, 1993, J CONTROL RELEASE, V27, P247; ZHU KJ, 1990, J APPL POLYM SCI, V39, P1, DOI 10.1002/app.1990.070390101	13	1742	1895	32	1253	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					860	862		10.1038/42218	http://dx.doi.org/10.1038/42218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278046				2022-12-28	WOS:A1997XT75400044
J	Weinstein, MR; Litt, M; Kertesz, DA; Wyper, P; Rose, D; Coulter, M; McGeer, A; Facklam, R; Ostach, C; Willey, BM; Borczyk, A; Low, DE				Weinstein, MR; Litt, M; Kertesz, DA; Wyper, P; Rose, D; Coulter, M; McGeer, A; Facklam, R; Ostach, C; Willey, BM; Borczyk, A; Low, DE			Invasive infections due to a fish pathogen, Streptococcus iniae	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 15-18, 1996	NEW ORLEANS, LA				ENTEROCOCCUS-SERIOLICIDA; SP-NOV; MENINGITIS; SUIS; MENINGOENCEPHALITIS; DIAGNOSIS; MASTITIS; CRITERIA; SYNONYM; STRAINS	Background Streptococcus iniae is a pathogen in fish, capable of causing invasive disease and outbreaks in aquaculture farms. During the winter of 1995-1996 in the greater Toronto area there was a cluster of four cases of invasive S. iniae infection in people who had recently handled fresh, whole fish from such farms. Methods We conducted a prospective and retrospective community-based surveillance for cases of S. iniae infection in humans. To obtain a large sample of isolates, we studied cultures obtained from the surface of fish from aquaculture farms. Additional isolates were obtained from the brains of infected tilapia (oreochromis species). All the isolates were characterized by pulsed-field gel electrophoresis (PFGE). Results During one year, our surveillance identified a total of nine patients with invasive S. iniae infection (cellulitis of the hand in eight and endocarditis in one). All the patients had handled live or freshly killed fish, and eight had percutaneous injuries. Six of the nine fish were tilapia, which are commonly used in Asian cooking. Thirteen additional S. iniae isolates (2 from humans and 11 from infected tilapia) were obtained from normally sterile sites. The isolates from the nine patients were indistinguishable by PFGE and were highly related to the other clinical isolates. There was substantial genetic diversity among the 42 surveillance isolates from the surface of fish, but in 10 isolates the PFGE patterns were identical to those from the patients with S. iniae infection. Conclusions S. iniae can produce invasive infection after skin injuries during the handling of fresh fish grown by aquaculture. We identified a clone of S. iniae that causes invasive disease in both humans and fish. (C) 1997, Massachusetts Medical Society.	MT SINAI HOSP,DEPT MICROBIOL,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; LAB CTR DIS CONTROL,OTTAWA,ON K1A 0L2,CANADA; SCARBOROUGH GRACE HOSP,SCARBOROUGH,ON,CANADA; PRINCESS MARGARET HOSPS,TORONTO,ON,CANADA; CITY SCARBOROUGH PUBL HLTH DEPT,SCARBOROUGH,ON,CANADA; PUBL HLTH LAB,TORONTO,ON,CANADA; CTR DIS CONTROL & PREVENT,ATLANTA,GA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Scarborough Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Centers for Disease Control & Prevention - USA			mcgeer, allison/H-7747-2014; Low, Donald/B-1726-2012; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				ARENDS JP, 1988, REV INFECT DIS, V10, P131; BAIRDPARKER AC, 1994, MICROBIOL-UK, V140, P687, DOI 10.1099/00221287-140-4-687; BARNHAM M, 1987, EPIDEMIOL INFECT, V99, P257, DOI 10.1017/S0950268800067728; CHAU PY, 1983, MED J AUSTRALIA, V1, P414, DOI 10.5694/j.1326-5377.1983.tb136138.x; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; ELDAR A, 1995, INT J SYST BACTERIOL, V45, P840, DOI 10.1099/00207713-45-4-840; ELDAR A, 1994, CURR MICROBIOL, V28, P139, DOI 10.1007/BF01571054; ELDAR A, 1995, VET MICROBIOL, V43, P33, DOI 10.1016/0378-1135(94)00052-X; HOOK EW, 1986, ARCH INTERN MED, V146, P295; KAIGE N, 1984, Fish Pathology, V19, P173; KITAO T, 1981, Fish Pathology, V15, P301; KUSUDA R, 1991, INT J SYST BACTERIOL, V41, P406, DOI 10.1099/00207713-41-3-406; Kusuda Riichi, 1992, Israeli Journal of Aquaculture Bamidgeh, V44, P140; LEE PC, 1985, J CLIN MICROBIOL, V22, P80, DOI 10.1128/JCM.22.1.80-83.1985; *METR TOR PLANN DE, 1995, MUN METR TOR KEY FAC; Michaud S, 1996, Can J Infect Dis, V7, P329; MOGOLLON JD, 1990, J CLIN MICROBIOL, V28, P2462, DOI 10.1128/JCM.28.11.2462-2466.1990; MURRAY BE, 1991, J INFECT DIS, V163, P780, DOI 10.1093/infdis/163.4.780; Musser JM, 1996, EMERG INFECT DIS, V2, P1, DOI 10.3201/eid0201.960101; *NAT COMM CLIN LAB, 1994, M7A3 NAT COMM CLIN L; Perera Ramesh P., 1994, Journal of Aquatic Animal Health, V6, P335, DOI 10.1577/1548-8667(1994)006&lt;0335:SIAWMO&gt;2.3.CO;2; PIER GB, 1976, INT J SYST BACTERIOL, V26, P545, DOI 10.1099/00207713-26-4-545; PIER GB, 1978, INT J SYST BACTERIOL, V28, P311, DOI 10.1099/00207713-28-2-311; ROBINSON JA, 1966, J BACTERIOL, V92, P512, DOI 10.1128/JB.92.2.512-512.1966; Ruoff Kathryn L., 1995, P299; SHARP MW, 1995, VET REC, V137, P128, DOI 10.1136/vr.137.5.128-b; Teixeira LM, 1996, INT J SYST BACTERIOL, V46, P664, DOI 10.1099/00207713-46-3-664; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Vandamme P, 1997, INT J SYST BACTERIOL, V47, P81, DOI 10.1099/00207713-47-1-81; Vidaver AK, 1996, ASM NEWS, V62, P583; Walsh B., 1992, Reviews in Medical Microbiology, V3, P65; WEINBERG AN, 1995, MANDELL DOUGLAS BENN, V2, P2790; Weinstein M, 1996, Can Commun Dis Rep, V22, P129; WINDSOR RS, 1975, J HYG-CAMBRIDGE, V75, P69, DOI 10.1017/S0022172400047070; 1996, MMWR-MORBID MORTAL W, V45, P650; 1975, LANCET, V1, P1286; 1994, C D R WKLY REP, V4, P241	37	217	239	2	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					589	594		10.1056/NEJM199708283370902	http://dx.doi.org/10.1056/NEJM199708283370902			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271480	Green Published			2022-12-28	WOS:A1997XT39400002
J	Daley, J; Delbanco, TL; Hartmann, EE				Daley, J; Delbanco, TL; Hartmann, EE			An 89-year-old woman with urinary incontinence, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Daley, 1996, JAMA-J AM MED ASSOC, V276, P1832	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					679	679		10.1001/jama.278.8.679	http://dx.doi.org/10.1001/jama.278.8.679			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272902				2022-12-28	WOS:A1997XR54700043
J	Kitzman, H; Olds, DL; Henderson, CR; Hanks, C; Cole, R; Tatelbaum, R; McConnochie, KM; Sidora, K; Luckey, DW; Shaver, D; Engelhardt, K; James, D; Barnard, K				Kitzman, H; Olds, DL; Henderson, CR; Hanks, C; Cole, R; Tatelbaum, R; McConnochie, KM; Sidora, K; Luckey, DW; Shaver, D; Engelhardt, K; James, D; Barnard, K			Of prenatal and infancy home visitation by nurses on pregnancy outcomes, childhood injuries, and repeated childbearing trial - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALCIUM SUPPLEMENTATION; CHILDREN; HEALTH; WOMEN; ABUSE; RISK; LIFE	Context.-Interest in home-visitation services as a way of improving maternal and child outcomes has grown out of the favorable results of a trial in semirural New York. The findings have not been replicated in other populations. Objective.-To test the effect of prenatal and infancy home visits by nurses on pregnancy-induced hypertension, preterm delivery, and low birth weight; on children's injuries, immunizations, mental development, and behavioral problems; and on maternal life course. Design.-Randomized controlled trial. Setting.-Public system of obstetric care in Memphis, Tenn. Participants.-A total of 1139 primarily African-American women at less than 29 weeks' gestation, with no previous live births, and with at least 2 sociodemographic risk characteristics (unmarried, <12 years of education, unemployed). Intervention.-Nurses made an average of 7 (range, 0-18) home visits during pregnancy and 26 (range, 0-71) visits from birth to the children's second birthdays. Main Outcome Measures.-Pregnancy-induced hypertension, preterm delivery, low birth weight, children's injuries, ingestions, and immunizations abstracted from medical records; mothers' reports of children's behavioral problems; tests of children's mental development; mothers' reports of subsequent pregnancy, educational achievement, and labor-force participation; and use of welfare derived from state records. Main Results.-In contrast to counterparts assigned to the comparison condition, fewer women visited by nurses during pregnancy had pregnancy-induced hypertension (13% vs 20%; P=.009). During the first 2 years after delivery, women visited by nurses during pregnancy and the first 2 years of the child's life had fewer health care encounters for children in which injuries or ingestions were detected (0.43 vs 0.55; P=.05); days that children were hospitalized with injuries or ingestions (0.03 vs 0.16; P<.001); and second pregnancies (36% vs 47%; P=.006). There were no program effects on preterm delivery or low birth weight; children's immunization rates, mental development, or behavioral problems; or mothers' education and employment. Conclusion.-This program of home visitation by nurses can reduce pregnancy-induced hypertension, childhood injuries, and subsequent pregnancies among low-income women with no previous live births.	UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, DENVER, CO 80203 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOSTAT, DENVER, CO 80203 USA; UNIV ROCHESTER, SCH NURSING, ROCHESTER, NY 14627 USA; UNIV ROCHESTER, DEPT PSYCHIAT, ROCHESTER, NY 14627 USA; UNIV ROCHESTER, DEPT OBSTET & GYNECOL, ROCHESTER, NY 14627 USA; UNIV ROCHESTER, DEPT PEDIAT, ROCHESTER, NY 14627 USA; CORNELL UNIV, DEPT HUMAN DEV, ITHACA, NY 14853 USA; BAYLOR UNIV, SCH NURSING, HOUSTON, TX 77030 USA; PRESBYTERIAN HLTH SERV, CHARLOTTE, NC USA; UNIV TENNESSEE, COLL NURSING, MEMPHIS, TN USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN USA; UNIV WASHINGTON, SCH NURSING, SEATTLE, WA 98195 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Rochester; University of Rochester; University of Rochester; University of Rochester; Cornell University; Baylor University; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle				Kitzman, Harriet/0000-0001-9470-7979	NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR001691] Funding Source: NIH RePORTER; NIMH NIH HHS [1-K05-MH01382-01] Funding Source: Medline; NINR NIH HHS [NRO1-01691-05] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Achenbach T. M., 1988, CHILD BEHAV CHECKLIS; Ainsworth M., 1978, PATTERNS ATTACHMENT; *AM COLL OBST GYN, 1996, TECHN B AM COLL OBST, V219, P1; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bavolek S. J., 1984, HDB AAPI ADULT ADOLE; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BLACK MM, 1994, PEDIATRICS, V94, P440; BRENNER WE, 1976, AM J OBSTET GYNECOL, V56, P52; Caldwell B.M., 1979, HOME OBSERVATION MEA; Carlson E.A., 1995, DEV PSYCHOPATHOL, P581; CARROLI G, 1994, BRIT J OBSTET GYNAEC, V101, P753, DOI 10.1111/j.1471-0528.1994.tb11940.x; DEPP R, 1993, AM J OBSTET GYNECOL, V169, P352; ELLIS RH, 1981, PSYCHOL REP, V48, P507, DOI 10.2466/pr0.1981.48.2.507; GUTELIUS MF, 1977, PEDIATRICS, V60, P294; HENDERSON CR, 1982, BIOMETRICS, V38, P623, DOI 10.2307/2530044; LOYD BH, 1985, J PEDIATR PSYCHOL, V10, P169, DOI 10.1093/jpepsy/10.2.169; *MA DEP PUBL HLTH, 1986, SAF SAF INSP NOT; MARCOUX S, 1989, J EPIDEMIOL COMMUN H, V43, P147, DOI 10.1136/jech.43.2.147; National Commission to Prevent Infant Mortality, 1989, HOM VIS OP DOORS AM; OLDS D, 1995, PEDIATRICS, V95, P365; Olds D, 1997, J COMMUNITY PSYCHOL, V25, P9; OLDS DL, 1986, PEDIATRICS, V77, P16; OLDS DL, 1993, MED CARE, V31, P155, DOI 10.1097/00005650-199302000-00006; OLDS DL, 1988, AM J PUBLIC HEALTH, V78, P1436, DOI 10.2105/AJPH.78.11.1436; OLDS DL, 1994, PEDIATRICS, V93, P89; OLDS DL, 1986, PEDIATRICS, V78, P65; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; OLDS DL, 1990, PEDIATRICS, V86, P108; OLDS DL, 1992, AM J DIS CHILD, V146, P704, DOI 10.1001/archpedi.1992.02160180062018; Olds DL., 1998, FUTURE CHILD, V3, P53, DOI [DOI 10.2307/1602543, 10.2307/1602543]; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; Shipley WC, 1940, J PSYCHOL, V9, P371, DOI 10.1080/00223980.1940.9917704; SOARES JF, 1983, COMMUN STAT-THEOR M, V12, P2017, DOI 10.1080/03610928308828586; SPARLING J, 1984, PARTNERS LEARNING; SUMNER GA, 1990, NCAST KEYS CAREGIVIN; U.S. Advisory Board on Child Abuse and Neglect, 1990, CHILD AB NEGL CRIT 1; *U WASH, 1994, NCAST CAR PAR CHILD; *US DEP COMM, 1992, CE903A53 US DEP COMM; Ware JE, 1985, REFINEMENTS MEASUREM; ZUCKERMAN BS, 1987, PEDIATRICS, V79, P110; 1994, NCAST CAREGIVER PARE	41	461	466	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					644	652		10.1001/jama.278.8.644	http://dx.doi.org/10.1001/jama.278.8.644			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR547	9272896				2022-12-28	WOS:A1997XR54700037
J	Landoni, F; Maneo, A; Colombo, A; Placa, F; Milani, R; Perego, P; Favini, G; Ferri, L; Mangioni, C				Landoni, F; Maneo, A; Colombo, A; Placa, F; Milani, R; Perego, P; Favini, G; Ferri, L; Mangioni, C			Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer	LANCET			English	Article							PELVIC LYMPHADENECTOMY; RADIATION-THERAPY; UTERINE CERVIX; HYSTERECTOMY; CARCINOMA; METASTASIS	Background Stage tb and Ila cervical carcinoma can be cured by radical surgery or radiotherapy. These two procedures are equally effective, but differ in associated morbidity and type of complications. In this prospective randomised trial of radiotherapy versus surgery, our aim was to assess the 5-year survival and the rate and pattern of complications and recurrences associated with each treatment. Methods Between September, 1986, and December, 1991, 469 women with newly diagnosed stage Ib and Ila cervical carcinoma were referred to our institute. 343 eligible patients were randomised: 172 to surgery and 171 to radical radiotherapy. Adjuvant radiotherapy was delivered after surgery for women with surgical stage pT2b or greater, less than 3 mm of safe cervical stroma, cut-through, or positive nodes. The primary outcome measures were 5-year survival and the rate of complications. The analysis of survival and recurrence was by intention to treat and analysis of complications was by treatment delivered. Findings 170 patients in the surgery group and 167 in the radiotherapy group were included in the intention-to-treat analysis; scheduled treatment was delivered to 169 and 158 women, respectively. 62 of 114 women with cervical diameters of 4 cm or smaller and 46 of 55 with diameters larger than 4 cm received adjuvant therapy. After a median follow-up of 87 (range 57-120) months, 5-year overall and disease-free survival were identical in the surgery and radiotherapy groups (83% and 74%, respectively, for both groups). 86 women developed recurrent disease: 42 (25%) in the surgery group and 44 (26%) in the radiotherapy group. Significant factors for survival in univariate and multivariate analyses were: cervical diameter, positive lymphanglography, and adeno-carcinomatous histotype. 48 (28%) surgery-group patients had severe morbidity compared with 19 (12%) radiotherapy-group patients (p=0.0004). Interpretation There is no treatment of choice for early-stage cervical carcinoma in terms of overall or disease-free survival. The combination of surgery and radiotherapy has the worst morbidity, especially urological complications. The optimum therapy for each patient should take account of clinical factors such as menopausal status, age, medical illness, histological type, and cervical diameter to yield the best cure with minimum complications.	UNIV MILAN, CLIN OSTETR GINECOL 3, MILAN, ITALY; IST SCI BIOMED S GERARDO, DIV RADIOTHERAPY, MONZA, MILAN, ITALY; IST SCI BIOMED S GERARDO, DEPT PATHOL, MONZA, MILAN, ITALY; IST SCI BIOMED S GERARDO, DEPT RADIOL, MONZA, MILAN, ITALY	University of Milan				landoni, fabio/0000-0001-6734-739X				ABAD RS, 1969, AM J OBSTET GYNECOL, V104, P517, DOI 10.1016/S0002-9378(16)34240-5; *AM JOINT COMM CAN, 1992, MAN STAG CANC, P155; CHASSAGNE D, 1993, RADIOTHER ONCOL, V26, P195, DOI 10.1016/0167-8140(93)90260-F; CHASSAGNE D, 1979, J RADIOL, V60, P371; GRIGSBY PW, 1988, RADIOTHER ONCOL, V12, P289, DOI 10.1016/0167-8140(88)90018-7; International Commission on Radiation Units and Measurements (ICRU), 1985, 38 ICRU; IRELAND D, 1985, OBSTET GYNECOL, V65, P82; KIM DS, 1988, GYNECOL ONCOL, V29, P321, DOI 10.1016/0090-8258(88)90231-4; KINNEY WK, 1989, GYNECOL ONCOL, V34, P258, DOI 10.1016/0090-8258(89)90156-X; KOTTMEIER HL, 1964, AM J OBSTET GYNECOL, V88, P854, DOI 10.1016/0002-9378(64)90733-1; MORLEY GW, 1976, AM J OBSTET GYNECOL, V126, P785, DOI 10.1016/0002-9378(76)90668-2; MORROW CP, 1980, GYNECOL ONCOL, V10, P105, DOI 10.1016/0090-8258(80)90071-2; NEWTON M, 1975, AM J OBSTET GYNECOL, V123, P535, DOI 10.1016/0002-9378(75)90041-1; PANICI PB, 1988, OBSTET GYNECOL, V71, P344; PIVER MS, 1975, OBSTET GYNECOL, V46, P507; PIVER MS, 1974, OBSTET GYNECOL, V44, P265; PIVER MS, 1988, AM J CLIN ONCOL-CANC, V11, P21, DOI 10.1097/00000421-198802000-00006; VANNAGELL JR, 1979, CANCER, V44, P2354, DOI 10.1002/1097-0142(197912)44:6<2354::AID-CNCR2820440653>3.0.CO;2-J	18	1226	1276	1	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	1997	350	9077					535	540		10.1016/S0140-6736(97)02250-2	http://dx.doi.org/10.1016/S0140-6736(97)02250-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284774				2022-12-28	WOS:A1997XT22100007
J	PowellTuck, J				PowellTuck, J			Glutamine supplementation in artificial nutritional support	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; TOTAL PARENTERAL-NUTRITION; DOUBLE-BLIND				PowellTuck, J (corresponding author), ROYAL LONDON HOSP,ST BARTHOLOMEWS & ROYAL LONDON HOSP SCH MED,RANK DEPT HUMAN NUTR,LONDON E1 1BB,ENGLAND.							Bozzetti F, 1997, NUTRITION, V13, P748, DOI 10.1016/S0899-9007(97)83038-9; GRIFFITHS RD, 1997, NUTRITION, V13, P302; JEBB SA, 1995, CLIN NUTR, V14, P143; Jensen GL, 1996, AM J CLIN NUTR, V64, P615, DOI 10.1093/ajcn/64.4.615; MORLION BJ, 1996, CLIN NUTR S1, V15, P48; ORIORDAIN MG, 1994, ANN SURG, V220, P212, DOI 10.1097/00000658-199408000-00014; POWELLTUCK J, 1997, NUTRITION, V13, P725; SCHLOERB PR, 1993, JPEN-PARENTER ENTER, V17, P407, DOI 10.1177/0148607193017005407; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					534	534		10.1016/S0140-6736(05)63136-4	http://dx.doi.org/10.1016/S0140-6736(05)63136-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284773				2022-12-28	WOS:A1997XT22100006
J	Bargmann, CI				Bargmann, CI			Olfactory receptors, vomeronasal receptors, and the organization of olfactory information	CELL			English	Review							EXPRESSION; EPITHELIUM; FAMILY; SYSTEM				Bargmann, CI (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT ANAT,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Bargmann, Cornelia/0000-0002-8484-0618				Berghard A, 1996, J NEUROSCI, V16, P909; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Weth F, 1996, P NATL ACAD SCI USA, V93, P13321, DOI 10.1073/pnas.93.23.13321; Yoshihara Y, 1997, J NEUROSCI, V17, P5830; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	16	71	76	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					585	587		10.1016/S0092-8674(00)80518-8	http://dx.doi.org/10.1016/S0092-8674(00)80518-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288738	Bronze			2022-12-28	WOS:A1997XT06600002
J	Anzick, SL; Kononen, J; Walker, RL; Azorsa, DO; Tanner, MM; Guan, XY; Sauter, G; Kallioniemi, OP; Trent, JM; Meltzer, PS				Anzick, SL; Kononen, J; Walker, RL; Azorsa, DO; Tanner, MM; Guan, XY; Sauter, G; Kallioniemi, OP; Trent, JM; Meltzer, PS			AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer	SCIENCE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; AMPLIFICATION; SEQUENCE	Members of the recently recognized SRC-1 family of transcriptional coactivators interact with steroid hormone receptors to enhance ligand-dependent transcription. AIB1, a member of the SRC-1 family, was cloned during a search on the long arm of chromosome 20 for genes whose expression and copy number were elevated in human breast cancers. AIB1 amplification and overexpression were observed in four of five estrogen receptor-positive breast and ovarian cancer cell lines. Subsequent evaluation of 105 unselected specimens of primary breast cancer found AIB1 amplification in approximately 10 percent and high expression in 64 percent of the primary tumors analyzed. AIB1 protein interacted with estrogen receptors in a ligand-dependent fashion, and transfection of AIB1 resulted in enhancement of estrogen-dependent transcription, These observations identify AIB1 as a nuclear receptor coactivator whose altered expression may contribute to development of steroid-dependent cancers.	NATL HUMAN GENOME RES INST,CANC GENET LAB,NIH,BETHESDA,MD 20892; UNIV TAMPERE,INST MED TECHNOL,CANC GENET LAB,FIN-33101 TAMPERE,FINLAND; TAMPERE UNIV HOSP,FIN-33101 TAMPERE,FINLAND; UNIV BASEL,INST PATHOL,CH-4003 BASEL,SWITZERLAND	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tampere University; Tampere University; Tampere University Hospital; University of Basel			Kallioniemi, Olli P/H-5111-2011; /A-3639-2009; Guan, Xin-Yuan/A-3639-2009	Kallioniemi, Olli P/0000-0002-3231-0332; /0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017; Kononen, Juha/0000-0002-0157-2137; Walker, Robert/0000-0001-8235-4686				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; Guan XY, 1996, CANCER RES, V56, P3446; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; ISOLA JJ, 1995, AM J PATHOL, V147, P905; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; ONATE SA, 1995, SCIENCE, V270, P1354; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Sallinen P, 1997, AM J PATHOL, V150, P1159; Sambrook J., 2002, MOL CLONING LAB MANU; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1996, CANCER RES, V56, P3441; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	21	1357	1401	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					965	968		10.1126/science.277.5328.965	http://dx.doi.org/10.1126/science.277.5328.965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252329	Green Submitted			2022-12-28	WOS:A1997XQ98500044
J	Murata, T; Ushikubi, F; Matsuoka, T; Hirata, M; Yamasaki, A; Sugimoto, Y; Ichikawa, A; Aze, Y; Tanaka, T; Yoshida, N; Ueno, A; Ohishi, S; Narumiya, S				Murata, T; Ushikubi, F; Matsuoka, T; Hirata, M; Yamasaki, A; Sugimoto, Y; Ichikawa, A; Aze, Y; Tanaka, T; Yoshida, N; Ueno, A; Ohishi, S; Narumiya, S			Altered pain perception and inflammatory response in mice lacking prostacyclin receptor	NATURE			English	Article							MOUSE; HYPERALGESIA; RATS; EXPRESSION; INJECTION; MORPHINE; GENE	Prostanoids are a group of bioactive lipids working as local mediators' and include D, E, F and I types of prostaglandins (PGs) and thromboxanes. Prostacyclin (PGI(2)) acts on platelets and blood vessels to inhibit platelet aggregation and to cause vasodilatation, and is thought to be important for vascular homeostasis(2). Aspirin-like drugs, including indomethacin, which inhibit prostanoid biosynthesis, Suppress fever, inflammatory swelling and pain, and interfere with female reproduction, suggesting that prostanoids are involved in these processes(1,3), although it is not clear which prostanoid is the endogenous mediator of a particular process, Prostanoids act on seven-transmembrane-domain receptors which are selective for each type(4). Here we disrupt the gene for the prostacyclin receptor(5) in mice by using homologous recombination. The receptor-deficient mice are viable, reproductive and normotensive. However, their susceptibility to thrombosis is increased, and their inflammatory and pain responses are reduced to the levels observed in indomethacin-treated wild-type mice, Our results establish that prostacyclin is an antithrombotic agent in vivo and provide evidence for its role as a mediator of inflammation and pain.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 60601,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,KYOTO 60601,JAPAN; ONO PHARMACEUT CO,FUKUI INST SAFETY RES,MIKUNI,FUKUI 913,JAPAN; RES INST OSAKA MED CTR MATERNAL & CHILD HLTH,DIV MOL & CELLULAR IMMUNOL,IZUMI,OSAKA 59002,JAPAN; KITASATO UNIV,SCH PHARMACEUT SCI,DEPT PHARMACOL,SHIROGANEDAI,TOKYO 108,JAPAN	Kyoto University; Kyoto University; Ono Pharmaceutical Co Ltd; Kitasato University			Tanaka, Takashi/O-8254-2015; Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Murata, Takahiko/0000-0003-0132-5424				ARMSTRONG RA, 1989, BRIT J PHARMACOL, V97, P657, DOI 10.1111/j.1476-5381.1989.tb12001.x; BUNTING S, 1983, BR MED B, V39, P371; CAMPBELL WB, 1996, PHARMACOL BASIS THER, P601; DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.immunol.2.1.335; DEJANA E, 1979, THROMB RES, V15, P191, DOI 10.1016/0049-3848(79)90064-1; DOHERTY NS, 1987, BRIT J PHARMACOL, V91, P39, DOI 10.1111/j.1476-5381.1987.tb08981.x; FERREIRA SH, 1981, TRENDS PHARMACOL SCI, V2, P183, DOI 10.1016/0165-6147(81)90306-0; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KOSTER R, 1959, FED PROC, V18, P412; KURZ KD, 1990, THROMB RES, V60, P269, DOI 10.1016/0049-3848(90)90106-M; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MILLAN MJ, 1991, J PHARMACOL EXP THER, V256, P983; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MURATA T, 1989, ARZNEIMITTEL-FORSCH, V39-2, P867; NAMBA T, 1994, J BIOL CHEM, V269, P9986; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; OKA T, 1993, BRAIN RES, V624, P61, DOI 10.1016/0006-8993(93)90060-Z; PIERCEY MF, 1981, EUR J PHARMACOL, V74, P135, DOI 10.1016/0014-2999(81)90523-9; RITTER JM, 1987, BRIT J PHARMACOL, V92, P857, DOI 10.1111/j.1476-5381.1987.tb11391.x; UENO A, 1995, EUR J PHARMACOL, V284, P211, DOI 10.1016/0014-2999(95)00439-R; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; UTSUNOMIYA I, 1994, EUR J PHARMACOL, V252, P213, DOI 10.1016/0014-2999(94)90599-1; VADAS P, 1981, NATURE, V293, P583, DOI 10.1038/293583a0; VANE JR, 1990, NEW ENGL J MED, V323, P27; WINTER CA, 1965, J PHARMACOL EXP THER, V150, P165	26	611	660	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					678	682		10.1038/41780	http://dx.doi.org/10.1038/41780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262402	Bronze			2022-12-28	WOS:A1997XQ86300050
J	Bjorntorp, P				Bjorntorp, P			Obesity	LANCET			English	Editorial Material							CHILDHOOD OBESITY; WEIGHT-LOSS; WOMEN; FAT				Bjorntorp, P (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT HEART & LUNG DIS,S-41345 GOTHENBURG,SWEDEN.							Bjorntorp P, 1993, Obes Res, V1, P206; BLACK DR, 1989, ADDICT BEHAV, V14, P279, DOI 10.1016/0306-4603(89)90059-2; BOUCHARD C, 1988, INT J OBESITY, V12, P205; Carlsson B, 1997, OBES RES, V5, P30, DOI 10.1002/j.1550-8528.1997.tb00280.x; CHADWICK DJ, 1996, ORRIGINS CONSEQUENCE; DESPRES JP, 1993, NUTR RES REV, V6, P1; DIETZ WH, 1993, HORM RES, V39, P86, DOI 10.1159/000182791; DIETZ WH, 1986, PEDIATR CLIN N AM, V33, P823; EPSTEIN LH, 1990, JAMA-J AM MED ASSOC, V264, P2519, DOI 10.1001/jama.264.19.2519; Guillaume M, 1996, AM J EPIDEMIOL, V144, P867, DOI 10.1093/oxfordjournals.aje.a009021; HAFFNER S, 1990, DIABETES, V39, P282; KRAL JG, 1992, OBESITY, P731; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; LUNDGREN H, 1989, INT J OBESITY, V13, P413; SEIDELL JC, 1994, PHARMACOECONOMICS, V5, P38, DOI 10.2165/00019053-199400051-00008; Skender ML, 1996, J AM DIET ASSOC, V96, P342, DOI 10.1016/S0002-8223(96)00096-X; SOBAL J, 1989, PSYCHOL BULL, V105, P260, DOI 10.1037/0033-2909.105.2.260; STUBBS RJ, 1995, AM J CLIN NUTR, V62, P316; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WHO, 1997, PREV MAN GLOB EP OB; *WHO REG OFF EUR, 1988, 125 EUR ICP WHO NUT; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; WING RR, 1979, INT J OBESITY, V3, P261; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232	25	225	233	2	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					423	426		10.1016/S0140-6736(97)04503-0	http://dx.doi.org/10.1016/S0140-6736(97)04503-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259667				2022-12-28	WOS:A1997XQ24800043
J	Price, H				Price, H			Deaths from venous thromboembolism associated with combined oral contraceptives	LANCET			English	Letter											Price, H (corresponding author), HM CORONER,EASTERN DIST GREATER LONDON,CORONERS COURT,LONDON E17 8QP,ENGLAND.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					450	450		10.1016/S0140-6736(05)64187-6	http://dx.doi.org/10.1016/S0140-6736(05)64187-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9289596				2022-12-28	WOS:A1997XQ24800074
J	Scherzinger, E; Lurz, R; Turmaine, M; Mangiarini, L; Hollenbach, B; Hasenbank, R; Bates, GP; Davies, SW; Lehrach, H; Wanker, EE				Scherzinger, E; Lurz, R; Turmaine, M; Mangiarini, L; Hollenbach, B; Hasenbank, R; Bates, GP; Davies, SW; Lehrach, H; Wanker, EE			Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo	CELL			English	Article							GLUTATHIONE-S-TRANSFERASE; NEURODEGENERATIVE DISEASES; GLUTAMINE REPEATS; LOCALIZATION; BRAIN; PRODUCT; SCRAPIE; EPITOPE	The mechanism by which an elongated polyglutamine sequence causes neurodegeneration in Huntington's disease (HD) is unknown. In this study, we show that the proteolytic cleavage of a GST-huntingtin fusion protein leads to the formation of insoluble high molecular weight protein aggregates only when the polyglutamine expansion is in the pathogenic range. Electron micrographs of these aggregates revealed a fibrillar or ribbon-like morphology, reminiscent of scrapie prions and beta-amyloid fibrils in Alzheimer's disease. Subcellular fractionation and ultrastructural techniques showed the in vivo presence of these structures in the brains of mice transgenic for the HD mutation. Our in vitro model will aid in an eventual understanding of the molecular pathology of HD and the development of preventative strategies.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,GUYS HOSP,DIV MED & MOL GENET,LONDON SE1 7EH,ENGLAND; MAX PLANCK INST MOL GENET,D-14195 BERLIN,DAHLEM,GERMANY; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Max Planck Society; University of London; University College London			Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305; Wanker, Erich/0000-0001-8072-1630				[Anonymous], ADV NEUROL; BATES GP, 1997, IN PRESS HUM MOL GEN; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CAPUTO CB, 1992, ARCH BIOCHEM BIOPHYS, V292, P199, DOI 10.1016/0003-9861(92)90068-8; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Harper PS, 1991, HUNTINGTONS DIS; HOOGEVEEN AT, 1993, HUM MOL GENET, V2, P2069, DOI 10.1093/hmg/2.12.2069; *HUNT DIS COLL RES, 1993, CELL, V72, P971; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; KALCHMAN MA, 1997, NAT GENET, V16, P4; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Onodera O, 1996, FEBS LETT, V399, P135, DOI 10.1016/S0014-5793(96)01301-4; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; ROOS RAC, 1983, J NEUROL SCI, V61, P37, DOI 10.1016/0022-510X(83)90053-9; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Sathasivam K, 1997, HUM GENET, V99, P692, DOI 10.1007/s004390050432; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TELLEZNAGEL I, 1974, J NEUROCYTOL, V3, P308; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487	41	1038	1076	1	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					549	558		10.1016/S0092-8674(00)80514-0	http://dx.doi.org/10.1016/S0092-8674(00)80514-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267034	Bronze			2022-12-28	WOS:A1997XQ06300018
J	Watson, JP; Davies, T				Watson, JP; Davies, T			ABC of mental health: Psychosexual problems	BRITISH MEDICAL JOURNAL			English	Review																		DAWSON C, 1996, ABC UROLOGY; GREGOIRE A, 1993, IMPOTENCE INTEGRATED; Spence S. H., 1991, PSYCHOSEXUAL THERAPY; Wellings K, 1994, SEXUAL BEHAV BRITAIN	4	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					239	242		10.1136/bmj.315.7102.239	http://dx.doi.org/10.1136/bmj.315.7102.239			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	9253274	Green Published			2022-12-28	WOS:A1997XN51700030
J	Siegel, M; Carol, J; Jordan, J; Hobart, R; Schoenmarklin, S; DuMelle, F; Fisher, P				Siegel, M; Carol, J; Jordan, J; Hobart, R; Schoenmarklin, S; DuMelle, F; Fisher, P			Preemption in tobacco control - Review of an emerging public health problem	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; INDUSTRY STRATEGIES; UNITED-STATES; CALIFORNIA; POLITICS; LEGISLATION; REGULATIONS; CONSUMPTION; BEHAVIOR; POLICY	Objective.-To describe the nature, extent, and public health significance of state legislation that preempts the local regulation of tobacco. Data Sources.-A computerized database of local tobacco control ordinances, state tobacco control laws, preemption bills introduced during the 1996 state legislative session, articles obtained through a MEDLINE search (1984-1996) using the key word ''preemption'' or identified from bibliographies of these articles, public opinion surveys, and newspaper articles. Study Selection.-All identified data sources were used. Data Extraction.-Content analyses of preemption bills and state laws were conducted independently by multiple observers. Data Synthesis.-There has been a striking increase in the adoption of local tobacco control ordinances during the past decade; by the end of 1995, approximately 1006 communities had enacted a local tobacco control ordinance. In response, the tobacco industry has advanced legislation in 29 states that preempts local authority to regulate tobacco. During the 1996 state legislative session alone, 26 bills containing preemption were introduced, and 2 were enacted. Emerging trends in the tobacco industry's strategy to advance preemption laws include (1) amending legitimate tobacco control bills to preempt local tobacco regulation, (2) using the Synar amendment as a vehicle to advance preemption, and (3) promoting ''superpreemption'' bills that eliminate all local control of tobacco policy. Conclusions.-Preemption of local tobacco regulation is an important tobacco industry strategy that undermines the public's health. Preventing the enactment of new preemption laws and repealing existing ones should become a public health priority.	AMER NONSMOKERS RIGHTS, BERKELEY, CA USA; AMER CANC SOC, ASSIST PROJECT, ATLANTA, GA 30329 USA; AMER CANC SOC, TOBACCO CONTROL ADVOCACY PROGRAM, MILWAUKEE, WI USA; AMER LUNG ASSOC, WASHINGTON, DC USA; NATL CTR TOBACCO FREE KIDS, WASHINGTON, DC USA	American Cancer Society; American Cancer Society	Siegel, M (corresponding author), BOSTON UNIV, SCH PUBL HLTH, DEPT SOCIAL & BEHAV SCI, 85 E NEWTON ST, ROOM 840, BOSTON, MA 02118 USA.			Siegel, Michael/0000-0002-2573-9616				AGUINAGA S, 1995, UNDERMINING POPULAR; *AM CANC SOC, 1993, SURV AM VOT ATT CIG; *AM CANC SOC, 1996, ACT SPEAK LOUD WORDS; Arno PS, 1996, JAMA-J AM MED ASSOC, V275, P1258, DOI 10.1001/jama.275.16.1258; BABCOCK CR, 1997, WASHINGTON POST 0217, pA23; Bearman N S, 1995, N C Med J, V56, P14; BEGAY ME, 1993, AM J PUBLIC HEALTH, V83, P1214, DOI 10.2105/AJPH.83.9.1214; BIENER L, 1989, AM J PUBLIC HEALTH, V79, P192, DOI 10.2105/AJPH.79.2.192; BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; BROKAW J, 1996, MOTHER JONES, V21, P56; CALIFANO JA, 1994, JAMA-J AM MED ASSOC, V272, P1217; CHALOUPKA F, 1991, J POLIT ECON, V99, P722, DOI 10.1086/261776; CHALOUPKA F, 1992, APPL ECON, V24, P193, DOI 10.1080/00036849200000118; Chaloupka FJ., 1996, PRICE TOBACCO CONTRO; CHRISTOFFEL T, 1982, HLTH LAW; *COAL RESP TOB RET, 1996, CORR NOT RET WHOL; CONLISK E, 1995, JAMA-J AM MED ASSOC, V273, P805, DOI 10.1001/jama.273.10.805; Davis RM, 1996, JAMA-J AM MED ASSOC, V275, P1281, DOI 10.1001/jama.275.16.1281; Ellis GA, 1996, J PUBLIC HEALTH POL, V17, P28, DOI 10.2307/3342656; FEDER BJ, 1996, NY TIMES        0315, pA1; FEDER BJ, 1996, NY TIMES        0315, pA9; Fielding JE, 1996, AM J PUBLIC HEALTH, V86, P1073, DOI 10.2105/AJPH.86.8_Pt_1.1073; *FOOD MARK I, 1994, STAT STAT AN CURR ST; FREYMAN R, 1995, GOVERNING, V9, P55; GELLENE D, 1995, LOS ANGELES TIM 1220, pD7; GLANTZ SA, 1994, JAMA-J AM MED ASSOC, V272, P1176, DOI 10.1001/jama.272.15.1176; Goldstein AO, 1996, AM J PUBLIC HEALTH, V86, P1137, DOI 10.2105/AJPH.86.8_Pt_1.1137; HART MA, 1996, PHILADELPHIA IN 0520, pA10; JACOBSON PD, 1993, J HEALTH POLIT POLIC, V18, P787; JORDAN J, 1994, PREEMPTION TOBACCO C; LEE G, 1991, WASHINGTON POST 0909, pA7; Longo DR, 1996, JAMA-J AM MED ASSOC, V275, P1252, DOI 10.1001/jama.275.16.1252; MACDONALD H, 1994, ANAL SMOKING TOBACCO; MACDONALD H, 1994, CALIFORNIAS PROPOSIT; MACDONALD H, IN PRESS AM J PUBLIC; Macdonald H R, 1997, Tob Control, V6, P41; MARCUS B H, 1992, Journal of Public Health Policy, V13, P42, DOI 10.2307/3343057; *MASS DEP PUBL HLT, 1996, MASS TOB CONTR PROGR; *MINN COAL RESP RE, 1996, MINN COAL RESP RET S; MONARDI F, 1996, TOBACCO IND POLITICA; MOORE S, 1994, JAMA-J AM MED ASSOC, V272, P1171, DOI 10.1001/jama.272.15.1171; *OP RES CORP, 1996, PUBL SUPP LOC CONTR; Pierce JP, 1994, TOB CONTROL, V3, P15, DOI DOI 10.1136/TC.3.1.15; Rosen George, 1958, HIST PUBLIC HLTH; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; SKOLNICK AA, 1995, JAMA-J AM MED ASSOC, V274, P199, DOI 10.1001/jama.1995.03530030021007; SORENSEN G, 1991, AM J PUBLIC HEALTH, V81, P202; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; SYLVESTER K, 1989, GOVERNING, V3, P34; TERET SP, 1993, AM J PREV MED, V9, P44, DOI 10.1016/S0749-3797(18)30678-0; TODD JS, 1995, JAMA-J AM MED ASSOC, V274, P256, DOI 10.1001/jama.274.3.256; TRAYNOR MP, 1993, JAMA-J AM MED ASSOC, V270, P479, DOI 10.1001/jama.270.4.479; *US DEP HHS, 1996, CDC PUBL; *US DEP HHS, 1996, HLTH PEOPL 2000 MIDC; *US DEP HHS, 1993, SMOK TOB CONTR MON, V3; *US DEP HHS, 1996, FED REG         0119, P61; WASSERMAN J, 1991, J HEALTH ECON, V10, P43, DOI 10.1016/0167-6296(91)90016-G; WOODRUFF TJ, 1993, ARCH INTERN MED, V153, P1485, DOI 10.1001/archinte.153.12.1485; WRIGHT JR, 1990, AM POLIT SCI REV, V84, P417, DOI 10.2307/1963527	59	59	59	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					858	863		10.1001/jama.278.10.858	http://dx.doi.org/10.1001/jama.278.10.858			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU552	9293996				2022-12-28	WOS:A1997XU55200043
J	Hamdy, S; Aziz, Q; Rothwell, JC; Crone, R; Hughes, D; Tallis, RC; Thompson, DG				Hamdy, S; Aziz, Q; Rothwell, JC; Crone, R; Hughes, D; Tallis, RC; Thompson, DG			Explaining oropharyngeal dysphagia after unilateral hemispheric stroke	LANCET			English	Article							HUMAN MOTOR CORTEX; NATURAL-HISTORY; CEREBROVASCULAR-DISEASE; MAGNETIC STIMULATION; CEREBRAL-CORTEX; CONSEQUENCES	Background Oropharyngeal dysphagia occurs in up to a third of patients presenting with a unilateral hemiplegic stroke, yet its neurophysiological basis remains unknown. To explore the relation between cortical motor function of swallowing and oropharyngeal dysphagia, mylohyoid, pharyngeal, and thenar electromyographic responses to stimulation of affected and unaffected hemispheres were recorded in dysphagic and non-dysphagic patients. Methods The 20 patients studied had unilateral hemispheric stroke confirmed by computed tomography. Eight of them had associated swallowing difficulties. Electromyographic responses were recorded after suprathreshold transcranial magneto-electric stimulation of affected and unaffected hemispheres with a figure-of-eight coil. Findings Stimulation of the unaffected hemisphere evoked smaller pharyngeal responses in dysphagic patients than in non-dysphagic patients (mean 64 mu V, median 48, interquartile range 44-86 vs 118 mu V, 81, 73-150) (p<0.02). With stimulation of the affected hemisphere, the pharyngeal responses were smaller than for the unaffected hemisphere but similar between the two patient groups (26 mu V, 0, 0-48 vs 54 mu V, 0, 0-80). Dysphagic and non-dysphagic patients showed similar mylohyoid and thenar responses to stimulation of the unaffected hemisphere as well as to stimulation of the affected hemisphere-unaffected mylohyoid (269 mu V, 239, 89-372 vs 239 mu V, 163, 133-307), thenar (572 mu V, 463, 175-638 vs 638 mu V, 485, 381-764); affected mylohyoid (60 mu V, 41, 0-129 vs 96 uV, 0, 0-195); thenar (259 mu V, 258, 0-538 vs 451 mu V, 206, 8-717). Interpretation The findings indicate that dysphagia after unilateral hemispheric stroke is related to the magnitude of pharyngeal motor representation in the unaffected hemisphere.	UNIV MANCHESTER,HOPE HOSP,DEPT GERIATR,SALFORD M6 8HD,LANCS,ENGLAND; UNIV MANCHESTER,HOPE HOSP,DEPT NEURORADIOL,SALFORD M6 8HD,LANCS,ENGLAND; UNIV MANCHESTER,HOPE HOSP,DEPT GASTROENTEROL,SALFORD M6 8HD,LANCS,ENGLAND; INST NEUROL,MRC,HUMAN MOVEMENT & BALANCE UNIT,LONDON WC1N 3BG,ENGLAND	University of Manchester; University of Manchester; University of Manchester; University of London; University College London			Hamdy, Shaheen/O-5039-2014; Aziz, Qasim/AAC-4730-2020	Hamdy, Shaheen/0000-0001-9640-7427; Rothwell, John/0000-0003-1367-6467; Aziz, Qasim/0000-0002-2718-2065				ALBERTS M J, 1992, Dysphagia, V7, P170, DOI 10.1007/BF02493452; Aziz Q, 1996, GASTROENTEROLOGY, V111, P855, DOI 10.1016/S0016-5085(96)70053-7; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BARER DH, 1989, J NEUROL NEUROSUR PS, V52, P236, DOI 10.1136/jnnp.52.2.236; BARKER AT, 1985, LANCET, V1, P1106; BRIDGERS SL, 1991, ELECTROEN CLIN NEURO, V43, P170; CHEN MYM, 1990, RADIOLOGY, V176, P641, DOI 10.1148/radiology.176.3.2389021; GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; Hamdy S, 1996, NAT MED, V2, P1217, DOI 10.1038/nm1196-1217; HEALD A, 1993, BRAIN, V116, P1355, DOI 10.1093/brain/116.6.1355; JALINOUS R, 1991, J CLIN NEUROPHYSIOL, V8, P10, DOI 10.1097/00004691-199101000-00004; JOHNSON ER, 1992, ARCH PHYS MED REHAB, V73, P419; KANDLER RH, 1991, CEREBROVASC DIS, V1, P239, DOI 10.1159/000108850; KIDD D, 1995, QJM-MON J ASSOC PHYS, V88, P409; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; LEE ET, 1980, STATISTICAL METHODS; Logemann JA, 1983, EVALUATION TREATMENT; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin Ruth E., 1993, Dysphagia, V8, P195, DOI 10.1007/BF01354538; MEADOWS JC, 1973, J NEUROL NEUROSUR PS, V36, P853, DOI 10.1136/jnnp.36.5.853; *MED RES COUNC, 1976, AIDS EX PER NERV SYS, P6; MILLER AJ, 1982, PHYSIOL REV, V62, P129, DOI 10.1152/physrev.1982.62.1.129; MILLS KR, 1992, ELECTROEN CLIN NEURO, V85, P17, DOI 10.1016/0168-5597(92)90096-T; Robbins J, 1988, Dysphagia, V3, P11, DOI 10.1007/BF02406275; ROBBINS JA, 1993, ARCH PHYS MED REHAB, V74, P1295, DOI 10.1016/0003-9993(93)90082-L; SEIGEL S, 1956, NONPARAMETRIC STAT; STARKSTEIN SE, 1988, BRAIN LANG, V34, P253, DOI 10.1016/0093-934X(88)90137-X; SUMI T, 1969, BRAIN RES, V15, P107, DOI 10.1016/0006-8993(69)90313-8; VEIS SL, 1985, ARCH PHYS MED REHAB, V66, P372; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R	30	185	206	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					686	692		10.1016/S0140-6736(97)02068-0	http://dx.doi.org/10.1016/S0140-6736(97)02068-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291902				2022-12-28	WOS:A1997XU97700008
J	Neuwirth, ZE				Neuwirth, ZE			Physician empathy - should we care?	LANCET			English	Editorial Material							SKILLS				Neuwirth, ZE (corresponding author), LENOX HILL HOSP,DEPT INTERNAL MED,NEW YORK,NY 10021, USA.							Balint M., 1957, DOCTOR; BARSKY AJ, 1981, ANN INTERN MED, V94, P492, DOI 10.7326/0003-4819-94-4-492; BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; FALVO D, 1988, J FAM PRACTICE, V26, P643; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678	9	33	34	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					606	606		10.1016/S0140-6736(05)63323-5	http://dx.doi.org/10.1016/S0140-6736(05)63323-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288041				2022-12-28	WOS:A1997XU28300006
J	Joyce, T; Henshaw, SK; Skatrud, JD				Joyce, T; Henshaw, SK; Skatrud, JD			The impact of Mississippi's mandatory delay law on abortions and births	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Beginning August 8, 1992, a woman in the state of Mississippi had to wait 24 hours after in-person receipt of state-mandated information regarding abortion and birth complications, fetal development, and alternatives to abortion before an abortion could be performed. Objective.-To analyze the effect of the law on the abortion and birth rates of Mississippi residents. Design.-A retrospective analysis of abortion and birth rates before and after the law in Mississippi as contrasted with abortion and birth rates in 2 comparison states, Georgia and South Carolina. Neither Georgia nor South Carolina enforced a mandatory delay law, but both states began enforcement of parental notification statutes during the study period, Patients.-Female residents of reproductive age in Mississippi, Georgia, and South Carolina between 1989 and 1994. Main Outcome Measures.-We compared birth rates, abortion rates, the per centage of late abortions, and the percentage of abortions performed outside the state of residence for all women and then by age and race before and after August 1992 among women of Mississippi, Georgia, and South Carolina. Results.-We found that rate ratios (RRs) of resident abortion rates (rate after law implementation/rate before law implementation) declined 12% more in Mississippi than in South Carolina (95% confidence interval [CI], 8%-15%) and 14% more in Mississippi than in Georgia (95% CI, 10%-17%) in the 12 months after the law went into effect, Rate ratios for white adults declined 22% more in Mississippi than in South Carolina (95% CI, 17%-27%) and 20% more in Mississippi than in Georgia (95% CI, 15%-25%). Changes among nonwhite adults and white teens were more modest but also statistically significant (P<.05). For all women, RRs of the percentage of abortions performed after 12 weeks' gestation increased 39% more in Mississippi than in either South Carolina or Georgia (P<.05); the increase in the percentage of abortions after 12 weeks' gestation was observed for white and nonwhite adults (P<.05). We also show that the percentage of abortions performed out of state increased 42% more among women in Mississippi relative to women in South Carolina after the law (95% CI, 34%-50%). Conclusion.-The timing of the decline in abortion rates in Mississippi, the lack of similar declines in comparison states, the rise in percentage of late abortions and abortions performed out of state and the apparent completeness of abortion reports suggest that Mississippi's mandatory delay statute was responsible for a decline in abortion rates and an increase in abortions performed later in pregnancy among residents of Mississippi, The effect of delay laws in other states will likely depend on whether statutes require 2 separate visits to the abortion provider tie, clinics, hospitals, or physicians' offices where abortions are performed) and the availability of abortion services.	CUNY BERNARD M BARUCH COLL,NEW YORK,NY 10010; ALAN GUTTMACHER INST,NEW YORK,NY 10005; UNIV N CAROLINA,CHAPEL HILL,NC 27515	City University of New York (CUNY) System; Baruch College (CUNY); University of North Carolina; University of North Carolina Chapel Hill	Joyce, T (corresponding author), NATL BUR ECON RES,50 E 42ND ST,17TH FLOOR,NEW YORK,NY 10017, USA.							ALTHAUS FA, 1994, FAM PLANN PERSPECT, V26, P228, DOI 10.2307/2135944; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; *BUR HLTH SERV ADM, 1996, 1992 IND TERM; CATES W, 1981, JAMA-J AM MED ASSOC, V246, P1109; DEARDORFF KE, 1995, PUBLICATION US BUREA; *DEP VIT REC MI DE, 1996, 1992 IND TERM; HENSHAW SK, 1994, FAM PLANN PERSPECT, V26, P100, DOI 10.2307/2136033; HENSHAW SK, 1995, FAM PLANN PERSPECT, V27, P120, DOI 10.2307/2136110; Joyce T, 1996, J HEALTH ECON, V15, P579, DOI 10.1016/S0167-6296(96)00496-1; *NAT AB REPR RIGHT, 1997, WHO DEC STAT STAT RE; Rothman K, 1986, MODERN EPIDEMIOLOGY; SELIK RM, 1981, AM J PUBLIC HEALTH, V71, P77, DOI 10.2105/AJPH.71.1.77; *STAT SERV BRANCH, 1996, 1992 IND TERM; US Bureau of the Census, 1995, STAT ABSTR US; US Census Bureau, 1994, STAT ABSTR US	15	42	42	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					653	658		10.1001/jama.278.8.653	http://dx.doi.org/10.1001/jama.278.8.653			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272897				2022-12-28	WOS:A1997XR54700038
J	Deconinck, AE; Rafael, JA; Skinner, JA; Brown, SC; Potter, AC; Metzinger, L; Watt, DJ; Dickson, JG; Tinsley, JM; Davies, KE				Deconinck, AE; Rafael, JA; Skinner, JA; Brown, SC; Potter, AC; Metzinger, L; Watt, DJ; Dickson, JG; Tinsley, JM; Davies, KE			Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy	CELL			English	Article							SKELETAL-MUSCLE FIBERS; MDX MOUSE; NEUROMUSCULAR-JUNCTION; ACETYLCHOLINE-RECEPTOR; PROTEIN; EXPRESSION; LOCALIZATION; ISOFORMS; MUTATION; BINDING	The absence of dystrophin at the muscle membrane leads to Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease that is inevitably fatal in early adulthood. In contrast, dystrophin-deficient mdx mice appear physically normal despite their underlying muscle pathology. We describe mice deficient for both dystrophin and the dystrophin-related protein utrophin. These mice show many signs typical of DMD in humans: they show severe progressive muscular dystrophy that results in premature death, they have ultrastructural neuromuscular and myotendinous junction abnormalities, and they aberrantly coexpress myosin heavy chain isoforms within a fiber. The data suggest that utrophin and dystrophin have complementing roles in normal functional or developmental pathways in muscle. Detailed study of these mice should provide novel insights into the pathogenesis of DMD and provide an improved model for rapid evaluation of gene therapy strategies.	UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND; UNIV LONDON,SCH BIOL SCI,SURREY TW20 0EX,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND	University of Oxford; University of London; Royal Holloway University London; Imperial College London			metzinger, laurent/AAY-4634-2021; Metzinger, Laurent/B-1426-2016; Rafael-Fortney, Jill/E-3909-2011	metzinger, laurent/0000-0002-7636-8480; Metzinger, Laurent/0000-0002-7636-8480; Brown, Sue/0000-0001-8112-933X				Amalfitano A, 1996, MUSCLE NERVE, V19, P1549, DOI 10.1002/(SICI)1097-4598(199612)19:12<1549::AID-MUS4>3.0.CO;2-A; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHO M, 1993, J CELL BIOL, V121, P795, DOI 10.1083/jcb.121.4.795; CLERK A, 1993, HISTOCHEM J, V25, P554; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; CULLEN MJ, 1988, ACTA NEUROPATHOL, V77, P69, DOI 10.1007/BF00688245; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; JERUSALEM F, 1974, BRAIN, V97, P123, DOI 10.1093/brain/97.1.123; JOLESZ F, 1981, ANNU REV PHYSIOL, V43, P531, DOI 10.1146/annurev.ph.43.030181.002531; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; LAW DJ, 1994, J CELL SCI, V107, P1477; LAW DJ, 1995, MUSCLE NERVE, V18, P216, DOI 10.1002/mus.880180211; LYONS PR, 1991, J NEUROCYTOL, V20, P969, DOI 10.1007/BF01187915; Marini J F, 1991, Neuromuscul Disord, V1, P397, DOI 10.1016/0960-8966(91)90003-B; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; NAGEL A, 1990, MUSCLE NERVE, V13, P742, DOI 10.1002/mus.880130813; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; PONS F, 1994, J NEUROL SCI, V122, P162, DOI 10.1016/0022-510X(94)90295-X; Prakash YS, 1996, J NEUROCYTOL, V25, P88, DOI 10.1007/BF02284788; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHIAFFINO S, 1994, J APPL PHYSIOL, V77, P493, DOI 10.1152/jappl.1994.77.2.493; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SEWRY CA, 1994, NEUROMUSCULAR DISORD, V4, P401, DOI 10.1016/0960-8966(94)90079-5; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Vincent A, 1997, TRENDS NEUROSCI, V20, P15, DOI 10.1016/S0166-2236(96)10066-7; WINDER SJ, 1995, J CELL SCI, V108, P63; YELLIN H, 1967, EXP NEUROL, V19, P92, DOI 10.1016/0014-4886(67)90009-X; [No title captured]	45	574	597	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					717	727		10.1016/S0092-8674(00)80532-2	http://dx.doi.org/10.1016/S0092-8674(00)80532-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288751	Bronze			2022-12-28	WOS:A1997XT06600015
J	Macdonald, AJD				Macdonald, AJD			ABC of mental health - Mental health in old age	BRITISH MEDICAL JOURNAL			English	Article											Macdonald, AJD (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,LONDON SE1 9RT,ENGLAND.							*BRIT MED ASS, 1995, ADV STAT MED TREATM; British Medical Association, 1995, ASS MENT CAP GUID DO; BURNS A, 1996, PSYCHIAT B, V20, P107	3	30	30	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					413	417		10.1136/bmj.315.7105.413	http://dx.doi.org/10.1136/bmj.315.7105.413			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR549	9277609	Green Published			2022-12-28	WOS:A1997XR54900026
J	Sahai, J; Gallicano, K; Swick, L; Tailor, S; Garber, G; Seguin, I; Oliveras, L; Walker, S; Rachlis, A; Cameron, DW				Sahai, J; Gallicano, K; Swick, L; Tailor, S; Garber, G; Seguin, I; Oliveras, L; Walker, S; Rachlis, A; Cameron, DW			Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT TUBERCULOSIS; MALABSORPTION; MEDICATIONS	Background: Reports suggest that antituberculosis drugs are malabsorbed in patients with advanced HIV disease, Objective: To evaluate the pharmacokinetics of antituberculosis agents in HIV-seropositive patients at different stages of disease, Design: Parallel study. Setting: Two hospital outpatient clinics. Participants: 12 healthy volunteers, 12 patients with asymptomatic HIV disease, 12 patients with symptomatic HIV disease, and 12 patients with symptomatic HIV disease and diarrhea. Measurements: Drug plasma concentrations were measured over 24 hours on day 4 of concurrent therapy. Intervention: Oral isoniazid (300 mg/d), rifampin (600 mg/d), pyrazinamide (1000 mg/d), and ethambutol (1000 mg/d). Results: Reduced total drug exposure to rifampin and pyrazinamide was associated with D-xylose malabsorption in persons with HIV infection or AIDS. Peak drug exposure to isoniazid was lower in patients with diarrhea. Conclusions: Reduced total drug exposure may be related to malabsorption in persons with HIV infection or AIDS.	UNIV OTTAWA, CLIN INVEST UNIT, OTTAWA GEN HOSP, OTTAWA, ON K1H 8L6, CANADA; HLTH CANADA, OTTAWA, ON K1A 0L2, CANADA; SUNNYBROOK HLTH SCI CTR, DEPT PHARM, TORONTO, ON M4N 3M5, CANADA; UNIV OTTAWA, DIV INFECT DIS, OTTAWA GEN HOSP, OTTAWA, ON K1H 8L6, CANADA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA GEN HOSP, OTTAWA, ON K1H 8L6, CANADA	University of Ottawa; Ottawa Hospital Research Institute; Health Canada; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute			Cameron, Bill/E-9180-2010	Cameron, Bill/0000-0002-0090-3539				ALFORD RH, 1995, PRINCIPLES PRACTICE, P389; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Barakat MT, 1996, BRIT MED J, V313, P1543; BERNING SE, 1992, NEW ENGL J MED, V327, P1817, DOI 10.1056/NEJM199212173272514; Bradford WZ, 1996, LANCET, V348, P928, DOI 10.1016/S0140-6736(96)03027-9; BROUARD A, 1985, J CHROMATOGR, V345, P453, DOI 10.1016/0378-4347(85)80188-2; DOWDY S, 1991, STATISTICS RES; Drobniewski F, 1997, LANCET, V349, P71, DOI 10.1016/S0140-6736(05)60878-1; EHRENPREIS ED, 1991, CLIN PHARMACOL THER, V49, P632, DOI 10.1038/clpt.1991.80; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GALLICANO K, 1994, ANTIMICROB AGENTS CH, V38, P894, DOI 10.1128/AAC.38.4.894; HUTCHINGS A, 1986, BRIT J CLIN PHARMACO, V22, P343, DOI 10.1111/j.1365-2125.1986.tb02897.x; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; Lambl BB, 1996, AIDS, V10, P739, DOI 10.1097/00002030-199606001-00007; OBINNA FC, 1995, AIDS, V9, P1009, DOI 10.1097/00002030-199509000-00005; PATEL KB, 1995, NEW ENGL J MED, V332, P336, DOI 10.1056/NEJM199502023320518; Peloquin CA, 1996, ANN PHARMACOTHER, V30, P919, DOI 10.1177/106002809603000901; PELOQUIN CA, 1993, NEW ENGL J MED, V329, P1122, DOI 10.1056/NEJM199310073291513; SVED S, 1977, J PHARM SCI, V66, P1761, DOI 10.1002/jps.2600661228; SWART KJ, 1992, J CHROMATOGR, V593, P21, DOI 10.1016/0021-9673(92)80260-2	20	129	132	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					289	293		10.7326/0003-4819-127-4-199708150-00006	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265429				2022-12-28	WOS:A1997XR26600008
J	Kendrick, KM; GuevaraGuzman, R; Zorrilla, J; Hinton, MR; Broad, KD; Mimmack, M; Ohkura, S				Kendrick, KM; GuevaraGuzman, R; Zorrilla, J; Hinton, MR; Broad, KD; Mimmack, M; Ohkura, S			Formation of olfactory memories mediated by nitric oxide	NATURE			English	Article							LONG-TERM POTENTIATION; ASPARTATE RECEPTOR ANTAGONIST; SOLUBLE GUANYLYL CYCLASE; SYNTHASE MESSENGER-RNA; SELECTIVE IMPAIRMENT; CARBON-MONOXIDE; RAT-BRAIN; HIPPOCAMPUS; INHIBITION; SYSTEM	Sheep learn to recognize the odours of their lambs within two hours of giving birth, and this learning involves synaptic changes within the olfactory bulb(1,2). Specifically, mitral cells become increasingly responsive to the learned odour, which stimulates release of both glutamate and GABA (gamma-aminobutyric acid) neurotransmitters from the reciprocal synapses between the excitatory mitral cells and inhibitory granule cells(1). Nitric oxide (NO) has been implicated in synaptic plasticity in other regions of the brain as a result of its modulation of cyclic GMP levels(3-7). Here we investigate the possible role of NO in olfactory learning. We find that the neuronal enzyme nitric oxide synthase (nNOS) is expressed in both mitral and granule cells, whereas the guanylyl cyclase subunits that are required for NO stimulation of cGMP formation(8) are expressed only in mitral cells. Immediately after birth, glutamate levels rise, inducing formation of NO and cGMP, which potentiate glutamate release at the mitral-to-granule cell synapses. Inhibition of nNOS or guanylyl cyclase activity prevents both the potentiation of glutamate release and formation of the olfactory memory. The effects of nNOS inhibition can be reversed by infusion of NO into the olfactory bulb, Once memory has formed, however, inhibition of nNOS or guanylyl cyclase activity cannot impair either its recall or the neurochemical release evoked by the learned lamb odour. Nitric oxide therefore seems to act as a retrograde and/or intracellular messenger, being released from both mitral and granule cells to potentiate glutamate release from mitral cells by modulating cGMP concentrations. We propose that the resulting changes in the functional circuitry of the olfactory bulb underlie the formation of olfactory memories.			Kendrick, KM (corresponding author), BABRAHAM INST,DEPT NEUROBIOL,CAMBRIDGE CB2 4AT,ENGLAND.		Guevara-Guzman, Rosalinda/GXV-2779-2022	Kendrick, Keith/0000-0002-0371-5904				Arancio O, 1996, CELL, V87, P1025, DOI 10.1016/S0092-8674(00)81797-3; BANNERMAN DM, 1994, J NEUROSCI, V14, P7404; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON CL, 1995, NEUROSCIENCE, V69, P699, DOI 10.1016/0306-4522(95)00349-N; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENNAN PA, 1989, NEUROSCIENCE, V33, P463, DOI 10.1016/0306-4522(89)90398-9; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DOZE VA, 1991, NEURON, V6, P889, DOI 10.1016/0896-6273(91)90229-S; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; FURUYAMA T, 1993, MOL BRAIN RES, V20, P335, DOI 10.1016/0169-328X(93)90060-3; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766; Kendrick KM, 1996, EUR J NEUROSCI, V8, P2619, DOI 10.1111/j.1460-9568.1996.tb01557.x; KENDRICK KM, 1994, BEHAV PROCESS, V33, P89, DOI 10.1016/0376-6357(94)90061-2; KISHIMOTO J, 1993, EUR J NEUROSCI, V5, P1684, DOI 10.1111/j.1460-9568.1993.tb00236.x; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; LEVY F, 1990, BEHAV NEUROSCI, V104, P464, DOI 10.1037/0735-7044.104.3.464; LEVY F, 1995, PHYSIOL BEHAV, V57, P97, DOI 10.1016/0031-9384(94)00200-O; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; SALTER M, 1995, NEUROPHARMACOLOGY, V34, P327, DOI 10.1016/0028-3908(94)00162-L; VANDENPOL AN, 1995, J COMP NEUROL, V359, P253, DOI 10.1002/cne.903590206; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	28	221	225	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					670	674		10.1038/41765	http://dx.doi.org/10.1038/41765			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262400				2022-12-28	WOS:A1997XQ86300048
J	Hegedus, L; Bennedbaek, FN				Hegedus, L; Bennedbaek, FN			Radioiodine for non-toxic diffuse goitre	LANCET			English	Article							NONTOXIC GOITER				Hegedus, L (corresponding author), ODENSE UNIV HOSP,DEPT ENDOCRINOL M,DK-5000 ODENSE C,DENMARK.							FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; HEGEDUS L, 1986, LANCET, V2, P339; HEGEDUS L, 1988, BRIT MED J, V297, P661, DOI 10.1136/bmj.297.6649.661; NYGAARD B, 1993, BRIT MED J, V307, P828, DOI 10.1136/bmj.307.6908.828; PERRILD H, 1982, ACTA ENDOCRINOL-COP, V100, P382, DOI 10.1530/acta.0.1000382	5	16	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					409	410		10.1016/S0140-6736(05)64132-3	http://dx.doi.org/10.1016/S0140-6736(05)64132-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259658				2022-12-28	WOS:A1997XQ24800014
J	Thomson, KR				Thomson, KR			Interventional radiology	LANCET			English	Article								One of the most interesting things about interventional radiology is how techniques have been borrowed from other areas. The lateral thinking which characterises this new specialty has allowed it to flourish even while it has lost ''turf'' to other specialties. Inevitably, primary referral to interventional radiologists will happen In the same way as referral to, say, surgeons or cardiologists does already. Those who administer health funds and medical education will need to adjust to this now situation. This article provides examples of many treatment tasks that the interventional radiologist now tackles.			Thomson, KR (corresponding author), ROYAL MELBOURNE HOSP,DEPT RADIOL,PARKVILLE,VIC 3050,AUSTRALIA.							Arya S, 1996, J VASC INTERV RADIOL, V7, P921, DOI 10.1016/S1051-0443(96)70871-0; BOOKSTEIN JJ, 1992, CARDIOVASC INTER RAD, V15, P228, DOI 10.1007/BF02733928; BROWN MM, LANCET; Cardella JF, 1996, J VASC INTERV RADIOL, V7, P5, DOI 10.1016/S1051-0443(96)70724-8; CASTELLANI L, 1995, J ENDOVASC SURG, V2, P341, DOI 10.1583/1074-6218(1995)002<0341:CFEVS>2.0.CO;2; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; Laham RJ, 1996, J AM COLL CARDIOL, V28, P820, DOI 10.1016/S0735-1097(96)00244-6; MCDERMOTT JC, 1991, CURRENT PRACTICE INT, P57; Nelsen KM, 1996, J VASC INTERV RADIOL, V7, P751, DOI 10.1016/S1051-0443(96)70844-8; ODonovan AN, 1997, J INTERVENT RADIOL, V12, P1; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; SELDINGER SI, 1953, ACTA RADIOL, V39, P368, DOI 10.3109/00016925309136722; SMITH TP, 1996, JVIR, V6, P627; Song HY, 1996, J VASC INTERV RADIOL, V7, P929, DOI 10.1016/S1051-0443(96)70872-2; *STAND PRACT COMM, 1996, JVIR, V7, P943; White RI, 1996, J VASC INTERV RADIOL, V7, P787, DOI 10.1016/S1051-0443(96)70851-5; Wolf G L, 1993, J Vasc Interv Radiol, V4, P639, DOI 10.1016/S1051-0443(93)71939-9; 1997, NEWSL AM BOARD RADIO, V2, P1	18	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					354	358		10.1016/S0140-6736(97)05516-5	http://dx.doi.org/10.1016/S0140-6736(97)05516-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251650				2022-12-28	WOS:A1997XP24200043
J	Makela, P; Valkonen, T; Martelin, T				Makela, P; Valkonen, T; Martelin, T			Contribution of deaths related to alcohol use to socioeconomic variation in mortality: Register based follow up study	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; INEQUALITIES	Objective: To estimate the contribution of excessive alcohol use to socioeconomic variation in mortality among men and women in Finland. Design: Register based follow up study. Subjects: The population covered by the 1985 and 1990 censuses, aged greater than or equal to 20 in the follow up period 1987-93. Main outcome measures: Total mortality and alcohol related mortality from all causes, from diseases, and from accidents and violence according to socioeconomic position. The excess mortality among other classes compared with upper non-manual employees and differences in life expectancy between the classes were used to measure mortality differentials. Results: Alcohol related mortality constituted 11% of all mortality among men aged greater than or equal to 20 and 2% among women and was higher among manual workers than among other classes. It accounted for 14% of the excess all cause mortality among manual workers over upper non-manual employees among men and 4% among women and for 24% and 9% of the differences in life expectancy, respectively. Half of the excess mortality from accidents and violence among mate manual workers and 38% among female manual workers was accounted for by alcohol related deaths, whereas in diseases the role of alcohol was modest. The contribution of alcohol related deaths to relative mortality differentials weakened with age. Conclusions: Class differentials in alcohol related mortality are an important factor in the socioeconomic mortality differentials in Finland, especially among men, among younger age groups, and in mortality from accidents and violence.			Makela, P (corresponding author), UNIV HELSINKI,DEPT SOCIOL,POPULAT RES UNIT,POB 18,FIN-00014 HELSINKI,FINLAND.		Mäkelä, Pia/C-5679-2015	Mäkelä, Pia/0000-0002-3343-2139				ARO S, 1986, SCAND J SOC MED, V4, P39; FEINSTEIN JS, 1993, MILBANK Q, V71, P279, DOI 10.2307/3350401; KNUPFER G, 1989, BRIT J ADDICT, V84, P1305; Koskinen SVP, 1996, BRIT MED J, V313, P975, DOI 10.1136/bmj.313.7063.975; KUNST AE, 1994, INT J EPIDEMIOL, V23, P742, DOI 10.1093/ije/23.4.742; *LAAK, 1986, TAUL 1987 OS 1 SYST; LECLERC A, 1984, SOC SCI MED, V19, P479, DOI 10.1016/0277-9536(84)90043-1; Lundberg O, 1990, ALKOHOLPOLITIK, V7, P196; MacIntyre S, 1997, SOC SCI MED, V44, P723, DOI 10.1016/S0277-9536(96)00183-9; MAKELA P, IN PRESS EUR J PUBL; Manton K. G., 1984, RECENT TRENDS MORTAL; MARMOT MG, 1984, LANCET, V1, P1003; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; *OFF POP CENS SURV, 1984, OCC MORT REG GEN DEC; Organization W. H., 1992, WORLD HLTH STAT ANN; POCOCK SJ, 1987, LANCET, V2, P197; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; PRESTON SH, 1994, DEMOGRAPHY AGING, P318; Rothman K, 1986, MODERN EPIDEMIOLOGY; Royal College of Physicians, 1987, GREAT GROW EV MED CO; SHRYOCK HS, 1976, METHODS MATERIALS DE; *STAT FINL, 1988, COUS DEATH 1987 1993; Townsend P., 1988, INEQUALITIES HLTH BL; VALKONEN T, 1993, SOCIOECONOMIC MORTAL	24	102	104	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					211	216		10.1136/bmj.315.7102.211	http://dx.doi.org/10.1136/bmj.315.7102.211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XN517	9253268	Green Published			2022-12-28	WOS:A1997XN51700020
J	Marlowe, M; Sugarman, P				Marlowe, M; Sugarman, P			ABC of mental health - Disorders of personality	BRITISH MEDICAL JOURNAL			English	Review																		American Psychiatric Association DSM-IV, 1994, DSM 4 DIAGN STAT MAN; Dolan Bridget, 1993, PSYCHOPATHIC ANTISOC; TYRER P, 1993, PERSONALITY DISORDER; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	4	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					176	179		10.1136/bmj.315.7101.176	http://dx.doi.org/10.1136/bmj.315.7101.176			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251551	Green Published			2022-12-28	WOS:A1997XM32100027
J	Rafferty, T; WilsonDavis, K; McGavock, H				Rafferty, T; WilsonDavis, K; McGavock, H			How has fundholding in Northern Ireland affected prescribing patterns? A longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PRIMARY-CARE; COSTS; SCHEME	Objective: To compare prescribing patterns in general practices before and after the introduction of fundholding in April 1993 to determine whether fundholding changed prescribing patterns among practices that joined the scheme. Design: Analysis of prescribing data from the Drug Utilisation Research Unit's database for all practices in Northern Ireland during April 1989 to March 1996. Setting: Northern Ireland. Subjects: 23 first wave fundholders, 34 second wave fundholders, 9 third wave fundholders, and 268 non-fundholders. Main outcome measures: Prescribing costs per 1000 patients, prescription items per 1000 patients, average cost per item, and rate of generic prescribing. Results: Prescribing costs and frequency increased in all groups throughout the study. Among the fundholders the rate of increase in costs after fundholding was significantly lower than among non-fundholders. The rate of increase in cost per item fell, coinciding with a significant increase in the rate of generic prescribing. However, with regard to first wave fundholders, their yearly increase in costs in their third year as fundholders (1995-6) was similar to that of the non-fundholders. The earlier practices that joined the scheme seemed to differ in some important respects from those that joined later. Conclusions: After fundholders joined the fundholding scheme their patterns of prescribing changed compared with those of non-fundholders: the rate of increase in costs fell and there was a significant rise in the rate of generic prescribing.			Rafferty, T (corresponding author), QUEENS UNIV BELFAST,DEPT THERAPEUT & PHARMACOL,DRUG UTILISAT RES UNIT,WHITLA MED BLDG,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.							AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bloor K, 1996, BRIT MED J, V312, P1525, DOI 10.1136/bmj.312.7045.1525; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; *DEP HLTH, 1996, STAT B, V17, P24; DOWELL JS, 1995, BRIT MED J, V310, P505, DOI 10.1136/bmj.310.6978.505; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; Harris CM, 1996, BRIT MED J, V313, P1531, DOI 10.1136/bmj.313.7071.1531; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MCGAVOCK H, 1994, HLTH TRENDS, V26, P22; SMITH GD, 1991, BRIT MED J, V302, P359, DOI 10.1136/bmj.302.6773.359; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; STEWARTBROWN S, 1995, BRIT MED J, V311, P1543, DOI 10.1136/bmj.311.7019.1543; WALLEY T, 1995, PHARMACOECONOMICS, V7, P320, DOI 10.2165/00019053-199507040-00006; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347; WILSONDAVIS K, 1993, PRESCRIBER, V124, P61; [No title captured]	17	29	29	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					166	170		10.1136/bmj.315.7101.166	http://dx.doi.org/10.1136/bmj.315.7101.166			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251548	Green Published			2022-12-28	WOS:A1997XM32100023
J	Muhe, L; Lulseged, S; Mason, KE; Simoes, EAF				Muhe, L; Lulseged, S; Mason, KE; Simoes, EAF			Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children	LANCET			English	Article							COMMUNITY	Background Pneumonia is the most important cause of morbidity and mortality in children aged under 5 years worldwide. Studies in developing countries have suggested an association between nutritional rickets and pneumonia. Since both nutritional rickets and pneumonia are common in Ethiopia, we did a case-control study to determine the role of nutritional rickets in the development of pneumonia. Methods Cases were children younger than 5 years admitted to the Ethio-Swedish Children's Hospital during a 5-year period with a diagnosis of pnuemonia (n=521), but data were incomplete for 21 of these and they were not included. Controls (n=500) were matched for admission within 3 months of cases and age within 3 months and had no evidence of pneumonia. Nutritional, demographic, and clinical and radiographic data for rickets and pneumonia were collected. Matched odd ratios and logistic regression were used to test the significance of the association of richets and pneumonia. Findings Rickets was present in 210 of 500 cases compared with 20 of 500 controls (odds ratio 22.11). There were significant differences between cases and controls for family size, birth order, crowding, and months of exclusive breastfeeding (p<0.05). After correction for these confounding factors by logistic regression, there was still a 13-fold higher incidence of rickets among children with pneumonia than among controls (13.37 [95% CI 8.08-24.22], p<0.001). Interpretation Vitamin D or calcium deficiency may be important predisposing factors for pneumonia in children aged under 5 years in developing countries. Efforts to prevent vitamin D deficiency or calcium supplementation may result in significant reductions in morbidity and mortality from pneumonia in these children.	CHILDRENS HOSP,DIV INFECT DIS,DENVER,CO 80218; UNIV ADDIS ABABA,FAC MED,DEPT PEDIAT & CHILD HLTH,ADDIS ABABA,ETHIOPIA; WHO,DIV CHILD HLTH & DEV,CH-1211 GENEVA,SWITZERLAND; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DIV INFECT DIS,DENVER,CO 80262	Children's Hospital Colorado; Addis Ababa University; World Health Organization; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AUST-KETTIS A., 1965, Ethiopian Medical Journal, V3, P109; DRIDZ TA, 1979, AM J CLIN NUTR, V32, P607; *ETH SWED CHILDR H, 1994, ANN REP ETH SWED CHI; Gupta S K, 1971, J Indian Med Assoc, V57, P141; HORTAL M, 1990, REV INFECT DIS, V12, pS966; Kirkwood BR, 1995, B WORLD HEALTH ORGAN, V73, P793; LAWSON DEM, 1987, HUM NUTR-CLIN NUTR, V41C, P199; LEMIRE JM, 1985, J IMMUNOL, V134, P3032; LUBANI MM, 1989, ANN TROP PAEDIATR, V3, P134; LULSEGED S, 1990, ETHIOPIAN MED J, V28, P175; MA XC, 1986, J PRAC PEDIAT, V1, P323; MUHE L, 1995, PUBLIC HEALTH, V109, P99, DOI 10.1016/S0033-3506(05)80003-4; Oginni LM, 1996, J PEDIATR-US, V128, P692, DOI 10.1016/S0022-3476(96)80137-5; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; ROOK GAW, 1986, IMMUNOLOGY, V57, P159; SALIMPOUR R, 1975, ARCH DIS CHILD, V50, P63, DOI 10.1136/adc.50.1.63; STRODER J, 1970, ACTA PAEDIATR SCAND, V59, P288, DOI 10.1111/j.1651-2227.1970.tb09005.x; VAHLQUIST B, 1975, ACTA PAEDIATR SCAND, V64, P161; Wellcome Trust Working Party, 1970, LANCET, V2, P302; *WHO, 1994, WHOARL9433; WOLDEMARIAM T, 1973, J PAEDIAT, V82, P876; *WORLD BANK, 1993, WORLD DEV REP	22	238	247	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1801	1804		10.1016/S0140-6736(96)12098-5	http://dx.doi.org/10.1016/S0140-6736(96)12098-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269215				2022-12-28	WOS:A1997XF73500011
J	Liu, D; Diorio, J; Tannenbaum, B; Caldji, C; Francis, D; Freedman, A; Sharma, S; Pearson, D; Plotsky, PM; Meaney, MJ				Liu, D; Diorio, J; Tannenbaum, B; Caldji, C; Francis, D; Freedman, A; Sharma, S; Pearson, D; Plotsky, PM; Meaney, MJ			Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; MEDIAN-EMINENCE; MESSENGER-RNA; ADULT-RATS; SECRETION; BEHAVIOR; ALTERS; FEEDBACK; NEUROENDOCRINE; CORTICOSTERONE	Variations in maternal care affect the development of individual differences in neuroen-docrine responses to stress in rats. As adults, the offspring of mothers that exhibited more licking and grooming of pups during the first 10 days of life showed reduced plasma adrenocorticotropic hormone and corticosterone responses to acute stress, increased hippocampal glucocorticoid receptor messenger RNA expression, enhanced glucocorticoid feedback sensitivity, and decreased levels of hypothalamic corticotropin-releasing hormone messenger RNA. Each measure was significantly correlated with the frequency of maternal licking and grooming (all r's > -0.6). These findings suggest that maternal behavior serves to ''program'' hypothalamic-pituitary-adrenal responses to stress in the offspring.	MCGILL UNIV, FAC MED,DEPT PSYCHIAT,DEV NEUROENDOCRINOL LAB, DOUGLAS HOSP,RES CTR, MONTREAL, PQ H4H 1R3, CANADA; MCGILL UNIV, FAC MED,DEPT NEUROL & NEUROSURG, DEV NEUROENDOCRINOL LAB,DOUGLAS HOSP, RES CTR, MONTREAL, PQ H4H 1R3, CANADA; EMORY UNIV, DEPT PSYCHIAT & BEHAV SCI, ATLANTA, GA 30322 USA	McGill University; McGill University; Emory University			Meaney, Michael/N-5931-2019					ALBERTS JR, 1989, HDB BEHAV NEUROBIOLO, V9, P1; BARNETT SA, 1967, NATURE, V213, P150, DOI 10.1038/213150a0; BELL R W, 1971, Developmental Psychobiology, V4, P181, DOI 10.1002/dev.420040209; BELL RW, 1980, MATERNAL INFLUENCES, P201; BHATNAGAR S, 1995, J NEUROENDOCRINOL, V7, P97, DOI 10.1111/j.1365-2826.1995.tb00672.x; BUTLER SR, 1978, SCIENCE, V199, P445; DALY M, 1973, BRIT J PSYCHOL, V64, P435, DOI 10.1111/j.2044-8295.1973.tb01370.x; DEKLOET ER, 1991, FRONT NEUROENDOCRIN, V12, P95; FLEMING AS, 1974, J COMP PHYSIOL PSYCH, V86, P221, DOI 10.1037/h0035937; Francis D, 1996, ANN NY ACAD SCI, V794, P136, DOI 10.1111/j.1749-6632.1996.tb32517.x; HALTMEYE.GC, 1967, PHYSIOL BEHAV, V2, P61, DOI 10.1016/0031-9384(67)90012-1; HESS JL, 1969, PHYSIOL BEHAV, V4, P109, DOI 10.1016/0031-9384(69)90023-7; Hofer M. A., 1983, SYMBIOSIS PARENT OFF, P61; IMAKI T, 1991, J NEUROSCI, V11, P585; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; JANS JE, 1990, DEV PSYCHOBIOL, V23, P519, DOI 10.1002/dev.420230607; KELLERWOOD ME, 1984, ENDOCR REV, V5, P1, DOI 10.1210/edrv-5-1-1; KREY LC, 1975, ENDOCRINOLOGY, V96, P1088, DOI 10.1210/endo-96-5-1088; KUHN CM, 1978, SCIENCE, V201, P1034, DOI 10.1126/science.684424; LEE MHS, 1974, ANIM BEHAV, V22, P679, DOI 10.1016/S0003-3472(74)80016-3; LEON M, 1978, PHYSIOL BEHAV, V21, P793, DOI 10.1016/0031-9384(78)90021-5; LEVINE S, 1959, SCIENCE, V129, P42, DOI 10.1126/science.129.3340.42; LEVINE S, 1957, SCIENCE, V126, P405, DOI 10.1126/science.126.3270.405; LEVINE S, 1962, SCIENCE, V135, P795, DOI 10.1126/science.135.3506.795-a; Levine S., 1975, SOC STRESS DIS, P43; Levine S, 1994, ANN NY ACAD SCI, V746, P260; LIU D, UNPUB; MEANEY MJ, 1991, NEUROBIOL AGING, V12, P31, DOI 10.1016/0197-4580(91)90036-J; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEANEY MJ, 1985, DEV BRAIN RES, V22, P301, DOI 10.1016/0165-3806(85)90183-X; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; MEANEY MJ, 1985, BEHAV NEUROSCI, V99, P765, DOI 10.1037/0735-7044.99.4.765; MOORE CL, 1984, DEV PSYCHOBIOL, V17, P347, DOI 10.1002/dev.420170403; MYERS MM, 1992, EXPERIENTIA, V48, P322, DOI 10.1007/BF01923426; MYERS MM, 1989, DEV PSYCHOBIOL, V22, P55, DOI 10.1002/dev.420220105; ODONNELL D, 1994, MOL BRAIN RES, V26, P242, DOI 10.1016/0169-328X(94)90096-5; PLOTSKY PM, 1986, ENDOCRINOLOGY, V119, P1126, DOI 10.1210/endo-119-3-1126; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; PLOTSKY PM, 1993, MOL BRAIN RES, V18, P195, DOI 10.1016/0169-328X(93)90189-V; SAPOLSKY RM, 1984, P NATL ACAD SCI-BIOL, V81, P6174, DOI 10.1073/pnas.81.19.6174; SAPOLSKY RM, 1995, NEUROSCIENCE, V66, P571; SARRIEAU A, 1988, DEV BRAIN RES, V43, P158, DOI 10.1016/0165-3806(88)90162-9; SAWCHENKO PE, 1987, J NEUROSCI, V7, P1093; SCHANBERG SM, 1987, CHILD DEV, V58, P1431, DOI 10.1111/j.1467-8624.1987.tb03856.x; SECKL JR, 1990, J NEUROENDOCRINOL, V2, P911, DOI 10.1111/j.1365-2826.1990.tb00659.x; SHANKS N, 1995, J NEUROSCI, V15, P376, DOI 10.1523/jneurosci.15-01-00376.1995; Vallee M, 1997, J NEUROSCI, V17, P2626; VIAU V, 1991, ENDOCRINOLOGY, V129, P2503, DOI 10.1210/endo-129-5-2503; VIAU V, 1993, J NEUROSCI, V13, P1097; WALKER CD, 1990, ENDOCRINOLOGY, V127, P832, DOI 10.1210/endo-127-2-832; WHITNALL MH, 1993, PROG NEUROBIOL, V40, P573, DOI 10.1016/0301-0082(93)90035-Q; WOODSIDE BC, UNPUB; ZARROW MX, 1972, P SOC EXP BIOL MED, V356, P141	54	2288	2336	6	254	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1659	1662		10.1126/science.277.5332.1659	http://dx.doi.org/10.1126/science.277.5332.1659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287218				2022-12-28	WOS:A1997XV68400049
J	Zimmerman, RK; Barker, WH; Strikas, RA; Ahwesh, ER; Mieczkowski, TA; Janosky, JE; Kanter, SL				Zimmerman, RK; Barker, WH; Strikas, RA; Ahwesh, ER; Mieczkowski, TA; Janosky, JE; Kanter, SL			Developing curricula to promote preventive medicine skills - The Teaching Immunization for Medical Education (TIME) project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	30th Annual Spring Conference of the Society-of-Teachers-of-Family-Medicine	MAY 05-07, 1997	BOSTON, MA	Soc Teachers Family Med			UNITED-STATES; MISSED OPPORTUNITIES; SENIOR CITIZENS; VACCINE; EPIDEMIOLOGY; VIROLOGY; MEASLES; DISEASE; COVERAGE; PROGRAMS	Context.-Vaccines are underused in the United States, resulting in needless morbidity, Many experts have concluded that clinician education is critical to increasing the nation's vaccination rates. Objective.-To develop and evaluate case-based curricular materials on immunizations that promote preventive medicine skills. Design.-Before-and-after trial of an educational intervention. Setting and Participants.-Medical schools and primary care residency programs from 20 institutions across the United States participated in the Teaching Immunization for Medical Education (TIME) project. Intervention.-A multidisciplinary team developed learning objectives, abstracted clinical cases, and created case-based modules that use contextual learning and small-group interaction to solve clinical and public health problems. The case-based methods are multistation clinical teaching scenarios (MCTS) and problem-based learning (PBL). Main Outcome Measures.-Knowledge gained by learners from pretest to posttest and the overall ratings of the sessions by learners and facilitators based on evaluation questionnaires. Results.-Pretest and posttest results were obtained on a total of 1122 learners for all modules combined, For the MCTS method, mean scores increased from the 10-item pretest to the posttest by 3.1 items for measles, 3.8 for influenza, 1.8 for hepatitis B, 3.9 for pertussis, 1.9 for adult vaccination, 1.9 for childhood vaccination, and 2.6 for Haemophilus influenzae type b (P<.01 for each), For the PBL method, mean scores increased by 3.4 items for measles, 3.3 for influenza, 2.6 for hepatitis B, and 2.5 for pertussis (P<.01 for each), Most learners (MCTS, 98%; PBL, 89%) and most facilitators (MCTS, 97%; PBL, 100%) rated the sessions overall as very good or good. Conclusions.-Use of TIME modules increases knowledge about immunizations, an essential step to improving vaccination practices of future clinicians. Given the realities of decreased faculty time and budgets, educators face major challenges in developing case-based curricula that prepare learners for the 21st century, Nationally tested libraries of cases such as the TIME modules address this dilemma.	UNIV PITTSBURGH, SCH MED, OFF MED EDUC, PITTSBURGH, PA 15261 USA; UNIV ROCHESTER, DEPT COMMUNITY & PREVENT MED, ROCHESTER, NY USA; CTR DIS CONTROL & PREVENT, NATL IMMUNIZAT PROGRAM, ATLANTA, GA 30333 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Rochester; Centers for Disease Control & Prevention - USA	Zimmerman, RK (corresponding author), UNIV PITTSBURGH, SCH MED, DEPT FAMILY MED & CLIN EPIDEMIOL, M-200 SCAIFE HALL, PITTSBURGH, PA 15261 USA.		Kanter, Steven L/B-1386-2009	Kanter, Steven L/0000-0002-0436-1503; Zimmerman, Richard/0000-0001-5941-6092; Santibanez, Tammy A./0000-0002-5784-7427	PHS HHS [U50/CCU300860] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*ACCR LIAIS COMM M, 1993, FUNCT STRUCT MED SCH; AHO WR, 1979, J GERONTOL, V34, P201, DOI 10.1093/geronj/34.2.201; ALBANESE MA, 1993, ACAD MED, V68, P52, DOI 10.1097/00001888-199301000-00012; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; Association of American Medical Colleges, 1984, PHYS 21 CENT GPEP RE; ATKINSON WL, 1994, AM J PREV MED, V10, P22, DOI 10.1016/S0749-3797(18)30512-9; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BARKER WH, 1994, AM J PREV MED, V10, P1; Barrows H., 1980, PROBLEM BASED LEARNI; Barrows H., 1985, DESIGN PROBLEM BASED; BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; Bloom B. S., 1956, HDB 1 COGNITIVE DOMA; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P369; COOLEY WW, 1986, DECISION ORIENTED ED; *CTR DIS CONTR PRE, 1993, MMWR-MORBID MORTAL W, V45, P853; CUTTS FT, 1992, ANNU REV PUBL HEALTH, V13, P385, DOI 10.1146/annurev.publhealth.13.1.385; FALTER KH, 1994, AM J PREV MED, V10, P4, DOI 10.1016/S0749-3797(18)30509-9; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V272, P1133, DOI 10.1001/jama.272.14.1133; Gamertsfelder D A, 1994, J Am Board Fam Pract, V7, P100; GROSS LJ, 1985, EVAL HEALTH PROF, V8, P469, DOI 10.1177/016327878500800407; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; *IMM MED ED ADV CO, 1994, AM J PREV MED S, V10, P18; JONAS HS, 1994, JAMA-J AM MED ASSOC, V272, P694; KAUFMAN A, 1985, LESSONS SUCCESSFUL I; LAFORCE FM, 1994, AM J PREV MED, V10, P31, DOI 10.1016/S0749-3797(18)30513-0; LeBaron CW, 1996, AM J PUBLIC HEALTH, V86, P1551, DOI 10.2105/AJPH.86.11.1551; MAGUIRE T, 1992, EVAL HEALTH PROF, V15, P434, DOI 10.1177/016327879201500406; MARKLAND RE, 1976, AM J PUBLIC HEALTH, V66, P168, DOI 10.2105/AJPH.66.2.168; MOYER LA, 1994, AM J PREV MED, V10, P45, DOI 10.1016/S0749-3797(18)30514-2; Peckham C, 1989, PECKHAM REPORT NATL; Reiser SJ, 1996, JAMA-J AM MED ASSOC, V276, P1429, DOI 10.1001/jama.276.17.1429; RODEWALD L, 1997, AMBULATORY CHILD HLT, V0003; RUNDALL TG, 1979, MED CARE, V17, P191, DOI 10.1097/00005650-197902000-00009; SCRIVEN M, 1967, PERSPECTIVES CURRICU, P1; STEVENS D, 1986, ARCH DIS CHILD, V61, P382, DOI 10.1136/adc.61.4.382; STRIKAS RA, 1994, AM J PREV MED, V10, P11, DOI 10.1016/S0749-3797(18)30510-5; STUFFLEBEAM DL, 1971, J RES DEV EDUC, V5, P19; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; Taylor JA, 1997, PEDIATRICS, V99, P209; Tyler CW, 1996, AM J PREV MED, V12, P6, DOI 10.1016/S0749-3797(18)30251-4; *US GEN ACC OFF, 1995, VACC CHILDR REEX PRO; *US PHS, 1991, HLTH PEOPL 2000 NAT; WETZEL M, 1991, MULTISTATION EXERCIS; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; WILLIAMS WW, 1988, ANN INTERN MED, V109, P348, DOI 10.7326/0003-4819-109-4-348_2; WOOD D, 1995, AM J PUBLIC HEALTH, V85, P850, DOI 10.2105/AJPH.85.6.850; Zimmerman R K, 1995, J Am Board Fam Pract, V8, P270; Zimmerman RK, 1997, AM J PREV MED, V13, P89, DOI 10.1016/S0749-3797(18)30204-6; Zimmerman RK, 1997, AM J PREV MED, V13, P78, DOI 10.1016/S0749-3797(18)30202-2; Zimmerman RK, 1997, ARCH PEDIAT ADOL MED, V151, P657, DOI 10.1001/archpedi.1997.02170440019004	50	36	36	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					705	711		10.1001/jama.278.9.705	http://dx.doi.org/10.1001/jama.278.9.705			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XT709	9286828				2022-12-28	WOS:A1997XT70900021
J	Michelotti, EF; Sanford, S; Levens, D				Michelotti, EF; Sanford, S; Levens, D			Marking of active genes on mitotic chromosomes	NATURE			English	Article							PROMOTER; DISPLACEMENT; PROPAGATION; REPLICATION; CHROMATIN; INVIVO	During development and differentiation, cellular phenotypes are stably propagated through numerous cell divisions(1). This epigenetic 'cell memory' helps to maintain stable patterns of gene expression(2). DNA methylation(3) and the propagation of specific chromatin structures may both contribute to cell memory(4). There are two impediments during the cell cycle that can hinder the inheritance of specific chromatin configurations: first, the pertinent structures must endure the passage of DNA-replication forks in S phase(5); second, the chromatin state must survive mitosis, when chromatin condenses, transcription is turned off, and almost all double-stranded DNA-binding proteins are displaced(6,7). After mitosis, the previous pattern of expressed and silent genes must be restored. This restoration might be governed by mass action, determined by the binding affinities and concentrations of individual components, Alternatively, a subset of factors might remain bound to mitotic chromosomes, providing a molecular bookmark to direct proper chromatin reassembly, Here we analyse DNA at transcription start sites during mitosis in vivo and find that it is conformationally distorted in genes scheduled for reactivation but is undistorted in repressed genes. These protein-dependent conformational perturbations could help to re-establish transcription after mitosis by 'marking' genes for re-expression.	NCI,PATHOL LAB,GENE REGULAT SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Levens, David/C-9216-2009	Levens, David/0000-0002-7616-922X				ALBERTS B, 1994, MOL BIOLCELL; BHAUMIK D, 1994, J BIOL CHEM, V269, P15861; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; CASTANO IB, 1996, GENE DEV, V10, P2546; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GROUDINE M, 1982, CELL, V30, P131, DOI 10.1016/0092-8674(82)90019-8; Juan G, 1996, EXP CELL RES, V227, P197, DOI 10.1006/excr.1996.0267; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KOIWAI O, 1988, BIOCHEM BIOPH RES CO, V154, P91, DOI 10.1016/0006-291X(88)90654-7; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; SCHWEIZER D, 1994, CHROMOSOME ANAL PROT; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3	21	136	139	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					895	899		10.1038/42282	http://dx.doi.org/10.1038/42282			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278053	Bronze			2022-12-28	WOS:A1997XT75400054
J	McCann, UD; Seiden, LS; Rubin, LJ; Ricaurte, GA				McCann, UD; Seiden, LS; Rubin, LJ; Ricaurte, GA			Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine - A systematic review of the evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TERM WEIGHT CONTROL; RAT-BRAIN; NERVE-TERMINALS; FOLLOW-UP; PHARMACOLOGICAL PROPERTIES; BEHAVIOR-MODIFICATION; LUNG TRANSPLANTATION; CALORIC RESTRICTION; SPECIES-DIFFERENCES; PLUS PHENTERMINE	Objectives.-Obesity is an important clinical problem, and the use of dexfenfluramine hydrochloride for weight reduction has been widely publicized since its approval by the Food and Drug Administration. However, animal and human studies have demonstrated toxic effects of fenfluramines that clinicians should be aware of when considering prescribing the drugs. Our purpose was to systematically review data on brain serotonin neurotoxicity in animals treated with fenfluramines and the evidence linking fenfluramines to primary pulmonary hypertension (PPH). Data Sources.-Archival articles and reviews identified through a computerized search of MEDLINE from 1966 to April 1997 using ''fenfluramine(s),'' ''serotonin,'' ''neurotoxicity,'' ''behavior,'' ''anorexigens,'' ''weight loss,'' and ''primary pulmonary hypertension'' as index terms. Study Selection.-Reports dealing with long-term effects of fenfluramines on brain serotonin neurons, body weight, and pulmonary function in animals and humans. Data Extraction.-Reports were reviewed by individuals with expertise in serotonin neurobiology, neurotoxicity, neuropsychiatry, and pulmonary medicine and evaluated for appropriateness for inclusion in this review, Data Synthesis.-Fenfluramines cause dose-related, long-lasting reductions in serotonin axonal markers in all the animal species tested and with all the routes of drug administration used. Doses of fenfluramines that produce signs of brain serotonin neurotoxicity in animals are on the same order as those used to treat humans for weight loss when one takes into account known relations between body mass and drug clearance. However, no human studies have been conducted, and the pathological and clinical potential for neurotoxicity in humans is unknown. Appetite suppressants-most commonly fenfluramines-increase the risk of developing PPH (odds ratio, 6.3), particularly when used for more than 3 months (odds ratio, >20). Conclusions.-Fenfluramine and dexfenfluramine have been demonstrated to damage brain serotonin neurons in animal studies. It is not known if such damage occurs in humans or if there are clinical consequences. Use of fenfluramines is associated with an increased risk of PPH. Future studies should address the long-term consequences of prolonged use of fenfluramines.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21218 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; UNIV MARYLAND, SCH MED, DEPT MED, BALTIMORE, MD 21201 USA	Johns Hopkins University; University of Chicago; University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005938, R29DA005707, R01DA006275, R01DA005707] Funding Source: NIH RePORTER; NIDA NIH HHS [DA05707, DA05938, R01DA06275] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; APPEL NM, 1990, SYNAPSE, V6, P33, DOI 10.1002/syn.890060105; APPEL NM, 1989, J PHARMACOL EXP THER, V249, P928; ATKINSON RL, 1994, AM J CLIN NUTR, V60, P153, DOI 10.1093/ajcn/60.2.153; Axt KJ, 1994, AMPHETAMINE ITS ANAL, P315; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; Baumann MH, 1996, DRUG ALCOHOL DEPEN, V41, P71, DOI 10.1016/0376-8716(96)01234-3; BAUMGARTEN G, 1992, LANCET, V339, P359, DOI 10.1016/0140-6736(92)91676-Y; BAUMGARTEN HG, 1971, ACTA PHYSIOL SCAND S, V373, P3; BJORKLUND A, 1973, BRAIN RES, V53, P117, DOI 10.1016/0006-8993(73)90771-3; BRENOT F, 1993, BRIT HEART J, V70, P537; CACCIA S, 1992, XENOBIOTICA, V22, P217, DOI 10.3109/00498259209046620; CACCIA S, 1993, EUR J PHARMACOL, V233, P71, DOI 10.1016/0014-2999(93)90350-Q; CACCIA S, 1992, NEUROPHARMACOLOGY, V31, P875, DOI 10.1016/0028-3908(92)90125-9; CACCIA S, 1982, ARCH INT PHARMACOD T, V258, P15; CARLTON J, 1984, PHARMACOL BIOCHEM BE, V20, P739, DOI 10.1016/0091-3057(84)90193-X; Chappell W., 1991, ADV DRUG RES, P1; CLEMENS JA, 1978, COMMUN PSYCHOPHARMAC, V2, P11; Clineschmidt B V, 1978, Ann N Y Acad Sci, V305, P222, DOI 10.1111/j.1749-6632.1978.tb31526.x; CLINESCHMIDT BV, 1976, EUR J PHARMACOL, V35, P211, DOI 10.1016/0014-2999(76)90318-6; COCCARO EF, 1990, SEROTONIN MAJOR PSYC; COLADO MI, 1993, BRIT J PHARMACOL, V108, P583, DOI 10.1111/j.1476-5381.1993.tb12846.x; CONNOLLY HM, IN PRESS N ENGL J ME; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; DEROMETREMBLAY M, 1989, SCIENCE, V43, P1989; FINNEGAN KT, 1988, BRAIN RES, V447, P141, DOI 10.1016/0006-8993(88)90974-2; FISCHER C, 1995, J NEUROSCI, V15, P5476; Fracasso C, 1995, NEUROPHARMACOLOGY, V34, P1653, DOI 10.1016/0028-3908(95)00140-9; FULLER RW, 1978, P SOC EXP BIOL MED, V157, P202; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; FUXE K, 1975, POSTGRAD MED J, V51, P35; GERFEN CR, 1985, J COMP NEUROL, V236, P454, DOI 10.1002/cne.902360404; GURTNER HP, 1985, COR VASA, V27, P160; GUYGRAND B, 1989, LANCET, V2, P1142; HARDING T, 1972, BRIT J PSYCHIAT, V121, P338, DOI 10.1192/bjp.121.3.338-a; HARVEY JA, 1977, J PHARMACOL EXP THER, V202, P581; HARVEY JA, 1975, PSYCHOPHARMACOL COMM, V1, P217; HARWOOD PD, 1963, SCIENCE, V139, P684, DOI 10.1126/science.139.3555.684; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; HIGENBOTTAM TW, 1993, BRIT HEART J, V70, P366; *INT PRIM PULM HYP, 1996, UNPUB FIN REP SUSP R; JOHNSON MP, 1990, PHARMACOL BIOCHEM BE, V36, P105, DOI 10.1016/0091-3057(90)90133-3; KALIA M, 1991, BRAIN RES, V548, P111, DOI 10.1016/0006-8993(91)91112-E; KALIA M, 1992, LANCET, V339, P360; KLEVEN MS, 1988, J PHARMACOL EXP THER, V246, P822; KLEVEN MS, 1989, BRAIN RES, V505, P351, DOI 10.1016/0006-8993(89)91467-4; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAFERRERE B, 1989, BRAIN RES, V504, P258, DOI 10.1016/0006-8993(89)91365-6; LEWIS SA, 1971, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5766.67; LOOGEN F, 1985, COR VASA, V27, P111; LUCOT JB, 1982, BRAIN RES, V247, P181, DOI 10.1016/0006-8993(82)91047-2; MARCHANT NC, 1992, XENOBIOTICA, V22, P1251, DOI 10.3109/00498259209053154; MARCHANT NC, 1991, PR PHARM CL, V8, P23; MARSHALL BD, 1989, J CLIN PSYCHOPHARM, V9, P110, DOI 10.1097/00004714-198904000-00007; MCCANN U, 1994, J PHARMACOL EXP THER, V269, P792; MCMURRAY J, 1986, BRIT MED J, V293, P51, DOI 10.1136/bmj.293.6538.51-d; MCTAVISH D, 1992, DRUGS, V43, P713, DOI 10.2165/00003495-199243050-00007; Mennini T, 1996, PHARMACOL BIOCHEM BE, V53, P155, DOI 10.1016/0091-3057(95)02010-1; MOLLIVER DC, 1990, BRAIN RES, V511, P165, DOI 10.1016/0006-8993(90)90237-6; Mordenti J., 1989, TOXICOKINETICS NEW D, P42; MYERS JE, 1993, BIOL PSYCHIAT, V34, P753, DOI 10.1016/0006-3223(93)90063-J; MYERS JE, 1994, BIOL PSYCHIAT, V35, P112, DOI 10.1016/0006-3223(94)91200-9; NALL KC, 1991, AM J MED, V91, P97, DOI 10.1016/0002-9343(91)90082-9; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OSWALD I, 1971, BMJ-BRIT MED J, V3, P70, DOI 10.1136/bmj.3.5766.70; PASQUE MK, 1991, CIRCULATION, V84, P2275, DOI 10.1161/01.CIR.84.6.2275; PINDER RM, 1975, DRUGS, V10, P241, DOI 10.2165/00003495-197510040-00001; POUWELS HMM, 1990, EUR RESPIR J, V3, P606; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; RICAURTE GA, 1991, LANCET, V338, P1487, DOI 10.1016/0140-6736(91)92301-H; RICAURTE GA, 1994, AMPHETAMINE ITS ANAL, P297; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; Rose S, 1996, NEURODEGENERATION, V5, P145, DOI 10.1006/neur.1996.0021; ROWLAND NE, 1986, LIFE SCI, V39, P2581, DOI 10.1016/0024-3205(86)90112-8; ROWLAND NE, 1993, BRAIN RES, V624, P35, DOI 10.1016/0006-8993(93)90057-T; ROWLAND NE, 1986, PROG NEUROBIOL, V27, P13, DOI 10.1016/0301-0082(86)90011-0; ROWLAND NE, 1994, PHARMACOL BIOCHEM BE, V49, P287, DOI 10.1016/0091-3057(94)90423-5; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; SANDERSBUSH E, 1975, J PHARMACOL EXP THER, V192, P33; SANDLER M, 1991, 5 HYDROXYTRYPTAMINE; SCHECHTER MD, 1990, PHARMACOL BIOCHEM BE, V37, P623; Scheffel U, 1996, SYNAPSE, V24, P395, DOI 10.1002/(SICI)1098-2396(199612)24:4<395::AID-SYN6>3.0.CO;2-8; SCHUSTER CR, 1986, PSYCHOPHARMACOL BULL, V22, P148; SOTELO C, 1991, BRAIN RES, V541, P309, DOI 10.1016/0006-8993(91)91032-V; STEEL JM, 1972, BMJ-BRIT MED J, V2, P26, DOI 10.1136/bmj.3.5817.26; STERANKA LR, 1979, BIOCHEM PHARMACOL, V28, P3103, DOI 10.1016/0006-2952(79)90619-1; STERANKA LR, 1979, NEUROPHARMACOLOGY, V18, P895, DOI 10.1016/0028-3908(79)90088-1; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P615, DOI 10.1038/clpt.1992.73; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P586, DOI 10.1038/clpt.1992.69; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P608, DOI 10.1038/clpt.1992.72; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P634, DOI 10.1038/clpt.1992.75; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P619, DOI 10.1038/clpt.1992.74; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P595, DOI 10.1038/clpt.1992.70; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P602, DOI 10.1038/clpt.1992.71; Weir EK, 1996, CIRCULATION, V94, P2216, DOI 10.1161/01.CIR.94.9.2216; WESTPHALEN RI, 1995, MOL NEUROBIOL, V11, P165, DOI 10.1007/BF02740693; WESTPHALEN RI, 1993, EUR J PHARMACOL, V238, P399; WESTPHALEN RI, 1993, PHARMACOL TOXICOL, V72, P249, DOI 10.1111/j.1600-0773.1993.tb01645.x; WILSON MA, 1994, GLIA, V11, P18, DOI 10.1002/glia.440110105; Yanovski SZ, 1996, JAMA-J AM MED ASSOC, V276, P1907, DOI 10.1001/jama.276.23.1907; YUAN XJ, 1996, CIRCULATION, V94, P1; ZACZEK R, 1990, J PHARMACOL EXP THER, V253, P104	105	92	93	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					666	672		10.1001/jama.278.8.666	http://dx.doi.org/10.1001/jama.278.8.666			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272900				2022-12-28	WOS:A1997XR54700041
J	Burtnick, LD; Koepf, EK; Grimes, J; Jones, EY; Stuart, DI; McLaughlin, PJ; Robinson, RC				Burtnick, LD; Koepf, EK; Grimes, J; Jones, EY; Stuart, DI; McLaughlin, PJ; Robinson, RC			The crystal structure of plasma gelsolin: Implications for actin severing, capping, and nucleation	CELL			English	Article							BINDING DOMAIN; F-ACTIN; PROTEIN; SEQUENCE; FILAMENT; IDENTIFICATION; CALCIUM; VILLIN; AMYLOIDOSIS; DEFINITION	The structure of gelsolin has been determined by crystallography and comprises six structurally related domains that, in a Ca2+-free environment, pack together to form a compact globular structure in which the putative actin-binding sequences are not sufficiently exposed to enable binding to occur. We propose that binding Ca2+ can release the connections that join the N- and C-terminal halves of gelsolin, enabling each half to bind actin relatively independently. Domain shifts are proposed in response to Ca2+ as bases for models of how gelsolin acts to sever, cap, or nucleate F-actin filaments. The structure also invites discussion of polyphosphoinositide binding to segment 2 and suggests how mutation at Asp-187 could initiate a series of events that lead to deposition of amyloid plaques, as observed in victims of familial amyloidosis (Finnish type).	UNIV OXFORD,DEPT BIOCHEM,LAB MOL BIOPHYS,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD CTR MOL SCI,OXFORD OX1 3QU,ENGLAND; UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z1,CANADA; UNIV EDINBURGH,DEPT BIOCHEM,EDINBURGH EH8 9XD,MIDLOTHIAN,SCOTLAND	University of Oxford; University of Oxford; University of British Columbia; University of Edinburgh			Jones, Yvonne/J-2293-2016; Robinson, Robert/G-9702-2011; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Robinson, Robert/0000-0001-6367-6903; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210; Grimes, Jonathan Mark/0000-0001-9698-0389	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDRE E, 1988, J BIOL CHEM, V263, P722; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRYAN J, 1986, J CELL BIOL, V102, P1439, DOI 10.1083/jcb.102.4.1439; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; FEINBERG J, 1995, BIOCHEM BIOPH RES CO, V209, P426, DOI 10.1006/bbrc.1995.1520; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HELLWEG T, 1993, BIOPHYS J, V65, P799, DOI 10.1016/S0006-3495(93)81121-4; HERRMANNSDOERFER AJ, 1993, AM J PHYSIOL, V265, pG1071, DOI 10.1152/ajpgi.1993.265.6.G1071; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P508; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARKUS MA, 1994, PROTEIN SCI, V3, P70; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; MCGOUGH A, 1995, J STRUCT BIOL, V115, P144, DOI 10.1006/jsbi.1995.1038; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; REID SW, 1993, ARCH BIOCHEM BIOPHYS, V302, P31, DOI 10.1006/abbi.1993.1176; SCHNUCHEL A, 1995, J MOL BIOL, V247, P21, DOI 10.1006/jmbi.1994.0118; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; SUN HQ, 1994, J BIOL CHEM, V269, P9473; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VanTroys M, 1996, FEBS LETT, V397, P191, DOI 10.1016/S0014-5793(96)01086-1; VASCONCELLOS CA, 1993, BLOOD, V82, P3648; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEEDS AG, 1995, FEBS LETT, V360, P227, DOI 10.1016/0014-5793(95)00109-M; WEEDS AG, 1993, FEBS LETT, V335, P119, DOI 10.1016/0014-5793(93)80452-Z; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; Wen DY, 1996, BIOCHEMISTRY-US, V35, P9700, DOI 10.1021/bi960920n; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YU FX, 1992, J BIOL CHEM, V267, P14616	50	239	244	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					661	670		10.1016/S0092-8674(00)80527-9	http://dx.doi.org/10.1016/S0092-8674(00)80527-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288746	Bronze			2022-12-28	WOS:A1997XT06600010
J	Sontheimer, EJ; Sun, SG; Piccirilli, JA				Sontheimer, EJ; Sun, SG; Piccirilli, JA			Metal ion catalysis during splicing of premessenger RNA	NATURE			English	Article							PRE-MESSENGER-RNA; SITE; SPLICEOSOME; DNA; 3'-THIOTHYMIDINE; STEREOCHEMISTRY; HEXOKINASE; PRECURSORS; COMPLEXES; SUBSTRATE	The removal of intervening sequences from premessenger RNA is essential for the expression of most eukaryotic genes. The spliceosome ribonucleoprotein complex catalyses intron removal by two sequential phosphotransesterification reactions', but the catalytic mechanisms are unknown. It has been proposed that two divalent metal ions may mediate catalysis of both reaction steps, activating the 2'-or 3'-hydroxyl groups for nucleophilic attack and stabilizing the 3'-oxyanion leaving groups by direct coordination(2). Here we show that in splicing reactions with a precursor RNA containing a 3'-sulphur substitution at the 5' splice site, interaction between metal ion and leaving group is essential for catalysis of the first reaction step. This establishes that the spliceosome is a metalloenzyme and demonstrates a direct parallel with the catalytic strategy used by the self-splicing group I intron from Tetrahymena(3). In contrast, 3'-sulphur substitution at the 3' splice site provides no evidence for a metal ion-leaving group interaction in the second reaction step, suggesting that the two steps of splicing proceed by different catalytic mechanisms and therefore in distinct active sites.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago				Sontheimer, Erik/0000-0002-0881-0310				ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; Anderegg G., 1987, COMPLEXONES, V2, P777; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; COSSTICK R, 1990, NUCLEIC ACIDS RES, V18, P829, DOI 10.1093/nar/18.4.829; Dantzman CL, 1996, J AM CHEM SOC, V118, P11715, DOI 10.1021/ja962265c; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; JAFFE EK, 1979, J BIOL CHEM, V254, P839; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Kramer A., 1995, PREMRNA PROCESSING, P35; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NARLIKAR GJ, 1995, P NATL ACAD SCI USA, V92, P3668, DOI 10.1073/pnas.92.9.3668; PEARSON RG, 1966, SCIENCE, V151, P172, DOI 10.1126/science.151.3707.172; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; Reyes J, 1996, RNA, V2, P213; SEIWERT SD, 1993, MOL CELL BIOL, V13, P3135, DOI 10.1128/MCB.13.6.3135; Sigel RKO, 1997, J AM CHEM SOC, V119, P744, DOI 10.1021/ja962970l; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TARN WY, IN PRESS BIOCHIMIE; VYLE JS, 1992, BIOCHEMISTRY-US, V31, P3012, DOI 10.1021/bi00126a024; Weinstein LB, 1996, J AM CHEM SOC, V118, P10341, DOI 10.1021/ja9616903	28	145	151	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					801	805		10.1038/42068	http://dx.doi.org/10.1038/42068			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285595	Bronze			2022-12-28	WOS:A1997XR66700057
J	Addiss, DG; Beach, MJ; Streit, TG; Lutwick, S; LeConte, FH; Lafontant, JG; Hightower, AW; Lammie, PJ				Addiss, DG; Beach, MJ; Streit, TG; Lutwick, S; LeConte, FH; Lafontant, JG; Hightower, AW; Lammie, PJ			Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children	LANCET			English	Article							ASCARIS-LUMBRICOIDES INFECTIONS; HIGH-DOSE IVERMECTIN; TRICHURIS-TRICHIURA; DIETHYLCARBAMAZINE; FILARIASIS; EFFICACY; HOOKWORM; RECIFE; BRAZIL; GROWTH	Background Lymphatic filariasis and intestinal helminth infections are important disorders in tropical areas. Periodic treatment with albendazole is now used in many school-based intestinal helminth-control programmes. However, few such programmes exist for lymphatic filariasis, despite evidence that single-dose treatment with ivermectin can greatly reduce the concentration of Wuchereria bancrofti microfilariae in the blood for months to years. We aimed to assess the potential for school-based control of lymphatic filariasis by investigating the efficacy and tolerability of combined ivermectin and albendazole in Haitian schoolchiidren. Methods in January, 1996, we collected 832 20 mu L capillary blood samples for inclusion in a randomised controlled study from children aged 5-11 years, and examined them by microscopy for W bancrofti microfilariae. Infected children were randomly assigned treatment with placebo (n=29), a single 200-400 mu g/kg dose of ivermectin (mean, 273 mu g/kg, n=28), 400 mg albendazole (n=29), or a combination of 200-400 mu g/kg ivermectin and 400 mg albendazole (n=24). Children with high concentrations of microfilariae in the blood were admitted to hospital and adverse reactions were monitored for 3-5 days, otherwise children were examined at school or during a visit to their home. 4 months after treatment, we examined blood samples again for microfilariae. Findings 113 microfilaraemic children were enrolled (mean age 7.8 years). 4 months after treatment, the proportion of children who remained positive for microfilariae was significantly lower in the ivermectin plus albendazole group (four [17%]), but there were no significant changes in the other three groups (20 [69%] placebo, 22 [76%] albendazole alone, 17 [61%] ivermectin alone remained positive; p=0004). Geometric mean microfilarial concentration decreased from 9.3 to 5.3 per 20 mu L blood among children who received placebo; from 15.5 to 1.5 per 20 mu L blood among those who received ivermectin only (p=0.032); from 14.1 to 5.1 per 20 mu L blood among those who received albendazole alone; and from 13.7 to 0.3 per 20 mu L blood among those who received both ivermectin and albendazole (p=0.0001). Systemic adverse reactions did not differ significantly between the four groups. Interpretation For children with W bancrofti microfilaraemia, combined treatment with ivermectin and albendazole was more effective than treatment with ivermectin only, with no measurable increase in severity of adverse reactions.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; UNIV GEORGIA,DEPT PARASITOL,ATHENS,GA 30602; MAIMONIDES HOSP,BROOKLYN,NY 11219; HOP ST CROIX,LEOGANE,HAITI	Centers for Disease Control & Prevention - USA; University System of Georgia; University of Georgia; Maimonides Medical Center	Addiss, DG (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,MAILSTOP F-22,4700 BUFORD HIGHWAY,ATLANTA,GA 30341, USA.							ADDISS DG, 1993, AM J TROP MED HYG, V48, P178, DOI 10.4269/ajtmh.1993.48.178; CHADOKEWITZ J, 1995, PARASITOL TODAY, V11, P233; DREYER G, 1994, T ROY SOC TROP MED H, V88, P232, DOI 10.1016/0035-9203(94)90311-5; DREYER G, 1995, T ROY SOC TROP MED H, V89, P98, DOI 10.1016/0035-9203(95)90674-6; Gyapong JO, 1996, ANN TROP MED PARASIT, V90, P39, DOI 10.1080/00034983.1996.11813024; Gyapong M, 1996, SOC SCI MED, V43, P235, DOI 10.1016/0277-9536(95)00365-7; Jayakody R. L., 1993, Tropical Biomedicine, V10, P19; KAZURA K, 1933, AM J TROP MED HYG, V49, P804; Marti H, 1996, AM J TROP MED HYG, V55, P477, DOI 10.4269/ajtmh.1996.55.477; MouliaPelat JP, 1995, T ROY SOC TROP MED H, V89, P682, DOI 10.1016/0035-9203(95)90443-3; NOKES C, 1992, PARASITOLOGY, V104, P539, DOI 10.1017/S0031182000063800; Noroes J, 1996, T ROY SOC TROP MED H, V90, P55, DOI 10.1016/S0035-9203(96)90478-2; Noroes J, 1997, T ROY SOC TROP MED H, V91, P78, DOI 10.1016/S0035-9203(97)90405-3; OTTESEN EA, 1990, NEW ENGL J MED, V322, P1113, DOI 10.1056/NEJM199004193221604; RICHARDS FO, 1991, AM J TROP MED HYG, V44, P3, DOI 10.4269/ajtmh.1991.44.3; STEPHENSON LS, 1989, AM J TROP MED HYG, V41, P78, DOI 10.4269/ajtmh.1989.41.78; STEPHENSON LS, 1993, J NUTR, V123, P1036; THEINHLAING, 1991, T ROY SOC TROP MED H, V85, P523, DOI 10.1016/0035-9203(91)90242-Q; *WHO, 1992, HLTH SCH CHILDR TREA; *WHO, 1994, WHO CTD TDR CONS M H; *WHO, 1996, WHOCTDSIP961	21	97	100	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					480	484		10.1016/S0140-6736(97)02231-9	http://dx.doi.org/10.1016/S0140-6736(97)02231-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274584				2022-12-28	WOS:A1997XR13500010
J	Maisel, WH; Kuntz, KM; Reimold, SC; Lee, TH; Antman, EM; Friedman, PL; Stevenson, WG				Maisel, WH; Kuntz, KM; Reimold, SC; Lee, TH; Antman, EM; Friedman, PL; Stevenson, WG			Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital	ANNALS OF INTERNAL MEDICINE			English	Article							ARRHYTHMIA SUPPRESSION TRIAL; CARDIOVERSION; QUINIDINE; EFFICACY; MORTALITY; AGE	Background: The risks of antiarrhythmic therapy are increasingly recognized, but the risks associated with the initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation are poorly defined. Objective: To determine the incidence, time course, and predictors of adverse cardiac events that require intervention during initiation of antiarrhythmic drug therapy for atrial fibrillation. Design: Retrospective chart review. Setting: University hospital. Participants: 417 consecutive patients who underwent a total of 597 drug trials during a total of 550 hospitalizations for atrial fibrillation. Intervention: Initiation of therapy with antiarrhythmic drugs: procainamide (189 trials), quinidine (179 trials), disopyramide (20 trials), propafenone (110 trials), flecainide (2 trials), sotalol (72 trials), and amiodarone (25 trials). Electrical conversion was performed during 247 trials. Measurements: Incidence of adverse events and daily hazard rate were measured. Logistic regression was done to identify risk factors. Results: During the 597 drug trials, 80 (13.4%) cardiac adverse events occurred in 73 patients. The risk was greatest during the first 24 hours of therapy. Bradyarrhythmias were the most common adverse event, occurring in 47 trials (7.9%); prolongation of the QT interval warranting discontinuation of drug therapy (9 trials; 1.5%) and ventricular arrhythmias (8 trials; 1.3%) were less frequent. In multivariate analysis, previous myocardial infarction was associated with increased risk (odds ratio, 1.90 [95% CI, 1.05 to 3.43]) and the association between older age and increased risk (odds ratio, 1.29 per decade [CI, 0.97 to 1.72]) was of borderline statistical significance. Conclusions: A significant risk for cardiac adverse events exists during initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation. Observation with electrocardiographic monitoring seems advisable for 24 to 48 hours during initiation of antiarrhythmic therapy, particularly for elderly patients and patients who have previously had myocardial infarction.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital								AKIYAMA T, 1992, J AM GERIATR SOC, V40, P666, DOI 10.1111/j.1532-5415.1992.tb01957.x; COLLETT D, 1994, MODELLING SURVIVAL D, P27; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; HILL JD, 1987, J ROY COLL GEN PRACT, V37, P172; HOHNLOSER SH, 1995, J AM COLL CARDIOL, V26, P852, DOI 10.1016/0735-1097(95)00286-5; MANCINI GBJ, 1982, AM HEART J, V104, P617; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; RODEN DM, 1994, NEW ENGL J MED, V331, P785; RUSKIN JN, 1989, NEW ENGL J MED, V321, P386, DOI 10.1056/NEJM198908103210608; STRATMANN HG, 1987, AM HEART J, V113, P1470, DOI 10.1016/0002-8703(87)90664-8; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	16	75	78	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					281	+		10.7326/0003-4819-127-4-199708150-00004	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265427				2022-12-28	WOS:A1997XR26600006
J	Stern, RS				Stern, RS			Psoriasis	LANCET			English	Article							ULTRAVIOLET-B; FAMILIAL PSORIASIS; THERAPY; KERATINOCYTE; PHOTOTHERAPY; ETRETINATE; RESPONSES; REMISSION; EFFICACY; IMMUNE				Stern, RS (corresponding author), HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DEPT DERMATOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NIAMS NIH HHS [N01-AR-9-42214] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSO JCT, 1991, BRIT J RHEUMATOL, V30, P245; BAKER H, 1976, BRIT J DERMATOL, V94, P83, DOI 10.1111/j.1365-2133.1976.tb02274.x; BATACSORGO Z, 1995, J INVEST DERMATOL, V105, pS89, DOI 10.1111/1523-1747.ep12316121; BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1569, DOI 10.1016/0006-2952(91)90426-6; BOYD AS, 1989, J AM ACAD DERMATOL, V21, P985, DOI 10.1016/S0190-9622(89)70287-5; BRAVERMAN IM, 1982, J INVEST DERMATOL, V78, P12, DOI 10.1111/1523-1747.ep12497850; Debets R, 1997, J IMMUNOL, V158, P2955; ELDER JT, 1994, ARCH DERMATOL, V130, P216, DOI 10.1001/archderm.130.2.216; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; FRITSCH PO, 1978, J INVEST DERMATOL, V70, P178, DOI 10.1111/1523-1747.ep12541294; Ghadially R, 1996, J INVEST DERMATOL, V107, P558, DOI 10.1111/1523-1747.ep12582813; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; Grossman RM, 1996, ARCH DERMATOL, V132, P623, DOI 10.1001/archderm.132.6.623; HENSELER T, 1995, J AM ACAD DERMATOL, V32, P982, DOI 10.1016/0190-9622(95)91336-X; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; KAPLAN RP, 1983, J AM ACAD DERMATOL, V8, P95, DOI 10.1016/S0190-9622(83)70012-5; Kienbaum S, 1996, BRIT J DERMATOL, V135, P647, DOI 10.1046/j.1365-2133.1996.d01-1060.x; KRUEGER JG, 1995, J EXP MED, V182, P2057, DOI 10.1084/jem.182.6.2057; LEBWOHL MG, 1995, DERMATOLOGY CLIN, V13; LEUNG DYM, 1995, J CLIN INVEST, V96, P2106, DOI 10.1172/JCI118263; LOWE NJ, 1984, J AM ACAD DERMATOL, V10, P69, DOI 10.1016/S0190-9622(84)80046-8; MATTHEWS D, 1995, J MED GENET, V32, P546, DOI 10.1136/jmg.32.7.546; Matthews D, 1996, NAT GENET, V14, P231, DOI 10.1038/ng1096-231; MAURER TA, 1994, J AM ACAD DERMATOL, V31, P372, DOI 10.1016/S0190-9622(94)70175-X; McKenna KE, 1997, J AM ACAD DERMATOL, V36, P388, DOI 10.1016/S0190-9622(97)80214-9; MELSKI JW, 1983, ARCH DERMATOL, V119, P655, DOI 10.1001/archderm.119.8.655; MEOLA T, 1991, ARCH DERMATOL, V127, P1708, DOI 10.1001/archderm.127.11.1708; MILLS CM, 1992, BRIT J DERMATOL, V127, P18, DOI 10.1111/j.1365-2133.1992.tb14818.x; Molin L, 1997, BRIT J DERMATOL, V136, P89, DOI 10.1111/j.1365-2133.1997.tb08752.x; Morison WL, 1996, PHOTOCHEM PHOTOBIOL, V64, P267, DOI 10.1111/j.1751-1097.1996.tb02456.x; Mrowietz U, 1997, BRIT J DERMATOL, V136, P542, DOI 10.1111/j.1365-2133.1997.tb02138.x; Naldi L, 1996, BRIT J DERMATOL, V134, P101, DOI 10.1111/j.1365-2133.1996.tb07846.x; Nevitt GJ, 1996, BRIT J DERMATOL, V135, P533, DOI 10.1046/j.1365-2133.1996.d01-1035.x; PARRISH JA, 1981, J INVEST DERMATOL, V76, P359, DOI 10.1111/1523-1747.ep12520022; PARRISH JA, 1974, NEW ENGL J MED, V291, P1207, DOI 10.1056/NEJM197412052912301; ROUJEAU JC, 1991, ARCH DERMATOL, V127, P1333, DOI 10.1001/archderm.127.9.1333; SCHAEFER H, 1980, BRIT J DERMATOL, V102, P571, DOI 10.1111/j.1365-2133.1980.tb07657.x; Schon MP, 1997, NAT MED, V3, P183, DOI 10.1038/nm0297-183; Skov L, 1997, AM J PATHOL, V150, P675; SNELLMAN E, 1992, PHOTODERMATOL PHOTO, V9, P83; Stern R, 1996, CUTANEOUS MED SURG, P295; STERN R S, 1988, Annals Academy of Medicine Singapore, V17, P473; STERN RS, 1995, J AM ACAD DERMATOL, V33, P44, DOI 10.1016/0190-9622(95)90008-X; STERN RS, 1986, J AM ACAD DERMATOL, V15, P546, DOI 10.1016/S0190-9622(86)70206-5; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; Stern RS, 1997, NEW ENGL J MED, V336, P1041, DOI 10.1056/NEJM199704103361501; TEFLER NR, 1992, ARCH DERMATOL, V128, P39; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; Zachariae H, 1996, DERMATOLOGY, V192, P343, DOI 10.1159/000246408; ZUG KA, 1995, ARCH DERMATOL, V131, P561, DOI 10.1001/archderm.131.5.561	50	98	99	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 2	1997	350	9074					349	353		10.1016/S0140-6736(97)05257-4	http://dx.doi.org/10.1016/S0140-6736(97)05257-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251649				2022-12-28	WOS:A1997XP24200042
J	Ruediger, N				Ruediger, N			For self-starting scientists a ''model'' career awaits	SCIENCE			English	Editorial Material																			0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					705	705						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9254432				2022-12-28	WOS:A1997XN90700045
J	Sharpe, M; Hawton, K; Clements, A; Cowen, PJ				Sharpe, M; Hawton, K; Clements, A; Cowen, PJ			Increased brain serotonin function in men with chronic fatigue syndrome	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,LITTLEMORE HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND; UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND	University of Oxford; University of Oxford				sharpe, michael/0000-0002-6474-9980; Cowen, Philip/0000-0001-5518-6138				BAKHEIT AMO, 1992, BRIT MED J, V304, P1010, DOI 10.1136/bmj.304.6833.1010; BEARN J, 1995, BIOL PSYCHIAT, V37, P245, DOI 10.1016/0006-3223(94)00121-I; CLEARE AJ, 1995, J AFFECT DISORDERS, V35, P283; Sharpe M, 1996, PSYCHIAT CLIN N AM, V19, P549, DOI 10.1016/S0193-953X(05)70305-1; YATHAM LN, 1995, CAN J PSYCHIAT, V40, P3	5	50	50	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					164	165		10.1136/bmj.315.7101.164	http://dx.doi.org/10.1136/bmj.315.7101.164			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XM321	9251547	Green Published			2022-12-28	WOS:A1997XM32100021
J	Farnham, FR; Ritchie, CW; James, DV; Kennedy, HG				Farnham, FR; Ritchie, CW; James, DV; Kennedy, HG			Pathology of love	LANCET			English	Article									CAMLET LODGE REG SECURE UNIT,ENFIELD,MIDDX,ENGLAND		Farnham, FR (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2PF,ENGLAND.		Kennedy, Harry G/AAE-6401-2020	Kennedy, Harry G/0000-0003-3174-3272				DELGADOESCUETA AV, 1981, NEW ENGL J MED, V305, P711, DOI 10.1056/NEJM198109173051231; MULLEN PE, 1994, AUST NZ J PSYCHIAT, V28, P469, DOI 10.3109/00048679409075876; SLATER E, 1963, BRIT J PSYCHIAT, V109, P95, DOI 10.1192/bjp.109.458.95; TAYLOR P, 1983, PSYCHOL MED, V13, P645, DOI 10.1017/S0033291700048054	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					710	710		10.1016/S0140-6736(97)05238-0	http://dx.doi.org/10.1016/S0140-6736(97)05238-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU977	9291906				2022-12-28	WOS:A1997XU97700012
J	Pang, PS				Pang, PS			Seeking Aesculapius	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					610	611		10.1001/jama.278.8.610	http://dx.doi.org/10.1001/jama.278.8.610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272876				2022-12-28	WOS:A1997XR54700002
J	Blobel, CP				Blobel, CP			Metalloprotease-disintegrins: Links to cell adhesion and cleavage of TNF alpha and notch	CELL			English	Review							SPERM-EGG FUSION; BINDING; DOMAIN				Blobel, CP (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.							ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105	17	326	336	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					589	592		10.1016/S0092-8674(00)80519-X	http://dx.doi.org/10.1016/S0092-8674(00)80519-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288739	Bronze			2022-12-28	WOS:A1997XT06600003
J	LeLorier, J; Gregoire, G; Benhaddad, A; Lapierre, J; Derderian, F				LeLorier, J; Gregoire, G; Benhaddad, A; Lapierre, J; Derderian, F			Discrepancies between meta-analyses and subsequent large randomized, controlled trials	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; LOW-MOLECULAR-WEIGHT; VITAMIN-A SUPPLEMENTATION; INTRAVENOUS-MAGNESIUM; ADJUVANT CHEMOTHERAPY; STANDARD HEPARIN; DOSE INTENSITY; HEART-DISEASE; STAGE-II; METAANALYSIS	Background Meta-analyses are now widely used to provide evidence to support clinical strategies. However, large randomized, controlled trials are considered the gold standard in evaluating the efficacy of clinical interventions. Methods We compared the results of large randomized, controlled trials (involving 1000 patients or more) that were published in four journals (the New England Journal of Medicine, the Lancet, the Annals of Internal Medicine, and the Journal of the American Medical Association) with the results of meta-analyses published earlier on the same topics. Regarding the principal and secondary outcomes, we judged whether the findings of the randomized trials agreed with those of the corresponding meta-analyses, and we determined whether the study results were positive (indicating that treatment improved the outcome) or negative (indicating that the outcome with treatment was the same or worse than without it) at the conventional level of statistical significance (P<0.05). Results We identified 12 large randomized, controlled trials and 19 meta-analyses addressing the same questions. For a total of 40 primary and secondary outcomes, agreement between the meta-analyses and the large clinical trials was only fair (kappa = 0.35; 95 percent confidence interval, 0.06 to 0.64). The positive predictive value of the meta-analyses was 68 percent, and the negative predictive value 67 percent. However, the difference in point estimates between the randomized trials and the meta-analyses was statistically significant for only 5 of the 40 comparisons (12 percent). Furthermore, in each case of disagreement a statistically significant effect of treatment was found by one method, whereas no statistically significant effect was found by the other. Conclusions The outcomes of the 12 large randomized, controlled trials that we studied were not predicted accurately 35 percent of the time by the meta-analyses published previously on the same topics. (C) 1997, Massachusetts Medical Society.	UNIV MONTREAL, FAC MED, DEPT MED, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal	LeLorier, J (corresponding author), HOP HOTEL DIEU, RES CTR, 3850 ST URBAIN ST, PAVIL MARIE DE LA FERRE, 2ND FL, MONTREAL, PQ H2W 1T8, CANADA.							ABRAMSON J H, 1990, Public Health Reviews, V18, P1; BAILAR JC, 1995, J CLIN EPIDEMIOL, V48, P149, DOI 10.1016/0895-4356(94)00149-K; BALL SG, 1993, LANCET, V342, P821; BEROYZ G, 1994, LANCET, V343, P619; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; CUTLER JA, 1990, AM J HYPERTENS, V3, pS137, DOI 10.1093/ajh/3.8.137; CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DEVITA C, 1994, LANCET, V343, P1115; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; FEINSTEIN AR, 1995, J CLIN EPIDEMIOL, V48, P71, DOI 10.1016/0895-4356(94)00110-C; FURBERG CD, 1988, AM J CARDIOL, V62, pA41, DOI 10.1016/S0002-9149(88)80084-5; *GHAN VAST STUD TE, 1993, LANCET, V342, P250; GLASZIOU PP, 1993, BMJ-BRIT MED J, V306, P366, DOI 10.1136/bmj.306.6874.366; GREGOIRE G, 1995, J CLIN EPIDEMIOL, V48, P159, DOI 10.1016/0895-4356(94)00098-B; HOLLIS JF, 1993, ANN INTERN MED, V118, P521, DOI 10.7326/0003-4819-118-7-199304010-00006; Horwitz R I, 1987, Am J Med, V82, P498, DOI 10.1016/0002-9343(87)90450-5; HORWITZ RI, 1995, J CLIN EPIDEMIOL, V48, P41, DOI 10.1016/0895-4356(94)00171-L; HRYNIUK W, 1986, J CLIN ONCOL, V4, P1162, DOI 10.1200/JCO.1986.4.8.1162; IMPERIALE TF, 1991, JAMA-J AM MED ASSOC, V266, P261; KAKKAR VV, 1993, LANCET, V341, P259, DOI 10.1016/0140-6736(93)92614-Y; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; LASSEN MR, 1991, SEMIN THROMB HEMOST, V17, P284; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCNEMAR Q, 1962, PSYCHOL STATISTICS; MEINERT CL, 1989, CONTROL CLIN TRIALS, V10, pS257; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PAOLASSO E, 1993, LANCET, V342, P767; PEDERSEN TR, 1994, LANCET, V344, P1383; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; RAVNSKOV U, 1992, BRIT MED J, V305, P505; ROSS DA, 1993, LANCET, V342, P7, DOI 10.1016/0140-6736(93)91879-Q; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; *TRIALS HYP PREV C, 1992, JAMA-J AM MED ASSOC, V267, P2330; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WHELTON PK, 1989, CIRCULATION S2, V80, P301; WOOD WC, 1994, NEW ENGL J MED, V331, P139; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1990, CIRCULATION, V82, P117; YUSUF S, 1988, LANCET, V1, P1088	46	909	922	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					536	542		10.1056/NEJM199708213370806	http://dx.doi.org/10.1056/NEJM199708213370806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262498	Bronze			2022-12-28	WOS:A1997XR54800006
J	Matlack, KES; Plath, K; Misselwitz, B; Rapoport, TA				Matlack, KES; Plath, K; Misselwitz, B; Rapoport, TA			Protein transport by purified yeast sec complex and Kar2p without membranes	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE; ER MEMBRANE; TRANSLOCATION; BIP; ENVIRONMENT; BINDING; DNAJ	Posttranslational protein translocation across the endoplasmic reticulum membrane of yeast requires a seven-component transmembrane complex (the Sec complex) in collaboration with the lumenal Kar2 protein (Kar2p). A translocation substrate was initially bound to the cytosolic face of the purified Sec complex in a signal-sequence-dependent but Kar2p- and nucleotide-independent manner. In a subsequent reaction, in which Kar2p interacted with the lumenal face of the Sec complex and hydrolyzed adenosine triphosphate, the substrate moved through a channel formed by the Sec complex and was released at the lumenal end. Movement through the channel occurred in detergent solution in the absence of a lipid bilayer.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Misselwitz, Benjamin/L-7193-2016	Misselwitz, Benjamin/0000-0002-8719-5175; Plath, Kathrin/0000-0001-7796-3372	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054238] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54238-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MATLACK KES, UNPUB; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NELSON MK, 1993, GENETICS, V134, P159; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677	20	63	63	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					938	941		10.1126/science.277.5328.938	http://dx.doi.org/10.1126/science.277.5328.938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252322				2022-12-28	WOS:A1997XQ98500037
J	Topol, EJ; Ferguson, JJ; Weisman, HF; Tcheng, JE; Ellis, SG; Kleiman, NS; Ivanhoe, RJ; Wang, AL; Miller, DP; Anderson, KM; Califf, RM				Topol, EJ; Ferguson, JJ; Weisman, HF; Tcheng, JE; Ellis, SG; Kleiman, NS; Ivanhoe, RJ; Wang, AL; Miller, DP; Anderson, KM; Califf, RM			Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta(3) blockade with percutaneous coronary intervention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; ARTERY DISEASE; BALLOON ANGIOPLASTY; CLINICAL-TRIALS; DOUBLE-BLIND; RESTENOSIS; PREVENTION; ANTIBODY	Abciximab, a monoclonal antibody fragment against the platelet receptor alpha(IIIb)beta(3) integrin, prevents platelet aggregation. A randomized, placebo-controlled study showed that abciximab improves outcomes for patients undergoing percutaneous coronary angioplasty at 30 days and at 6 months. Objective.-to determine whether abciximab improves outcomes 3 years after coronary angioplasty. Design.-Double-blind, placebo-controlled, randomized trial. Setting.-A total of 56 academic and community hospitals in the United States. Patients.-A total of 2099 high-risk patients undergoing coronary angioplasty were randomized. Sufficient time elapsed for 2.5 years of follow-up among 2001 patients and for 3 years of follow-up among 1599 patients. Interventions.-Abciximab bolus of 0.25 mg/kg followed by infusion at 10 mu g/min for 12 hours; abciximab bolus of 0.25 mg/kg followed by placebo infusion; or placebo bolus followed by placebo infusion. Main Outcomes Measures.-The primary outcome was the composite of death, myocardial infarction, or coronary revascularization. Secondary outcomes were death, myocardial infarction, or coronary revascularization individually. Subgroups having refractory unstable angina or evolving myocardial infarction and having different elevations of creatine kinase during initial angioplasty were analyzed. Results.-At 3 years, composite end points occurred in 41.1% of those receiving abciximab bolus plus infusion; 47.4% of those receiving abciximab bolus only; and 47.2% of those receiving placebo only (for abciximab bolus plus infusion vs placebo, P=.009). Death occurred in 6.8%, 8.0%, and 8.6%, respectively (for abciximab bolus plus infusion vs placebo, P=.20); myocardial infarction in 10.7%, 12.2%, and 13.6%, respectively (for abciximab bolus plus infusion vs placebo, P=.08); and revascularization in 34.8%, 38.6%, and 40.1%, respectively (for abciximab bolus plus infusion vs placebo, P=.02). Among those with refractory unstable angina or evolving myocardia[ infarction, death occurred in 5.1%, 9.2%, and 12.7%, respectively (for abciximab bolus plus infusion vs placebo, P=.01). Death rates increased as periprocedural creatine kinase levels increased. Conclusions.-Abciximab bolus with infusion given at the time of coronary angioplasty improves outcomes as long as 3 years after the procedure.	BAYLOR COLL MED, HOUSTON, TX 77030 USA; TEXAS HEART INST, DIV CARDIOL, HOUSTON, TX 77025 USA; FLORIDA HEART GRP, ORLANDO, FL USA; DUKE UNIV, DEPT MED, DUKE CLIN RES INST, DURHAM, NC USA; CENTOCOR INC, MALVERN, PA 19355 USA	Baylor College of Medicine; Texas Heart Institute; Duke University; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Topol, EJ (corresponding author), CLEVELAND CLIN FDN, DEPT CARDIOL, DESK F25, CLEVELAND, OH 44195 USA.			Miller, Dave/0000-0003-2947-152X; Topol, Eric/0000-0002-1478-4729				ABDELMEGUID AE, 1995, CIRCULATION, V91, P2733, DOI 10.1161/01.CIR.91.11.2733; Abdelmeguid AE, 1996, AM HEART J, V131, P1097, DOI 10.1016/S0002-8703(96)90083-6; Abdelmeguid AE, 1996, CIRCULATION, V94, P1528, DOI 10.1161/01.CIR.94.7.1528; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BALCON R, 1992, CIRCULATION, V86, P100; *BAR INV, 1996, NEW ENGL J MED, V335, P1217; Betriu A, 1997, NEW ENGL J MED, V336, P1621; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CHOI ET, 1994, J VASC SURG, V19, P125, DOI 10.1016/S0741-5214(94)70127-X; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; HERRMAN JPR, 1993, DRUGS, V46, P249, DOI 10.2165/00003495-199346020-00003; HILLEGASS WB, 1994, TXB INTERVENTIONAL C, P415; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kong TQ, 1997, JAMA-J AM MED ASSOC, V277, P461, DOI 10.1001/jama.277.6.461; LATINI R, 1995, CIRCULATION, V92, P3132, DOI 10.1161/01.CIR.92.10.3132; LEAF A, 1994, CIRCULATION, V90, P2248, DOI 10.1161/01.CIR.90.5.2248; LeBreton H, 1996, CIRCULATION, V94, P3024; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; NELSON W, 1988, J QUAL TECHNOL, V20, P24, DOI 10.1080/00224065.1988.11979080; PEDERSEN TR, 1994, LANCET, V344, P1383; POPMA JJ, 1991, CIRCULATION, V84, P1426, DOI 10.1161/01.CIR.84.3.1426; REDWOOD SR, 1995, CIRCULATION S1, V92, P544; Reverter JC, 1996, J CLIN INVEST, V98, P863, DOI 10.1172/JCI118859; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; SERRUYS PW, 1993, CIRCULATION, V88, P1588, DOI 10.1161/01.CIR.88.4.1588; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Tardiff Barbara E., 1996, Journal of the American College of Cardiology, V27, p83A; TEO KK, 1988, JAMA-J AM MED ASSOC, V269, P1910; TOPOL EJ, 1993, CIRCULATION, V87, P1489, DOI 10.1161/01.CIR.87.5.1489; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; TOPOL EJ, 1994, NEW ENGL J MED, V331, P539, DOI 10.1056/NEJM199408253310811; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002; WONG CB, 1995, AM J CARDIOL, V76, P598, DOI 10.1016/S0002-9149(99)80163-5; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903	39	382	395	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					479	484		10.1001/jama.278.6.479	http://dx.doi.org/10.1001/jama.278.6.479			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP243	9256222				2022-12-28	WOS:A1997XP24300029
J	Steiner, DF; Rubenstein, AH				Steiner, DF; Rubenstein, AH			Biomedicine - Proinsulin C-peptide-biological activity?	SCIENCE			English	Editorial Material									UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago	Steiner, DF (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.							Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Ido Y, 1997, SCIENCE, V277, P563, DOI 10.1126/science.277.5325.563; Steiner D., 1995, ENDOCRINOLOGY, P1296; WAHREN J, 1994, DIABETOLOGIA, V37, P99; [No title captured]	5	50	51	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					531	532		10.1126/science.277.5325.531	http://dx.doi.org/10.1126/science.277.5325.531			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9254422				2022-12-28	WOS:A1997XM86700040
J	Michalet, X; Ekong, R; Fougerousse, F; Rousseaux, S; Schurra, C; Hornigold, N; vanSlegtenhorst, M; Wolfe, J; Povey, S; Beckmann, JS; Bensimon, A				Michalet, X; Ekong, R; Fougerousse, F; Rousseaux, S; Schurra, C; Hornigold, N; vanSlegtenhorst, M; Wolfe, J; Povey, S; Beckmann, JS; Bensimon, A			Dynamic molecular combing: Stretching the whole human genome for high-resolution studies	SCIENCE			English	Article							IN-SITU HYBRIDIZATION; TUBEROUS-SCLEROSIS; PRENATAL-DIAGNOSIS; HUMAN-CHROMOSOMES; CANDIDATE REGION; COSMID CONTIGS; DNA; CHROMATIN; 9Q34; CELLS	DNA in amounts representative of hundreds of eukaryotic genomes was extended on silanized surfaces by dynamic molecular combing. The precise measurement of hybridized DNA probes was achieved directly without requiring normalization. This approach was validated with the high-resolution mapping of cosmid contigs on a yeast artificial chromosome (YAC) within yeast genomic DNA. It was extended to human genomic DNA for precise measurements ranging from T to 150 kilobases, of gaps within a contig, and of microdeletions in the tuberous sclerosis 2 gene on patients' DNA. The simplicity, reproducibility, and precision of this approach makes it a powerful tool for a variety of genomic studies.	INST PASTEUR, DEPT BIOTECHNOL, LAB BIOPHYS ADN, F-75724 PARIS 15, FRANCE; UCL, MRC, HUMAN BIOCHEM GENET UNIT, LONDON NW1 2HE, ENGLAND; GENETHON, URA 1922, F-91002 EVRY, FRANCE; UCL, DEPT BIOL, GALTON LAB, LONDON NW1 2HE, ENGLAND; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, NL-3015 GE ROTTERDAM, NETHERLANDS	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of London; University College London; University of London; University College London; Erasmus University Rotterdam			Beckmann, Jacques S/A-9772-2008; Michalet, Xavier/A-9704-2009; Rousseaux, Sophie/G-1697-2013	Beckmann, Jacques S/0000-0002-9741-1900; Michalet, Xavier/0000-0001-6602-7693; Rousseaux, Sophie/0000-0001-5246-5350; Ekong, Rosemary/0000-0002-5984-7893	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEMAND JF, IN PRESS BIOPHYS J; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON A, 1995, PHYS REV LETT, V76, P4754; BLANCATO JK, 1995, J REPROD MED, V40, P537; Boysen C, 1997, GENOME RES, V7, P330, DOI 10.1101/gr.7.4.330; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; CHUMAKOV IM, 1995, NATURE S, V373, P175; DAVIES KE, 1988, GENOME ANAL PRACTICA; EKONG R, UNPUB; EVANS IH, 1996, METHOD MOL BIOL, V53, P71; FIDLEROVA H, 1994, CYTOGENET CELL GENET, V65, P203, DOI 10.1159/000133632; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLORIJN RJ, 1995, HUM MOL GENET, V4, P831, DOI 10.1093/hmg/4.5.831; FOUGEROUSSE F, 1994, HUM MOL GENET, V3, P285, DOI 10.1093/hmg/3.2.285; GIBBS RA, 1995, NAT GENET, V11, P121, DOI 10.1038/ng1095-121; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; GROFFEAU A, 1996, SCIENCE, V274, P546; HAAF T, 1994, HUM MOL GENET, V3, P697, DOI 10.1093/hmg/3.5.697; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; HEISKANEN M, 1995, GENOMICS, V30, P31, DOI 10.1006/geno.1995.0005; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; MENG X, 1995, NAT GENET, V9, P432, DOI 10.1038/ng0495-432; MICHALET X, UNPUB; NAHMIAS J, 1995, EUR J HUM GENET, V3, P65; NELLIST M, 1993, CELL, V75, P1305; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; PERTL B, 1994, LANCET, V343, P1197, DOI 10.1016/S0140-6736(94)92404-X; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; RICHARD I, 1995, MAMM GENOME, V6, P754, DOI 10.1007/BF00354303; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAMPSON J, COMMUNICATION; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; SENGER G, 1994, HUM MOL GENET, V3, P1275, DOI 10.1093/hmg/3.8.1275; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VANSLEGTENHORST M, 1995, EUR J HUM GENET, V3, P78; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; WEIER HUG, 1995, HUM MOL GENET, V4, P1903; WIEGANT J, 1992, HUM MOL GENET, V1, P587, DOI 10.1093/hmg/1.8.587; Yokota H, 1997, NUCLEIC ACIDS RES, V25, P1064, DOI 10.1093/nar/25.5.1064	48	482	528	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1518	1523		10.1126/science.277.5331.1518	http://dx.doi.org/10.1126/science.277.5331.1518			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278517				2022-12-28	WOS:A1997XV42900044
J	Beasley, BW; Wright, SM; Cofrancesco, J; Babbott, SF; Thomas, PA; Bass, EB				Beasley, BW; Wright, SM; Cofrancesco, J; Babbott, SF; Thomas, PA; Bass, EB			Promotion criteria for clinician-educators in the United States and Canada - A survey of promotion committee chairpersons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-SCHOOLS; FACULTY; EXPERIENCE; VIEWS	Context.-Clinician-educators have concerns about their ability to be promoted and the criteria used by medical school promotion committees. Objective.-To discover the criteria and methods that medical school promotion committees use to make decisions about the promotion of clinician-educators. Methods.-In June 1996 we mailed a questionnaire to chairpersons of all medical school promotion committees in the United States and Canada. Results.-Of 142 schools surveyed, 115 (81%) responded; 45% of respondents had a clinician-educator promotion track. On a scale from 1 (minimally important) to 7 (extremely important), the mean importance ratings of aspects of clinician-educators' performance were the following: teaching skills (6.3), clinical skills (5.8), mentoring (5.7), academic administration (5.3), developing educational programs (5.3), nonresearch scholarship (5.1), clinical research (4.8), service coordination (4.7), and education research (4.5). Methods to evaluate each aspect of performance were rated by respondents for importance and frequency of use, The 4 most important methods for evaluating teaching were awards, peer evaluation, learner evaluation, and teaching portfolio, 70% or more of schools used these frequently or always. The 4 most important methods of evaluating clinical skills were peer evaluation, awards, trainee evaluation, and objective measures, which were used frequently or always by 78%, 65%, 58%, and 29% of schools, respectively. Clinician-educators were expected to have fewer peer-reviewed publications to be promoted than investigators (5.7 vs 10.6, P<.001). Schools with separate clinician-educator tracks differed little in survey responses from schools without such tracks. Conclusion-Most, but not all, promotion committees now assign high importance to the special contributions of clinician-educators and use a variety of methods to assess these, regardless of whether they have a separate clinician-educator promotion track.	JOHNS HOPKINS UNIV,SCH MED,DIV GEN INTERNAL MED,BALTIMORE,MD; JOHNS HOPKINS BAYVIEW MED CTR,BALTIMORE,MD; BAYSTATE MED CTR,BOSTON,MA; TUFTS UNIV,SCH MED,BOSTON,MA 02111	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Baystate Medical Center; Tufts University			Beasley, Brent/AAE-9466-2021	Beasley, Brent/0000-0002-0997-9636; Bass, Eric/0000-0001-9106-527X				BALDWIN CD, 1995, ACAD MED, V70, pS97, DOI 10.1097/00001888-199501000-00032; BARONDESS JA, 1991, ANN INTERN MED, V115, P962, DOI 10.7326/0003-4819-115-12-962; BATSHAW ML, 1988, NEW ENGL J MED, V318, P741, DOI 10.1056/NEJM198803243181204; BICKEL J, 1991, ACAD MED, V66, P249, DOI 10.1097/00001888-199105000-00002; Boyer EL, 1990, SCHOLARSHIP RECONSID; BRANCH WT, 1997, SGIM FORUM, V20, P5; BRANCH WT, 1997, SGIM FORUM, V20, P10; CANTOR JC, 1991, JAMA-J AM MED ASSOC, V265, P1002, DOI 10.1001/jama.265.8.1002; CAREY RM, 1993, ACAD MED, V68, P813, DOI 10.1097/00001888-199311000-00001; FRIEDMAN RH, 1982, ANN INTERN MED, V96, P2333; GREER DS, 1990, J GEN INTERN MED, V5, pS53, DOI 10.1007/BF02600438; Irby D M, 1985, Diabetes Educ, V11 Suppl, P37; JACOBS MB, 1993, ACAD MED, V68, P126, DOI 10.1097/00001888-199302000-00004; JACOBS MB, 1992, ACAD MED, V67, P623, DOI 10.1097/00001888-199210000-00001; JENSEN NM, 1993, SGIM NEWS, V16, P7; JONES RF, 1994, ACAD MED, V69, P476, DOI 10.1097/00001888-199406000-00015; Lovejoy FH, 1995, ACAD MED, V70, P1079, DOI 10.1097/00001888-199512000-00009; Lubitz RM, 1997, J GEN INTERN MED, V12, pS71, DOI 10.1046/j.1525-1497.12.s2.10.x; MCHUGH PR, 1994, ACAD MED, V69, P877, DOI 10.1097/00001888-199411000-00003; SIMPSON D, 1994, TEACH LEARN MED, V6, P203; STAFFORD RS, 1991, JAMA-J AM MED ASSOC, V265, P59, DOI 10.1001/jama.265.1.59; STOLINE MR, 1981, AM STAT, V35, P134, DOI 10.2307/2683979; STONE E, 1995, AM J MED, V99, P590; STOSSEL TA, 1991, ANN INTERN MED, V106, P146; VONKORFF M, 1994, ANN INTERN MED, V121, P187, DOI 10.7326/0003-4819-121-3-199408010-00005	25	162	163	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					723	728		10.1001/jama.278.9.723	http://dx.doi.org/10.1001/jama.278.9.723			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286831	Green Submitted			2022-12-28	WOS:A1997XT70900024
J	Stupp, SI; Braun, PV				Stupp, SI; Braun, PV			Molecular manipulation of microstructures: Biomaterials, ceramics, and semiconductors	SCIENCE			English	Article							ARTIFICIAL BONE; MESOPOROUS SILICA; MACROMOLECULES; SIEVES; ORGANOAPATITES; SUPERLATTICES; INTERFACES; MONOLAYERS; CALCITE; FILMS	Organic molecules can alter inorganic microstructures, offering a very powerful tool for the design of novel materials. In biological systems, this tool is often used to create microstructures in which the organic manipulators are a minority component. Three groups of materials-biomaterials, ceramics, and semiconductors-have been selected to illustrate this concept as used by nature and by synthetic laboratories exploring its potential in materials technology. In some of nature's biomaterials, macromolecules such as proteins, glycoproteins, and polysaccharides are used to control nucleation and growth of mineral phases and thus manipulate microstructure and physical properties. This concept has been used synthetically to generate apatite-based materials that can function as artificial bone in humans. Synthetic polymers and surfactants can also drastically change the morphology of ceramic particles, impart new functional properties, and provide new processing methods for the formation of useful objects. Interesting opportunities also exist in creating semiconducting materials in which molecular manipulators connect quantum dots or template cavities, which change their electronic properties and functionality.	UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,MAT RES LAB,DEPT CHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	Stupp, SI (corresponding author), UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,MAT RES LAB,DEPT MAT SCI & ENGN,1304 W GREEN ST,URBANA,IL 61801, USA.		Stupp, Samuel/AGV-1942-2022; Stupp, Samuel/B-6737-2009		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005945] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 05945] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aizenberg J, 1996, ADV MATER, V8, P222, DOI 10.1002/adma.19960080307; Beck JS, 1996, CURR OPIN SOLID ST M, V1, P76, DOI 10.1016/S1359-0286(96)80014-3; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; BECKER GL, 1974, J CELL BIOL, V61, P316, DOI 10.1083/jcb.61.2.316; Becze CE, 1997, J MATER RES, V12, P566, DOI 10.1557/JMR.1997.0081; BERMAN A, 1990, SCIENCE, V250, P664, DOI 10.1126/science.250.4981.664; BERMAN A, 1988, NATURE, V331, P546, DOI 10.1038/331546a0; BRAUN PA, UNPUB; Braun PV, 1996, NATURE, V380, P325, DOI 10.1038/380325a0; Brinker C.J., 1990, SOL GEL SCI, DOI [10.1016/B978-0-08-057103-4.50013-1, DOI 10.1016/C2009-0-22386-5]; BUNKER BC, 1994, SCIENCE, V264, P48, DOI 10.1126/science.264.5155.48; CUMMINS CC, 1992, CHEM MATER, V4, P27, DOI 10.1021/cm00019a011; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; FENDLER JH, 1995, ADV MATER, V7, P607, DOI 10.1002/adma.19950070703; FENDLER JH, 1994, MEMBRANE MIMETIC CHE; Feng X, 1997, SCIENCE, V276, P923, DOI 10.1126/science.276.5314.923; FIROUZI A, 1995, SCIENCE, V267, P1138, DOI 10.1126/science.7855591; FLEISCHMANN R, 1992, PHYS REV LETT, V68, P1367, DOI 10.1103/PhysRevLett.68.1367; Harrison CC, 1996, PHYTOCHEMISTRY, V41, P37, DOI 10.1016/0031-9422(95)00576-5; HERRON N, 1993, SCIENCE, V259, P1426, DOI 10.1126/science.259.5100.1426; HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; HWANG JH, UNPUB; KANG W, 1993, PHYS REV LETT, V71, P3850, DOI 10.1103/PhysRevLett.71.3850; Kingery W.D., 1976, INTRO CERAMICS; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; LANDAU EM, 1986, MOL CRYST LIQ CRYST, V134, P323, DOI 10.1080/00268948608079593; LAWN BR, 1993, FRACTURE BRITTLE SOL, pCH6; Liu J, 1996, ADV COLLOID INTERFAC, V69, P131, DOI 10.1016/S0001-8686(96)00309-0; LIVAGE J, 1988, PROG SOLID STATE CH, V18, P259, DOI 10.1016/0079-6786(88)90005-2; MESSERSMITH PB, 1992, MATER RES SOC SYMP P, V245, P191; MESSERSMITH PB, 1992, J MATER RES, V7, P2599, DOI 10.1557/JMR.1992.2599; MESSERSMITH PB, 1995, CHEM MATER, V7, P454, DOI 10.1021/cm00051a004; MITZI DB, 1995, SCIENCE, V267, P1473, DOI 10.1126/science.267.5203.1473; MITZI DB, 1994, NATURE, V369, P467, DOI 10.1038/369467a0; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; OSENAR P, UNPUB; OSERIAR P, 1996, ADV MAT, V8, P1022; Peng XG, 1997, ANGEW CHEM INT EDIT, V36, P145, DOI 10.1002/anie.199701451; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; PILENI MP, 1993, J PHYS CHEM-US, V97, P6961, DOI 10.1021/j100129a008; POSNER AS, 1978, METAB BONE DIS RELAT, V1, P179, DOI 10.1016/0221-8747(78)90057-7; RIEKE PC, 1994, LANGMUIR, V10, P619, DOI 10.1021/la00015a003; SchultzeLam S, 1996, CHEM GEOL, V132, P171, DOI 10.1016/S0009-2541(96)00053-8; SCHULTZELAM S, 1992, J BACTERIOL, V174, P7971, DOI 10.1128/JB.174.24.7971-7981.1992; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; STUPP SI, 1992, J BIOMED MATER RES, V26, P169, DOI 10.1002/jbm.820260204; STUPP SI, 1993, J BIOMED MATER RES, V27, P289, DOI 10.1002/jbm.820270303; STUPP SI, 1993, J BIOMED MATER RES, V27, P301, DOI 10.1002/jbm.820270304; STUPP SI, UNPUB; TANEV PT, 1994, NATURE, V368, P321, DOI 10.1038/368321a0; TIAN YC, 1994, ADV MATER, V6, P959, DOI 10.1002/adma.19940061213; Tian ZR, 1997, SCIENCE, V276, P926, DOI 10.1126/science.276.5314.926; Tohver V, 1997, CHEM MATER, V9, P1495, DOI 10.1021/cm970068m; VOSSMEYER T, 1995, SCIENCE, V267, P1476, DOI 10.1126/science.267.5203.1476; Weiner S, 1997, J MATER CHEM, V7, P689, DOI 10.1039/a604512j; WEISS D, 1991, PHYS REV LETT, V66, P2790, DOI 10.1103/PhysRevLett.66.2790; WHITESIDES GM, 1995, SCI AM, V273, P146; Yang H, 1996, NATURE, V381, P589, DOI 10.1038/381589a0; Yang H, 1997, NATURE, V386, P692, DOI 10.1038/386692a0; Yang H, 1996, NATURE, V379, P703, DOI 10.1038/379703a0	63	758	799	2	259	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 29	1997	277	5330					1242	1248		10.1126/science.277.5330.1242	http://dx.doi.org/10.1126/science.277.5330.1242			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271562				2022-12-28	WOS:A1997XT82700034
J	Bodenheimer, T				Bodenheimer, T			The Oregon Health Plan - Lessons for the nation .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAID; WILL; CARE		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BENNETT WM, 1992, NEW ENGL J MED, V327, P642; BROOK RH, 1991, JAMA-J AM MED ASSOC, V265, P2998, DOI 10.1001/jama.265.22.2998; DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; Eddy DM, 1996, JAMA-J AM MED ASSOC, V275, P650, DOI 10.1001/jama.275.8.650; FRIEDMAN E, 1990, HEALTHCARE FORUM J, V33, P11; GORE A, 1990, ACAD MED, V65, P634, DOI 10.1097/00001888-199010000-00007; Held P J, 1985, Health Care Financ Rev, V7, P49; Holahan J, 1997, HEALTH AFFAIR, V16, P157, DOI 10.1377/hlthaff.16.2.157; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; *OR OFF MED ASS PR, 1995, OR HLTH PLAN ADM RUL; *OR OFF MED ASS PR, 1997, JOINT COMM WAYS MEAN; ROSENBAUM S, 1995, MEDICAID 1115 DEMONS; Schroeder SA, 1996, NEW ENGL J MED, V334, P1130, DOI 10.1056/NEJM199604253341713; STEINBROOK R, 1992, NEW ENGL J MED, V326, P340, DOI 10.1056/NEJM199201303260511; Tengs TO, 1996, MED DECIS MAKING, V16, P99, DOI 10.1177/0272989X9601600201; *US BUR CENS, 1996, CURR POP SURV HLTH I; WELCH HG, 1988, NEW ENGL J MED, V319, P171, DOI 10.1056/NEJM198807213190310; Wooldridge Judith, 1996, MATH POLICY RES; 1997, OR HLTH FOR MAY	20	91	91	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					651	655		10.1056/NEJM199708283370923	http://dx.doi.org/10.1056/NEJM199708283370923			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271486				2022-12-28	WOS:A1997XT39400032
J	Forti, L; Bossi, M; Bergamaschi, A; Villa, A; Malgaroli, A				Forti, L; Bossi, M; Bergamaschi, A; Villa, A; Malgaroli, A			Loose-patch recordings of single quanta at individual hippocampal synapses	NATURE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC CURRENTS; RAT HIPPOCAMPUS; NEURONS; SLICES; VARIABILITY; MINIATURE; CHANNELS; CLAMP; CA3	Synapses in the central nervous system are typically studied by recording electrical responses from the cell body of the postsynaptic cell. Because neurons are normally connected by multiple synaptic contacts, these postsynaptic responses reflect the combined activity of many thousands synapses, and it remains unclear to what extent the properties of individual synapses can be deduced from the population response(1-5). We have therefore developed a method for recording the activity of individual hippocampal synapses. By capturing an isolated presynaptic bouton inside a loose-patch pipette and recording from the associated patch of postsynaptic membrane, we were able to detect miniature excitatory postsynaptic currents ('minis') arising from spontaneous vesicle exocytosis at a single synaptic site, and to compare these with minis recorded simultaneously from the cell body. The average peak conductance at a single synapse was about 900 pS, corresponding roughly to the opening of 90 AMPA-type glutamate-receptor channels, The variability in this conductance was about 30%, matching the value reported for the neuromuscular junction(6). Given that our synapses displayed single postsynaptic densities (PSDs), this variability is larger than would be predicted from the random opening of receptor channels, suggesting that they are not saturated by the content of a single vesicle. Therefore the response to a quantum of neurotransmitter at these synapses is not limited by the number of available postsynaptic receptors.	SAN RAFFAELE SCI INST,DIBIT,DEPT BIOL & TECHNOL RES,I-20123 MILAN,ITALY; UNIV MILAN,CELLULAR & MOL PHARMACOL CTR,CNR,DEPT PHARMACOL,I-20123 MILAN,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); University of Milan			Forti, Lia/AAU-8156-2020; Forti, Lia/E-9957-2018; Malgaroli, Antonio/I-5090-2013; Villa, Antonello/B-4781-2012	Forti, Lia/0000-0003-3979-0284; Forti, Lia/0000-0003-3979-0284; Malgaroli, Antonio/0000-0003-3758-7477; Villa, Antonello/0000-0002-3820-8072	Telethon [D.044] Funding Source: Medline	Telethon(Fondazione Telethon)		Bauerfeind Rudol, 1994, Trends in Cell Biology, V4, P155, DOI 10.1016/0962-8924(94)90191-0; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EDWARDS FA, 1995, PHYSIOL REV, V75, P759, DOI 10.1152/physrev.1995.75.4.759; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FABER DS, 1992, SCIENCE, V258, P1494, DOI 10.1126/science.1279813; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; FERKING M, 1996, CURR OPIN NEUROBIOL, V6, P395; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JACK JJB, 1994, ADV SEC MESS PHOSPH, V29, P275; JACK JJB, 1983, ELECTRIC CURRENT FLO; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KORN H, 1994, ADV SEC MESS PHOSPH, V29, P301; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; Lewis CA, 1996, J NEUROPHYSIOL, V76, P461, DOI 10.1152/jn.1996.76.1.461; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; Stricker C, 1996, J PHYSIOL-LONDON, V490, P419, DOI 10.1113/jphysiol.1996.sp021155; STUEHMER W, 1983, SINGLE CHANNEL RECOR, P123	30	145	148	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					874	878		10.1038/42251	http://dx.doi.org/10.1038/42251			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278048	Bronze			2022-12-28	WOS:A1997XT75400049
J	Ramakrishnan, L				Ramakrishnan, L			Images in clinical medicine - Mycobacterium marinum infection of the hand	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Ramakrishnan, L (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94305, USA.			Ramakrishnan, Lalita/0000-0003-0692-5533					0	18	18	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					612	612		10.1056/NEJM199708283370906	http://dx.doi.org/10.1056/NEJM199708283370906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271484				2022-12-28	WOS:A1997XT39400006
J	Kolodkin, AL; Levengood, DV; Rowe, EG; Tai, YT; Giger, RJ; Ginty, DD				Kolodkin, AL; Levengood, DV; Rowe, EG; Tai, YT; Giger, RJ; Ginty, DD			Neuropilin is a Semaphorin III receptor	CELL			English	Article							GROWTH CONE GUIDANCE; NEURONAL RECOGNITION MOLECULE; COLLAPSIN-1 MESSENGER-RNA; CHICK NERVOUS-SYSTEM; SPINAL-CORD; DIFFERENTIAL EXPRESSION; NEURITE OUTGROWTH; AXON GUIDANCE; C-ELEGANS; PROTEIN	The semaphorin family contains a large number of phylogenetically conserved proteins and includes several members that have been shown to function in repulsive axon guidance. Semaphorin III (Sema III) is a secreted protein that in vitro causes neuronal growth cone collapse and chemorepulsion of neurites, and in vivo is required for correct sensory afferent innervation and other aspects of development. The mechanism of Sema III function, however, is unknown. Here, we report that neuropilin, a type I transmembrane protein implicated in aspects of neurodevelopment, is a Sema III receptor. We also describe the identification of neuropilin-2, a related neuropilin family member, and show that neuropilin and neuropilin-2 are expressed in overlapping, yet distinct, populations of neurons in the rat embryonic nervous system.			Kolodkin, AL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.							Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HIRATA T, 1993, NEUROSCI RES, V17, P159, DOI 10.1016/0168-0102(93)90092-5; IVAINS JK, 1991, J NEUROSCI, V11, P1597; KAWAKAMI A, 1995, J NEUROBIOL, V29, P1; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KINDT RM, 1995, NEURON, V15, P79, DOI 10.1016/0896-6273(95)90066-7; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4065; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; Puschel AW, 1996, EUR J NEUROSCI, V8, P1317, DOI 10.1111/j.1460-9568.1996.tb01593.x; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Sambrook J., 2002, MOL CLONING LAB MANU; SATODA M, 1995, J NEUROSCI, V15, P942; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHEPHERD, 1997, DEVELOPMENT, V124, P1377; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Wang LH, 1996, J NEUROSCI, V16, P6197; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; Zhou L, 1997, MOL CELL NEUROSCI, V9, P26, DOI 10.1006/mcne.1997.0607	45	957	1004	0	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					753	762		10.1016/S0092-8674(00)80535-8	http://dx.doi.org/10.1016/S0092-8674(00)80535-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288754	hybrid			2022-12-28	WOS:A1997XT06600018
J	Schorey, JS; Carroll, MC; Brown, EJ				Schorey, JS; Carroll, MC; Brown, EJ			A macrophage invasion mechanism of pathogenic mycobacteria	SCIENCE			English	Article							COMPLEMENT RECEPTORS; IMMUNE-COMPLEXES; HUMAN-MONOCYTES; TUBERCULOSIS; PHAGOCYTOSIS; ACTIVATION; ANTIBODIES; INFECTION; DEFICIENT; SECRETION	Tuberculosis is the leading cause of death due to an infectious organism, killing an estimated 3 million people annually, Mycobacterium tuberculosis, the causative agent of tuberculosis, and other pathogenic mycobacteria require entry into host macrophages to initiate infection, An invasion mechanism was defined that was shared among pathogenic mycobacteria including M. tuberculosis, M. leprae, and M. avium but not by nonpathogenic mycobacteria or nonmycobacterial intramacrophage pathogens. This pathway required the association of the complement cleavage product C2a with mycobacteria resulting in the formation of a C3 convertase. The mycobacteria-associated C2a cleaved C3, resulting in C3b opsonization of the mycobacteria and recognition by macrophages.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV INFECT DIS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOL MICROBIOL, ST LOUIS, MO 63110 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033348] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33348] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA KSSS, 1990, TUBERCLE, V71, P103, DOI 10.1016/0041-3879(90)90004-R; BROSTOFF J, 1981, TUBERCLE, V62, P169, DOI 10.1016/0041-3879(81)90002-7; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CARR RI, 1980, CLIN EXP IMMUNOL, V39, P562; COLE FS, 1980, J IMMUNOL, V125, P1120; ELLNER JJ, 1991, J INFECT DIS, V163, P1326, DOI 10.1093/infdis/163.6.1326; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; LAUNOIS P, 1992, INT J LEPROSY, V60, P225; LEPOW IH, 1963, J EXP MED, V117, P983, DOI 10.1084/jem.117.6.983; MULLEREBERHARD HJ, 1967, J EXP MED, V125, P359, DOI 10.1084/jem.125.2.359; POLLEY MJ, 1968, J EXP MED, V128, P533, DOI 10.1084/jem.128.3.533; ROACH TIA, 1993, J IMMUNOL, V150, P1886; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SCHORLEMMER HU, 1977, IMMUNOLOGY, V32, P929; SCHORLEMMER HU, 1976, IMMUNOLOGY, V31, P781; SITOMER G, 1966, IMMUNOCHEMISTRY, V3, P57, DOI 10.1016/0019-2791(66)90282-5; STOKES RW, 1993, J IMMUNOL, V151, P7067; STROUD RM, 1966, IMMUNOCHEMISTRY, V3, P163, DOI 10.1016/0019-2791(66)90182-0; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; WEISSLER JC, 1993, AM J MED SCI, V305, P52, DOI 10.1097/00000441-199301000-00009; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	28	135	143	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	1997	277	5329					1091	1093		10.1126/science.277.5329.1091	http://dx.doi.org/10.1126/science.277.5329.1091			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262476				2022-12-28	WOS:A1997XT03300033
J	Shen, WC; Green, MR				Shen, WC; Green, MR			Yeast TAF(II)145 functions as a core promoter selectivity factor, not a general coactivator	CELL			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; BOX-BINDING; DNA; ELEMENTS; COMPLEX; DOWNSTREAM; SEQUENCES	In yeast, TATA box binding protein associated factors (TAF(II)s) are dispensable for transcription of most genes. Here we use differential display to identify a small subset of yeast genes whose transcription in vivo requires yTAF(II)145. Promoter-mapping studies reveal, unexpectedly, that the region of a gene that renders it yTAF(II)145-dependent is not the upstream activating sequence, which contains the activator-binding sites, but rather the core promoter. In fact, a core promoter requiring yTAF(II)145 retained that requirement when its transcription was directed by several unrelated upstream activating sequences and even in the absence of an activator. Taken together, our results indicate that yTAF(II)145 functions in recognition and selection of core promoters by a mechanism not involving upstream activators.			Shen, WC (corresponding author), UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOL MED, WORCESTER, MA 01605 USA.							Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Baker RT, 1996, J BIOL CHEM, V271, P13549, DOI 10.1074/jbc.271.23.13549; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CROSS FR, 1994, MOL CELL BIOL, V14, P4779, DOI 10.1128/MCB.14.7.4779; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; GE H, 1994, J BIOL CHEM, V269, P17136; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; Guthrie C, 1991, GUIDE YEAST GENETICS; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IGNATOVICH O, 1995, NUCLEIC ACIDS RES, V23, P4616, DOI 10.1093/nar/23.22.4616; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INOSTROZA JA, 1992, CELL, V70, P477; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441; LEER RJ, 1982, NUCLEIC ACIDS RES, V10, P5869, DOI 10.1093/nar/10.19.5869; Lenfant F, 1996, EMBO J, V15, P3974, DOI 10.1002/j.1460-2075.1996.tb00771.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Planta RJ, 1995, BIOCHEM CELL BIOL, V73, P825, DOI 10.1139/o95-090; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; SYPES MA, 1994, NUCLEIC ACIDS RES, V22, P807, DOI 10.1093/nar/22.5.807; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TORNOW J, 1990, GENE, V90, P79, DOI 10.1016/0378-1119(90)90441-S; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; WOOLFORD JL, 1991, MOL CELLULAR BIOL YE, V1, P587; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	69	165	166	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					615	624		10.1016/S0092-8674(00)80523-1	http://dx.doi.org/10.1016/S0092-8674(00)80523-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288742	Bronze			2022-12-28	WOS:A1997XT06600006
J	Sutani, T; Yanagida, M				Sutani, T; Yanagida, M			DNA renaturation activity of the SMC complex implicated in chromosome condensation	NATURE			English	Article							UBIQUITOUS PROTEIN FAMILY; DOSAGE COMPENSATION; FISSION YEAST; RECA PROTEIN; GENE; SEGREGATION; SCAFFOLD; DEFINES; STRANDS	Chromosome condensation occurs in mitosis before the separation of sister chromatids, and requires DNA topoisomerase II (refs 1, 2) and a group of proteins called SMCs3-5. The resulting condensed chromosomes in metaphase have a complex hierarchical structure(6,7). SMCs, the components of condensed chromosomes, are also required for the separation of sister chromatids and gene dosage compensation, and are found in a range of organisms from yeasts to mammals(8-13). However, the mechanisms by which the SMCs contribute to chromosome condensation are unknown. We have studied chromosomes in fission-yeast SMC mutants cut3-477 and cut14-208 (ref. 9), which remain largely non-condensed during mitosis at the restrictive temperature (36 degrees C)(9). To test their role in DNA condensation, we isolated the proteins Cut3 and Cut14 as an oligomeric complex, and tested their interactions with isolated DNA. The complex efficiently promoted the DNA renaturation reactions (the winding up of single-strand DNAs into double helical DNA) as much as similar to 70-fold more efficiently than RecA(14), which is a bacterial protein with similar activity. The activity of the mutant complex was heat sensitive. As DNA winding by renaturation is a potential cause of supercoiling, the SMC complex may be implicated in promoting the higher-order DNA coiling found in condensed chromosomes.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Sutani, Takashi/0000-0002-9959-9513				BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BRYANT FR, 1989, BIOCHEMISTRY-US, V28, P1062, DOI 10.1021/bi00429a021; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; FUNABIKI H, 1996, NATURE, V381, P468; GASSER SM, 1995, CURR BIOL, V5, P357, DOI 10.1016/S0960-9822(95)00071-6; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Swedlow JR, 1993, CURR OPIN CELL BIOL, V5, P412, DOI 10.1016/0955-0674(93)90005-B	23	112	113	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					798	801		10.1038/42062	http://dx.doi.org/10.1038/42062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285594				2022-12-28	WOS:A1997XR66700056
J	Zuo, J; DeJager, PL; Takahashi, KA; Jiang, WN; Linden, DJ; Heintz, N				Zuo, J; DeJager, PL; Takahashi, KA; Jiang, WN; Linden, DJ; Heintz, N			Neurodegeneration in Lurcher mice caused by mutation in delta 2 glutamate receptor gene	NATURE			English	Article							CEREBELLAR PURKINJE-CELLS; POLYMERASE CHAIN-REACTION; HUMPBACK-WHALES; SIMPLE SEQUENCES; DNA; MOUSE; POPULATION; EXPRESSION; SUBUNIT; MAINE	Lurcher (Lc) is a spontaneous, semidominant mouse neurological mutation(1). Heterozygous Lurcher mite (Lc/+) display ataxia as a result of a selective, coil-autonomous and apoptotic death of cerebellar Purkinje cells during postnatal develoment(2-4). Homozygous Lurcher mice (Lc/Lc) die shortly after birth because of a massive loss of mid-and hindbrain neurons during late embryogenesis(5). We have used positional cloning to identify the mutations responsible for neurodegeneration in two independent Lc alleles as G-to-A transitions that change a highly conserved alanine to a threonine residue in transmembrane domain III of the mouse delta 2 glutamate receptor gene (GluR delta 2). Lc/+ Purkinje cells have a very high membrane conductance and a depolarized resting potential, indicating the presence of a large, constitutive inward current. Expression of the mutant GluR delta 2(Lc) protein in Xenopus oocytes confirmed these results, demonstrating that Lc is inherited as a neurodegenerative disorder resulting from a gain-of-function mutation in a glutamate receptor gene. Thus the activation of apoptotic neuronal death in Lurcher mice may provide a physiologically relevant model for excitotoxic cell death.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOL BIOL LAB,NEW YORK,NY 10021; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Rockefeller University; Johns Hopkins University					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051106, R37MH051106, R29MH051106] Funding Source: NIH RePORTER; NIMH NIH HHS [MH51106] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMOS B, 1993, SCIENCE, V260, P670, DOI 10.1126/science.8480176; [Anonymous], 1982, ESTIMATION ANIMAL AB; ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; Barlow J, 1997, ECOLOGY, V78, P535; Berube M, 1996, MOL ECOL, V5, P283; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; Cheng SSW, 1997, J NEUROSCI, V17, P2400, DOI 10.1523/jneurosci.17-07-02400.1997; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P1065, DOI 10.1139/z93-142; CLAPHAM PJ, 1993, MAR MAMMAL SCI, V9, P213, DOI 10.1111/j.1748-7692.1993.tb00448.x; Clapham PJ, 1997, P ROY SOC B-BIOL SCI, V264, P95, DOI 10.1098/rspb.1997.0014; CLAPHAM PJ, 1995, MAR MAMMAL SCI, V11, P227, DOI 10.1111/j.1748-7692.1995.tb00520.x; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P440, DOI 10.1139/z93-063; CONSTABLE JJ, 1995, NATURE, V373, P393, DOI 10.1038/373393a0; DeJager PL, 1997, GENOME RES, V7, P736, DOI 10.1101/gr.7.7.736; DEJAGER PL, IN PRESS MAMM GENOME; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; GERLOFF U, 1995, MOL ECOL, V4, P515, DOI 10.1111/j.1365-294X.1995.tb00247.x; Hammond PS, 1990, REPORT INT WHALING C, P440; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; Katona S.K., 1981, Polar Record, V20, P439; KATONA S. K., 1990, REPORT INT WHALING C, P295; LAMBERTSEN RH, 1987, J MAMMAL, V68, P443, DOI 10.2307/1381495; Landsend AS, 1997, J NEUROSCI, V17, P834, DOI 10.1523/jneurosci.17-02-00834.1997; Larsen AH, 1996, P ROY SOC B-BIOL SCI, V263, P1611, DOI 10.1098/rspb.1996.0236; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; Maniatis T., 1982, MOL CLONING; MATTILA DK, 1989, CAN J ZOOL, V67, P251; MAYAT E, 1995, J NEUROSCI, V15, P2533, DOI 10.1523/JNEUROSCI.15-03-02533.1995; MORIN PA, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P63; NORMAN DJ, 1995, DEVELOPMENT, V121, P1183; PAETKAU D, 1994, MOL ECOL, V3, P489, DOI 10.1111/j.1365-294X.1994.tb00127.x; PALSBALL PJ, IN PRESS MOL ECOL; Palsboll P.J., 1991, Reports of the International Whaling Commission Special Issue, P71; PALSBOLL PJ, 1995, MAR ECOL PROG SER, V116, P1, DOI 10.3354/meps116001; PATEL N, 1995, NAT GENET, V11, P126; PHILLIPS RITA J. S., 1960, JOUR GENET, V57, P35, DOI 10.1007/BF02985337; QUICK MW, 1994, METH NEUROSCI, V19, P261; ROY MS, 1994, MOL BIOL EVOL, V11, P553; STEVICK PT, IN PRESS MAR MAMM SC; Takayama C, 1996, DEV BRAIN RES, V92, P147, DOI 10.1016/0165-3806(95)00212-X; TAKAYAMA C, 1995, NEUROSCI LETT, V188, P89, DOI 10.1016/0304-3940(95)11403-J; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEBER JL, 1989, AM J HUM GENET, V44, P388; WETTS R, 1982, J EMBRYOL EXP MORPH, V68, P87; ZUO J, 1995, GENOME RES, V5, P381, DOI 10.1101/gr.5.4.381	51	429	435	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					769	773		10.1038/42009	http://dx.doi.org/10.1038/42009			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285588	Bronze			2022-12-28	WOS:A1997XR66700050
J	Rivara, FP; Mueller, BA; Somes, G; Mendoza, CT; Rushforth, NB; Kellermann, AL				Rivara, FP; Mueller, BA; Somes, G; Mendoza, CT; Rushforth, NB; Kellermann, AL			Alcohol and illicit drug abuse and the risk of violent death in the home	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN OWNERSHIP; SUICIDE; CONSUMPTION; SMOKING; DRINKING; BEHAVIOR; YOUTH	Context.-While acute alcohol and illicit drug use are common in homicide and suicide victims, the role of chronic substance use in violent death is unclear. Objective.-To measure the magnitude of risk of violent death in the home associated with alcohol use or chronic abuse and use of illicit drugs. Data Sources.-Data obtained from a case-control study of risk factors for homicide and suicide in 3 large metropolitan areas of the United States. Design.-Matched case-control study including 388 homicide cases, 438 suicide cases, and equal numbers of controls matched for age, sex, race, neighborhood, and county. Data were analyzed by means of conditional logistic regressions in which other potential risk factors for violent death were also considered. Outcome and Exposure Measures.-Homicide and suicide victims were identified from medical examiner reports in Shelby County, Tennessee; King County, Washington; and Cuyahoga County, Ohio. Structured interviews were conducted with proxy respondents close to the decedents to obtain information about alcohol or illicit drug use, and history of alcohol-related hospitalization or trouble at work because of drinking by the subject. Data about alcohol use by others living in the same house as the subject were also obtained. Results.-The risks of homicide and suicide associated with alcohol or illicit drug use were elevated, as were the risks of violent death associated with several indicators of chronic alcohol abuse. In addition, nondrinkers living in a home with alcohol users were at increased risk of homicide (odds ratio, 1.7; 95% confidence interval, 0.98-3.0), and non-drug-using individuals residing in homes with illicit drug users were at greatly increased risk of homicide (odds ratio, 11.3, 95% confidence interval, 4.4-28.8). Conclusions.-Alcohol and illicit drug use appear to be associated with an increased risk of violent death. The risk of homicide was increased for non-substance-abusing individuals living in households in which other members abused alcohol or drugs. The concept of the individual at risk of homicide should be broadened to include not only the abuser but also those who may be at risk because of their exposure to others.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN; CASE WESTERN RESERVE UNIV,DEPT BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CTR ADOLESCENT HLTH,CLEVELAND,OH 44106; EMORY UNIV,EMORY CTR INJURY CONTROL,ATLANTA,GA 30322	University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Health Science Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Emory University	Rivara, FP (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,325 9TH AVE,POB 359960,SEATTLE,WA 98104, USA.				PHS HHS [R49/CCR002570, CCR402424] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bailey JE, 1997, ARCH INTERN MED, V157, P777, DOI 10.1001/archinte.157.7.777; Biro M, 1991, Crisis, V12, P64; Blumstein A, 1995, J CRIM LAW CRIM, V86, P10, DOI 10.2307/1143998; BRENT DA, 1987, JAMA-J AM MED ASSOC, V257, P3369, DOI 10.1001/jama.257.24.3369; Breslow N, 1980, STATISTICAL METHODS, V32; CHEREK DR, 1985, J STUD ALCOHOL, V46, P321, DOI 10.15288/jsa.1985.46.321; COLLINS JJ, 1988, J STUD ALCOHOL, V49, P516, DOI 10.15288/jsa.1988.49.516; Collins JJ, 1993, ALCOHOL HEALTH RES W, V17, P93; CORNELIUS JR, 1995, AM J PSYCHIAT, V152, P358; Farrington D. P., 1990, CRIMINALITY PERSONAL, P115, DOI DOI 10.1007/978-3-642-75418-0_9; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; GOODMAN RA, 1991, J STUD ALCOHOL, V52, P156, DOI 10.15288/jsa.1991.52.156; GREENBERG SW, 1981, DRINKING CRIME PERSP, P253; HOLDER HD, 1993, J STUD ALCOHOL, V54, P23, DOI 10.15288/jsa.1993.54.23; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; LI GH, 1994, AM J PUBLIC HEALTH, V84, P1402, DOI 10.2105/AJPH.84.9.1402; Lindqvist P, 1986, Int J Law Psychiatry, V8, P19, DOI 10.1016/0160-2527(86)90081-6; MACK TM, 1986, JNCI-J NATL CANCER I, V76, P49; MERRILL J, 1992, BRIT J ADDICT, V87, P83; MICZEK KA, 1994, UNDERSTANDING PREVEN, V3, P377; Miller B A, 1990, NIDA Res Monogr, V103, P177; MURDOCH D, 1990, INT J ADDICT, V25, P1065, DOI 10.3109/10826089009058873; Pernanen K., 1991, ALCOHOL HUMAN VIOLEN; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; PULKKINEN L, 1983, J YOUTH ADOLESCENCE, V12, P253, DOI 10.1007/BF02088726; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; RICHARDSON J, 1994, HEALTH ECON, V3, P73, DOI 10.1002/hec.4730030204; RIVARA FP, 1995, ANN EMERG MED, V26, P609, DOI 10.1016/S0196-0644(95)70013-7; ROSSOW I, 1995, ADDICTION, V90, P685, DOI 10.1111/j.1360-0443.1995.tb02206.x; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; STEPHENSCHERPIT.CJ, 1988, ALCOHOLISM CLIN EXP, V12, P105; Tinklenberg J. R., 1981, BIOBEHAVIORAL ASPECT, P121; Wagenaar A C, 1994, J Public Health Policy, V15, P37, DOI 10.2307/3342606; Wolfgang M. E., 1958, PATTERNS CRIMINAL HO; YU MC, 1983, CANCER RES, V43, P6077	37	84	85	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					569	575		10.1001/jama.278.7.569	http://dx.doi.org/10.1001/jama.278.7.569			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XQ986	9268278				2022-12-28	WOS:A1997XQ98600031
J	Hook, EB; Czeizel, AE				Hook, EB; Czeizel, AE			Can terathanasia explain the protective effect of folic-acid supplementation on birth defects?	LANCET			English	Editorial Material							NEURAL-TUBE DEFECTS; PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; FINAL REPORT; PREVENTION; TERATOGENS; LIVEBIRTHS; MORTALITY		UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; NATL INST HLTH PROMOT,BUDAPEST,HUNGARY	University of California System; University of California San Francisco	Hook, EB (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,WARREN HALL,MC 7360,BERKELEY,CA 94720, USA.							BYRNE J, 1985, TERATOLOGY, V32, P297, DOI 10.1002/tera.1420320218; Czeizel AE, 1996, AM J MED GENET, V62, P179, DOI 10.1002/(SICI)1096-8628(19960315)62:2<179::AID-AJMG12>3.0.CO;2-L; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; CZEIZEL AE, 1994, ARCH GYNECOL OBSTET, V255, P131; HOOK EB, 1982, AM J EPIDEMIOL, V116, P743, DOI 10.1093/oxfordjournals.aje.a113463; HOOK EB, 1993, AM J EPIDEMIOL, V137, P660, DOI 10.1093/oxfordjournals.aje.a116724; HOOK EB, 1991, TERATOLOGY, V43, P53, DOI 10.1002/tera.1420430107; JURILOFF DM, 1985, TERATOLOGY, V31, P319, DOI 10.1002/tera.1420310302; KHOURY MJ, 1989, AM J EPIDEMIOL, V130, P361, DOI 10.1093/oxfordjournals.aje.a115342; KLINE J, 1989, CONCEPTION BIRTH EPI, P55; *MRC VIT STUD RES, 1991, LANCET, V338, P131; ROBERTS CJ, 1975, LANCET, V1, P498; SMITHELLS RW, 1989, LANCET, V2, P498; SMITHELLS RW, 1980, LANCET, V1, P339; STEIN Z, 1975, AM J EPIDEMIOL, V102, P275, DOI 10.1093/oxfordjournals.aje.a112163; Tonz O, 1996, SCHWEIZ MED WSCHR, V126, P177; WALD N, 1993, ANN NY ACAD SCI, V678, P112; WARKANY J, 1978, TERATOLOGY, V17, P187; WARKANY J, 1981, TERATOLOGY, V23, P175, DOI 10.1002/tera.1420230203; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	20	69	69	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					513	515		10.1016/S0140-6736(97)01342-1	http://dx.doi.org/10.1016/S0140-6736(97)01342-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274597				2022-12-28	WOS:A1997XR13500042
J	Babl, FE; Pascucci, R				Babl, FE; Pascucci, R			Retropharyngeal abscess	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									CHILDRENS HOSP,BOSTON,MA 02115	Harvard University; Boston Children's Hospital	Babl, FE (corresponding author), BOSTON MED CTR,BOSTON,MA 02118, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					472	472		10.1056/NEJM199708143370706	http://dx.doi.org/10.1056/NEJM199708143370706			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250850				2022-12-28	WOS:A1997XQ49900006
J	Fuster, V; Califf, RM; Chesebro, JH; Cohen, M; Comp, PC; Gheorghiade, M; Hall, J; Halperin, J; Khan, S; Kopecky, S; Langer, A; Molk, B; Moss, A; OConnor, CM; OGara, PT; Raskob, E; Sutton, J; Braunwald, E; Bell, WR; Furberg, C; Rapaport, E; DeMets, D; Goldstein, S; Richardson, D; Hillis, D; Bonow, R; Kistler, JP; Mohr, JP; Sherman, D; Fisher, M; Feyzi, J; Cook, T; Califf, RM; Harrington, RA; Berkowitz, SD; Jett, L; Berdan, L; McDougal, M; Friedman, E; Daniel, J; Roncskevitz, E; Hwang, S; Crowell, D; Paganini, M; Andahl, L; OConnor, C; Lucas, K; Collins, GJ; Mark, RJ; Siegel, RM; Koehnemann, G; Greer, S; Schweitzer, AC; Lawrence, JE; Allen, SM; Wiseman, AH; Warwick, DJ; Bennett, WT; Simmons, K; Sheikh, KH; Hengerer, T; Campbell, PT; Patterson, JT; Bates, M; Mathews, A; Roark, SF; Marquis, N; Goldner, DB; Brown, G; Parker, JP; Wells, CB; McGrew, FA; Hamilton, B; Carney, RJ; Crispin, S; Cummins, FE; Nonnweiler, JM; Collins, GV; Hathaway, J; Conn, E; McWilliams, C; Geroge, JM; Roncevich, T; Reeves, BR; Dinsmore, N; Bender, R; DeRosa, K; OConnor, CM; Hoffman, S; Wertheimer, J; Turner, S; Crandall, CW; Higgins, DL; Berger, BC; Palazzo, D; Fontanet, H; Ford, E; Chu, AA; Pierson, M; Seaworth, JF; Jensen, J; Hoche, JP; Ford, EA; Goodfield, P; Sprowls, H; Schmidt, PJ; Ness, C; ODonnell, G; McNamee, S; Koren, MJ; Baker, J; Hassel, CD; Hartley, D; Unks, M; Rodgers, K; Muhlestein, JB; Allen, A; Sacchi, TJ; Major, A; Kmonicek, JM; Shane, JW; Goulah, RD; Harner, R; Bannon, PJ; Heyl, AE; Wall, TC; Milks, S; Ramo, BW; Heimgartner, K; Vranian, RB; Louder, DR; Stack, RK; Jackson, LL; Berman, EJ; Hawkins, D; Aycock, GR; Wilcox, T; West, SR; Fowler, P; Alagona, P; Moore, A; Hines, J; Minor, JR; Kereiakes, DJ; Martin, LH; Frid, DJ; Homan, JA; Burks, JM; Kirby, JC; Puma, J; Jones, L; Schneider, RM; Lyttle, B; Talley, JD; Ashcraft, S; Joseph, A; CorumHartly, J; McNeer, JF; Laden, DL; Belkin, RN; Williamson, J; Langer, A; Hill, C; Buttoo, K; Kachra, A; Langer, G; Kavannaugh, L; Shrives, DM; Strauss, H; Anderson, P; Kwok, K; Kern, C; Cheung, MT; Nawrocki, H; Darcel, IC; Ali, N; Campbell, D; Sluzar, V; Hink, H; Lam, J; Marquis, J; Parker, JD; Wilson, J; James, R; Nolf, B; Zawadowski, A; Bhargava, R; Gupta, M; Sevitt, B; Fitzsimons, J; Burke, BR; Chomyc, R; Singh, N; Bozek, B; Roth, SL; Smith, J; Fell, DA; Willoughy, L; Ranganathan, N; Nawrocki, H; Langer, A; Hill, C; Morgan, C; Balleza, L; Sasson, Z; Nolf, B; LenkeiKerwin, S; Wilson, J; McAlister, NH; Karhra, N; Gangbar, E; Willoughby, L; Hess, A; Gaudet, M; Bhesania, T; Burge, D; OGara, P; Haggan, C; Gibson, M; Slater, A; Stone, PH; Clemente, C; Polansky, BJ; Clements, PJ; Schael, F; McGough, E; Daum, RM; Carey, G; Gillam, LD; Hall, DJ; Venditti, FJ; Woodhead, G; Birkhead, RG; McConnell, D; Jang, IK; Haggan, C; Sadaniantz, A; Staples, E; Weinshel, AJ; Weinshel, G; Cohen, M; Sherwood, J; Palabrica, T; Brown, AM; Hack, TC; Pavao, F; McKendall, FR; Wheeler, JL; Gaughan, C; Medici, SE; Losordo, DW; Hallette, N; Waldman, H; Criasia, M; Battle, R; Rowen, M; Klein, ME; Hankin, B; Radford, MJ; Kearney, L; Becker, RC; Ball, SP; Sharma, GVRK; Lapsley, DP; Watrous, BG; Stanton, A; Kopecky, S; Holland, A; Shelhamer, L; Gudmonson, K; Basu, HN; Brickman, D; Ramee, SR; Landry, KJ; Heltne, CE; Bergal, LA; Lyons, RM; Bussey, HI; Asinger, R; Fifield, JH; Bruns, DL; Gadient, L; Kincaid, D; Berg, S; Storvick, E; Westphal, D; Rezkalla, SH; White, E; Safford, RE; Doucette, K; Cookman, JJ; Fangman, L; Anderson, BJ; Swan, M; Kouba, C; Theige, T; Vacek, JL; Nolte, B; Hurley, DV; Kaskie, K; Gard, JR; Harre, SJ; Solberg, L; Miller, K; Miller, RR; Rickards, J; Yawn, RA; Kurland, M; Haugland, JM; Slivken, R; Hession, WT; Strum, S; Stowers, SA; Abuan, T; DeWood, MA; Reinhardt, S; Kopecky, SL; Richardson, D; Isele, R; Block, C; Swenson, LJ; Vittum, KA; Weeks, G; Brennan, M; Chapman, D; ThomMorgan, J; Chelliah, N; Carter, D; Friedman, B; Haffey, K; Webel, R; Rood, M; Andrews, TC; July, ME; Edin, AE; Hester, TS; Sutton, J; McCollough, T; Schulman, D; Deloplaine, K; Besley, D; Dunn, S; Richards, F; Shipman, D; Josephson, RA; Jasso, D; Fleischer, L; Lofrano, S; Spriggs, D; Wahl, S; Font, VE; Trottier, M; Sutton, J; DeLuca, SA; Schwarz, EF; Beckham, T; Mickolich, JR; Snyder, M; Langholz, D; Johnson, E; Beaver, BB; Tedrick, R; Boyd, JJ; Probst, P; Bear, PA; Craig, MB; Blumenthal, RS; Carnes, T; Villa, AE; Atkins, F; Storer, WQ; Payne, MA; ODonnell, MJ; Prochnow, L; Yakubov, S; Noethen, A; Gonzalez, M; Jopperi, E; Joyce, D; Mishak, S; Reen, BM; Whisnant, DR; Gacioch, GM; Chiodo, V; Effron, MB; Utley, K; Frank, S; Dankoski, C; Krauthamer, D; Welcom, GT; Aguirre, FV; Stonner, T; Cannon, L; Harris, M; Brown, DL; MoeHufford, K; Hattemer, CR; Howard, W; Gilmore, PS; Wofford, R; Bates, ER; Alexandris, C; McClure, JM; Dinninger, J; Molk, B; Danhour, G; Pacheco, JP; Longo, JA; Molk, BL; Bickett, K; Baum, RS; Jenkins, R; Brockington, L; Harding, C; Luckasen, GJ; Rayder, K; Ptasnik, MJ; Harding, C; Brachfeld, CA; Vincze, T; Cadigan, RA; Wubbena, BA; Smith, BR; ONeill, D; Pachelo, GM; Godfrey, CC; Fecik, C; Larson, D; Rayder, K; Backup, LD; Drake, Z; Miklin, JS; Aris, G; Schwartz, DJ; Stark, S; Smith, S; Eastburn, T; Marsh, R; Lorenz, S; Thompson, R; Kleinman, J; Aris, G; Breckinridge, JC; Dauber, IM; Bell, W; VanBenthuysen, K; Prevedel, J; Fecik, C; Stringer, KA; Whiterock, A; Levitt, PW; Petras, J; Cohen, M; Stoakes, K; Daniels, S; Sternberg, C; Mazuz, M; Frymoyer, BS; Dickstein, RA; Banger, D; Kramer, JH; Evans, C; Victor, M; Luhmann, S; Worley, WJ; Tuzi, J; Janzer, SF; Lysgaard, JK; Stillabower, ME; DiSabatino, A; Voyce, S; Keating, D; Cohen, M; Stoakes, K; Zakrzewski, M; Hayes, C; Owens, JS; Amburg, C; Zatuchni, J; Boyle, M; Gheorghiade, M; Mistovich, M; Zayac, J; DeGirolami, D; Peterson, D; Glick, G; Reda, A; Hueter, D; Weszt, S; Wynne, J; Ladd, DF; Mathew, J; Davidson, S; Borzak, S; Cruz, TA; Chiu, C; Sedlarz, P; Shanes, JG; Calkins, M; Alexander, J; Steckel, L; McKierman, TL; Galbraith, E; Sorkin, RP; Moxley, B; Sagar, KB; Mauermann, SK; Fairbairn, JP; Walczak, D; Willis, PW; Boichot, H; Barr, LA; Burns, A; Fintel, D; Feiereisel, P; Tommaso, C; McDermott, EV; Rosenson, RS; Spokas, D; AlHani, A; Andrade, M; Schreiber, TL; Trevino, C; Meisenbach, JA; Bigler, P; Evans, J; Arslanian, C; Rich, S; Genthner, DE; Eisenberg, P; Fasholz, JE; Chua, KG; Schneider, JM; Timmis, GC; Golias, R; Jafri, S; Flandorfer, C; Halperin, J; Rothlauf, E; Forman, R; Furia, S; Bhalodkar, NC; Valeria, A; Miller, DA; Silvasi, D; DeLeon, J; Quyyami, B; Mueller, HS; Cosico, J; Vorchheimer, D; Guzman, IC; Levin, RI; Mele, KA; Morrison, J; Ward, M; Gregory, J; Romano, J; Macina, G; Kikel, M; Kwan, T; Julien, R; Zeldis, SM; Bilodeau, SE; Comp, P; Gates, JL; Sigal, SL; Oyer, LF; Moss, A; Brown, M; Braden, GA; Wesley, DJ; Gillespie, JA; Cohen, L; Krone, RJ; Humphrey, JR; Bodenheimer, MM; Kelly, N; Lichstein, E; Budzilowicz, L; VanVoorhees, L; Silverman, A; Arora, R; Blowers, A; Greenberg, H; McAnulty, M; Hochman, J; Goldstein, RE; Shapiro, S; Marcus, FI; Gear, K; Hall, J; Faussett, D; Border, JF; Dinehart, A; Atassi, K; Smith, F; Hahn, R; ViellieuFischer, B; Graham, JD; Cheng, WM; Rink, LD; Satterfield, JL; Slack, JD; Burkert, M; Tavel, ME; Childress, S; Sadiq, RM; Sands, P; Jennings, M; Freestone, J; Hall, JH; Linden, P; Lapp, M; Habig, E; Shelburne, S; Khan, S; Gray, R; Defensor, L; Fleisher, JH; Patterson, JA; Russell, V; Karlsberg, RP; Maccioni, S; Cercek, B; Conte, S; Sowka, L; Torgerson, M; Levy, MC; Alejandro, PM; Polito, S; Roll, K; French, WJ; Terrell, D; Shook, TL; Junio, LN; Swan, DA; Ujiiye, D; Mahrer, P; Noceda, J; Kaushik, V; Mueco, A; Wallis, J; Abrahamson, D; Seiler, B; Merz, RH; Martin, D; Ladenheim, M; LozykZehr, GM; Brodsky, M; Chaim, S; Bersohn, MM; Silbar, C; Pandian, MG; Eldridge, P; Lob, IK; Smith, C				Fuster, V; Califf, RM; Chesebro, JH; Cohen, M; Comp, PC; Gheorghiade, M; Hall, J; Halperin, J; Khan, S; Kopecky, S; Langer, A; Molk, B; Moss, A; OConnor, CM; OGara, PT; Raskob, E; Sutton, J; Braunwald, E; Bell, WR; Furberg, C; Rapaport, E; DeMets, D; Goldstein, S; Richardson, D; Hillis, D; Bonow, R; Kistler, JP; Mohr, JP; Sherman, D; Fisher, M; Feyzi, J; Cook, T; Califf, RM; Harrington, RA; Berkowitz, SD; Jett, L; Berdan, L; McDougal, M; Friedman, E; Daniel, J; Roncskevitz, E; Hwang, S; Crowell, D; Paganini, M; Andahl, L; OConnor, C; Lucas, K; Collins, GJ; Mark, RJ; Siegel, RM; Koehnemann, G; Greer, S; Schweitzer, AC; Lawrence, JE; Allen, SM; Wiseman, AH; Warwick, DJ; Bennett, WT; Simmons, K; Sheikh, KH; Hengerer, T; Campbell, PT; Patterson, JT; Bates, M; Mathews, A; Roark, SF; Marquis, N; Goldner, DB; Brown, G; Parker, JP; Wells, CB; McGrew, FA; Hamilton, B; Carney, RJ; Crispin, S; Cummins, FE; Nonnweiler, JM; Collins, GV; Hathaway, J; Conn, E; McWilliams, C; Geroge, JM; Roncevich, T; Reeves, BR; Dinsmore, N; Bender, R; DeRosa, K; OConnor, CM; Hoffman, S; Wertheimer, J; Turner, S; Crandall, CW; Higgins, DL; Berger, BC; Palazzo, D; Fontanet, H; Ford, E; Chu, AA; Pierson, M; Seaworth, JF; Jensen, J; Hoche, JP; Ford, EA; Goodfield, P; Sprowls, H; Schmidt, PJ; Ness, C; ODonnell, G; McNamee, S; Koren, MJ; Baker, J; Hassel, CD; Hartley, D; Unks, M; Rodgers, K; Muhlestein, JB; Allen, A; Sacchi, TJ; Major, A; Kmonicek, JM; Shane, JW; Goulah, RD; Harner, R; Bannon, PJ; Heyl, AE; Wall, TC; Milks, S; Ramo, BW; Heimgartner, K; Vranian, RB; Louder, DR; Stack, RK; Jackson, LL; Berman, EJ; Hawkins, D; Aycock, GR; Wilcox, T; West, SR; Fowler, P; Alagona, P; Moore, A; Hines, J; Minor, JR; Kereiakes, DJ; Martin, LH; Frid, DJ; Homan, JA; Burks, JM; Kirby, JC; Puma, J; Jones, L; Schneider, RM; Lyttle, B; Talley, JD; Ashcraft, S; Joseph, A; CorumHartly, J; McNeer, JF; Laden, DL; Belkin, RN; Williamson, J; Langer, A; Hill, C; Buttoo, K; Kachra, A; Langer, G; Kavannaugh, L; Shrives, DM; Strauss, H; Anderson, P; Kwok, K; Kern, C; Cheung, MT; Nawrocki, H; Darcel, IC; Ali, N; Campbell, D; Sluzar, V; Hink, H; Lam, J; Marquis, J; Parker, JD; Wilson, J; James, R; Nolf, B; Zawadowski, A; Bhargava, R; Gupta, M; Sevitt, B; Fitzsimons, J; Burke, BR; Chomyc, R; Singh, N; Bozek, B; Roth, SL; Smith, J; Fell, DA; Willoughy, L; Ranganathan, N; Nawrocki, H; Langer, A; Hill, C; Morgan, C; Balleza, L; Sasson, Z; Nolf, B; LenkeiKerwin, S; Wilson, J; McAlister, NH; Karhra, N; Gangbar, E; Willoughby, L; Hess, A; Gaudet, M; Bhesania, T; Burge, D; OGara, P; Haggan, C; Gibson, M; Slater, A; Stone, PH; Clemente, C; Polansky, BJ; Clements, PJ; Schael, F; McGough, E; Daum, RM; Carey, G; Gillam, LD; Hall, DJ; Venditti, FJ; Woodhead, G; Birkhead, RG; McConnell, D; Jang, IK; Haggan, C; Sadaniantz, A; Staples, E; Weinshel, AJ; Weinshel, G; Cohen, M; Sherwood, J; Palabrica, T; Brown, AM; Hack, TC; Pavao, F; McKendall, FR; Wheeler, JL; Gaughan, C; Medici, SE; Losordo, DW; Hallette, N; Waldman, H; Criasia, M; Battle, R; Rowen, M; Klein, ME; Hankin, B; Radford, MJ; Kearney, L; Becker, RC; Ball, SP; Sharma, GVRK; Lapsley, DP; Watrous, BG; Stanton, A; Kopecky, S; Holland, A; Shelhamer, L; Gudmonson, K; Basu, HN; Brickman, D; Ramee, SR; Landry, KJ; Heltne, CE; Bergal, LA; Lyons, RM; Bussey, HI; Asinger, R; Fifield, JH; Bruns, DL; Gadient, L; Kincaid, D; Berg, S; Storvick, E; Westphal, D; Rezkalla, SH; White, E; Safford, RE; Doucette, K; Cookman, JJ; Fangman, L; Anderson, BJ; Swan, M; Kouba, C; Theige, T; Vacek, JL; Nolte, B; Hurley, DV; Kaskie, K; Gard, JR; Harre, SJ; Solberg, L; Miller, K; Miller, RR; Rickards, J; Yawn, RA; Kurland, M; Haugland, JM; Slivken, R; Hession, WT; Strum, S; Stowers, SA; Abuan, T; DeWood, MA; Reinhardt, S; Kopecky, SL; Richardson, D; Isele, R; Block, C; Swenson, LJ; Vittum, KA; Weeks, G; Brennan, M; Chapman, D; ThomMorgan, J; Chelliah, N; Carter, D; Friedman, B; Haffey, K; Webel, R; Rood, M; Andrews, TC; July, ME; Edin, AE; Hester, TS; Sutton, J; McCollough, T; Schulman, D; Deloplaine, K; Besley, D; Dunn, S; Richards, F; Shipman, D; Josephson, RA; Jasso, D; Fleischer, L; Lofrano, S; Spriggs, D; Wahl, S; Font, VE; Trottier, M; Sutton, J; DeLuca, SA; Schwarz, EF; Beckham, T; Mickolich, JR; Snyder, M; Langholz, D; Johnson, E; Beaver, BB; Tedrick, R; Boyd, JJ; Probst, P; Bear, PA; Craig, MB; Blumenthal, RS; Carnes, T; Villa, AE; Atkins, F; Storer, WQ; Payne, MA; ODonnell, MJ; Prochnow, L; Yakubov, S; Noethen, A; Gonzalez, M; Jopperi, E; Joyce, D; Mishak, S; Reen, BM; Whisnant, DR; Gacioch, GM; Chiodo, V; Effron, MB; Utley, K; Frank, S; Dankoski, C; Krauthamer, D; Welcom, GT; Aguirre, FV; Stonner, T; Cannon, L; Harris, M; Brown, DL; MoeHufford, K; Hattemer, CR; Howard, W; Gilmore, PS; Wofford, R; Bates, ER; Alexandris, C; McClure, JM; Dinninger, J; Molk, B; Danhour, G; Pacheco, JP; Longo, JA; Molk, BL; Bickett, K; Baum, RS; Jenkins, R; Brockington, L; Harding, C; Luckasen, GJ; Rayder, K; Ptasnik, MJ; Harding, C; Brachfeld, CA; Vincze, T; Cadigan, RA; Wubbena, BA; Smith, BR; ONeill, D; Pachelo, GM; Godfrey, CC; Fecik, C; Larson, D; Rayder, K; Backup, LD; Drake, Z; Miklin, JS; Aris, G; Schwartz, DJ; Stark, S; Smith, S; Eastburn, T; Marsh, R; Lorenz, S; Thompson, R; Kleinman, J; Aris, G; Breckinridge, JC; Dauber, IM; Bell, W; VanBenthuysen, K; Prevedel, J; Fecik, C; Stringer, KA; Whiterock, A; Levitt, PW; Petras, J; Cohen, M; Stoakes, K; Daniels, S; Sternberg, C; Mazuz, M; Frymoyer, BS; Dickstein, RA; Banger, D; Kramer, JH; Evans, C; Victor, M; Luhmann, S; Worley, WJ; Tuzi, J; Janzer, SF; Lysgaard, JK; Stillabower, ME; DiSabatino, A; Voyce, S; Keating, D; Cohen, M; Stoakes, K; Zakrzewski, M; Hayes, C; Owens, JS; Amburg, C; Zatuchni, J; Boyle, M; Gheorghiade, M; Mistovich, M; Zayac, J; DeGirolami, D; Peterson, D; Glick, G; Reda, A; Hueter, D; Weszt, S; Wynne, J; Ladd, DF; Mathew, J; Davidson, S; Borzak, S; Cruz, TA; Chiu, C; Sedlarz, P; Shanes, JG; Calkins, M; Alexander, J; Steckel, L; McKierman, TL; Galbraith, E; Sorkin, RP; Moxley, B; Sagar, KB; Mauermann, SK; Fairbairn, JP; Walczak, D; Willis, PW; Boichot, H; Barr, LA; Burns, A; Fintel, D; Feiereisel, P; Tommaso, C; McDermott, EV; Rosenson, RS; Spokas, D; AlHani, A; Andrade, M; Schreiber, TL; Trevino, C; Meisenbach, JA; Bigler, P; Evans, J; Arslanian, C; Rich, S; Genthner, DE; Eisenberg, P; Fasholz, JE; Chua, KG; Schneider, JM; Timmis, GC; Golias, R; Jafri, S; Flandorfer, C; Halperin, J; Rothlauf, E; Forman, R; Furia, S; Bhalodkar, NC; Valeria, A; Miller, DA; Silvasi, D; DeLeon, J; Quyyami, B; Mueller, HS; Cosico, J; Vorchheimer, D; Guzman, IC; Levin, RI; Mele, KA; Morrison, J; Ward, M; Gregory, J; Romano, J; Macina, G; Kikel, M; Kwan, T; Julien, R; Zeldis, SM; Bilodeau, SE; Comp, P; Gates, JL; Sigal, SL; Oyer, LF; Moss, A; Brown, M; Braden, GA; Wesley, DJ; Gillespie, JA; Cohen, L; Krone, RJ; Humphrey, JR; Bodenheimer, MM; Kelly, N; Lichstein, E; Budzilowicz, L; VanVoorhees, L; Silverman, A; Arora, R; Blowers, A; Greenberg, H; McAnulty, M; Hochman, J; Goldstein, RE; Shapiro, S; Marcus, FI; Gear, K; Hall, J; Faussett, D; Border, JF; Dinehart, A; Atassi, K; Smith, F; Hahn, R; ViellieuFischer, B; Graham, JD; Cheng, WM; Rink, LD; Satterfield, JL; Slack, JD; Burkert, M; Tavel, ME; Childress, S; Sadiq, RM; Sands, P; Jennings, M; Freestone, J; Hall, JH; Linden, P; Lapp, M; Habig, E; Shelburne, S; Khan, S; Gray, R; Defensor, L; Fleisher, JH; Patterson, JA; Russell, V; Karlsberg, RP; Maccioni, S; Cercek, B; Conte, S; Sowka, L; Torgerson, M; Levy, MC; Alejandro, PM; Polito, S; Roll, K; French, WJ; Terrell, D; Shook, TL; Junio, LN; Swan, DA; Ujiiye, D; Mahrer, P; Noceda, J; Kaushik, V; Mueco, A; Wallis, J; Abrahamson, D; Seiler, B; Merz, RH; Martin, D; Ladenheim, M; LozykZehr, GM; Brodsky, M; Chaim, S; Bersohn, MM; Silbar, C; Pandian, MG; Eldridge, P; Lob, IK; Smith, C			Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; PRIMARY PREVENTION; VALVE REPLACEMENT; CLINICAL-TRIALS; HIGH-RISK; THERAPY; REINFARCTION; ACTIVATION; MORTALITY; ANGINA	Background Antiplatelet therapy with aspirin and systematic anticoagulation with warfarin reduce cardiovascular morbidity and mortality after myocardial infarction when given alone. In the Coumadin Aspirin Reinfarction Study (CARS), we aimed to find out whether a combination of low-dose warfarin and low-dose aspirin would give superior results to standard aspirin monotherapy without excessive bleeding risk. Methods We used a randomised double-blind study design. At 293 sites, we randomly assigned 8803 patients who had had myocardial infarction, treatment with 160 mg aspirin, 3 mg warfarin with 80 mg aspirin, or 1 mg warfarin with 80 mg aspirin. Patients took a single tablet daily, and attended for prothrombin time (PT) measurements at weeks 1, 2, 3, 4, 6, and 12, and then every 3 months. Patients were followed up for a maximum of 33 months (median 14 months). Findings The primary event was first occurrence of reinfarction, non-fatal ischaemic stroke, or cardiovascular death. 1-year life-table estimates for the primary event were 8.6% (95% Cl 7.6-9.6) for 160 mg aspirin, 8.4% (7.4-9.4) for 3 mg warfarin with 80 mg aspirin, and 8.8% (7.6-10) for 1 mg warfarin with 80 mg aspirin. Primary comparisons were done with all follow-up data. The relative risk of the primary event for the 160 mg aspirin group compared with the 3 mg warfarin with 80 mg aspirin group was 0.95 (0.81-1.12, p=0.57). For spontaneous major haemorrhage (not procedure related), 1-year life-table estimates were 0.74% (0.43-1.1) in the 160 mg aspirin group and 1.4% (0.94-1.8) in the 3 mg warfarin with 80 mg aspirin group (p=0.014 log rank on follow-up). For the 3382 patients assigned 3 mg warfarin with 80 mg aspirin, the INR results were: at week 1 (n=2985) median 1.51 (IQR 1.23-2.13); at week 4 (n=2701) 1.27 (1.13-1.64); at month 6 (n=2145) 1.19 (1.08-1.44). Interpretation Low, fixed-dose warfarin (1 mg or 3 mg) combined with low-dose aspirin (80 mg) in patients who have had myocardial infarction does not provide clinical benefit beyond that achievable with 160 mg aspirin monotherapy.	UNIV WISCONSIN, DATA ANAL CTR, MADISON, WI 53706 USA; COUMADIN ASPIRIN REINFARCT STUDY ORG, WRITING & STEERING COMM, NEW YORK, NY 10029 USA; COUMADIN ASPIRIN REINFARCH STUDY ORG, DATA & SAFETY MONITORING COMM, NEW YORK, NY 10029 USA; COUMADIN ASPIRIN REINFARCT STUDY ORG, EVENTS CLASSIFICAT COMM, NEW YORK, NY 10029 USA; DUKE UNIV, COORDINATING CTR, DURHAM, NC 27706 USA; SMITHKLINE BEECHAM CLIN LABS, CENT INR LAB, PISCATAWAY, NJ USA	University of Wisconsin System; University of Wisconsin Madison; Duke University; GlaxoSmithKline			Effron, Mark B./P-9300-2015; Mohr, J/AAO-9694-2020; Blumenthal, Roger S/H-3223-2018; Jafri, Wasim/AAE-5085-2020; Halperin, Jonathan/AAJ-4721-2020; Fuster, Valentin/H-4319-2015; Berkowitz, Scott Darrell/AAS-9397-2021	Effron, Mark B./0000-0003-4050-5030; Blumenthal, Roger S/0000-0003-1910-3168; Halperin, Jonathan/0000-0002-8318-5471; Fuster, Valentin/0000-0002-9043-9986; Berkowitz, Scott Darrell/0000-0002-9428-4408				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ALTMAN R, 1976, J THORAC CARDIOV SUR, V72, P127; ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; [Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1994, Lancet, V343, P499; [Anonymous], 1980, Circulation, V62, pV59; Breddin K, 1980, Circulation, V62, pV63; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; Cowburn P, 1996, EUR HEART J, V17, P1129; DALE J, 1980, AM HEART J, V99, P746, DOI 10.1016/0002-8703(80)90625-0; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1980, CIRCULATION, V62, P53; Ferguson JJ, 1996, CIRCULATION, V94, P1; FUSTER V, 1993, CIRCULATION, V87, P659, DOI 10.1161/01.CIR.87.2.659; GOODMAN SG, 1994, AM J CARDIOL, V74, P657, DOI 10.1016/0002-9149(94)90305-0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MEADE TW, 1988, EUR HEART J, V9, P836, DOI 10.1093/oxfordjournals.eurheartj.a062576; MEADE TW, 1995, AM J CARDIOL, V75, pB23, DOI 10.1016/0002-9149(95)80006-E; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1996, ORAL ANTICOAGULANTS, P130; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; MORRISSEY JH, 1993, BLOOD, V81, P734; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Salomaa V V, 1994, J Cardiovasc Risk, V1, P241; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; Vorchheimer, 1995, J Thromb Thrombolysis, V2, P171	31	245	247	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	1997	350	9075					389	396						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259652				2022-12-28	WOS:A1997XQ24800008
J	Neal, DE				Neal, DE			Watchful waiting or drug therapy for benign prostatic hyperplasia?	LANCET			English	Editorial Material							PROSTATECTOMY; SYMPTOMS				Neal, DE (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT SURG,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Neal, David/0000-0002-6033-5086				Andersen JT, 1997, UROLOGY, V49, P839, DOI 10.1016/S0090-4295(97)00185-4; Barry MJ, 1997, J UROLOGY, V157, P10, DOI 10.1016/S0022-5347(01)65267-4; EMBERTON M, 1995, BRIT J UROL, V75, P301, DOI 10.1111/j.1464-410X.1995.tb07341.x; JACOBSEN SJ, 1997, J UROL S, V17, P191; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; NEAL DE, 1987, BRIT J UROL, V60, P554, DOI 10.1111/j.1464-410X.1987.tb05041.x; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202	7	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					305	306		10.1016/S0140-6736(05)63382-X	http://dx.doi.org/10.1016/S0140-6736(05)63382-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251630				2022-12-28	WOS:A1997XP24200003
J	Hurley, SF; Jolley, DJ; Kaldor, JM				Hurley, SF; Jolley, DJ; Kaldor, JM			Effectiveness of needle-exchange programmes for prevention of HIV infection	LANCET			English	Article							INJECTING DRUG-USERS	Background Needle-exchange programmes (NEPs) are potentially a key strategy for containing the spread of HIV infection among injecting drug users, but their implementation has been limited by uncertainty about their effectiveness. We used an ecological study design to compare changes over time in HIV seroprevalence in injecting drug users worldwide, for cities with and without NEPs. Methods Published reports of HIV seroprevalence in injecting drug users were identified, and unpublished information on HIV seroprevalence for injecting drug users entering drug treatment in the USA between 1988 and 1993 was obtained from the Centers for Disease Control and Prevention. Details of the implementation of NEPs were obtained from published reports and experts. For each of the 81 cities with HIV seroprevalence data from more than 1 year and NEP implementation details, the rate of change of seroprevalence was estimated by regression analysis. The average difference in this rate for cities with and without NEPs was calculated. Findings On average, seroprevalence increased by 5.9% per year in the 52 cities without NEPs, and decreased by 5.8% per year in the 29 cities with NEPs. The average annual change in seroprevalence was 11% lower in cities with NEPs (95% CI - 17.6 to -3.9, p = 0.004). Interpretation A plausible explanation for this difference is that NEPs led to a reduction in HIV incidence among injecting drug users. Despite the possibility of confounding, our results, together with the clear theoretical mechanisms by which NEPs could reduce HIV incidence, strongly support the view that NEPs are effective.	UNIV MELBOURNE, DEPT PUBL HLTH & COMMUNITY MED, PARKVILLE, VIC 3052, AUSTRALIA; UNIV NEW S WALES, NATL CTR HIV EPIDEMIOL & CLIN RES, SYDNEY, NSW, AUSTRALIA	University of Melbourne; University of New South Wales Sydney; Kirby Institute			Kaldor, John M/D-4545-2011					Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; HAGAN H, 1995, AM J PUBLIC HEALTH, V85, P1531, DOI 10.2105/AJPH.85.11.1531; Hills, 1993, STAT MODELS EPIDEMIO; *I HLTH POL STUD, 1993, PUBL HLTH IMP NEEDL; Jarlais DCD, 1996, LANCET, V348, P987, DOI 10.1016/S0140-6736(96)02536-6; KAPLAN EH, 1994, AIDS, V8, P567, DOI 10.1097/00002030-199405000-00001; KAPLAN EH, 1994, STAT MED, V13, P2179, DOI 10.1002/sim.4780131923; NICOLOSI A, 1992, AM J EPIDEMIOL, V135, P225, DOI 10.1093/oxfordjournals.aje.a116275; *PAN NEEDL EXCH BL, 1995, PREV HIV TRANSM ROL; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; STIMSON GV, 1989, AIDS, V3, P253, DOI 10.1097/00002030-198905000-00001; *US GEN ACC OFF, 1993, NEEDL EXCH PROGR RES	14	254	256	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	1997	349	9068					1797	1800		10.1016/S0140-6736(96)11380-5	http://dx.doi.org/10.1016/S0140-6736(96)11380-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269214				2022-12-28	WOS:A1997XF73500010
J	Krasnopolsky, VA; Mumma, MJ; Abbott, M; Flynn, BC; Meech, KJ; Yeomans, BK; Feldman, PD; Cosmovici, CB				Krasnopolsky, VA; Mumma, MJ; Abbott, M; Flynn, BC; Meech, KJ; Yeomans, BK; Feldman, PD; Cosmovici, CB			Detection of soft x-rays and a sensitive search for noble gases in comet Hale-Bopp (C/1995 O1)	SCIENCE			English	Article							ONE-ELECTRON CAPTURE; CROSS-SECTIONS; B2 HYAKUTAKE; P/HALLEY; COLLISIONS; IONS; EVOLUTION; HELIUM; SOLAR; EUVE	An image of comet Hale-Bopp (C/1995 O1) in soft x-rays reveals a central emission offset from the nucleus, as well as an extended emission feature that does not correlate with the dust jets seen at optical wavelengths, Neon was found to be depleted in the cometary ice by more than a factor of 25 relative to solar abundance, which suggests that ices in Hale-Bopp formed at (or later experienced) temperatures higher than 25 kelvin, A helium line emission at a wavelength of 584 angstroms was detected and may be attributable to charge transfer of solar wind alpha particles in the cometary coma, Ionized oxygen and another helium line contribute to an emission observed at 538 angstroms.	NASA, GODDARD SPACE FLIGHT CTR, GREENBELT, MD 20771 USA; UNIV CALIF BERKELEY, CTR EXTREME ULTRAVIOLET ASTROPHYS, BERKELEY, CA 94720 USA; UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; CNR, IST FIS SPAZIO INTERPLANETARIO, I-00044 FRASCATI, ITALY	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of California System; University of California Berkeley; University of Hawaii System; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Johns Hopkins University; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF)	Krasnopolsky, VA (corresponding author), CATHOLIC UNIV AMER, WASHINGTON, DC 20064 USA.		Krasnopolsky, Vladimir/L-5085-2013; Meech, Karen/CAH-1412-2022; mumma, michael j/I-2764-2013; Flynn, Brigid/ABC-2003-2021	mumma, michael j/0000-0003-4627-750X; Flynn, Brigid/0000-0002-9329-724X				Abbott MJ, 1996, ASTROPHYS J SUPPL S, V107, P451, DOI 10.1086/192371; AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; ALTWEGG K, 1993, ASTRON ASTROPHYS, V279, P260; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BARNUN A, 1988, ASTROPHYS J, V324, pL31, DOI 10.1086/185084; Bingham R, 1997, SCIENCE, V275, P49, DOI 10.1126/science.275.5296.49; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; Bowyer S., 1991, EXTREME ULTRAVIOLET, P397; BREKKE P, 1993, ASTROPHYS J, V408, P735, DOI 10.1086/172633; CHAKRABARTI S, 1983, J GEOPHYS RES-SPACE, V88, P4898, DOI 10.1029/JA088iA06p04898; Cravens TE, 1997, GEOPHYS RES LETT, V24, P105, DOI 10.1029/96GL03780; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; DIJKKAMP D, 1985, J PHYS B-AT MOL OPT, V18, P737, DOI 10.1088/0022-3700/18/4/018; FELDMAN PD, 1991, ASTROPHYS J, V379, pL37, DOI 10.1086/186148; FELDMAN PD, 1987, ASTRON ASTROPHYS, V187, P325; GLADSTONE GR, 1994, GEOPHYS RES LETT, V21, P461, DOI 10.1029/93GL03290; GLADSTONE GR, 1995, SCIENCE, V268, P1595, DOI 10.1126/science.268.5217.1595; GOLDSTEIN BE, 1987, ASTRON ASTROPHYS, V187, P174; GRINGAUZ KI, 1990, COMET HALLEY INVESTI, P147; Haberli RM, 1997, SCIENCE, V276, P939, DOI 10.1126/science.276.5314.939; HODGKINSON JM, 1995, J PHYS B-AT MOL OPT, V28, pL393, DOI 10.1088/0953-4075/28/12/001; JANEV RK, 1988, ATOM DATA NUCL DATA, V40, P249, DOI 10.1016/0092-640X(88)90008-3; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; KELLY RL, 1987, J PHYS CHEM REF DATA, V16, P1; Krasnopolsky V, 1997, ICARUS, V128, P368, DOI 10.1006/icar.1997.5722; Krasnopolsky V, 1997, PHYS WORLD, V10, P21; KRASNOPOLSKY VA, 1991, ASTRON ASTROPHYS, V245, P662; KRASNOPOLSKY VA, 1994, ICARUS, V109, P337, DOI 10.1006/icar.1994.1098; Krasnopolsky VA, 1996, J GEOPHYS RES-SPACE, V101, P15765, DOI 10.1029/96JA01080; KRASNOPOLSKY VA, 1996, B AM ASTRON SOC, V28, P1095; LIDE DR, 1995, CRC HDB CHEM PHYSICS; Lisse CM, 1996, SCIENCE, V274, P205, DOI 10.1126/science.274.5285.205; MCCULLOUGH RW, 1992, J PHYS B-AT MOL OPT, V25, pL193, DOI 10.1088/0953-4075/25/7/007; MCDONALD K, 1994, ASTRON J, V108, P1843, DOI 10.1086/117197; MEIER RR, 1991, SPACE SCI REV, V58, P1, DOI 10.1007/BF01206000; Millis R.L., 1996, B AM ASTRON SOC, V28, P1095; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; MUMMA MJ, 1993, PROTOSTARS PLANETS, V3, P1172; MUMMA MJ, 1997, 6696 IAU; Northrop TG, 1997, ICARUS, V127, P246, DOI 10.1006/icar.1997.5694; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; Rauer H, 1997, SCIENCE, V275, P1909, DOI 10.1126/science.275.5308.1909; RICHARDS PG, 1994, J GEOPHYS RES-SPACE, V99, P8981, DOI 10.1029/94JA00518; RYUFUKU H, 1980, PHYS REV A, V21, P745, DOI 10.1103/PhysRevA.21.745; Safronov V S., 1969, EVOLUTION PROTOPLANE; Safronov V.S., 1972, EVOLUTION PROTOPLANE; Schleicher DG, 1997, SCIENCE, V275, P1913, DOI 10.1126/science.275.5308.1913; SHAH MB, 1974, J PHYS B-AT MOL OPT, V7, P256, DOI 10.1088/0022-3700/7/2/011; STERN SA, 1992, ICARUS, V95, P157, DOI 10.1016/0019-1035(92)90198-G; STEWART AIF, 1987, ASTRON ASTROPHYS, V187, P369; VEMAZZA JE, 1978, ASTROPHYS J SUPPL SE, V37, P485; Weaver HA, 1997, SCIENCE, V275, P1900, DOI 10.1126/science.275.5308.1900; WEAVER HA, 1987, ASTRON ASTROPHYS, V187, P411; Wickramasinghe NC, 1996, ASTROPHYS SPACE SCI, V239, P121, DOI 10.1007/BF00653772	55	93	93	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1488	1491		10.1126/science.277.5331.1488	http://dx.doi.org/10.1126/science.277.5331.1488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278508	Green Submitted			2022-12-28	WOS:A1997XV42900035
J	Fan, QR; Mosyak, L; Winter, CC; Wagtmann, N; Long, EO; Wiley, DC				Fan, QR; Mosyak, L; Winter, CC; Wagtmann, N; Long, EO; Wiley, DC			Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors	NATURE			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; HUMAN GROWTH-HORMONE; HUMAN TISSUE FACTOR; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; HUMAN CD4; COMPLEX; BINDING; 2.8-ANGSTROM; MOLECULE	Abnormal cells deficient in class I major histocompatibility complex (MHC) expression are lysed by a class of lymphocytes called natural killer (NK) cells(1). This lysis provides a defence against pathogens and tumour cells that downregulate MHC expression to avoid an MHC-restricted, T-cell immune response. Normal cells escape lysis because their MHC molecules are recognized by NK-cell inhibitory receptors, which inhibit lysis(2). Several such inhibitory receptor families have been described in humans and mice (reviewed in Ief. 2). In the human killer-cell inhibitory receptor family, individual p58 members are specific for a subset of class I human leukocyte antigen (HLA)-C molecules. The human p58 natural killer-cell inhibitory receptor done 42 recognizes HLA-Cw4, -Cw2 and -Cw6, but not HLA-Cw3, -Cw2, -Cw7 or -Cw8, which are recognized by p58 killer-cell inhibitor receptor clone 43 (ref. 3). We have determined the X-ray structure of the p58 NK-cell inhibitory receptor clone 42 at 1.7-Angstrom resolution. The structure has tandem immunoglobulin-like domains positioned at an acute, 60-degree angle. Loops on the outside of the elbow between the domains form a binding site projected away from the NK-cell surface. The topology of the domains and their arrangement relative to each other reveal a relationship to the haematopoietic receptor family, with implications for the signalling mechanism in NK cells.	NIAID, IMMUNOGENET LAB, NIH, ROCKVILLE, MD 20852 USA; HARVARD UNIV, HOWARD HUGHES MED INST, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Howard Hughes Medical Institute			Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Fan QR, 1996, P NATL ACAD SCI USA, V93, P7178, DOI 10.1073/pnas.93.14.7178; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LJUGGREN HG, 1990, IMMUNOL TODAY, V11, P237; Long EO, 1997, IMMUNOL REV, V155, P135, DOI 10.1111/j.1600-065X.1997.tb00946.x; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; Pende D, 1996, J EXP MED, V184, P505, DOI 10.1084/jem.184.2.505; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Winter CC, 1997, J IMMUNOL, V158, P4026	31	148	153	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					96	100		10.1038/38028	http://dx.doi.org/10.1038/38028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288975				2022-12-28	WOS:A1997XU59600053
J	Tarasow, TM; Tarasow, SL; Eaton, BE				Tarasow, TM; Tarasow, SL; Eaton, BE			RNA-catalysed carbon-carbon bond formation	NATURE			English	Article							LEWIS-ACID CATALYSIS; DIELS-ALDER REACTION; PORPHYRIN METALATION; RIBOZYMES; WORLD; EVOLUTION; WATER	The 'RNA world' hypothesis(1-3), which assumes that the chemical processes that led to the appearance of life were carried out by RNA molecules, has stimulated interest in catalytic reactions involving oligonucleotides such as catalytic RNA (ribozymes)(4). Naturally occurring ribozymes have, for example, been shown to efficiently catalyse the formation and cleavage of nucleic-acid phosphodiester bonds(4-8), and this narrow range of RNA-catalysed reactions has been subsequently expanded by in vitro selection methods to include ester(9) and amide(10,24) bond formation S(N)2 reactions and porphyrin metallations(11,12). Carbon-carbon bond formation and the creation of asymmetric centres are both of great importance biochemically, but have not yet been accomplished by RNA catalysis, A widely used reaction that creates two new carbon-carbon bonds and up to four stereo-centres is the Diels-Alder cycloaddition, which occurs between a 1,3-butadiene and an alkene. Here we report the successful application of in vitro selection to isolate pyridine-modified RNA molecules that catalyse a Diels-Alder cycloaddition, We find that the RNA molecules accelerate the reaction rate by a factor of up to 800 relative to the uncatalysed reaction.	NEXSTAR PHARMACEUT INC,BOULDER,CO 80301									BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; Conn MM, 1996, J AM CHEM SOC, V118, P7012, DOI 10.1021/ja961249c; Cotton F. A., 1988, ADV INORGANIC CHEM; Dewey TM, 1996, NUCLEOS NUCLEOT, V15, P1611, DOI 10.1080/07328319608002461; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P644; Joyce GF, 1996, CURR BIOL, V6, P965, DOI 10.1016/S0960-9822(02)00640-1; JOYCE GF, 1991, NEW BIOL, V3, P399; JOYCE GF, 1996, CHEM BIOL, V3, P405; KAZAKOV SA, 1996, T BIOORG BIOL CHEM, P244; KUMAR PKR, 1995, FASEB J, V9, P1183, DOI 10.1096/fasebj.9.12.7672511; Li YF, 1996, NAT STRUCT BIOL, V3, P743, DOI 10.1038/nsb0996-743; Lohse PA, 1996, NATURE, V381, P442, DOI 10.1038/381442a0; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MORRIS KN, 1994, P NATL ACAD SCI USA, V91, P13028, DOI 10.1073/pnas.91.26.13028; Ni JS, 1996, ANAL CHEM, V68, P1989, DOI 10.1021/ac960270t; OTTO S, 1995, TETRAHEDRON LETT, V36, P2645, DOI 10.1016/0040-4039(95)00304-U; Otto S, 1996, J AM CHEM SOC, V118, P7702, DOI 10.1021/ja960318k; Pomerantz SC, 1997, J AM CHEM SOC, V119, P3861, DOI 10.1021/ja963875f; Tarasow TM, 1997, BIOCONJUGATE CHEM, V8, P89, DOI 10.1021/bc960082+; WIEGAND TW, IN PRESS CHEM BIOL; Williams J W, 1979, Methods Enzymol, V63, P437	24	300	322	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					54	57		10.1038/37950	http://dx.doi.org/10.1038/37950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288965				2022-12-28	WOS:A1997XU59600041
J	Cornwall, J				Cornwall, J			Tuberculosis: a clinical problem of international importance	LANCET			English	Article																			0	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					660	661		10.1016/S0140-6736(96)12039-0	http://dx.doi.org/10.1016/S0140-6736(96)12039-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288062				2022-12-28	WOS:A1997XU28300044
J	Raviglione, MC; Dye, C; Schmidt, S; Kochi, A				Raviglione, MC; Dye, C; Schmidt, S; Kochi, A			Assessment of worldwide tuberculosis control	LANCET			English	Article							UNITED-STATES; EPIDEMIOLOGY; TRENDS; EUROPE	Background Because worldwide tuberculosis (TB) control had never been assessed, WHO set up a surveillance and monitoring project in 1995. The objectives were to assess the performance of national TB programmes; to assess the extent of implementation of the WHO strategy of TB control; and to attempt a comparison between regions that had adopted the WHO strategy and those that had not. Methods In June, 1996, we sent data-collection forms requesting information on national TB programmes' control policies, 1995 case treatment results to 216 territories. We assessed the performance of national TB programmes by comparing case notifications with estimated incidence and by outcome of treatment in cohorts of patients. We also investigated worldwide treatment success and case detection among sputum-smear-positive patients. Findings 180 (83%) of the 216 countries, areas, and replied to WHO (98% of the In 1995, the WHO control strategy had been implemented in 75 countries, and in 39 of these implementation was countrywide. Up to 23% of the worldwide population lived in regions where the strategy was available. In 1995, 3 297 688 cases of TB (all types) were reported, of which 1 161 411 (35%) were sputum-smear positive. 54% of all reported cases in countries that used the WHO strategy were sputum-smear positive, compared with 30% in other countries. The worldwide case-detection rate of new sputum-smear-positive cases was 35%. 92% of cases registered for treatment in 1994 in regions that used WHO strategy were assessed for outcome and 76% were treated successfully, compared with 54% and 42%, respectively, in regions that had not implemented the WHO strategy. Among cases reported worldwide in 1994, the documented treatment-success rate was 43%. Interpretation National TB programmes that have control adopted the WHO TB strategy achieve higher cure rates, but their impact on TB is modest on a worldwide scale. Wider continuous coverage with the WHO strategy is needed for effective worldwide TB control.			Raviglione, MC (corresponding author), WHO, GLOBAL TB PROGRAMME, 20 AVE APPIA, CH-1211 GENEVA 27, SWITZERLAND.		Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793; RAVIGLIONE, Mario/0000-0002-9331-2067				CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; Enarson D A, 1991, Bull Int Union Tuberc Lung Dis, V66, P195; Harries AD, 1996, LANCET, V347, P807, DOI 10.1016/S0140-6736(96)90874-0; Jain NK, 1992, IND J TUBERC, V92, P145; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; *NAT TUB I, 1974, B WORLD HEALTH ORGAN, V51, P473; RAVIGLIONE MC, 1994, TUBERCLE LUNG DIS, V75, P400, DOI 10.1016/0962-8479(94)90113-9; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; SPRINGETT V H, 1971, Tubercle, V52, P73, DOI 10.1016/0041-3879(71)90015-8; SRYBLO K, 1989, REV INFECT DIS S2, V11, pS339; Styblo K., 1985, B INT UNION TUBERC, V60, P117; UPLEKAR MW, 1993, TUBERCLE LUNG DIS, V74, P332, DOI 10.1016/0962-8479(93)90108-A; *WHO, 1997, WHOTB97225; *WHO, 1991, 44WORLD HLTH ASS GEN; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2; World Health Organization, 1994, WHOTB94179; Yanai H, 1996, AIDS, V10, P527, DOI 10.1097/00002030-199605000-00012; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1	22	153	158	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					624	629		10.1016/S0140-6736(97)04146-9	http://dx.doi.org/10.1016/S0140-6736(97)04146-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288045				2022-12-28	WOS:A1997XU28300010
J	Lodmell, JS; Dahlberg, AE				Lodmell, JS; Dahlberg, AE			A conformational switch in Escherichia coli 16S ribosomal RNA during decoding of messenger RNA	SCIENCE			English	Article							DIRECTED CROSS-LINKING; AFFECT TRANSLATIONAL FIDELITY; HIGHER-ORDER STRUCTURE; SECONDARY STRUCTURE; 30S SUBUNIT; A-SITE; P-SITE; REGION; BINDING; INITIATION	Direct evidence is presented for a conformational switch in 16S ribosomal RNA (rRNA) that affects tRNA binding to the ribosome and decoding of messenger RNA (mRNA). These data support the hypothesis that dynamic changes in rRNA structure occur during translation. The switch involves two alternating base-paired arrangements apparently facilitated by ribosomal proteins S5 and S12, and produces significant changes in the rRNA structure, Chemical probing shows reciprocal enhancements or protections at sites in 16S rRNA that are at or very near sites that were previously crosslinked to mRNA. These data indicate that the switch affects codon-anticodon arrangement acid proper selection of tRNA at the ribosomal A site, and that the switch is a fundamental mechanism in all ribosomes.	BROWN UNIV, DEPT MOL & CELL BIOL & BIOCHEM, PROVIDENCE, RI 02912 USA	Brown University					NIGMS NIH HHS [GM19756, GM07601] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAD JP, 1994, J MOL BIOL, V235, P1251, DOI 10.1006/jmbi.1994.1078; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; ANDERSSON DI, 1982, MOL GEN GENET, V187, P467, DOI 10.1007/BF00332630; ANDERSSON DI, 1986, BIOCHIMIE, V68, P705, DOI 10.1016/S0300-9084(86)80164-X; BILGIN N, 1990, EMBO J, V9, P735, DOI 10.1002/j.1460-2075.1990.tb08167.x; BOHMAN K, 1984, MOL GEN GENET, V198, P90, DOI 10.1007/BF00328706; BRAKIERGINGRAS L, COMMUNICATION; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRINK MF, 1993, EMBO J, V12, P3987, DOI 10.1002/j.1460-2075.1993.tb06076.x; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x; CURRAN JF, 1989, J MOL BIOL, V209, P65, DOI 10.1016/0022-2836(89)90170-8; DAMMEL CS, 1993, GENE DEV, V7, P660, DOI 10.1101/gad.7.4.660; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; Ehrenberg M, 1995, BIOCHEM CELL BIOL, V73, P1049, DOI 10.1139/o95-112; EHRESMANN C, 1986, NUCLEIC ACIDS RES, V14, P4803, DOI 10.1093/nar/14.12.4803; ERICSON G, 1995, J MOL BIOL, V250, P407, DOI 10.1006/jmbi.1995.0386; GESTELAND RF, 1993, RNA WORLD; GLOTZ C, 1980, NUCLEIC ACIDS RES, V8, P2377, DOI 10.1093/nar/8.11.2377; Gorini L., 1974, RIBOSOMES; GRAVEL M, 1987, BIOCHEMISTRY-US, V26, P6227, DOI 10.1021/bi00393a041; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; Heilek GM, 1996, SCIENCE, V272, P1659, DOI 10.1126/science.272.5268.1659; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HUI A, 1987, P NATL ACAD SCI USA, V84, P4762, DOI 10.1073/pnas.84.14.4762; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; Karimi R, 1996, EMBO J, V15, P1149, DOI 10.1002/j.1460-2075.1996.tb00453.x; KURLAND CG, 1990, RIBOSOME, P513; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; LATEANA A, 1995, RNA, V1, P772; LAUGHREA M, 1992, BIOCHEMISTRY-US, V31, P12035, DOI 10.1021/bi00163a011; Liebman Stuart., COMMUNICATION; LODMELL JS, 1995, P NATL ACAD SCI USA, V92, P10555, DOI 10.1073/pnas.92.23.10555; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; LODMELL JS, UNPUB; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V191, P483, DOI 10.1016/0022-2836(86)90143-9; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1996, RIBOSOMAL RNA STRUCT, P239; OCONNOR M, 1992, NUCLEIC ACIDS RES, V20, P4221, DOI 10.1093/nar/20.16.4221; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1995, RNA, V1, P194; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; RHEINBERGER HJ, 1983, EUR J BIOCHEM, V134, P421, DOI 10.1111/j.1432-1033.1983.tb07584.x; RINKEAPPEL J, 1994, NUCLEIC ACIDS RES, V22, P3018, DOI 10.1093/nar/22.15.3018; RINKEAPPEL J, 1993, NUCLEIC ACIDS RES, V21, P2853, DOI 10.1093/nar/21.12.2853; Rodnina MV, 1995, BIOCHEM CELL BIOL, V73, P1221, DOI 10.1139/o95-132; Sergiev PV, 1997, RNA, V3, P464; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SIPLEY J, 1993, P NATL ACAD SCI USA, V90, P2315, DOI 10.1073/pnas.90.6.2315; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TRIMAN K, 1989, J MOL BIOL, V209, P645, DOI 10.1016/0022-2836(89)92000-7; VandePeer Y, 1996, NUCLEIC ACIDS RES, V24, P86, DOI 10.1093/nar/24.1.86; VANRYK DI, 1995, NUCLEIC ACIDS RES, V23, P3563, DOI 10.1093/nar/23.17.3563; VILA A, 1994, P NATL ACAD SCI USA, V91, P11148, DOI 10.1073/pnas.91.23.11148; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WATANABE S, 1972, J MOL BIOL, V67, P443, DOI 10.1016/0022-2836(72)90462-7; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; ZAMIR A, 1971, J MOL BIOL, V60, P347, DOI 10.1016/0022-2836(71)90299-3; ZIMMERMANN RA, 1996, RIBOSOMAL RNA STRUCT, P277	67	183	192	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	1997	277	5330					1262	1267		10.1126/science.277.5330.1262	http://dx.doi.org/10.1126/science.277.5330.1262			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271564				2022-12-28	WOS:A1997XT82700043
J	Cabral, JHM; Jackson, AP; Smith, CV; Shikotra, N; Maxwell, A; Liddington, RC				Cabral, JHM; Jackson, AP; Smith, CV; Shikotra, N; Maxwell, A; Liddington, RC			Crystal structure of the breakage-reunion domain of DNA gyrase	NATURE			English	Article							A PROTEIN; COMPLEX; TOPOISOMERASE; TRANSPORT; GRAPHICS; PROGRAM	DNA gyrase is a type II DNA topoisomerase from bacteria that introduces supercoils into DNA(1,2). It catalyses the breakage of a DNA duplex (the G segment), the passage of another segment (the T segment) through the break, and then the reunification of the break. This activity involves the opening and dosing of a series of molecular 'gates' which is coupled to ATP hydrolysis. Here we present the crystal structure of the 'breakage-reunion' domain of the gyrase at 2.8 Angstrom resolution. Comparison of the structure of this 59K (relative molecular mass, 59,000) domain with that of a 92K fragment of yeast topoisomerase II (ref. 3) reveals a very different quaternary organization, and we propose that the two structures represent two principal conformations that participate in the enzymatic pathway. The gyrase structure reveals a new dimer contact with a grooved concave surface for binding the G segment and a duster of conserved charged residues surrounding the active-site tyrosines. It also shows how breakage of the G segment can occur and, together with the topoisomerase II structure, suggests a pathway by which the T segment can be released through the second gate of the enzyme. Mutations that confer resistance to the quinolone antibacterial agents cluster at the new dimer interface, indicating how these drugs might interact with the gyrase-DNA complex.	UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND	University of Leicester			Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716; Maxwell, Anthony/0000-0002-5756-6430				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Caron P R, 1994, Adv Pharmacol, V29B, P271; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Wigley D.B., 1995, NUCL ACIDS MOL BIOL, P165; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126	22	382	388	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					903	906		10.1038/42294	http://dx.doi.org/10.1038/42294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278055	Bronze			2022-12-28	WOS:A1997XT75400056
J	Connolly, HM; Crary, JL; McGoon, MD; Hensrud, DD; Edwards, BS; Edwards, WD; Schaff, HV				Connolly, HM; Crary, JL; McGoon, MD; Hensrud, DD; Edwards, BS; Edwards, WD; Schaff, HV			Valvular heart disease associated with fenfluramine-phentermine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY PULMONARY-HYPERTENSION; ECHOCARDIOGRAPHY	Background Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. Methods We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. Results Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. Conclusions These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease. (C) 1997, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN,DIV CARDIOVASC DIS & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV PREVENT & OCCUPAT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV ENDOCRINOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV ANAT PATHOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV THORAC & CARDIOVASC SURG,ROCHESTER,MN 55905; MERITCARE MED CTR,HEART SERV,FARGO,ND	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic				Schaff, Hartzell/0000-0003-0994-027X				Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; BECKETT AH, 1972, J PHARM PHARMACOL, V24, P108, DOI 10.1111/j.2042-7158.1972.tb08942.x; BRENOT F, 1993, BRIT HEART J, V70, P537; HEUER L, 1978, CHIR PRAX, V23, P497; Klein A L, 1990, J Am Soc Echocardiogr, V3, P54; LANGRETH R, 1997, WALL STREET J   0331, pB8; MCMURRAY J, 1986, BRIT MED J, V292, P239, DOI 10.1136/bmj.292.6515.239-a; MITCHELL P, 1990, J AFFECT DISORDERS, V19, P43, DOI 10.1016/0165-0327(90)90008-V; MORITA T, 1983, AM REV RESPIR DIS, V127, P747; NISHIMURA RA, 1985, MAYO CLIN PROC, V60, P321, DOI 10.1016/S0025-6196(12)60540-0; PELLIKKA PA, 1993, CIRCULATION, V87, P1188, DOI 10.1161/01.CIR.87.4.1188; REDFIELD MM, 1992, ANN INTERN MED, V117, P50, DOI 10.7326/0003-4819-117-1-50; REDFIELD MM, 1994, TOP CLIN CARDIOL, P63; ROBIOLIO PA, 1995, CIRCULATION, V92, P790, DOI 10.1161/01.CIR.92.4.790; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; Thorson AH, 1958, ACTA MED SCAND, V334, P99; WEINTRAUB M, 1984, ARCH INTERN MED, V144, P1143, DOI 10.1001/archinte.144.6.1143; Weir EK, 1996, CIRCULATION, V94, P2216, DOI 10.1161/01.CIR.94.9.2216	18	1141	1169	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					581	588		10.1056/NEJM199708283370901	http://dx.doi.org/10.1056/NEJM199708283370901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271479				2022-12-28	WOS:A1997XT39400001
J	Severin, FF; Sorger, PK; Hyman, AA				Severin, FF; Sorger, PK; Hyman, AA			Kinetochores distinguish GTP from GDP forms of the microtubule lattice	NATURE			English	Article							SLOWLY HYDROLYZABLE ANALOG; NEWT LUNG-CELLS; DYNAMIC INSTABILITY; BUDDING YEAST; MITOTIC SPINDLE; PROTEIN COMPLEX; LIVING CELLS; IN-VITRO; CENTROMERE; HYDROLYSIS	During prometaphase in mitotic cell division, chromosomes attach to the walls of microtubules and subsequently move to microtubule ends, where they stay throughout mitosis(1,2). This end-attachment seems to be essential for correct chromosome segregating. However, the mechanism by which kinetochores, the multiprotein complexes that link chromosomes to the microtubules of the mitotic spindle(3,4), recognize and stay attached to microtubule ends is not understood. One due comes from the hydrolysis of GTP that occurs during microtubule polymerization. Although tubulin dimers must contain GTP to polymerize, this GTP is rapidly hydrolysed following the addition of dimers to a growing polymer. This creates a microtubule consisting largely of GDP-tubulin, with a small cap of GTP-tubulin at the ends. It is possible that kinetochores distinguish the different structural states of a GTP-versus a GDP-microtubule lattice, We have examined this question in vitro using reconstituted kinetochores from the yeast Saccharomyces cerevisiae. We found that kinetochores in vitro bind preferentially to GTP-rather than GDP-microtubules, and to the plus-end preferentially over the lattice. Our results could explain how kinetochores stay at microtubule ends and thus segregate chromosomes correctly during mitosis in vivo. This result demonstrates that proteins exist that can distinguish the GTP conformation of the microtubule lattice.	EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	European Molecular Biology Laboratory (EMBL); Massachusetts Institute of Technology (MIT)			Severin, Fedor/AAD-5444-2019; Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Sorger, Peter/0000-0002-3364-1838; Severin, Fedor/0000-0001-6703-1256				ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; BAILEY NTJ, 1995, STATISTICAL METHODS; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; EARNSHAW W C, 1992, Current Opinion in Cell Biology, V4, P86, DOI 10.1016/0955-0674(92)90063-I; HUITOREL P, 1988, J CELL BIOL, V106, P151, DOI 10.1083/jcb.106.1.151; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; KINGSBURY J, 1991, CELL, V66, P483, DOI 10.1016/0092-8674(81)90012-X; KINGSBURY J, 1993, MOL BIOL CELL, V4, P859, DOI 10.1091/mbc.4.8.859; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; MILLER JM, 1990, J CELL BIOL, V110, P703, DOI 10.1083/jcb.110.3.703; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHILSTRA MJ, 1987, BIOCHEM BIOPH RES CO, V147, P588, DOI 10.1016/0006-291X(87)90971-5; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WANG W, 1993, J BIOL CHEM, V268, P24796	31	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					888	891		10.1038/42270	http://dx.doi.org/10.1038/42270			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278051	Bronze			2022-12-28	WOS:A1997XT75400052
J	Ralston, SH				Ralston, SH			Science, medicine, and the future - Osteoporosis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NITRIC-OXIDE; BONE; MICE				Ralston, SH (corresponding author), UNIV ABERDEEN, SCH MED, ABERDEEN AB25 2ZD, SCOTLAND.							Arai H, 1997, J BONE MINER RES, V12, P915, DOI 10.1359/jbmr.1997.12.6.915; CHAMBRES TJ, 1991, VITAM HORM, P40; Cooper GS, 1996, J BONE MINER RES, V11, P1841; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Evans DM, 1996, J BONE MINER RES, V11, P300; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Graafmans WC, 1997, J BONE MINER RES, V12, P1241, DOI 10.1359/jbmr.1997.12.8.1241; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GUEGUEN R, 1995, J BONE MINER RES, V10, P2017; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Ralston SH, 1997, QJM-MON J ASSOC PHYS, V90, P247, DOI 10.1093/qjmed/90.4.247; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0	18	28	39	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	1997	315	7106					469	472		10.1136/bmj.315.7106.469	http://dx.doi.org/10.1136/bmj.315.7106.469			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284669	Green Published			2022-12-28	WOS:A1997XT71400024
J	Han, M				Han, M			Gut reaction to Wnt signaling in worms	CELL			English	Review							C-ELEGANS; ENCODES; PROTEIN				Han, M (corresponding author), UNIV COLORADO,DEPT MOL CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.							Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; DRASNOW RE, 1995, DEVELOPMENT, V121, P4095; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; Harris J, 1996, DEVELOPMENT, V122, P3117; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Peifer M, 1996, SCIENCE, V272, P974, DOI 10.1126/science.272.5264.974; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schnabel R., 1997, C ELEGANS, P361; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; THORPE JC, 1997, CELL, V90, P695; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411	18	51	63	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					581	584		10.1016/S0092-8674(00)80517-6	http://dx.doi.org/10.1016/S0092-8674(00)80517-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288737	Bronze			2022-12-28	WOS:A1997XT06600001
J	Wellings, DJ; Unsworth, J				Wellings, DJ; Unsworth, J			Environmental control systems for people with a disability: an update	BRITISH MEDICAL JOURNAL			English	Article							DISABLED PEOPLE; TECHNOLOGY; COMMUNICATION; DEVICES; HOMES				Wellings, DJ (corresponding author), REG REHABIL CTR,BIRMINGHAM B29 6JA,W MIDLANDS,ENGLAND.							ARRUABARRENA A, 1989, J MED ENG TECHNOL, V13, P28, DOI 10.3109/03091908909030190; BARNES MP, 1994, BRIT MED J, V309, P1181, DOI 10.1136/bmj.309.6963.1181; Barnes MP, 1994, CLIN REHABIL, V8, P362; Bell F, 1987, Int Rehabil Med, V8, P105; *BRIT SOC REH MED, 1994, PRESCR IND; Curtin M., 1994, BRIT J OCCUPATIONAL, V57, P376; CURTIN M, 1994, B J OCC THER, P419; *DEP HLTH, 1993, ENV CONTR SYST; DICEY R, 1987, AM J OCCUP THER, V41, P717; Dymond E, 1996, CLIN REHABIL, V10, P93, DOI DOI 10.1177/026921559601000202; DYMOND EA, 1988, J BIOMED ENG, V10, P483, DOI 10.1016/0141-5425(88)90105-7; EFTHIMIOU J, 1981, ARCH PHYS MED REHAB, V62, P131; FLACHBERGER C, 1995, EUROPEAN CONTEXT ASS, V105, P13; Jenkin R, 1967, Spec Educ, V56, P9; JONES RD, 1980, MED BIOL ENG COMPUT, V18, P607, DOI 10.1007/BF02443133; KIRBY N, 1989, NURS CLIN N AM, V70, P621; KWEE H, 1995, IEEE ENG MED BIOL, P330; MANDELSTAM M, 1992, ENV CONTROL SYSTEMS; MCDONALD DW, 1989, ARCH PHYS MED REHAB, V70, P621; MCKENNA M, 1992, 101 U YORK CTR HLTH; *MED DEV AG, 1994, ENV CONTROL SYSTEMS; *NAT AUD OFF, 1992, HLTH SERV PHYS DIS P; NOYES JM, 1989, APPL ERGON, V20, P293, DOI 10.1016/0003-6870(89)90193-2; PEHRINGER JL, 1989, OTOLARYNG CLIN N AM, V22, P143; PLATTS R, 1993, PARAPLEGIA, V313, P280; PLATTS RGS, 1994, BRIT MED J, V309, P1182, DOI 10.1136/bmj.309.6963.1182; Prouse P, 1991, Health Trends, V23, P105; SUMMERS G, 1988, CLIN REHABIL, V2, P231; SYMINGTON DC, 1986, ARCH PHYS MED REHAB, V67, P322; THORNETT CEE, 1990, J MED ENG TECHNOL, V14, P87, DOI 10.3109/03091909009015419; THORNETT CEE, 1990, J BIOMED ENG, V12, P205, DOI 10.1016/0141-5425(90)90042-L; von Maltzahn W. W., 1995, IEEE Transactions on Rehabilitation Engineering, V3, P222, DOI 10.1109/86.392365; Woods B M, 1990, Int Disabil Stud, V12, P137	33	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					409	412		10.1136/bmj.315.7105.409	http://dx.doi.org/10.1136/bmj.315.7105.409			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR549	9277608	Green Published			2022-12-28	WOS:A1997XR54900025
J	Kerneis, S; Bogdanova, A; Kraehenbuhl, JP; Pringault, E				Kerneis, S; Bogdanova, A; Kraehenbuhl, JP; Pringault, E			Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria	SCIENCE			English	Article							VIBRIO-CHOLERAE; EXPRESSION; BINDING; CACO-2; VILLIN; MODEL; LINE	The epithelium that lines the gut is impermeable to macromolecules and microorganisms, except in Peyer's patches (PPs), where the lymphoid follicle-associated epithelium (FAE) contains M cells that transport antigens and microorganisms. A cultured system that reproduces the main characteristics of FAE and M cells was established by cultivation of PP lymphocytes with the differentiated human intestinal cell line Caco-2. Lymphocytes settled into the epithelial monolayer, inducing reorganization of the brush border and a temperature-dependent transport of particles and Vibrio cholerae. This model system could prove useful for intestinal physiology, vaccine research, and drug delivery studies.	UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	University of Lausanne; Swiss Institute Experimental Cancer Research; University of Lausanne								Bens M, 1996, AM J PHYSIOL-CELL PH, V270, pC1666, DOI 10.1152/ajpcell.1996.270.6.C1666; Bienenstock J., 1994, HDB MUCOSAL IMMUNOLO, P403; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DANIELSEN EM, 1994, BIOCHEMISTRY-US, V33, P1599, DOI 10.1021/bi00172a041; DEBEAUREGARD MAC, 1995, EMBO J, V14, P409, DOI 10.1002/j.1460-2075.1995.tb07017.x; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FREEMAN TC, 1995, PFLUG ARCH EUR J PHY, V430, P394, DOI 10.1007/BF00373915; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; KAOUTZANI P, 1994, J CLIN INVEST, V94, P788, DOI 10.1172/JCI117398; KEMEIS S, UNPUB; Kerneis S, 1996, GASTROENTEROLOGY, V110, P515, DOI 10.1053/gast.1996.v110.pm8566599; KRAEHENBUHL JP, UNPUB; MACDONALD TT, 1982, IMMUNOLOGY, V45, P769; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; OWEN RL, 1983, AM J ANAT, V168, P199, DOI 10.1002/aja.1001680207; OWEN RL, 1986, J INFECT DIS, V153, P1108, DOI 10.1093/infdis/153.6.1108; PANIGRAHI P, 1990, INFECT IMMUN, V58, P3415, DOI 10.1128/IAI.58.10.3415-3424.1990; PAPPO J, 1989, CLIN EXP IMMUNOL, V76, P144; PINTO M, 1983, BIOL CELL, V47, P323; SAVIDGE TC, 1994, PFLUG ARCH EUR J PHY, V428, P391, DOI 10.1007/BF00724523; SAVIDGE TC, 1995, ADV EXP MED BIOL, V371, P239; Siebers A, 1996, TRENDS MICROBIOL, V4, P22, DOI 10.1016/0966-842X(96)81501-0; SMITH MW, 1985, J CELL PHYSIOL, V124, P219, DOI 10.1002/jcp.1041240208	24	490	509	5	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					949	952		10.1126/science.277.5328.949	http://dx.doi.org/10.1126/science.277.5328.949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252325				2022-12-28	WOS:A1997XQ98500040
J	CourtoisCoutry, N; Roush, D; Rajendran, V; McCarthy, JB; Geibel, J; Kashgarian, M; Caplan, MJ				CourtoisCoutry, N; Roush, D; Rajendran, V; McCarthy, JB; Geibel, J; Kashgarian, M; Caplan, MJ			A tyrosine-based signal targets H/K-ATPase to a regulated compartment and is required for the cessation of gastric acid secretion	CELL			English	Article							HELICOBACTER-PYLORI; MENETRIERS DISEASE; HYPERTROPHIC GASTROPATHY; PARIETAL-CELLS; TRANSFERRIN RECEPTOR; NATURAL-HISTORY; TRANSGENIC MICE; ENDOCYTOSIS; INTERNALIZATION; IDENTIFICATION	Gastric acid secretion is mediated by the H/K-ATPase of parietal cells. Activation of acid secretion involves insertion of H/K-ATPase into the parietal cell plasmalemma, while its cessation is associated with reinternalization of the H/K-ATPase into an intracellular storage compartment The cytoplasmic tail of the H/K-ATPase beta subunit includes a four residue sequence homologous to tyrosine-based endocytosis signals. We generated transgenic mice expressing H/K-ATPase beta subunit in which this motif's tyrosine residue is mutated to alanine. Gastric glands from animals expressing mutant beta subunit constitutively secrete acid and continuously express H/K-ATPase at their cell surfaces. Thus, the beta subunit's tyrosine-based signal is required for the internalization of H/K-ATPase and for the termination of acid secretion. As a consequence of chronic hyperacidity, the mice develop gastric ulcers and a hypertrophic gastropathy resembling Menetrier's disease.	YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT SURG,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University			COUTRY, Nathalie/O-9352-2017	COUTRY, Nathalie/0000-0001-5830-4013; Caplan, Michael/0000-0001-5768-4405				[Anonymous], 1993, Gut, V34, P1672; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAYERDORFFER E, 1993, NEW ENGL J MED, V329, P60, DOI 10.1056/NEJM199307013290116; BAYERDORFFER E, 1994, GUT, V35, P701, DOI 10.1136/gut.35.5.701; BERGLINDH T, 1980, AM J PHYSIOL, V238, pG165, DOI 10.1152/ajpgi.1980.238.3.G165; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; BLASER MJ, 1987, GASTROENTEROLOGY, V93, P371, DOI 10.1016/0016-5085(87)91028-6; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CHEW CS, 1986, AM J PHYSIOL, V250, pG814, DOI 10.1152/ajpgi.1986.250.6.G814; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS JM, 1977, ANN SURG, V185, P456, DOI 10.1097/00000658-197704000-00015; FORTE TM, 1977, GASTROENTEROLOGY, V73, P941; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; FRANK BW, 1967, GASTROENTEROLOGY, V53, P953; GEIBEL J, 1995, GASTROENTEROLOGY, V109, P1060, DOI 10.1016/0016-5085(95)90563-4; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; HOGAN B, 1986, MANIPULATING MOUSE E; KIRKPATRICK PM, 1980, GASTROENTEROLOGY, V79, P4; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; LENCER WI, 1990, J CELL BIOL, V111, P379, DOI 10.1083/jcb.111.2.379; Menetrier P, 1888, ARCH PHYSL NORM PATH, V1, P32; Menetrier P, 1888, ARCH PHYSL NORM PATH, V1, P236; MERCIER F, 1989, J CELL BIOL, V108, P441, DOI 10.1083/jcb.108.2.441; Murer H, 1996, ANNU REV PHYSIOL, V58, P607, DOI 10.1146/annurev.physiol.58.1.607; PETTITT JM, 1995, J CELL SCI, V108, P1127; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SCHARSCHMIDT BF, 1977, AM J MED, V63, P644, DOI 10.1016/0002-9343(77)90210-8; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; SCHOFIELD GC, 1979, J ANAT, V128, P669; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; STOLTE M, 1993, Z GASTROENTEROL, V31, P289; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; Wang L, 1996, AM J PHYSIOL-GASTR L, V271, pG613, DOI 10.1152/ajpgi.1996.271.4.G613; WOLFSEN HC, 1993, GASTROENTEROLOGY, V104, P1310, DOI 10.1016/0016-5085(93)90339-E; ZOLLINGER RM, 1955, ANN SURG, V142, P709, DOI 10.1097/00000658-195510000-00015	44	94	98	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					501	510		10.1016/S0092-8674(00)80510-3	http://dx.doi.org/10.1016/S0092-8674(00)80510-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267030	hybrid			2022-12-28	WOS:A1997XQ06300014
J	Domian, IJ; Quon, KC; Shapiro, L				Domian, IJ; Quon, KC; Shapiro, L			Cell type-specific phosphorylation and proteolysis of a transcriptional regulator controls the G1-to-S transition in a bacterial cell cycle	CELL			English	Article							HISTIDINE PROTEIN-KINASE; CAULOBACTER-CRESCENTUS; ESCHERICHIA-COLI; CHROMOSOMAL ORIGIN; DNA-REPLICATION; GENE-EXPRESSION; ACTIVATOR; DIVISION; SITE; DIFFERENTIATION	The global transcriptional regulator CtrA controls multiple events in the Caulobacter cell cycle, including the initiation of DNA replication, DNA methylation, cell division, and flagellar biogenesis. CtrA is a member of the response regulator family of two component signal transduction systems and is activated by phosphorylation. We report here that this phosphorylation signal enters the cell cycle at mid S phase. In addition, CtrA function is modulated by temporally and spatially controlled proteolysis. When an active CtrA protein is present at the wrong time in the cell cycle, owing to expression of a mutant CtrA derivative that is active in the absence of phosphorylation and is not turned over during the cell cycle, the G1-to-S transition is blocked and the cell cycle aborts. Thus, both phosphorylation and proteolysis are critical determinants of bacterial cell cycle control in a manner that is analogous to the control of the eukaryotic cell cycle.			Domian, IJ (corresponding author), STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, R01GM032506] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51426, GM32506/5120MZ] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; BENSON AK, 1994, P NATL ACAD SCI USA, V91, P4989, DOI 10.1073/pnas.91.11.4989; BROWN JL, 1994, EMBO J, V13, P5186, DOI 10.1002/j.1460-2075.1994.tb06849.x; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Creighton T. E., 1993, PROTEINS STRUCTURES; DEGNEN ST, 1972, J BACTERIOL, V110, P852, DOI 10.1128/JB.110.3.852-856.1972; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; DINGWALL A, 1992, J BACTERIOL, V174, P1760, DOI 10.1128/jb.174.6.1760-1768.1992; ELY B, 1991, METHOD ENZYMOL, V204, P372; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; Hendrix R. W, 1983, LAMBDA, VII; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARCZYNSKI GT, 1992, J MOL BIOL, V226, P959, DOI 10.1016/0022-2836(92)91045-Q; MARCZYNSKI GT, 1995, GENE DEV, V9, P1543, DOI 10.1101/gad.9.12.1543; Meisenzahl AC, 1997, J BACTERIOL, V179, P592, DOI 10.1128/jb.179.3.592-600.1997; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; NAYSMITH K, 1993, CURR OPIN CELL BIOL, V5, P166; OHTA N, 1992, P NATL ACAD SCI USA, V89, P10297, DOI 10.1073/pnas.89.21.10297; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Pogliano K, 1997, J BACTERIOL, V179, P3331, DOI 10.1128/jb.179.10.3331-3341.1997; Quardokus E, 1996, P NATL ACAD SCI USA, V93, P6314, DOI 10.1073/pnas.93.13.6314; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Stephens C, 1996, P NATL ACAD SCI USA, V93, P1210, DOI 10.1073/pnas.93.3.1210; STEPHENS CM, 1993, MOL MICROBIOL, V9, P1169, DOI 10.1111/j.1365-2958.1993.tb01246.x; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; Wingrove JA, 1996, SCIENCE, V274, P597, DOI 10.1126/science.274.5287.597; WINZELER E, 1995, J MOL BIOL, V251, P346, DOI 10.1006/jmbi.1995.0439; Wright R, 1996, GENE DEV, V10, P1532, DOI 10.1101/gad.10.12.1532; YU J, 1992, J BACTERIOL, V174, P3327, DOI 10.1128/jb.174.10.3327-3338.1992; ZWEIGER G, 1994, J MOL BIOL, V235, P472, DOI 10.1006/jmbi.1994.1007	43	329	330	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					415	424		10.1016/S0092-8674(00)80502-4	http://dx.doi.org/10.1016/S0092-8674(00)80502-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267022	Bronze			2022-12-28	WOS:A1997XQ06300006
J	PalBhadra, M; Bhadra, U; Birchler, JA				PalBhadra, M; Bhadra, U; Birchler, JA			Cosuppression in Drosophila: Gene silencing of Alcohol dehydrogenase by white-Adh transgenes is Polycomb dependent	CELL			English	Article							MELANOGASTER; EXPRESSION; COMPLEX; ZESTE; CHROMATIN; POSITION; ELEMENT; STATE; LOCUS	When two to six copies of a white promoter-Alcohol dehydrogenase (Adh) reporter fusion gene are introduced into the genome, the expression is progressively reduced both in larvae and adults rather than the expected gene dosage effect. In addition, multiple transgenes reduce endogenous Adh transcripts, a result that is strongly analogous to ''cosuppression'' phenomena described in many plant species but which has not been previously observed in animals. Silencing of the Adh gene is not influenced by zeste-dependent transvection but strongly affected by the Polycomb and Polycomblike mutations. Polycomb and polyhomeotic proteins are bound to the chromatin at the sites of the repressed w-Adh transgenes.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BABU P, 1980, DEV NEUROBIOLOGY DRO, P35; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BENYAJATI C, 1982, NUCLEIC ACIDS RES, V10, P7261, DOI 10.1093/nar/10.22.7261; BIALOJAN S, 1984, EMBO J, V3, P2543, DOI 10.1002/j.1460-2075.1984.tb02170.x; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; Depicker A., 1996, MECH APPL GENE SILEN, P71; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; FJOSE A, 1984, EMBO J, V3, P2087, DOI 10.1002/j.1460-2075.1984.tb02095.x; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GELBART WM, 1985, COLD SPRING HARB SYM, V50, P119, DOI 10.1101/SQB.1985.050.01.017; GREEN MM, 1959, HEREDITY, V13, P302; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; JACK JW, 1979, P NATL ACAD SCI USA, V76, P1368, DOI 10.1073/pnas.76.3.1368; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; KAUFMAN TC, 1973, GENETICS, V75, P299; LAURIE CC, 1994, GENETICS, V138, P379; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; RABINOW L, 1991, GENETICS, V129, P463; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; ROBERTSON HM, 1988, GENETICS, V118, P461; SCHMIDT ER, 1988, CHROMOSOMA, V96, P353, DOI 10.1007/BF00330701; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; Ursprnng H, 1970, Wilhelm Roux Arch. EntwMech. Org., V164, P201, DOI 10.1007/BF00582032; VANBLOKLAND R, 1994, PLANT J, V6, P861, DOI 10.1046/j.1365-313X.1994.6060861.x	31	190	202	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					479	490		10.1016/S0092-8674(00)80508-5	http://dx.doi.org/10.1016/S0092-8674(00)80508-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267028	Bronze			2022-12-28	WOS:A1997XQ06300012
J	Singh, D; Angel, J; Bentley, G				Singh, D; Angel, J; Bentley, G			Fortnightly review - Plantar fasciitis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PAINFUL HEEL SYNDROME		ROYAL NATL ORTHOPAED HOSP, INST ORTHOPAED, STANMORE HA7 4LP, MIDDX, ENGLAND; BAYLOR COLL MED, HOUSTON, TX 77030 USA	University of London; University College London; Royal National Orthopaedic Hospital NHS Trust; Baylor College of Medicine	Singh, D (corresponding author), ROYAL NATL ORTHOPAED HOSP, FOOT & ANKLE UNIT, STANMORE HA7 4LP, MIDDX, ENGLAND.							AMIS J, 1988, FOOT ANKLE, V9, P91, DOI 10.1177/107110078800900206; ANDERSON RB, 1989, FOOT ANKLE, V9, P317, DOI 10.1177/107110078900900616; Barrett S L, 1995, J Foot Ankle Surg, V34, P51; BLOCKEY NJ, 1956, BRIT MED J, V1, P1277, DOI 10.1136/bmj.1.4978.1277; Cyriax JH, 1983, ILLUSTRATED MANUAL O, P123; DALY PJ, 1992, FOOT ANKLE, V13, P188, DOI 10.1177/107110079201300404; DAVIS PF, 1994, FOOT ANKLE INT, V15, P531, DOI 10.1177/107110079401501002; DEMAIO M, 1993, ORTHOPEDICS, V16, P1153; DUVRIES HL, 1957, ARCH SURG-CHICAGO, V74, P536; FUREY JG, 1975, J BONE JOINT SURG AM, V57, P672, DOI 10.2106/00004623-197557050-00016; GIDUMAL R, 1985, FOOT ANKLE, V6, P44, DOI 10.1177/107110078500600109; INTENZO CM, 1991, CLIN NUCL MED, V16, P325, DOI 10.1097/00003072-199105000-00006; JAHSS MH, 1992, FOOT ANKLE, V13, P227, DOI 10.1177/107110079201300501; KIBLER WB, 1991, AM J SPORT MED, V19, P66, DOI 10.1177/036354659101900111; Kier R, 1994, Magn Reson Imaging Clin N Am, V2, P97; LEACH RE, 1986, FOOT ANKLE, V7, P156, DOI 10.1177/107110078600700305; MESSIER SP, 1988, MED SCI SPORT EXER, V20, P501; Pfeffer GB, 1995, FOOT ANKLE SPORT, P195; RUBIN G, 1963, Am J Orthop, V5, P38; SCHEPSIS AA, 1991, CLIN ORTHOP RELAT R, P185; SELLMAN JR, 1994, FOOT ANKLE INT, V15, P376, DOI 10.1177/107110079401500706; Tanz S S, 1963, Clin Orthop Relat Res, V28, P169; Wall J R, 1993, Foot Ankle, V14, P465; WAPNER KL, 1991, FOOT ANKLE, V12, P135, DOI 10.1177/107110079101200301; WEINER BE, 1979, J AM POD ASSOC, V69, P723, DOI 10.7547/87507315-69-12-723; WILLIAMS PL, 1987, FOOT ANKLE, V7, P345, DOI 10.1177/107110078700700607; WOLGIN M, 1994, FOOT ANKLE INT, V15, P97, DOI 10.1177/107110079401500303	27	106	111	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	1997	315	7101					172	175		10.1136/bmj.315.7101.172	http://dx.doi.org/10.1136/bmj.315.7101.172			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251550	Green Published			2022-12-28	WOS:A1997XM32100026
J	Sinclair, DA; Mills, K; Guarente, L				Sinclair, DA; Mills, K; Guarente, L			Accelerated aging and nucleolar fragmentation yeast sgs1 mutants	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CLONING; GENE; DNA; HELICASE; HOMOLOG; RECQ; TRANSCRIPTION; INTERACTS; TELOMERES	The SGS1 gene of yeast encodes a DNA helicase with homology to the human WRN gene. Mutations in WRN result in Werner's syndrome, a disease with symptoms resembling premature aging. Mutation of SGS1 is shown to cause premature aging in yeast mother cells on the basis of a shortened life-span and the aging-induced phenotypes of sterility and redistribution of the Sir3 silencing protein from telomeres to the nucleolus. Further, in old sgs1 cells the nucleolus is enlarged and fragmented-changes that also occur in old wild-type cells. These findings suggest a conserved mechanism of cellular aging that may be related to nucleolar structure.			Sinclair, DA (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [AG11119] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011119, R01AG011119] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMSTONE FB, 1979, J MORPHOL, V154, P459; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FOREMAN PK, 1994, GENE, V144, P63, DOI 10.1016/0378-1119(94)90204-6; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HALLE J, IN PRESS EUR J CELL; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kim S, 1996, BIOCHEM BIOPH RES CO, V219, P370, DOI 10.1006/bbrc.1996.0240; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; MARTIN GM, 1985, ADV EXP MED BIOL, V190, P161; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; PUVIONDUTILLEUL F, 1983, EXP CELL RES, V138, P423; RINE J, 1987, GENETICS, V116, P9; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEINSTEIN ME, 1988, MECH AGEING DEV, V42, P215, DOI 10.1016/0047-6374(88)90048-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	36	310	317	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 29	1997	277	5330					1313	1316		10.1126/science.277.5330.1313	http://dx.doi.org/10.1126/science.277.5330.1313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271578				2022-12-28	WOS:A1997XT82700057
J	Chapman, AH				Chapman, AH			Changing work patterns	LANCET			English	Article							OBSTETRIC ULTRASOUND; RADIOGRAPHERS; EMERGENCY; ACCIDENT; PROGRAM	In the UH and elsewhere radiographers have taken over some of the work traditionally done by radiologists and this is blurring the boundaries between the two professions. Radiologists may wonder where such changes will lead. This article explores the reasons behind these changes, the practical and medicolegal constraints, and the effect of such changes on the provision of radiology services in the future.			Chapman, AH (corresponding author), ST JAMESS UNIV HOSP,DEPT RADIOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							ANTINEN I, 1993, CLIN RADIOL, V48, P414; ARONSON RL, 1997, RADIOLOGY, V203, pA43; BATES JA, 1994, CLIN RADIOL, V49, P617, DOI 10.1016/S0009-9260(05)81878-1; BERMAN L, 1986, Radiography, V52, P143; Blouin AS, 1996, J NURS ADMIN, V26, P10, DOI 10.1097/00005110-199604000-00004; BRINDLE M, 1997, RCR NEWSL, V50, P3; Chan V, 1996, RADIOLOGY, V199, P555, DOI 10.1148/radiology.199.2.8668811; Craig EJ, 1996, J PERINAT NEONAT NUR, V10, P29, DOI 10.1097/00005237-199606000-00005; *DEP HLTH, 1993, HOSP DOCT TRAIN FUT; Dowling S, 1996, BRIT MED J, V312, P1211; Ferris EJ, 1997, RADIOLOGY, V202, P593, DOI 10.1148/radiology.202.3.9051002; Field S., 1995, RCR NEWSL, V45, P10; FREJI RM, 1996, J ACCID EMERG MED, V13, P41; *GEN MED COUNC, 1995, GOOD MED PRACT; Guido G W, 1995, AACN Clin Issues, V6, P99, DOI 10.1097/00044067-199502000-00013; HAIART DC, 1991, BRIT J CLIN PRACT, V45, P43; KASSIRER JP, 1994, NEW ENGL J MED, V20, P304; MACLEOD AJ, 1992, ARCH EMERG MED, V9, P19; MANNION RAJ, 1995, CLIN RADIOL, V50, P715, DOI 10.1016/S0009-9260(05)83319-7; MEEK SJ, 1995, J ACCID EMERG MED, V12, P177; MEIRE HB, 1986, BRIT MED J, V292, P77, DOI 10.1136/bmj.292.6513.77; *ROYAL COLL RAD, 1993, MED LEG ASP DEL FCR2; *ROYAL COLL RAD, 1993, MED STAFF WORKL CLIN; Tessler FN, 1996, RADIOLOGY, V199, P551, DOI 10.1148/radiology.199.2.8668810; THURFJELL EL, 1994, RADIOLOGY, V191, P241, DOI 10.1148/radiology.191.1.8134580; WITCOMBE JB, 1986, BRIT MED J, V292, P113, DOI 10.1136/bmj.292.6513.113; 1996, NURS TIMES, V92, P26	27	13	13	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					581	583		10.1016/S0140-6736(97)07076-1	http://dx.doi.org/10.1016/S0140-6736(97)07076-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284790				2022-12-28	WOS:A1997XT22100045
J	Kimura, K; Hirano, T				Kimura, K; Hirano, T			ATP-dependent positive supercoiling of DNA by 13S condensin: A biochemical implication for chromosome condensation	CELL			English	Article							UBIQUITOUS PROTEIN FAMILY; ESCHERICHIA-COLI; DOSAGE COMPENSATION; CRUCIFORM DNA; SMC FAMILY; GENE; TOPOISOMERASE; TEMPLATE; DOMAINS; DEFINES	13S condensin is a five-subunit protein complex that plays a central role in mitotic chromosome condensation in Xenopus egg extracts. Two core subunits of this complex, XCAP-C and XCAP-E, belong to an emerging family of putative ATPases, the SMC family. We report here that 13S condensin has a DNA-stimulated ATPase activity and exhibits a high affinity for structured DNAs such as cruciform DNA. 13S condensin is able to introduce positive supercoils into a closed circular DNA in the presence of bacterial or eukaryotic topoisomerase I. The supercoiling reaction is ATP-dependent. We propose that 13S condensin wraps DNA in a right-handed direction by utilizing the energy of ATP hydrolysis. This reaction may represent a key mechanism underlying the compaction of chromatin fibers during mitosis.			Kimura, K (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53926] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; Earnshaw WC, 1991, CURR OPIN STRUC BIOL, V1, P237, DOI 10.1016/0959-440X(91)90068-5; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; MULLINGER AM, 1980, J CELL SCI, V46, P61; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; Oguro A, 1995, DNA Res, V2, P95, DOI 10.1093/dnares/2.2.95; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SEDAT J, 1977, COLD SPRING HARB SYM, V42, P331, DOI 10.1101/SQB.1978.042.01.035; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; TANABE K, 1991, CANCER RES, V51, P4903; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YANG L, 1989, P NATL ACAD SCI USA, V86, P6121, DOI 10.1073/pnas.86.16.6121; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	48	310	318	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					625	634		10.1016/S0092-8674(00)80524-3	http://dx.doi.org/10.1016/S0092-8674(00)80524-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288743	Bronze			2022-12-28	WOS:A1997XT06600007
J	Pierre, P; Turley, SJ; Gatti, E; Hull, M; Meltzer, J; Mirza, A; Inaba, K; Steinman, RM; Mellman, I				Pierre, P; Turley, SJ; Gatti, E; Hull, M; Meltzer, J; Mirza, A; Inaba, K; Steinman, RM; Mellman, I			Developmental regulation of MHC class II transport in mouse dendritic cells	NATURE			English	Article							LANGERHANS CELLS; COMPARTMENTS; MOLECULES; COMPLEX; EXPRESSION; ENDOSOMES; LYSOSOMES; MEMBRANE; PEPTIDE	Dendritic cells (DCs) have the unique capacity to initiate primary and secondary immune responses(1-3). They acquire antigens in peripheral tissues and migrate to lymphoid organs where they present processed peptides to T cells. DCs must therefore exist in distinct functional states, an idea that is supported by observations that they downregulate endocytosis and upregulate surface molecules of the class II major histocompatibility complex (MHC) upon maturation(4-7). Here we investigate the features of DC maturation by reconstituting the terminal differentiation of mouse DCs in vitro and in situ. We find that early DCs, corresponding to those found in peripheral tissues, exhibit a phenotype in which most class II molecules are intracellular and localized to lysosomes. Upon maturation, these cells give rise to a new intermediate phenotype in which intracellular class II molecules are found in peripheral non-lysosomal vesicles, similar to the specialized CIIV population seen in B cells. The intermediate cells then differentiate into late DCs which express almost all of their class II molecules on the plasma membrane. These variations in class II compartmentalization are accompanied by dramatic alterations in the intracellular transport of the ne iv class II molecules and in antigen presentation. We found that although early DCs could not present antigen immediately after uptake, efficient presentation of the previously internalized antigen occurred after maturation, 24-48 hours later. By regulating class II transport and compartmentalization, DCs are able to delay antigen display, a property crucial to their role in immune surveillance.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520; ROCKEFELLER UNIV,NEW YORK,NY 10021	Yale University; Rockefeller University			Steinman, Ralph/F-7729-2012; Mellman, Ira/ABG-5896-2020; Gatti, Evelina/B-7941-2012	Gatti, Evelina/0000-0002-0667-0799; pierre, philippe/0000-0003-0863-8255				AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Austyn JM, 1996, J EXP MED, V183, P1287, DOI 10.1084/jem.183.4.1287; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; CAUX C, 1996, BLOOD CELL BIOCH, P263; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KLEIJMEER MJ, 1995, J IMMUNOL, V154, P5715; LARSEN CP, 1994, J IMMUNOL, V152, P5208; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; THOMAS R, 1997, IMMUNOL TODAY, V17, P559; WILLIAMS LA, 1994, INT REV CYTOL, V153, P41, DOI 10.1016/S0074-7696(08)62188-9	26	632	641	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					787	792		10.1038/42039	http://dx.doi.org/10.1038/42039			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285592	Bronze			2022-12-28	WOS:A1997XR66700054
J	Ray, WA; Taylor, JA; Meador, KG; Thapa, PB; Brown, AK; Kajihara, HK; Davis, C; Gideon, P; Griffin, MR				Ray, WA; Taylor, JA; Meador, KG; Thapa, PB; Brown, AK; Kajihara, HK; Davis, C; Gideon, P; Griffin, MR			A randomized trial of a consultation service to reduce falls in nursing homes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIP FRACTURE; RISK-FACTORS; PSYCHOTROPIC-DRUGS; ELDERLY PATIENTS; RESIDENTS; INJURIES; PREVENTION; COMMUNITY; PROGRAM; LONG	Context.-Falls are a major health problem in nursing homes, but no interventions have been shown to prevent falls in nursing home residents. Objective.-To evaluate an intervention program designed to prevent falls and associated injuries in high-risk nursing home residents. Design.-Randomized controlled trial. Setting and Participants.-Seven pairs of middle Tennessee nursing homes with 1 facility in each pair randomly assigned to the intervention. Facilities had 482 (261 control, 221 intervention) residents who qualified for the study because they had high risk of falls and a potential safety problem that could be addressed by the intervention. Intervention.-Comprehensive structured individual assessment with specific safety recommendations that targeted suboptimal practices for environmental and personal safety, wheelchair use, psychotropic drug use, and transferring and ambulation. Facility staff were encouraged to implement the individual recommendations and to improve overall facility safety. Main Outcome Measures.-The mean proportion of recurrent fallers and incidence rate of injurious falls in the facility in the year following the intervention. Results.-The mean proportion of recurrent fallers in intervention facilities (43.8%) was 19.1% (95% confidence interval, 2.4%-35.8%) lower than that in control facilities (54.1%, P=.03). Intervention facilities had a nonsignificant trend toward a lower mean rate of injurious falls (13.7 vs 19.9 per 100 person-years, reduction of 31.2%, P=.22). Subgroup analyses suggested greatest benefits for residents for whom the recommended interventions were carried out or who had 3 or more falls in the preceding year. Conclusion.-The high rate of falls and related injuries in nursing homes should not be viewed as inevitable, but as outcomes that can be substantially improved through structured safety programs.	BELMONT UNIV, DEPT OCCUPAT THERAPY, NASHVILLE, TN USA; DUKE UNIV, VET AFFAIRS MED CTR, DEPT PSYCHIAT, DURHAM, NC USA	Belmont University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ray, WA (corresponding author), VANDERBILT UNIV, SCH MED, DEPT PREVENT MED, DIV PHARMACOEPIDEMIOL, 221 KIRKLAND HALL, NASHVILLE, TN 37232 USA.				PHS HHS [R49/CCR407306] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1992, LANCET, V340, P1263; AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; Breslow N. E., 1987, STATISTICAL METHODS, VII; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; GIBSON MJ, 1987, DAN MED BULL, V34, P1; GRYFE C I, 1977, Age and Ageing, V6, P201, DOI 10.1093/ageing/6.4.201; GURWITZ JH, 1994, J AM GERIATR SOC, V42, P33, DOI 10.1111/j.1532-5415.1994.tb06070.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LICHTENSTEIN MJ, 1994, AM J EPIDEMIOL, V140, P830, DOI 10.1093/oxfordjournals.aje.a117331; Meador KG, 1997, J AM GERIATR SOC, V45, P207, DOI 10.1111/j.1532-5415.1997.tb04509.x; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; RAY WA, 1992, J CLIN PSYCHOPHARM, V12, P386; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1991, ARCH INTERN MED, V151, P754, DOI 10.1001/archinte.151.4.754; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RAY WA, 1992, J GERONTOL, V47, pM9, DOI 10.1093/geronj/47.1.M9; RAY WA, 1992, ANNU REV GERONTOL, V12, P183; RODRIGUEZ JG, 1995, ACCIDENT ANAL PREV, V27, P625, DOI 10.1016/0001-4575(95)00016-S; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; Snedecor GW, 1980, STAT METHODS, V7th; TAYLOR JA, 1995, MANAGING BEHAV SYMPT; THAPA PB, 1995, AM J EPIDEMIOL, V142, P202, DOI 10.1093/oxfordjournals.aje.a117619; THAPA PB, 1994, J AM GERIATR SOC, V42, P280, DOI 10.1111/j.1532-5415.1994.tb01752.x; THAPA PB, 1989, J GERONTOL, V44, pM112; TIDEIKSAAR R, 1989, GERIATRICS, V44, P57; TIDEIKSAAR R, 1993, FALLS OLDER PERSONS; TINETTI ME, 1994, PREV MED, V23, P756, DOI 10.1006/pmed.1994.1130; Tinetti ME, 1996, AM J EPIDEMIOL, V144, P389; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1990, J AM GERIATR SOC, V38, P1311, DOI 10.1111/j.1532-5415.1990.tb03453.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1992, ANN INTERN MED, V116, P369, DOI 10.7326/0003-4819-116-5-369; TINETTI ME, 1987, J AM GERIATR SOC, V35, P644, DOI 10.1111/j.1532-5415.1987.tb04341.x; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; US Bureau of the Census, 1992, CURR POP REP SPEC ST	40	184	188	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					557	562		10.1001/jama.278.7.557	http://dx.doi.org/10.1001/jama.278.7.557			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XQ986	9268276				2022-12-28	WOS:A1997XQ98600029
J	Cousens, SN; Zeidler, M; Esmonde, TF; DeSilva, R; Wilesmith, JW; Smith, PG; Will, RG				Cousens, SN; Zeidler, M; Esmonde, TF; DeSilva, R; Wilesmith, JW; Smith, PG; Will, RG			Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96	BRITISH MEDICAL JOURNAL			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; ENGLAND; BSE	Objective: To identify changes in the occurrence of Creutzfeldt-Jakob disease that might be related to the epidemic of bovine spongiform encephalopathy. Design: Epidemiological surveillance of the United Kingdom population for Creutzfeldt-Jakob disease based on (a) referral of suspected cases by neurologists, neuropathologists, and neurophysiologists and (b) death certificates. Setting: England and Wales during 1970-84, and whole of the United Kingdom during 1985-96. Subjects: AU 662 patients identified as sporadic cases of Creutzfeldt-Jakob disease. Main outcome measures: Age distribution of patients, age specific time trends of disease, occupational exposure to cattle, potential exposure to causative agent of bovine spongiform encephalopathy. Results: During 1970-96 there was an increase in the number of sporadic cases of Creutzfeldt-Jakob disease recorded yearly in England and Wales. The greatest increase was among people aged over 70. There was a statistically significant excess of cases among dairy farm workers and their spouses and among people at increased risk of contact with live cattle infected with bovine spongiform encephalopathy. During 1994-6 there were six deaths from sporadic Creutzfeldt-Jakob disease in the United Kingdom in patients aged under 30. Conclusions: The increase in the incidence of sporadic Creutzfeldt-Jakob disease and the high incidence in dairy farmers in the United Kingdom may be unrelated to bovine spongiform encephalopathy. The most striking change in the pattern of Creutzfeldt-Jakob disease in the United Kingdom after the epidemic of bovine spongiform encephalopathy is provided by the incidence in a group of exceptionally young patients with a consistent and unusual neuropathological profile. The outcome of mouse transmission studies and the future incidence of the disease in the United Kingdom and elsewhere, will be important in judging whether the agent causing bovine spongiform encephalopathy has infected humans.	WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; CENT VET LAB,ADDLESTONE KT15 3NB,SURREY,ENGLAND	University of Edinburgh	Cousens, SN (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT INFECT & TROP DIS,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560				AYLIN P, 1996, POPUL TRENDS, V85, P34; BELL JE, 1993, BRIT MED BULL, V49, P738, DOI 10.1093/oxfordjournals.bmb.a072645; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Bruton CJ, 1995, NEURODEGENERATION, V4, P357, DOI 10.1006/neur.1995.0043; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; DAVIES PTG, 1993, LANCET, V342, P680, DOI 10.1016/0140-6736(93)91787-M; HARRIESJONES R, 1988, J NEUROL NEUROSUR PS, V51, P113; Hill AF, 1997, LANCET, V350, P188, DOI 10.1016/S0140-6736(05)62356-2; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MEYER LA, 1996, THESIS; *NAT CJD SURV UN, 1995, 4 ANN REP DEP HLTH; SAWCER SJ, 1993, LANCET, V341, P642, DOI 10.1016/0140-6736(93)90414-C; SMITH PEM, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92734-4; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; Wickham A, 1996, BRIT MED J, V312, P1038; WILESMITH JW, 1988, VET REC, V123, P638; WILESMITH JW, 1994, SEMIN VIROL, V5, P179, DOI 10.1006/smvy.1994.1018; WILL RG, 1986, J NEUROL NEUROSUR PS, V49, P749, DOI 10.1136/jnnp.49.7.749; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; Will Robert G., 1996, P119; Young GR, 1996, LANCET, V348, P610, DOI 10.1016/S0140-6736(05)64822-2	24	90	91	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					389	395		10.1136/bmj.315.7105.389	http://dx.doi.org/10.1136/bmj.315.7105.389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277601	Green Published			2022-12-28	WOS:A1997XR54900017
J	Greenhalgh, T				Greenhalgh, T			How to read a paper - Statistics for the non-statistician .2. ''significant'' relations and their pitfalls	BRITISH MEDICAL JOURNAL			English	Article											Greenhalgh, T (corresponding author), UCL, SCH MED, ROYAL FREE HOSP, WHITTINGTON HOSP, DEPT PRIMARY CARE & POPULAT SCI, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				ALTMAN DG, 1995, PRACTICAL STAT MED R, P210; Bland M, 1987, INTRO MED STAT; GUYATT G, 1995, CAN MED ASSOC J, V152, P497; HAINES A, 1995, CRITICAL READING PRI, P124; Taylor R., 1997, BMJ, V315	5	64	65	1	51	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					422	425		10.1136/bmj.315.7105.422	http://dx.doi.org/10.1136/bmj.315.7105.422			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277611	Green Published			2022-12-28	WOS:A1997XR54900029
J	Cohen, JI				Cohen, JI			Epstein-Barr virus and the immune system - Hide and seek	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BURKITTS-LYMPHOMA CELLS; B-CELLS; LYMPHOPROLIFERATIVE DISEASE; EXPRESSION; SURVEILLANCE; LYMPHOCYTES; INFECTION; EBV				Cohen, JI (corresponding author), NIAID,MED VIROL SECT,CLIN INVEST LAB,NIH,BLDG 10,ROOM 11N214,BETHESDA,MD 20892, USA.							CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; COHEN JI, 1991, MEDICINE, V70, P137, DOI 10.1097/00005792-199103000-00005; DECAMPOSLIMA PO, 1994, J EXP MED, V179, P1297, DOI 10.1084/jem.179.4.1297; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; LI QX, 1995, J VIROL, V69, P3987, DOI 10.1128/JVI.69.7.3987-3994.1995; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MORGAN AJ, 1995, DEV EPSTEINBARR VIRU; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROONEY CM, 1985, NATURE, V317, P629, DOI 10.1038/317629a0; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; Sgadari C, 1996, P NATL ACAD SCI USA, V93, P13791, DOI 10.1073/pnas.93.24.13791; Spriggs MK, 1996, J VIROL, V70, P5557, DOI 10.1128/JVI.70.8.5557-5563.1996; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STRAUS SE, 1993, ANN INTERN MED, V118, P45, DOI 10.7326/0003-4819-118-1-199301010-00009; SWAMINATHAN S, 1994, VIROCEPTORS VIROKINE, P111; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; TOSATO G, 1994, BLOOD, V83, P776; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	24	23	25	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					510	513		10.1001/jama.278.6.510	http://dx.doi.org/10.1001/jama.278.6.510			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP243	9256227				2022-12-28	WOS:A1997XP24300034
J	Sultan, AA; Thathy, V; Frevert, U; Robson, KJH; Crisanti, A; Nussenzweig, V; Nussenzweig, RS; Menard, R				Sultan, AA; Thathy, V; Frevert, U; Robson, KJH; Crisanti, A; Nussenzweig, V; Nussenzweig, RS; Menard, R			TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites	CELL			English	Article							MALARIA CIRCUMSPOROZOITE PROTEIN; HOST-CELL INVASION; FALCIPARUM SPOROZOITES; PROTECTIVE ANTIGEN; ANONYMOUS PROTEIN; SURFACE PROTEIN-2; EIMERIA-TENELLA; SALIVARY-GLAND; BLOOD STAGES; REGION-II	Many protozoans of the phylum Apicomplexa are invasive parasites that exhibit a substrate-dependent gliding motility. Plasmodium (malaria) sporozoites, the stage of the parasite that invades the salivary glands of the mosquito vector and the liver of the vertebrate host, express a surface protein called thrombospondin-related anonymous protein (TRAP) that has homologs in other Apicomplexa. By gene targeting in a rodent Plasmodium, we demonstrate that TRAP is critical for sporozoite infection of the mosquito salivary glands and the rat liver, and is essential for sporozoite gliding motility in vitro. This suggests that in Plasmodium sporozoites, and likely in other Apicomplexa, gliding locomotion and cell invasion have a common molecular basis.	NYU, MED CTR,MICHAEL HEIDELBERGER DIV IMMUNOL, DEPT PATHOL,KAPLAN CANC CTR, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT MED & MOL PARASITOL, NEW YORK, NY 10016 USA; JOHN RADCLIFFE HOSP, INST MOL MED, MRC, MOL HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND	New York University; New York University; University of Oxford; Imperial College London				Frevert, Ute/0000-0001-9556-7330; Thathy, Vandana/0000-0001-7797-8638				AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; ARROWOOD MJ, 1991, J PARASITOL, V77, P315, DOI 10.2307/3283104; BALL GH, 1961, J PARASITOL, V47, P787, DOI 10.2307/3275472; BELER JC, 1993, PARASITOL TODAY, V9, P210; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; DUBREMETZ JF, 1978, J ULTRA MOL STRUCT R, V62, P94, DOI 10.1016/S0022-5320(78)90012-6; DUBREMETZ JF, 1985, EXP PARASITOL, V59, P24, DOI 10.1016/0014-4894(85)90053-0; ENTZEROTH R, 1989, PARASITOL RES, V76, P174, DOI 10.1007/BF00930842; FINE E, 1984, AM J TROP MED HYG, V33, P220, DOI 10.4269/ajtmh.1984.33.220; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; HOLLINGDALE MR, 1982, J IMMUNOL, V128, P1929; JENSEN JB, 1978, J PROTOZOOL, V25, P169, DOI 10.1111/j.1550-7408.1978.tb04391.x; KING CA, 1988, PARASITOL TODAY, V4, P315, DOI 10.1016/0169-4758(88)90113-5; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; NAGASAWA H, 1988, EXP PARASITOL, V66, P27, DOI 10.1016/0014-4894(88)90047-1; Nussenzweig RS, 1997, NEW ENGL J MED, V336, P128, DOI 10.1056/NEJM199701093360210; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; PIMENTA PF, 1994, J EUKARYOT MICROBIOL, V41, P608, DOI 10.1111/j.1550-7408.1994.tb01523.x; Robson KJH, 1997, MOL BIOCHEM PARASIT, V84, P1, DOI 10.1016/S0166-6851(96)02774-0; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, MOL BIOCHEM PARASIT, V53, P45, DOI 10.1016/0166-6851(92)90005-5; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; RUSSELL DG, 1981, J CELL SCI, V50, P345; RYNING FW, 1978, INFECT IMMUN, V20, P739, DOI 10.1128/IAI.20.3.739-743.1978; Shakibaei M, 1996, J EXP MED, V184, P1699, DOI 10.1084/jem.184.5.1699; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Sinnis P, 1996, INFECT AGENT DIS, V5, P182; Sinnis Photini, 1996, P15; SPEER CA, 1985, J PARASITOL, V71, P33, DOI 10.2307/3281974; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; STEWART MJ, 1991, J PROTOZOOL, V38, P411, DOI 10.1111/j.1550-7408.1991.tb01379.x; STEWART MJ, 1992, J PROTOZOOL, V39, P663, DOI 10.1111/j.1550-7408.1992.tb04446.x; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Templeton TJ, 1997, MOL BIOCHEM PARASIT, V84, P13, DOI 10.1016/S0166-6851(96)02775-2; TOMLEY FM, 1991, MOL BIOCHEM PARASIT, V49, P277, DOI 10.1016/0166-6851(91)90071-D; VANDERBERG J, 1967, J PROTOZOOL, V14, P82, DOI 10.1111/j.1550-7408.1967.tb01452.x; VANDERBERG JP, 1975, J PARASITOL, V61, P43, DOI 10.2307/3279102; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; VANDERBERG JP, 1990, J PROTOZOOL, V37, P528, DOI 10.1111/j.1550-7408.1990.tb01260.x; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; vanDijk MR, 1996, SCIENCE, V271, P662, DOI 10.1126/science.271.5249.662; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X; WARBURG A, 1992, EXP PARASITOL, V75, P303, DOI 10.1016/0014-4894(92)90215-V; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745	60	470	492	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					511	522		10.1016/S0092-8674(00)80511-5	http://dx.doi.org/10.1016/S0092-8674(00)80511-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267031	hybrid			2022-12-28	WOS:A1997XQ06300015
J	Maldonado, R; Saiardi, A; Valverde, O; Samad, TA; Roques, BP; Borrelli, E				Maldonado, R; Saiardi, A; Valverde, O; Samad, TA; Roques, BP; Borrelli, E			Absence of opiate rewarding effects in mice lacking dopamine D2 receptors	NATURE			English	Article							VENTRAL TEGMENTAL AREA; MORPHINE-WITHDRAWAL SYNDROME; NUCLEUS-ACCUMBENS; MESOLIMBIC SYSTEM; RATS; HEROIN; INVOLVEMENT; STIMULATION; INCREASE; COCAINE	Dopamine receptors have been implicated in the behavioural response to drugs of abuse. These responses are mediated particularly by the mesolimbic dopaminergic pathway arising in the ventral tegmental area and projecting to the limbic system, The rewarding properties of opiates(1) and the somatic expression of morphine abstinence(2) have been related to changes in mesolimbic dopaminergic activity that could constitute the neural substrate for opioid addiction(3), These adaptive responses to repeated morphine administration have been investigated in mice with a genetic disruption of the dopaminergic D2 receptors(4). Although the behavioural expression of morphine withdrawal was unchanged in these mice, a total suppression of morphine rewarding properties was observed in a place-preference test. This effect is specific to the drug, as mice lacking D2 receptors behaved the same as wild-type mice when food is used as reward, We conclude that the D2 receptor plays a crucial role in the motivational component of drug addiction.	UNIV STRASBOURG 1, INST GENET & BIOL MOL & CELLULAIRE, CNRS, INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV PARIS 05, DEPT PHARMACOCHIM MOL & STRUCT,CNRS,URA D1500, INSERM,U266, F-75270 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Valverde, Olga/D-8654-2012; Borrelli, Emiliana/M-8994-2018; Maldonado, Rafael/F-5657-2014	Valverde, Olga/0000-0003-2264-7852; Maldonado, Rafael/0000-0002-4359-8773				BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; BORG PJ, 1994, PHARMACOL BIOCHEM BE, V47, P633, DOI 10.1016/0091-3057(94)90169-4; BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X; BOZARTH MA, 1994, NEUROSCI BIOBEHAV R, V18, P373, DOI 10.1016/0149-7634(94)90050-7; BROEKKAMP CL, 1979, PHARMACOL BIOCHEM BE, V11, P289, DOI 10.1016/0091-3057(79)90137-0; DAUGE V, 1989, PSYCHOPHARMACOLOGY, V99, P168, DOI 10.1007/BF00442803; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; ELMER GI, 1995, PSYCHOPHARMACOLOGY, V117, P23, DOI 10.1007/BF02245094; ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151; FOURNIEZALUSKI MC, 1992, J MED CHEM, V35, P2473, DOI 10.1021/jm00091a016; HARRIS GC, 1994, NATURE, V371, P155, DOI 10.1038/371155a0; JOYCE EM, 1979, NEUROSCI LETT, V14, P207, DOI 10.1016/0304-3940(79)96149-4; KALIVAS PW, 1986, AM J PHYSIOL, V251, pR243, DOI 10.1152/ajpregu.1986.251.2.R243; KALIVAS PW, 1983, J PHARMACOL EXP THER, V227, P229; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LONGONI R, 1987, PSYCHOPHARMACOLOGY, V93, P401, DOI 10.1007/BF00187265; MACKEY WB, 1985, PHARMACOL BIOCHEM BE, V22, P101, DOI 10.1016/0091-3057(85)90492-7; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MALDONADO R, 1992, J PHARMACOL EXP THER, V261, P669; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441; PHILLIPS AG, 1980, PHARMACOL BIOCHEM BE, V12, P965, DOI 10.1016/0091-3057(80)90460-8; Salamone JD, 1996, J NEUROSCI METH, V64, P137, DOI 10.1016/0165-0270(95)00125-5; SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8; SMITH JE, 1985, PHARMACOL BIOCHEM BE, V23, P843, DOI 10.1016/0091-3057(85)90080-2; SPYRAKI C, 1983, PSYCHOPHARMACOLOGY, V79, P278, DOI 10.1007/BF00427827; STINUS L, 1989, BIOL PSYCHIAT, V26, P363, DOI 10.1016/0006-3223(89)90052-8; Valverde O, 1996, PSYCHOPHARMACOLOGY, V123, P119, DOI 10.1007/BF02246168; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469	30	358	391	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 7	1997	388	6642					586	589		10.1038/41567	http://dx.doi.org/10.1038/41567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252189	Bronze			2022-12-28	WOS:A1997XP72200050
J	Taha, TE; Biggar, RJ; Broadhead, RL; Mtimavalye, LAR; Justesen, AB; Liomba, GN; Chiphangwi, JD; Miotti, PG				Taha, TE; Biggar, RJ; Broadhead, RL; Mtimavalye, LAR; Justesen, AB; Liomba, GN; Chiphangwi, JD; Miotti, PG			Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: Clinical trial	BRITISH MEDICAL JOURNAL			English	Article							VAGINAL CHLORHEXIDINE DISINFECTION; HUMAN-IMMUNODEFICIENCY-VIRUS; GROUP-B STREPTOCOCCI; VERTICAL TRANSMISSION; INFECTION; INFANT; LABOR	Objective: To determine if cleansing the birth canal with an antiseptic at del Design: Clinical trial; two months of no intervention were followed by three months of intervention and a final month of no intervention. Setting: Queen Elizabeth Central Hospital (tertiary care urban hospital), Blantyre, Malawi. Subjects: A total of 6965 women giving birth in a six month period and their 7160 babies. Intervention: Manual wipe of the maternal canal with a 0.25% chlorhexidine solution at every vaginal examination before delivery. Babies born during the intervention were also wiped with chlorhexidine. Main Outcome Measures: Effects of the intervention on neonatal and maternal morbidity and mortality. Results: 3635 women giving birth to 3743 babies were enrolled in the intervention phase and 3330 women giving birth to 3417 babies were enrolled in the non-intervention phase, There were no adverse reactions related to the intervention among the mothers al their children. Among infants bent in the intervention phase, overall neonatal admissions were reduced (634/3743 (16.9%) v 661/3417 (19.3%), P < 0.01), as were admissions for neonatal sepsis (7.8 v 17.9 per 1000 live births, P < 0.0002), overall neonatal mortality (28.6 v 36.9 per 1000 live births, P < 0.06), and mortality due to infectious causes (2.4 v 7.3 per 1000 Live births, P < 0.005). Among mothers receiving the intervention, admissions related to delivery were reduced (29.4 v 40.2 per 1000 deliveries, P< 0.02). as iz ere admissions due to postpartum infections (1.7 v 5.1 per 1000 deliveries, P = 0.02) and duration of hospitalisation (Wilcoxan P = 0.008). Conclusions: Cleansing the birth canal with chlorhexidine reduced early neonatal and maternal postpartum infectious problems, The safety, simplicity and low cost of the procedure suggest that it should be considered as standard care to lower infant and maternal morbidity and mortality.	NCI, VIRAL EPIDEMIOL BRANCH, BETHESDA, MD 20852 USA; UNIV MALAWI, COLL MED, BLANTYRE, MALAWI	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Malawi	Taha, TE (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, INFECT DIS PROGRAMME, RM E6011, BALTIMORE, MD 21205 USA.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Taha, Taha/0000-0001-9814-4894				ADRIAANSE AH, 1995, EUR J OBSTET GYN R B, V61, P135, DOI 10.1016/0301-2115(95)02134-S; BEHRMAN RE, 1992, NELSON TXB PEDIAT, P501; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; BURMAN LG, 1992, LANCET, V340, P65, DOI 10.1016/0140-6736(92)90393-H; HARBISON MA, 1989, J ACQ IMMUN DEF SYND, V2, P16; MAHMOUD MM, 1992, TXB PEDIAT INFECT DI, V1, P891; MICHIE CA, 1995, ARCH DIS CHILD, V73, pF46; MTIMAVALYE L, 1995, NEW ENGL J MED, V332, P890, DOI 10.1056/NEJM199503303321313; PRIMHAK RA, 1993, ARCH DIS CHILD-FETAL, V69, P317, DOI 10.1136/adc.69.3_Spec_No.317; TAHA TE, 1994, E AFR MED J, V71, P712; TAHA TE, 1995, INT J EPIDEMIOL, V24, P1022, DOI 10.1093/ije/24.5.1022; Taha TET, 1996, AIDS, V10, P111, DOI 10.1097/00002030-199601000-00021	12	107	111	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					216	219		10.1136/bmj.315.7102.216	http://dx.doi.org/10.1136/bmj.315.7102.216			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	9253269	Green Published			2022-12-28	WOS:A1997XN51700021
J	Brown, N; Young, T; Gray, D; Skene, AM; Hampton, JR				Brown, N; Young, T; Gray, D; Skene, AM; Hampton, JR			Inpatient deaths from acute myocardial infarction, 1982-92: Analysis of data in the Nottingham heart attack register	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NON-Q-WAVE; COMMUNITY-WIDE PERSPECTIVE; HOSPITAL MORTALITY; RANDOMIZED TRIALS; TRENDS; THROMBOLYSIS; DECLINE; DISEASE; CARE; POPULATION	Objective: To assess longitudinal trends in admissions, management, and inpatient mortality from acute myocardial infarction over 10 years. Design: Retrospective analysis based on the Nottingham heart attack register. Setting: Two district general hospitals serving a defined urban and rural population. Subjects: All patients admitted with a confirmed acute myocardial infarction during 1982-4 and 1989-92 (excluding 1991, when data were not collected). Main outcome measures: Numbers of patients, background characteristics, time from onset of symptoms to admission, ward of admission, treatment, and inpatient mortality. Results: Admissions with acute myocardial infarction increased from 719 cases in 1982 to 960 in 1992. The mean age increased from 62.1 years to 66.6 years (P < 0.001), the duration of stay fell from 8.7 days to 7.2 days (P < 0.001), and the proportion of patients aged 75 years and over admitted to a coronary care unit increased significantly from 29.1% to 61.2%. A higher proportion of patients were admitted to hospital within 6 hours of onset of their symptoms in 1989-92 than in 1982-4, but 15% were still admitted after the time window for thrombolysis. Use of beta blockers increased threefold between 1982 and 1992, aspirin was used in over 70% of patients after 1989, and thrombolytic use increased 1.3-fold between 1989 and 1992. Age and sex adjusted odds ratios for inpatient mortality remained unchanged over the study period. Conclusions: Despite an increasing uptake of the ''proved'' treatments, inpatient mortality from myocardial infarction did not change between 1982 and 1992.	UNIV NOTTINGHAM, DEPT MATH, BRITISH HEART FDN, CARDIOVASC STAT UNIT, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	Brown, N (corresponding author), UNIV NOTTINGHAM HOSP, QUEENS MED CTR, DIV CARDIOVASC MED, NOTTINGHAM NG7 2UH, ENGLAND.		Young, Tracey A/A-4543-2010	Young, Tracey/0000-0001-8467-0471				[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; *CENTR STAT OFF, 1992, REG TRENDS, V27; CHRISTIANSEN I, 1971, ACTA MED SCAND, V189, P285; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; CLARKE KW, 1995, BR HEART J S3, V73, P49; COLLINS R, 1991, BRIT HEART J, V66, P250; DELLBORG M, 1994, EUR HEART J, V15, P5, DOI 10.1093/oxfordjournals.eurheartj.a060379; EDLAVITCH SA, 1991, CIRCULATION, V83, P492, DOI 10.1161/01.CIR.83.2.492; Gheorghiade M, 1996, AM HEART J, V131, P250, DOI 10.1016/S0002-8703(96)90349-X; GOLDBERG RJ, 1987, AM HEART J, V113, P273, DOI 10.1016/0002-8703(87)90265-1; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GOLDMAN L, 1982, CIRCULATION, V65, P936, DOI 10.1161/01.CIR.65.5.936; GORE JM, 1987, ARCH INTERN MED, V147, P1729, DOI 10.1001/archinte.147.10.1729; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GRAY D, 1992, Q J MED, V84, P659; GREENBAUM RA, 1995, BRIT HEART J, V74, P493; HAMPTON J, 1993, LANCET, V342, P759; Higgins MW, 1988, TRENDS CORONARY HEAR; HOFVENDAL S, 1971, ACTA MED SCAND S1, V51, P1; JULIAN DG, 1987, BRIT HEART J, V57, P497; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; NAYLOR CD, 1994, J AM COLL CARDIOL, V24, P1431, DOI 10.1016/0735-1097(94)90136-8; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; OGAWA H, 1986, AM HEART J, V111, P513, DOI 10.1016/0002-8703(86)90056-6; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PHIBBS B, 1983, J AM COLL CARDIOL, V1, P561, DOI 10.1016/S0735-1097(83)80090-4; ROWLEY JM, 1992, BRIT HEART J, V67, P255; SPODICK DH, 1983, AM J CARDIOL, V51, P913, DOI 10.1016/S0002-9149(83)80160-X; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; THANAVARO S, 1980, CIRCULATION, V61, P29, DOI 10.1161/01.CIR.61.1.29; ULVENSTAM G, 1985, EUR HEART J, V6, P294, DOI 10.1093/oxfordjournals.eurheartj.a061856; WILCOX RG, 1988, LANCET, V2, P525; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZEMA MJ, 1985, AM J MED, V78, P391, DOI 10.1016/0002-9343(85)90329-8; 1993, S PLUS GUIDE STAT MA	41	47	49	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	1997	315	7101					159	164		10.1136/bmj.315.7101.159	http://dx.doi.org/10.1136/bmj.315.7101.159			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251546	Green Published			2022-12-28	WOS:A1997XM32100020
J	PebayPeyroula, E; Rummel, G; Rosenbusch, JP; Landau, EM				PebayPeyroula, E; Rummel, G; Rosenbusch, JP; Landau, EM			X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases	SCIENCE			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; DRIVEN PROTON PUMP; HALOBACTERIUM-HALOBIUM; PURPLE MEMBRANE; 3-DIMENSIONAL CRYSTALS; ELECTRON-MICROSCOPY; NEUTRON-DIFFRACTION; MOLECULAR-DYNAMICS; TRANSLOCATION; LIGHT	Lipidic cubic phases provide a continuous three-dimensional bilayer matrix that facilitates nucleation and growth of bacteriorhodopsin microcrystals. The crystals diffract x-rays isotropically to 2.0 angstroms. The structure of this light-driven proton pump was solved at a resolution of 2.5 angstroms by molecular replacement, using previous results from electron crystallographic studies as a model, The earlier structure was generally confirmed, but several differences were found, including loop conformations and side chain residues, Eight water molecules are now identified experimentally in the proton pathway. These findings reveal the constituents of the proton translocation pathway in the ground state.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel	PebayPeyroula, E (corresponding author), UNIV GRENOBLE 1,CNRS,INST BIOL STRUCT,CEA,41 AVE MARTYRS,F-38027 GRENOBLE 1,FRANCE.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BLAUROCK AE, 1975, J MOL BIOL, V93, P139, DOI 10.1016/0022-2836(75)90124-2; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2023, DOI 10.1073/pnas.77.4.2023; FERRAND M, 1993, FEBS LETT, V327, P256, DOI 10.1016/0014-5793(93)80999-B; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HEBERLE J, UNPUB; HENDERSON R, 1975, J MOL BIOL, V93, P123, DOI 10.1016/0022-2836(75)90123-0; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1980, J MOL BIOL, V139, P99, DOI 10.1016/0022-2836(80)90298-3; HUMPHREY W, 1994, BIOCHEMISTRY-US, V33, P3668, DOI 10.1021/bi00178a025; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHORANA HG, 1979, P NATL ACAD SCI USA, V76, P5046, DOI 10.1073/pnas.76.10.5046; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KREBS MP, 1991, P NATL ACAD SCI USA, V88, P859, DOI 10.1073/pnas.88.3.859; Landau EM, 1997, J PHYS CHEM B, V101, P1935, DOI 10.1021/jp963347q; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; leCoutre J, 1996, FEBS LETT, V398, P333, DOI 10.1016/S0014-5793(96)01254-9; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MICHEL H, 1980, P NATL ACAD SCI-BIOL, V77, P1283, DOI 10.1073/pnas.77.3.1283; MICHEL H, 1982, EMBO J, V1, P1267, DOI 10.1002/j.1460-2075.1982.tb00023.x; NI B, 1990, GENE, V90, P169, DOI 10.1016/0378-1119(90)90456-2; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P66; OVCHINNIKOV YA, 1979, FEBS LETT, V100, P219, DOI 10.1016/0014-5793(79)80338-5; PAPADOPOULOS G, 1990, J MOL BIOL, V214, P15, DOI 10.1016/0022-2836(90)90140-H; Riesle J, 1996, BIOCHEMISTRY-US, V35, P6635, DOI 10.1021/bi9600456; Russell VA, 1997, SCIENCE, V276, P575, DOI 10.1126/science.276.5312.575; SASAKI J, 1992, J BIOL CHEM, V267, P20782; SCHARNAGL C, 1995, J PHYS CHEM-US, V99, P7787, DOI 10.1021/j100019a068; SCHERTLER GFX, 1993, J MOL BIOL, V234, P156, DOI 10.1006/jmbi.1993.1570; SCHULTEN K, 1978, NATURE, V272, P85, DOI 10.1038/272085a0; SZARAZ S, 1994, BIOPHYS J, V67, P1706, DOI 10.1016/S0006-3495(94)80644-7; TAKEI H, 1994, J BIOL CHEM, V269, P7387; TITTOR J, 1994, BIOPHYS J, V67, P1682, DOI 10.1016/S0006-3495(94)80642-3; ULRICH AS, 1994, BIOCHEMISTRY-US, V33, P5370, DOI 10.1021/bi00184a003; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; WEISSBUCH I, 1995, ACTA CRYSTALLOGR B, V51, P115, DOI 10.1107/S0108768194012061; WILKINS MHF, 1971, NATURE-NEW BIOL, V230, P72, DOI 10.1038/newbio230072a0; Xu D, 1995, BIOPHYS J, V69, P2745, DOI 10.1016/S0006-3495(95)80146-3	48	800	815	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1676	1681		10.1126/science.277.5332.1676	http://dx.doi.org/10.1126/science.277.5332.1676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287223				2022-12-28	WOS:A1997XV68400054
J	Galimand, M; Guiyoule, A; Gerbaud, G; Rasoamanana, B; Chanteau, S; Carniel, E; Courvalin, P				Galimand, M; Guiyoule, A; Gerbaud, G; Rasoamanana, B; Chanteau, S; Carniel, E; Courvalin, P			Multidrug resistance in Yersinia pestis mediated by a transferable plasmid	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FUSIDIC ACID; CHLORAMPHENICOL; ANTIBIOTICS		INST PASTEUR, NATL REFERENCE LAB, WHO, COLLABORATING CTR YERSINIA, F-75724 PARIS 15, FRANCE; INST PASTEUR, NATL REFERENCE CTR ANTIBIOT, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE AGENTS ANTIBACTERIENS, F-75724 PARIS 15, FRANCE; INST PASTEUR, PLAGUE CENT LAB, ANTANANARIVO, MADAGASCAR	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; World Health Organization; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar								[Anonymous], 1996, WKLY EPIDEMIOL REC, V71, P165; Barnes AM, 1992, INFECT DIS, P1285; BENNETT AD, 1983, BIOCHEM J, V215, P29, DOI 10.1042/bj2150029; BISSONNETTE L, 1992, J BACTERIOL, V174, P1248, DOI 10.1128/jb.174.4.1248-1257.1992; BUKHARI AI, 1977, DNA INSERTION ELEMEN, P601; COURVALIN PM, 1978, ANTIMICROB AGENTS CH, V13, P716, DOI 10.1128/AAC.13.5.716; DATTA N, 1974, J GEN MICROBIOL, V83, P191, DOI 10.1099/00221287-83-1-191; FERBER DM, 1981, INFECT IMMUN, V31, P839, DOI 10.1128/IAI.31.2.839-841.1981; Frean JA, 1996, ANTIMICROB AGENTS CH, V40, P2646, DOI 10.1128/AAC.40.11.2646; GARROD LP, 1962, J CLIN PATHOL, V15, P328, DOI 10.1136/jcp.15.4.328; Haas M J, 1975, Methods Enzymol, V43, P611; LLANES C, 1994, J BACTERIOL, V176, P3403, DOI 10.1128/jb.176.11.3403-3407.1994; POYARTSALMERON C, 1990, LANCET, V335, P1422, DOI 10.1016/0140-6736(90)91447-I; RASOAMANANA B, 1989, Archives de l'Institut Pasteur de Madagascar, V56, P37; Rasoamanana B., 1995, Archives de l'Institut Pasteur de Madagascar, V62, P108; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRAG SJ, 1995, TRENDS ECOL EVOL, V10, P319, DOI 10.1016/S0169-5347(00)89118-1; SMITH MD, 1995, ANTIMICROB AGENTS CH, V39, P2153, DOI 10.1128/AAC.39.9.2153; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; 1994, MMWR-MORBID MORTAL W, V43, P242	22	324	352	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					677	680		10.1056/NEJM199709043371004	http://dx.doi.org/10.1056/NEJM199709043371004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU349	9278464				2022-12-28	WOS:A1997XU34900004
J	Sewankambo, N; Gray, RH; Wawer, MJ; Paxton, L; McNairn, D; WabwireMangen, F; Serwadda, D; Li, CJ; Kiwanuka, N; Hillier, SL; Rabe, L; Gaydos, CA; Quinn, TC; KondeLule, J				Sewankambo, N; Gray, RH; Wawer, MJ; Paxton, L; McNairn, D; WabwireMangen, F; Serwadda, D; Li, CJ; Kiwanuka, N; Hillier, SL; Rabe, L; Gaydos, CA; Quinn, TC; KondeLule, J			HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; SEXUALLY-TRANSMITTED DISEASES; PELVIC INFLAMMATORY DISEASE; PREGNANT-WOMEN; GRAM STAIN; SEROPREVALENCE; TYPE-1; SYSTEM; HEALTH; COHORT	Background In-vitro research has suggested that bacterial vaginosis may increase the survival of HIV-1 in the genital tract. Therefore, we investigated the association of HIV-1 infection with vaginal flora abnormalities, including bacterial vaginosis and depletion of lactobacilli, after adjustment for sexual activity and the presence of other sexually transmitted diseases(STDs). Methods During the initial survey round of our community-based trial of STD control for HIV-1 prevention in rural Rakai District, southwestern Uganda, we selected 4718 women aged 15-59 years. They provided interview information, blood for HIV-1 and syphilis serology, urine for detection of Chlamydia trachomatis and Neisseria gonorrhoeae, and two self-administered vaginal swabs for culture of Trichomonas vaginalis and gram-stain detection of vaginal flora, classified by standardised, quantitative, morphological scoring. Scores 0-3 were normal vaginal flora (predominant lactobacilli). Higher scores suggested replacement of lactobacilli by gram-negative, anaerobic microorganisms (4-6 intermediate; 7-8 and 9-10 moderate and severe bacterial vaginosis). Findings HIV-1 frequency was 14.2% among women with normal vaginal flora and 26.7% among those with severe bacterial vaginosis (p<0.001). We found an association between bacterial vaginosis and increased HIV-1 infection among younger women, but not among women older than 40 years; the association could not be explained by differences in sexual activity or concurrent infection with other STDs. The frequency of bacterial vaginosis was similar among HIV-l-infected women with symptoms (55.0%) and without symptoms (55.7%). The adjusted odds ratio of HIV-1 infection associated with any vaginal flora abnormality (scores 4-10) was 1.52 (95% CI 1.22-1.90), for moderate bacterial vagniosis (scores 7-8) it was 1.50 (1.18-1.89), and for severe bacterial vaginosis (scores 9-10) it was 2.08 (1.48-2.94). Interpretation This cross-sectional study cannot show whether disturbed vaginal flora increases susceptibility to HIV-1 infection. Nevertheless, the increased frequency of HIV-1 associated with abnormal flora among younger women, for whom HIV-1 acquisition is likely to be recent, but not among older women, in whom HIV-1 is likely to have been acquired earlier, suggests that loss of lactobacilli or presence of bacterial vaginosis may increase susceptibility to HIV-1 acquisition. If this inference is correct, control of bacterial vaginosis could reduce HIV-1 transmission.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21205 USA; MAKERERE UNIV, KAMPALA, UGANDA; COLUMBIA UNIV, NEW YORK, NY USA; UGANDA VIRUS RES INST, RAKAI PROJECT, ENTEBBE, UGANDA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA	Johns Hopkins University; Makerere University; Columbia University; Uganda Virus Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010	Sewankambo, Nelson/0000-0001-9362-053X	NIAID NIH HHS [R01 AI34826-03] Funding Source: Medline; NICHD NIH HHS [5P30HD06268] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034826] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COHEN CR, 1995, AIDS, V9, P1093, DOI 10.1097/00002030-199509000-00017; DRAPER D, 1993, J CLIN MICROBIOL, V31, P1016, DOI 10.1128/JCM.31.4.1016-1018.1993; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HILL JA, 1992, AM J OBSTET GYNECOL, V166, P720, DOI 10.1016/0002-9378(92)91703-D; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; HILLIER SL, 1993, AM J OBSTET GYNECOL, V169, P455, DOI 10.1016/0002-9378(93)90340-O; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; HOSMER DW, 1989, APPL LOGISTIC REGRES; KAMENGA MC, 1995, AM J OBSTET GYNECOL, V172, P919, DOI 10.1016/0002-9378(95)90022-5; KLEBANOFF SJ, 1991, J EXP MED, V174, P289, DOI 10.1084/jem.174.1.289; KORN AP, 1995, OBSTET GYNECOL, V85, P387, DOI 10.1016/0029-7844(94)00400-8; KORN AP, 1995, J ACQ IMMUN DEF SYND, V9, P361; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MARTIN HL, 1996, 11 INT C AIDS JUL, P7; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; MULDER D, 1995, BRIT MED J, V311, P833, DOI 10.1136/bmj.311.7009.833; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; PAAVONEN J, 1987, BRIT J OBSTET GYNAEC, V94, P454, DOI 10.1111/j.1471-0528.1987.tb03125.x; SMITH KR, 1995, J CLIN MICROBIOL, V33, P455, DOI 10.1128/JCM.33.2.455-457.1995; SWEET RL, 1993, AM J OBSTET GYNECOL, V169, P479, DOI 10.1016/0002-9378(93)90346-K; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303	23	444	461	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	1997	350	9077					546	550		10.1016/S0140-6736(97)01063-5	http://dx.doi.org/10.1016/S0140-6736(97)01063-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284776	hybrid			2022-12-28	WOS:A1997XT22100009
J	Thorpe, CJ; Schlesinger, A; Carter, JC; Bowerman, B				Thorpe, CJ; Schlesinger, A; Carter, JC; Bowerman, B			Wnt signaling polarizes an early C-elegans blastomere to distinguish endoderm from mesoderm	CELL			English	Article							ASYMMETRIC CELL DIVISIONS; CAENORHABDITIS-ELEGANS; MATERNAL GENES; EMBRYOS; GLP-1; PROTEIN; AXES; GUT; IDENTIFICATION; ESTABLISHMENT	A polarizing signal induces endoderm production by a 4-cell stage blastomere in C. elegans called EMS. We identified 16 mutations in five genes, mom-1 through mom-5, required for EMS to produce endoderm. mom-1, mom-2, and mom-3 are required in the signaling cell, P-2, while mom-4 is required in EMS. P-2 signaling downregulates an HMG domain protein, POP-1, in one EMS daughter. The sequence of mom-2 predicts that it encodes a member of the Wnt family of secreted glycoproteins, which in other systems activate HMG domain proteins. Defective mitotic spindle orientations in mom mutant embryos indicate that Wnt signaling influences cytoskeletal polarity in blastomeres throughout the early embryo.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NICHD NIH HHS [HD07348] Funding Source: Medline; NIGMS NIH HHS [GM07413, GM49869] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BRENNER S, 1974, GENETICS, V77, P71; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; DU SJ, 1995, MOL CELL BIOL, V15, P2625; EDGAR LG, 1995, CAENORHABDITIS ELEGA, P303; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1995, J CELL BIOL, V129, P1071, DOI 10.1083/jcb.129.4.1071; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; Gonczy P, 1996, TRENDS CELL BIOL, V6, P382, DOI 10.1016/0962-8924(96)10035-0; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Hird SN, 1996, DEVELOPMENT, V122, P1303; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HUTTER H, 1994, DEVELOPMENT, V120, P2051; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MANGO SE, 1994, DEVELOPMENT, V120, P3019; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; Shelton CA, 1996, DEVELOPMENT, V122, P2043; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	43	409	425	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					695	705		10.1016/S0092-8674(00)80530-9	http://dx.doi.org/10.1016/S0092-8674(00)80530-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288749	Bronze			2022-12-28	WOS:A1997XT06600013
J	Lakshmi, BB; Martin, CR				Lakshmi, BB; Martin, CR			Enantioseparation using apoenzymes immobilized in a porous polymeric membrane	NATURE			English	Article							ENZYME-FACILITATED TRANSPORT; ALPHA-AMINO-ACID; OPTICAL RESOLUTION; ORGANIC-ACIDS; SEPARATION; SURFACE	Chemical separations represent a large portion of the cost of bringing any new pharmaceutical product to the market. Membrane-based separation technologies(1,2), in which the target molecule is selectively extracted and transported across a membrane, are potentially more economical and easier to implement than competing separations methods; but membranes with higher transport selectivities are required, Here we describe an approach for preparing highly selective membranes which involves immobilizing apoenzymes within a microporous composite. The apoenzyme selectively recognizes its substrate molecule and transports it across the composite membrane, without effecting the unwanted chemical conversion of the substrate molecule to product, We demonstrate this approach using three different apoenzymes, Most importantly, it can be used to make enantioselective membranes for chiral separations, one of the most challenging and important problems in bioseparations technology, We are able to achieve a fivefold difference between the transport rates of D-and L-amino acids.	COLORADO STATE UNIV,DEPT CHEM,FT COLLINS,CO 80523	Colorado State University			Martin, Charles/AAA-1040-2019					[Anonymous], 1991, MEMBRANE SEPARATION; BORMAN S, 1990, CHEM ENG NEWS, V68, P9, DOI 10.1021/cen-v068n028.p009; BOYER PD, 1975, ENZYMES; Chen XS, 1996, B CHEM SOC JPN, V69, P255, DOI 10.1246/bcsj.69.255; Collins A.N., 1992, CHIRALITY IND; DIXON M, 1965, BIOCHIM BIOPHYS ACTA, V96, P368, DOI 10.1016/0005-2787(65)90557-5; DORDICK JS, 1989, BIOCATALYSTS IND, P311; HIGUCHI A, 1993, DESALINATION, V90, P127, DOI 10.1016/0011-9164(93)80170-R; HIGUCHI A, 1994, J MEMBRANE SCI, V93, P157, DOI 10.1016/0376-7388(94)80004-9; JENSEN RD, 1994, SCIENCE, V263, P1425; KAKUCHI T, 1990, POLYM J, V22, P199, DOI 10.1295/polymj.22.199; LAKSHMI B, UNPUB; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Martin CR, 1996, CHEM MATER, V8, P1739, DOI 10.1021/cm960166s; MARUYAMA A, 1990, MACROMOLECULES, V23, P2748, DOI 10.1021/ma00212a027; MATSON SL, 1989, FRONTIERS BIOPROCESS; NISHIZAWA M, 1995, SCIENCE, V268, P700, DOI 10.1126/science.268.5211.700; NOBLE RD, 1989, CHEM ENG PROG, V85, P58; NOBLE RD, 1992, J MEMBRANE SCI, V75, P121, DOI 10.1016/0376-7388(92)80011-8; PARTHASARATHY A, 1994, J MEMBRANE SCI, V94, P249, DOI 10.1016/0376-7388(93)E0206-Y; PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0; PENNER RM, 1988, J PHYS CHEM-US, V92, P5274, DOI 10.1021/j100329a042; RETHWISCH DG, 1994, J MEMBRANE SCI, V95, P83, DOI 10.1016/0376-7388(94)85031-3; RETHWISCH DG, 1990, J AM CHEM SOC, V112, P1649, DOI 10.1021/ja00160a065; SCHOLANDER PF, 1960, SCIENCE, V131, P585, DOI 10.1126/science.131.3400.585; STANLEY TJ, 1987, CHEM ENG SCI, V42, P2313, DOI 10.1016/0009-2509(87)80104-5; STEIN WD, 1967, MOVEMENT MOL ACROSS; STINSON SC, 1995, CHEM ENG NEWS, V73, P44, DOI 10.1021/cen-v073n041.p044; Winston W.S., 1992, MEMBRANE HDB; Worthington CC, 1988, WORTHINGTON MANUAL; YOSHIKAWA M, 1995, J MEMBRANE SCI, V108, P171, DOI 10.1016/0376-7388(95)00160-8	31	145	152	5	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					758	760		10.1038/41978	http://dx.doi.org/10.1038/41978			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285586				2022-12-28	WOS:A1997XR66700046
J	Rennie, D; Yank, V; Emanuel, L				Rennie, D; Yank, V; Emanuel, L			When authorship fails - A proposal to make contributors accountable	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PUBLICATION; GHOSTS	A published article is the primary means whereby new work is communicated, priority is established, and academic promotion is determined, Publication depends on trust and requires that authors be held to standards of honesty, completeness, and fairness in their reporting, and to accountability for their statements. The system of authorship, while appropriate for articles with only 1 author, has become inappropriate as the average number of authors of an article has increased; as the work of coauthors has become more specialized and relationships between them have become more complex; and as both credit and, even more, responsibility have become obscured and diluted. Credit and accountability cannot be assessed unless the contributions of those named as authors are disclosed to readers, so the system is flawed. We argue for a radical conceptual and systematic change, to reflect the realities of multiple author ship and to buttress accountability, We propose dropping the outmoded notion of author in favor of the more useful and realistic one of contributor. This requires disclosure to readers of the contributions made to the research and to the manuscript by the contributors, so that they can accept both credit and responsibility, In addition, certain named contributors take on the role of guarantor for the integrity of the entire work. The requirement that all participants be named as contributors will eliminate the artificial distinction between authors and acknowledgees and will enhance the integrity of publication.	AMER MED ASSOC, DIV ETH STAND, CHICAGO, IL 60610 USA	American Medical Association	Rennie, D (corresponding author), UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, 1388 SUTTER ST, 11TH FLOOR, SAN FRANCISCO, CA 94109 USA.							ALBERTS B, 1994, SCIENCE, V266, P1660, DOI 10.1126/science.7992048; ALTMAN LK, 1980, NY TIMES        0809, pA1; *AM ASS ADV SCI, 1995, SURV J COND AM ASS A; ANDERSON C, 1992, NATURE, V355, P101, DOI 10.1038/355101a0; [Anonymous], 1997, JAMA, V277, P927; Baskin TI, 1997, SCIENCE, V275, P14; BATSHAW ML, 1988, NEW ENGL J MED, V318, P741, DOI 10.1056/NEJM198803243181204; Benson K, 1991, CANC B, V43, P324; BRENNAN TA, 1994, NEW ENGL J MED, V331, P673, DOI 10.1056/NEJM199409083311012; Broad W., 1982, BETRAYERS TRUTH; BURMAN KD, 1982, ANN INTERN MED, V97, P602, DOI 10.7326/0003-4819-97-4-602; CARBONE PP, 1992, NEW ENGL J MED, V326, P1084; COLLINS R, 1995, LANCET, V345, P669; CULLITON BJ, 1988, SCIENCE, V241, P525, DOI 10.1126/science.3399886; Davies D, 1996, CAN MED ASSOC J, V155, P877; DAVIS PJ, 1969, NEW ENGL J MED, V281, P989, DOI 10.1056/NEJM196910302811805; De Solla Price D. J., 1963, LITTLE SCI BIG SCI, DOI 10.7312/pric91844; DEBAKEY L, 1995, JAMA-J AM MED ASSOC, V274, P870; deSa P, 1996, SCIENCE, V274, P1593; Drenth Joost P H, 1996, Sci Eng Ethics, V2, P469, DOI 10.1007/BF02583933; ENGLER RL, 1987, NEW ENGL J MED, V317, P1383, DOI 10.1056/NEJM198711263172205; EPSTEIN RJ, 1993, BRIT MED J, V306, P765, DOI 10.1136/bmj.306.6880.765; FLANAGIN A, 1995, JAMA-J AM MED ASSOC, V273, P73, DOI 10.1001/jama.1995.03520250089041; FRANKEL MS, 1993, RESPONSIBLE SCI ENSU, V2; GARFIELD E, 1983, ESSAYS INFORMATION S, V5; Gilson MK, 1997, SCIENCE, V275, P14; Glass R M, 1992, JAMA, V268, P99, DOI 10.1001/jama.268.1.99; Godlee F, 1996, BRIT MED J, V312, P1501, DOI 10.1136/bmj.312.7045.1501a; GREEN MS, 1994, JAMA-J AM MED ASSOC, V271, P1904, DOI 10.1001/jama.1994.03510480028013; GUSTON DH, 1993, RESPONSIBLE SCI ENSU, V2; Hopfield JJ, 1997, SCIENCE, V275, P1403; HORNBEIN T, 1995, ANESTH ANALG, V81, P887, DOI 10.1097/00000539-199510000-00053; Horton R, 1997, LANCET, V350, P5, DOI 10.1016/S0140-6736(05)66236-8; HOUK VN, 1990, ETHICS POLICY SCI PU; HUNT R, 1991, NATURE, V352, P187, DOI 10.1038/352187a0; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; HUTH EJ, 1986, ANN INTERN MED, V104, P257, DOI 10.7326/0003-4819-104-2-257; HUTH EJ, 1990, ETHICS POLICY SCI PU; *INT COMM MED J ED, 1993, JAMA-J AM MED ASSOC, V269, P2282; KASPER CK, 1994, JAMA-J AM MED ASSOC, V271, P1904, DOI 10.1001/jama.1994.03510480028014; KASSIRER JP, 1995, SCIENCE, V268, P785; KENNEDY D, 1985, COMMUNICATION   0918; LEDERBERG J, 1993, SCIENTIST, V7, P10; LEV M, 1981, LANCET, V2, P941; Loehle C, 1997, SCIENCE, V275, P14; Lundberg GD, 1996, JAMA-J AM MED ASSOC, V276, P75, DOI 10.1001/jama.276.1.75; MANCINI GBJ, 1990, ANN INTERN MED, V113, P723, DOI 10.7326/0003-4819-113-9-723_1; Marshall E, 1996, SCIENCE, V274, P908, DOI 10.1126/science.274.5289.908; MOULOPOULOS SD, 1983, BRIT MED J, V287, P1608, DOI 10.1136/bmj.287.6405.1608; *NAT AC SCI NAT AC, 1993, RESP SCI ENS INT RES, V2; *NAT AC SCI NAT AC, 1995, BEING SCI; *OFF SCI INT, 1989, REP INV PAN STANF U; OVER R, 1970, NATURE, V228, P1357, DOI 10.1038/2281357a0; Pasachoff JM, 1997, SCIENCE, V275, P14; Porter R, 1992, MED J MED KNOWLEDGE; POTKIN SG, 1978, NEW ENGL J MED, V298, P1151; REGALADO A, 1995, SCIENCE, V268, P25, DOI 10.1126/science.7701334; RELMAN AS, 1983, NEW ENGL J MED, V308, P1415, DOI 10.1056/NEJM198306093082311; RELMAN AS, 1990, NEW ENGL J MED, V323, P56, DOI 10.1056/NEJM199007053230111; RELMAN AS, 1984, NEW ENGL J MED, V310, P1048, DOI 10.1056/NEJM198404193101609; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P1205, DOI 10.1001/jama.271.15.1205; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; RENNIE D, 1989, JAMA-J AM MED ASSOC, V261, P2543, DOI 10.1001/jama.261.17.2543; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1762; RENNIE D, 1990, ETHICS POLICY SCI PU; RENNIE D, 1995, JAMA-J AM MED ASSOC, V274, P870; SAFFRAN M, 1989, SCIENTIST, V3, P9; SAFFRAN M, 1989, SCIENTIST       0320, V3, P11; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438; Squires BP, 1996, CAN MED ASSOC J, V155, P897; STRUB RL, 1976, LANCET, V2, P1090; *US DHHS, 1995, INT MISC RES REP COM; VIRCHOW R, 1977, SCI QUOTATIONS HARVE, P154; WINSLOW R, 1994, WALL STREET J   0908, P12; Wooley CF, 1996, SCIENCE, V274, P1593; WYLLIE E, 1989, JAMA-J AM MED ASSOC, V261, P2499, DOI 10.1001/jama.1989.03420170041013; ZUCKERMAN HA, 1968, AM J SOCIOL, V74, P276, DOI 10.1086/224641; 1990, NEW SCI         0512, V126, P31; 1993, ANESTH ANALG       S, V77, pS1; 1994, BRIT MED J, V309, P1530; 1995, REGISTER GUARDI 0510, P10; 1993, LANCET, V342, P1498; 1992, ARCH OPHTHALMOL-CHIC, V111, P15	83	434	454	2	60	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					579	585		10.1001/jama.278.7.579	http://dx.doi.org/10.1001/jama.278.7.579			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268280				2022-12-28	WOS:A1997XQ98600033
J	Marr, KA; Sexton, DJ; Conlon, PJ; Corey, GR; Schwab, SJ; Kirkland, KB				Marr, KA; Sexton, DJ; Conlon, PJ; Corey, GR; Schwab, SJ; Kirkland, KB			Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis	ANNALS OF INTERNAL MEDICINE			English	Article							VASCULAR ACCESS; INFECTION; MECHANISMS; EXPERIENCE; TRIAL; CUFF	Background: Dual-lumen cuffed catheters are used for vascular access in patients undergoing hemodialysis. The incidence and appropriate management of catheter-related bacteremia are unknown, Objective: To determine the incidence and outcome of catheter-related bacteremia and to assess the efficacy of catheter salvage. Design: Prospective, observational study. Setting: University hospital inpatient service and four affiliated outpatient dialysis units. Patients: 102 patients with end-stage renal disease who underwent hemodialysis with dual-lumen cuffed catheters between 1 April 1995 and 1 January 1996, Measurements: Number of days that the catheter remained in situ, treatment (catheter removal or attempted salvage with antibiotic therapy), and outcome of bacteremia. Microbiological cultures were done to identify catheter-related bacteremia. Results: 102 patients had a total of 16 081 catheter-days. Forty-one patients (40%) developed 62 episodes of bacteremia (3.9 episodes per 1000 catheter-days [95% CI, 3.0 to 4.9 episodes per 1000 catheter-days]). Twenty-four catheters (39%) were removed immediately, and 38 (61%) were left in place during treatment. Only 12 (32%) of the 38 catheters were salvaged successfully. Salvage was less likely to succeed in patients with gram-positive bacteremia than in patients with gram-negative bacteremia, but this difference was not statistically significant (P = 0.14). Nine of the 41 patients (22%) who developed bacteremia had the following complications: osteomyelitis (6 patients), septic arthritis (1 patient), infective endocarditis (4 patients), and death (2 patients). All complications followed an episode of gram-positive bacteremia, and none was associated with attempted catheter salvage, Conclusions: Bacteremia frequently occurs in patients undergoing hemodialysis with dual-lumen catheters. Antibiotic therapy without catheter removal is unlikely to eradicate catheter-related bacteremia in these patients, but attempted salvage may not increase the risk for complications.	DUKE UNIV, MED CTR, DIV INFECT DIS, DURHAM, NC 27705 USA; DUKE UNIV, MED CTR, DIV NEPHROL, DURHAM, NC 27705 USA	Duke University; Duke University				Sexton, Daniel J/0000-0001-9604-5948				ALMIRALL J, 1989, AM J NEPHROL, V9, P454, DOI 10.1159/000168012; CAPDEVILA JA, 1993, NEPHROL DIAL TRANSPL, V8, P231; CHEESBROUGH JS, 1986, J INFECT DIS, V154, P579, DOI 10.1093/infdis/154.4.579; DAHLBERG PJ, 1995, INFECT CONT HOSP EP, V16, P506; DOBKIN JF, 1978, ANN INTERN MED, V88, P28, DOI 10.7326/0003-4819-88-1-28; DRYDEN MS, 1991, J HOSP INFECT, V19, P257, DOI 10.1016/0195-6701(91)90243-2; FAN PY, 1992, J AM SOC NEPHROL, V3, P1; GROEGER JS, 1993, ANN INTERN MED, V119, P1168, DOI 10.7326/0003-4819-119-12-199312150-00003; KAMAL GD, 1991, JAMA-J AM MED ASSOC, V265, P2364, DOI 10.1001/jama.265.18.2364; KESSLER M, 1993, NEPHRON, V64, P95, DOI 10.1159/000187285; KOZENY GA, 1984, ARCH INTERN MED, V144, P1787, DOI 10.1001/archinte.144.9.1787; MAILLOUX LU, 1991, AM J KIDNEY DIS, V18, P326, DOI 10.1016/S0272-6386(12)80091-6; MOSS AH, 1990, AM J KIDNEY DIS, V16, P211, DOI 10.1016/S0272-6386(12)81020-1; QUEIROS J, 1994, NEPHROLOGIE, V15, P113; SCHWAB SJ, 1988, AM J KIDNEY DIS, V11, P166, DOI 10.1016/S0272-6386(88)80206-3; SCHWARZBECK A, 1978, T AM SOC ART INT ORG, V24, P27; Suhocki PV, 1996, AM J KIDNEY DIS, V28, P379, DOI 10.1016/S0272-6386(96)90495-3; SWARTZ RD, 1994, J AM SOC NEPHROL, V4, P1719; TOULON J, 1994, NEPHROLOGIE, V15, P95; ULDALL PR, 1979, DIALYSIS TRANSPLANT, V8, P963; ULDALL PR, 1981, LANCET, V1, P1373; WINDUS DW, 1993, AM J KIDNEY DIS, V21, P457, DOI 10.1016/S0272-6386(12)80391-X	22	396	402	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					275	+		10.7326/0003-4819-127-4-199708150-00003	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265426				2022-12-28	WOS:A1997XR26600005
J	Riordan, SM; Williams, R				Riordan, SM; Williams, R			Treatment of hepatic encephalopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PORTAL-SYSTEMIC ENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; ORAL ZINC SUPPLEMENTATION; BLIND CONTROLLED TRIAL; CIRRHOTIC-PATIENTS; LIVER-FAILURE; GLOBUS-PALLIDUS; CLINICAL-TRIAL; LACTULOSE; NEOMYCIN		UCL, SCH MED, INST HEPATOL, LONDON WC1E 6HX, ENGLAND	University of London; University College London; UCL Medical School								[Anonymous], 1983, HEPATIC COMA SYNDROM; ATTERBURY CE, 1978, AM J DIG DIS, V23, P398, DOI 10.1007/BF01072921; Balo J, 1932, ARCH PATHOL, V13, P80; BERK DP, 1970, ANN INTERN MED, V73, P393, DOI 10.7326/0003-4819-73-3-393; BERNUAU J, 1986, HEPATOLOGY, V6, P648, DOI 10.1002/hep.1840060417; BIANCHI GP, 1993, J INTERN MED, V233, P385, DOI 10.1111/j.1365-2796.1993.tb00689.x; BLANC P, 1992, HEPATOLOGY, V15, P222, DOI 10.1002/hep.1840150209; BLEICHNER G, 1986, BRIT J SURG, V73, P724, DOI 10.1002/bjs.1800730916; BLOM HJ, 1991, HEPATOLOGY, V13, P445, DOI 10.1016/0270-9139(91)90297-9; Bresci G, 1993, Eur J Med, V2, P414; BUCCI L, 1993, CURR MED RES OPIN, V13, P109, DOI 10.1185/03007999309111539; BUTTERWORTH RF, 1987, NEUROCHEM PATHOL, V6, P1, DOI 10.1007/BF02833598; CAMMA C, 1993, DIGEST DIS SCI, V38, P916, DOI 10.1007/BF01295920; CHAINUVATI T, 1977, ACTA HEPATO-GASTRO, V24, P434; Charlton MR, 1996, GASTROENTEROLOGY, V111, P252, DOI 10.1053/gast.1996.v111.agast961110252; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; CONN HO, 1977, GASTROENTEROLOGY, V72, P573; COTZIAS GC, 1958, PHYSIOL REV, V38, P503, DOI 10.1152/physrev.1958.38.3.503; DAGENAIS MH, 1991, WORLD J SURG, V15, P109, DOI 10.1007/BF01658978; Fabbri A, 1996, JPEN-PARENTER ENTER, V20, P159, DOI 10.1177/0148607196020002159; Ferenci P., 1991, OXFORD TXB CLIN HEPA, V1, P473; FISCHER JE, 1971, LANCET, V2, P75, DOI 10.1016/s0140-6736(71)92048-4; GILBERSTADT SJ, 1980, ARCH INTERN MED, V140, P519, DOI 10.1001/archinte.140.4.519; GITLIN N, 1986, J HEPATOL, V3, P75, DOI 10.1016/S0168-8278(86)80149-0; GITLIN N, 1996, HEPATOLOGY TXB LIVER, V1, P605; GRIMM G, 1988, LANCET, V2, P1392; Groeneweg M, 1996, ELECTROEN CLIN NEURO, V98, P29, DOI 10.1016/0013-4694(95)00200-6; HAUENSTEIN KH, 1995, RADIOLOGY, V194, P175, DOI 10.1148/radiology.194.1.7997547; HERLONG HF, 1980, ANN INTERN MED, V93, P545, DOI 10.7326/0003-4819-93-4-545; HORST D, 1984, HEPATOLOGY, V4, P279, DOI 10.1002/hep.1840040218; HU HL, 1992, BIOL TRACE ELEM RES, V34, P19, DOI 10.1007/BF02783894; ITO S, 1995, LANCET, V346, P124, DOI 10.1016/S0140-6736(95)92147-8; KEAYS RT, 1993, J HEPATOL, V18, P205, DOI 10.1016/S0168-8278(05)80247-8; KEELING PWN, 1980, GUT, V21, P561, DOI 10.1136/gut.21.7.561; KIRCHEIS G, 1994, HEPATIC ENCEPHALOPAT, P373; KRIEGER D, 1995, NEUROLOGY, V45, pA299; KRIEGER D, 1995, LANCET, V346, P270, DOI 10.1016/S0140-6736(95)92164-8; KY SQ, 1992, BRIT J IND MED, V49, P66; LIEHR H, 1992, J GASTROEN HEPATOL, V7, pA106; LOGUERCIO C, 1995, J HEPATOL, V23, P39, DOI 10.1016/0168-8278(95)80309-2; MACBETH WAA, 1965, LANCET, V1, P399; Marchesini G, 1996, HEPATOLOGY, V23, P1084; MENDENHALL CL, 1986, AM J GASTROENTEROL, V81, P540; MICHEL H, 1980, GASTROENTEROLOGY, V79, P207; MORGAN MH, 1982, GUT, V23, P1, DOI 10.1136/gut.23.1.1; MULLEN KD, 1990, LANCET, V336, P81, DOI 10.1016/0140-6736(90)91594-Z; NOMPLEGGI DJ, 1994, HEPATOLOGY, V19, P518; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; PLAUTH M, 1993, J HEPATOL, V17, P308, DOI 10.1016/S0168-8278(05)80210-7; POMIERLAYRARGUES G, 1992, HEPATOLOGY, V16, pA122; POWELL EE, 1990, GASTROENTEROLOGY, V98, P1079, DOI 10.1016/0016-5085(90)90036-Z; PUJOL A, 1993, NEUROLOGY, V43, P65, DOI 10.1212/WNL.43.1_Part_1.65; READ AE, 1961, LANCET, V1, P961; READ AE, 1966, BMJ-BRIT MED J, V1, P1267, DOI 10.1136/bmj.1.5498.1267; REDING P, 1984, LANCET, V2, P493; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIGGIO O, 1991, DIGEST DIS SCI, V36, P1204, DOI 10.1007/BF01307509; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; SCHOLMERICH J, 1986, GASTROENTEROLOGY, V90, P1765; SOMBERG KA, 1995, AM J GASTROENTEROL, V90, P549; SUSHMA S, 1992, HEPATOLOGY, V16, P138, DOI 10.1002/hep.1840160123; THULUVATH PJ, 1995, HEPATOLOGY, V21, P440, DOI 10.1002/hep.1840210227; URIBE M, 1987, HEPATOLOGY, V7, P639, DOI 10.1002/hep.1840070404; URIBE M, 1980, DIGEST DIS SCI, V25, P924, DOI 10.1007/BF01308043; URIBE M, 1979, GASTROENTEROLOGY, V76, P1347; Uribe M., 1994, HEPATIC ENCEPHALOPAT, P331; VANDERRIJT CCD, 1991, GASTROENTEROLOGY, V100, P1114, DOI 10.1016/0016-5085(91)90290-2; VAVASSEUR D, 1994, CARDIOVASC INTER RAD, V17, P298; WALTON J, 1993, BRAINS DIS NERVOUS S, P542; WEBER FL, 1982, GASTROENTEROLOGY, V82, P213; WEBER FL, 1994, HEPATIC ENCEPHALOPAT, P285; WENDON JA, 1994, HEPATOLOGY, V19, P1407, DOI 10.1016/0270-9139(94)90235-6; Wiedmann B., 1996, Hepatology, V24, p453A	73	259	280	2	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					473	479		10.1056/NEJM199708143370707	http://dx.doi.org/10.1056/NEJM199708143370707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250851				2022-12-28	WOS:A1997XQ49900007
J	Speller, DCE; Johnson, AP; James, D; Marples, RR; Charlett, A; George, RC				Speller, DCE; Johnson, AP; James, D; Marples, RR; Charlett, A; George, RC			Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95	LANCET			English	Article							VIRULENCE	Background Methicillin-resistant Staphylococcus aureus (MRSA) strains are colonising hospital patients in most areas of England and Wales, UK. The extent to which they cause invasive infection can be gauged from their presence in isolates from blood or cerebrospinal fluid. Methods About 200 clinical laboratories reported the results of susceptibility testing of between 4501 and 6370 isolates of S aureus from blood or cerebrospinal fluid in each of the years 1989-95. We assessed the rate of resistance to methicillin and other antibiotics for each of these years. Findings Resistance to methicillin was stable at about 1.5% of isolates during 1989-91, but increased thereafter to 13.2% in 1995 (p<0.001). At the same time there was a significant increase in the percentage of isolates resistant to erythromycin, clindamycin, ciprofloxacin, gentamicin, trimethoprim, and rifampicin (p<0.001 for each)-resistance characteristics often seen in MRSA. Resistance to benzylpenicillin increased slightly but significantly (p>0.001); resistance to fusidic acid was stable (p>0.05); resistance to tetracycline decreased significantly (P<0.001). Interpretation Among cases of S aureus bacteraemia, the proportion due to MRSA has increased significantly. Bacteraemia due to MRSA has a poor prognosis, especially if not treated with suitable antibiotics. Therefore, these findings are important, especially for management of patients and the development of antibiotic policies.	CENT PUBL HLTH LAB,LAB HOSP INFECT,LONDON NW9 5HT,ENGLAND; CENT PUBL HLTH LAB,RESP & SYST INFECT LAB,LONDON NW9 5HT,ENGLAND; CENT PUBL HLTH LAB,STAT UNIT,LONDON NW9 5HT,ENGLAND	Public Health England; Public Health England; Public Health England			Johnson, Alan P/F-4420-2014					CASEWELL MW, 1995, J HOSP INFECT, V30, P465, DOI 10.1016/0195-6701(95)90050-0; FRENCH GL, 1990, J HOSP INFECT, V15, P117, DOI 10.1016/0195-6701(90)90120-D; HERSHOW RC, 1992, INFECT CONT HOSP EP, V13, P587, DOI 10.2307/30148461; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; LACEY RW, 1987, J HOSP INFECT, V9, P103, DOI 10.1016/0195-6701(87)90046-6; MACKINTOSH CA, 1991, J HOSP INFECT, V18, P279, DOI 10.1016/0195-6701(91)90185-B; Marples R R, 1992, Commun Dis Rep CDR Rev, V2, pR25; SNELL JJS, 1994, J ANTIMICROB CHEMOTH, V33, P1, DOI 10.1093/jac/33.1.1; WENZEL RP, 1991, AM J MED, V91, pS221, DOI 10.1016/0002-9343(91)90372-5; 1995, J HOSP INFECT, V31, P1; 1997, COMMUN DIS REP CDR W, V6, P191	11	133	138	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					323	325		10.1016/S0140-6736(97)12148-1	http://dx.doi.org/10.1016/S0140-6736(97)12148-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251636				2022-12-28	WOS:A1997XP24200009
J	Pfrieger, FW; Barres, BA				Pfrieger, FW; Barres, BA			Synaptic efficacy enhanced by glial cells in vitro	SCIENCE			English	Article							RETINAL GANGLION-CELLS; NEURONS; TRANSMISSION; POTENTIALS; SURVIVAL; CULTURE; GROWTH; SWITCH	In the developing nervous system, glial cells guide axons to their target areas, but it is unknown whether they help neurons to establish functional synaptic connections, The role of glial cells in synapse formation and function was studied in cultures of purified neurons from the rat central nervous system, In glia-free cultures, retinal ganglion cells formed synapses with normal ultrastructure but displayed little spontaneous synaptic activity and high failure rates in evoked synaptic transmission, In cocultures with neuroglia, the frequency and amplitude of spontaneous postsynaptic currents were potentiated by 70-fold and 5-fold, respectively, and fewer transmission failures occurred, Glial cells increased the action potential-independent guantal release by 12-fold without affecting neuronal survival, Thus, developing neurons in culture form inefficient synapses that require glial signals to become fully functional.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Pfrieger, Frank/AAX-3208-2020	Pfrieger, Frank/0000-0001-7085-1431				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; KUWADA JY, 1986, SCIENCE, V233, P740, DOI 10.1126/science.3738507; MacKenzie PJ, 1996, NEURON, V16, P783, DOI 10.1016/S0896-6273(00)80098-7; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McLachlan E M, 1978, Int Rev Physiol, V17, P49; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Peters A., 1991, FINE STRUCTURE NERVO; PFRIEGER FW, 1994, NEURON, V12, P97, DOI 10.1016/0896-6273(94)90155-4; PFRIEGER FW, 1995, CELL, V83, P671, DOI 10.1016/0092-8674(95)90178-7; Pfrieger FW, 1996, CURR OPIN NEUROBIOL, V6, P615, DOI 10.1016/S0959-4388(96)80093-6; PFRIEGER FW, UNPUB; POMEROY SL, 1988, J CELL BIOL, V107, P1167, DOI 10.1083/jcb.107.3.1167; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; Ramon y Cajal S, 1995, HISTOLOGY NERVOUS SY; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; Tsacopoulos M, 1996, J NEUROSCI, V16, P877	23	568	611	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1684	1687		10.1126/science.277.5332.1684	http://dx.doi.org/10.1126/science.277.5332.1684			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287225	Green Submitted			2022-12-28	WOS:A1997XV68400056
J	Prior, AJ; Kenyon, GS				Prior, AJ; Kenyon, GS			A running nose	LANCET			English	Article									UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL,DEPT ENT SURG,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London								BROCKBANK MJ, 1989, J LARYNGOL OTOL, V103, P281, DOI 10.1017/S0022215100108710; Dalton A C, 1995, J La State Med Soc, V147, P68; Loew F, 1984, Adv Tech Stand Neurosurg, V11, P169; TROLAND CE, 1960, ARCHIV OTOLARYNGOL, V72, P254; Wax MK, 1997, OTOLARYNG HEAD NECK, V116, P442, DOI 10.1016/S0194-5998(97)70292-4	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					634	634		10.1016/S0140-6736(97)06284-3	http://dx.doi.org/10.1016/S0140-6736(97)06284-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288047				2022-12-28	WOS:A1997XU28300012
J	Olds, DL; Eckenrode, J; Henderson, CR; Kitzman, H; Powers, J; Cole, R; Sidora, K; Morris, P; Pettitt, LM; Luckey, D				Olds, DL; Eckenrode, J; Henderson, CR; Kitzman, H; Powers, J; Cole, R; Sidora, K; Morris, P; Pettitt, LM; Luckey, D			Long-term effects of home visitation on maternal life course and child abuse and neglect - Fifteen-year follow-up of a randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTELLECTUAL IMPAIRMENT; SMOKE CIGARETTES; WOMEN; PREGNANCY; HEALTH	Context.-Home-visitation services have been promoted as a means of improving maternal and child health and functioning. However, long-term effects have not been examined. Objective.-To examine the long-term effects of a program of prenatal and early childhood home visitation by nurses on women's life course and child abuse and neglect, Design.-Randomized trial. Setting.-Semirural community in New York. Participants.-Of 400 consecutive pregnant women with no previous live births enrolled, 324 participated in a follow-up study when their children were 15 years old. Intervention.-families received a mean of 9 home visits during pregnancy and 23 home visits from the child's birth through the second birthday. Data Sources and Measures.-Women's use of welfare and number of subsequent children were based on self-report; their arrests and convictions were based on self-report and archived data from New York State. Verified reports of child abuse and neglect were abstracted from state records. Main Results.-During the 15-year period after the birth of their first child, in contrast to women in the comparison group, women who were visited by nurses during pregnancy and infancy were identified as perpetrators of child abuse and neglect in 0.29 vs 0.54 verified reports (P<.001), Among women who were unmarried and from households of low socioeconomic status at initial enrollment, in contrast to those in the comparison group, nurse-visited women had 1.3 vs 1.6 subsequent births (P=.02), 65 vs 37 months between the birth of the first and a second child (P=.001), 60 vs 90 months' receiving Aid to Families With Dependent Children (P=.005), 0.41 vs 0.73 behavioral impairments due to use of alcohol and other drugs (P=.03), 0.18 vs 0.58 arrests by self-report (P<.001), and 0.16 vs 0.90 arrests disclosed by New York State records (P<.001). Conclusions.-This program of prenatal and early childhood home visitation by nurses can reduce the number of subsequent pregnancies, the use of welfare, child abuse and neglect, and criminal behavior on the part of low-income, unmarried mothers for up to 15 years after the birth of the first child.	CORNELL UNIV,NEW YORK,NY; UNIV ROCHESTER,ROCHESTER,NY; UNIV DENVER,DEPT PSYCHOL,DENVER,CO 80208	Cornell University; University of Rochester; University of Denver	Olds, DL (corresponding author), UNIV COLORADO,HLTH SCI CTR,303 E 17TH AVE,SUITE 200,DENVER,CO 80203, USA.			Kitzman, Harriet/0000-0001-9470-7979	NIMH NIH HHS [1-K05-MH01382-01, R01-MH49381] Funding Source: Medline; ASC OASH HHS [96ASPE278A] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001382, R01MH049381] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); ASC OASH HHS; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLACK MM, 1994, PEDIATRICS, V94, P440; DUGGAN AK, 1996, ANN M AMB PED ASS MA; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; GUTELIUS MF, 1977, PEDIATRICS, V60, P294; HENDERSON CR, 1982, BIOMETRICS, V38, P623, DOI 10.2307/2530044; HOLLINGSHEAD AB, 1976, 4 FACTOR INDEX SOCIA; Karoly Lynn A., 1997, BENEFITS COSTS EARLY; Kessler Ronald C., 1994, International Review of Psychiatry, V6, P365, DOI 10.3109/09540269409023274; Kitzman H, 1997, JAMA-J AM MED ASSOC, V278, P644, DOI 10.1001/jama.278.8.644; LANDSVERK J, 1995, SAN DIEGO HLTH FAMIL; OLDS D, 1995, PEDIATRICS, V95, P365; Olds D, 1997, J COMMUNITY PSYCHOL, V25, P9; OLDS D, IN PRESS J COMMUNITY; Olds D, 1988, 14 OUNCES PREVENTION; OLDS DL, 1994, PEDIATRICS, V93, P228; OLDS DL, 1986, PEDIATRICS, V77, P16; OLDS DL, 1993, MED CARE, V31, P155, DOI 10.1097/00005650-199302000-00006; OLDS DL, 1988, AM J PUBLIC HEALTH, V78, P1436, DOI 10.2105/AJPH.78.11.1436; OLDS DL, 1994, PEDIATRICS, V93, P89; OLDS DL, 1986, PEDIATRICS, V78, P65; OLDS DL, 1990, PEDIATRICS, V86, P108; OLDS DL, 1994, PEDIATRICS, V93, P221; Olds DL., 1998, FUTURE CHILD, V3, P53, DOI [DOI 10.2307/1602543, 10.2307/1602543]; ROTTER JB, 1966, PSYCHOL MONOGR, V80, P1, DOI 10.1037/h0092976	24	817	823	5	77	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					637	643		10.1001/jama.278.8.637	http://dx.doi.org/10.1001/jama.278.8.637			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272895				2022-12-28	WOS:A1997XR54700036
J	Connor, WE; Connor, SL				Connor, WE; Connor, SL			Should a low-fat, high-carbohydrate diet be recommended for everyone?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHOLESTEROL				Connor, WE (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,L465,PORTLAND,OR 97201, USA.							*AM CANC SOC 1996, 1996, CA CANC J CLIN, V43, P325; Anitschkow N.N., 1933, ARTERIOSCLEROSIS, P271; [Anonymous], 1988, CIRCULATION, V77, p721A; ARMSTRONG ML, 1970, CIRC RES, V27, P59, DOI 10.1161/01.RES.27.1.59; Bang HO, 1980, ADV NUTR RES, P1, DOI [DOI 10.1007/978-1-4757-4448-4_1, 10.1007/978-1-4757-4448-4_1]; CONNOR WE, 1961, GERIATRICS, V16, P407; DE LANGEN C. D., 1922, Geneeskundig Tijdschrift voor Nederlandsche-Indie, V62, P1; *DEP AGR, 1995, IN PRESS STAT B; *DEP AGR AGR RES S, 1995, DAT TABL RES USDAS 1; *EXP PAN DET EV TR, 1993, JAMA-J AM MED ASSOC, V269, P3015; Kennedy E, 1996, J AM DIET ASSOC, V96, P234, DOI 10.1016/S0002-8223(96)00072-7; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; SCHAEFER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1450, DOI 10.1001/jama.274.18.1450; SPADY DK, 1988, J CLIN INVEST, V81, P300, DOI 10.1172/JCI113321; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	15	122	125	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					562	563						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262503				2022-12-28	WOS:A1997XR54800011
J	Rittinger, K; Walker, PA; Eccleston, JF; Nurmahomed, K; Owen, D; Laue, E; Gamblin, SJ; Smerdon, SJ				Rittinger, K; Walker, PA; Eccleston, JF; Nurmahomed, K; Owen, D; Laue, E; Gamblin, SJ; Smerdon, SJ			Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP	NATURE			English	Article							H-RAS P21; BINDING PROTEINS; MECHANISM; HYDROLYSIS	Small G proteins transduce signals from plasma-membrane receptors to control a wide range of cellular functions(1,2). These proteins are clustered into distinct families but all act as molecular switches, active in their GTP-bound form but inactive when GDP-bound. The Rho family of G proteins, which includes Cdc42Hs, activate effecters involved in the regulation of cytoskeleton formation, cell proliferation and the JNK signalling pathway(3-9). G proteins generally have a low intrinsic GTPase hydrolytic activity but there are family-specific groups of GTPase-activating proteins (GAPs) that enhance the rate of GTP hydrolysis by up to 10(5) times(10,11). We report here the crystal structure of Cdc42Hs, with the non-hydrolysable GTP analogue GMPPNP, in complex with the GAP domain of p50rhoGAP at 2.7 Angstrom resolution. In the complex Cdc42Hs interacts, mainly through its switch I and II regions, with a shallow pocket on rhoGAP which is lined with conserved residues. Arg 85 of rhoGAP interacts with the P-loop of Cdc42Hs, but from biochemical data and by analogy with the G-protein subunit G(i alpha 1) (ref. 12), we propose that it adopts a different conformation during the catalytic cycle which enables it to stabilize the transition state of the GTP-hydrolysis reaction.	NATL INST MED RES,RIDGEWAY,LONDON NW7 1AA,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge			Rittinger, Katrin/D-2586-2014; Rittinger, Katrin/N-3344-2019	Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Laue, Ernest/0000-0002-7476-4148; Smerdon, Stephen/0000-0001-5688-8465	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4	29	223	235	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					693	697		10.1038/41805	http://dx.doi.org/10.1038/41805			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262406	Bronze			2022-12-28	WOS:A1997XQ86300054
J	Dore, GJ; Kaldor, JM; McCaughan, GW				Dore, GJ; Kaldor, JM; McCaughan, GW			Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus	BRITISH MEDICAL JOURNAL			English	Article							TO-INFANT TRANSMISSION; VERTICAL TRANSMISSION; PERINATAL TRANSMISSION; SEXUAL TRANSMISSION; ORGAN DONORS; NON-A; RNA; MOTHERS; INFECTIVITY; POPULATION	Objective: To assess the role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. Design: Published studies of hepatitis C transmission were examined. Twenty nine studies with identified sources of hepatitis C infection who were tested for presence of hepatitis C RNA by polymerase chain reaction were reviewed, including studies of vertical transmission (n = 21), transmission after transplantation (n = 3), transfusion of blood components (n = 3), and needlestick exposure (n = 2). Subjects: All patients identified in studies. Results: A total of 2022 people who had been exposed to sources positive for antibody to hepatitis C were identified. Among 1148 people exposed to sources positive by polymerase chain reaction 148 cases of transmission occurred compared with no definite case among 874 people exposed to negative sources. Rates of transmission from positive sources were 6.2% for perinatal exposure, 6.1% after needlestick exposure, 78% after solid organ or bone marrow transplantation, and 83% after transfusion of blood components. Other factors influencing risk of vertical transmission were coinfection with HIV and level of hepatitis C viraemia. Conclusions: Negative results by polymerase chain reaction indicate an extremely low probability of transmission of hepatitis C from a person with antibody to hepatitis C.	ROYAL PRINCE ALFRED HOSP,AW MORROW GASTROENTEROL & LIVER CTR,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Sydney	Dore, GJ (corresponding author), UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,DARLINGHURST,NSW 2010,AUSTRALIA.		Dore, Gregory John/ABD-5665-2021; Kaldor, John M/D-4545-2011	Dore, Gregory John/0000-0002-4741-2622; MCCAUGHAN, GEOFFREY/0000-0002-1483-1636				AKAHANE Y, 1994, ANN INTERN MED, V120, P748, DOI 10.7326/0003-4819-120-9-199405010-00005; ALTER MJ, 1994, NEW ENGL J MED, V330, P784, DOI 10.1056/NEJM199403173301111; BRESTERS D, 1993, LANCET, V342, P210, DOI 10.1016/0140-6736(93)92300-I; BUSCH MP, 1992, TRANSFUSION, V32, P420, DOI 10.1046/j.1537-2995.1992.32592327714.x; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; *COMM DIS REP, 1995, COMMUN DIS REP CDR W, V5, P26; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; Fischler B, 1996, SCAND J INFECT DIS, V28, P353, DOI 10.3109/00365549609037918; Foberg U, 1996, SCAND J INFECT DIS, V28, P21, DOI 10.3109/00365549609027144; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GARSON JA, 1994, FEMS MICROBIOL REV, V14, P229, DOI 10.1016/0168-6445(94)90037-X; GIACCHINO R, 1995, LANCET, V345, P1122; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KURAUCHI O, 1993, ARCH GYNECOL OBSTET, V253, P121, DOI 10.1007/BF02767328; LAM JPH, 1993, J INFECT DIS, V167, P572, DOI 10.1093/infdis/167.3.572; LIN HH, 1994, J INFECT DIS, V169, P638, DOI 10.1093/infdis/169.3.638; LUNEL F, 1995, J VIROL METHODS, V54, P159, DOI 10.1016/0166-0934(95)00037-U; MacDonald M, 1996, EPIDEMIOL REV, V18, P137, DOI 10.1093/oxfordjournals.epirev.a017921; MANZINI P, 1995, HEPATOLOGY, V21, P328, DOI 10.1016/0270-9139(95)90088-8; MATSUBARA T, 1995, EUR J PEDIATR, V154, P973, DOI 10.1007/BF01958640; MEISEL H, 1995, LANCET, V345, P1209, DOI 10.1016/S0140-6736(95)91992-9; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; MORIYA T, 1995, BIOMED PHARMACOTHER, V49, P59, DOI 10.1016/0753-3322(96)82587-X; NAKASHIMA K, 1995, JAMA-J AM MED ASSOC, V274, P1459, DOI 10.1001/jama.274.18.1459; NORDA R, 1995, SCAND J INFECT DIS, V27, P449, DOI 10.3109/00365549509047044; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; PACCAGNINI S, 1995, PEDIATR INFECT DIS J, V14, P195, DOI 10.1097/00006454-199503000-00005; PEREIRA BJG, 1992, NEW ENGL J MED, V327, P910, DOI 10.1056/NEJM199209243271302; Pipan C, 1996, EUR J CLIN MICROBIOL, V15, P116, DOI 10.1007/BF01591483; POWER JP, 1995, LANCET, V346, P372; REINUS JF, 1992, ANN INTERN MED, V117, P881, DOI 10.7326/0003-4819-117-11-881; RESTI M, 1995, ACTA PAEDIATR, V84, P251, DOI 10.1111/j.1651-2227.1995.tb13624.x; ROTH D, 1992, ANN INTERN MED, V117, P470, DOI 10.7326/0003-4819-117-6-470; ROUDOTTHORAVAL F, 1993, HEPATOLOGY, V17, P772, DOI 10.1002/hep.1840170504; Sabatino G, 1996, EUR J EPIDEMIOL, V12, P443, DOI 10.1007/BF00143994; SHUHART MC, 1994, BLOOD, V84, P3229; SODEYAMA T, 1993, ARCH INTERN MED, V153, P1565, DOI 10.1001/archinte.153.13.1565; TOR J, 1990, BRIT MED J, V301, P1130, DOI 10.1136/bmj.301.6761.1130; UEHARA S, 1993, TOHOKU J EXP MED, V171, P195, DOI 10.1620/tjem.171.195; VANDERPOEL CL, 1994, LANCET, V344, P1475, DOI 10.1016/S0140-6736(94)90293-3; VRIELINK H, 1995, LANCET, V345, P95, DOI 10.1016/S0140-6736(95)90063-2; Wejstal R, 1992, ANN INTERN MED, V117, P887, DOI 10.7326/0003-4819-117-11-887; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3; ZANETTI AR, 1995, LANCET, V345, P289, DOI 10.1016/S0140-6736(95)90277-5; ZUCCOTTI GV, 1995, J PEDIATR-US, V127, P278, DOI 10.1016/S0022-3476(95)70309-8	46	93	93	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					333	337						13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270453				2022-12-28	WOS:A1997XQ86400018
J	Dove, AW; Racaniello, VR				Dove, AW; Racaniello, VR			The polio eradication effort: Should vaccine eradication be next?	SCIENCE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University								BEALE AJ, 1991, PEDIATR INFECT DIS J, V10, P970, DOI 10.1097/00006454-199112000-00029; ConynvanSpaendonck MAE, 1996, AM J EPIDEMIOL, V143, P929, DOI 10.1093/oxfordjournals.aje.a008836; HURST CJ, 1989, CAN J MICROBIOL, V35, P474, DOI 10.1139/m89-073; KEW O, 1996, LECT AM SOC VIR ANN; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; Knolle H, 1995, Gesundheitswesen, V57, P351; MELNICK PD, 1996, BIOLOGICALS, V6, P1; MINOR PD, 1993, BIOLOGICALS, V21, P357, DOI 10.1006/biol.1993.1096; NAKAJIMA K, 1978, NATURE, V274, P334, DOI 10.1038/274334a0; RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; ROBERTSON SE, 1994, B WORLD HEALTH ORGAN, V72, P907; SWARTZ TA, 1994, PUBLIC HLTH REV, V21, P157; Van Wijngaarden JK, 1993, PUBLIC HLTH REV, V21, P107; WHO, 1996, GLOB POL ER YEAR 200; YATES MV, 1985, APPL ENVIRON MICROB, V49, P778, DOI 10.1128/AEM.49.4.778-781.1985; [No title captured]	17	38	38	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					779	780		10.1126/science.277.5327.779	http://dx.doi.org/10.1126/science.277.5327.779			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9273700				2022-12-28	WOS:A1997XQ24700031
J	Pulleyblank, DE				Pulleyblank, DE			Molecular biology - Of Topo and Maxwell's dream	SCIENCE			English	Editorial Material							TOPOLOGICALLY KNOTTED DNA; SUPERHELICAL TURNS; TOPOISOMERASE; GYRASE; ENZYME				Pulleyblank, DE (corresponding author), UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA.							CHAMPOUX JJ, 1972, P NATL ACAD SCI USA, V69, P143, DOI 10.1073/pnas.69.1.143; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DOUCRASY S, 1986, P NATL ACAD SCI USA, V83, P7152, DOI 10.1073/pnas.83.19.7152; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; HSIEH TS, 1980, CELL, V21, P115, DOI 10.1016/0092-8674(80)90119-1; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1981, NUCLEIC ACIDS RES, V9, P3979, DOI 10.1093/nar/9.16.3979; MIZUUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P1847, DOI 10.1073/pnas.77.4.1847; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	15	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					648	649		10.1126/science.277.5326.648	http://dx.doi.org/10.1126/science.277.5326.648			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9254431				2022-12-28	WOS:A1997XN90700026
J	Fass, D; Davey, RA; Hamson, CA; Kim, PS; Cunningham, JM; Berger, JM				Fass, D; Davey, RA; Hamson, CA; Kim, PS; Cunningham, JM; Berger, JM			Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution	SCIENCE			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; ENVELOPE GLYCOPROTEINS; PROTEIN; GENE; CLASSIFICATION; DETERMINANTS; ALIGNMENT; SEQUENCE; VECTORS; DOMAIN	An essential step in retrovirus infection is the binding of the virus to its receptor on a target cell. The structure of the receptor-binding domain of the envelope glycoprotein from Friend murine leukemia virus was determined to 2.0 angstrom resolution by x-ray crystallography. The core of the domain is an antiparallel beta sandwich, with two interstrand loops forming a helical subdomain atop the sandwich, The residues in the helical region, but not in the beta sandwich, are highly variable among mammalian C-type retroviruses with distinct tropisms, indicating that the helical subdomain determines the receptor specificity of the virus.	MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, DEPT BIOL, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, SCH MED,BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST,DIV HEMATOL, DEPT MED, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute				Davey, Robert/0000-0001-9168-2892				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BATTINI JL, 1995, J VIROL, V69, P713, DOI 10.1128/JVI.69.2.713-719.1995; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVEY RA, IN PRESS J VIROL; FASS D, 1997, THESIS MIT CAMBRIDGE; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; HEARD JM, 1991, J VIROL, V65, P4026, DOI 10.1128/JVI.65.8.4026-4032.1991; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; JONES TA, 1992, O MANUAL; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOCH W, 1983, J VIROL, V45, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINDER M, 1992, EUR J BIOCHEM, V203, P65, DOI 10.1111/j.1432-1033.1992.tb19828.x; MacKrell AJ, 1996, J VIROL, V70, P1768, DOI 10.1128/JVI.70.3.1768-1774.1996; MORGAN RA, 1993, J VIROL, V67, P4712, DOI 10.1128/JVI.67.8.4712-4721.1993; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTT D, 1992, J VIROL, V66, P4632, DOI 10.1128/JVI.66.8.4632-4638.1992; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Peredo C, 1996, J VIROL, V70, P3142, DOI 10.1128/JVI.70.5.3142-3152.1996; PINTER A, 1982, VIROLOGY, V116, P499, DOI 10.1016/0042-6822(82)90143-X; SMITH AE, 1995, ANNU REV MICROBIOL, V49, P807; ValsesiaWittmann S, 1996, J VIROL, V70, P2059, DOI 10.1128/JVI.70.3.2059-2064.1996; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; ZHANG KYJ, 1994, PROTEIN SCI, V3, P687; 1992, NATURE, V355, P472	37	173	178	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1662	1666		10.1126/science.277.5332.1662	http://dx.doi.org/10.1126/science.277.5332.1662			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287219				2022-12-28	WOS:A1997XV68400050
J	Compston, JE				Compston, JE			Designer oestrogens: fact or fantasy?	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ESTROGEN; RISK; RALOXIFENE				Compston, JE (corresponding author), UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.							Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Compston JE, 1997, DRUGS, V53, P727, DOI 10.2165/00003495-199753050-00001; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DELMAS PD, IN PRESS P ENDOCR SO; Draper MW, 1996, J BONE MINER RES, V11, P835; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	11	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					676	677		10.1016/S0140-6736(97)22036-2	http://dx.doi.org/10.1016/S0140-6736(97)22036-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291896				2022-12-28	WOS:A1997XU97700002
J	Wall, TL; Peterson, CM; Peterson, KP; Johnson, ML; Thomasson, HR; Cole, M; Ehlers, CL				Wall, TL; Peterson, CM; Peterson, KP; Johnson, ML; Thomasson, HR; Cole, M; Ehlers, CL			Alcohol metabolism in Asian-American men with genetic polymorphisms of aldehyde dehydrogenase	ANNALS OF INTERNAL MEDICINE			English	Article							LIVER-DISEASE; GENOTYPES; ACETALDEHYDE; SENSITIVITY; CIRRHOSIS; DOMINANT; ETHANOL	Background: About half of certain Asians have a deficiency of the low-K-m aldehyde dehydrogenase (ALDH2) isoenzyme. This deficiency results from inheritance of a mutant ALDH2*2 allele. Objective: To determine whether Asian Americans with ALDH2*2 alleles differ from Asian Americans without this mutation in terms of blood levels of alcohol and acetaldehyde after ingestion of a moderate amount of alcohol. Design: Double-blind, crossover study. Setting: Private research institute. Participants: 35 healthy Asian-American men. Three men who became ill after alcohol ingestion and one who had outlying data were excluded. Intervention: Alcoholic beverage, containing 0.56 g of alcohol per kg of body weight, or placebo beverage, containing 3 mL of alcohol, given orally on separate occasions. Measurements: Blood levels of alcohol and acetaldehyde measured before and several times after ingestion of the alcoholic or placebo beverage. Results: Participants with ALDH2*2 alleles had significantly higher blood acetaldehyde levels after ingesting alcoholic and placebo beverages than did participants with ALDH2*1 alleles, despite similar blood alcohol concentrations. Conclusions: Blood acetaldehyde levels rather than blood alcohol concentration may mediate enhanced alcohol sensitivity among Asians with ALDH2*2 alleles.	SANSUM MED RES FDN, SANTA BARBARA, CA 93105 USA; ELI LILLY & CO, INDIANAPOLIS, IN 46285 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Eli Lilly; Scripps Research Institute	Wall, TL (corresponding author), UNIV CALIF SAN DIEGO, VET AFFAIRS MED CTR, DEPT PSYCHIAT, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.		Peterson, Karen/E-8084-2015	Peterson, Karen/0000-0001-6737-8698; Wall, Tamara/0000-0003-0605-8660	NCRR NIH HHS [M01 RR000833] Funding Source: Medline; NIAAA NIH HHS [AA-00098, AA-06420, R01 AA011257, AA-00155, P60 AA007611, P60 AA006420] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA006420, R01AA011257, P60AA006420, P60AA007611] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		CHAO YC, 1994, HEPATOLOGY, V19, P360, DOI 10.1002/hep.1840190214; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; ENOMOTO N, 1991, HEPATOLOGY, V13, P1071, DOI 10.1002/hep.1840130611; ENOMOTO N, 1991, ALCOHOL CLIN EXP RES, V15, P141, DOI 10.1111/j.1530-0277.1991.tb00532.x; GOEDDE HW, 1979, HUM GENET, V51, P331; HIGUCHI S, 1995, AM J PSYCHIAT, V152, P1219; Luu Sy-Ueng, 1995, Proceedings of the National Science Council Republic of China Part B Life Sciences, V19, P129; MEIERTACKMANN D, 1990, ALCOHOL, V7, P413, DOI 10.1016/0741-8329(90)90025-8; MENDELSON J H, 1984, Alcohol, V1, P417, DOI 10.1016/0741-8329(84)90014-4; MIZOI Y, 1994, ALCOHOL ALCOHOLISM, V29, P707; PETERSON CM, 1987, ALCOHOL, V4, P477, DOI 10.1016/0741-8329(87)90089-9; POKLIS A, 1982, CLIN CHEM, V28, P2125; TAKADA A, 1994, ALCOHOL ALCOHOLISM, V29, P719; TAKESHITA T, 1994, HUM GENET, V94, P217; THOMASSON HR, 1993, BEHAV GENET, V23, P131, DOI 10.1007/BF01067417; THOMASSON HR, 1991, AM J HUM GENET, V48, P677; WALL TL, 1992, ALCOHOL CLIN EXP RES, V16, P991, DOI 10.1111/j.1530-0277.1992.tb01907.x; Xiao Q, 1996, J CLIN INVEST, V98, P2027, DOI 10.1172/JCI119007; YAMAUCHI M, 1995, HEPATOLOGY, V22, P1136, DOI 10.1016/0270-9139(95)90621-5; Yokoyama A, 1996, CANCER EPIDEM BIOMAR, V5, P99	20	85	94	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					376	379		10.7326/0003-4819-127-5-199709010-00007	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273829				2022-12-28	WOS:A1997XU10000006
J	Corrigan, JJ				Corrigan, JJ			Treatment dilemma in childhood idiopathic thrombocytopenic purpura	LANCET			English	Editorial Material											Corrigan, JJ (corresponding author), TULANE UNIV,SCH MED,DEPT PEDIAT HAEMATOL ONCOL,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.							EDEN OB, 1992, ARCH DIS CHILD, V67, P1056, DOI 10.1136/adc.67.8.1056; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; HALPERIN DS, 1988, AM J DIS CHILD, V142, P508, DOI 10.1001/archpedi.1988.02150050046027; REID MM, 1992, ACTA PAEDIATR, V81, P1052, DOI 10.1111/j.1651-2227.1992.tb12175.x; Warrier I, 1997, J PEDIAT HEMATOL ONC, V19, P197, DOI 10.1097/00043426-199705000-00004	5	5	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					602	603		10.1016/S0140-6736(97)22035-0	http://dx.doi.org/10.1016/S0140-6736(97)22035-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288037				2022-12-28	WOS:A1997XU28300002
J	Behrman, P				Behrman, P			Art in hospitals: why is it there and what is it for?	LANCET			English	Article											Behrman, P (corresponding author), NEW ACAD GALLERY,34 WINDMILL ST,LONDON W1P 1HH,ENGLAND.							BARON JH, 1986, LANCET, V2, P1438; DENARBONNE R, 1988, HOSPICES BEAUNE HOTE; *DHSS WELSH OFF, 1988, BUILD HLTH SERV, V14; HOMAN V, 1991, EVALUATING ART HOSP; NIGHTINGALE F, 1980, NOTES NURSING WHAT I, P45; Phillips E. D., 1987, ASPECTS GREEK MED; WARNE S, 1993, HOSP DOCTOR, V22; WILTSHER A, 1992, HOSP DOCTOR     0514, P47	8	11	11	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					584	585		10.1016/S0140-6736(97)03019-5	http://dx.doi.org/10.1016/S0140-6736(97)03019-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284791				2022-12-28	WOS:A1997XT22100046
J	Chinnery, PF; Turnbull, DM; Walls, TJ; Reading, PJ				Chinnery, PF; Turnbull, DM; Walls, TJ; Reading, PJ			Recurrent strokes in a 34-year-old man	LANCET			English	Article									UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT NEUROL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; NEWCASTLE GEN HOSP,REG NEUROSCI CTR,DEPT NEUROL,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle General Hospital				Chinnery, Patrick/0000-0002-7065-6617				Barinagarrementeria F, 1996, CEREBROVASC DIS, V6, P75, DOI 10.1159/000108001; BOGOUSSLAVSKY J, 1992, NEUROL CLIN, V10, P113, DOI 10.1016/S0733-8619(18)30236-6; CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408; Shoffner JM, 1996, LANCET, V348, P1283, DOI 10.1016/S0140-6736(96)09138-6; Taylor RW, 1996, ANN NEUROL, V40, P459, DOI 10.1002/ana.410400318	5	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					560	560		10.1016/S0140-6736(97)05005-8	http://dx.doi.org/10.1016/S0140-6736(97)05005-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284779				2022-12-28	WOS:A1997XT22100012
J	Lundby, L; Jensen, JV; Overgaard, J; Laurberg, S				Lundby, L; Jensen, JV; Overgaard, J; Laurberg, S			Long-term colorectal function after postoperative radiotherapy for colorectal cancer	LANCET			English	Article									AARHUS UNIV HOSP,AAKH,DEPT EXPT CLIN ONCOL,DANISH CANC SOC,DK-8000 AARHUS C,DENMARK	Aarhus University; Danish Cancer Society	Lundby, L (corresponding author), AARHUS UNIV HOSP,AAS,DEPT SURG L,SURG RES UNIT,DK-8000 AARHUS C,DENMARK.							BALSLEV IB, 1986, CANCER-AM CANCER SOC, V58, P22, DOI 10.1002/1097-0142(19860701)58:1<22::AID-CNCR2820580106>3.0.CO;2-Q; *MRC RECT CANC WOR, 1996, LANCET, V348, P1610; *MRC RECT CANC WOR, 1996, LANCET, V348, P1605; *NHI CONS C, 1990, JAMA-J AM MED ASSOC, V264, P1444; *SWED RECT CANC TR, 1997, NEW ENGL J MED, V336, P980	5	54	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					564	564		10.1016/S0140-6736(05)63141-8	http://dx.doi.org/10.1016/S0140-6736(05)63141-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284785				2022-12-28	WOS:A1997XT22100018
J	Sigrist, SJ; Lehner, CF				Sigrist, SJ; Lehner, CF			Drosophila fizzy-related down-regulates mitotic cyclins and is required for cell proliferation arrest and entry into endocycles	CELL			English	Article							S-PHASE; SACCHAROMYCES-CEREVISIAE; REPLICATION ORIGINS; DNA-REPLICATION; PROTEIN-KINASE; B-CYCLIN; MITOSIS; GENE; EMBRYOGENESIS; YEAST	We demonstrate that fizzy-related (fir), a conserved eukaryotic gene, negatively regulates the levers of cyclins A, B, and B3. These mitotic cyclins that bind and activate cdk1(cdc2) are rapidly degraded during exit from M and during G1. While Drosophila fizzy has previously been shown to be required for cyclin destruction during M phase, fir is required for cyclin removal during G1 when the embryonic epidermal cell proliferation stops and during G2 preceding salivary gland endoreduplication. Loss of fzr causes progression through an extra division cycle in the epidermis and inhibition of endoreduplication in the salivary gland, in addition to failure of cyclin removal. Conversely, premature fir overexpression down-regulates mitotic cyclins, inhibits mitosis, and transforms mitotic cycles into endoreduplication cycles.			Sigrist, SJ (corresponding author), UNIV BAYREUTH,DEPT GENET,D-95440 BAYREUTH,GERMANY.							AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Frank LH, 1996, DEVELOPMENT, V122, P1343; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hayashi S, 1996, DEVELOPMENT, V122, P1051; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IMIGER S, 1995, CELL, V81, P269; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SMITH AV, 1991, DEVELOPMENT, V112, P997; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thomas BJ, 1997, GENE DEV, V11, P1289, DOI 10.1101/gad.11.10.1289; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; WIESCHAUS E, 1983, ROUX ARCH DEVEL BIOL, V193, P296; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	53	365	369	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					671	681		10.1016/S0092-8674(00)80528-0	http://dx.doi.org/10.1016/S0092-8674(00)80528-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288747	hybrid			2022-12-28	WOS:A1997XT06600011
J	Anto, JM				Anto, JM			Health effects due to inhalation of oilseed rape emissions	LANCET			English	Editorial Material							POTENT ANTIGEN				Anto, JM (corresponding author), INST MUNICIPAL INVEST MED,RESP & ENVIRONM HLTH RES UNIT,E-08003 BARCELONA,SPAIN.		Anto, J M/H-2676-2014	Anto, J M/0000-0002-4736-8529				BUTCHER RD, 1995, CLIN EXP ALLERGY, V25, P985, DOI 10.1111/j.1365-2222.1995.tb00401.x; COLBORN T, 1995, ENVIRON HEALTH PERSP, V103, P81, DOI 10.2307/3432353; FELL PJ, 1992, CLIN EXP ALLERGY, V22, P501, DOI 10.1111/j.1365-2222.1992.tb00154.x; Hemmer W, 1997, CLIN EXP ALLERGY, V27, P156; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; *MED RES COUNC I E, 1997, IEH ASS OILS RAP ALL; NINAN TK, 1990, LANCET, V336, P808, DOI 10.1016/0140-6736(90)93266-R; PARRATT D, 1990, LANCET, V335, P121, DOI 10.1016/0140-6736(90)90599-Z; SOUTAR A, 1994, THORAX, V49, P352, DOI 10.1136/thx.49.4.352; SOUTAR A, 1995, OCCUP ENVIRON MED, V52, P575, DOI 10.1136/oem.52.9.575	10	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					458	459		10.1016/S0140-6736(05)63076-0	http://dx.doi.org/10.1016/S0140-6736(05)63076-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274579				2022-12-28	WOS:A1997XR13500005
J	Raad, I; Darouiche, R; Dupuis, J; AbiSaid, D; Gabrielli, A; Hachem, R; Wall, M; Harris, R; Jones, J; Buzaid, A; Robertson, C; Shenaq, S; Curling, P; Burke, T; Ericsson, C; Greenberg, S; Hanania, N; Yosher, D; Gibson, D; Reardon, M; Reardon, P; Darnule, T; Mansouri, M; Rolston, K; Whimbey, E; Bivins, C; Huaringa, A; Price, K; Safar, H				Raad, I; Darouiche, R; Dupuis, J; AbiSaid, D; Gabrielli, A; Hachem, R; Wall, M; Harris, R; Jones, J; Buzaid, A; Robertson, C; Shenaq, S; Curling, P; Burke, T; Ericsson, C; Greenberg, S; Hanania, N; Yosher, D; Gibson, D; Reardon, M; Reardon, P; Darnule, T; Mansouri, M; Rolston, K; Whimbey, E; Bivins, C; Huaringa, A; Price, K; Safar, H			Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections - A randomized, double-blind trial	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; METHICILLIN-RESISTANT; CRITICALLY ILL; COMBINATION; BACTEREMIA; CULTURES	Background: Central venous catheters are a principal source of nosocomial bloodstream infections, which are difficult to control. Objective: To determine the efficacy of catheters coated with minocycline and rifampin in preventing catheter-related colonization and bloodstream infections. Design: Multicenter, randomized clinical trial. Setting: Five university-based medical centers. Patients: 281 hospitalized patients who required 298 triple-lumen, polyurethane venous catheters. Intervention: 147 catheters were pretreated with tridodecylmethyl-ammonium chloride and coated with minocycline and rifampin. Untreated, uncoated catheters (n = 151) were used as controls. Measurements: Quantitative catheter cultures, blood cultures, and molecular typing of organisms to determine catheter-related colonization and bloodstream infections. Results: The group with coated catheters and the group with uncoated catheters were similar with respect to age, sex, underlying diseases, degree of immunosuppression, therapeutic interventions, and risk factors for catheter infections. Colonization occurred in 36 (26%) uncoated catheters and 11 (8%) coated catheters (P < 0.001). Catheter-related bloodstream infection developed in 7 patients (5%) with uncoated catheters and no patients with coated catheters (P < 0.01). Multivariate logistic regression analysis showed that coating catheters with minocycline and rifampin was an independent protective factor against catheter-related colonization (P < 0.05). No adverse effects related to the coated catheters or antimicrobial resistance were seen. An estimate showed that the use of coated catheters could save costs. Conclusions: Central venous catheters coated with minocycline and rifampin can significantly reduce the risk for catheter-related colonization and bloodstream infections. The use of these catheters may save costs.	BAYLOR COLL MED, VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; BEN TAUB GEN HOSP, HARRIS CTY HOSP DIST, HOUSTON, TX 77030 USA; METHODIST HOSP, HOUSTON, TX 77030 USA; UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); The Methodist Hospital System; The Methodist Hospital - Houston; University of Texas System; University of Texas Health Science Center Houston	Raad, I (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, SECT INFECT CONTROL, BOX 47, HOUSTON, TX 77030 USA.		Hanania, Nicola A/C-5875-2016; Reardon, Michael/ABF-8880-2021	Hanania, Nicola A/0000-0003-3087-9530; 				*CDCP, 1995, FED REGISTER, V60, P49978; DAROUICHE RO, 1995, INT J ANTIMICROB AG, V6, P31, DOI 10.1016/0924-8579(95)00017-3; GRAYBILL JR, 1983, REV INFECT DIS, V5, pS620; HEISELMAN D, 1994, JAMA-J AM MED ASSOC, V272, P1819, DOI 10.1001/jama.272.23.1819; JARVIS WR, 1991, AM J MED, V91, pS185, DOI 10.1016/0002-9343(91)90367-7; KAMAL GD, 1991, JAMA-J AM MED ASSOC, V265, P2364, DOI 10.1001/jama.265.18.2364; KARCHMER AW, 1983, REV INFECT DIS, V5, pS543; KLASTERSKY J, 1972, CHEMOTHERAPY, V17, P51, DOI 10.1159/000220838; LAWLOR MT, 1990, J INFECT DIS, V161, P812, DOI 10.1093/infdis/161.4.812; LEVY RS, 1979, J A EINSTEIN MED CTR, V18, P67; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1981, AM J MED, V70, P739, DOI 10.1016/0002-9343(81)90605-7; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1989, INFECTIONS ASS INDWE, P161; MAKI DG, 1992, HOSP INFECT, P849; MAKI DG, 1991, CRIT CARE MED S, V19, pS99; MANDELL GL, 1983, REV INFECT DIS, V5, pS463; Maslow Joel N., 1993, P563; MINUTH JN, 1974, ANTIMICROB AGENTS CH, V6, P411, DOI 10.1128/AAC.6.4.411; MORRIS AB, 1993, ANTIMICROB AGENTS CH, V37, P1, DOI 10.1128/AAC.37.1.1; National Committee for Clinical Laboratory Standards, 1990, M7A2 NCCLS; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Raad I, 1996, J INFECT DIS, V173, P418, DOI 10.1093/infdis/173.2.418; RAAD I, 1995, ANTIMICROB AGENTS CH, V39, P2397, DOI 10.1128/AAC.39.11.2397; RAAD II, 1992, DIAGN MICR INFEC DIS, V15, P13, DOI 10.1016/0732-8893(92)90052-U; RAAD II, 1995, CLIN INFECT DIS, V20, P593, DOI 10.1093/clinids/20.3.593; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; SANDE MA, 1983, REV INFECT DIS, V5, pS399; SCHWARTZ C, 1990, J CLIN ONCOL, V8, P1591, DOI 10.1200/JCO.1990.8.9.1591; SEGRETI J, 1989, DIAGN MICR INFEC DIS, V12, P253, DOI 10.1016/0732-8893(89)90022-9; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; SHERERTZ RJ, 1993, J INFECT DIS, V167, P98, DOI 10.1093/infdis/167.1.98; WATERWORTH PM, 1974, J CLIN PATHOL, V27, P269, DOI 10.1136/jcp.27.4.269; YOURASSOWSKY E, 1981, J CLIN PATHOL, V34, P559, DOI 10.1136/jcp.34.5.559; YUK JH, 1991, REV INFECT DIS, V13, P1023; ZINNER SH, 1981, J INFECT DIS, V144, P365, DOI 10.1093/infdis/144.4.365	36	452	474	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					267	+		10.7326/0003-4819-127-4-199708150-00002	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265425				2022-12-28	WOS:A1997XR26600004
J	Tokunaga, M; Larrow, JF; Kakiuchi, F; Jacobsen, EN				Tokunaga, M; Larrow, JF; Kakiuchi, F; Jacobsen, EN			Asymmetric catalysis with water: Efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis	SCIENCE			English	Article								Epoxides are versatile building blocks for organic synthesis. However, terminal epoxides are arguably the most important subclass of these compounds, and no general and practical method exists for their production in enantiomerically pure form. Terminal epoxides are available very inexpensively as racemic mixtures, and kinetic resolution is an attractive strategy for the production of optically active epoxides, given an economical and operationally simple method. Readily accessible synthetic catalysts (chiral cobalt-based salen complexes) have been used for the efficient asymmetric hydrolysis of terminal epoxides. This process uses water as the only reagent, no added solvent, and low loadings of a recyclable catalyst (<0.5 mole percent), and it affords highly valuable terminal epoxides and 1,2-diols in high yield with high enantiomeric enrichment.			Tokunaga, M (corresponding author), HARVARD UNIV,DEPT CHEM & CHEM BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043214, R37GM043214] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43214] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal VK, 1996, J AM CHEM SOC, V118, P7004, DOI 10.1021/ja961144+; CUMMINS J, COMMUNICATION; ELIEL EL, 1994, STEREOCHEMISTRY ORGA, P95; FABER K, 1992, BIOTRANSFORMATIONS O; Hansen KB, 1996, J AM CHEM SOC, V118, P10924, DOI 10.1021/ja962600x; Jacobsen EN, 1997, TETRAHEDRON LETT, V38, P773, DOI 10.1016/S0040-4039(96)02414-8; JACOBSEN EN, 1995, COMPRENHENSIVE ORGAN, V12; KAGAN HB, 1987, TOP STEREOCHEM, V14, P249; KOLB HC, 1994, CHEM REV, V94, P2483, DOI 10.1021/cr00032a009; Larrow JF, 1996, J AM CHEM SOC, V118, P7420, DOI 10.1021/ja961708+; Sato K, 1996, J ORG CHEM, V61, P8310, DOI 10.1021/jo961287e; SINIGALIA R, 1987, ORGANOMETALLICS, V6, P728, DOI 10.1021/om00147a009; Vanhessche KPM, 1997, CHEM-EUR J, V3, P517, DOI 10.1002/chem.19970030406; Weijers CAGM, 1997, TETRAHEDRON-ASYMMETR, V8, P639, DOI 10.1016/S0957-4166(97)00012-8	14	1238	1289	8	290	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					936	938		10.1126/science.277.5328.936	http://dx.doi.org/10.1126/science.277.5328.936			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252321				2022-12-28	WOS:A1997XQ98500036
J	Novack, DH; Suchman, AL; Clark, W; Epstein, RM; Najberg, E; Kaplan, C				Novack, DH; Suchman, AL; Clark, W; Epstein, RM; Najberg, E; Kaplan, C			Calibrating the physician - Personal awareness and effective patient care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MEDICAL-PRACTICE; SUPPORT GROUP; ADVANCE DIRECTIVES; INTERNAL MEDICINE; WOMEN PHYSICIANS; RISK PREFERENCE; BALINT GROUP; DOCTOR; COMMUNICATION; HOUSE	Physicians' personal characteristics, their past experiences, values, attitudes, and biases can have important effects on communication with patients; being aware of these characteristics can enhance communication. Because medical training and continuing education programs rarely undertake an organized approach to promoting personal awareness, we propose a ''curriculum'' of 4 core topics for reflection and discussion. The topics are physicians' beliefs and attitudes, physicians' feelings and emotional responses in patient care, challenging clinical situations, and physician self-care. We present examples of organized activities that can promote physician personal awareness such as support groups, Balint groups, and discussions of meaningful experiences in medicine. Experience with these activities suggests that through enhancing personal awareness physicians can improve their clinical care and increase satisfaction with work, relationships, and themselves.	UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY USA; MIDCOAST HOSP, ADDICT RESOURCE CTR, BATH, ME USA; ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT, LONDON, ENGLAND	University of Rochester; University of London; Queen Mary University London	Novack, DH (corresponding author), ALLEGHENY UNIV HLTH SCI, MED COLL PENN & HAHNEMANN UNIV, SCH MED, DIV MED EDUC, 2900 QUEEN LANE, PHILADELPHIA, PA 19129 USA.							AOUN H, 1992, ANN INTERN MED, V116, P335, DOI 10.7326/0003-4819-116-4-335; Balint M, 1972, DOCTOR HIS PATIENT I; BEAN G, 1982, SOC SCI MED, V16, P1377, DOI 10.1016/0277-9536(82)90035-1; Becker HS., 1991, BOYS WHITE; BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365; BENNETT G, 1987, WOUND DOCTOR HEALING, P246; BERNSTEIN B, 1981, MED CARE, V19, P600, DOI 10.1097/00005650-198106000-00004; BERTAKIS KD, 1995, MED CARE, V33, P407, DOI 10.1097/00005650-199504000-00007; Bone LI, 1996, ANN INTERN MED, V124, P1091, DOI 10.7326/0003-4819-124-12-199606150-00013; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P1216, DOI 10.1001/jama.276.15.1216; BONE RC, 1995, JAMA-J AM MED ASSOC, V273, P518, DOI 10.1001/jama.273.7.518; BONE RC, 1995, JAMA-J AM MED ASSOC, V274, P1656, DOI 10.1001/jama.274.21.1656; BOSK CL, 1979, FORGIVE REMEMBER; Botelho R J, 1990, Fam Med, V22, P293; BRANCH W, 1993, NEW ENGL J MED, V329, P1130, DOI 10.1056/NEJM199310073291518; BRANCH WT, 1990, AM J MED, V88, P56, DOI 10.1016/0002-9343(90)90128-Z; BRASHEAR DB, 1987, J MED EDUC, V62, P418; Brock C D, 1990, Fam Med, V22, P33; Brunton S A, 1992, J Am Board Fam Pract, V5, P581; BURACK RC, 1991, J GEN INTERN MED, V6, P355, DOI 10.1007/BF02597438; Candib L., 1995, MED FAMILY FEMINIST; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; Charon R., 1993, EMPATHY PRACTICE MED, P147; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; CHRISTIESEELY J, 1986, CAN FAM PHYSICIAN, V32, P360; COHENCOLE SA, 1991, MED INTERVIEWS 3 FUN; COULOMBE L, 1995, CAN FAM PHYSICIAN, V41, P423; Covey S, 1994, 1 THINGS 1; Crouch M, 1986, Fam Med, V18, P93; DIMSDALE JE, 1984, PERSPECT BIOL MED, V27, P213; DOKTER HJ, 1986, FAM PRACT, V3, P155, DOI 10.1093/fampra/3.3.155; DUBOVSKY SL, 1983, JAMA-J AM MED ASSOC, V250, P3057, DOI 10.1001/jama.250.22.3057; EPSTEIN R, 1994, ARCH FAM MED, V3, P9; EPSTEIN RM, 1993, J FAM PRACTICE, V37, P377; Erikson E.H., 1963, CHILDHOOD SOC, P247; FARBER N, IN PRESS INTERN MED; Field D, 1996, MED EDUC, V30, P246, DOI 10.1111/j.1365-2923.1996.tb00825.x; FISCELLA K, 1927, JAMA-J AM MED ASSOC, V88, P877; Fisher R., 2011, GETTING YES NEGOTIAT; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; FUNKENSTEIN DH, 1968, J MED EDUC, V43, P883; GABBARD GO, 1989, JAMA-J AM MED ASSOC, V261, P2378, DOI 10.1001/jama.261.16.2378; GABBARD GO, 1995, JAMA-J AM MED ASSOC, V273, P1445, DOI 10.1001/jama.273.18.1445; Gilligan C., 1982, DIFFERENT VOICE; GORDON GH, 1995, FRONT PR CA, P436; GORDON LH, 1993, PASSAGE INTIMACY; GORLIN R, 1983, NEW ENGL J MED, V308, P1059, DOI 10.1056/NEJM198305053081804; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; Hahn SR, 1996, J GEN INTERN MED, V11, P1, DOI 10.1007/BF02603477; Hartmann P M, 1989, Int J Psychosom, V36, P86; HILFIKER D, 1984, NEW ENGL J MED, V310, P118, DOI 10.1056/NEJM198401123100211; INUI TS, 1982, MED CARE, V20, P535, DOI 10.1097/00005650-198206000-00001; KAPLAN C, 1988, J MED EDUC, V63, P906; Kaye J, 1994, J Cancer Educ, V9, P77; KERN DE, 1989, J GEN INTERN MED, V4, P421, DOI 10.1007/BF02599696; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KREUTER MW, 1995, J GEN INTERN MED, V10, P119, DOI 10.1007/BF02599664; LACOMBE M, 1994, BEING DOCTOR; LAPUMA J, 1992, JAMA-J AM MED ASSOC, V267, P1810, DOI 10.1001/jama.267.13.1810; Lazare A., 1989, OUTPATIENT PSYCHIAT, P381; LERNER H, 1995, DANCE ANGER; LEVINSON W, 1989, JAMA-J AM MED ASSOC, V261, P2252, DOI 10.1001/jama.261.15.2252; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Lichstein PR, 1996, J GEN INTERN MED, V11, P406, DOI 10.1007/BF02600187; LINN LS, 1985, MED CARE, V23, P1171, DOI 10.1097/00005650-198510000-00006; LIPKIN M, 1984, ANN INTERN MED, V100, P277, DOI 10.7326/0003-4819-100-2-277; Lipkin M, 1995, MED INTERVIEW; LONGHURST M, 1988, CAN MED ASSOC J, V139, P121; LUBANPLOZZA B, 1995, PATIENT EDUC COUNS, V26, P257, DOI 10.1016/0738-3991(95)00756-P; Lurie N, 1997, J GEN INTERN MED, V12, P34; LURIE N, 1993, NEW ENGL J MED, V329, P478, DOI 10.1056/NEJM199308123290707; MARSHALL AA, 1995, AM J GASTROENTEROL, V90, P4; MARTIN AR, 1986, J GEN INTERN MED, V1, P252, DOI 10.1007/BF02596195; Maslach C, 2016, MASLACH BURNOUT INVE; MATTHEWS DA, 1988, J MED EDUC, V63, P539; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; MCCORMICK TR, 1995, WESTERN J MED, V163, P236; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; MCCUE JD, 1985, AM J MED, V78, P985, DOI 10.1016/0002-9343(85)90222-0; MCCUE JD, 1985, NEW ENGL J MED, V312, P449, DOI 10.1056/NEJM198502143120725; MCCUE JD, 1991, ARCH INTERN MED, V151, P2273, DOI 10.1001/archinte.151.11.2273; MCDANIEL SH, 1989, FAM SYST MED, V7, P1; McKegney C P, 1989, Fam Med, V21, P452; Mengel MB, 1987, FAM SYST MED, V5, P176; METZ WP, 1993, AM J DIS CHILD, V147, P781, DOI 10.1001/archpedi.1993.02160310083024; Mizrahi T., 1986, GETTING RID PATIENTS; MOORE T, 1992, CARE SOUL; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MOWER WR, 1993, ARCH INTERN MED, V153, P375, DOI 10.1001/archinte.153.3.375; Murray H. A., 1938, EXPLOR PERS, P36; MUSHIN IC, 1993, ARCH INTERN MED, V153, P729, DOI 10.1001/archinte.153.6.729; Nasir L S, 1994, Fam Med, V26, P625; NESBITT D, 1988, ANN INTERN MED, V109, P154, DOI 10.7326/0003-4819-109-2-154; NIGHTINGALE SD, 1987, J GEN INTERN MED, V2, P25, DOI 10.1007/BF02596246; NIGHTINGALE SD, 1988, CHEST, V93, P684, DOI 10.1378/chest.93.4.684; NIGHTINGALE SD, 1991, J GEN INTERN MED, V6, P420, DOI 10.1007/BF02598163; NORELL J, 1991, FAM PRACT, V8, P378, DOI 10.1093/fampra/8.4.378; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; NOVACK DH, 1993, JAMA-J AM MED ASSOC, V269, P2101, DOI 10.1001/jama.269.16.2101; NOVACK DH, 1989, JAMA-J AM MED ASSOC, V261, P2980, DOI 10.1001/jama.261.20.2980; NOVACK DH, 1985, PSYCHOSOMATICS, V26, P853, DOI 10.1016/S0033-3182(85)72776-4; NOVACK DH, 1993, BRIT J HOSP MED, V50, P573; NOVACK DH, 1993, ANN INTERN MED, V119, P424, DOI 10.7326/0003-4819-119-5-199309010-00013; NOVACK DH, 1989, PSYCHOSOMATICS, V30, P213, DOI 10.1016/S0033-3182(89)72304-5; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; Peck S., 1978, ROAD LESS TRAVELLED; QUILL TE, 1991, ARCH INTERN MED, V151, P463; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; RAMIREZ AJ, 1995, BRIT J CANCER, V71, P1263, DOI 10.1038/bjc.1995.244; Ramirez AJ, 1996, LANCET, V347, P724, DOI 10.1016/S0140-6736(96)90077-X; REUBEN DB, 1983, SOUTHERN MED J, V76, P380, DOI 10.1097/00007611-198303000-00024; REUBEN DB, 1984, PSYCHOSOMATICS, V25, P815, DOI 10.1016/S0033-3182(84)72942-2; ROTER D, 1991, MED CARE, V29, P1083; ROWNTREE R, 1993, HIPPOCRATES      FEB, P35; Ryff CD, 1996, PSYCHOTHER PSYCHOSOM, V65, P14, DOI 10.1159/000289026; SAMUEL O, 1989, FAM PRACT, V6, P108, DOI 10.1093/fampra/6.2.108; Schechter GP, 1996, AM J MED, V101, P210, DOI 10.1016/S0002-9343(96)80078-7; SHAPIRO D, 1965, NEUROTIC STYLES, P1; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; SMITH RC, 1991, J GEN INTERN MED, V6, P535, DOI 10.1007/BF02598223; SMITH RC, 1994, J GEN INTERN MED, V9, P390, DOI 10.1007/BF02629520; SNIBBE JR, 1989, PSYCHOL REP, V65, P775, DOI 10.2466/pr0.1989.65.3.775; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; SUCHMAN AL, 1995, MED INTERVIEW, P368; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022; VAILLANT GE, 1972, NEW ENGL J MED, V287, P372, DOI 10.1056/NEJM197208242870802; VAILLANT GE, 1986, ARCH GEN PSYCHIAT, V43, P786; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; Wallen J, 1979, Women Health, V4, P135, DOI 10.1300/J013v04n02_03; WEDDING D, 1995, BEHAV MED; WHYTE D, 1994, HEART AROUSED; WILLIAMSON PR, 1991, J GEN INTERN MED, V6, P179, DOI 10.1007/BF02598321; Witman AB, 1996, ARCH INTERN MED, V156, P2565, DOI 10.1001/archinte.156.22.2565; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; WU AW, 1993, WESTERN J MED, V159, P565; YARNOLD PR, 1990, MED DECIS MAKING, V10, P215, DOI 10.1177/0272989X9001000309; ZINN WM, 1988, JAMA-J AM MED ASSOC, V259, P3296, DOI 10.1001/jama.259.22.3296; ZINN WM, 1990, ANN INTERN MED, V113, P293, DOI 10.7326/0003-4819-113-4-293; 1969, ARCH INTERN MED, V124, P385	141	356	365	1	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					502	509		10.1001/jama.278.6.502	http://dx.doi.org/10.1001/jama.278.6.502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP243	9256226				2022-12-28	WOS:A1997XP24300033
J	Sandle, GI; Lodge, JPA				Sandle, GI; Lodge, JPA			A 32-year-old man with recurrent cholangitis	LANCET			English	Article							CAROLIS-DISEASE		ST JAMES UNIV HOSP,LIVER UNIT,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Saint James's University Hospital	Sandle, GI (corresponding author), UNIV MANCHESTER,HOPE HOSP,DEPT MED,SALFORD M6 8HD,LANCS,ENGLAND.							BENHAMOU JP, 1990, SURG LIVER BILIARY T, P1013; DAYTON MT, 1983, AM J SURG, V145, P41, DOI 10.1016/0002-9610(83)90164-2; FAUVERT R, 1974, LIVER ITS DISEASES, P283; KERR DNS, 1962, CLIN RADIOL, V12, P85; RAMOND MJ, 1984, DIGEST DIS SCI, V29, P367, DOI 10.1007/BF01318526	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					408	408		10.1016/S0140-6736(97)06172-2	http://dx.doi.org/10.1016/S0140-6736(97)06172-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259656				2022-12-28	WOS:A1997XQ24800012
J	Hull, HF; Aylward, RB				Hull, HF; Aylward, RB			Ending polio immunization	SCIENCE			English	Article											Hull, HF (corresponding author), WHO, EXPANDED PROGRAMME IMMUNIZAT, CH-1211 GENEVA 27, SWITZERLAND.							Banerjee K, 1997, LANCET, V349, P1630, DOI 10.1016/S0140-6736(05)61675-3; COCKBURN TA, 1961, SCIENCE, V133, P1050, DOI 10.1126/science.133.3458.1050; DOMOK I, 1982, BRIT MED J, V1, P743; Dove AW, 1997, SCIENCE, V277, P779, DOI 10.1126/science.277.5327.779; Dowdle WR, 1997, J INFECT DIS, V175, pS286, DOI 10.1093/infdis/175.Supplement_1.S286; EVANS AS, 1984, REV INFECT DIS, V6, pS571; FOX JP, 1961, 5 INT POL C, P368; Hull HF, 1997, SCIENCE, V275, P40, DOI 10.1126/science.275.5296.40; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; Kew OM, 1995, SEMIN VIROL, V6, P401, DOI 10.1016/S1044-5773(05)80017-4; LEE JW, 1997, NEW GENERATION VACCI, P79; MULDERS MN, 1997, IN PRESS J INFECT DI, V175; OCHOA E G, 1987, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V31, P381; ROBINSON D, 1984, REV INFECT DIS, V6, pS586; 1997, WEEKLY EPIDEMIOL REC, V72, P189; 1997, MMWR-MORBID MORTAL W, V46, P641	16	17	17	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					780	780		10.1126/science.277.5327.780	http://dx.doi.org/10.1126/science.277.5327.780			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9273701				2022-12-28	WOS:A1997XQ24700032
J	Calder, JAM				Calder, JAM			Listeria meningitis in adults	LANCET			English	Editorial Material							BACTERIAL-MENINGITIS; UNITED-STATES				Calder, JAM (corresponding author), NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013, USA.		Calder, Jennifer/F-4508-2015	Calder, Jennifer/0000-0003-4758-611X				BUCHNER LH, 1968, AM J MED, V45, P904, DOI 10.1016/0002-9343(68)90189-7; CHERUBIN CE, 1981, AM J MED, V71, P199, DOI 10.1016/0002-9343(81)90106-6; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; JENSEN A, 1994, SCAND J INFECT DIS, V26, P171, DOI 10.3109/00365549409011781; LAVETTER A, 1971, NEW ENGL J MED, V285, P598, DOI 10.1056/NEJM197109092851103; MICHES LI, 1994, CRIT CARE NURSE  AUG, P22; Sigurdardottir B, 1997, ARCH INTERN MED, V157, P425, DOI 10.1001/archinte.157.4.425; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; *WHO, 1993, B WORLD HEALTH ORGAN, V71, P259	10	16	17	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					307	308		10.1016/S0140-6736(05)63384-3	http://dx.doi.org/10.1016/S0140-6736(05)63384-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251632				2022-12-28	WOS:A1997XP24200005
J	Blattler, T; Brandner, S; Raeber, AJ; Klein, MA; Voigtlander, T; Weissmann, C; Aguzzi, A				Blattler, T; Brandner, S; Raeber, AJ; Klein, MA; Voigtlander, T; Weissmann, C; Aguzzi, A			PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain	NATURE			English	Article							CREUTZFELDT-JAKOB DISEASE; CENTRAL-NERVOUS-SYSTEM; HOST PRION PROTEIN; MICE; MOUSE; PATHOGENESIS; REPLICATION; AGENT; SPREAD	Much available evidence points to a pathological isoform of the prion protein PrP being the infectious agent that causes transmissible spongiform encephalopathies, but the mechanisms controlling the neurotropism of prions are still unclear. We have previously shown that mice that do not express PrP (Prnp(o/o) mice) are resistant to infection by prions(1,2), and that if a Prnp(+/+) neurograft is introduced into such animals and these are infected intracerebrally with scrapie, the graft but not the surrounding tissue shows scrapie pathology(3). Here we show that PrP-expressing neurografts in Prnp(o/o) mice do not develop scrapie histopathology after intraperitoneal or intravenous inoculation with scrapie prions. Prion titres were undetectable in spleens of inoculated Prnp(o/o) mice, but were restored to wild-type levels upon reconstitution of the host lymphohaemopoietic system with PrP-expressing cells. Surprisingly, however, i.p. or i.v. inoculation failed to produce scrapie pathology in the neurografts of 27 out of 28 reconstituted animals, in contrast to intracerebral inoculation. We conclude that transfer of infectivity from the spleen to the central nervous system is crucially dependent on the expression of PrP in a tissue compartment that cannot be reconstituted by bone marrow transfer. Thus the requirement for the normal isoform of PrP in peripheral tissues represents a bottleneck for the spread of prions from peripheral sites to the central nervous system.	UNIV ZURICH,INST NEUROPATHOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST MOL BIOL,CH-8093 ZURICH,SWITZERLAND	University of Zurich; University of Zurich			Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Aguzzi, Adriano/0000-0002-0344-6708				Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown KL, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P159; BROWN P, 1990, NEUROLOGY, V40, P887, DOI 10.1212/WNL.40.6.887; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER HR, 1992, NATURE, V256, P577; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; FRASER H, 1978, J COMP PATHOL, V88, P563, DOI 10.1016/0021-9975(78)90010-5; Isenmann S, 1996, NEUROPATH APPL NEURO, V22, P118; KIMBERLIN RH, 1983, J NEUROL SCI, V61, P315, DOI 10.1016/0022-510X(83)90165-X; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Lasmezas CI, 1996, J VIROL, V70, P1292; OROURKE KI, 1994, J GEN VIROL, V75, P1511, DOI 10.1099/0022-1317-75-6-1511; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620	21	223	228	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					69	73		10.1038/37981	http://dx.doi.org/10.1038/37981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288968				2022-12-28	WOS:A1997XU59600046
J	Andersen, RE; Blair, SN; Cheskin, LJ; Bartlett, SJ				Andersen, RE; Blair, SN; Cheskin, LJ; Bartlett, SJ			Encouraging patients to become more physically active: The physician's role	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ALL-CAUSE MORTALITY; SKELETAL-MUSCLE; PRIMARY-CARE; EXERCISE; FITNESS; HEALTH; WOMEN; MEN; ASSOCIATION; RESTRICTION	A sedentary lifestyle is recognized as a risk factor for poor health. Only 22% of adults in the United States are currently active enough to derive health benefits from their activity. Inactive persons who improve their physical fitness are less likely to die of all causes and of cardiovascular disease than are those who remain sedentary. Many physicians do not feel adequately prepared to prescribe exercise to their patients. An active lifestyle does not require patients to follow a formal, uninterrupted, vigorous exercise program. Recent recommendations about physical activity have been simplified to encourage activity for the promotion of health and the prevention of disease. Physicians are advised to routinely counsel sedentary patients to accumulate 30 minutes of moderate-intensity activity - equivalent to walking at 3 to 4 mph for most healthy adults - on most, preferably all, days of the week. The most sedentary patients should be encouraged to simply begin doing something and to make gradual changes over time. With continued support and encouragement from their physicians and families, these persons may progress to higher levels of activity that will further reduce their risk for disease.	COOPER INST AEROB RES, DALLAS, TX 75230 USA	Cooper Institute	Andersen, RE (corresponding author), JOHNS HOPKINS UNIV, SCH MED,DEPT MED,DIV GASTROENTEROL,333 CASSELL DR, SUITE 1640, BALTIMORE, MD 21224 USA.		Cheskin, Lawrence/AAM-1094-2021; Bartlett, Susan Joan/AAD-4103-2020; Bartlett, Susan J./J-9864-2012	Cheskin, Lawrence/0000-0003-0262-1030; Bartlett, Susan Joan/0000-0001-9755-2490; 	NHLBI NIH HHS [HL48597] Funding Source: Medline; NIA NIH HHS [AGO6945] Funding Source: Medline; NIDDK NIH HHS [1 F32 DK 09241-01 ZRG1 03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG006945, R01AG006945] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American College of Sports Medicine, 1975, GUID EX TEST PRESCR; ANDERSEN RE, 1995, MED EXERC NUTR HLTH, V4, P57; [Anonymous], 1990, Med Sci Sports Exerc, V22, P265; [Anonymous], 1996, JAMA, V276, P241; BALLOR DL, 1994, INT J OBESITY, V18, P35; BALLOR DL, 1988, AM J CLIN NUTR, V47, P19, DOI 10.1093/ajcn/47.1.19; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BLAIR SN, 1992, MED EXERCISE NUTRITI, V1, P54; BLAIR SN, 1991, LIVING EXERCISE; CAMPBELL MK, 1994, AM J PUBLIC HEALTH, V84, P783, DOI 10.2105/AJPH.84.5.783; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; DEBUSK RF, 1990, AM J CARDIOL, V65, P1010, DOI 10.1016/0002-9149(90)91005-Q; Dishman RK., 1988, EXERCISE ADHERENCE I; DUNCAN JJ, 1991, JAMA-J AM MED ASSOC, V266, P3295, DOI 10.1001/jama.266.23.3295; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; KING AC, 1992, MED SCI SPORT EXER, V24, pS221; LEWIS BS, 1993, PREV MED, V22, P110, DOI 10.1006/pmed.1993.1008; LOGSDON DN, 1989, AM J PREV MED, V5, P249, DOI 10.1016/S0749-3797(18)31065-1; Long BJ, 1996, AM J PREV MED, V12, P73, DOI 10.1016/S0749-3797(18)30348-9; MARCUS BH, 1995, MED EXERC NUTR HLTH, V4, P325; National Center for Chronic Disease Prevention and Health Promotion, 1996, PHYS ACT HLTH REP SU; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PATRICK K, 1994, PHYSICIAN SPORTSMED, V22, P45, DOI 10.1080/00913847.1994.11947706; ROHMYOUNG D, 1995, MED EXERCISE NUTR HL, V4, P335; ROSEN MA, 1984, PREV MED, V13, P535, DOI 10.1016/0091-7435(84)90022-7; ROSS R, 1995, AM J CLIN NUTR, V61, P1179, DOI 10.1093/ajcn/61.6.1179; SCHAPPERT SM, 1993, NATL AMBULATORY MED; STRECHER VJ, 1991, J GEN INTERN MED, V6, P9, DOI 10.1007/BF02599383; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Weaver F J, 1978, Health Values, V2, P249; WELLS KB, 1986, AM J PUBLIC HEALTH, V76, P1009, DOI 10.2105/AJPH.76.8.1009	36	67	68	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					395	400		10.7326/0003-4819-127-5-199709010-00010	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273831				2022-12-28	WOS:A1997XU10000009
J	Plemper, RK; Bohmler, S; Bordallo, J; Sommer, T; Wolf, DH				Plemper, RK; Bohmler, S; Bordallo, J; Sommer, T; Wolf, DH			Mutant analysis links the translocon and BiP to retrograde protein transport for ER degradation	NATURE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; UBIQUITIN-PROTEASOME PATHWAY; SEC61P COMPLEX; YEAST; HOMOLOGS; ROUTE; KAR2; GENE	Proteins enter the secretory pathway through the endoplasmic reticulum(1), which delivers properly folded proteins to their site of action(2) and contains a quality-control system to monitor and prevent abnormal proteins from being delivered(3), Many of these proteins are degraded by the cytoplasmic proteasome(4-8), which requires their retrograde transport to the cytoplasm(5,6). Based on a co-immunoprecipitation of major histocompatibility complex (MHC) class I heavy-chain breakdown intermediates with the translocon subunit Sec61p (refs 9, 10), it was speculated that Sec61p maybe involved in retrograde transport(11), Here we present functional evidence from genetic studies that Sec61p mediates retrograde transport of a mutated lumenal yeast carboxypeptidase ycsY (CPY*) in vivo. The endoplasmic reticulum lumenal chaperone BiP (Kar2p) and Sec63p, which are also subunits of the import machinery(10,12), are involved in export of CPY* to the cytosol, Thus our results demonstrate that retrograde transport of proteins is mediated by a functional translocon. We consider the export of endoplasmic reticulum-localized proteins to the cytosol by the translocon for proteasome degradation to be a general process in eukaryotic cell biology.	UNIV STUTTGART,INST BIOCHEM,D-70569 STUTTGART,GERMANY; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY	University of Stuttgart; Helmholtz Association; Max Delbruck Center for Molecular Medicine			bordallo, javier/X-5360-2019	bordallo, javier/0000-0002-5786-3929				Ausubel FM, 1992, CURRENT PROTOCOLS MO; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; CYYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	29	451	454	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					891	895		10.1038/42276	http://dx.doi.org/10.1038/42276			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278052	Bronze			2022-12-28	WOS:A1997XT75400053
J	Branche, CM; Conn, JM; Annest, JL				Branche, CM; Conn, JM; Annest, JL			Personal watercraft-related injuries - A growing public health concern	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							JET-SKI ACCIDENT	Context.-An increase in the recreational use of personal watercraft (PWC) raises concern about an increase in associated injuries on a national level. Objective.-To estimate the relative frequency, types of injury, and demographic features of persons injured while using PWC in the United States. Design.-Case series. Setting.-Emergency department (ED) visits to hospitals participating a national probability sample. Participants.-All persons treated for PWC-related injury from January 1, 1990, through December 31, 1995. Results.-An estimated 32 954 persons (95% confidence interval [CI], 22919-42 989) with PWC-related injuries were treated in US hospital EDs, of which 3.5% were hospitalized. Personal watercraft-related injuries have increased significantly from an estimated 2860 in 1990 to more than 12 000 in 1995. During this period, the number of PWC in operation increased 3-fold from approximately 241 500 in 1990 to an estimated 760 000 in 1995. The most prevalent diagnoses were lacerations, contusions, and fractures. Main Outcome Measures.-The estimated number and percentage of patients treated in EDs for PWC-related injuries, by year, age, sex, and the number and rate per 1000 of PWC in operation by year. Conclusions.-Since 1990, there has been at least a 4-fold increase in injuries associated with an increase in the recreational use of PWC. The rate of ED-treated injuries related to PWC was about 8.5 times higher (95% CI, 8.2-8.8; 1992 data) than the rate of those from motorboats. Specific training and adult supervision is recommended for miners using PWC. Furthermore, medical practitioners should encourage personal flotation device use and other protection for their patients who are known water enthusiasts.			Branche, CM (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,PUBL HLTH SERV,US DEPT HHS,ATLANTA,GA 30341, USA.							Annest J, 1996, INVENTORY FEDERAL DA; ARMITAGE P, 1994, STAT METHODS MED RES, P408; BEVER DL, 1996, SAFETY PERSONAL FOCU, P391; BRANCHEDORSEY CM, 1993, STUDY BOAT BOAT PROP; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P331; Francis R A, 1994, Mo Med, V91, P241; HAEFNER HK, 1991, OBSTET GYNECOL, V78, P986; HAMMAN BL, 1993, J PEDIATR SURG, V28, P920, DOI 10.1016/0022-3468(93)90697-J; Jeffery R S, 1991, Br J Sports Med, V25, P232; MARKER D, 1988, NEISS SAMPLE UPDATE; Muller R J, 1993, J La State Med Soc, V145, P27; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; *US COAST GUARD, 1995, BOAT STAT 1994; *US CONS PROD SAF, 1994, NAT EL INJ SURV SYST; WEIN P, 1990, AUST NZ J OBSTET GYN, V30, P384, DOI 10.1111/j.1479-828X.1990.tb02038.x	15	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					663	665		10.1001/jama.278.8.663	http://dx.doi.org/10.1001/jama.278.8.663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272899				2022-12-28	WOS:A1997XR54700040
J	Steinhubl, SR; Topol, EJ				Steinhubl, SR; Topol, EJ			Stenting for acute myocardial infarction	LANCET			English	Editorial Material							CORONARY		CLEVELAND CLIN FDN,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,CLEVELAND,OH 44195; OHIO STATE UNIV,DEPT MED,CLEVELAND,OH 44195	Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Steinhubl, SR (corresponding author), CLEVELAND CLIN FDN,DEPT CARDIOL,CLEVELAND,OH 44195, USA.			Topol, Eric/0000-0002-1478-4729				Antoniucci D., 1997, Journal of the American College of Cardiology, V29, p456A; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Grines C. L., 1997, Journal of the American College of Cardiology, V29, p389A; *GUSTO 2B ANG SUBS, 1997, NEW ENGL J MED, V336, P1621; HOORNTJE JC, 1996, CIRCULATION S1, V94, P570; Horstkotte D., 1996, European Heart Journal, V17, P297; Monassier Jean Pierre, 1996, Journal of the American College of Cardiology, V27, p68A; Nakagawa Y, 1996, AM J CARDIOL, V78, P980, DOI 10.1016/S0002-9149(96)00520-6; NATH FC, 1993, J AM COLL CARDIOL, V21, P622, DOI 10.1016/0735-1097(93)90093-G; Rodriguez A., 1997, Journal of the American College of Cardiology, V29, p221A; Saito S., 1997, Journal of the American College of Cardiology, V29, p390A; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201	13	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					532	533		10.1016/S0140-6736(05)63135-2	http://dx.doi.org/10.1016/S0140-6736(05)63135-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284772				2022-12-28	WOS:A1997XT22100005
J	Schwab, M; Lutum, AS; Seufert, W				Schwab, M; Lutum, AS; Seufert, W			Yeast Hct1 is a regulator of Clb2 cyclin proteolysis	CELL			English	Article							MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; G1 CYCLINS; CDC20 GENE; S-PHASE; UBIQUITIN; DEGRADATION; MITOSIS	Stage-specific proteolysis of mitotic cyclins is fundamental to eukaryotic cell cycle regulation. We found that yeast Hct1, a conserved protein of eukaryotes, is a necessary and rate-limiting component of this proteolysis pathway. In hct1 mutants, the mitotic cyclin Clb2 is highly stabilized and inappropriately induces DNA replication, while G1 cyclins and other proteolytic substrates remain short-lived. Viability of hct1 mutants depends on SIC1. This and further results suggest that inhibition of cyclin-dependent kinases may compensate for defects in cyclin proteolysis. Remarkably, elevated levels of Hct1 ectopically activate destruction box-and Cdc23-dependent degradation of Clb2 and cause phenotypic effects characteristic for a depletion of M-phase cyclins. Hct1 and the related Cdc20 may function as substrate-specific regulators of proteolysis during mitosis.			Schwab, M (corresponding author), UNIV STUTTGART,INST IND GENET,ALLMANDRING 31,D-70569 STUTTGART,GERMANY.		Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KAISER C, 1994, MEHTODS YEAST GENETI; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHWOB E, 1994, CELL, V79, P239; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	41	427	432	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					683	693		10.1016/S0092-8674(00)80529-2	http://dx.doi.org/10.1016/S0092-8674(00)80529-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288748	Bronze			2022-12-28	WOS:A1997XT06600012
J	Shimamura, M; Yasue, H; Ohshima, K; Abe, H; Kato, H; Kishiro, T; Goto, M; Munechika, I; Okada, N				Shimamura, M; Yasue, H; Ohshima, K; Abe, H; Kato, H; Kishiro, T; Goto, M; Munechika, I; Okada, N			Molecular evidence from retroposons that whales form a clade within even-toed ungulates	NATURE			English	Article							SEQUENCES; ELEMENTS; PHYLOGENY; SINES	The origin of whales and their transition from terrestrial life to a fully aquatic existence has been studied in depth. Palaeontological(1,2), morphological(3) and molecular studies(4-7) suggest that the order Cetacea (whales, dolphins and porpoises) is more closely related to the order Artiodactyla (even-toed ungulates, including cows, camels and pigs) than to other ungulate orders. The traditional view that the order Artiodactyla is monophyletic has been challenged by molecular analyses of variations in mitochondrial and nuclear DNA(5-7). We have characterized two families of short interspersed elements (SINEs) that were present exclusively in the genomes of whales, ruminants and hippopotamuses, but not in those of camels and pigs. We made an extensive survey of retropositional events that might have occurred during the divergence of whales and even-toed ungulates. We have characterized nine retropositional events of a SINE unit, each of which provides phylogenetic resolution of the relationships among whales, ruminants, hippopotamuses and pigs. Our data provide evidence that whales, ruminants and hippopotamuses form a monophyletic group.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,YOKOHAMA,KANAGAWA 226,JAPAN; NATL INST ANIM IND,ANIM GENOME RES GRP,KUKIZAKI,IBARAKI 305,JAPAN; NATL INST FAR SEAS FISHERIES,LARGE CETACEAN SECT,SHIMIZU,SHIZUOKA 424,JAPAN; INST CETACEAN RES,GENET ECOL SECT,CHUO KU,TOKYO 104,JAPAN; CHIBA ZOOL PK,WAKABA KU,CHIBA 264,JAPAN	Tokyo Institute of Technology; National Agriculture & Food Research Organization - Japan			Ohshima, Kazuhiko/AAJ-1347-2021	Ohshima, Kazuhiko/0000-0001-8437-4744; Abe, Hideaki/0000-0002-8965-8970; Okada, Norihiro/0000-0002-3655-8060				Adachi J, 1996, MOL PHYLOGENET EVOL, V6, P72, DOI 10.1006/mpev.1996.0059; FORDYCE RE, 1994, ANNU REV EARTH PL SC, V22, P419, DOI 10.1146/annurev.ea.22.050194.002223; Gatesy J, 1996, MOL BIOL EVOL, V13, P954, DOI 10.1093/oxfordjournals.molbev.a025663; Gentry AW, 1988, PHYLOGENY CLASSIFICA, V35B, P235; GINGERICH PD, 1990, SCIENCE, V249, P154, DOI 10.1126/science.249.4965.154; GOLZ DJ, 1976, NATURAL HIST MUSEUM, V26, P1; GRAUR D, 1994, MOL BIOL EVOL, V11, P357; Hasegawa M, 1996, MOL BIOL EVOL, V13, P710, DOI 10.1093/oxfordjournals.molbev.a025632; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Irwin David M., 1994, Journal of Mammalian Evolution, V2, P37, DOI 10.1007/BF01464349; LENSTRA JA, 1993, ANIM GENET, V24, P33, DOI 10.1111/j.1365-2052.1993.tb00916.x; MILINKOVITCH MC, 1993, NATURE, V361, P346, DOI 10.1038/361346a0; MURATA S, 1993, P NATL ACAD SCI USA, V90, P6995, DOI 10.1073/pnas.90.15.6995; Murata S, 1996, GENETICS, V142, P915; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; OKADA N, 1991, TRENDS ECOL EVOL, V6, P358, DOI 10.1016/0169-5347(91)90226-N; Okada N., 1995, IMPACT SHORT INTERSP, P61; Philippe Herve, 1994, Journal of Mammalian Evolution, V2, P133, DOI 10.1007/BF01464365; Prothero D., 1988, PHYLOGENY CLASSIFICA, P201; ROSE KD, 1982, SCIENCE, V216, P621, DOI 10.1126/science.216.4546.621; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; TAKAHASHI H, 1992, ANIM GENET, V23, P443, DOI 10.1111/j.1365-2052.1992.tb02164.x; Thewissen J. G. M., 1994, Journal of Mammalian Evolution, V2, P157, DOI 10.1007/BF01473527; THEWISSEN JGM, 1993, NATURE, V361, P444, DOI 10.1038/361444a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215	25	313	324	1	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					666	670		10.1038/41759	http://dx.doi.org/10.1038/41759			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262399	Bronze			2022-12-28	WOS:A1997XQ86300047
J	Sacks, LM				Sacks, LM			Res Ipsa Loquitur	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					471	472						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP243	9256211				2022-12-28	WOS:A1997XP24300012
J	Alm, JS; Lilja, G; Pershagen, G; Scheynius, A				Alm, JS; Lilja, G; Pershagen, G; Scheynius, A			Early BCG vaccination and development of atopy	LANCET			English	Article							CYTOKINE PRODUCTION; CHILDREN; TUBERCULOSIS; PREVALENCE; PREVENTION; INDUCTION	Background The increase in atopic diseases may be partly explicable by a decline of certain infectious diseases, dr changes in childhood Vaccination programmes, or both. We investigated whether BCG vaccination against tuberculosis influences the development of atopy. Methods We did a retrospective cohort study of 216 children with atopic heredity, born in Stockholm between 1989 and 1992, who received BCG vaccination when they were younger than 6 months, and 358 age-matched controls who had not been vaccinated. Both groups attended Sachs' Children's Hospital, Stockholm, Sweden, during 1995-96 for assessment of atopic history and clinical signs of atopic disease. All children also underwent skin-prick testing (SPT) and serum was analysed for allergen-specific IgE antibodies. Serum from parents was also analysed for IgE antibodies. Findings 77 (36%) children in the BCG group and 145 (41%) in the control group had a positive history or clinical signs of atopic disease, in the vaccinated group, 26 (12%) children had one or more positive SPT, and 61 (31%) had circulating allergen-specific IgE antibodies, whereas in the control group, the numbers were 35 (10%) and 84 (27%) respectively. Atopy was confirmed by serology in parents of almost two-thirds of the children in each group. Other risk factors for atopic disease were evenly distributed between the two groups. Interpretation early BCG vaccination in children with atopic heredity does not seem to affect the development of atopic disease before school age.	KAROLINSKA HOSP & INST, INST ENVIRONM MED, DIV ENVIRONM EPIDEMIOL, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA HOSP & INST, DEPT LAB MED, DIV CLIN IMMUNOL, S-17176 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Alm, JS (corresponding author), KAROLINSKA INST, SACHS CHILDRENS HOSP, S-17176 STOCKHOLM, SWEDEN.			Pershagen, Goran/0000-0002-9701-1130; Alm, Johan/0000-0002-9062-4479				ALKASSIMI FA, 1995, AM J RESP CRIT CARE, V152, P1575, DOI 10.1164/ajrccm.152.5.7582297; AURELIUS G, 1995, CHILD HLTH CARE STOC, P20; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; COLDITZ GA, 1995, PEDIATRICS, V96, P29; DELPRETE G, 1992, ALLERGY, V47, P450; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HARADA M, 1990, DIABETES RES CLIN PR, V8, P85, DOI 10.1016/0168-8227(90)90017-N; Kajosaari M, 1994, Pediatr Allergy Immunol, V5, P26, DOI 10.1111/j.1399-3038.1994.tb00344.x; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; LARSSON LO, 1991, SENSITIVITY SENSITIN, P6; Lilja G, 1996, CLIN EXP ALLERGY, V26, P1073; MEHRA VL, 1990, NEW GENERATION VACCI, P611; Pepys J., 1975, , Clinical aspects of immunology., P877; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMANUS V, 1992, TUBERCLE LUNG DIS, V73, P150, DOI 10.1016/0962-8479(92)90149-E; ROMANUS V, 1996, SWEDISH TUBERCULOSIS; RYLANDER E, 1993, EUR J EPIDEMIOL, V9, P517, DOI 10.1007/BF00209530; Sander B, 1995, IMMUNOLOGY, V86, P512; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; SHEHADEH N, 1994, LANCET, V343, P706, DOI 10.1016/S0140-6736(94)91583-0; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIGURS N, 1992, PEDIATRICS, V89, P735; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; WARD BJ, 1991, CLIN IMMUNOL IMMUNOP, V61, P236, DOI 10.1016/S0090-1229(05)80027-3; WARD BJ, 1993, CLIN IMMUNOL IMMUNOP, V67, P171, DOI 10.1006/clin.1993.1061; Wichmann HE, 1996, CLIN EXP ALLERGY, V26, P621, DOI 10.1111/j.1365-2222.1996.tb00587.x	28	213	218	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	1997	350	9075					400	403		10.1016/S0140-6736(97)02207-1	http://dx.doi.org/10.1016/S0140-6736(97)02207-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259654				2022-12-28	WOS:A1997XQ24800010
J	Bingham, PM				Bingham, PM			Cosuppression comes to the animals	CELL			English	Review							CHROMATIN; SEQUENCES; REPEATS; PLANTS				Bingham, PM (corresponding author), SUNY STONY BROOK, STONY BROOK, NY 11794 USA.							Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI DOI 10.1515/9781400858712; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Dawkins Richard, 1976, SELFISH GENE; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hatada I, 1997, J BIOL CHEM, V272, P9120, DOI 10.1074/jbc.272.14.9120; Hurst LD, 1996, Q REV BIOL, V71, P317, DOI 10.1086/419442; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; Williams G. C., 1966, P307; WU CT, 1993, J CELL BIOL, V120, P587, DOI 10.1083/jcb.120.3.587	20	45	56	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					385	387		10.1016/S0092-8674(00)80496-1	http://dx.doi.org/10.1016/S0092-8674(00)80496-1			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267017	Bronze			2022-12-28	WOS:A1997XQ06300001
J	Wrangham, RW				Wrangham, RW			Behavior - Subtle, secret female chimpanzees	SCIENCE			English	Editorial Material											Wrangham, RW (corresponding author), HARVARD UNIV,DEPT ANTHROPOL,CAMBRIDGE,MA 02138, USA.							Baker Kate C., 1994, P227; Gagneux P, 1997, NATURE, V387, P358, DOI 10.1038/387358a0; Hrdy SarahB., 1983, SOCIAL BIOL FEMALE V, P3; Pusey A, 1997, SCIENCE, V277, P828, DOI 10.1126/science.277.5327.828; WRANGHAM RW, 1993, HUM NATURE-INT BIOS, V4, P47, DOI 10.1007/BF02734089	5	6	7	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					774	775		10.1126/science.277.5327.774	http://dx.doi.org/10.1126/science.277.5327.774			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9273699				2022-12-28	WOS:A1997XQ24700027
J	Zou, H; Henzel, WJ; Liu, XS; Lutschg, A; Wang, XD				Zou, H; Henzel, WJ; Liu, XS; Lutschg, A; Wang, XD			Apaf-1, a human protein homologous to C-elegans CED-4, participates in cytochrome c-dependent activation of caspase-3	CELL			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; GENE; APOPTOSIS; ENCODES	We report here the purification and cDNA cloning of Apaf-1, a novel 130 kd protein from HeLa cell cytosol that participates in the cytochrome c-dependent activation of caspase-3. The NH2-terminal 85 amino acids of Apaf-1 show 21% identity and 53% similarity to the NH2-terminal prodomain of the Caenorhabditis elegans caspase, CED-3. This is followed by 320 amino acids that show 22% identity and 48% similarity to CED-4, a protein that is believed to initiate apoptosis in C. elegans. The COOH-terminal region of Apaf-1 comprises multiple WD repeats, which are proposed to mediate protein-protein interactions. Cytochrome c binds to Apaf-1, an event that may trigger the activation of caspase-3, leading to apoptosis.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; GENENTECH INC,DIV PROT CHEM,S SAN FRANCISCO,CA 94080	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Roche Holding; Genentech				Henzel, William/0000-0003-2940-3797; Wang, Xiaodong/0000-0001-9885-356X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boulakia CA, 1996, ONCOGENE, V12, P529; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hasegawa J, 1996, CANCER RES, V56, P1713; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ibrado AM, 1996, CANCER RES, V56, P4743; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAUFMANN R, 1994, INT J MASS SPECTROM, V131, P355, DOI 10.1016/0168-1176(93)03876-N; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Maniatis T., 1989, MOL CLONING LAB MAN; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	45	2641	2764	4	137	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					405	413		10.1016/S0092-8674(00)80501-2	http://dx.doi.org/10.1016/S0092-8674(00)80501-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267021	Bronze			2022-12-28	WOS:A1997XQ06300005
J	Remuzzi, G; Schieppati, A				Remuzzi, G; Schieppati, A			Dearing - a report to be embraced	LANCET			English	Editorial Material											Remuzzi, G (corresponding author), MARIO NEGRI INST PHARMACOL RES,NEGRI BERGAMO LABS,I-24125 BERGAMO 11,ITALY.		Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				[Anonymous], 1997, THE DEARING REPORT	1	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					308	308		10.1016/S0140-6736(05)63385-5	http://dx.doi.org/10.1016/S0140-6736(05)63385-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251633				2022-12-28	WOS:A1997XP24200006
J	Roberts, I; Barker, M; Li, L				Roberts, I; Barker, M; Li, L			Analysis of trends in deaths from accidental drug poisoning in teenagers, 1985-95	BRITISH MEDICAL JOURNAL			English	Article											Roberts, I (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL,CHILD HLTH MONITORING UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.							FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; HENRY JA, 1992, BRIT MED J, V305, P5, DOI 10.1136/bmj.305.6844.5; WRIGHT JD, 1995, BRIT MED J, V310, P20, DOI 10.1136/bmj.310.6971.20	3	20	20	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					289	289		10.1136/bmj.315.7103.289	http://dx.doi.org/10.1136/bmj.315.7103.289			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274550	Green Published			2022-12-28	WOS:A1997XP75000024
J	Hemminki, E; McPherson, K				Hemminki, E; McPherson, K			Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT THERAPY; POST-MENOPAUSAL OSTEOPOROSIS; PLACEBO-CONTROLLED TRIAL; BONE LOSS; LONG-TERM; PROGESTIN THERAPY; WOMEN; PREVENTION; CALCIUM; 2-YEAR	Objective: To examine the incidence of cardiovascular diseases and cancer from published clinical trials that studied other outcomes of postmenopausal hormone therapy as some surveys have suggested that it may decrease the incidence of cardiovascular diseases and increase the incidence of hormone dependent cancers. Design: Trials that compared hormone therapy with placebo, no therapy, or vitamins and minerals in comparable groups of postmenopausal women and reported cardiovascular or cancer outcomes were searched from the literature. Subjects: 22 trials with 4124 women were identified. In each group, the numbers of women with cardiovascular and cancer events were summed and divided by the numbers of women originally allocated to the groups. Results: Data on cardiovascular events and cancer were usually given incidentally, either as a reason for dropping out of a study or in a list of adverse effects. The calculated odds ratios for women taking hormones versus those not taking hormones was 1.39 (95% confidence interval 0.48 to 3.95) for cardiovascular events without pulmonary embolus and deep vein thrombosis and 1.64 (0.65 to 4.18) with them. It is unlikely that such results would have occurred if the true odds ratio were 0.7 or less. For cancers, the numbers of reported events were too low for a useful conclusion. Conclusions: The results of these pooled data do not support the notion that postmenopausal hormone therapy prevents cardiovascular events.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Hemminki, E (corresponding author), NATL RES & DEV CTR WELF & HLTH,HLTH SERV RES UNIT,POB 220,HELSINKI 00531,FINLAND.							AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; ALOIA JF, 1995, AM J OBSTET GYNECOL, V172, P896, DOI 10.1016/0002-9378(95)90018-7; ALOIA JF, 1994, ANN INTERN MED, V120, P97, DOI 10.7326/0003-4819-120-2-199401150-00001; BACKE B, 1992, Scandinavian Journal of Primary Health Care, V10, P179, DOI 10.3109/02813439209014058; BARRETTCONNOR E, 1986, WESTERN J MED, V144, P620; CHRISTENSEN MS, 1982, AM J OBSTET GYNECOL, V144, P873, DOI 10.1016/0002-9378(82)90176-4; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; CHRISTIANSEN C, 1981, EUR J CLIN INVEST, V11, P305, DOI 10.1111/j.1365-2362.1981.tb02121.x; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Coope J, 1981, J R Coll Gen Pract, V31, P134; DERMAN RJ, 1995, INT J FERTIL MENOP S, V40, P73; DIXON WJ, 1988, BMDP STAT SOFTW MAN, P262; GALLAGHER JC, 1991, AM J MED, V90, P171; GENANT HK, 1990, OBSTET GYNECOL, V76, P579; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENDALE GA, 1990, J GEN INTERN MED, V5, P464, DOI 10.1007/BF02600870; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HASSAGER C, 1989, METABOLISM, V38, P662, DOI 10.1016/0026-0495(89)90104-2; HASSAGER C, 1987, CIRCULATION, V76, P753, DOI 10.1161/01.CIR.76.4.753; HEMMINKI E, 1993, MATURITAS, V16, P163, DOI 10.1016/0378-5122(93)90062-M; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; JENSEN J, 1989, MATURITAS, V11, P117, DOI 10.1016/0378-5122(89)90004-2; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MACLENNAN SC, 1995, MED J AUSTRALIA, V162, P491, DOI 10.5694/j.1326-5377.1995.tb140014.x; MARSLEW U, 1992, OBSTET GYNECOL, V79, P202; MOLANDER U, 1990, MATURITAS, V12, P113, DOI 10.1016/0378-5122(90)90089-O; MUNKJENSEN N, 1988, BRIT MED J, V296, P1150, DOI 10.1136/bmj.296.6630.1150; MUNKJENSEN N, 1994, AM J OBSTET GYNECOL, V171, P132, DOI 10.1016/0002-9378(94)90458-8; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; OBEL EB, 1993, MATURITAS, V16, P13, DOI 10.1016/0378-5122(93)90129-6; *OFF TECHN ASS, 1995, EFF COSTS OST SCREEN; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; RESCH H, 1990, ACTA ENDOCRINOL-COP, V123, P14, DOI 10.1530/acta.0.1230014; RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802; RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, pB6165; RODRIGUEZ C, 1995, AM J EPIDEMIOL, V141, P828, DOI 10.1093/oxfordjournals.aje.a117518; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; SVENDSEN OL, 1992, SCAND J CLIN LAB INV, V52, P831, DOI 10.3109/00365519209088388; TONSTAD S, 1995, J INTERN MED, V238, P39, DOI 10.1111/j.1365-2796.1995.tb00897.x; TOPO P, 1995, MATURITAS, V22, P89, DOI 10.1016/0378-5122(95)00932-B; VANDENBROUCKE JP, 1995, EPIDEMIOLOGY, V6, P207; *WHO STUD GROUP, 1994, ASSESSMENT FRACTURE; WIMALAWANSA SJ, 1995, AM J MED, V99, P36, DOI 10.1016/S0002-9343(99)80102-8; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	47	198	206	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					149	153		10.1136/bmj.315.7101.149	http://dx.doi.org/10.1136/bmj.315.7101.149			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251544	Green Published			2022-12-28	WOS:A1997XM32100017
J	DeMaria, R; Lenti, L; Malisan, F; dAgostino, F; Tomassini, B; Zeuner, A; Rippo, MR; Testi, R				DeMaria, R; Lenti, L; Malisan, F; dAgostino, F; Tomassini, B; Zeuner, A; Rippo, MR; Testi, R			Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis	SCIENCE			English	Article							FAS-MEDIATED APOPTOSIS; ACIDIC SPHINGOMYELINASE; EXPRESSION CLONING; G(D3) SYNTHASE; CELL-DEATH; PROTEASE; INVOLVEMENT; RECEPTOR; SIGNAL; MEMBRANE	Gangliosides participate in development and tissue differentiation, Cross-linking of the apoptosis-inducing CD95 protein (also called Fas or APO-1) in lymphoid and myeloid tumor cells triggered GD3 ganglioside synthesis and transient accumulation. CD95-induced GD3 accumulation depended on integral receptor ''death domains'' and on activation of a family of cysteine proteases called caspases. Cell-permeating ceramides, which are potent inducers of apoptosis, also triggered GD3 synthesis, GD3 disrupted mitochondrial transmembrane potential (Delta psi(m),), and induced apoptosis, in a caspase-independent fashion. Transient overexpression of the GD3 synthase gene directly triggered apoptosis, Pharmacological inhibition of GD3 synthesis and exposure to GD3 synthase antisense oligodeoxynucleotides prevented CD95-induced apoptosis. Thus, GD3 ganglioside mediates the propagation of CD95-generated apoptotic signals in hematopoietic cells.	UNIV ROMA TOR VERGATA,DEPT EXPT MED & BIOCHEM SCI,I-00133 ROME,ITALY; UNIV ROMA LA SAPIENZA,DEPT EXPT MED & PATHOL,I-00161 ROME,ITALY	University of Rome Tor Vergata; Sapienza University Rome			De Maria, Ruggero/S-6385-2019; Zeuner, Ann/K-8607-2016; Zeuner, Ann/A-8529-2010	De Maria, Ruggero/0000-0003-2255-0583; RIPPO, Maria Rita/0000-0003-3024-3495; MALISAN, FLORENCE/0000-0002-0213-9407; Zeuner, Ann/0000-0002-8295-3715				ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cascino I, 1996, J IMMUNOL, V156, P13; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; DEMARIA R, UNPUB; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MATYAS GR, 1987, BIOCHIM BIOPHYS ACTA, V921, P599, DOI 10.1016/0005-2760(87)90089-0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Radin N S, 1981, Methods Enzymol, V72, P673; RADIN NS, 1993, ADV LIPID RES, V26, P183; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SARTI P, 1990, BIOCHEM J, V267, P413, DOI 10.1042/bj2670413; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670	30	327	337	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1652	1655		10.1126/science.277.5332.1652	http://dx.doi.org/10.1126/science.277.5332.1652			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287216				2022-12-28	WOS:A1997XV68400047
J	Hammer, SM; Squires, KE; Hughes, MD; Grimes, JM; Demeter, LM; Currier, JS; Eron, JJ; Feinberg, JE; Balfour, HH; Dayton, LR; Chodakewitz, JA; Fischl, MA				Hammer, SM; Squires, KE; Hughes, MD; Grimes, JM; Demeter, LM; Currier, JS; Eron, JJ; Feinberg, JE; Balfour, HH; Dayton, LR; Chodakewitz, JA; Fischl, MA			A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ZIDOVUDINE COMBINATION THERAPY; HIV-1 INFECTION; VIRAL INFECTIVITY; CLINICAL-TRIALS; TYPE-1 RNA; PLASMA; PROTEASE; LAMIVUDINE; EFFICACY; MONOTHERAPY	Background The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. Methods A total of 1156 patients not previously treated with lamivudine or protease inhibitors were stratified according to CD4 cell count (50 or fewer vs. 51 to 200 cells per cubic millimeter) and randomly assigned to one of two daily regimens: 600 mg of zidovudine and 300 mg of lamivudine, or that regimen with 2400 mg of indinavir. Stavudine could be substituted for zidovudine. The primary end point was the time to the development of the acquired immunodeficiency syndrome (AIDS) or death. Results The proportion of patients whose disease progressed to AIDS or death was lower with indinavir, zidovudine (or stavudine), and lamivudine (6 percent) than with zidovudine (or stavudine) and lamivudine alone (11 percent; estimated hazard ratio, 0.50; 95 percent confidence interval, 0.33 to 0.76; P = 0.001). Mortality in the two groups was 1.4 percent and 3.1 percent, respectively (estimated hazard ratio, 0.43; 95 percent confidence interval, 0.19 to 0.99; P = 0.04). The effects of treatment were similar in both CD4 cell strata. The responses of CD4 cells and plasma HIV-1 RNA paralleled the clinical results. Conclusions Treatment with indinavir, zidovudine, and lamivudine as compared with zidovudine and lamivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidovudine. (C) 1997, Massachusetts Medical Society.	HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV ALABAMA, BIRMINGHAM, AL USA; LONDON SCH HYG & TROP MED, LONDON WC1, ENGLAND; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; UNIV ROCHESTER, ROCHESTER, NY USA; UNIV SO CALIF, LOS ANGELES, CA USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; UNIV MINNESOTA, MINNEAPOLIS, MN USA; UNIV CINCINNATI, CINCINNATI, OH USA; NIAID, DIV AIDS, BETHESDA, MD 20892 USA; MERCK & CO INC, W POINT, PA USA; UNIV MIAMI, MIAMI, FL 33152 USA; NORTHWESTERN UNIV, EVANSTON, IL 60208 USA; GLAXO WELLCOME INC, RES TRIANGLE PK, NC 27709 USA; BRISTOL MYERS SQUIBB, NEW BRUNSWICK, NJ 08903 USA	Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; University of London; London School of Hygiene & Tropical Medicine; Harvard University; Harvard T.H. Chan School of Public Health; University of Rochester; University of Southern California; University of North Carolina; University of North Carolina Chapel Hill; University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Merck & Company; University of Miami; Northwestern University; GlaxoSmithKline; Bristol-Myers Squibb								Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; CAMERON DW, 1996, 11 INT C AIDS VANC B, V1, P24; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; *DIV AIDS, 1996, DIV AIDS TABL GRAD S; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HARRIGAN R, 1997, 4 C RETR OPP INF WAS, P67; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; HIRSCH M, 1997, 4 C RETR OPP INF WAS, P207; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUGHES MD, 1988, STAT MED, V7, P1231, DOI 10.1002/sim.4780071204; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pocock SJ., 2013, CLIN TRIALS PRACTICA; POWDERLY W, 1997, 4 C RETR OPP INF WAS, P132; RUIZ N, 1997, 4 C RETR OPP INF WAS, P206; SALGO MP, 1996, 11 INT C AIDS VANC B, V1, P24; *SAS I INC, 1989, SAS STAT US GUID VER, P997; SCHOOLEY RT, 1997, 4 C RETR OPP INF WAS, P206; SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612; Staszewski S, 1996, JAMA-J AM MED ASSOC, V276, P111, DOI 10.1001/jama.276.2.111; STEIN D, 1997, 4 C RETR OPP INF WAS, P100; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; WONG JK, 1997, 4 C RETR OPP INF WAS, P207	47	2201	2241	0	85	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					725	733		10.1056/NEJM199709113371101	http://dx.doi.org/10.1056/NEJM199709113371101			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287227	Green Submitted			2022-12-28	WOS:A1997XV17400001
J	Makgoba, MW				Makgoba, MW			Molecular basis of resistance and susceptibility to malaria	LANCET			English	Editorial Material							ADHESION; SEQUESTRATION				Makgoba, MW (corresponding author), UNIV WITWATERSRAND,DEPT MOL IMMUNOL,ZA-2000 JOHANNESBURG,SOUTH AFRICA.							BERENDT AR, 1994, PARASITOLOGY, V108, pS19, DOI 10.1017/S0031182000075685; Bunn HF, 1991, HARRISONS PRINCIPLES, P1543; FERNANDEZREYESD, 1997, HUM MOL GENET, V6, P1357; MAKGOBA MW, 1992, EUR J CLIN INVEST, V22, P443, DOI 10.1111/j.1365-2362.1992.tb01489.x; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TURNER GDH, 1994, AM J PATHOL, V145, P1057	8	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					678	679		10.1016/S0140-6736(05)63507-6	http://dx.doi.org/10.1016/S0140-6736(05)63507-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291898				2022-12-28	WOS:A1997XU97700004
J	Sanchez, Y; Wong, C; Thoma, RS; Richman, R; Wu, RQ; PiwnicaWorms, H; Elledge, SJ				Sanchez, Y; Wong, C; Thoma, RS; Richman, R; Wu, RQ; PiwnicaWorms, H; Elledge, SJ			Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25	SCIENCE			English	Article							CELL-CYCLE CONTROL; FISSION YEAST; KINASE; PHOSPHORYLATION; IDENTIFICATION; ARREST; MUTATION; MITOSIS; CANCER; P21	In response to DNA damage, mammalian cells prevent cell cycle progression through the control of critical cell cycle regulators. A human gene was identified that encodes the protein Chk1, a homolog of the Schizosaccharomyces pombe Chk1 protein kinase, which is required for the DNA damage checkpoint. Human Chk1 protein was modified in response to DNA damage. In vitro Chk1 bound to and phosphorylated the dual-specificity protein phosphatases Cdc25A, Cdc25B, and Cdc25C, which control cell cycle transitions by dephosphorylating cyclin-dependent kinases. Chk1 phosphorylates Cdc25C on serine-216. As shown in an accompanying paper by Peng et al. in this issue, serine-216 phosphorylation creates a binding site for 14-3-3 protein and inhibits function of the phosphatase. These results suggest a model whereby in response to DNA damage, Chk1 phosphorylates and inhibits Cdc25C, thus preventing activation of the Cdc2-cyclin B complex and mitotic entry.	BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Washington University (WUSTL); Baylor College of Medicine; Howard Hughes Medical Institute			Wu, R.Q./AAD-1067-2021; Piwnica-Worms, Helen/C-5214-2012	Wu, R.Q./0000-0002-6156-7874; 	NIGMS NIH HHS [GM44664, GM17763] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664, F32GM017763] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; DENG C, 1995, CELL, V82, P67; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; Gabra H, 1996, CANCER RES, V56, P950; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; Lakin ND, 1996, ONCOGENE, V13, P2707; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; SANCHEZ Y, UNPUB; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Vorechovsky I, 1996, CANCER RES, V56, P2726; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353	26	1122	1180	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1497	1501		10.1126/science.277.5331.1497	http://dx.doi.org/10.1126/science.277.5331.1497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278511				2022-12-28	WOS:A1997XV42900038
J	Barzansky, B; Jonas, HS; Etzel, SI				Barzansky, B; Jonas, HS; Etzel, SI			Educational programs in US medical schools, 1996-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								We use data from the 1996-1997 Liaison Committee on Medical Education Annual Medical School Questionnaire, which had a 100% response rate, to describe medical education programs in the United States. In the 1996-1997 academic year, there were 95 568 full-time medical school faculty members, a 4.5% increase from 1995-1996. In clinical departments, the largest increases were in emergency medicine (a 29% increase from 1995-1996) and family medicine (a 13% increase). Of all full-time faculty members in clinical departments, 76.9% have an MD or DO as the highest degree, 4.5% have both an MD and PhD, 13.9% have a PhD, and 4.7% have an academic or professional bachelor's or master's degree as their final degree. The total number of applicants for the class entering in 1996 was 46 968 (0.8% increase from 1995), while the number of first-time applicants decreased 1% from 1995. First-year medical students who were members of underrepresented minority groups numbered 2236, a 4% decrease from 1995. In 1996-1997, the total number of medical students was 66 712 (0.3% less than in 1995-1996). For students graduating during the 1995-1996 academic year, 13% took longer than 4 years to complete the program. There were 47 medical schools that reported that 1 or more hospitals used for required clinical clerkships had changed ownership, merged, or closed during 1996. Medical schools used an average of 6 (range, 1-36) hospitals for core clinical clerkship. Ninety-five schools required a passing grade on Step 1 of the US Medical Licensing Examination (USMLE) for promotion or graduation; 54 schools required a passing grade on Step 2 of the USMLE.	AMER MED ASSOC,DEPT RES & DATA ANAL,CHICAGO,IL 60610	American Medical Association	Barzansky, B (corresponding author), AMER MED ASSOC,DIV UNDERGRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							Barzansky B, 1996, JAMA-J AM MED ASSOC, V276, P714, DOI 10.1001/jama.276.9.714; Brieger GH, 1997, ACAD MED, V72, P362, DOI 10.1097/00001888-199705000-00014; Houpt JL, 1997, ACAD MED, V72, P180, DOI 10.1097/00001888-199703000-00010; Liaison Committee on Medical Education, 1997, FUNCT STRUCT MED SCH; *NAT RES MATCH PRO, 1997, NRMP DAT	5	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					744	749		10.1001/jama.278.9.744	http://dx.doi.org/10.1001/jama.278.9.744			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286835				2022-12-28	WOS:A1997XT70900028
J	ChanYeung, M; Muller, NL				ChanYeung, M; Muller, NL			Cryptogenic fibrosing alveolitis	LANCET			English	Article							IDIOPATHIC PULMONARY FIBROSIS; INFILTRATIVE LUNG-DISEASE; EPSTEIN-BARR-VIRUS; DESQUAMATIVE INTERSTITIAL PNEUMONIA; GROUND-GLASS ATTENUATION; HIGH-RESOLUTION CT; BRONCHOALVEOLAR LAVAGE; CHEST RADIOGRAPHY; PATHOLOGIC CORRELATION; OCCUPATIONAL EXPOSURE		UNIV BRITISH COLUMBIA,DEPT RADIOL,VANCOUVER,BC V5Z 3J5,CANADA	University of British Columbia	ChanYeung, M (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED,DIV RESP,2775 HEATHER ST,RM 111B,VANCOUVER,BC V5Z 3J5,CANADA.							AKIRA M, 1993, RADIOLOGY, V189, P687, DOI 10.1148/radiology.189.3.8080483; AUGSTI C, 1996, THORAX, V51, P841; BARBERA JA, 1992, AM REV RESPIR DIS, V145, P940, DOI 10.1164/ajrccm/145.4_Pt_1.940; BAUGHMAN RP, 1992, CHEST, V102, P1090, DOI 10.1378/chest.102.4.1090; BERNSARD DD, 1993, CHEST, V103, P765; BILLINGS CG, 1994, EUR RESPIR J, V7, P1172; BITTERMAN PB, 1986, NEW ENGL J MED, V314, P1343, DOI 10.1056/NEJM198605223142103; BOOMARS KA, 1995, THORAX, V50, P1087, DOI 10.1136/thx.50.10.1087; BROWN CH, 1971, Q J MED, V158, P289; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; CHAPMAN JR, 1984, AM REV RESPIR DIS, V130, P439; CHERNIACK RM, 1995, AM J RESP CRIT CARE, V151, P1180; CHERNIACK RM, 1991, AM REV RESPIR DIS, V144, P892, DOI 10.1164/ajrccm/144.4.892; CHERNIAK RM, 1990, AM REV RESPIR DIS, V141, pS169; COLBY RB, 1996, J THORACIC IMAGING, V11, P1; Coultas DB, 1996, THORAX, V51, P717, DOI 10.1136/thx.51.7.717; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967, DOI 10.1164/ajrccm.150.4.7921471; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; DAYTON CS, 1993, CHEST, V103, P69, DOI 10.1378/chest.103.1.69; DEREMEE RA, 1994, EUR RESPIR J, V7, P427, DOI 10.1183/09031936.94.07030427; EGAN JJ, 1995, THORAX, V50, P1234, DOI 10.1136/thx.50.12.1234; FULMER JD, 1979, J CLIN INVEST, V63, P665, DOI 10.1172/JCI109349; GAENSLER EA, 1964, NEW ENGL J MED, V270, P1319, DOI 10.1056/NEJM196406182702501; GAENSLER EA, 1975, PROGR RESPIRATORY RE, V8, P223; GRENIER P, 1994, RADIOLOGY, V191, P383, DOI 10.1148/radiology.191.2.8153310; HARTMAN D L, 1992, American Review of Respiratory Disease, V145, pA750; Hartman TE, 1996, CHEST, V110, P378, DOI 10.1378/chest.110.2.378; HASLAM PL, 1979, CLIN EXP IMMUNOL, V37, P381; HASLAM PL, 1980, THORAX, V35, P328, DOI 10.1136/thx.35.5.328; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; Hubbard R, 1996, THORAX, V51, P711, DOI 10.1136/thx.51.7.711; Hubbard R, 1996, LANCET, V347, P284, DOI 10.1016/S0140-6736(96)90465-1; HUNNINGHAKE GW, 1995, AM J RESP CRIT CARE, V151, P915; HYDE DM, 1992, AM REV RESPIR DIS, V146, P1042, DOI 10.1164/ajrccm/146.4.1042; IWAI K, 1994, AM J RESP CRIT CARE, V150, P670, DOI 10.1164/ajrccm.150.3.8087336; Jaklitsch MT, 1996, CHEST, V110, P751, DOI 10.1378/chest.110.3.751; JOHNSON MA, 1989, THORAX, V44, P280, DOI 10.1136/thx.44.4.280; JOHNSTON I, 1990, BRIT MED J, V301, P1017, DOI 10.1136/bmj.301.6759.1017; Johnston IDA, 1997, THORAX, V52, P38, DOI 10.1136/thx.52.1.38; JOHNSTON IDA, 1993, EUR RESPIR J, V6, P891; KATZENSTEIN ALA, 1994, AM J SURG PATHOL, V18, P136, DOI 10.1097/00000478-199402000-00003; KEOGH BA, 1983, AM REV RESPIR DIS, V127, P18, DOI 10.1164/arrd.1983.127.1.18; KEOGH BA, 1980, CHEST, V78, P856, DOI 10.1378/chest.78.6.856; LEE JS, 1992, RADIOLOGY, V184, P451, DOI 10.1148/radiology.184.2.1620846; LEUNG AN, 1993, RADIOLOGY, V188, P209, DOI 10.1148/radiology.188.1.8511299; Mannino DM, 1996, AM J RESP CRIT CARE, V153, P1548, DOI 10.1164/ajrccm.153.5.8630600; MAPLE DW, 1996, CHEST, V110, P1058; MATHIESON JR, 1989, RADIOLOGY, V171, P111, DOI 10.1148/radiology.171.1.2928513; MATSUI R, 1994, THORAX, V49, P201, DOI 10.1136/thx.49.3.201; MAUDERLY JL, 1983, AM REV RESPIR DIS, V127, P163; McAdams HP, 1996, RADIOGRAPHICS, V16, P1009, DOI 10.1148/radiographics.16.5.8888388; MCLOUD TC, 1983, RADIOLOGY, V149, P353, DOI 10.1148/radiology.149.2.6622676; MOOLMAN JA, 1991, THORAX, V46, P592, DOI 10.1136/thx.46.8.592; MULLER NL, 1987, RADIOLOGY, V165, P731; MULLER NL, 1986, RADIOLOGY, V160, P585; Muller NL, 1997, RADIOGRAPHICS, V17, P1016; ORENS JB, 1995, CHEST, V108, P109, DOI 10.1378/chest.108.1.109; PADLEY SPG, 1991, CLIN RADIOL, V44, P222, DOI 10.1016/S0009-9260(05)80183-7; PANOS RJ, 1990, AM J MED, V88, P396, DOI 10.1016/0002-9343(90)90495-Y; PETERS SG, 1993, CHEST, V103, P101, DOI 10.1378/chest.103.1.101; PRIMACK SL, 1993, RADIOLOGY, V189, P681, DOI 10.1148/radiology.189.3.8234691; PRIOR C, 1992, CLIN EXP IMMUNOL, V88, P280; RAGHU G, 1991, AM REV RESPIR DIS, V144, P291, DOI 10.1164/ajrccm/144.2.291; RAGHU G, 1995, AM J RESP CRIT CARE, V151, P909; REMYJARDIN M, 1993, RADIOLOGY, V189, P693, DOI 10.1148/radiology.189.3.8234692; RUDD RM, 1981, AM REV RESPIR DIS, V124, P1; SCADDING JG, 1970, BRIT MED J, V2, P557, DOI 10.1136/bmj.2.5709.557; SCHWARTZ DA, 1994, AM J RESP CRIT CARE, V149, P450, DOI 10.1164/ajrccm.149.2.8306044; SCOTT DGI, 1980, THORAX, V35, P725, DOI 10.1136/thx.35.10.725; SCOTT J, 1990, BRIT MED J, V301, P1015, DOI 10.1136/bmj.301.6759.1015; SMITH C M, 1990, American Review of Respiratory Disease, V141, pA62; STAPLES CA, 1987, RADIOLOGY, V162, P377, DOI 10.1148/radiology.162.2.3797650; Trulock EP, 1997, AM J RESP CRIT CARE, V155, P789, DOI 10.1164/ajrccm.155.3.9117010; TUKIAINEN P, 1983, THORAX, V38, P349, DOI 10.1136/thx.38.5.349; TURNERWARWICK M, 1987, AM REV RESPIR DIS, V135, P26; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171; VANOORTEGEM K, 1994, EUR RESPIR J, V7, P1950; VENUTA F, 1993, J HEART LUNG TRANSPL, V12, P909; VERGNON JM, 1984, LANCET, V2, P768; WALLACE WAH, 1994, THORAX, V49, P1139, DOI 10.1136/thx.49.11.1139; WALLACE WAH, 1995, CLIN EXP IMMUNOL, V101, P436; WATTERS LC, 1986, AM REV RESPIR DIS, V133, P97, DOI 10.1164/arrd.1986.133.1.97; WATTERS LC, 1987, AM REV RESPIR DIS, V135, P696; WELLS AU, 1993, AM J ROENTGENOL, V161, P1159, DOI 10.2214/ajr.161.6.8249719; WELLS AU, 1993, AM REV RESPIR DIS, V148, P1076, DOI 10.1164/ajrccm/148.4_Pt_1.1076; WINTERBAUER RH, 1978, AM J MED, V65, P661, DOI 10.1016/0002-9343(78)90855-0	86	19	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					651	656		10.1016/S0140-6736(97)06303-4	http://dx.doi.org/10.1016/S0140-6736(97)06303-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288060				2022-12-28	WOS:A1997XU28300042
J	Layman, LC; Lee, EJ; Peak, DB; Namnoum, AB; Vu, KV; vanLingen, BL; Gray, MR; McDonough, PG; Reindollar, RH; Jameson, JL				Layman, LC; Lee, EJ; Peak, DB; Namnoum, AB; Vu, KV; vanLingen, BL; Gray, MR; McDonough, PG; Reindollar, RH; Jameson, JL			Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	42nd Annual Meeting of the Society-for-Gynecologic-Investigation	MAR 15-18, 1995	CHICAGO, IL	Soc Gynecol Investigat			ADRENAL HYPOPLASIA CONGENITA; LUTEINIZING-HORMONE; RECEPTOR GENE; HYPOGONADOTROPIC HYPOGONADISM; OVARIAN FAILURE; GONADOTROPIN		NORTHWESTERN UNIV,DIV ENDOCRINOL METAB & MOL MED,CHICAGO,IL 60611; TUFTS UNIV,SCH MED,DIV REPROD ENDOCRINOL,DEPT OBSTET & GYNECOL,BOSTON,MA 02111; JOHNS HOPKINS UNIV,DIV REPROD ENDOCRINOL,DEPT OBSTET & GYNECOL,BALTIMORE,MD; BETH ISRAEL MED CTR,SECT REPROD ENDOCRINOL,DEPT OBSTET & GYNECOL,BOSTON,MA; MED COLL GEORGIA,DEPT OBSTET & GYNECOL,SECT REPROD ENDOCRINOL INFERTIL & GENET,AUGUSTA,GA 30912	Northwestern University; Tufts University; Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; University System of Georgia; Augusta University	Layman, LC (corresponding author), UNIV CHICAGO,DEPT OBSTET & GYNECOL,SECT REPROD ENDOCRINOL & INFERTIL,5841 S MARYLAND AVE,MC 2050,CHICAGO,IL 60637, USA.			Jameson, James/0000-0001-9538-4059	NICHD NIH HHS [U54-HD29164] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; ALANSARI AAK, 1984, FERTIL STERIL, V42, P618; ChristinMaitre S, 1996, J CLIN ENDOCR METAB, V81, P2080, DOI 10.1210/jc.81.6.2080; FOREST MG, 1995, ENDOCRINOLOGY, V2, P1901; Habiby RL, 1996, J CLIN INVEST, V98, P1055, DOI 10.1172/JCI118866; HAGG E, 1978, SCAND J UROL NEPHROL, V12, P287; HARDELIN JP, 1993, HUM MOL GENET, V2, P373, DOI 10.1093/hmg/2.4.373; JAMESON JL, 1988, MOL ENDOCRINOL, V2, P806, DOI 10.1210/mend-2-9-806; Jameson JL, 1996, MOL CELL ENDOCRINOL, V125, P143; KEENE JL, 1989, J BIOL CHEM, V264, P4769; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Latronico AC, 1996, NEW ENGL J MED, V334, P507, DOI 10.1056/NEJM199602223340805; LAUE L, 1995, HUM MOL GENET, V4, P1429, DOI 10.1093/hmg/4.8.1429; LAYMAN LC, 1993, FERTIL STERIL, V60, P852; LEUNG PCK, 1980, ANNU REV PHYSIOL, V42, P71, DOI 10.1146/annurev.ph.42.030180.000443; MAROULIS GB, 1977, FERTIL STERIL, V28, P818; MATTHEWS CH, 1993, NAT GENET, V5, P83, DOI 10.1038/ng0993-83; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P713; MCCONNON J, 1979, LANCET, V2, P525; MOZAFFARIAN GA, 1983, J ANDROL, V4, P393; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NAGAYA T, 1994, PITUITARY GLAND, P63; RABIN D, 1972, NEW ENGL J MED, V287, P1313, DOI 10.1056/NEJM197212282872602; SMYTH CD, 1993, ENDOCRINOLOGY, V133, P1532, DOI 10.1210/en.133.4.1532; Tapanainen JS, 1997, NAT GENET, V15, P205, DOI 10.1038/ng0297-205; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; YEN SSC, 1991, REPRODUCTIVE ENDOCRI, P576	30	186	194	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					607	611		10.1056/NEJM199708283370905	http://dx.doi.org/10.1056/NEJM199708283370905			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271483				2022-12-28	WOS:A1997XT39400005
J	Gitanjali, B; Shashindran, CH; Tripathi, KD; Sethuraman, KR				Gitanjali, B; Shashindran, CH; Tripathi, KD; Sethuraman, KR			Are drug advertisements in Indian edition of BMJ unethical?	BRITISH MEDICAL JOURNAL			English	Article											Gitanjali, B (corresponding author), JAWAHARLAL INST POSTGRAD MED EDUC & RES,PONDICHERRY 605006,INDIA.							WHO, 1988, ETH CRIT MED DRUG PR	1	9	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					459	459		10.1136/bmj.315.7106.459	http://dx.doi.org/10.1136/bmj.315.7106.459			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284662	Green Published			2022-12-28	WOS:A1997XT71400017
J	Arsuaga, JL; Carretero, JM; Lorenzo, C; Gracia, A; Martinez, I; deCastro, JMB; Carbonell, E				Arsuaga, JL; Carretero, JM; Lorenzo, C; Gracia, A; Martinez, I; deCastro, JMB; Carbonell, E			Size variation in Middle Pleistocene humans	SCIENCE			English	Article							SIERRA-DE-ATAPUERCA; SEXUAL DIMORPHISM; CRANIAL REMAINS; SPAIN; HOMINIDS; BONES; SITE	It has been suggested that European Middle Pleistocene humans, Neandertals, and prehistoric modern humans had a greater sexual dimorphism than modern humans. Analysis of body size variation and cranial capacity variation in the large sample from the Sima de los Huesos site in Spain showed instead that the sexual dimorphism is comparable in Middle Pleistocene and modern populations.	UNIV BURGOS,FAC HUMANIDADES & EDUC,DEPT CIENCIAS HIST & GEOG,BURGOS 09071,SPAIN; UNIV CALIF BERKELEY,MUSEUM VERTEBRATE ZOOL,LAB HUMAN EVOLUT STUDIES,BERKELEY,CA 94720; CSIC,MUSEO NACL CIENCIAS NAT,E-28006 MADRID,SPAIN; UNIV ROVIRA & VIRGILI,LAB ARQUEOL,TARRAGONA 43005,SPAIN	Universidad de Burgos; University of California System; University of California Berkeley; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); Universitat Rovira i Virgili	Arsuaga, JL (corresponding author), UNIV COMPLUTENSE MADRID,FAC CIENCIAS GEOL,INST GEOL ECON,DEPT PALAEONTOL,CIUDAD UNIV,E-28040 MADRID,SPAIN.		Díaz, José-Miguel Carretero/L-1703-2018; Carbonell, Eudald/G-3003-2015; Carretero, José-Miguel/AAN-1926-2020; Lorenzo, Carlos/E-4290-2015	Díaz, José-Miguel Carretero/0000-0003-0409-8087; Carretero, José-Miguel/0000-0003-0409-8087; Lorenzo, Carlos/0000-0001-5706-293X; Arsuaga, Juan Luis/0000-0001-5361-2295; martinez, ignacio/0000-0002-1835-9199; Bermudez de Castro, Jose Maria/0000-0003-1314-3273				ARSUAGA JL, 1991, J HUM EVOL, V20, P191, DOI 10.1016/0047-2484(91)90073-5; Arsuaga JL, 1997, J HUM EVOL, V33, P109, DOI 10.1006/jhev.1997.0132; ARSUAGA JL, 1993, NATURE, V362, P534, DOI 10.1038/362534a0; Arsuaga JL, 1997, J HUM EVOL, V33, P219, DOI 10.1006/jhev.1997.0133; ARSUAGA JL, 1994, AM J PHYS ANTHROPOL, V93, P241, DOI 10.1002/ajpa.1330930208; ARSUAGA JL, 1995, HUMAN EVOLUTION EURO, P283; Begun David, 1993, P326; Bischoff JL, 1997, J HUM EVOL, V33, P129, DOI 10.1006/jhev.1997.0130; BORGOGNINITARLI SM, 1986, HUM EVOL, V1, P51; Carretero JM, 1997, J HUM EVOL, V33, P357, DOI 10.1006/jhev.1997.0128; CuencaBescos G, 1997, J HUM EVOL, V33, P175, DOI 10.1006/jhev.1997.0153; DECASTRO JMB, 1993, J HUM EVOL, V24, P43; DECASTRO JMB, 1995, HUMAN EVOLUTION EURO, P263; DELUMLEY H, 1973, PHYS ANTHR, V17, P162; EFRON B, 1993, INTRODUCTION BOOTSTR; FRAYER DW, 1980, J HUM EVOL, V9, P399, DOI 10.1016/0047-2484(80)90050-0; Garcia N, 1997, J HUM EVOL, V33, P155, DOI 10.1006/jhev.1997.0154; GRINE FE, 1993, AM J PHYS ANTHROPOL, V92, P411, DOI 10.1002/ajpa.1330920402; Josephson SC, 1996, AM J PHYS ANTHROPOL, V100, P191; LIEBERMAN DE, 1988, J HUM EVOL, V17, P503, DOI 10.1016/0047-2484(88)90039-5; Lockwood CA, 1996, J HUM EVOL, V31, P537, DOI 10.1006/jhev.1996.0078; Lovejoy C.O., 1989, P103; MAIANETO MA, 1957, CONTRIB ESTUDO ANTRO, V6, P141; Martin R., 1957, LEHRBUCH ANTHR, V3rd; MCHENRY HM, 1976, AM J PHYS ANTHROPOL, V44, P295, DOI 10.1002/ajpa.1330440212; PLAVCAN JM, 1994, AM J PHYS ANTHROPOL, V94, P465, DOI 10.1002/ajpa.1330940403; RICHMOND BG, 1995, J HUM EVOL, V29, P229, DOI 10.1006/jhev.1995.1058; Simmons Katherine, 1942, HUMAN BIOL, V14, P473; STEELE DG, 1976, AM J PHYS ANTHROPOL, V45, P581, DOI 10.1002/ajpa.1330450323; Tobias PV, 1971, BRAIN HOMINID EVOLUT; TRINKAUS E, 1980, J HUM EVOL, V9, P377, DOI 10.1016/0047-2484(80)90049-4; WOLPOFF MH, 1980, J HUM EVOL, V9, P339, DOI 10.1016/0047-2484(80)90047-0; WOOD BA, 1976, J ZOOL, V180, P15	33	89	90	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1086	1088		10.1126/science.277.5329.1086	http://dx.doi.org/10.1126/science.277.5329.1086			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XT033	9262474				2022-12-28	WOS:A1997XT03300031
J	Rocheleau, CE; Downs, WD; Lin, RL; Wittmann, C; Bei, YX; Cha, YH; Ali, M; Priess, JR; Mello, CC				Rocheleau, CE; Downs, WD; Lin, RL; Wittmann, C; Bei, YX; Cha, YH; Ali, M; Priess, JR; Mello, CC			Wnt signaling and an APC-related gene specify endoderm in early C-elegans embryos	CELL			English	Article							CAENORHABDITIS-ELEGANS; TISSUE POLARITY; ARMADILLO CONNECTION; CELL-INTERACTIONS; DROSOPHILA; WINGLESS; PROTEIN; ENCODES; INDUCTION; GUT	In a 4-cell stage C. elegans embryo, signaling by the P-2 blastomere induces anterior-posterior polarity in the adjacent EMS blastomere, leading to endoderm formation. We have taken genetic and reverse genetic approaches toward understanding the molecular basis for this induction. These studies have identified a set of genes with sequence similarity to genes that have been shown to be, or are implicated in, Wnt/Wingless signaling pathways in other systems. The C. elegans genes described here are related to wnt/wingless,porcupine, frizzled, beta-catenin/armadillo, and the human adenomatous polyposis coil gene, APC. We present evidence that there may be partially redundant inputs into endoderm specification and that a subset of these genes appear also to function in determining cytoskeletal polarity in certain early blastomeres.	UNIV MASSACHUSETTS, CTR CANC, DEPT CELL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; FRED HUTCHINSON CANC RES CTR, HOWARD HUGHES MED INST, SEATTLE, WA 98109 USA; UNIV WASHINGTON, DEPT ZOOL, SEATTLE, WA 98195 USA	University of Massachusetts System; University of Massachusetts Worcester; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle				Rocheleau, Christian/0000-0001-6738-5636				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ADLER PN, 1990, GENETICS, V126, P401; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; BRENNER S, 1974, GENETICS, V77, P71; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; EDGAR LG, 1994, DEVELOPMENT, V120, P443; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; Goldstein B, 1996, DEVELOPMENT, V122, P1467; GOLDSTEIN B, 1993, DEVELOPMENT, P279; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUBB D, 1993, DEVELOPMENT, P269; Guedes S, 1997, DEVELOPMENT, V124, P731; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; HUTTER H, 1995, DEVELOPMENT, V121, P1559; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; KEMPHUES KJ, 1996, NEMATODE C ELEGANS, P335; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; Peifer M, 1996, SCIENCE, V272, P974, DOI 10.1126/science.272.5264.974; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; SCHNABEL R, 1995, DEVELOPMENT, V121, P2219; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; THEISEN H, 1994, DEVELOPMENT, V120, P347; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	54	525	554	2	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					707	716		10.1016/S0092-8674(00)80531-0	http://dx.doi.org/10.1016/S0092-8674(00)80531-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288750	Bronze			2022-12-28	WOS:A1997XT06600014
J	Woodell, MI				Woodell, MI			Notes from the inner territories	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					543	543		10.1001/jama.278.7.543	http://dx.doi.org/10.1001/jama.278.7.543			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268265				2022-12-28	WOS:A1997XQ98600012
J	Wan, Q; Xiong, ZG; Man, YH; Ackerley, CA; Braunton, J; Lu, WY; Becker, LE; MacDonald, JF; Wang, YT				Wan, Q; Xiong, ZG; Man, YH; Ackerley, CA; Braunton, J; Lu, WY; Becker, LE; MacDonald, JF; Wang, YT			Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin	NATURE			English	Article							LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; INHIBITION; SYNAPSES; RAT; CELLS; EXPRESSION; CHANNELS; RELEASE; LTP	Modification of synaptic strength in the mammalian central nervous system (CNS) occurs at both pre- and postsynaptic sites(1,2). However, because postsynaptic receptors are likely to be saturated by released transmitter, an increase in the number of active postsynaptic receptors may be a more efficient way of strengthening synaptic efficacy(3-7). But there has been no evidence for a rapid recruitment of neurotransmitter receptors to the postsynaptic membrane in the CNS, Here we report that insulin causes the type A gamma-aminobutyric acid (GABA(A)) receptor, the principal receptor that mediates synaptic inhibition in the CNS8, to translocate rapidly from the intracellular compartment to the plasma membrane in transfected HEK 293 cells, and that this relocation requires the beta 2 subunit of the GABA(A) receptor. In CNS neurons, insulin increases the expression of GABA(A) receptors on the postsynaptic and dendritic membranes. We found that insulin increases the number of functional postsynaptic GABA(A) receptors, thereby increasing the amplitude of the GABA(A)-receptor-mediated miniature inhibitory postsynaptic currents (mIPSCs) without altering their time course. These results provide evidence for a rapid recruitment of functional receptors to the postsynaptic plasmamembrane, suggesting a fundamental mechanism for the generation of synaptic plasticity.	UNIV TORONTO,HOSP SICK CHILDREN,DIV PATHOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DIV NEUROSCI,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto			Lu, Wei-Yang/K-4404-2013; Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015					BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Benson DL, 1996, J NEUROSCI, V16, P6424; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BUSCH C, 1990, COLD SH Q B, V55, P69; COHEN GA, 1992, NEURON, V9, P325, DOI 10.1016/0896-6273(92)90171-9; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1995, PHYSIOL REV, V75, P759, DOI 10.1152/physrev.1995.75.4.759; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; GARRY DJ, 1986, DIABETES, V35, P1090, DOI 10.2337/diabetes.35.10.1090; HAMILTON BJ, 1993, NEUROSCI LETT, V153, P206, DOI 10.1016/0304-3940(93)90323-D; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JESSELL TM, 1993, NEURON S, V10, P1; KAMATCHI GL, 1984, LIFE SCI, V34, P2297; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; NUSSER Z, 1995, J NEUROSCI, V15, P2948; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; Ueno S, 1996, MOL PHARMACOL, V50, P931; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WANG YT, 1991, NEUROSCIENCE, V40, P759, DOI 10.1016/0306-4522(91)90010-L; WOZNIAK M, 1995, NEUROCHEM INT, V22, P1	30	438	453	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					686	690		10.1038/41792	http://dx.doi.org/10.1038/41792			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262404	Bronze			2022-12-28	WOS:A1997XQ86300052
J	Marquis, MS; Long, SH				Marquis, MS; Long, SH			Federalism and health system reform - Prospects for state action	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess the prospect that the states, acting independently, would undertake health insurance coverage expansions that together would result in meaningful reductions in the extent of uninsurance nationally. Design.-We use microsimulation methods to contrast the federal income tax payments needed to finance a national program covering the uninsured with the state income tax payments needed to finance a state-specific program for the same purpose. The contrast reveals the effects on the tax burdens of differences among states in uninsured rates and tax capacity. Setting.-Continental United States. Patients or Other Participants.-Observations from the 1990 through 1993 Current Population Survey (N=305 477 families), weighted to represent the population of each state. Intervention.-Illustrative public health insurance program for families with incomes below 250% of poverty, not covered by current public or employer-sponsored health insurance. Main Outcome Measures.-Change in percent uninsured, change in per capita total tax payments. Results.-The per capita cost of a state-specific program is directly related to current uninsured rates, $130 in states with low uninsured rates (10%) to $230 in states with high uninsured rates (21%). This would represent increases in state total tax effort of 10% to 19%, respectively. In contrast, equal tax effort to finance a national program would imply per capita yields of about $200 in the low-uninsured states and about $150 in the high-uninsured states. Conclusions.-Substantial state tax effort would be necessary to cover the low-income uninsured-especially in states with the highest uninsured rates, which also have the lowest tax capacity. Targeted federal financial assistance may be necessary, if policymakers wish to induce many states to provide health insurance coverage for their uninsured.			Marquis, MS (corresponding author), RAND CORP,1333 H ST NW,WASHINGTON,DC 20005, USA.							BROWN LD, 1994, NATL HLTH REFORM WHA; CANTOR JC, 1995, HEALTH AFFAIR, V14, P199, DOI 10.1377/hlthaff.14.2.199; CRITTENDEN RA, 1995, HEALTH AFFAIR, V14, P302, DOI 10.1377/hlthaff.14.2.302; FRIEDMAN E, 1994, JAMA-J AM MED ASSOC, V271, P875; HAHN B, 1992, ANN EXP SOURC PAYM H; *HLTH CAR FIN ADM, 1993, PERS HLTH CAR EXP ST; LEICHTER HM, 1993, HEALTH AFFAIR, V12, P48, DOI 10.1377/hlthaff.12.2.48; Letsch S W, 1992, Health Care Financ Rev, V14, P1; LONG SH, 1994, HEALTH AFFAIR, V13, P211, DOI 10.1377/hlthaff.13.2.211; MASHAW JL, 1995, CONN L REV, V28, P115; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; NEUBAUER D, 1993, HEALTH AFFAIR, V12, P31, DOI 10.1377/hlthaff.12.2.31; Oates WE, 1972, FISCAL FEDERALISM; Peterson P.E., 1995, PRICE FEDERALISM; Skolnick AA, 1996, JAMA-J AM MED ASSOC, V276, P931; Sparer, 1996, MEDICAID LIMITS STAT; STONE D, 1992, AM PROSPECT, V9, P51; *US BUR CENS, 1994, 1994 STAT ABSTR US, P305; VOELKER R, 1995, JAMA-J AM MED ASSOC, V273, P187	19	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					514	517		10.1001/jama.278.6.514	http://dx.doi.org/10.1001/jama.278.6.514			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP243	9256228				2022-12-28	WOS:A1997XP24300035
J	Ashworth, M; Gerada, C				Ashworth, M; Gerada, C			ABC of mental health - Addiction and dependence .2. Alcohol	BRITISH MEDICAL JOURNAL			English	Review									CONSULTANCY LIAISON ADDICTION TEAM DRUGS & ALCOHO,LONDON,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								CHICK J, 1994, SEMINARS ALCOHOL DRU; Edwardss G., 1987, TREATMENT DRINKING P; HAIGH R, 1990, BMJ-BRIT MED J, V301, P848, DOI 10.1136/bmj.301.6756.848; ROLLMICK S, 1992, J MENTAL HLTH, V1, P35; *WHO, 1993, ALC ACT PLAN EUR; WILLIAMS H, 1996, PREVENTION MENTAL IL, P223	6	27	27	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					358	360						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270461				2022-12-28	WOS:A1997XQ86400026
J	Fraser, J; Mok, Q; Tasker, R				Fraser, J; Mok, Q; Tasker, R			Survey of occupancy of paediatric intensive care units by children who are dependent on ventilators	BRITISH MEDICAL JOURNAL			English	Article											Fraser, J (corresponding author), HOSP SICK CHILDREN,PAEDIAT INTENS CARE UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Mok, Quen/AAA-2648-2019; Tasker, Robert C/R-5837-2019	Mok, Quen/0000-0003-4807-9275; Tasker, Robert/0000-0003-3647-8113				British Paediatric Association, 1993, REP MULT WORK PART P; DEWITT PK, 1993, CHEST, V103, P1560, DOI 10.1378/chest.103.5.1560; James I, 1996, BRIT MED J, V312, P1476, DOI 10.1136/bmj.312.7044.1476b	3	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					347	348						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270456				2022-12-28	WOS:A1997XQ86400021
J	Kromhout, D; Bloemberg, B; Doornbos, G				Kromhout, D; Bloemberg, B; Doornbos, G			Reversibility of rise in Russian mortality rates	LANCET			English	Editorial Material											Kromhout, D (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT, DIV PUBL HLTH RES, POB 1, NL-3720 BA BILTHOVEN, NETHERLANDS.		Kromhout, Daan/A-8566-2014					*COLL WHO ECEH UN, 1997, IN PRESS ATL MORT EU; Kromhout D, 1996, LANCET, V348, pS20, DOI 10.1016/S0140-6736(96)98007-1; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Sans S, 1997, EUR HEART J, V18, P1231; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	1997	350	9075					379	380		10.1016/S0140-6736(05)64128-1	http://dx.doi.org/10.1016/S0140-6736(05)64128-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259647				2022-12-28	WOS:A1997XQ24800003
J	Vaux, DL				Vaux, DL			CED-4 - The third horseman of apoptosis	CELL			English	Review							PROGRAMMED CELL-DEATH; C-ELEGANS; ENCODES; BCL-2				Vaux, DL (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PO ROYAL MELBOURNE HOSP,PARKVILLE,VIC 3050,AUSTRALIA.		Vaux, David L/C-7249-2013	Vaux, David L/0000-0003-2703-1651				Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	17	102	113	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					389	390		10.1016/S0092-8674(00)80497-3	http://dx.doi.org/10.1016/S0092-8674(00)80497-3			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267018	Bronze			2022-12-28	WOS:A1997XQ06300002
J	Castillo, PE; Janz, R; Sudhof, TC; Tzounopoulos, T; Malenka, RC; Nicoll, RA				Castillo, PE; Janz, R; Sudhof, TC; Tzounopoulos, T; Malenka, RC; Nicoll, RA			Rab3A is essential for mossy fibre long-term potentiation in the hippocampus	NATURE			English	Article							FIBER LTP; 2 FORMS; PROTEIN; RABPHILIN-3A; FACILITATION; SYNAPSINS; NEURONS	Repetitive activation of excitatory synapses in the central nervous system results in a long-lasting increase in synaptic transmission called long-term potentiation (LTP). It is generally believed that this synaptic plasticity may underlie certain forms of learning and memory. LTP at most synapses involves the activation of the NMDA (N-methyl-D-aspartate) subtype of glutamate receptor, but LTP at hippocampal messy fibre synapses is independent of NMDA receptors and has a component that is induced and expressed presynaptically(1). It appears to be triggered by a rise in presynaptic Ca2+ (refs 2, 3), and requires the activation of protein kinase A(4-6), which leads to an increased release of glutamate(3,7-10). A great deal is known about the biochemical steps involved in the vesicular release of transmitter(11-13), but none of these steps has been directly implicated in long-term synaptic plasticity. Here we show that, although a variety of short-term plasticities are normal, LTP at messy fibre synapses is abolished in mice lacking the synaptic vesicle protein Rab3A.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Janz, Roger/0000-0002-9872-0596; Castillo, Pablo/0000-0002-9834-1801				BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DIXON D, 1989, J NEUROSCI, V9, P4246; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LopezGarcia JC, 1996, P NATL ACAD SCI USA, V93, P4712, DOI 10.1073/pnas.93.10.4712; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; REGEHR WG, 1994, J NEUROSCI, V14, P523; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SPILLANE DM, 1995, NEUROPHARMACOLOGY, V34, P1573, DOI 10.1016/0028-3908(95)00107-H; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tong G, 1996, NEURON, V16, P1147, DOI 10.1016/S0896-6273(00)80141-5; WANG Y, 1997, NATURE, V387; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	281	288	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					590	593		10.1038/41574	http://dx.doi.org/10.1038/41574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252190	Bronze			2022-12-28	WOS:A1997XP72200051
J	Brown, M; Barraclough, B				Brown, M; Barraclough, B			Epidemiology of suicide pacts in England and Wales, 1988-92	BRITISH MEDICAL JOURNAL			English	Article								Objective: To describe the epidemiology of suicide pacts in England and Wales Design: Analysis of the death certificates and coroners' records of all people who died In pacts between 1 January 1958 and 31 December 1992. Subjects: 124 people who committed suicide in 62 pacts. Results: Suicide in a pact accounted for 0.6% of all suicides (124/19 721), a rate of 0.6 per million people aged 15 and over. Forty eight pacts were between married couples and five were between family members. The mean age was 56 years. 99 of the 124 subjects were of occupational social classes I-III. Poisoning by car exhaust fumes and drugs accounted for 116 deaths, with both members of each pair using the same method. Conclusions: Suicide pacts are rare and less common than they were 35 years ago, although the epidemiological profile is similar. People who commit suicide in a pact are more Likely than those who commit suicide alone to be female, older, married. and of a high social class.	UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,FAC MED HLTH & BIOL SCI PSYCHIAT,SOUTHAMPTON SO14 0YG,HANTS,ENGLAND	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital								BARRACLOUGH GM, 1987, SUICIDE CLIN EPIDEMI; BROWN M, 1995, BRIT J PSYCHIAT, V167, P448, DOI 10.1192/bjp.167.4.448; Charlton J., 1993, POPULATION TRENDS, V71, P34; COHEN J, 1961, Mem Acad Chir (Paris), V29, P144; FISHBAIN DA, 1985, J CLIN PSYCHIAT, V45, P154; HOLDING TA, 1978, BRIT J PSYCHIAT, V133, P542, DOI 10.1192/bjp.133.6.542; *OFF POP CENS SURV, 1991, MORT STAT 1989 DH2; *OFF POP CENS SURV, 1992, MORT STAT 1990 DH2; *OFF POP CENS SURV, 1990, MORT STAT 1988 DH2; *OFF POP CENS SURV, 1993, MORT STAT 1991 DH2; *OFF POP CENS SURV, 1994, MORT STAT 1992 DH2; SEAGER CP, 1965, BRIT J PSYCHIAT, V111, P919, DOI 10.1192/bjp.111.479.919; SHEPHERD D, 1974, BMJ-BRIT MED J, V2, P600, DOI 10.1136/bmj.2.5919.600; World Health Organization, 1977, INT CLASS DIS; YOUNG D, 1984, J CLIN PSYCHIAT, V45, P470	15	27	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					286	287		10.1136/bmj.315.7103.286	http://dx.doi.org/10.1136/bmj.315.7103.286			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XP750	9274548	Green Published			2022-12-28	WOS:A1997XP75000022
J	Harris, K; Davies, K; Dumont, S; Stephenson, BM				Harris, K; Davies, K; Dumont, S; Stephenson, BM			A pain in the groin	LANCET			English	Article							ADIPOSIS DOLOROSA; SPIGELIAN HERNIA; DISEASE		ROYAL GWENT HOSP,DEPT SURG,NEWPORT NP92 U13,GWENT,WALES	Royal Gwent Hospital								BALTHAZAR EJ, 1984, GASTROINTEST RADIOL, V9, P81, DOI 10.1007/BF01887808; NAHIR AM, 1983, ISRAEL J MED SCI, V19, P858; PALMER ED, 1981, AM FAM PHYSICIAN, V24, P155; PETERSEN P, 1987, PAIN, V28, P77, DOI 10.1016/0304-3959(87)91062-1; SPANGEN L, 1989, WORLD J SURG, V13, P573, DOI 10.1007/BF01658873	5	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					334	334		10.1016/S0140-6736(97)05334-8	http://dx.doi.org/10.1016/S0140-6736(97)05334-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251639				2022-12-28	WOS:A1997XP24200012
J	Sammon, TJ				Sammon, TJ			March music	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		BUTLER C, 1995, MED PROBL PERFORM AR, V10, P24	1	1	1	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					816	816		10.1001/jama.1997.03550100040019	http://dx.doi.org/10.1001/jama.1997.03550100040019			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU552	9293979				2022-12-28	WOS:A1997XU55200019
J	Frank, SH; Stange, KC; Langa, D; Workings, M				Frank, SH; Stange, KC; Langa, D; Workings, M			Direct observation of community-based ambulatory encounters involving medical students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE; PRODUCTIVITY; ATTITUDES; COSTS	Context.-The current shift of predoctoral medical education from inpatient tertiary settings to community-based, ambulatory practice has raised questions about the effect of the medical student on the process of patient care. Objective.-To determine how the presence of a medical student during the ambulatory medical encounter affects the use of clinical time and patient satisfaction. Design.-Cross-sectional, multimethod study using direct observation of ambulatory care by research-trained nurses. Setting.-A total of 16 community-based family practice offices accepting family practice clerkship students. Patients.-A total of 452 outpatient visits with and without student involvement. Main Outcome Measures.-Clinical time use as measured by the Davis Observation Code; patient satisfaction was assessed with the Medical Outcomes Study 9-item visit rating scale. Results.-When students were involved, physicians spent more time discussing visit expectations (P=.03) and less time in history taking (P=.007), providing assessment (P=.01), and answering questions (P=.04), Despite these differences, patients were equally satisfied with explanations received, and there was no change in the rank order of the 5 most commonly observed physician behaviors. There was no difference in time spent in treatment planning, physical examination, health education, or social chatting. The physician spent equal time with the patient with (10.3 minutes) and without (9.9 minutes, P=.6) student involvement, There was no decrease in patient satisfaction when students were involved. Physicians were more likely to discuss another family member's problems when a student was present (P=.001). Students were directed to care for minority patients at a disproportionate rate (P=.001), controlling for confounding variables. Conclusions.-Medical student involvement alters the content but not the duration of the ambulatory medical encounter. Application of validated measures indicate that students did not impair patient satisfaction or hinder the physicians' ability to ensure that patient expectations for the visit were met.	CASE WESTERN RESERVE UNIV, DEPT SOCIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CTR CANC RES, CLEVELAND, OH 44106 USA; HENRY FORD HLTH SYST, DEPT FAMILY MED, DETROIT, MI USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Henry Ford Health System; Henry Ford Hospital	Frank, SH (corresponding author), CASE WESTERN RESERVE UNIV, DEPT FAMILY MED, 10900 EUCLID AVE, CLEVELAND, OH 44106 USA.		Frank, Scott/R-5727-2019	Frank, Scott/0000-0002-2303-5922	NCI NIH HHS [1R01 CA60862] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM AC FAM PHYS, 1994, FACTS FAM PRACT; [Anonymous], 1993, ACAD MED, V68, P1; Bertakis K D, 1992, Fam Med, V24, P307; Bertakis K D, 1993, Fam Med, V25, P530; Callahan E J, 1993, Fam Pract Res J, V13, P171; Callahan E J, 1996, Fam Med, V28, P346; Callahan E J, 1991, Fam Med, V23, P19; Crandall L A, 1986, J Rural Health, V2, P7, DOI 10.1111/j.1748-0361.1986.tb00142.x; Delbanco T L, 1988, J Gen Intern Med, V3, pS34, DOI 10.1007/BF02600250; Doyle G A, 1997, Fam Med, V29, P12; FIELDS SA, 1994, ACAD MED, V69, pS87, DOI 10.1097/00001888-199410000-00052; FLOCKE SA, IN PRESS J FAM PRACT; GARG ML, 1991, ACAD MED, V66, P348, DOI 10.1097/00001888-199106000-00009; KEARL GW, 1993, ACAD MED, V68, P166, DOI 10.1097/00001888-199302000-00017; KIRZ HL, 1986, JAMA-J AM MED ASSOC, V256, P734, DOI 10.1001/jama.256.6.734; PAWLSON LG, 1980, J FAM PRACTICE, V10, P847; PERKOFF GT, 1986, NEW ENGL J MED, V314, P27, DOI 10.1056/NEJM198601023140105; PETERSDORF RG, 1989, JAMA-J AM MED ASSOC, V262, P826, DOI 10.1001/jama.262.6.826; Robbins J A, 1993, Fam Med, V25, P17; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SCHAPPERT SM, 1996, ADV DATA, V273, P1; SIMONS RJ, 1995, J GEN INTERN MED, V10, P251, DOI 10.1007/BF02599880; SOSTOK MA, 1995, ACAD MED, V70, P949, DOI 10.1097/00001888-199511000-00003; STIMMEL B, 1992, JAMA-J AM MED ASSOC, V268, P2060, DOI 10.1001/jama.268.15.2060; VINSON DC, 1994, ACAD MED, V69, P237, DOI 10.1097/00001888-199403000-00020; Vinson DC, 1996, J FAM PRACTICE, V42, P243; WARE JE, 1992, MEASURING FUNCTIONIN, P291; YORK NL, 1995, AM J SURG, V169, P421, DOI 10.1016/S0002-9610(99)80189-5	28	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					712	716		10.1001/jama.278.9.712	http://dx.doi.org/10.1001/jama.278.9.712			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286829				2022-12-28	WOS:A1997XT70900022
J	Dein, S				Dein, S			ABC of mental health - Mental health in a multiethnic society	BRITISH MEDICAL JOURNAL			English	Review							ETHNIC-GROUPS		PRINCESS ALEXANDRA HOSP,HARLOW,ESSEX,ENGLAND	Princess Alexandra Hospital NHS Trust	Dein, S (corresponding author), UNIV COLL & MIDDLESEX SCH MED,LONDON,ENGLAND.							Bhui K, 1995, INT J SOC PSYCHIATR, V41, P242, DOI 10.1177/002076409504100402; Cole E, 1995, BRIT J PSYCHIAT, V167, P770, DOI 10.1192/bjp.167.6.770; KING M, 1994, BMJ-BRIT MED J, V309, P1115, DOI 10.1136/bmj.309.6962.1115; *NHS EX MENT HLTH, 1994, BLACK MENT HLTH DIAL; YEE L, 1995, IMPROVING SUPPORT BL	5	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					473	476		10.1136/bmj.315.7106.473	http://dx.doi.org/10.1136/bmj.315.7106.473			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XT714	9284670	Green Published			2022-12-28	WOS:A1997XT71400025
J	Wada, T; Tachibana, T; Shimura, Y; Okada, K				Wada, T; Tachibana, T; Shimura, Y; Okada, K			Epidermal cell differentiation in Arabidopsis determined by a Myb homolog, CPC	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; REGULATORY GENE; ROOT; THALIANA; PROTEIN; DOMAIN; PLANT; ORGANIZATION; ENCODES	The roots of plants normally carry small hairs arranged in a regular pattern. Transfer DNA-tagged lines of Arabidopsis thaliana included a mutant with few, randomly distributed root hairs. The mutated gene CAPRICE (CPC) encoded a protein with a Myb-like DNA binding domain typical of transcription factors involved in animal and plant development. Analysis in combination with other root hair mutations showed that CPC may work together with the TTG gene and upstream of the GL2 gene, Transgenic plants overexpressing CPC had more root hairs and fewer trichomes than normal. Thus, the CPC gene determines the fate of epidermal cell differentiation in Arabidopsis.	KYOTO UNIV,GRAD SCH SCI,DEPT BOT,KYOTO 60601,JAPAN; NATL INST BASIC BIOL,DIV GENE EXPRESS & REGULAT 1,OKAZAKI,AICHI 444,JAPAN; KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University				Tachibana, Tatsuhiko/0000-0001-8339-3986				ANZAI H, 1990, NUCLEIC ACIDS RES, V18, P1890, DOI 10.1093/nar/18.7.1890; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1994, TRENDS GENET, V10, P84, DOI 10.1016/0168-9525(94)90230-5; CHANG SS, 1994, PLANT J, V5, P551, DOI 10.1046/j.1365-313X.1994.5040551.x; CONE KC, 1993, PLANT CELL, V5, P1795, DOI 10.1105/tpc.5.12.1795; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DOLAN L, 1994, DEVELOPMENT, V120, P2465; DOLAN L, 1993, DEVELOPMENT, V119, P71; GALWAY ME, 1994, DEV BIOL, V166, P710; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4687; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Massucci JD, 1996, DEVELOPMENT, V122, P1253; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; NODA K, 1994, NATURE, V369, P661, DOI 10.1038/369661a0; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OKADA K, 1990, SCIENCE, V250, P274, DOI 10.1126/science.250.4978.274; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3353; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; WADA T, UNPUB	24	440	480	6	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1113	1116		10.1126/science.277.5329.1113	http://dx.doi.org/10.1126/science.277.5329.1113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262483				2022-12-28	WOS:A1997XT03300040
J	Cohen, LM				Cohen, LM			Positive Tzanck smear	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Cohen, LM (corresponding author), HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02139, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					535	535		10.1056/NEJM199708213370805	http://dx.doi.org/10.1056/NEJM199708213370805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262497				2022-12-28	WOS:A1997XR54800005
J	Portenoy, RK; Dole, V; Joseph, H; Lowinson, J; Rice, C; Segal, S; Richman, BL				Portenoy, RK; Dole, V; Joseph, H; Lowinson, J; Rice, C; Segal, S; Richman, BL			Pain management and chemical dependency - Evolving perspectives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ADDICTION; CANCER		MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,PAIN & PALLIAT CARE SERV,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021; NEW YORK STATE OFF ALCOHOLISM & SUBST ABUSE SERV,NEW YORK,NY	Memorial Sloan Kettering Cancer Center; Rockefeller University	Portenoy, RK (corresponding author), BETH ISRAEL MED CTR,DEPT PAIN MED & PALLIAT CARE,1ST AVE & 16TH ST,NEW YORK,NY 10003, USA.							*AD HOC COMM CANC, 1992, J CLIN ONCOL, V10, P1976; ANGAROLA RT, 1989, ADV PAIN RES THER, V11, P213; [Anonymous], [No title captured]; BESSON JM, 1987, PHYSIOL REV, V67, P67, DOI 10.1152/physrev.1987.67.1.67; BREITBART W, 1996, PAIN, V65, P239; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COOPER JR, 1992, JAMA-J AM MED ASSOC, V268, P1306, DOI 10.1001/jama.268.10.1306; ELLIOTT KJ, IN PRESS ANESTHESIA; Jacox A, 1994, AHCPR PUBLICATION; JORANSON DE, 1992, FED B, V4, P415; NESTLER EJ, 1994, NEUROPSYCHOPHARMACOL, V11, P77, DOI 10.1038/npp.1994.37; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; PORTENOY RK, 1997, SUBSTANCE ABUSE COMP, P563; SEES KL, 1993, J PAIN SYMPTOM MANAG, V8, P257, DOI 10.1016/0885-3924(93)90154-N; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L; World Health Organization, 1996, CANC PAIN REL GUID O	16	53	55	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					592	593		10.1001/jama.278.7.592	http://dx.doi.org/10.1001/jama.278.7.592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268282				2022-12-28	WOS:A1997XQ98600035
J	Desai, AD; Chun, S; Sung, RJ				Desai, AD; Chun, S; Sung, RJ			The role of intravenous amiodarone in the management of cardiac arrhythmias	ANNALS OF INTERNAL MEDICINE			English	Article							REFRACTORY VENTRICULAR-TACHYCARDIA; ACUTE MYOCARDIAL-INFARCTION; ONSET ATRIAL-FIBRILLATION; SHORT-TERM TREATMENT; ORAL AMIODARONE; SINUS RHYTHM; HISTORICAL DEVELOPMENT; ADRENERGIC ANTAGONISM; CLINICAL EFFICACY; CRITICALLY ILL	Purpose: To review the electropharmacology, clinical applications, side effects, and hemodynamic profile of intravenous amiodarone. Data Sources: The MEDLINE database was searched for English-language material, including reports of clinical trials and in vivo studies, review articles, and abstracts presented al national symposia, that was published between 1985 and 1996. Bibliographies of textbooks and articles were also examined. Study Selection: Studies that reported on the efficacy, toxicity, and hemodynamic profile of intravenous amiodarone and studies that examined the pharmacologic behavior of intravenous amiodarone in laboratory models were reviewed. Data Extraction: Study design and quality and relevant data on efficacy of suppression and treatment of arrhythmias with oral and intravenous amiodarone therapy, the reported mechanisms of antiarrhythmic effect, and hemodynamic changes seen with therapy were analyzed. Data Synthesis: Amiodarone is a unique antiarrhythmic agent that is now available in oral and intravenous forms in the United States. The use of intravenous amiodarone in the short-term treatment of life-threatening or hemodynamically unstable rhythm disturbances has generated much interest. Amiodarone has many electropharmacologic actions, some of which differ between the oral and intravenous forms. The wide clinical application of amiodarone includes treatment and prevention of supraventricular and ventricular arrhythmias and arrhythmias related to myocardial infarction. Intravenous amiodarone is effective for supraventricular and ventricular arrhythmias that are resistant to other antiarrhythmic agents. The effectiveness of intravenous amiodarone as short-term treatment also suggests that the drug has an important role in protocols of advanced cardiac life support. Intravenous amiodarone seems to have an overall favorable hemodynamic profile and does not produce many of the unwanted long-term side effects associated with oral therapy. Conclusion: Intravenous amiodarone shows much promise for the short-term treatment of unstable arrhythmias. Its favorable hemodynamic effects and minimal short-term side effects make it an attractive option in the management of cardiac arrhythmias.	STANFORD UNIV, MED CTR, DIV CARDIOVASC MED, STANFORD, CA 94305 USA	Stanford University								ANASTASIOUNANA MI, 1994, J AM COLL CARDIOL, V23, P253, DOI 10.1016/0735-1097(94)90528-2; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLEVINS RD, 1987, ARCH INTERN MED, V147, P1401, DOI 10.1001/archinte.147.8.1401; Boriani Giuseppe, 1996, Journal of the American College of Cardiology, V27, p80A; BRAUNWALD E, 1992, HEART DIS TXB CARDIO, P1239; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CAPUCCI A, 1992, AM J CARDIOL, V70, P69, DOI 10.1016/0002-9149(92)91392-H; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CHAPMAN MJ, 1993, INTENS CARE MED, V19, P48, DOI 10.1007/BF01709278; CHUN SH, 1995, AM J CARDIOL, V76, P47, DOI 10.1016/S0002-9149(99)80799-1; CONNOLLY SJ, 1984, J CARDIOVASC PHARM, V6, P531, DOI 10.1097/00005344-198405000-00023; Cybulski J, 1996, CLIN CARDIOL, V19, P563, DOI 10.1002/clc.4960190708; DONOVAN KD, 1995, AM J CARDIOL, V75, P693, DOI 10.1016/S0002-9149(99)80655-9; DREXLER H, 1986, INENSIVMEDIZIN, V23, P179; DU XJ, 1995, CIRCULATION, V91, P462, DOI 10.1161/01.CIR.91.2.462; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; GRABOYS TB, 1983, AM HEART J, V106, P870, DOI 10.1016/0002-8703(83)90009-1; GREENE HL, 1992, J AM COLL CARDIOL, V19, P894, DOI 10.1016/0735-1097(92)90267-Q; HOHLOSER SH, 1992, J CARDIOVASC PHARM, V20, pS63; HOHNLOSER SH, 1991, AM HEART J, V121, P89, DOI 10.1016/0002-8703(91)90960-P; HORNER SM, 1992, ACTA CARDIOL, V47, P473; HOROWITZ LN, 1982, CIRCULATION, V66, P222; HOROWITZ LN, 1985, J AM COLL CARDIOL, V6, P1402, DOI 10.1016/S0735-1097(85)80232-1; HOU ZY, 1995, EUR HEART J, V16, P521, DOI 10.1093/oxfordjournals.eurheartj.a060945; IKEDA N, 1984, AM HEART J, V108, P890, DOI 10.1016/0002-8703(84)90451-4; KADISH A, 1989, PROG CARDIOVASC DIS, V31, P281, DOI 10.1016/0033-0620(89)90034-0; KADISH AH, 1990, J AM COLL CARDIOL, V16, P1240, DOI 10.1016/0735-1097(90)90560-C; Kerin NZ, 1996, ARCH INTERN MED, V156, P49, DOI 10.1001/archinte.156.1.49; KLEIN RC, 1988, AM HEART J, V115, P96, DOI 10.1016/0002-8703(88)90523-6; KOJIMA S, 1995, J PHARMACOL EXP THER, V275, P254; KOWEY PR, 1995, CIRCULATION, V92, P3255, DOI 10.1161/01.CIR.92.11.3255; Levine JH, 1996, J AM COLL CARDIOL, V27, P67, DOI 10.1016/0735-1097(95)00427-0; MASON JW, 1984, CIRC RES, V55, P277, DOI 10.1161/01.RES.55.3.278; MAYUGA RD, 1992, CARDIOVASC RES, V26, P571, DOI 10.1093/cvr/26.6.571; MITCHELL LB, 1989, CIRCULATION, V80, P34, DOI 10.1161/01.CIR.80.1.34; MOOSS AN, 1990, AM J CARDIOL, V65, P609, DOI 10.1016/0002-9149(90)91039-9; MORADY F, 1986, J AM COLL CARDIOL, V7, P148, DOI 10.1016/S0735-1097(86)80273-X; MORADY F, 1983, AM J CARDIOL, V51, P156, DOI 10.1016/S0002-9149(83)80027-7; MORAN JL, 1995, CRIT CARE MED, V23, P1816, DOI 10.1097/00003246-199511000-00005; NACCARELLI GC, 1995, CIRCULATION, V92, P3154, DOI 10.1161/01.CIR.92.11.3154; NALOS PC, 1991, AM HEART J, V122, P1629, DOI 10.1016/0002-8703(91)90280-U; NATTEL S, 1987, CIRCULATION, V76, P442, DOI 10.1161/01.CIR.76.2.442; NEGRINI M, 1991, Journal of the American College of Cardiology, V17, p131A; NORRIS RM, 1984, LANCET, V2, P883; OCHI RP, 1989, AM J CARDIOL, V64, P599, DOI 10.1016/0002-9149(89)90486-4; PODRID PJ, 1995, ANN INTERN MED, V122, P689, DOI 10.7326/0003-4819-122-9-199505010-00008; POLSTER P, 1976, BIOCHEM PHARMACOL, V25, P131, DOI 10.1016/0006-2952(76)90279-3; REMME WJ, 1991, AM HEART J, V122, P96, DOI 10.1016/0002-8703(91)90764-9; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; RODEN DM, 1993, AM J CARDIOL, V72, pF45, DOI 10.1016/0002-9149(93)90962-C; SAGRISTASAULEDA J, 1992, AM HEART J, V123, P1536, DOI 10.1016/0002-8703(92)90806-7; SAKSENA S, 1984, AM J CARDIOL, V54, P347, DOI 10.1016/0002-9149(84)90195-4; SCHEINMAN MM, 1995, CIRCULATION, V92, P3264, DOI 10.1161/01.CIR.92.11.3264; SCHUTZENBERGER W, 1989, BRIT HEART J, V62, P367; SINGH BN, 1989, PROG CARDIOVASC DIS, V31, P249, DOI 10.1016/0033-0620(89)90033-9; SINGH BN, 1983, AM HEART J, V106, P788, DOI 10.1016/0002-8703(83)90002-9; SINGH BN, 1983, AM HEART J, V106, P857, DOI 10.1016/0002-8703(83)90008-X; TALAJIC M, 1987, CIRCULATION, V75, P265, DOI 10.1161/01.CIR.75.1.265; TWIDALE N, 1993, AM HEART J, V126, P122, DOI 10.1016/S0002-8703(07)80018-4; VIETTIRAMUS G, 1992, INT J CARDIOL, V35, P77, DOI 10.1016/0167-5273(92)90058-B; VITOLO E, 1981, ACTA CARDIOL, V36, P431; WELLENS HJJ, 1984, CIRCULATION, V69, P120, DOI 10.1161/01.CIR.69.1.120; WILLIAMS ML, 1989, ANN INTERN MED, V110, P839, DOI 10.7326/0003-4819-110-10-839; YABEK SM, 1986, J CARDIOVASC PHARM, V8, P197, DOI 10.1097/00005344-198601000-00029; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZEHENDER M, 1992, J AM COLL CARDIOL, V19, P1054, DOI 10.1016/0735-1097(92)90294-W; 1995, MED LETT DRUGS THER, V37, P114; 1995, PHYSICIANS DESK REFE, P2659	71	57	62	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					294	303		10.7326/0003-4819-127-4-199708150-00007	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265430				2022-12-28	WOS:A1997XR26600009
J	Price, CSC				Price, CSC			Conspecific sperm precedence in Drosophila	NATURE			English	Article							MELANOGASTER; DISPLACEMENT; HOMOGAMY; FEMALES; PROTEIN	Traits that influence the interactions between males and females can evolve very rapidly through sexual selection(1) or sexually antagonistic coevolution(2). Rapid change in the fertilization systems of independent populations can give rise to reproductive incompatibilities between populations(3,4), and may contribute to speciation(5). Here I provide evidence for cryptic reproductive divergence among three sibling species of Drosophila that leads to a form of postmating isolation. When a female mates with both a conspecific and a heterospecific male, the conspecific sperm fertilize the vast majority of the eggs, regardless of the order of the matings. Heterospecific sperm fertilize fewer eggs after these double matings than after single matings. Experiments using spermless males show that the seminal fluid of the conspecific male is largely responsible for this conspecific sperm precedence. Moreover, when two males of the same species mate sequentially with a female from a different species, a highly variable pattern of sperm precedence replaces the second-male sperm precedence that is consistently found within species. These results indicate that females mediate sperm competition, and that second-male sperm precedence is not an automatic consequence of the mechanics of sperm storage.			Price, CSC (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.							[Anonymous], [No title captured]; BELLA JL, 1992, HEREDITY, V68, P345, DOI 10.1038/hdy.1992.49; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CLARK AG, 1995, GENETICS, V139, P189; COYNE JA, 1993, EVOLUTION, V47, P778, DOI 10.1111/j.1558-5646.1993.tb01233.x; DAVID J, 1974, ANN GENET-PARIS, V17, P235; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; Fisher R.A., 1930, GENETICAL THEORY NAT; GREGORY PG, 1997, EVOLUTION, V48, P705; GROMKO MH, 1964, SPERM COMPETITION EV, P371; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; HERNDON LA, 1995, P NATL ACAD SCI USA, V92, P10114, DOI 10.1073/pnas.92.22.10114; HEWITT GM, 1989, HEREDITY, V62, P343, DOI 10.1038/hdy.1989.49; Hughes KA, 1997, GENETICS, V145, P139; INGMANBAKER J, 1980, BIOCHEM GENET, V18, P809, DOI 10.1007/BF00484595; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; PALUMBI SR, 1991, MOL BIOL EVOL, V8, P227; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; PYLE DW, 1978, EXPERIENTIA, V34, P449, DOI 10.1007/BF01935920; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; WADE MJ, 1994, HEREDITY, V72, P163, DOI 10.1038/hdy.1994.23	22	161	163	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					663	666		10.1038/41753	http://dx.doi.org/10.1038/41753			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262398	Bronze			2022-12-28	WOS:A1997XQ86300046
J	Gurfinkel, E; Bozovich, G; Daroca, A; Beck, E; Mautner, B				Gurfinkel, E; Bozovich, G; Daroca, A; Beck, E; Mautner, B			Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study	LANCET			English	Article							CHLAMYDIA-PNEUMONIAE; HEART-DISEASE; ASSOCIATION	Background There is serological evidence for an association between Chlamydia pneumoniae and coronary heart disease. We investigated the hypothesis that an antichlamydial macrolide antibiotic, roxithromycin, can prevent or reduce recurrent major ischaemic events in patients with unstable angina. Methods The effect of roxithromycin was assessed in a double-blind, randomised, prospective, multicentre, parallel-group, placebo-controlled pilot study of 202 patients with unstable angina or non-Q-wave myocardial infarction. Patients were randomly assigned either roxithromycin 150 mg orally twice a day (n=102) or placebo orally twice a day (n=100). The treatment was for 30 days, Patients were followed up for 6 months, We report the primary clinical endpoints (cardiac ischaemic death, myocardial infarction, and severe recurrent ischaemia), assessed at day 31, in 202 patients on an intention-to-treat basis. Findings A statistically significant reduction in the primary composite triple endpoint rates was observed in the roxithromycin group; p=0.032. The rate of severe recurrent ischaemia, myocardial infarction, and ischaemic death was 5.4%, 2.2%, and 2.2% in the placebo group and 1.1%, 0%, and 0%, in the roxithromycin group, respectively. No major drug-related adverse effects were observed. Interpretation Antichlamydial antibiotics may be useful in therapeutic intervention addition to standard medication in patients with coronary-artery disease. Large-scale trials are needed to confirm these preliminary observations.	HOSP DURAND,BUENOS AIRES,DF,ARGENTINA	University of Buenos Aires	Gurfinkel, E (corresponding author), FAVALORO FDN,AVE BELGRANO 1746,RA-1093 BUENOS AIRES,DF,ARGENTINA.							AGEN C, 1993, AGENTS ACTIONS, V38, P85, DOI 10.1007/BF02027218; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BRAUNWALD E, 1994, CLIN PRACTICE GUIDEL, V10, P154; EPSTEIN SE, 1996, LANCET S, V348, P13; Gurfinkel E., 1996, European Heart Journal, V17, P578; KADOTA JL, 1996, J CLIN MICROB INFECT, V1, P220; KITA E, 1993, J ANTIMICROB CHEMOTH, V32, P285, DOI 10.1093/jac/32.2.285; LABRO MT, 1996, J CLIN MICROB INFECT, V1, P24; LINNANMAKI E, 1993, CIRCULATION, V87, P1130, DOI 10.1161/01.CIR.87.4.1130; LIUZZO G, 1997, J AM COLL CARDIOL, V29, P760; LOPESVIRELLA MF, 1985, CLIN IMMUNOL IMMUNOP, V37, P377, DOI 10.1016/0090-1229(85)90107-2; MORENO PR, 1996, ROLE IMMUNE MECH CAR, P213; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Sylven C, 1995, EUR HEART J, V16, P1800, DOI 10.1093/oxfordjournals.eurheartj.a060831; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; *TIMI IIIB INV, 1994, CIRCULATION, V89, P1545	18	455	467	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					404	407		10.1016/S0140-6736(97)07201-2	http://dx.doi.org/10.1016/S0140-6736(97)07201-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259655				2022-12-28	WOS:A1997XQ24800011
J	Shen, CP; Jan, LY; Jan, YN				Shen, CP; Jan, LY; Jan, YN			Miranda is required for the asymmetric localization of Prospero during mitosis in Drosophila	CELL			English	Article							C-ELEGANS EMBRYOS; PREDICTING COILED COILS; CAENORHABDITIS-ELEGANS; 2-HYBRID SYSTEM; CELL-DIVISION; GENE; PROTEIN; NUMB; SEGREGATION; FATES	Asymmetric division of Drosophila neuroblasts, sensory organ precursor cells, and cells in the procephalic neurogenic region involves the segregation of Numb and Prospero proteins into one of the two daughter cells. We have isolated a novel gene, miranda, based on the ability of its gene product to interact with the Prospero asymmetric localization domain. miranda expression coincides spatially and temporally with asymmetric cell divisions and asymmetric localization of Prospero. Miranda protein is localized asymmetrically, along with Prospero, to the basal cell membrane during mitosis. Loss of miranda gene function abolishes asymmetric Prospero localization during mitosis. The asymmetric localization of Miranda protein requires inscuteable. Our results suggest that miranda functions downstream of inscuteable and works as an adapter that connects Prospero to the basal cell membrane during asymmetric cell division.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shen, CP (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BARTEL PL, 1993, USING 2 HYBRID SYSTE; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STAUGER C, 1993, CURR OPIN CELL BIOL, V5, P226; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P942; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	40	230	235	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					449	458		10.1016/S0092-8674(00)80505-X	http://dx.doi.org/10.1016/S0092-8674(00)80505-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267025	Bronze			2022-12-28	WOS:A1997XQ06300009
J	Tomb, JF; White, O; Kerlavage, AR; Clayton, RA; Sutton, GG; Fleischmann, RD; Ketchum, KA; Klenk, HP; Gill, S; Dougherty, BA; Nelson, K; Quackenbush, J; Zhou, LX; Kirkness, EF; Peterson, S; Loftus, B; Richardson, D; Dodson, R; Khalak, HG; Glodek, A; McKenney, K; Fitzegerald, LM; Lee, N; Adams, MD; Hickey, EK; Berg, DE; Gocayne, JD; Utterback, TR; Peterson, JD; Kelley, JM; Cotton, MD; Weldman, JM; Fujii, C; Bowman, C; Watthey, L; Wallin, E; Hayes, WS; Weidman, JM; Fujii, C; Borodovsky, M; Karp, PD; Smith, HO; Fraser, CM; Venter, JC				Tomb, JF; White, O; Kerlavage, AR; Clayton, RA; Sutton, GG; Fleischmann, RD; Ketchum, KA; Klenk, HP; Gill, S; Dougherty, BA; Nelson, K; Quackenbush, J; Zhou, LX; Kirkness, EF; Peterson, S; Loftus, B; Richardson, D; Dodson, R; Khalak, HG; Glodek, A; McKenney, K; Fitzegerald, LM; Lee, N; Adams, MD; Hickey, EK; Berg, DE; Gocayne, JD; Utterback, TR; Peterson, JD; Kelley, JM; Cotton, MD; Weldman, JM; Fujii, C; Bowman, C; Watthey, L; Wallin, E; Hayes, WS; Weidman, JM; Fujii, C; Borodovsky, M; Karp, PD; Smith, HO; Fraser, CM; Venter, JC			The complete genome sequence of the gastric pathogen Helicobacter pylori	NATURE			English	Article							MYCOPLASMA-GENITALIUM; GENE; PROTEIN; IDENTIFICATION; EPITHELIUM; INFECTION; MUTATION	Helicobacter pylori, strain 26695, has a circular genome of 1,667,867 base pairs and 1,590 predicted coding sequences, Sequence analysis indicates that H. pylori has well-developed systems for motility, for scavenging iron, and for DNA restriction and modification, Many putative adhesins, lipoproteins and other outer membrane proteins were identified, underscoring the potential complexity of host-pathogen interaction, Based on the large number of sequence-related genes encoding outer membrane proteins and the presence of homopolymeric tracts and dinucleotide repeats in coding sequences, H. pylori, like several other mucosal pathogens, probably uses recombination and slipped-strand mispairing within repeats as mechanisms for antigenic variation and adaptive evolution, Consistent with its restricted niche, H. pylori has a few regulatory networks, and a limited metabolic repertoire and biosynthetic capacity, Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL,ST LOUIS,MO 63110; UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN; GEORGIA TECH RES INST,SCH BIOL,ATLANTA,GA 30332; SRI INT,CTR ARTIFICIAL INTELLIGENCE,MENLO PK,CA 94025; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	Washington University (WUSTL); Stockholm University; University System of Georgia; Georgia Institute of Technology; SRI International; Johns Hopkins University	Tomb, JF (corresponding author), INST GENOM RES,9712 MED CTR DR,ROCKVILLE,MD 20850, USA.		; Karp, Peter/C-3514-2012	loftus, brendan/0000-0001-8871-8356; Fraser, Claire/0000-0003-1462-2428; Kerlavage, Anthony/0000-0002-3954-9653; Quackenbush, John/0000-0002-2702-5879; Karp, Peter/0000-0002-5876-6418				Akopyants Natalia S., 1996, Gut, V39, pA67; AKOPYANTS NS, 1995, INFECT IMMUN, V63, P116, DOI 10.1128/IAI.63.1.116-121.1995; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; BAKER PJ, 1994, INFECT IMMUN, V62, P2257, DOI 10.1128/IAI.62.6.2257-2269.1994; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BORODOVSKY M, 1994, NUCLEIC ACIDS RES, V22, P4756, DOI 10.1093/nar/22.22.4756; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLEMENS J, 1995, J INFECT DIS, V171, P1653, DOI 10.1093/infdis/171.6.1653; Cover TL, 1996, ADV INTERNAL MED, V41, P85; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; DOIG P, 1995, J BACTERIOL, V177, P5447, DOI 10.1128/jb.177.19.5447-5452.1995; EARHART CF, 1996, CELLULAR MOL BIOL, P1075; EVANS DJ, 1995, GENE, V153, P123, DOI 10.1016/0378-1119(94)00774-M; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRAZIER BA, 1993, J BACTERIOL, V175, P966, DOI 10.1128/JB.175.4.966-972.1993; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GO MF, 1994, J GASTROENTROL HEP S, V9, P8; HUGHES NJ, 1995, J BACTERIOL, V177, P3953, DOI 10.1128/jb.177.14.3953-3959.1995; Ilver D., 1996, Gut, V39, pA55; Jones A. C., 1996, Gut, V39, pA62; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; Karp PD, 1997, NUCLEIC ACIDS RES, V25, P43, DOI 10.1093/nar/25.1.43; KORNBERG A, 1992, REPLICATION MECH OPE, P471; Labigne A, 1996, INFECT AGENT DIS, V5, P191; LINN S, 1996, CELLULAR MOL BIOL, P764; MACNAB RM, 1996, CELLULAR MOL BIOL, P123; MARCZYNSKI GT, 1993, CURR OPIN GENET DEV, V3, P775, DOI 10.1016/S0959-437X(05)80098-X; Matin A, 1996, INFECT IMMUN, V64, P1434, DOI 10.1128/IAI.64.4.1434-1436.1996; McGowan CC, 1996, GASTROENTEROLOGY, V110, P926, DOI 10.1053/gast.1996.v110.pm8608904; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Melchers K., 1996, Gut, V39, pA67; MENDZ GL, 1995, INT J BIOCHEM CELL B, V27, P1085, DOI 10.1016/1357-2725(95)00069-2; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; Moran AP, 1996, ALIMENT PHARM THER, V10, P39, DOI 10.1046/j.1365-2036.1996.22164004.x; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Odenbreit S, 1996, MOL MICROBIOL, V20, P361, DOI 10.1111/j.1365-2958.1996.tb02623.x; Peek R. M., 1996, Gut, V39, pA71; PETERSON SN, 1995, P NATL ACAD SCI USA, V92, P11829, DOI 10.1073/pnas.92.25.11829; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SONNHAMMER ELL, IN PRESS PROTEINS; STROM MS, 1994, METHOD ENZYMOL, V235, P527; SUERBAUM S, 1995, TRENDS MICROBIOL, V3, P168, DOI 10.1016/S0966-842X(00)88913-1; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x; WARREN JR, 1983, LANCET, V1, P1273; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7	50	2874	3665	6	195	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					539	547		10.1038/41483	http://dx.doi.org/10.1038/41483			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252185	Bronze			2022-12-28	WOS:A1997XP72200038
J	Buckley, CD				Buckley, CD			Science, medicine, and the future - Treatment of rheumatoid arthritis	BRITISH MEDICAL JOURNAL			English	Review							DISEASE				Buckley, CD (corresponding author), UNIV BIRMINGHAM,DEPT RHEUMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							Akbar AN, 1997, IMMUNOL TODAY, V18, P72, DOI 10.1016/S0167-5699(97)01003-7; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Maini RN, 1996, J ROY COLL PHYS LOND, V30, P344; Moreland LW, 1997, ARTHRITIS RHEUM, V40, P397, DOI 10.1002/art.1780400302; Muller-Ladner Ulf, 1995, Current Opinion in Rheumatology, V7, P222, DOI 10.1097/00002281-199505000-00011; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; SALMON M, 1992, Current Opinion in Rheumatology, V4, P342, DOI 10.1097/00002281-199206000-00011; SHARP JT, 1991, ARTHRITIS RHEUM, V34, P660, DOI 10.1002/art.1780340606; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; WILSKE K, 1996, RHEUMATOLOGY EUROPE, V25, P145; ZIFF M, 1990, J RHEUMATOL, V17, P127	14	38	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					236	238		10.1136/bmj.315.7102.236	http://dx.doi.org/10.1136/bmj.315.7102.236			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	9253273	Green Published			2022-12-28	WOS:A1997XN51700029
J	Caldas, C				Caldas, C			Molecular staging of cancer: Is it time?	LANCET			English	Editorial Material							IDENTIFICATION; MUTATIONS				Caldas, C (corresponding author), UNIV CAMBRIDGE,SCH CLIN MED,CRC ACAD DEPT ONCOL,CAMBRIDGE CB2 2QQ,ENGLAND.		Caldas, Carlos/A-7543-2008; Caldas, Carlos/U-7250-2019	Caldas, Carlos/0000-0003-3547-1489				BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; Caldas C., 1997, Lancet (North American Edition), V349, P16; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123	4	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					231	231		10.1016/S0140-6736(05)62219-2	http://dx.doi.org/10.1016/S0140-6736(05)62219-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9265090				2022-12-28	WOS:A1997XM86600003
J	DeLaet, CEDH; vanHout, LB; Burger, H; Hofman, A; Pols, HAP				DeLaet, CEDH; vanHout, LB; Burger, H; Hofman, A; Pols, HAP			Bone density and risk of hip fracture in men and women: Cross sectional analysis	BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; ELDERLY MEN; OSTEOPOROSIS; EPIDEMIOLOGY; PREDICTION; MASS; AGE	Objective: To determine the relative contribution of decline in bone density to the increase in risk of hip fracture with age in men and women. Design: Incidence data of hip fracture from the general population were combined with the bone density distribution in a sample from the same population and with a risk estimate of low bone density known fi om literature. Setting: The Netherlands. Subjects: All people with a hospital admission for a hip fracture in 1993, and bone density measured in a sample of 5814 men and women aged 55 years and over in a district of Rotterdam. Main outcome measure: One year cumulative risk of hip fracture by age, sex, and bone density measured at the femoral neck. Results: A quarter of all hip fractures occurred in men. Men reached the same incidence as women at five years older. Controlled for age, the risk of hip fracture by bone density was similar in men and women. The risk of hip fracture increased 13-fold from age 60 to 80; decrease in bone density associated with age contributed 1.9 (95% confidence interval 1.5 to 2.4) in women and 1.6 (1.3 to 1.8) in men. Conclusions: The risk of hip fracture by age and bone density is similar in men and women. The decrease in bone density associated with age makes a limited contribution to the exponential increase of the risk of hip fracture with age.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,NL-3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,NL-3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,INST MED TECHNOL ASSESSMENT,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam				De Laet, Chris/0000-0002-1951-2079				BLACK DM, 1992, J BONE MINER RES, V7, P639; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BOEREBOOM FTJ, 1992, OSTEOPOROSIS INT, V2, P279, DOI 10.1007/BF01623183; *CENTR BUR STAT, 1994, STAT JB 1994; *CONS DEV C, 1993, AM J MED, V94, P646; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352; Kanis JA, 1996, OSTEOPOROSIS INT, V6, P256, DOI 10.1007/BF01622743; KANIS JA, 1996, BONE S3, V18, P127; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MELTON LJ, 1993, BONE, V14, pS1; NEVITT MC, 1994, OSTEOPOROSIS INT, V4, P325, DOI 10.1007/BF01622192; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; Nguyen TV, 1996, AM J EPIDEMIOL, V144, P255, DOI 10.1093/oxfordjournals.aje.a008920; PEARSON J, 1995, OSTEOPOROSIS INT, V5, P174, DOI 10.1007/BF02106097; *SPSS, 1995, STAT PACK SOC SCI RE; STEIGER P, 1992, J BONE MINER RES, V7, P625; TOSS G, 1992, J INTERN MED, V231, P181, DOI 10.1111/j.1365-2796.1992.tb00521.x; VANBURGER H, 1994, BONE MINER, V25, P1	24	255	257	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					221	225		10.1136/bmj.315.7102.221	http://dx.doi.org/10.1136/bmj.315.7102.221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	9253270	Green Published			2022-12-28	WOS:A1997XN51700024
J	Grun, L; TassanoSmith, J; Carder, C; Johnson, AM; Robinson, A; Murray, E; Stephenson, J; Haines, A; Copas, A; Ridgway, G				Grun, L; TassanoSmith, J; Carder, C; Johnson, AM; Robinson, A; Murray, E; Stephenson, J; Haines, A; Copas, A; Ridgway, G			Comparison of two methods of screening for genital chlamydial infection in women attending in general practice: Cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							LIGASE CHAIN-REACTION; FAMILY-PLANNING CLINICS; TRACHOMATIS INFECTION; URINE SPECIMENS; REACTION ASSAY; DIAGNOSIS; TESTS; ABORTION	Objectives: To estimate the prevalence of Chlamydia trachomatis in asymptomatic women attending general practice; to assess the potential of the ligase chain reaction as a screening tool; and to evaluate selective screening criteria. Design: Cross sectional survey. Setting: Four general practices in northeast London. Subjects: 890 women aged 18-35 years attending general practice for a cervical smear or a ''young well woman'' check between October 1994 and January 1996. The women were tested for C trachomatis with confirmed enzyme immunoassay (endocervical specimens) and ligase cl-lain reaction assay on urine specimens. Main outcome measures: Prevalence of C trachomatis infection in women aged 18-35 on the basis of each test; sensitivity and specificity of both tests in this population. Results: Prevalence of confirmed infection was 2.6% (95% confidence interval 1.6% to 3.6%) in all women. Prevalence on the basis of enzyme immunoassay was 1.6% (0.8% to 2.7%), with a sensitivity of 60% and a specificity of 100%. Prevalence on the basis of ligase chain reaction was 2.5% (1.5% to 3.9%), with 90% sensitivity and 99.8% specificity. Screening all women aged less than or equal to 25 and all women who had had two or more partners in the past year would have detected 87% (20/23) of infections. Conclusion: Ligase chain reaction on urine samples performs at least as well as enzyme immunoassay on cervical specimens in this low prevalence population, It offers potential as a non-invasive screening tool, A simple selective screening strategy might be appropriate and would be able to detect most cases of infection, However, a rigorous economic evaluation of possible screening strategies is needed first.	WHITTINGTON HOSP, UCLMS, JOINT DEPT PRIMARY CARE & POPULAT SCI, LONDON N19 5NF, ENGLAND; WHITTINGTON HOSP, ROYAL FREE HOSP, SCH MED, LONDON N19 5NF, ENGLAND; UCL HOSP TRUST, DEPT MICROBIOL, LONDON WC1E 6AU, ENGLAND	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	Grun, L (corresponding author), UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, MORTIMER ST, ONDON WC1E 6AU, ENGLAND.			Haines, Andy/0000-0002-8053-4605; Johnson, Anne/0000-0003-1330-7100; Murray, Elizabeth/0000-0002-8932-3695; Copas, Andrew/0000-0001-8968-5963				BASSIRI M, 1995, J CLIN MICROBIOL, V33, P898, DOI 10.1128/JCM.33.4.898-900.1995; Berman Stuart M., 1993, Morbidity and Mortality Weekly Report, V42, P1; *CDC, 1985, MMWR-MORBID MORTAL W, V34, P53; CHERNESKY MA, 1994, J INFECT DIS, V170, P1308, DOI 10.1093/infdis/170.5.1308; ESTANY A, 1989, SEX TRANSM DIS, V16, P21, DOI 10.1097/00007435-198901000-00005; *GOVT STAT SERV, 1996, DEP HLTH STAT B, P1; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; Johnson AM, 1994, SEXUAL ATTITUDES LIF; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MAGDID D, 1996, ANN INTERN MED, V124, P389; OAKESHOTT P, 1995, LANCET, V346, P648, DOI 10.1016/S0140-6736(95)91489-7; OSTERGAARD T, 1996, BRIT MED J, V313, P1186; OWEN PA, 1991, BRIT J GEN PRACT, V41, P279; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; Ridgway GL, 1996, J CLIN PATHOL, V49, P116, DOI 10.1136/jcp.49.2.116; RIDGWAY GL, 1983, BRIT MED J, V286, P1478, DOI 10.1136/bmj.286.6376.1478-a; SCHACHTER J, 1995, J INFECT DIS, V172, P1411, DOI 10.1093/infdis/172.5.1411; SCHACHTER J, 1983, WESTERN J MED, V138, P375; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SMITH JR, 1991, BRIT MED J, V302, P82, DOI 10.1136/bmj.302.6768.82; SOUTHGATE L, 1989, BRIT MED J, V299, P1136, DOI 10.1136/bmj.299.6708.1136; SOUTHGATE LJ, 1983, BRIT MED J, V287, P879, DOI 10.1136/bmj.287.6396.879; TAYLORROBINSON D, 1994, BMJ-BRIT MED J, V308, P150, DOI 10.1136/bmj.308.6922.150; THOMPSON C, 1994, BR J GEN PRACT, V302, P82; TRACHTENBERG AI, 1988, OBSTET GYNECOL, V71, P101; Wilson J JG, 1968, PUBLIC HLTH PAPERS, V34	26	63	64	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					226	230		10.1136/bmj.315.7102.226	http://dx.doi.org/10.1136/bmj.315.7102.226			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	9253271	Green Published			2022-12-28	WOS:A1997XN51700026
J	Brandts, CH; Ndjave, M; Graninger, W; Kremsner, PG				Brandts, CH; Ndjave, M; Graninger, W; Kremsner, PG			Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; FEVER; CHILDREN; ACETAMINOPHEN; INVIVO; INVITRO; QUININE; GABON	Background Routine antipyretic therapy in children with infectious diseases has long been the source of controversy. Each year, in addition to antimalarial medication, millions of children with Plasmodium falciparum malaria receive paracetamol to reduce fever. However, the usefulness of this practice has not been proven. Methods In a randomised trial in Lambarene, Gabon, 50 children with P falciparum malaria were treated with intravenous quinine, and received either mechanical antipyresis alone, or in combination with paracetamol. Rectal body temperature and parasitaemia were recorded every 6 h for 4 days. Plasma concentrations and inducible concentrations of tumour necrosis factor (TNF) and interleukin-6 were measured every 24 h. In addition, production of oxygen radicals was measured in both groups. Findings The mean fever clearance time was 32 h for children treated with paracetamol and 43 h for those who received mechanical antipyresis alone; however, this 11 h difference was not significant (95% CI -2 to 24 h; p=0.176). Parasite clearance time was significantly prolonged in patients who received paracetamol with a difference of 16 h (8-24 h; p=0.004). Plasma concentrations of TNF and interleukin-6 were similar in both groups during the study. However, the induced concentrations of TNF, and the production of oxygen radicals, were significantly lower in children treated with paracetamol than those who received mechanical antipyresis alone. Interpretation These data suggest that paracetamol has no antipyretic benefits over mechanical antipyresis alone in P falciparum malaria. Moreover, paracetamol prolongs parasite clearance time, possibly by decreased production of TNF and oxygen radicals.	UNIV TUBINGEN, INST TROP MED, DEPT PARASITOL, D-72074 TUBINGEN, GERMANY; ALBERT SCHWEITZER HOSP, RES UNIT, LAMBARENE, GABON; UNIV VIENNA, DEPT INFECT DIS, A-1010 VIENNA, AUSTRIA	Eberhard Karls University of Tubingen; University of Vienna				Brandts, Christian H./0000-0003-1732-2535				ADAM D, 1994, EUR J PEDIATR, V153, P394; [Anonymous], 1990, Trans R Soc Trop Med Hyg, V84 Suppl 2, P1; CLARK IA, 1987, J IMMUNOL, V139, P3493; DORAN TF, 1989, J PEDIATR-US, V114, P1045, DOI 10.1016/S0022-3476(89)80461-5; FRIEDMAN A D, 1990, Pediatric Emergency Care, V6, P6, DOI 10.1097/00006565-199003000-00003; JEPSON AP, 1995, J INFECT DIS, V172, P316, DOI 10.1093/infdis/172.1.316; JOHANSSON A, 1989, J LEUKOCYTE BIOL, V45, P444, DOI 10.1002/jlb.45.5.444; KARUNAWEERA ND, 1992, P NATL ACAD SCI USA, V89, P3200, DOI 10.1073/pnas.89.8.3200; Kitchen S. F., 1949, MALARIOLOGY, V2, P966; KLUGER MJ, 1992, LANCET, V339, P70; KRAMER MS, 1991, LANCET, V337, P591, DOI 10.1016/0140-6736(91)91648-E; KREMSNER PG, 1995, ANTIMICROB AGENTS CH, V39, P1603, DOI 10.1128/AAC.39.7.1603; KREMSNER PG, 1988, J INFECT DIS, V158, P1368, DOI 10.1093/infdis/158.6.1368; KREMSNER PG, 1995, AM J TROP MED HYG, V53, P532, DOI 10.4269/ajtmh.1995.53.532; KRISHNA S, 1995, T ROY SOC TROP MED H, V89, P197, DOI 10.1016/0035-9203(95)90494-8; KRISHNA S, 1995, T ROY SOC TROP MED H, V89, P507, DOI 10.1016/0035-9203(95)90087-X; KWIATKOWSKI D, 1995, PARASITOL TODAY, V11, P206, DOI 10.1016/0169-4758(95)80079-4; KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361; KWIATKOWSKI D, 1993, Q J MED, V86, P91; KWIATKOWSKI D, 1989, J EXP MED, V169, P357, DOI 10.1084/jem.169.1.357; KWIATKOWSKI D, 1990, IMMUNOL LETT, V25, P213, DOI 10.1016/0165-2478(90)90117-9; Metzger WG, 1995, T ROY SOC TROP MED H, V89, P637, DOI 10.1016/0035-9203(95)90423-9; Mordmuller BG, 1997, EUR CYTOKINE NETW, V8, P29; NGUYEN HP, 1995, T ROY SOC TROP MED H, V89, P200; Philipps J, 1996, T ROY SOC TROP MED H, V90, P42, DOI 10.1016/S0035-9203(96)90474-5; SHALABY MR, 1989, CLIN IMMUNOL IMMUNOP, V53, P488, DOI 10.1016/0090-1229(89)90010-X; STAMM D, 1994, ARCH PEDIATRIE, V1, P193; TAVERNE J, 1987, CLIN EXP IMMUNOL, V67, P1; TAYLOR TE, 1995, NEW ENGL J MED, V332, P1441, DOI 10.1056/NEJM199505253322110; Waruiru CM, 1996, T ROY SOC TROP MED H, V90, P152, DOI 10.1016/S0035-9203(96)90120-0; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; WILAIRATANA P, 1994, ANN TROP MED PARASIT, V88, P359, DOI 10.1080/00034983.1994.11812877; WILDLING E, 1995, TROP MED PARASITOL, V46, P77; WINKLER S, 1994, TROP MED PARASITOL, V45, P214	34	128	130	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	1997	350	9079					704	709		10.1016/S0140-6736(97)02255-1	http://dx.doi.org/10.1016/S0140-6736(97)02255-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291905				2022-12-28	WOS:A1997XU97700011
J	Basso, MA; Wurtz, RH				Basso, MA; Wurtz, RH			Modulation of neuronal activity by target uncertainty	NATURE			English	Article							FRONTAL EYE FIELD; SUPERIOR COLLICULUS; VISUAL-SEARCH; ATTENTION; SELECTION; MONKEY; CORTEX	Visual scenes are composed of many elements and although we can appreciate a scene as a whole, we can only move our eyes to one element of the scene at a time. As visual scenes become more complex, the number of potential targets in the scene increases, and the uncertainty that any particular one will be selected for an eye movement also increases. How motor systems accommodate this target uncertainty remains unknown. The activities of neurons in both the cerebral cortex(1-5) and superior colliculus(6-8) are modulated by this selection process. We reasoned that activity associated with target uncertainty should be evident in the saccadic motor system at the final stages of neural processing, in the superior colliculus(9,10). By systematically changing the number of stimuli from which a selection must be made and recording from superior colliculus neurons, we found that as the target uncertainty increased,the neural activity preceding target selection decreased. These results indicate that neurons within the final common pathway for movement generation are active well in advance of the selection of a particular movement. This early activity varies with the probability that a particular movement will be selected.			Basso, MA (corresponding author), NEI,SENSORIMOTOR RES LAB,BETHESDA,MD 20892, USA.							BRAVO MJ, 1992, PERCEPT PSYCHOPHYS, V51, P465, DOI 10.3758/BF03211642; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; GOLDBERG ME, 1972, J NEUROPHYSIOL, V35, P560, DOI 10.1152/jn.1972.35.4.560; Kustov AA, 1996, NATURE, V384, P74, DOI 10.1038/384074a0; KUSTOV AA, 1995, SOC NEUR ABSTR, V21, P665; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; Miyashita N, 1996, EXP BRAIN RES, V112, P187; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; MUNOZ DP, 1995, J NEUROPHYSIOL, V73, P2313, DOI 10.1152/jn.1995.73.6.2313; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; SCHALL JD, 1995, J NEUROSCI, V15, P6905; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; SPARKS DL, 1989, NEUROBIOLOGY SACCADI, V3, P213; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0	16	261	263	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					66	69		10.1038/37975	http://dx.doi.org/10.1038/37975			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288967				2022-12-28	WOS:A1997XU59600045
J	Mangione, S; Nieman, LZ				Mangione, S; Nieman, LZ			Cardiac auscultatory skills of internal medicine and family practice trainees - A comparison of diagnostic proficiency	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	62nd Annual Scientific Assembly of the American-College-of-Chest-Physicians	OCT 26-31, 1996	SAN FRANCISCO, CA	Amer Coll Chest Physicians			PHYSICAL-EXAMINATION; MURMURS	Context.-Medical educators have had a growing sense that proficiency in physical diagnostic skills is waning, but few data have examined the question critically. Objective, Design, and Setting.-To compare the cardiac auscultatory proficiency of medical students and physicians in training. A multicenter cross-sectional assessment of students and house staff, A total of 8 internal medicine and 23 family practice programs of the mid-Atlantic area. Participants.-A total of 453 physicians in training and 88 medical students. Interventions.-All participants listened to 12 cardiac events directly recorded from patients, which they identified by completing a multiple-choice questionnaire. Main Outcome Measures.-Scores were expressed as the percentage of participants, for year and type of training, who correctly identified each event, Cumulative scores were expressed as the total number of events correctly recognized, An adjusted score was calculated whenever participants selected not only the correct finding but also findings that are acoustically similar and yet absent. Results.-Trainees' cumulative scores ranged between 0 and 7 for both internal medicine and family practice residents (median, 2.5 and 2.0, respectively), Internal medicine residents had the highest cumulative adjusted scores for the 6 extra sounds and for all 12 cardiac events tested (P=.01 and .02, respectively), On average, internal medicine and family practice residents recognized 20% of all cardiac events; the number of correct identifications improved little with year of training and was not significantly higher than the number identified by medical students. Conclusions.-Both internal medicine and family practice trainees had a disturbingly low identification rate for 12 important and commonly encountered cardiac events. This study suggests a need to improve the teaching and assessment of cardiac auscultation during generalists' training, particularly with the advent of managed care and its search for more cost-effective uses of technology.	ALLEGHENY UNIV HLTH SCI,OFF FAC AFFAIRS,PHILADELPHIA,PA 19129; ALLEGHENY UNIV HLTH SCI,DEPT FAMILY MED,PHILADELPHIA,PA 19129	Drexel University; Drexel University	Mangione, S (corresponding author), ALLEGHENY UNIV HLTH SCI,DEPT MED,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003052] Funding Source: NIH RePORTER; NHLBI NIH HHS [K07 HL03052-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DANFORD DA, 1993, PEDIATRICS, V91, P365; KAUFMAN M, 1991, PHILADELPHIA IN 1027, pC3; KERN DC, 1985, JAMA-J AM MED ASSOC, V254, P70, DOI 10.1001/jama.254.1.70; LEMBO NJ, 1988, NEW ENGL J MED, V318, P1572, DOI 10.1056/NEJM198806163182404; MANGIONE S, 1993, ANN INTERN MED, V119, P47, DOI 10.7326/0003-4819-119-1-199307010-00009; MANGIONE S, 1993, CHEST, V104, pS70; MANGIONE S, IN PRESS ACAD MED; Montagu A., 1986, TOUCHING HUMAN SIGNI; NASSAR ME, 1988, J ROY SOC MED, V81, P501, DOI 10.1177/014107688808100903; PAAUW DS, 1995, JAMA-J AM MED ASSOC, V274, P1380, DOI 10.1001/jama.274.17.1380; PETERSON MC, 1992, WESTERN J MED, V156, P163; RAHKO PS, 1989, ANN INTERN MED, V111, P466, DOI 10.7326/0003-4819-111-6-466; Roldan CA, 1996, AM J CARDIOL, V77, P1327, DOI 10.1016/S0002-9149(96)00200-7; SMITH RC, 1995, J GEN INTERN MED, V10, P315, DOI 10.1007/BF02599950; STCLAIR EW, 1992, ANN INTERN MED, V117, P751, DOI 10.7326/0003-4819-117-9-751; Verrees M, 1996, JAMA-J AM MED ASSOC, V276, P1285, DOI 10.1001/jama.276.16.1285; Westberg J, 1994, Fam Med, V26, P278; WIENER S, 1976, JAMA-J AM MED ASSOC, V236, P852, DOI 10.1001/jama.236.7.852	18	401	411	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					717	722		10.1001/jama.278.9.717	http://dx.doi.org/10.1001/jama.278.9.717			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286830				2022-12-28	WOS:A1997XT70900023
J	LaCombe, MA				LaCombe, MA			Caring for strangers	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					329	330		10.7326/0003-4819-127-4-199708150-00013	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265435				2022-12-28	WOS:A1997XR26600014
J	Jack, DB				Jack, DB			One hundred years of aspirin	LANCET			English	Article											Jack, DB (corresponding author), HILLCREST, 23 SPIERSBRIDGE RD, GLASGOW G46 7SL, LANARK, SCOTLAND.							[Anonymous], 1988, J AM COLL CARDIOL, V12, pA3; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; Dreser M. H., 1970, PFLUGERS ARCH, V76, P306, DOI [10.1007/bf01662127, DOI 10.1007/BF01662127]; Elder DJE, 1996, LANCET, V348, P485, DOI 10.1016/S0140-6736(05)64591-6; Gerhardt C., 1853, LIEBIGS ANN, V87, P149; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Leroux H., 1830, J CHIMIE MED, V6, P341; Lindsay J, 1997, STROKE, V28, P526, DOI 10.1161/01.STR.28.3.526; Maclagan T., 1876, LANCET, V108, P601, DOI [10.1016/S0140-6736(02)49509-8, DOI 10.1016/S0140-6736(02)49509-8]; Mann J., 1992, MURDER MAGIC MED; Piria R., 1838, CR HEBD ACAD SCI, V6, P620; SCHADEWALDT H, 1990, STROKE, V21, P5; SNEADER W, 1985, DRUG DISCOVERY; Stone E., 1763, PHILOS T, V53, P195; Vane J. R., 1992, ASPIRIN OTHER SALICY; WELCH KMA, 1993, NEW ENGL J MED, V329, P1476	16	125	132	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	1997	350	9075					437	439		10.1016/S0140-6736(97)07087-6	http://dx.doi.org/10.1016/S0140-6736(97)07087-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259670				2022-12-28	WOS:A1997XQ24800046
J	Scott, JES; Swallow, V; Coulthard, MG; Lambert, HJ; Lee, REJ				Scott, JES; Swallow, V; Coulthard, MG; Lambert, HJ; Lee, REJ			Screening of newborn babies for familial ureteric reflux	LANCET			English	Article							URINARY-TRACT; VESICOURETERAL REFLUX; INFECTION	Background Vesicoureteric reflux [VUR) is not usually diagnosed until it is complicated by urinary infection, Prevention probably requires diagnosis in a newborn baby before urinary infection occurs because the peak incidence for infection is in early infancy. VUR is a familial disorder. We sought to find out whether an at-risk group of newborn babies could be identified on the basis of the parents' family history. Methods Over a 3-year period, pregnant women attending the antenatal clinics of three hospitals in the northeast of England were screened for evidence of urinary-tract disease in themselves or their families with a view to eliciting a history of VUR. When a woman, her partner, or a member of either family had a definite (by cystography records) or probable positive history, we recruited the mother to our study. Renal ultrasonography and cystography were done on the newborn babies soon after delivery, and a dimercaptosuccinic acid (DMSA] radioisotope scan at 3 months was done on those with VUR. Findings The estimated number of deliveries during the study period was 34 555; 20 891 women were screened; and 211 were recruited and delivered. The index cases were identified from a wide range of family relationships, though over half consisted of mothers and siblings. 19 babies had more than one index case and in 21 families there was one index for more than one baby or a link between families. Cystography was carried out on 186 newborn babies; 38 (20.4%) had VUR. The proportion of newborn babies with VUR among linked index families was 31%, Mothers and siblings amounted to 71% of the index cases-for newborn babies with VUR. The difference between confirmed and assumed index cases in VUR prediction was not significant, The female/male sex ratio among index cases was more than 4, but among newborn babies with VUR it was 1.5, Renal ultrasound showed no correlation with VUR, and ail DMSA scans but one were normal. No newborn baby developed complications resulting from cystography. Interpretation The screening of pregnant women for familial VUR is worthwhile because the frequency of VUR among the newborn babies of those with such a history is significantly higher than in the general population (frequency of VUR 1-2%), particularly if the family history involves more than one member, or more than one generation.	ROYAL VICTORIA INFIRM, DEPT PAEDIAT NEPHROL, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; ROYAL VICTORIA INFIRM, DEPT RADIOL, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND	Newcastle University - UK; Newcastle University - UK	Scott, JES (corresponding author), NO MATERN SURVEY OFF, 25 CLAREMONT PL, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND.		Swallow, Veronica/AAV-2046-2020; swallow, veronica/G-5138-2014	Lambert, Heather/0000-0003-4389-4078; swallow, veronica/0000-0001-8504-4704				AGGARWAL VK, 1989, ARCH DIS CHILD, V64, P1538, DOI 10.1136/adc.64.11.1538; BAILEY RR, 1984, REFLUX NEPHROPATHY U, P102; BREDIN HC, 1975, J UROLOGY, V113, P623, DOI 10.1016/S0022-5347(17)59538-5; ELKHATIB M, 1994, CLIN NEPHROL, V41, P50; ERICSSON N O, 1960, Acta Paediatr, V49, P196, DOI 10.1111/j.1651-2227.1960.tb07722.x; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; KENDA RB, 1992, ARCH DIS CHILD, V67, P506, DOI 10.1136/adc.67.4.506; RANSLEY PG, 1975, UROL RES, V3, P105; RING E, 1988, ARCH DIS CHILD, V63, P818, DOI 10.1136/adc.63.7.818; SCHIMMENTI LA, 1995, AM J MED GENET, V59, P204, DOI 10.1002/ajmg.1320590217; SCOTT JES, 1991, LANCET, V338, P1571, DOI 10.1016/0140-6736(91)92385-F; SMELLIE JM, 1980, MANAGEMENT URINARY T, P29; STEPHENS F D, 1955, Aust N Z J Surg, V24, P192, DOI 10.1111/j.1445-2197.1955.tb05092.x; UEHLING DT, 1992, BRIT J UROL, V69, P534, DOI 10.1111/j.1464-410X.1992.tb15604.x; VERNON S, 1994, LANCET, V344, P612, DOI 10.1016/S0140-6736(94)91996-8	15	55	57	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	1997	350	9075					396	400		10.1016/S0140-6736(97)01515-8	http://dx.doi.org/10.1016/S0140-6736(97)01515-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259653				2022-12-28	WOS:A1997XQ24800009
J	Greenhalgh, T				Greenhalgh, T			How to read a paper - Medline database	BRITISH MEDICAL JOURNAL			English	Article											Greenhalgh, T (corresponding author), UCL, ROYAL FREE HOSP, WHITTINGTON HOSP, DEPT PRIMARY CARE & POPULAT SCI, SCH MED, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; CAMAN D, 1995, BR J GEN P, V45, P485; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; SEEMAN E, 1992, J BONE MINER RES, V7, P1467	4	145	149	4	49	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					180	183		10.1136/bmj.315.7101.180	http://dx.doi.org/10.1136/bmj.315.7101.180			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251552	Green Published			2022-12-28	WOS:A1997XM32100029
J	Graham, JE; Rockwood, K; Beattie, BL; Eastwood, R; Gauthier, S; Tuokko, H; McDowell, I				Graham, JE; Rockwood, K; Beattie, BL; Eastwood, R; Gauthier, S; Tuokko, H; McDowell, I			Prevalence and severity of cognitive impairment with and without dementia in an elderly population	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALZHEIMERS-DISEASE	Background Not all cognitively impaired people have dementia, but those who do not meet current criteria for dementia have received little study. We report a comprehensive estimate of the prevalence of ''cognitive impairment, no dementia'' (CIND) in an elderly population. Methods The Canadian Study of Health and Aging gathered population representation information about elderly Canadians aged 65 and over from 36 cities and surrounding areas in five regions. In each region, the sample size was 1800 people in the community and 250 people in institutions. Patients in the community were screened for cognitive impairment by means of the modified mini-mental state examination. Those who scored below the cut-off point (n=1106) and a randomly selected sample of those who scored above the cut-off point (n=494) were referred for clinical examination. 59 individuals unable to take the screening test were also assessed clinically. We selected 17 long-term care institutions in each region, and then randomly selected consenting residents of these institutions for clinical assessment (n=1255). Results The prevalence of CIND was 16.8%, which was more than all types of dementia combined (8.0%). The prevalence of all types of cognitive impairment, including dementias, increased with age. Patients with CIND were three times more likely to be living in institutions than were cognitively unimpaired patients (odds ratio 3.1 [95% CI 2.4-3.9]). Circumscribed memory loss has a prevalence of 5.3% in the elderly Canadian population, and was the most common category. CIND was related to some degree of functional impairment in elderly patients. Interpretation CIND is commonly associated with functional disability and a need for institutional care. This diagnostic category includes a costly group of disorders that merit further study.	DALHOUSIE UNIV,DIV GERIATR MED,QEII HLTH SCI CTR,HALIFAX,NS B3H 2E1,CANADA; UNIV BRITISH COLUMBIA,DIV GERIATR MED,VANCOUVER,BC V5Z 1M9,CANADA; ST LOUIS UNIV,DEPT PSYCHIAT,ST LOUIS,MO 63103; DOUGLAS HOSP,MCGILL CTR STUDIES AGING,VERDUN,PQ,CANADA; UNIV VICTORIA,CTR AGING,VICTORIA,BC V8W 2Y2,CANADA; UNIV OTTAWA,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON K1N 6N5,CANADA	Dalhousie University; Queen Elizabeth II Health Sciences Centre; University of British Columbia; Saint Louis University; McGill University; University of Victoria; University of Ottawa			Rockwood, Kenneth/AAD-8951-2019	Graham, Janice/0000-0002-6326-8122				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; Birge SJ, 1996, J AM GERIATR SOC, V44, P865, DOI 10.1111/j.1532-5415.1996.tb03749.x; BLACKFORD RC, 1989, DEV NEUROPSYCHOL, V5, P295, DOI 10.1080/87565648909540440; Bowen J, 1997, LANCET, V349, P763, DOI 10.1016/S0140-6736(96)08256-6; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; Cochran W.G., 2007, SAMPLING TECHNIQUES; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; EBLY EM, 1995, ARCH NEUROL-CHICAGO, V52, P612, DOI 10.1001/archneur.1995.00540300086018; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FLICKER C, 1993, J GERIATR PSYCH NEUR, V6, P84, DOI 10.1177/089198879300600205; Graham JE, 1996, NEUROEPIDEMIOLOGY, V15, P246, DOI 10.1159/000109914; Morris JC, 1996, NEUROLOGY, V46, P707, DOI 10.1212/WNL.46.3.707; OSTBYE T, 1994, CAN MED ASSOC J, V151, P1457; Persson G, 1992, J Geriatr Psychiatry Neurol, V5, P172; PFEFFER RI, 1987, AM J EPIDEMIOL, V125, P420, DOI 10.1093/oxfordjournals.aje.a114548; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Rozzini R, 1996, J AM GERIATR SOC, V44, P1025, DOI 10.1111/j.1532-5415.1996.tb02932.x; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; *WRIT COMM, 1996, LANCET, V347, P1303; Zaudig M, 1992, Int Psychogeriatr, V4 Suppl 2, P203; 1994, CMAJ, V150, P899	27	685	725	0	47	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1793	1796		10.1016/S0140-6736(97)01007-6	http://dx.doi.org/10.1016/S0140-6736(97)01007-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XF735	9269213				2022-12-28	WOS:A1997XF73500009
J	Mitler, MM; Miller, JC; Lipsitz, JJ; Walsh, JK; Wylie, CD				Mitler, MM; Miller, JC; Lipsitz, JJ; Walsh, JK; Wylie, CD			The sleep of long-haul truck drivers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ETHANOL	Background Fatigue and sleep deprivation are important safety issues for long-haul truck drivers. Methods We conducted round-the-clock electrophysiologic and performance monitoring of four groups of 20 male truck drivers who were carrying revenue-producing loads. We compared four driving schedules, two in the United States (five 10-hour trips of day driving beginning about the same time each day or of night driving beginning about 2 hours earlier each day) and two in Canada (four 13-hour trips of late-night-to-morning driving beginning at about the same time each evening or of afternoon-to-night driving beginning 1 hour later each day). Results Drivers averaged 5.18 hours in bed per day and 4.78 hours of electrophysiologically verified sleep per day over the five-day study (range, 3.83 hours of sleep for those on the steady 13-hour night schedule to 5.38 hours of sleep for those on the steady 10-hour day schedule). These values compared with a mean (+/-SD) self-reported ideal amount of sleep of 7.1+/-1 hours a day. For 35 drivers (44 percent), naps augmented the sleep obtained by an average of 0.45+/-0.31 hour. No crashes or other vehicle mishaps occurred. Two drivers had undiagnosed sleep apnea, as detected by polysomnography. Two other drivers had one episode each of stage 1 sleep while driving, as detected by electroencephalography. Forty-five drivers (56 percent) had at least 1 six-minute interval of drowsiness while driving, as judged by analysis of video recordings of their faces; 1067 of the 1989 six-minute segments (54 percent) showing drowsy drivers involved just eight drivers. Conclusions Long-haul truck drivers in this study obtained less sleep than is required for alertness on the job. The greatest vulnerability to sleep or sleep-like states is in the late night and early morning. (C) 1997, Massachusetts Medical Society.	SCRIPPS CLIN,LA JOLLA,CA 92037; SLEEP DISORDERS CTR METROPOLITAN TORONTO,TORONTO,ON,CANADA; SLEEP MED & RES CTR,CHESTERFIELD,MO; WYLIE & ASSOCIATES,GOLETA,CA	Scripps Research Institute				Miller, James/0000-0002-3897-8376; Mitler, Merrill/0000-0002-7829-880X	NINDS NIH HHS [R01 NS020459-05] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020459] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BONNET MH, 1991, PRINCIPLES PRACTICE, P50; CARSKADON MA, 1981, PSYCHOPHYSIOLOGY, V18, P107, DOI 10.1111/j.1469-8986.1981.tb02921.x; CARSKADON MA, 1982, SLEEP, V5, pS73, DOI 10.1093/sleep/5.S2.S73; CARSKADON MA, 1994, PRINCIPLES PRACTICE, P16; *CTR NAT TRUCK STA, 1996, UMTRI9640 CTR NAT TR; *DEP TRANSP, 1995, 1995 TRUCK BUS SAF S; Dinges D., 1989, SLEEP ALERTNESS CHRO; DOUGLASS AB, 1994, SLEEP, V17, P160, DOI 10.1093/sleep/17.2.160; FINDLEY L, 1995, CHEST, V108, P619, DOI 10.1378/chest.108.3.619; FROBERG JE, 1985, HOURS WORK TEMPORAL, P67; *GALL ORG, 1997, SLEEP AM, V2; GROSS M, 1996, PUBLICATION VOLPE NA; GUILLEMINAULT C, 1982, SLEEPING WAKING DISO; Knipling RR., 1994, CRASHES FATALITIES R; KRIPKE DF, 1979, ARCH GEN PSYCHIAT, V36, P103; LESSNAU JM, 1991, SLEEP RES, V20, P430; MILLER JC, 1995, BIOL PSYCHOL, V40, P209, DOI 10.1016/0301-0511(95)05114-7; Mitler MM, 1996, BEHAV MED, V21, P171, DOI 10.1080/08964289.1996.9933755; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; *NAT TRANSP SAF BO, 1995, NTSBSS9501, V1; *NIH, 1996, NAT SLEEP DIS RES PL; OHanlon J. F., 1977, VIGILANCE, P87; Rechtschaffen A, 1968, NIH PUBLICATION, V204; ROEHRS T, 1992, ALCOHOL CLIN EXP RES, V16, P553, DOI 10.1111/j.1530-0277.1992.tb01416.x; ROEHRS T, 1993, NEUROPSYCHOPHARMACOL, V9, P239, DOI 10.1038/npp.1993.60; ROSEKIND MR, 1994, CREW FACTORS FLIGHT, V9; SIEGEL S., 1956, NONPARAMETRIC STAT B; Timms R. M., 1988, J POLYSOMNOGRAPH SPR, P13; TORSVALL L, 1987, ELECTROEN CLIN NEURO, V66, P502, DOI 10.1016/0013-4694(87)90096-4; TREAT JR, 1979, PUBLICATION INDIANA; Walczak T., 1994, SLEEP DISORDERS MED, P95; Wilkinson R.T., 1966, PSYCHON SCI, V5, P471, DOI [10.3758/BF03328474, DOI 10.3758/BF03328474]; WINER BJ, 1962, STATISTICAL PRINCIPL; WYLIE D, 1996, COMMERCIAL DRIVER FA	34	239	244	1	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					755	761		10.1056/NEJM199709113371106	http://dx.doi.org/10.1056/NEJM199709113371106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287232	Green Accepted			2022-12-28	WOS:A1997XV17400006
J	Savage, MP; Douglas, JS; Fischman, DL; Pepine, CJ; King, SB; Werner, JA; Bailey, SR; Overlie, PA; Fenton, SH; Brinker, JA; Leon, MB; Goldberg, S				Savage, MP; Douglas, JS; Fischman, DL; Pepine, CJ; King, SB; Werner, JA; Bailey, SR; Overlie, PA; Fenton, SH; Brinker, JA; Leon, MB; Goldberg, S			Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANGIOGRAPHIC FOLLOW-UP; SAPHENOUS-VEIN GRAFTS; ARTERY DISEASE; AORTOCORONARY BYPASS; EXPANDABLE-STENT; IMPLANTATION; SURGERY; MULTICENTER; EXPERIENCE; LESIONS	Background Treatment of stenosis in saphenous-vein grafts after coronary-artery bypass surgery is a difficult challenge. The purpose of this study was to compare the effects of stent placement with those of balloon angioplasty on clinical and angiographic outcomes in patients with obstructive disease of saphenous-vein grafts. Methods A total of 220 patients with new lesions in aortocoronary-venous bypass grafts were randomly assigned to placement of Palmaz-Schatz stents or standard balloon angioplasty. Coronary angiography was performed during the index procedure and six months later. Results As compared with the patients assigned to angioplasty, those assigned to stenting had a higher rate of procedural efficacy, defined as a reduction in stenosis to less than 50 percent of the vessel diameter without a major cardiac complication (92 percent vs. 69 percent, P<0.001), but they had more frequent hemorrhagic complications (17 percent vs. 5 percent, P<0.01). Patients in the stent group had a larger mean (+/-SD) increase in luminal diameter immediately after the procedure (1.92+/-0.30 mm, as compared with 1.21+/-0.37 mm in the angioplasty group; P<0.001) and a greater mean net gain in luminal diameter at six months (0.85+/-0.96 vs. 0.54+/-0.91 mm, P = 0.002). Restenosis occurred in 37 percent of the patients in the stent group and in 46 percent of the patients in the angioplasty group (P = 0.24). The outcome in terms of freedom from death, myocardial infarction, repeated bypass surgery, or revascularization of the target lesion was significantly better in the stent group (73 percent vs. 58 percent, P = 0.03). Conclusions As compared with balloon angioplasty, stenting of selected venous bypass-graft lesions resulted in superior procedural outcomes, a larger gain in luminal diameter, and a reduction in major cardiac events. However, there was no significant benefit in the rate of angiographic restenosis, which was the primary end point of the study. (C) 1997, Massachusetts Medical Society.	EMORY UNIV HOSP,ATLANTA,GA 30322; UNIV FLORIDA,GAINESVILLE,FL; PROVIDENCE SEATTLE MED CTR,SEATTLE,WA; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX; CARDIOL ASSOCIATES LUBBOCK,LUBBOCK,TX; JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21287; WASHINGTON HOSP CTR,WASHINGTON,DC 20010; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; WILLIAM BEAUMONT HOSP,ROYAL OAK,MI 48072; YALE UNIV HOSP,NEW HAVEN,CT; SCRIPPS CLIN,LA JOLLA,CA 92037; JOHNSON & JOHNSON INTERVENT SYST,WARREN,NJ	Emory University; State University System of Florida; University of Florida; University of Texas System; University of Texas Health San Antonio; Johns Hopkins University; Johns Hopkins Medicine; MedStar Washington Hospital Center; Harvard University; Massachusetts General Hospital; Beaumont Health; Yale University; Scripps Research Institute; Johnson & Johnson	Savage, MP (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DIV CARDIOL,SUITE 410,COLL BLDG,1025 WALNUT ST,PHILADELPHIA,PA 19107, USA.							BOCK RD, 1975, MULTIVARIATE STAT ME, P266; BOURASSA MG, 1985, CIRCULATION, V72, P71; BOURASSA MG, 1984, AM J CARDIOL, V53, pC102, DOI 10.1016/0002-9149(84)90759-8; CAMERON A, 1988, CIRCULATION, V78, P158; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; DEFEYTER PIMJ, 1993, J AM COLL CARDIOL, V21, P1539, DOI 10.1016/0735-1097(93)90366-9; DIXON WJ, 1992, BMDP STATISTICAL SOF, V2, P1259; DORROS G, 1984, J THORAC CARDIOV SUR, V87, P17; DOUGLAS JS, 1983, J AM COLL CARDIOL, V2, P745, DOI 10.1016/S0735-1097(83)80315-5; ELLIS SG, 1992, CIRCULATION, V86, P1836, DOI 10.1161/01.CIR.86.6.1836; FENTON SH, 1994, AM J CARDIOL, V74, P1187, DOI 10.1016/0002-9149(94)90545-2; FISCHMAN DL, 1991, J AM COLL CARDIOL, V18, P1445, DOI 10.1016/0735-1097(91)90673-W; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FISCHMAN DL, 1993, DEV CARDIOVASC MED, V137, P553; FITZGIBBON GM, 1991, J AM COLL CARDIOL, V17, P1075, DOI 10.1016/0735-1097(91)90834-V; HAMBY RI, 1979, CIRCULATION, V60, P901, DOI 10.1161/01.CIR.60.4.901; HOLMES DR, 1995, CIRCULATION, V91, P1966, DOI 10.1161/01.CIR.91.7.1966; LAIRDMEETER K, 1987, BRIT HEART J, V57, P427; LAWRIE GM, 1976, AM J CARDIOL, V38, P856, DOI 10.1016/0002-9149(76)90798-0; LEFKOVITS J, 1995, CIRCULATION, V92, P734, DOI 10.1161/01.CIR.92.4.734; LEON MB, 1996, CIRCULATION S1, V94, P683; LOOP FD, 1986, MOD CONC CARDIOV DIS, V55, P31; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; MANCINI GBJ, 1987, CIRCULATION, V75, P452, DOI 10.1161/01.CIR.75.2.452; MANCINI GBJ, 1987, CIRCULATION, V75, P1199; MORICE MC, 1995, CATHETER CARDIO DIAG, V35, P1, DOI 10.1002/ccd.1810350102; PIANA RN, 1994, J AM COLL CARDIOL, V23, P1296, DOI 10.1016/0735-1097(94)90370-0; PLATKO WP, 1989, J AM COLL CARDIOL, V14, P1645, DOI 10.1016/0735-1097(89)90010-7; REEVES F, 1991, AM HEART J, V122, P620, DOI 10.1016/0002-8703(91)90503-A; SAVAGE MP, 1994, J AM COLL CARDIOL, V24, P1207, DOI 10.1016/0735-1097(94)90099-X; SCHAFF HV, 1983, J THORAC CARDIOV SUR, V85, P508; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; STRUMPF RK, 1992, AM HEART J, V123, P1329, DOI 10.1016/0002-8703(92)91041-X; Virmani R, 1988, Cardiovasc Clin, V18, P41; WONG SC, 1995, J AM COLL CARDIOL, V26, P704, DOI 10.1016/0735-1097(95)00217-R	37	413	424	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					740	747		10.1056/NEJM199709113371103	http://dx.doi.org/10.1056/NEJM199709113371103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287229				2022-12-28	WOS:A1997XV17400003
J	Agid, Y; Destee, A; Durif, F; Montastruc, JL; Pollak, P				Agid, Y; Destee, A; Durif, F; Montastruc, JL; Pollak, P			Tolcapone, bromocriptine, and Parkinson's disease	LANCET			English	Article									HOP LILLE,LILLE,FRANCE; HOP FONTMAURE,CHAMALIERES,FRANCE; FAC MED TOULOUSE,TOULOUSE,FRANCE; HOP NORD,GRENOBLE,FRANCE	Universite de Lille - ISITE; CHU Lille; CHU Grenoble Alpes	Agid, Y (corresponding author), HOP LA PITIE SALPETRIERE,INSERM,U289,F-75013 PARIS,FRANCE.							DAVIS TL, 1995, CLIN NEUROPHARMACOL, V18, P333, DOI 10.1097/00002826-199508000-00005; Kurth MC, 1997, NEUROLOGY, V48, P81, DOI 10.1212/WNL.48.1.81; LEWITT PA, 1992, NEUROL CLIN, V10, P511, DOI 10.1016/S0733-8619(18)30224-X; MONTASTRUC JL, 1993, DRUGS, V46, P384, DOI 10.2165/00003495-199346030-00005; TOLOSA ES, 1994, NEUROLOGY, V44, pS35	5	24	24	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					712	713		10.1016/S0140-6736(05)63511-8	http://dx.doi.org/10.1016/S0140-6736(05)63511-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291909				2022-12-28	WOS:A1997XU97700015
J	Paech, K; Webb, P; Kuiper, GGJM; Nilsson, S; Gustafsson, JA; Kushner, PJ; Scanlan, TS				Paech, K; Webb, P; Kuiper, GGJM; Nilsson, S; Gustafsson, JA; Kushner, PJ; Scanlan, TS			Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites	SCIENCE			English	Article							OVARIECTOMIZED RATS; RALOXIFENE; TAMOXIFEN; GENE; IDENTIFICATION; TRANSCRIPTION; ANTIESTROGENS; BONE	The transactivation properties of the two estrogen receptors, ER alpha and ER beta, were examined with different ligands in the context of an estrogen response element and an AP1 element. ER alpha and ER beta were shown to signal in opposite ways when complexed with the natural hormone estradiol from an AP1 site: with ER alpha, 17 beta-estradiol activated transcription, whereas with ER beta, 17 beta-estradiol inhibited transcription, Moreover, the antiestrogens tamoxifen, raloxifene, and imperial Chemical industries 164384 were potent transcriptional activators with ER beta at an AP1 site. Thus, the two ERs signal in different ways depending on ligand and response element, This suggests that ER alpha and ER beta may play different roles in gene regulation.	UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN; KARO BIO AB,NOVUM,S-14157 HUDDINGE,SWEDEN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet					NIGMS NIH HHS [GM 50672] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; GRANDIEN K, UNPUB; JONES CD, 1984, J MED CHEM, V27, P1057, DOI 10.1021/jm00374a021; Katzenellenbogen JA, 1996, CHEM BIOL, V3, P529, DOI 10.1016/S1074-5521(96)90143-X; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KULPER GGJ, 1996, P NATL ACAD SCI USA, V93, P5925; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; PAECH K, UNPUB; RYLANDER T, UNPUB; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	22	1926	2012	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1508	1510		10.1126/science.277.5331.1508	http://dx.doi.org/10.1126/science.277.5331.1508			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278514				2022-12-28	WOS:A1997XV42900041
J	Guo, F; Gopaul, DN; VanDuyne, GD				Guo, F; Gopaul, DN; VanDuyne, GD			Structure of Cre recombinase complexed with DNA in a site-specific recombination synapse	NATURE			English	Article							HOLLIDAY JUNCTION; INTEGRASE FAMILY; ESCHERICHIA-COLI; PROTEIN; LOXP; BINDING; MICE; TYROSINE; HOMOLOGY; STRANDS	During site-specific DMA recombination, which brings about genetic rearrangement in processes such as viral integration and excision and chromosomal segregation, recombinase enzymes recognize specific DNA sequences and catalyse the reciprocal exchange of DNA strands between these sites. The bacteriophage recombinase Cre catalyses site-specific recombination between two 34-base-pair loxP sites. The crystal structure at 2.4 Angstrom resolution of Cre bound to aloxP substrate reveals an intermediate in the recombination reaction, fin which a Cre molecule has cleaved the substrate to form a covalent 3'-phosphotyrosine linkage with the DNA. Four recombinases and two loxP sites form a synapsed structure in which the DNA resembles models of four-way Holliday-junction intermediates. The Cre-loxP complex challenges models of site-specific recombination that require large changes in quaternary structure. Subtle allosteric changes at the carboxy termini of the Cre subunits may instead coordinate the cleavage and strand-exchange reactions.	UNIV PENN,SCH MED,JOHNSON RES FDN,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			Guo, Feng/HIK-3259-2022	GOPAUL, Deshmukh/0000-0003-1631-3303				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Arciszewska L, 1997, EMBO J, V16, P3731, DOI 10.1093/emboj/16.12.3731; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Azaro MA, 1997, EMBO J, V16, P3744, DOI 10.1093/emboj/16.12.3744; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; BLAKELY GW, 1996, MOL MICROBIOL, V20, P233; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P93; Leslie A. G. W., 1991, CCP4 STUDY WEEKEND, P80; METZGER D, 1995, P NATL ACAD SCI USA, V92, P6991, DOI 10.1073/pnas.92.15.6991; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; QIAN XH, 1990, J BIOL CHEM, V265, P21779; QIN MM, 1994, P NATL ACAD SCI USA, V91, P1706, DOI 10.1073/pnas.91.5.1706; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SIGAL N, 1972, J MOL BIOL, V71, P789, DOI 10.1016/S0022-2836(72)80039-1; STARK WM, 1995, TRENDS GENET, V11, P121; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STERNBERG N, 1981, COLD SPRING HARB SYM, V1, P297; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tsurushita N, 1996, GENE, V172, P59, DOI 10.1016/0378-1119(96)00170-9; VanDuyne GD, 1996, J MOL BIOL, V256, P377, DOI 10.1006/jmbi.1996.0093; ZOU YR, 1994, CURR BIOL, V4, P1099, DOI 10.1016/S0960-9822(00)00248-7	50	459	518	2	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					40	46		10.1038/37925	http://dx.doi.org/10.1038/37925			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288963				2022-12-28	WOS:A1997XU59600037
J	Takizawa, PA; Sil, A; Swedlow, JR; Herskowitz, I; Vale, RD				Takizawa, PA; Sil, A; Swedlow, JR; Herskowitz, I; Vale, RD			Actin-dependent localization of an RNA encoding a cell-fate determinant in yeast	NATURE			English	Article							MESSENGER-RNA; MICROFILAMENTS; MICROTUBULES; OOCYTES; MYOSIN; ASH1P; MOVE	The cytoplasmic localization of messenger RNA creates an asymmetric distribution of proteins that specify cell fate during development in multicellular eukaryotes(1,2). The protein Ash1 is a cell-fate determinant in budding yeast which localizes preferentially to the presumptive daughter nucleus, where it inhibits mating-type switching(3'4). Here we show that Ash1 mRNA is localized to the distal tip of daughter buds in post-anaphase cells. Three-dimensional imaging reveals that Ash1 mRNA is assembled into particles that associate with the cell cortex, To achieve this localization, Ash1 mRNA must have its 3' untranslated region and the actin cytoskeleton must be intact, Ash1 mRNA is not localized correctly in the absence of a myosin (Myo4) and is mislocalized to the mother-bud neck in the absence of a regulator of the actin cytoskeleton known as Bni1. We propose that Ash1 mRNA particles are transported into the daughter bud along actin filaments and are anchored at the distal tip. Thus, as in higher eukaryotes, Saccharomyces cerevisiae employs RNA localization to generate an asymmetric distribution of proteins and hence to determine cell fate.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOL PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Swedlow, Jason/0000-0002-2198-1958				ADAMS A E M, 1991, P729; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; [Anonymous], 1997, DECONVOLUTION IMAGES; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	17	310	314	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					90	93		10.1038/38015	http://dx.doi.org/10.1038/38015			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288973				2022-12-28	WOS:A1997XU59600051
J	Zimmerman, MD; Appadurai, K; Scott, JG; Jellett, LB; Garlick, FH				Zimmerman, MD; Appadurai, K; Scott, JG; Jellett, LB; Garlick, FH			Survival	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							WERNICKES ENCEPHALOPATHY; VOLUNTARY		ROYAL BRISBANE HOSP, BRISBANE, QLD 4029, AUSTRALIA	Royal Brisbane & Women's Hospital	Zimmerman, MD (corresponding author), PATAN HOSP, BOX 252, Kathmandu, NEPAL.		Scott, James G/D-5900-2012; Appadurai, Kanaganayagam/A-3419-2016	Scott, James G/0000-0002-0744-0688; Appadurai, Kanaganayagam/0000-0002-6097-0223				ALLEYNE GAO, 1977, PROTEIN ENERGY MALNU, P93; APOVIAN CM, 1990, CRIT CARE MED, V18, P1030, DOI 10.1097/00003246-199009000-00021; *BIBLE, 1 KINGS, V19; DEVATHASAN G, 1982, LANCET, V2, P1108; DRENICK EJ, 1966, NEW ENGL J MED, V274, P937, DOI 10.1056/NEJM196604282741705; FALZI G, 1990, FORENSIC SCI INT, V47, P17, DOI 10.1016/0379-0738(90)90281-3; FELIG P, 1970, NEW ENGL J MED, V282, P166; FROMMEL D, 1984, LANCET, V1, P1451, DOI 10.1016/S0140-6736(84)91941-X; GLASSMAN J, 1983, CANC SURVIVORS; HANDLER CE, 1982, LANCET, V2, P771; HEATH D, 1981, MAN HIGH ALTITUDE PA, P216; HERMAN JL, 1992, TRAUMA RECOVERY, P57; HOFFER LJ, 1988, MODERN NUTRITION HLT, P774; KAHANA E, 1988, HUMAN ADAPTATION EXT, P55; KNOCHEL JP, 1985, KIDNEY INT, V27, P489, DOI 10.1038/ki.1985.37; LINDBERG MC, 1990, AM FAM PHYSICIAN, V41, P1205; OCONNOR A, 1988, MED SCI LAW, V28, P62, DOI 10.1177/002580248802800115; OCONNOR LR, 1977, NEW ENGL J MED, V297, P901, DOI 10.1056/NEJM197710272971702; PEARLIN L, 1978, FAMILY STRESS COPING, P109; PENTLAND B, 1982, POSTGRAD MED J, V58, P427, DOI 10.1136/pgmj.58.681.427; ROCHE SW, 1988, ANN NEUROL, V23, P312, DOI 10.1002/ana.410230320; ROUD PC, 1986, INT J PSYCHIAT MED, V16, P113, DOI 10.2190/H72W-0PPX-HXT3-WP44; SHIMIZU H, 1991, J MED, V22, P201; Siegel BS., 1986, LOVE MED MIRACLES LE; SKELTON WP, 1989, POSTGRAD MED, V85, P301; SOARES MJ, 1991, EUR J CLIN NUTR, V45, P363; SOLOMON SM, 1990, JPEN-PARENTER ENTER, V14, P90, DOI 10.1177/014860719001400190; SOUBA W, 1988, MODERN NUTR HLTH DIS, P1314; STEIN S, 1989, GERONTOLOGIST, V29, P224, DOI 10.1093/geront/29.2.224; Victor M., 1989, WERNICKE KORSAKOFF S, V2nd; WATERSTON JA, 1986, MED J AUSTRALIA, V145, P154, DOI 10.5694/j.1326-5377.1986.tb113778.x	31	5	5	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					405	409		10.7326/0003-4819-127-5-199709010-00013	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273834				2022-12-28	WOS:A1997XU10000012
J	Greenhalgh, T				Greenhalgh, T			How to read a paper - Papers that report drug trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREDICTING PROGRESSION; PLACEBO; SURVIVAL; MARKERS; AIDS				Greenhalgh, T (corresponding author), UCL, ROYAL FREE HOSP SCH MED, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY CARE & POPULAT, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				AICKIN M, 1994, J CELL BIOCH S19, V56, P91; BARDELAY D, 1995, PRESCRIRE INT, V4, P120; Bero LA, 1996, INT J TECHNOL ASSESS, V12, P209, DOI 10.1017/S0266462300009582; BLATT SP, 1995, J INFECT DIS, V171, P837, DOI 10.1093/infdis/171.4.837; BOSTWICK DG, 1994, J CELL BIOCHEM, P283; DESAINTONGE DMC, 1994, LANCET, V344, P995, DOI 10.1016/S0140-6736(94)91647-0; EPSTEIN AE, 1993, JAMA-J AM MED ASSOC, V270, P2451, DOI 10.1001/jama.270.20.2451; Ferner RE, 1996, BRIT MED J, V313, P1157, DOI 10.1136/bmj.313.7066.1157; GOTZSCHE PC, 1994, LANCET, V344, P925; Gotzsche PC, 1996, INT J TECHNOL ASSESS, V12, P238, DOI 10.1017/S0266462300009594; HYATT JM, 1995, CLIN PHARMACOKINET, V28, P143, DOI 10.2165/00003088-199528020-00005; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; JOYCE CRB, 1994, LANCET, V344, P1279, DOI 10.1016/S0140-6736(94)90757-9; KIMBROUGH RD, 1994, CLIN CHEM, V40, P1448; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; LAPORTE JR, 1994, LANCET, V344, P1206, DOI 10.1016/S0140-6736(94)90515-0; LIPICKY RJ, 1993, J AM COLL CARDIOL, V22, pA179, DOI 10.1016/0735-1097(93)90487-L; LIPKIN M, 1994, J CELL BIOCH S19, V56, P94; MCQUAY H, BRIT MED J, V1008, P96; Rothman KJ, 1996, BMJ-BRIT MED J, V313, P3, DOI 10.1136/bmj.313.7048.3a; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, P187; SELIGMANN M, 1994, LANCET, V343, P871; Shaughnessy AF, 1996, BRIT MED J, V312, P1494, DOI 10.1136/bmj.312.7045.1494; THOMAS KB, 1994, LANCET, V344, P1066, DOI 10.1016/S0140-6736(94)91716-7; TSOUKAS CM, 1994, CLIN MICROBIOL REV, V7, P14, DOI 10.1128/CMR.7.1.14-28.1994; 1996, DRUG THER B, V34, P9; 1983, DRUG THER B, V21, P13; 1995, DRUG THER B, V33, P33	29	33	33	1	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	1997	315	7106					480	483		10.1136/bmj.315.7106.480	http://dx.doi.org/10.1136/bmj.315.7106.480			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284672	Green Published			2022-12-28	WOS:A1997XT71400027
J	Madara, JL				Madara, JL			Chameleon within: Improving antigen delivery	SCIENCE			English	Editorial Material							EPITHELIAL-CELLS; CHOLERA-TOXIN; CADHERIN; MICE				Madara, JL (corresponding author), EMORY UNIV,SCH MED,DEPT PATHOL & LAB MED,ATLANTA,GA 30322, USA.							COLGAN SP, 1994, AM J PHYSIOL, V267, pC402, DOI 10.1152/ajpcell.1994.267.2.C402; ELSON CO, 1984, J IMMUNOL, V132, P2736; Fasano A, 1997, J CLIN INVEST, V99, P1158, DOI 10.1172/JCI119271; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; MAYER L, 1987, J EXP MED, V166, P1471, DOI 10.1084/jem.166.5.1471; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; PAPPENHEIMER JR, 1994, P NATL ACAD SCI USA, V91, P1942, DOI 10.1073/pnas.91.5.1942; ZHANG S, 1992, GASTROENTEROLOGY, V103, P1162, DOI 10.1016/0016-5085(92)91499-T	11	24	25	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					910	911		10.1126/science.277.5328.910	http://dx.doi.org/10.1126/science.277.5328.910			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281072				2022-12-28	WOS:A1997XQ98500028
J	Rosenthal, GE; Harper, DL; Quinn, LM; Cooper, GS				Rosenthal, GE; Harper, DL; Quinn, LM; Cooper, GS			Severity-adjusted mortality and length of stay in teaching and nonteaching hospitals - Results of a regional study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACADEMIC-MEDICAL-CENTERS; ACUTE MYOCARDIAL-INFARCTION; INTENSIVE-CARE; RAPID CHANGES; CASE-MIX; OUTCOMES; ILLNESS; COSTS; ADMISSIONS; QUALITY	Context.-Major teaching hospitals are perceived as being more expensive than other hospitals and, thug, unattractive to managed care. However, little empirical data exist about their relative quality and efficiency. The current study compared severity-adjusted mortality and length of stay (LOS) in teaching and nonteaching hospitals. Design.-Retrospective cohort study. Setting.-Thirty hospitals in northeast Ohio. Patients.-A total of 89 851 consecutive eligible patients discharged in 1991 through 1993 with myocardial infarction, congestive heart failure, obstructive airway disease, gastrointestinal hemorrhage, pneumonia, or stroke. Main Outcome Measures.-In-hospital mortality and LOS of patients in major teaching (n=5), minor teaching (n=6), and nonteaching (n=19) hospitals were adjusted for admission severity of illness using multivariable models based on demographic and clinical data abstracted from patients' medical records. Results.-The adjusted odds of death was 19% lower (95% confidence interval [CI]I 2%-34%; P=.03) for patients in major teaching hospitals compared with nonteaching hospitals but was similar (95% CI, 7% lower to 28% higher; P=.28) for patients in minor teaching hospitals. The findings were generally consistent in analyses stratified according to diagnosis, age, race, predicted risk of death, and other covariates. In addition, risk-adjusted LOS was 9% lower (95% CI, 8%-10%; P<.001) among patients in major teaching hospitals relative to nonteaching hospitals but was similar (95% CI, 2% lower to 11% higher; P=.17) in minor teaching hospitals. Major teaching hospitals also cared for higher proportions of nonwhite and poorly insured patients. Conclusions.-Risk-adjusted mortality and LOS were lower for patients in major teaching hospitals than for patients in minor teaching and nonteaching hospitals. If generalizable to other regions, the results provide evidence that hospital performance, as assessed by 2 commonly used indicators, may be higher in major teaching hospitals. These findings are noteworthy at a time when the viability of many major teaching hospitals is threatened by powerful health care market forces and by potential changes in federal financing of graduate medical education.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,CLEVELAND,OH 44106; VET ADM MED CTR,PROGRAM HLTH CARE RES,CLEVELAND,OH; QUAL INFORMAT MANAGEMENT CORP,CLEVELAND,OH	Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rosenthal, GE (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,ROOM WG-37,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.							ASHLEY JSA, 1971, LANCET           DEC, P1308; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BELK HD, 1991, J OCCUP MED, V33, P376; BERMAN RA, 1986, J MED EDUC, V61, P1; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; CAREY WD, 1995, GASTROINTEST ENDOSC, V41, P640; CHASSIN MR, 1989, HEALTH SERV RES, V24, P1; Cooper GS, 1996, GASTROENTEROLOGY, V111, P385, DOI 10.1053/gast.1996.v111.pm8690203; COX JL, 1994, J GEN INTERN MED, V9, P674; EPSTEIN AM, 1995, JAMA-J AM MED ASSOC, V273, P1203, DOI 10.1001/jama.273.15.1203; ESCARCE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2389, DOI 10.1001/jama.264.18.2389; FOREMAN S, 1995, ACAD MED, V70, P510; FRICK AP, 1985, MED CARE, V23, P283, DOI 10.1097/00005650-198504000-00001; GARBER AM, 1984, NEW ENGL J MED, V310, P1231, DOI 10.1056/NEJM198405103101906; GORDON GS, 1991, WESTERN J MED, V155, P616; Gordon HS, 1996, MED CARE, V34, P295, DOI 10.1097/00005650-199604000-00002; Gordon HS, 1996, JAMA-J AM MED ASSOC, V276, P1639, DOI 10.1001/jama.276.20.1639; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HORN SD, 1985, NEW ENGL J MED, V313, P20, DOI 10.1056/NEJM198507043130105; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; *IA HLTH DAT COMM, 1992, IA HOSP RES OUTC REP; IEZZONI LI, 1990, JAMA-J AM MED ASSOC, V264, P1426, DOI 10.1001/jama.264.11.1426; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; IGLEHART JK, 1995, NEW ENGL J MED, V332, P407, DOI 10.1056/NEJM199502093320624; IGLEHART JK, 1988, HEALTH AFFAIR, V7, P79, DOI 10.1377/hlthaff.7.1.79; JAPSEN B, 1994, MOD HEALTHCARE, V7, P36; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; LEE JAH, 1957, LANCET           OCT, P785; LEE JAH, 1960, LANCET           JAN, P170; MILLER MG, 1994, JAMA-J AM MED ASSOC, V271, P1493, DOI 10.1001/jama.271.19.1493; *PA HLTH CAR CONT, 1991, HOSP EFF REP; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; RICHARDS T, 1988, MED CARE, V26, pS1, DOI 10.1097/00005650-198805001-00001; Rosenthal G E, 1997, Am J Med Qual, V12, P103, DOI 10.1177/0885713X9701200204; ROSENTHAL GE, 1994, JOINT COMM J QUAL IM, V20, P425, DOI 10.1016/S1070-3241(16)30088-8; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; UDVARHELYI IS, 1990, AM J PUBLIC HEALTH, V80, P1095, DOI 10.2105/AJPH.80.9.1095; WHITCOMB ME, 1993, ACAD MED, V68, P729, DOI 10.1097/00001888-199310000-00001; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009; 1997, STATA REFERENCE MANU, V3, P145	42	252	253	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					485	490		10.1001/jama.278.6.485	http://dx.doi.org/10.1001/jama.278.6.485			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP243	9256223				2022-12-28	WOS:A1997XP24300030
J	Li, SH; Li, Y; Carthew, RW; Lai, ZC				Li, SH; Li, Y; Carthew, RW; Lai, ZC			Photoreceptor cell differentiation requires regulated proteolysis of the transcriptional repressor Tramtrack	CELL			English	Article							DROSOPHILA EYE DEVELOPMENT; ZINC-FINGER PROTEINS; ETS DOMAIN PROTEIN; FATE DETERMINATION; GENE; PATHWAY; ACTIVATION; BINDING; KINASE; SINA	The transcription repressor Tramtrack (TTK) is found in cone cells but not photoreceptor cells of the Drosophila eye. We show that down-regulation of TTK expression occurs in photoreceptor cells and is required for their fate determination. Down-regulation requires the presence of Phyllopod (PHYL), which is induced by the RAS pathway, and Seven In Absentia (SINA). Loss of either gene causes accumulation of TTK in photoreceptor cells, and TTK does not accumulate in cone cells if both PHYL and SINA are present. We report that SINA and PHYL promote ubiquitination and rapid degradation of TTK by the proteasome pathway in cell culture, and both SINA and PHYL bind to the N-terminal domain of TTK. These results argue that photoreceptor differentiation is regulated by the RAS pathway through targeted proteolysis of the TTK repressor.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260; PENN STATE UNIV,DEPT BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Li, Songhui/AAI-2919-2021		NEI NIH HHS [EY10111] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010111] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Boddy MN, 1996, ONCOGENE, V13, P971; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTHEW RW, 1994, P NATL ACAD SCI USA, V91, P11689, DOI 10.1073/pnas.91.24.11689; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON BJ, 1995, CELL, V80, P543; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Kauffmann RC, 1996, GENE DEV, V10, P2167, DOI 10.1101/gad.10.17.2167; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Maufroid JP, 1996, INT J DEV BIOL, V40, P609; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Seyfert VL, 1996, ONCOGENE, V12, P2331; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; Yamamoto D, 1996, ROUX ARCH DEV BIOL, V205, P215, DOI 10.1007/BF00365799; Zhu AH, 1996, DEVELOPMENT, V122, P1577; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	37	184	187	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					469	478		10.1016/S0092-8674(00)80507-3	http://dx.doi.org/10.1016/S0092-8674(00)80507-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267027	Bronze			2022-12-28	WOS:A1997XQ06300011
J	Scully, R; Chen, JJ; Ochs, RL; Keegan, K; Hoekstra, M; Feunteun, J; Livingston, DM				Scully, R; Chen, JJ; Ochs, RL; Keegan, K; Hoekstra, M; Feunteun, J; Livingston, DM			Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage	CELL			English	Article							ATAXIA-TELANGIECTASIA GENE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; FAMILIAL BREAST; CELL-CYCLE; RECOMBINATION; CHECKPOINTS; CANCER; YEAST; DIFFERENTIATION	BRCA1 localizes to discrete nuclear foci (dots) during S phase. Hydroxyurea-mediated DNA synthesis arrest of S phase MCF7 cells led to a loss of BRCA1 from these structures. Ultraviolet light, mitomycin C, or gamma irradiation produced a similar effect but with no concurrent arrest of DNA synthesis. BARD1 and Rad51, two proteins associated with the BRCA1 dots, behaved similarly. Loss of the BRCA1 foci was accompanied by a specific, dose-dependent change(s) in the state of BRCA1 phosphorylation. Three distinct DNA damaging agents preferentially induced this change in S phase. The S phase BRCA1 phosphorylation response to DNA damage occurred in cells lacking, respectively, two DNA damage-sensing protein kinases, DNA-PK and Atm, implying that neither plays a prime role in this process. Finally, after BRCA1 dot dispersal, BRCA1, BARD1, and Rad51 accumulated, focally, on PCNA(+) replication structures, implying an interaction of BRCA1/BARD1/Rad51 containing complexes with damaged, replicating DNA. Taken together, the data imply that the BRCA1 S phase foci are dynamic physiological elements, responsive to DNA damage, and that BRCA1-containing multiprotein complexes participate in a replication checkpoint response.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; ICOS CORP, BOTHELL, WA 98021 USA; INST GUSTAVE ROUSSY, CNRS, F-94805 VILLEJUIF, FRANCE	Scripps Research Institute; Icos Corporation; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Scully, R (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.		Scully, Ralph/F-5008-2013; Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/BF00352222; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bhatia PK, 1996, CURR OPIN GENET DEV, V6, P146, DOI 10.1016/S0959-437X(96)80043-8; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; FORNACE AJ, 1983, NATURE, V304, P552, DOI 10.1038/304552a0; FRIEDBERG EC, 1995, DNA REPAIR; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	55	787	810	2	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					425	435		10.1016/S0092-8674(00)80503-6	http://dx.doi.org/10.1016/S0092-8674(00)80503-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267023	Bronze			2022-12-28	WOS:A1997XQ06300007
J	Tan, SY; ODonnell, PJ				Tan, SY; ODonnell, PJ			HIV-associated nephropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Tan, SY (corresponding author), UNIV LONDON KINGS COLL HOSP,DENMARK HILL,LONDON SE5 9RS,ENGLAND.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					754	754		10.1056/NEJM199709113371105	http://dx.doi.org/10.1056/NEJM199709113371105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287231				2022-12-28	WOS:A1997XV17400005
J	Serjeant, GR				Serjeant, GR			Sickle-cell disease	LANCET			English	Article							ACUTE CHEST SYNDROME; BONE-MARROW TRANSPLANTATION; ACUTE SPLENIC SEQUESTRATION; RISK-FACTORS; PAINFUL CRISIS; PNEUMOCOCCAL INFECTION; PREPUBERTAL GROWTH; BLOOD-TRANSFUSION; RECURRENT STROKE; NATURAL-HISTORY				Serjeant, GR (corresponding author), UNIV W INDIES,MRC LABS,KINGSTON 7,JAMAICA.							ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; ALAWAMY B, 1984, J PEDIATR-US, V104, P714, DOI 10.1016/S0022-3476(84)80950-6; BALKARAN B, 1992, J PEDIATR-US, V120, P360, DOI 10.1016/S0022-3476(05)80897-2; BAUM KF, 1987, ARCH INTERN MED, V147, P1231, DOI 10.1001/archinte.147.7.1231; BEKLLKET PS, 1995, NEW ENGL J MED, V333, P699; Castro O, 1996, HEMATOL ONCOL CLIN N, V10, P1289, DOI 10.1016/S0889-8588(05)70401-9; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; Chakrabarty A, 1996, J UROLOGY, V155, P1419, DOI 10.1016/S0022-5347(01)66298-0; CHARACHE S, 1995, NEW ENGL J MED, V332, P1217; CHEBLOUNE Y, 1988, P NATL ACAD SCI USA, V85, P4431, DOI 10.1073/pnas.85.12.4431; CHESNEY PJ, 1995, J PEDIATR-US, V127, P526, DOI 10.1016/S0022-3476(95)70107-9; DOUGLAS L, 1990, BRIT J UROL, V65, P533, DOI 10.1111/j.1464-410X.1990.tb14803.x; DOVER GJ, 1994, BLOOD, V84, P339; EMOND AM, 1985, J PEDIATR-US, V107, P201, DOI 10.1016/S0022-3476(85)80125-6; EMRE U, 1995, J PEDIATR-US, V127, P901, DOI 10.1016/S0022-3476(95)70025-0; FALLETTA JM, 1995, J PEDIATR-US, V127, P685, DOI 10.1016/S0022-3476(95)70154-0; Ferster A, 1996, BLOOD, V88, P1960, DOI 10.1182/blood.V88.6.1960.bloodjournal8861960; Fuggle P, 1996, ARCH DIS CHILD, V75, P199, DOI 10.1136/adc.75.3.199; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GAUSCH A, 1996, KIDNEY INT, V49, P786; GERALD B, 1980, AM J ROENTGENOL, V134, P1209, DOI 10.2214/ajr.134.6.1209; GILL FM, 1995, BLOOD, V86, P776, DOI 10.1182/blood.V86.2.776.bloodjournal862776; GRIFFIN TC, 1994, NEW ENGL J MED, V330, P733, DOI 10.1056/NEJM199403173301101; HIGGS DR, 1982, NEW ENGL J MED, V306, P1441, DOI 10.1056/NEJM198206173062402; HOMI J, 1979, BMJ-BRIT MED J, V1, P1599, DOI 10.1136/bmj.1.6178.1599; Howard RJ, 1995, BRIT J OBSTET GYNAEC, V102, P947, DOI 10.1111/j.1471-0528.1995.tb10900.x; Jayabose S, 1996, J PEDIATR-US, V129, P559, DOI 10.1016/S0022-3476(96)70121-X; JOHN AB, 1984, BRIT MED J, V288, P1567, DOI 10.1136/bmj.288.6430.1567; JOHNSON FL, 1984, NEW ENGL J MED, V311, P780, DOI 10.1056/NEJM198409203111207; JURKOVIC D, 1995, HUM REPROD, V10, P1287, DOI 10.1093/oxfordjournals.humrep.a136135; KNIGHT S, 1995, ARCH DIS CHILD, V73, P316, DOI 10.1136/adc.73.4.316; KOSHY M, 1988, NEW ENGL J MED, V319, P1447, DOI 10.1056/NEJM198812013192204; KOSHY M, 1995, BLOOD, V86, P3676, DOI 10.1182/blood.V86.10.3676.bloodjournal86103676; KULOZIK AE, 1986, AM J HUM GENET, V39, P239; Laird L, 1996, BRIT MED J, V313, P407; Lee A, 1995, BRIT MED J, V311, P160; LOPEZ R, 1973, AM J DIS CHILD, V125, P544, DOI 10.1001/archpedi.1973.04160040052011; Lynch AM, 1996, INFECT DIS CLIN N AM, V10, P693, DOI 10.1016/S0891-5520(05)70322-6; MALLOUH AA, 1988, AM J DIS CHILD, V142, P178, DOI 10.1001/archpedi.1988.02150020080034; MILLER ST, 1995, J UROLOGY, V154, P844, DOI 10.1016/S0022-5347(01)67182-9; Moser FG, 1996, AM J NEURORADIOL, V17, P965; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; PONCZ M, 1985, J PEDIATR-US, V107, P861, DOI 10.1016/S0022-3476(85)80176-1; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; POWERS D, 1983, PEDIATRICS, V71, P927; ROBERTSON PL, 1988, ANN NEUROL, V23, P614, DOI 10.1002/ana.410230615; ROGERS DW, 1978, LANCET, V2, P963; RUCKNAGEL DL, 1991, LANCET, V337, P831, DOI 10.1016/0140-6736(91)92525-7; Scott JP, 1996, J PEDIATR-US, V128, P820, DOI 10.1016/S0022-3476(96)70335-9; Serjeant G, 1996, BRIT J HAEMATOL, V92, P143, DOI 10.1046/j.1365-2141.1996.284816.x; Serjeant GR, 1997, BRIT J HAEMATOL, V97, P253, DOI 10.1046/j.1365-2141.1997.02701.x; SERJEANT GR, 1975, CLIN HAEMATOL, V4, P109; SERJEANT GR, 1985, LANCET, V2, P1274; SERJEANT GR, 1981, LANCET, V2, P595; SERJEANT GR, 1994, BRIT J HAEMATOL, V87, P586, DOI 10.1111/j.1365-2141.1994.tb08317.x; SERJEANT GR, 1990, J CLIN PATHOL, V43, P789, DOI 10.1136/jcp.43.10.789; SHAPIRO BS, 1995, PAIN, V61, P139, DOI 10.1016/0304-3959(94)00164-A; SHER GD, 1995, NEW ENGL J MED, V332, P1606, DOI 10.1056/NEJM199506153322404; Singhal A, 1996, ARCH DIS CHILD, V74, P502, DOI 10.1136/adc.74.6.502; SINGHAL A, 1995, ARCH DIS CHILD, V72, P227, DOI 10.1136/adc.72.3.227; Smith JA, 1996, OBSTET GYNECOL, V87, P199, DOI 10.1016/0029-7844(95)00367-3; SPRINKLE RH, 1986, AM J PEDIAT HEMATOL, V8, P105; SPRINKLE RH, 1994, ARCH PEDIAT ADOL MED, V148, P461, DOI 10.1001/archpedi.1994.02170050019004; STEVENS MCG, 1986, PEDIATRICS, V78, P124; TOPLEY JM, 1981, ARCH DIS CHILD, V56, P765, DOI 10.1136/adc.56.10.765; TRUDEL M, 1994, BLOOD, V84, P3189; VANAGTMAEL MA, 1994, ARCH INTERN MED, V154, P557, DOI 10.1001/archinte.154.5.557; VICHINSKY E, 1994, BLOOD, V83, P3107; VICHINSKY EP, 1995, NEW ENGL J MED, V333, P206, DOI 10.1056/NEJM199507273330402; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; Wang WC, 1996, J PEDIAT HEMATOL ONC, V18, P140, DOI 10.1097/00043426-199605000-00008; WANG WC, 1991, J PEDIATR-US, V118, P377, DOI 10.1016/S0022-3476(05)82150-X; WANG XH, 1994, PRENATAL DIAG, V14, P851, DOI 10.1002/pd.1970140914; WEBB DKH, 1989, ARCH DIS CHILD, V64, P693, DOI 10.1136/adc.64.5.693; Williams LL, 1996, J PEDIAT HEMATOL ONC, V18, P257, DOI 10.1097/00043426-199608000-00004; WINTER SS, 1994, J PEDIATR-US, V125, P747, DOI 10.1016/S0022-3476(94)70069-9; Wright J, 1997, J PEDIATR-US, V130, P394, DOI 10.1016/S0022-3476(97)70201-4; ZARKOWSKY HS, 1986, J PEDIATR-US, V109, P579, DOI 10.1016/S0022-3476(86)80216-5	80	194	209	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					725	730		10.1016/S0140-6736(97)07330-3	http://dx.doi.org/10.1016/S0140-6736(97)07330-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291916				2022-12-28	WOS:A1997XU97700043
J	Adami, J; Nyren, O; Bergstrom, R; Ekbom, A; McLaughlin, JK; Hogman, C; Fraumeni, JF; Glimelius, B				Adami, J; Nyren, O; Bergstrom, R; Ekbom, A; McLaughlin, JK; Hogman, C; Fraumeni, JF; Glimelius, B			Blood transfusion and non-Hodgkin lymphoma: Lack of association	ANNALS OF INTERNAL MEDICINE			English	Article						blood transfusion; lymphoma, non-Hodgkin's; case-control studies; leukemia, lymphocytic, chronic; immunosuppression	C VIRUS-INFECTION; POSTOPERATIVE INFECTIONS; CANCER RISK; SELECTION; INCREASE; SURGERY; SWEDEN; WOMEN	Background: Non-Hodgkin lymphoma is the seventh most commonly diagnosed malignant condition worldwide, and its incidence has increased markedly in recent decades. Blood transfusions have been implicated as a possible risk factor for non-Hodgkin lymphoma. Objective: To determine whether blood transfusions are associated with an elevated risk for non-Hodgkin lymphoma. Design: Population-based, nested case-control study. Setting: Nationwide cohort in Sweden. Patients: 361 patients with non-Hodgkin lymphoma and 705 matched controls, nested within a population-based cohort of 96 795 patients at risk for blood transfusion between 1970 and 1983. Prospectively collected information on exposure was retrieved from computerized transfusion registries. Measurements: Odds ratios obtained from conditional logistic regression models were used as measures of relative risks. Results: No association was found between blood transfusions and the risk for non-Hodgkin lymphoma when patients who had received transfusions were compared with patients who had not received transfusions (odds ratio, 0.93 [95% Cf, 0.71 to 1.23]). A reduction in risk was seen among persons who received transfusion of blood without leukocyte depletion (odds ratio, 0.72 [CI, 0.53 to 0.97]). Risk was not related to number of transfusions, and no interaction was seen with latency after transfusion. Conclusion: The findings in this study do not support previous observations of an association between blood transfusions and the risk for non-Hodgkin lymphoma.	INT EPIDEMIOL INST LTD, ROCKVILLE, MD 20850 USA; UPPSALA UNIV, UPPSALA, SWEDEN; NCI, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Uppsala University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	Adami, J (corresponding author), KAROLINSKA INST, DEPT MED EPIDEMIOL, BOX 281, S-17177 STOCKHOLM, SWEDEN.		Adami, Johanna/AAA-3312-2021					Biggar Robert J., 1992, Current Opinion in Oncology, V4, P883, DOI 10.1097/00001622-199210000-00011; BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; BLUMBERG N, 1994, SCI BASIS TRANSFUSIO, P580; Brandt L, 1996, BRIT J CANCER, V73, P1148, DOI 10.1038/bjc.1996.220; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; CARLI PM, 1994, BRIT J CANCER, V70, P713, DOI 10.1038/bjc.1994.380; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; DAVIS W, 1980, STAT METHODS CANC RE, V1; DEVESA SS, 1992, CANCER RES, V52, pS5432; FERRI C, 1994, BRIT J HAEMATOL, V88, P392, DOI 10.1111/j.1365-2141.1994.tb05036.x; FILIPOVICH AH, 1990, NONHODGKINS LYMPHOMA, P135; Hakulinen T, 1986, Acta Pathol Microbiol Immunol Scand Suppl, V288, P1; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; HARRIS NL, 1994, BLOOD, V84, P1361; Hjalgrim H, 1996, BRIT J CANCER, V73, P951, DOI 10.1038/bjc.1996.170; HOGMAN CF, 1970, TRANSFUSION, V10, P121; Izumi T, 1996, BLOOD, V87, P5380, DOI 10.1182/blood.V87.12.5380.bloodjournal87125380; KINLEN L, 1982, CANCER SURV, V1, P565; MARTINSSON U, 1992, ACTA ONCOL, V31, P275, DOI 10.3109/02841869209108173; MEMON A, 1994, INT J CANCER, V58, P366, DOI 10.1002/ijc.2910580310; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MUELLER BU, 1995, J PEDIATR-US, V126, P1, DOI 10.1016/S0022-3476(95)70491-4; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; Nilsson A C, 1994, Lakartidningen, V91, P603; Nilsson AC, 1994, LAKARTIDNINGEN, V91, P603; NYREN O, 1995, JNCI-J NATL CANCER I, V87, P28, DOI 10.1093/jnci/87.1.28; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; PENN I, 1988, CANCER DETECT PREV, V12, P39; Pioltelli P, 1996, LANCET, V347, P624, DOI 10.1016/S0140-6736(96)91328-8; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; *SWED CANC REG, 1996, CANC INC SWED; TARTTER PI, 1988, BRIT J SURG, V75, P789, DOI 10.1002/bjs.1800750822; TARTTER PI, 1989, TRANSFUSION, V29, P456, DOI 10.1046/j.1537-2995.1989.29589284149.x; TARTTER PI, 1993, BEITR INFUS, V31, P52; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; TRIULZI DJ, 1990, TRANSFUSION MEDICINE IN THE 1990S, P1; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1042, DOI 10.1093/oxfordjournals.aje.a116398; ZHENG TZ, 1992, CANCER, V70, P840, DOI 10.1002/1097-0142(19920815)70:4&lt;840::AID-CNCR2820700420&gt;3.0.CO;2-I	41	31	32	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					365	+		10.7326/0003-4819-127-5-199709010-00004	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273827				2022-12-28	WOS:A1997XU10000004
J	Laor, A; Stevenson, DK; Shemer, J; Gale, R; Seidman, DS				Laor, A; Stevenson, DK; Shemer, J; Gale, R; Seidman, DS			Size at birth, maternal nutritional status in pregnancy, and blood pressure at age 17: population based analysis	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; FETAL INFLUENCES; WEIGHT; HYPERTENSION; CHILDHOOD; GROWTH; ADOLESCENCE; CHILDREN; INFANTS; WOMEN	Objective: To assess the effect of size at birth, maternal nutrition, and body mass index on blood pressure in late adolescence. Design: Population based analysis of birth weight corrected for gestational age, mother's weight before pregnancy and weight gain in pregnancy, obtained from the Jerusalem perinatal study, and blood pressure and body mass index at age 17, available from military draft records. Setting: Jerusalem, Israel. Subjects: 10 883 subjects (6684 men and 4199 women) born in Jerusalem during 1974-6 and subsequently drafted to the army. Main outcome measures: Systolic and diastolic blood pressures measured at age 17 and their correlation with birth weight, size at birth, mother's body mass index and weight gain during pregnancy, and height and weight at age 17. Results: Systolic and diastolic blood pressures were significantly and positively correlated with body weight, height, body mass index at age 17, and with mother's body weight and body mass index before pregnancy, but not with birth weight or mother's weight gain in pregnancy. Conclusion: Variables reflecting poor intrauterine nutrition, including low maternal body mass index before pregnancy, poor maternal weight gain in pregnancy, and being born small for gestational age, were not associated with a higher blood pressure in late adolescence.	CHAIM SHEBA MED CTR,DEPT OBSTET & GYNECOL,IL-52621 TEL HASHOMER,ISRAEL; CARMEL HOSP,DEPT INTERNAL MED,HAIFA,ISRAEL; STANFORD UNIV,SCH MED,DEPT PEDIAT,STANFORD,CA 94305; TEL AVIV UNIV,SACKLER SCH MED,CHAIM SHEBA MED CTR,DEPT INTERNAL MED,TEL HASHOMER,ISRAEL; BIKUR CHOLIM HOSP,DEPT NEONATOL,JERUSALEM,ISRAEL	Chaim Sheba Medical Center; Clalit Health Services; Carmel Medical Center; Stanford University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine								BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; CAMBELL DM, 1996, BRIT J OBSTET GYNAEC, V103, P273; DANN PM, 1985, ACTA PAEDIATR SC   S, V319, P7; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; Forrester TE, 1996, BRIT MED J, V312, P156; GODFREY KM, 1994, BRIT J OBSTET GYNAEC, V101, P398, DOI 10.1111/j.1471-0528.1994.tb11911.x; HARLAP S, 1979, NEW ENGL J MED, V300, P1445, DOI 10.1056/NEJM197906283002601; HARLAP S, 1977, ISRAEL J MED SCI, V13, P1073; HARLAP S, 1978, PILLS BIRTHS JERUSAL; JONES DW, 1994, J HYPERTENS, V12, P1433, DOI 10.1097/00004872-199412000-00018; KARK JD, 1986, ISRAEL J MED SCI, V12, P318; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW C, 1995, J HUM HYPERTENS, V9, P649; LAW CM, 1994, J HYPERTENS, V12, P1329; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Lindsay CA, 1997, OBSTET GYNECOL, V89, P377, DOI 10.1016/S0029-7844(96)00517-0; LUCAS A, 1994, BRIT MED J, V309, P302; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; SEIDMAN DS, 1989, OBSTET GYNECOL, V74, P240; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	26	88	94	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					449	453		10.1136/bmj.315.7106.449	http://dx.doi.org/10.1136/bmj.315.7106.449			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284660	Green Published			2022-12-28	WOS:A1997XT71400014
J	Mayaud, P				Mayaud, P			Tackling bacterial vaginosis and HIV in developing countries	LANCET			English	Editorial Material							SEXUALLY-TRANSMITTED DISEASES; INFECTION				Mayaud, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT INFECT & TROP DIS,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			MAYAUD, Philippe/0000-0001-5730-947X				COHEN CR, 1995, AIDS, V9, P1093, DOI 10.1097/00002030-199509000-00017; Govender L, 1996, INT J GYNECOL OBSTET, V55, P23, DOI 10.1016/0020-7292(96)02744-0; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HILLIER SH, 1990, SEXUALLY TRANSMITTED; LAGA M, 1994, AIDS S1, V8, pS119; Ledru S, 1996, SEX TRANSM DIS, V23, P151, DOI 10.1097/00007435-199603000-00011; Mayaud P, 1995, B WORLD HEALTH ORGAN, V73, P621; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001	10	13	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					530	531		10.1016/S0140-6736(97)22034-9	http://dx.doi.org/10.1016/S0140-6736(97)22034-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284769				2022-12-28	WOS:A1997XT22100002
J	Pearlman, M; Faix, R				Pearlman, M; Faix, R			No rush to obliterate genital tract colonisation in pregnant women	LANCET			English	Editorial Material							INFECTIONS; BIRTH		UNIV MICHIGAN,CTR MED,DEPT PAEDIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Pearlman, M (corresponding author), UNIV MICHIGAN,CTR MED,DEPT OBSTET & GYNAECOL,ANN ARBOR,MI 48109, USA.							BARTLETT JG, 1977, J INFECT DIS, V136, P271, DOI 10.1093/infdis/136.2.271; ESCHENBACH DA, 1991, AM J OBSTET GYNECOL, V164, P734, DOI 10.1016/0002-9378(91)90506-M; HALL RT, 1976, AM J OBSTET GYNECOL, V124, P630, DOI 10.1016/0002-9378(76)90065-X; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; Krohn MA, 1997, J INFECT DIS, V175, P606, DOI 10.1093/infdis/175.3.606; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; MEIS PJ, 1995, AM J OBSTET GYNECOL, V173, P1231, DOI 10.1016/0002-9378(95)91360-2; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8	8	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					531	532		10.1016/S0140-6736(05)63133-9	http://dx.doi.org/10.1016/S0140-6736(05)63133-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284770				2022-12-28	WOS:A1997XT22100003
J	Walma, EP; Hoes, AW; vanDooren, C; Prins, A; vanderDoes, E				Walma, EP; Hoes, AW; vanDooren, C; Prins, A; vanderDoes, E			Withdrawal of long term diuretic medication in elderly patients: a double blind randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION; THERAPY; RISK	Objectives: About 20% of elderly people use long term diuretic medication, but there is doubt whether prolonged diuretic medication on such a large scale is necessary. The performed a study to assess what proportion may successfully be withdrawn from diuretic therapy. Design: Double blind randomised controlled trial with six month follow up. Setting: General practice. Subjects: 202 patients taking long term diuretics without manifest heart failure or hypertension. Interventions: Patients were allocated to either placebo (withdrawal group, n=102) or continuation of diuretic treatment (control group, n = 100). Main outcome measure: Occurrence of clinical conditions requiring diuretic therapy based on fixed criteria. Results: During follow up diuretic therapy was required in 50 patients in the withdrawal group and 13 in the control group (risk difference 36%; 95% confidence interval 22% to 50%). Heart failure was The most frequent cause of prescribing diuretic therapy (n = 25). Cessation of diuretic therapy caused a mean increase in systolic blood pressure of 13.5 (9.2 to 17.8) mm Hg and in diastolic pressure of 4.6 (1.9 to 7.3) mm Hg. Conclusion: Withdrawal of long term diuretic treatment in elderly patients leads to symptoms of heart failure or increase in blood pressure to hypertensive values in most cases. Any attempt to withdraw diuretic therapy requires careful monitoring conditions, notably during the initial four weeks.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam	Walma, EP (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT GEN PRACTICE, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							BURR M L, 1977, Age and Ageing, V6, P38; Cartwright A, 1988, ELDERLY PEOPLE THEIR; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; FINK A, 1987, JAMA-J AM MED ASSOC, V258, P1905, DOI 10.1001/jama.258.14.1905; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GRINSTEAD WC, 1994, AM J CARDIOL, V73, P881; HOES AW, 1995, ANN INTERN MED, V123, P481, DOI 10.7326/0003-4819-123-7-199510010-00001; KONSTAM M, 1994, HEART FAILURE EVALUA; McInnes Gordon T., 1992, P491; Mosterd A, 1997, EUR J EPIDEMIOL, V13, P491; Myers M G, 1982, Age Ageing, V11, P213, DOI 10.1093/ageing/11.4.213; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; STEWART RB, 1991, J CLIN EPIDEMIOL, V44, P1353, DOI 10.1016/0895-4356(91)90096-R; WALMA EP, 1995, J HUM HYPERTENS, V9, P169; WALMA EP, 1995, HUISARTS WET, V38, P300; *WORKSH PHARM TREA, 1993, PHARM TREATM HEART F	19	78	82	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	1997	315	7106					464	468		10.1136/bmj.315.7106.464	http://dx.doi.org/10.1136/bmj.315.7106.464			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284668	Green Published			2022-12-28	WOS:A1997XT71400023
J	Sorensen, HT; Sabroe, S; Olsen, J; Rothman, KJ; Gillman, MW; Fischer, P				Sorensen, HT; Sabroe, S; Olsen, J; Rothman, KJ; Gillman, MW; Fischer, P			Birth weight and cognitive function in young adult life: historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							INFANTS	Objective: To examine the relation between birth weight and cognitive function in young adult life. Design: Retrospective cohort study based on birth registry data and cognitive function measured during evaluation for military service. Subjects: 4300 Danish conscripts born between 1973 and 1975. Main outcome measures: Mean score in the Boerge Prien test of cognitive function; score is the number of correct answers to 78 questions and correlates with full scale intelligence quotient (IQ). Results: Mean score in the Boerge Prien test increased from 39.9 at a birth weight of less than or equal to 2500 g to 44.6 at a birth weight of 4200 g even after adjustment for gestational age and length at birth, maternal age and parity and other variables. Above a birth weight of 4200 g the test score decreased slightly. Conclusion: Birth weight is associated with cognitive performance in young adult life, Interference with fetal growth may influence adult cognitive performance.	AARHUS UNIV HOSP,DEPT INTERNAL MED 5,DK-8000 AARHUS C,DENMARK; BOSTON UNIV,SCH MED,DEPT EPIDEMIOL & PREVENT MED,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02215; HARVARD PILGRIM HLTH CARE,BOSTON,MA 02215; CONSCRIPT ADM,COUNTY N JUTLAND,DK-9000 AALBORG,DENMARK	Aarhus University; Boston University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care			Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Rothman, Kenneth/0000-0003-2398-1705				Barker D. J. P., 1994, MOTHERS BABIES DIS L; ELARDO R, 1975, CHILD DEV, V46, P71; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; LANTING CI, 1994, LANCET, V344, P1319, DOI 10.1016/S0140-6736(94)90692-0; Martyn CN, 1996, BRIT MED J, V312, P1393; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; Mortensen EL, 1989, SCAND J PSYCHOL, V30, P3115; OLSEN J, 1994, SCAND J SOC MED, V22, P213, DOI 10.1177/140349489402200310; Osofsky H J, 1975, Obstet Gynecol Surv, V30, P227, DOI 10.1097/00006254-197504000-00001; TEMBOURY MC, 1994, J PEDIATR GASTR NUTR, V18, P32, DOI 10.1097/00005176-199401000-00005	10	164	168	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					401	403		10.1136/bmj.315.7105.401	http://dx.doi.org/10.1136/bmj.315.7105.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR549	9277604	Green Published			2022-12-28	WOS:A1997XR54900020
J	Nakamura, TM; Morin, GB; Chapman, KB; Weinrich, SL; Andrews, WH; Lingner, J; Harley, CB; Cech, TR				Nakamura, TM; Morin, GB; Chapman, KB; Weinrich, SL; Andrews, WH; Lingner, J; Harley, CB; Cech, TR			Telomerase catalytic subunit homologs from fission yeast and human	SCIENCE			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; TETRAHYMENA TELOMERASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; IMMORTAL CELLS; DNA; RNA; SEQUENCES; CANCER; GENES	Catalytic protein subunits of telomerase from the ciliate Euplotes aediculatus and the yeast Saccharomyces cerevisiae contain reverse transcriptase motifs. Here the homologous genes from the fission yeast Schizosaccharomyces pombe and human are identified. Disruption of the S. pombe gene resulted in telomere shortening and senescence, and expression of mRNA from the human gene correlated with telomerase activity in cell lines. Sequence comparisons placed the telomerase proteins in the reverse transcriptase family but revealed hallmarks that distinguish them from retroviral and retrotransposon relatives. Thus, the proposed telomerase catalytic subunits are phylogenetically conserved and represent a deep branch in the evolution of reverse transcriptases.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; GERON CORP,MENLO PK,CA 94025	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Geron Corporation			Morin, Gregg B/E-9123-2012; Nakamura, Toru M/B-2055-2008	Morin, Gregg B/0000-0001-8949-4374; Nakamura, Toru M/0000-0001-5752-0814; Lingner, Joachim/0000-0002-2853-5803	NIGMS NIH HHS [GM28039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028039, R01GM028039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C., 1993, EXPT FISSION YEAST; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, IN PRESS P NATL ACAD; Eickbush Thomas H., 1994, P121; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P4673; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1996, DNA REPLICATION EUKA, P619; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Javerzat JP, 1996, NUCLEIC ACIDS RES, V24, P4676, DOI 10.1093/nar/24.23.4676; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lendvay TS, 1996, GENETICS, V144, P1399; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEVIS RW, 1993, CELL, V75, P1; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Pardue ML, 1996, TRENDS GENET, V12, P48, DOI 10.1016/0168-9525(96)81399-0; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; Ricchetti M, 1996, BIOCHEMISTRY-US, V35, P14970, DOI 10.1021/bi961274v; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHANG MQ, 1994, NUCLEIC ACIDS RES, V22, P1750, DOI 10.1093/nar/22.9.1750	41	2007	2186	3	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					955	959		10.1126/science.277.5328.955	http://dx.doi.org/10.1126/science.277.5328.955			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252327				2022-12-28	WOS:A1997XQ98500042
J	Greenhalgh, T				Greenhalgh, T			How to read a paper - Statistics for the non-statistician .1. Different types of data need different statistical tests	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BASIC STATISTICS; CLINICIAN				Greenhalgh, T (corresponding author), UCL, WHITTINGTON HOSP, ROYAL FREE HOSP SCH MED, DEPT PRIMARY CARE & POPULAT, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				Altman DG., 1995, PRACTICAL STAT MED R; [Anonymous], 1988, BRIT MED J, V296, P320; Bland M, 1987, INTRO MED STAT; *CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53; GUYATT G, 1995, CAN MED ASSOC J, V152, P497; GUYATT G, 1995, CAN MED ASSOC J, V152, P169; GUYATT G, 1995, CAN MED ASSOC J, V152, P27; HUGHES MD, 1988, STAT MED, V7, P1231, DOI 10.1002/sim.4780071204; JAENSCHKE R, 1995, CAN MED ASSOC J, V152, P351; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Stewart LA, 1996, INT J TECHNOL ASSESS, V12, P264, DOI 10.1017/S0266462300009612	11	49	51	0	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 9	1997	315	7104					364	366						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270463				2022-12-28	WOS:A1997XQ86400028
J	Murray, TS; Campbell, LM				Murray, TS; Campbell, LM			Finance, not learning needs, makes general practitioners attend courses: a database survey	BRITISH MEDICAL JOURNAL			English	Article											Murray, TS (corresponding author), W SCOTLAND POSTGRAD MED EDUC BOARD,GLASGOW G12 9LX,LANARK,SCOTLAND.							*DEP HLTH WELSH OF, 1989, GEN PRACT NAT HLTH S; McKnight A, 1996, BRIT J GEN PRACT, V46, P679; MURRAY TS, 1993, BRIT J GEN PRACT, V43, P467; MURRAY TS, 1993, BRIT J GEN PRACT, V43, P19; MURRAY TS, 1992, POSTGRAD ED GEN PRAC, V3, P62	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					353	353						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270459				2022-12-28	WOS:A1997XQ86400024
J	DiDonato, JA; Hayakawa, M; Rothwarf, DM; Zandi, E; Karin, M				DiDonato, JA; Hayakawa, M; Rothwarf, DM; Zandi, E; Karin, M			A cytokine-responsive I kappa B kinase that activates the transcription factor NF-kappa B	NATURE			English	Article							ALPHA PROTEOLYSIS; PHOSPHORYLATION; FAMILY; DISSOCIATION; DEGRADATION; SUFFICIENT; PROTEINS; RECEPTOR; DOMAIN	Nuclear transcription factors of the NF-kappa B/Rel family are inhibited by I kappa B proteins, which inactivate NF-kappa B by trapping it in the cell cytoplasm. Phosphorylation of I kappa Bs marks them out for destruction, thereby relieving their inhibitory effect on NF-kappa B. A cytokine-activated protein kinase complex, IKK (for I kappa B kinase), has now been purified that phosphorylates I kappa Bs on the sites that trigger their degradation. A component of IKK was molecularly cloned and identified as a serine kinase. IKK turns out to be the long-sought-after protein kinase that mediates the critical regulatory step In NF-kappa B activation.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LAB GENE REGULAT & SIGNAL TRANSDUCT,LA JOLLA,CA 92093	University of California System; University of California San Diego			Hazen, Stanley L/ABD-5845-2021					ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CAO Z, 1996, SCIENCE, V383, P443; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	31	1845	1946	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					548	554		10.1038/41493	http://dx.doi.org/10.1038/41493			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252186	Bronze			2022-12-28	WOS:A1997XP72200039
J	Miyawaki, A; Llopis, J; Heim, R; McCaffery, JM; Adams, JA; Ikura, M; Tsien, RY				Miyawaki, A; Llopis, J; Heim, R; McCaffery, JM; Adams, JA; Ikura, M; Tsien, RY			Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin	NATURE			English	Article							ENDOPLASMIC-RETICULUM; POINT MUTATIONS; INTACT-CELLS; 2 SERIES; BINDING; AEQUORIN; SITES	Important Ca2+ signals in the cytosol and organelles are often extremely localized and hard to measure. To overcome this problem we have constructed new fluorescent indicators for Ca2+ that are genetically encoded without cofactors and are targetable to specific intracellular locations. We have dubbed these fluorescent indicators 'cameleons', They consist of tandem fusions of a blue-or cyan-emitting mutant of the green fluorescent protein (GFP)(1,2), calmodulin(3-5), the calmodulin-binding peptide M13 (ref, 6), and an enhanced green-or yellow-emitting GFP(7-9). Binding of Ca2+ makes calmodulin wrap around the M13 domain, increasing the fluorescence resonance energy transfer (FRET) between the flanking GFPs(2), Calmodulin mutations can tune the Ca2+ affinities to measure free Ca2+ concentrations in the range 10(-8) to 10(-2) M, We have visualized free Ca2+ dynamics in the cytosol, nucleus and endoplasmic reticulum of single HeLa cells transfected with complementary DNAs encoding chimaeras bearing appropriate localization signals, Ca2+ concentration in the endoplasmic reticulum of individual cells ranged from 60 to 400 mu M at rest, and 1 to 50 mu M after Ca2+ mobilization, FRET is also an indicator of the reversible intermolecular association of cyan-GFP-labelled calmodulin with yellow-GFP-labelled M13, Thus FRET between GFP mutants can monitor localized Ca2+ signals and protein heterodimerization in individual live cells.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; SAN DIEGO STATE UNIV, DEPT CHEM, SAN DIEGO, CA 92182 USA; UNIV TORONTO, ONTARIO CANC INST, DIV MOL & STRUCT BIOL, TORONTO, ON M5G 2M9, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5G 2M9, CANADA; UNIV TSUKUBA, CTR TSUKUBA ADV RES ALLIANCE, TSUKUBA, IBARAKI 305, JAPAN	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; California State University System; San Diego State University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba			Miyawaki, Atsushi/K-3569-2014; Wood, David W/B-2992-2012; Llopis, Juan/I-2622-2012	Miyawaki, Atsushi/0000-0002-2329-3235; Llopis, Juan/0000-0002-9460-0642; Ikura, Mitsuhiko/0000-0002-9524-1303				Adams S.R., 1993, FLUORESCENT PROBES B, P133; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; BRINI M, 1994, CELL CALCIUM, V16, P259, DOI 10.1016/0143-4160(94)90089-2; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; Bygrave FL, 1996, CELL CALCIUM, V19, P547, DOI 10.1016/S0143-4160(96)90064-0; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; GAO ZH, 1993, J BIOL CHEM, V268, P20096; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; Kendall JM, 1996, BIOCHEM J, V318, P383, DOI 10.1042/bj3180383; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Martin SR, 1996, BIOCHEMISTRY-US, V35, P3508, DOI 10.1021/bi952522a; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PORUMB T, 1994, PROTEIN ENG, V7, P109, DOI 10.1093/protein/7.1.109; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; SMIT MJ, 1993, EUR J PHARM-MOLEC PH, V247, P223, DOI 10.1016/0922-4106(93)90082-K; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	30	2410	2596	21	789	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					882	887		10.1038/42264	http://dx.doi.org/10.1038/42264			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278050	Bronze			2022-12-28	WOS:A1997XT75400051
J	Arnow, PM; Flaherty, JP				Arnow, PM; Flaherty, JP			Fever of unknown origin	LANCET			English	Article							UNDETERMINED ORIGIN; PROLONGED FEVER; CHANGING SPECTRUM; STILLS DISEASE; FOLLOW-UP; DIAGNOSIS; INFECTION; ADULT; SCINTIGRAPHY; CHILDREN				Arnow, PM (corresponding author), UNIV CHICAGO HOSP,DEPT MED,INFECT DIS SECT,CHICAGO,IL 60637, USA.							ADUAN RP, 1979, ANN INTERN MED, V90, P230, DOI 10.7326/0003-4819-90-2-230; AHMANN DL, 1966, CANCER-AM CANCER SOC, V19, P461, DOI 10.1002/1097-0142(196604)19:4<461::AID-CNCR2820190402>3.0.CO;2-X; BARBADO FJ, 1992, POSTGRAD MED J, V68, P884, DOI 10.1136/pgmj.68.805.884; BISSUEL F, 1994, J INTERN MED, V236, P529, DOI 10.1111/j.1365-2796.1994.tb00840.x; BRUSCH JL, 1988, MED CLIN N AM, V72, P1247, DOI 10.1016/S0025-7125(16)30739-8; CHANG JC, 1984, AM J MED, V76, P597, DOI 10.1016/0002-9343(84)90283-3; COHEN JI, 1985, MEDICINE, V64, P100, DOI 10.1097/00005792-198503000-00003; COPPER GS, 1994, CLIN INFECT DIS, V19, P146; CRONIN RE, 1976, MEDICINE, V55, P291, DOI 10.1097/00005792-197607000-00002; Cunha BA, 1996, INFECT DIS CLIN N AM, V10, P33, DOI 10.1016/S0891-5520(05)70284-1; DEKLEIJN EMHA, 1995, ARCH INTERN MED, V155, P1989, DOI 10.1001/archinte.155.18.1989; deKleijn EMHA, 1997, NETH J MED, V50, P69, DOI 10.1016/S0300-2977(96)00086-1; DEKLEIJN EMHA, 1995, NETH J MED, V47, P54, DOI 10.1016/0300-2977(95)00037-N; ESPOSITO AL, 1979, ARCH INTERN MED, V139, P575, DOI 10.1001/archinte.139.5.575; HAMILTON CR, 1971, MEDICINE, V50, P1, DOI 10.1097/00005792-197101000-00001; HOWARD P, 1977, TEX MED, V73, P56; IIKUNI Y, 1994, INTERNAL MED, V33, P67, DOI 10.2169/internalmedicine.33.67; JACOBY GA, 1973, NEW ENGL J MED, V289, P1407, DOI 10.1056/NEJM197312272892607; KANZANJIAN P, 1992, CLIN INFECT DIS, V15, P968; KLASTERSKY J, 1973, EUR J CANCER, V9, P649, DOI 10.1016/0014-2964(73)90007-8; Knockaert DC, 1996, ARCH INTERN MED, V156, P618, DOI 10.1001/archinte.156.6.618; KNOCKAERT DC, 1993, J AM GERIATR SOC, V41, P1187, DOI 10.1111/j.1532-5415.1993.tb07301.x; KNOCKAERT DC, 1993, MEDICINE, V72, P184; KNOCKAERT DC, 1994, CLIN INFECT DIS, V18, P601, DOI 10.1093/clinids/18.4.601; KNOCKAERT DC, 1992, ARCH INTERN MED, V152, P51, DOI 10.1001/archinte.152.1.51; LARSON EB, 1984, MEDICINE, V63, P82, DOI 10.1097/00005792-198403000-00002; LARSON EB, 1982, MEDICINE, V61, P269, DOI 10.1097/00005792-198209000-00001; LOHR JA, 1977, CLIN PEDIATR, V16, P768, DOI 10.1177/000992287701600905; LUFT FC, 1976, AM J MED SCI, V272, P65, DOI 10.1097/00000441-197607000-00008; MAARTENS G, 1990, AM J MED, V89, P291, DOI 10.1016/0002-9343(90)90340-J; MACKOWIAK PA, 1987, ANN INTERN MED, V106, P728, DOI 10.7326/0003-4819-106-5-728; MCCLUNG HJ, 1972, AM J DIS CHILD, V124, P544, DOI 10.1001/archpedi.1972.02110160082009; MITCHELL DP, 1977, ARCH INTERN MED, V137, P1001, DOI 10.1001/archinte.137.8.1001; Peters AM, 1996, EUR J NUCL MED, V23, P239, DOI 10.1007/BF00837620; PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001; PETERSDORF RG, 1992, ARCH INTERN MED, V152, P21, DOI 10.1001/archinte.152.1.21; PIZZO PA, 1975, PEDIATRICS, V55, P468; PONCEDELEONROSALES S, 1994, CLIN INFECT DIS, V19, P353, DOI 10.1093/clinids/19.2.353; QUINN MJ, 1980, RADIOLOGY, V136, P407, DOI 10.1148/radiology.136.2.7403516; Raoult D, 1996, ANN INTERN MED, V125, P646, DOI 10.7326/0003-4819-125-8-199610150-00004; ROWLAND MD, 1987, J INFECT DIS, V156, P408, DOI 10.1093/infdis/156.2.408; RUBIN RH, 1989, NEW ENGL J MED, V321, P935, DOI 10.1056/NEJM198910053211404; SHEON RP, 1963, AM J MED, V34, P486, DOI 10.1016/0002-9343(63)90072-X; SHOJI S, 1994, INTERNAL MED, V33, P74, DOI 10.2169/internalmedicine.33.74; SOLISHERRUZO JA, 1981, ENDOSCOPY, V13, P207, DOI 10.1055/s-2007-1021685; SYRJALA MT, 1987, J NUCL MED, V28, P155; WOUTERS JMGW, 1986, Q J MED, V61, P1055	47	183	190	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					575	580		10.1016/S0140-6736(97)07061-X	http://dx.doi.org/10.1016/S0140-6736(97)07061-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284789				2022-12-28	WOS:A1997XT22100044
J	Walker, SS; Shen, WC; Reese, JC; Apone, LM; Green, MR				Walker, SS; Shen, WC; Reese, JC; Apone, LM; Green, MR			Yeast TAF(II)145 required for transcription of G1/S cyclin genes and regulated by the cellular growth state	CELL			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; ACTIVATION; COMPLEX; KINASE; CELLS; TRANSITION; MITOSIS; TARGETS	TFIID comprises the TATA box-binding protein and a set of highly conserved associated factors (TAF(II)s). yTAF(II)145, the core subunit of the yeast TAF(II) complex, is dispensable for transcription of most yeast genes but specifically required for progression through G1/S. Here we show that transcription of G1 and certain B-type cyclin genes is dependent upon yTAF(II)145. At high cell density or following nutrient deprivation, yeast cells cease division, enter a G(0)-like state, and terminate transcription of most genes. In this stationary phase, we find that the levels of yTAF(II)145, several other yTAF(II)s, and TBP are drastically reduced. Collectively, our results indicate that yTAF(II)145 and other TFIID components have a specialized role in transcriptional regulation of cell cycle progression and growth control.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIA LL, 1979, MOL GEN GENET, V170, P137, DOI 10.1007/BF00337788; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Guthrie C, 1991, GUIDE YEAST GENETICS; Harlow E., 1988, ANTIBODIES LAB MANUA; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; Hung DT, 1996, CHEM BIOL, V3, P623, DOI 10.1016/S1074-5521(96)90129-5; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLENK HP, 1994, CURR BIOL, V4, P920, DOI 10.1016/S0960-9822(00)00206-2; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LIU HT, 1985, J BIOL CHEM, V260, P3269; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; Moore DD, 1995, GLOB MOB SURV; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; POON D, 1993, J BIOL CHEM, V268, P15325; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SIKORSKI RS, 1989, GENETICS, V122, P19; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	46	125	125	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					607	614		10.1016/S0092-8674(00)80522-X	http://dx.doi.org/10.1016/S0092-8674(00)80522-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288741	Bronze			2022-12-28	WOS:A1997XT06600005
J	Wilson, PWF; Hoeg, JM; DAgostino, RB; Silbershatz, H; Belanger, AM; Poehlmann, H; OLeary, D; Wolf, PA				Wilson, PWF; Hoeg, JM; DAgostino, RB; Silbershatz, H; Belanger, AM; Poehlmann, H; OLeary, D; Wolf, PA			Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ARTERY WALL THICKNESS; ELEVATED SERUM-CHOLESTEROL; RISK FACTOR; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR HEALTH; ATHEROSCLEROSIS RISK; OLDER PERSONS; FRAMINGHAM; LIPOPROTEIN	Background Single measurements of cardiovascular risk factors may not accurately reflect a person's past exposure to those risk factors. We therefore studied the long-term associations of cardiovascular risk factors such as high serum cholesterol levels, high blood pressure, and cigarette smoking with the prevalence of carotid stenosis. Methods We studied cross-sectional and longitudinal information from a sample of 429 men and 661 women in the Framingham Heart Study who underwent B-mode ultrasound measurements of the carotid artery. Their mean age was 75 years, and each had attended most of the biennial clinic examinations over the 34 years before the carotid ultrasound study. We used time-integrated measurements to assess the associations between various cardiovascular risk factors and the degree of carotid stenosis. Results Moderate carotid stenosis (greater than or equal to 25 percent) was present in 189 men and 226 women. We assessed the odds ratios for this degree of stenosis as compared with minimal stenosis (<25 percent) according to increases in risk factors. In the men, the odds ratio for moderate carotid stenosis associated with an increase of 20 mm Hg in systolic blood pressure was 2.11 (95 percent confidence interval, 1.51 to 2.97). The odds ratio for an increase of 10 mg per deciliter (0.26 mmol per liter) in the cholesterol level was 1.10 (95 percent confidence interval, 1.03 to 1.16), and for an increase of five pack-years of smoking it was 1.03 (95 percent confidence interval, 1.03 to 1.13). The results were similar in the women. Time-integrated measurements of diastolic blood pressure showed significant associations with carotid stenosis in men and insignificant associations in women. Conclusions Over the long term, high systolic blood pressure, high cholesterol levels, and smoking were associated with an increased risk of carotid stenosis in this elderly population. (C) 1997, Massachusetts Medical Society.	NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; TUFTS UNIV, MED CTR, DEPT RADIOL, MEDFORD, MA 02155 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Tufts University	Wilson, PWF (corresponding author), NHLBI, FRAMINGHAM HEART STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA.		Wilson, Peter W.F./J-2455-2016	Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [5R01-NS17950] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELL LL, 1952, J BIOL CHEM, V195, P357; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1995, Lancet, V345, P209; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BROWN SA, 1993, ARTERIOSCLER THROMB, V13, P1558, DOI 10.1161/01.ATV.13.11.1558; COOPER GR, 1992, JAMA-J AM MED ASSOC, V267, P1652, DOI 10.1001/jama.267.12.1652; COOPER GR, 1994, CLIN CHEM, V40, P227; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; CROUSE JR, 1995, AM J CARDIOL, V75, P862; FABRIS F, 1994, STROKE, V25, P1133, DOI 10.1161/01.STR.25.6.1133; FOLSOM AR, 1994, STROKE, V25, P66, DOI 10.1161/01.STR.25.1.66; GORDON T, 1977, JAMA-J AM MED ASSOC, V238, P497, DOI 10.1001/jama.238.6.497; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; HOEG JM, 1994, ARTERIOSCLER THROMB, V14, P1066, DOI 10.1161/01.ATV.14.7.1066; HOEG JM, 1994, JAMA-J AM MED ASSOC, V271, P543, DOI 10.1001/jama.271.7.543; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; KANNEL WB, 1981, JAMA-J AM MED ASSOC, V245, P1225, DOI 10.1001/jama.245.12.1225; KANNEL WB, 1979, LANCET, V2, P950; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P124; KRITCHEVSKY SB, 1995, CIRCULATION, V92, P2142, DOI 10.1161/01.CIR.92.8.2142; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; *NAT CHOL ED PROGR, 1988, CLIN CHEM, V34, P193; O'Leary D H, 1992, Ann Epidemiol, V2, P147, DOI 10.1016/1047-2797(92)90049-V; OLeary DH, 1996, STROKE, V27, P224, DOI 10.1161/01.STR.27.2.224; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; PERSSON J, 1994, ARTERIOSCLER THROMB, V14, P261, DOI 10.1161/01.ATV.14.2.261; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; Schmidt HHJ, 1996, AM J CARDIOL, V77, P575, DOI 10.1016/S0002-9149(97)89309-5; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; Sidhu P S, 1996, J Cardiovasc Risk, V3, P61, DOI 10.1097/00043798-199602000-00009; Stamler J, 1989, Hypertension, V13, pI2; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TELL GS, 1994, CIRCULATION, V90, P2905, DOI 10.1161/01.CIR.90.6.2905; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WILSON PWF, 1994, J GERONTOL, V49, pM252, DOI 10.1093/geronj/49.6.M252; WILSON PWF, 1995, ARCH INTERN MED, V155, P2146; WILSON PWF, 1993, AM J GERIATR CARDIOL, V2, P52	46	202	210	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					516	522		10.1056/NEJM199708213370802	http://dx.doi.org/10.1056/NEJM199708213370802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262494				2022-12-28	WOS:A1997XR54800002
J	Ray, P; Black, S; Shinefield, H; Dillon, A; Schwalbe, J; Holmes, S; Hadler, S; Chen, R; Cochi, S; Wassilak, S				Ray, P; Black, S; Shinefield, H; Dillon, A; Schwalbe, J; Holmes, S; Hadler, S; Chen, R; Cochi, S; Wassilak, S			Risk of chronic arthropathy among women after rubella vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RHEUMATOID-ARTHRITIS; PROLONGED ARTHRITIS; JOINT REACTIONS; PREGNANCY; IMMUNIZATION; ASSOCIATION; VIREMIA	Context.-A review by the institute of Medicine found a possible relationship between rubella vaccination and chronic arthritis among women. Objective.-To evaluate the risk of persistent joint and neurologic symptoms in rubella seronegative women subsequently vaccinated with RA 27/3 rubella vaccine. Design.-Retrospective cohort study based on computerized laboratory data and medical record review. Records were reviewed for symptoms occurring within 2 years before and after the date of serological testing and to identify vaccinees. Possible cases were evaluated by a rheumatologist blinded to serological findings and vaccination status. Setting.-Large health maintenance organization in northern California. Patients.-Women aged 15 to 59 years serotested for rubella during 1990 with continuous health plan membership for 2 years before and after the date of their serological test. Seronegative women immunized within 1 year of serotesting (n=971) were defined as exposed. Primary comparison groups included all unvaccinated, seronegative women (n=924) and randomly selected, seropositive, unvaccinated women (n=2421) matched to exposed subjects on serological test date and age (+/-3 years). Main Outcome Measures.-Prevalence and incidence of chronic joint and neurologic symptoms during 1-year follow-up period stratified by age and serological findings, immunization, and postpartum status. Results.-No significantly increased risk was associated with receipt of rubella vaccine for any outcome except for prevalence of carpal tunnel syndrome in vaccinated women at least 30 years old compared with seropositive, unvaccinated women (2.9% vs 1.4%; P=.03), A total of 34 women had onset of conditions within the 1-year follow-up period; 9 of these were in the group of seronegative, immunized women, of whom 6 had onset of symptoms within 6 weeks of vaccination. Among these 6 women, symptoms included transient arthritis or arthralgias (6 weeks duration) in 4 women, arthralgia of indeterminate chronicity in 1 woman, and carpal tunnel syndrome in 1 woman. Postpartum women across all groups were less likely to be seen for nontraumatic arthropathies than nonpostpartum women (4.5% vs 7.2%, P=.08 in vaccinated women; 4.8% vs 8.1%, P=.09 in seronegative controls; and 4.8% vs 10.0%, P=.01 in seropositive controls). Conclusions.-In this large retrospective cohort analysis there was no evidence of any increased risk of new onset chronic arthropathies or neurologic conditions in women receiving the RA 27/3 rubella vaccine. These data support the continued vaccination of rubella-susceptible women to reduce the risk of congenital rubella syndrome.	NO CALIF KAISER PERMANENTE VACCINE STUDY CTR, OAKLAND, CA USA; EASTERN VIRGINIA MED SCH, CTR PEDIAT RES, NORFOLK, VA 23501 USA; CTR DIS CONTROL & PREVENT, NATL IMMUNIZAT PROGRAM, ATLANTA, GA 30333 USA	Kaiser Permanente; Eastern Virginia Medical School; Centers for Disease Control & Prevention - USA								*CDC, 1990, MMWR-MORBID MORTAL W, V39, P10; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P329; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; DASILVA JAP, 1992, CLIN RHEUMATOL, V11, P189, DOI 10.1007/BF02207955; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; FREY T, 1994, J INFECT DIS, V170, P507; HOWSON CP, 1992, CLIN INFECT DIS, V15, P307, DOI 10.1093/clinids/15.2.307; *I MED, 1991, ADV EFF PERT RUB VAC; KAPLAN KM, 1990, AM J DIS CHILD, V144, P118, DOI 10.1001/archpedi.1990.02150250130050; LANSINK M, 1993, CLIN EXP RHEUMATOL, V11, P171; LERMAN SJ, 1971, ANN INTERN MED, V74, P67, DOI 10.7326/0003-4819-74-1-67; LINOS A, 1980, AM J EPIDEMIOL, V111, P87, DOI 10.1093/oxfordjournals.aje.a112878; MITCHELL LA, 1993, ARCH INTERN MED, V153, P2268, DOI 10.1001/archinte.153.19.2268; MORTONKUTE L, 1985, ANN INTERN MED, V102, P563, DOI 10.7326/0003-4819-102-4-563_3; NEELY NT, 1977, TEX MED, V73, P59; OSTENSEN M, 1983, SCAND J RHEUMATOL, V12, P69, DOI 10.3109/03009748309102886; OSTENSEN M, 1983, ARTHRITIS RHEUM, V26, P1155, DOI 10.1002/art.1780260915; PELTOLA H, 1986, LANCET, V1, P939; Persellin R H, 1976, Bull Rheum Dis, V27, P922; POLK BF, 1982, AM J EPIDEMIOL, V115, P19, DOI 10.1093/oxfordjournals.aje.a113276; SCHUMACHER HR, 1993, PRIMER RHEUMATIC DIS, P328; SILMAN AJ, 1986, ANN RHEUM DIS, V45, P1031, DOI 10.1136/ard.45.12.1031; SLATER PE, 1995, VACCINE, V13, P1529, DOI 10.1016/0264-410X(95)00096-J; SPRUANCE SL, 1977, ARTHRITIS RHEUM, V20, P741, DOI 10.1002/art.1780200216; THOMPSON GR, 1971, ARTHRITIS RHEUM, V14, P19, DOI 10.1002/art.1780140104; THOMPSON GR, 1973, AM J DIS CHILD, V125, P526, DOI 10.1001/archpedi.1973.04160040040008; TINGLE AJ, 1983, INFECT IMMUN, V40, P22, DOI 10.1128/IAI.40.1.22-28.1983; TINGLE AJ, 1985, J INFECT DIS, V152, P606, DOI 10.1093/infdis/152.3.606; TINGLE AJ, 1986, ANN RHEUM DIS, V45, P110, DOI 10.1136/ard.45.2.110; TINGLE AJ, 1984, LANCET, V1, P1475; VALENSIN PE, 1987, VACCINE, V5, P289, DOI 10.1016/0264-410X(87)90154-X	31	57	60	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					551	556		10.1001/jama.278.7.551	http://dx.doi.org/10.1001/jama.278.7.551			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268275				2022-12-28	WOS:A1997XQ98600028
J	Bottaci, L; Drew, PJ; Hartley, JE; Hadfield, MB; Farouk, R; Lee, PWR; Macintyre, IMC; Duthie, GS; Monson, JRT				Bottaci, L; Drew, PJ; Hartley, JE; Hadfield, MB; Farouk, R; Lee, PWR; Macintyre, IMC; Duthie, GS; Monson, JRT			Artificial neural networks applied to outcome prediction for colorectal cancer patients in separate institutions	LANCET			English	Article							MYOCARDIAL-INFARCTION; SURVIVAL ANALYSIS; CENSORED-DATA; CLASSIFICATION; BREAST	Background Artificial neural networks are computer programs that can be used to discover complex relations within data sets. They permit the recognition of patterns in complex biological data sets that cannot be detected with conventional linear statistical analysis. One such complex problem is the prediction of outcome for individual patients treated for colorectal cancer. Predictions of outcome in such patients have traditionally been based on population statistics. However, these predictions have little meaning for the individual patient. We report the training of neural networks to predict outcome for individual patients from one institution and their predictive performance on data from a different institution in another region. Methods 5-year follow-up data from 334 patients treated for colorectal cancer were used to train and validate six neural networks designed for the prediction of death within 9, 12, 15, 18, 21, and 24 months. The previously trained 12-month neural network was then applied to 2-year followup data from patients from a second institution; outcome was concealed. No further training of the neural network was undertaken. The network's predictions were compared with those of two consultant colorectal surgeons supplied with the same data. Findings All six neural networks were able to achieve overall accuracy greater than 80% for the prediction of death for individual patients al institution I within 9, 12, 15, 18, 21, and 24 months. The mean sensitivity and specificity were 60% and 88%. When the neural network trained to predict death within 12 months was applied to data from the second institution, overall accuracy of 90% (95% CI 84-96) was achieved, compared with the overall accuracy of the colorectal surgeons of 79% (71-87) and 75% (66-84). Interpretation The neural networks were able to predict outcome for individual patients with colorectal cancer much more accurately than the currently available clinicopathological methods. Once trained on data from one institution, the neural networks were able to predict outcome for patients from an unrelated institution.	UNIV HULL, ACAD SURG UNIT, CASTLE HILL HOSP, KINGSTON UPON HULL HU16 5JQ, N HUMBERSIDE, ENGLAND; UNIV HULL, KINGSTON UPON HULL HU6 7RX, N HUMBERSIDE, ENGLAND; WESTERN GEN HOSP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Hull; University of Hull; University of Edinburgh			Farouk, Ridzuan/T-5968-2017	Macintyre, Iain/0000-0003-2716-8500; Farouk, Ridzuan/0000-0002-7644-4682				ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BAXT WG, 1994, MED DECIS MAKING, V14, P217, DOI 10.1177/0272989X9401400303; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; Bishop CM., 1995, NEURAL NETWORKS PATT; CARPENTER GA, 1993, P WORLD C NEURAL NET, V1, P501; CLARK GM, 1994, BREAST CANCER RES TR, V32, P105, DOI 10.1007/BF00666211; CROFT DJ, 1974, ANN BIOMED ENG, V2, P69, DOI 10.1007/BF02368087; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; DELAURENTIIS M, 1994, BREAST CANCER RES TR, V32, P113, DOI 10.1007/BF00666212; DELAURENTIIS M, 1994, CANCER LETT, V77, P127, DOI 10.1016/0304-3835(94)90095-7; Downs J, 1996, ARTIF INTELL MED, V8, P403, DOI 10.1016/0933-3657(95)00044-5; DOYE HR, 1994, ANN SURG, V219, P408; Engle Ralph L., 1963, ARCH INTERN MED, V112, P108; ENGLE RL, 1963, ARCH INTERN MED, V112, P512, DOI 10.1001/archinte.1963.03860040108009; FISHER ER, 1989, CANCER, V64, P2354, DOI 10.1002/1097-0142(19891201)64:11<2354::AID-CNCR2820641127>3.0.CO;2-#; Hartman EJ, 1990, NEURAL COMPUT, V2, P210, DOI 10.1162/neco.1990.2.2.210; HORROCKS JC, 1972, BMJ-BRIT MED J, V2, P5, DOI 10.1136/bmj.2.5804.5; JASS JR, 1987, LANCET, V1, P1303; KAPLAN D, 1995, UNDERSTANDING NONLIN; MA Z, 1996, EXPLANATION GEN RULE; Mackay D., 1994, MODELS NEURAL NETWOR; MCGUIRE WL, 1992, J NATL CANCER I MONO, V11, P173; NEWLAND RC, 1994, CANCER, V73, P2076, DOI 10.1002/1097-0142(19940415)73:8<2076::AID-CNCR2820730811>3.0.CO;2-6; RAVDIN PM, 1992, BREAST CANCER RES TR, V22, P285, DOI 10.1007/BF01840841; RAYDIN PM, 1992, BREAST CANCER RES TR, V21, P47, DOI 10.1007/BF01811963; Rumelhart D., 1986, PARALLEL DISTRIBUTED; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Shortliffe, 1984, READINGS MED ARTIFIC; *U STUTTG, STUTTG NEUR NETW SIM	30	138	142	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	1997	350	9076					469	472		10.1016/S0140-6736(96)11196-X	http://dx.doi.org/10.1016/S0140-6736(96)11196-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274582				2022-12-28	WOS:A1997XR13500008
J	Chamberlain, DA; Fox, KAA; Henderson, RA; Julian, DG; Parker, DJ; Pocock, SJ; Meade, TW; Cobbe, SM; Evans, SJW; Hampton, JR; Joy, MD; Holmberg, S; Shaw, DB; Clayton, T; Marley, C; Youard, B; Ilsley, C; Farrel, T; Paul, V; Knight, R; Brooks, N; Bennett, D; Bray, C; Levy, R; Ward, C; Coppinger, T; Pumphrey, C; Brecker, S; Ward, D; Murtagh, AM; Bucknall, C; BrennandRoper, D; Chambers, J; Cooke, R; Jackson, G; Holt, P; Sulke, N; Tan, K; Karani, S; OKeefe, DB; Murtagh, JG; Richardson, SG; Scott, ME; Graffin, S; Balcon, R; Layton, C; Mills, P; Rothman, M; Timmis, A; Atkins, C; Mackintosh, AF; Larkin, H; Lewis, RV; Stoker, JB; Tan, LB; Williams, GJ; Brown, Y; PittsCrick, J; Barnes, E; Boreham, P; ChamberlainWebber, R; Papouchado, M; Halestrap, M; Tagney, J; Swanton, RH; Walker, JM; Firman, E; Reid, D; Adams, PC; Bexton, R; Evemy, K; Furniss, S; Williams, D; McDermott, A; Jewitt, D; Richardson, P; Thomas, M; Wainwright, RJ; Jacob, A; Maurer, B; Buckley, A; Dinn, E; Begley, F; Watson, R; Singh, SP; Cadd, L; Perry, R; Epstein, G; Carey, R; Crean, P; Ghaisas, N; Hughes, D; Dymond, D; Banim, S; Nathan, AW; Spurrell, RAJ; Jones, H; Elstob, J; Gribbin, B; Forfar, C; Ormerod, O; Longney, T; Gray, H; Dawkins, K; Seymour, J; Simpson, I; McGuirk, M; Shiu, MJ; Sugrue, D; Egan, B; Holigan, B				Chamberlain, DA; Fox, KAA; Henderson, RA; Julian, DG; Parker, DJ; Pocock, SJ; Meade, TW; Cobbe, SM; Evans, SJW; Hampton, JR; Joy, MD; Holmberg, S; Shaw, DB; Clayton, T; Marley, C; Youard, B; Ilsley, C; Farrel, T; Paul, V; Knight, R; Brooks, N; Bennett, D; Bray, C; Levy, R; Ward, C; Coppinger, T; Pumphrey, C; Brecker, S; Ward, D; Murtagh, AM; Bucknall, C; BrennandRoper, D; Chambers, J; Cooke, R; Jackson, G; Holt, P; Sulke, N; Tan, K; Karani, S; OKeefe, DB; Murtagh, JG; Richardson, SG; Scott, ME; Graffin, S; Balcon, R; Layton, C; Mills, P; Rothman, M; Timmis, A; Atkins, C; Mackintosh, AF; Larkin, H; Lewis, RV; Stoker, JB; Tan, LB; Williams, GJ; Brown, Y; PittsCrick, J; Barnes, E; Boreham, P; ChamberlainWebber, R; Papouchado, M; Halestrap, M; Tagney, J; Swanton, RH; Walker, JM; Firman, E; Reid, D; Adams, PC; Bexton, R; Evemy, K; Furniss, S; Williams, D; McDermott, A; Jewitt, D; Richardson, P; Thomas, M; Wainwright, RJ; Jacob, A; Maurer, B; Buckley, A; Dinn, E; Begley, F; Watson, R; Singh, SP; Cadd, L; Perry, R; Epstein, G; Carey, R; Crean, P; Ghaisas, N; Hughes, D; Dymond, D; Banim, S; Nathan, AW; Spurrell, RAJ; Jones, H; Elstob, J; Gribbin, B; Forfar, C; Ormerod, O; Longney, T; Gray, H; Dawkins, K; Seymour, J; Simpson, I; McGuirk, M; Shiu, MJ; Sugrue, D; Egan, B; Holigan, B			Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial	LANCET			English	Article							ARTERY DISEASE; SINGLE-VESSEL; MYOCARDIAL-INFARCTION; BALLOON ANGIOPLASTY; SURGERY; SURVIVAL; CASS	Background The role of percutaneous transluminal coronary angioplasty (PTCA) in the management of patients with angina remains controversial, particularly in patients whose symptoms are adequately controlled by medical treatment. Methods RITA-2 is a randomised trial comparing the long-term effects of PTCA and conservative (medical) care in patients with coronary artery disease considered suitable for either treatment option. 1018 patients were recruited from 20 cardiology centres in UK and Ireland. The 504 randomised to PTCA were intended to have dilatation within 3 months. The 514 assigned to medical treatment received antianginal drugs; those whose symptoms were not controlled by optimum medical therapy could cross-over to myocardial revascularisation. The primary endpoint was the combined frequency of death from all causes and definite non-fatal myocardial infarction. Findings This report covers a median 2.7 years' follow-up. At randomisation 53% of patients had grade 2 or worse angina, and 40% had two or more diseased coronary arteries. 93% of patients randomised to PTCA had this procedure carried out, within a median of 5 weeks. Death or definite myocardial infarction occurred in 32 patients (6.3%) treated with PTCA and in 17 patients (3.3%) with medical care (absolute difference 3.0% [95% CI 0.4-5.7%], p=0.02). This difference was mainly due to one death and seven non-fatal myocardial infarctions related to the randomised procedures. There were 18 deaths (11 PTCA, seven medical) of which ten were not due to heart disease. Of the patients in the PTCA group, 40 (7.9%) required coronary artery bypass grafting (CABG), including nine instead of PTCA and seven emergencies following unsuccessful PTCA. 56 other PTCA patients (11.1%) required further non-randomised PTCA. In the medical group 118 patients (23.0%) underwent a revascularisation procedure during follow-up, mostly because of worsening symptoms. Angina improved in both groups, but more so in the PTCA group. There was a 165% absolute excess of grade 2 or worse angina in the medical group 3 months after randomisation (p<0.001), which attenuated to 7.6% after 2 years. Total exercise time (Bruce protocol) also improved in both groups, again with a treatment difference in favour of PTCA: mean advantage of 35 s at 3 months (p<0.001). These benefits of PTCA were greater in patients with more severe angina at baseline, judged by high initial grade of angina and short initial exercise-time. Interpretation In patients with coronary artery disease considered suitable for either PTCA or medical care, early intervention with PTCA was associated with greater symptomatic improvement, especially in patients with more severe angina. When managing individuals with angina, clinicians must balance these benefits against the small excess hazard associated with PTCA due to procedure-related complications.	UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; HAREFIELD HOSP, HAREFIELD UB9 6JH, MIDDX, ENGLAND; WYTHENSHAWE HOSP, MANCHESTER M23 9LT, LANCS, ENGLAND; UNIV LONDON ST GEORGES HOSP, LONDON SW17 0RE, ENGLAND; GUYS HOSP, LONDON SE1 9RT, ENGLAND; BELFAST CITY HOSP, BELFAST BT9 7AD, ANTRIM, NORTH IRELAND; LONDON CHEST HOSP, LONDON E2 9JX, ENGLAND; KILLINGBECK HOSP, LEEDS LS14 6UQ, W YORKSHIRE, ENGLAND; UNIV BRISTOL, BRISTOL ROYAL INFIRM, BRISTOL BS2 8HW, AVON, ENGLAND; MIDDLESEX HOSP, LONDON, ENGLAND; FREEMAN RD HOSP, NEWCASTLE UPON TYNE, TYNE & WEAR, ENGLAND; UNIV LONDON KINGS COLL HOSP, LONDON, ENGLAND; ST VINCENTS HOSP, DUBLIN 4, IRELAND; CITY HOSP, BIRMINGHAM, W MIDLANDS, ENGLAND; BROADGREEN HOSP, LIVERPOOL L14 3LB, MERSEYSIDE, ENGLAND; ST JAMES HOSP, DUBLIN 8, IRELAND; ST BARTHOLOMEWS HOSP, LONDON, ENGLAND; JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND; SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND; WALSGRAVE GEN HOSP, COVENTRY CV2 2DY, W MIDLANDS, ENGLAND; MATER MISERICORDIAE HOSP, DUBLIN 7, IRELAND	University of London; London School of Hygiene & Tropical Medicine; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; St Georges University London; Guy's & St Thomas' NHS Foundation Trust; Belfast City Hospital; University of London; Queen Mary University London; Bristol Royal Infirmary; University of Bristol; University of London; University College London; Newcastle Freeman Hospital; Newcastle University - UK; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University College Dublin; University of Birmingham; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Trinity College Dublin; University of London; Queen Mary University London; University of Oxford; University of Southampton; Mater Misericordiae University Hospital; University College Dublin			Fox, keith A A/I-3742-2013					Abdelmeguid AE, 1996, AM HEART J, V131, P1097, DOI 10.1016/S0002-8703(96)90083-6; ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; Alderman EL, 1996, NEW ENGL J MED, V335, P217; BRUCE R A, 1963, Pediatrics, V32, P742; CALIFF RM, 1983, CIRCULATION, V67, P283, DOI 10.1161/01.CIR.67.2.283; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Davies RF, 1997, CIRCULATION, V95, P2037, DOI 10.1161/01.CIR.95.8.2037; ELLIS SG, 1989, AM HEART J, V118, P208, DOI 10.1016/0002-8703(89)90178-6; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Folland ED, 1997, J AM COLL CARDIOL, V29, P1505, DOI 10.1016/S0735-1097(97)00097-1; GIROUD D, 1992, AM J CARDIOL, V69, P729, DOI 10.1016/0002-9149(92)90495-K; HAMPTON JR, 1993, LANCET, V341, P573; HLATKY MA, 1983, AM J CARDIOL, V52, P225, DOI 10.1016/0002-9149(83)90112-1; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; Jones RH, 1996, J THORAC CARDIOV SUR, V111, P1013, DOI 10.1016/S0022-5223(96)70378-1; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V18, P904, DOI 10.1016/0735-1097(91)90745-U; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEDERSEN TR, 1994, LANCET, V344, P1383; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; RINGQVIST I, 1983, J CLIN INVEST, V71, P1854, DOI 10.1172/JCI110941; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIEVERS B, 1993, CIRCULATION, V88, P297; Sirnes PA, 1996, J AM COLL CARDIOL, V28, P1444, DOI 10.1016/S0735-1097(96)00349-X; Tcheng JE, 1997, LANCET, V349, P1422; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	30	405	416	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	1997	350	9076					461	468						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274581				2022-12-28	WOS:A1997XR13500007
J	Irving, JB				Irving, JB			Psychosocial rehabilitation for patients recovering from acute myocardial infarction	LANCET			English	Editorial Material											Irving, JB (corresponding author), ST JOHNS HOSP,DEPT CARDIOL,EDINBURGH EH54 6PP,MIDLOTHIAN,SCOTLAND.							CAY EL, 1972, J PSYCHOSOM RES, V16, P425, DOI 10.1016/0022-3999(72)90068-2; HACKETT TP, 1968, NEW ENGL J MED, V279, P1365, DOI 10.1056/NEJM196812192792504; Jones DA, 1996, BRIT MED J, V313, P1517, DOI 10.1136/bmj.313.7071.1517; LEWIN B, 1992, LANCET, V339, P1036, DOI 10.1016/0140-6736(92)90547-G	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					457	457		10.1016/S0140-6736(05)63074-7	http://dx.doi.org/10.1016/S0140-6736(05)63074-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR135	9274577				2022-12-28	WOS:A1997XR13500003
J	Werner, JA; Gottschlich, S				Werner, JA; Gottschlich, S			Recent advances - Otorhinolaryngology	BRITISH MEDICAL JOURNAL			English	Review							HEAD; RECONSTRUCTION; SURGERY				Werner, JA (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,GUTENBERGSTR 76-78,D-24105 KIEL,GERMANY.							Abramo AC, 1996, AESTHET PLAST SURG, V20, P59, DOI 10.1007/s002669900007; Adams SG, 1996, LARYNGOSCOPE, V106, P296, DOI 10.1097/00005537-199603000-00010; Apfelberg DB, 1996, ANN PLAS SURG, V36, P522, DOI 10.1097/00000637-199605000-00015; BEUMER J, 1995, SEMIN SURG ONCOL, V11, P200, DOI 10.1002/ssu.2980110305; BOYD JB, 1995, PLAST RECONSTR SURG, V95, P1018, DOI 10.1097/00006534-199505000-00010; Carney AS, 1996, J LARYNGOL OTOL, V110, P322, DOI 10.1017/S0022215100133559; David LM, 1995, DERMATOL SURG, V21, P1031, DOI 10.1111/j.1524-4725.1995.tb00553.x; Dhingra JK, 1996, ARCH OTOLARYNGOL, V122, P1181; DILKES MG, 1995, J LARYNGOL OTOL, V109, P1072, DOI 10.1017/S0022215100132050; EDGERTON BJ, 1982, ANN OTO RHINOL LARYN, V91, P117; Foster RD, 1996, ARCH SURG-CHICAGO, V131, P960; Freeman, 1996, CURR OPIN OTOLARYNGO, V4, P223; Goodman G J, 1996, Australas J Dermatol, V37, P125, DOI 10.1111/j.1440-0960.1996.tb01029.x; Gunkel AR, 1996, 3RD EUROPEAN CONGRESS OF THE EUROPEAN FEDERATION OF OTO-RHINO-LARYNGOLOGICAL SOCIETIES - EUFOS, P261; HARRIES ML, 1995, J LARYNGOL OTOL, V109, P108, DOI 10.1017/S002221510012941X; Holzer SES, 1996, LARYNGOSCOPE, V106, P86; Ingrams DR, 1997, HEAD NECK-J SCI SPEC, V19, P27, DOI 10.1002/(SICI)1097-0347(199701)19:1<27::AID-HED5>3.3.CO;2-3; Kates JM, 1996, J ACOUST SOC AM, V99, P3138, DOI 10.1121/1.414798; Kiessling J, 1996, FOLIA PHONIATR LOGO, V48, P156, DOI 10.1159/000266403; Kruckels G, 1996, SURG ENDOSC-ULTRAS, V10, P453, DOI 10.1007/s004649910090; LASZIG R, 1995, J LARYNGOL OTOL, V109, P385, DOI 10.1017/S0022215100130257; Leunig A, 1996, AM J SURG, V172, P674, DOI 10.1016/S0002-9610(96)00312-1; Lowe NJ, 1995, DERMATOL SURG, V21, P1017, DOI 10.1111/j.1524-4725.1995.tb00550.x; Marangos N, 1996, FOLIA PHONIATR LOGO, V48, P131, DOI 10.1159/000266399; NASRI S, 1995, LARYNGOSCOPE, V105, P585, DOI 10.1288/00005537-199506000-00005; Paul MD, 1996, AESTHET PLAST SURG, V20, P129, DOI 10.1007/s002669900013; Ross DA, 1996, LARYNGOSCOPE, V106, P14, DOI 10.1097/00005537-199601000-00004; RUDERT HH, 1995, EUR ARCH OTO-RHINO-L, V252, P146; Schweitzer H C, 1996, J Am Acad Audiol, V7, P230; SLATTERY WH, 1995, AM J OTOL, V16, P315; Steffens T, 1996, HNO, V44, P273; Steffens T, 1996, HNO, V44, P213; Steiner W, 1988, Adv Otorhinolaryngol, V39, P135; Steiner W, 1996, 3RD EUROPEAN CONGRESS OF THE EUROPEAN FEDERATION OF OTO-RHINO-LARYNGOLOGICAL SOCIETIES - EUFOS, P369; TAMI TA, 1996, CURR OPIN OTOLARYNGO, V4, P217; TRUELSON JM, 1994, OTOLARYNG HEAD NECK, V111, P557, DOI 10.1016/S0194-5998(94)70521-6; ZARGI M, 1997, EUR ARCH OTO-RHINO-L, V254, P113	37	4	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					354	357						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270460				2022-12-28	WOS:A1997XQ86400025
J	Li, P; Yang, XH; Wasser, M; Cai, Y; Chia, W				Li, P; Yang, XH; Wasser, M; Cai, Y; Chia, W			Inscuteable and staufen mediate asymmetric localization and segregation of prospero RNA during Drosophila neuroblast cell divisions	CELL			English	Article							OSKAR MESSENGER-RNA; POSTERIOR DETERMINANT; PROTEIN; GENE; OOCYTE; EMBRYO; NANOS; NUMB; SPECIFICATION; ORIENTATION	When neuroblasts divide, inscuteable acts to coordinate protein localization and mitotic spindle orientation, ensuring that asymmetrically localized determinants like Prospero partition into one progeny. staufen encodes a dsRNA-binding protein implicated in mRNA transport in oocytes. We demonstrate that prospero RNA is also asymmetrically localized and partitioned during neuroblast cell divisions, a process requiring both inscuteable and staufen. Inscuteable and Staufen interact and colocalize with prospero RNA on the apical cortex of interphase neuroblasts. Staufen binds prospero RNA in its 3'UTR. Our findings suggest that Inscuteable nucleates an apical complex and is required for protein localization, spindle orientation, and RNA localization. Stau, as one component of this complex, is required only for RNA localization. Hence staufen also acts zygotically, downstream of inscuteable, to effect aspects of neuroblast asymmetry.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,DEV NEUROBIOL LAB,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Cai, Yu/R-7737-2019	Cai, Yu/0000-0003-2044-3290; Wasser, Martin/0000-0002-8753-2346				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; DAVIS I, 1993, COLD SPRING HARB SYM, V58, P793, DOI 10.1101/SQB.1993.058.01.086; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1995, NEURON, V15, P991, DOI 10.1016/0896-6273(95)90088-8; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; FERRANDON D, 1994, CELL, V79, P1121; FINLEY RL, 1994, GENE PROBES PRACTICA; FrancisLang H, 1996, EMBO J, V15, P640, DOI 10.1002/j.1460-2075.1996.tb00396.x; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JAN YN, 1995, NEURON, V14, P1; KarlinMcginness M, 1996, DEV GENET, V19, P238, DOI 10.1002/(SICI)1520-6408(1996)19:3<238::AID-DVG7>3.0.CO;2-A; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LUNDELL MJ, 1994, BIOTECHNIQUES, V16, P434; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; STERNBERG PW, 1984, ANNU REV GENET, V18, P489, DOI 10.1146/annurev.ge.18.120184.002421; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; TAUTZ D, 1989, DROSOPHILA LAB MANUA, P194; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; UEMERA T, 1989, CELL, V5, P349; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K	44	194	199	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					437	447		10.1016/S0092-8674(00)80504-8	http://dx.doi.org/10.1016/S0092-8674(00)80504-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267024	Bronze			2022-12-28	WOS:A1997XQ06300008
J	Mannings, V; Koerner, DW; Sargent, AI				Mannings, V; Koerner, DW; Sargent, AI			A rotating disk of gas and dust around a young counterpart to beta Pictoris	NATURE			English	Article							T-TAURI STARS; CIRCUMSTELLAR DISKS; GRAINS; ABSORPTION	beta Pictoris is the best known example of a main-sequence star encircled by a tenuous disk(1), Optical(2,3) and infrared(4) images of beta Pic suggest that the disk is composed of dust grains which have been interpreted(1) as the debris generated by the disruption of the asteroid-sized remnants of planet-formation processes(5), The star itself is relatively old, with an age in excess of 100 Myr, Here we present high-resolution millimetre-wave images of continuum and molecular-line emission from dust and gas surrounding a much younger star, MWC480: the stellar properties of MWC480 are similar to those of beta Pic, but its age is just 6 Myr, The morphology of the circumstellar material and a comparison with the predictions of kinematic modelling indicate the presence of a rotating disk, gravitationally bound to the star, Moreover, the mass of the disk is greater than the minimum required to form a planetary system like our own(5), We therefore suggest that the disk around the young star MWC480 could be a progenitor of debris disks of the type associated with older stars such as beta Pic, and so holds much promise for the study of both the origin of debris disks and the early stages of the formation of planetary systems.	CALTECH,JET PROP LAB,PASADENA,CA 91109	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Mannings, V (corresponding author), CALTECH,DIV PHYS MATH & ASTRON,MS 105-24,PASADENA,CA 91125, USA.							AUMANN HH, 1984, ASTROPHYS J, V278, pL23, DOI 10.1086/184214; Backman D. E., 1993, PROTOSTARS PLANETS, P1253; Beckwith SVW, 1996, NATURE, V383, P139, DOI 10.1038/383139a0; BECKWITH SVW, 1990, ASTRON J, V99, P924, DOI 10.1086/115385; BECKWITH SVW, 1991, ASTROPHYS J, V381, P250, DOI 10.1086/170646; BEUST H, 1994, ASTRON ASTROPHYS, V282, P804; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; DENT WRF, 1995, MON NOT R ASTRON SOC, V277, pL25; DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480; DUTREY A, 1994, ASTRON ASTROPHYS, V286, P149; GOLIMOWSKI DA, 1993, ASTROPHYS J, V411, pL41, DOI 10.1086/186907; Herbig G. H., 1960, AP J SUPPL, V4, P337, DOI DOI 10.1086/190050; HILDEBRAND RH, 1983, Q J ROY ASTRON SOC, V24, P267; KOERNER DW, 1993, ICARUS, V106, P2, DOI 10.1006/icar.1993.1154; KOERNER DW, 1997, 25 YEARS MILLIMETER, V170, P162; LAGAGE PO, 1994, NATURE, V369, P628, DOI 10.1038/369628a0; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; MANNINGS V, 1994, MON NOT R ASTRON SOC, V267, P361, DOI 10.1093/mnras/267.2.361; MANNINGS V, IN PRESS ASTROPHYS J; MIYAKE K, 1993, ICARUS, V106, P20, DOI 10.1006/icar.1993.1156; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; SARGENT AI, 1996, DISKS OUTFLOWS YOUNG, P1; SCOVILLE NZ, 1986, ASTROPHYS J, V303, P416, DOI 10.1086/164086; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; Sylvester RJ, 1996, MON NOT R ASTRON SOC, V279, P915, DOI 10.1093/mnras/279.3.915; WEIDENSCHILLING S, IN PRESS ICARUS; WRIGHT EL, 1987, ASTROPHYS J, V320, P818, DOI 10.1086/165597	27	90	90	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					555	557		10.1038/41505	http://dx.doi.org/10.1038/41505			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252187				2022-12-28	WOS:A1997XP72200040
J	Oscherwitz, T; Peterson, J; Roger, S; Sciortino, S; Alpers, A; Royce, S; Lo, B				Oscherwitz, T; Peterson, J; Roger, S; Sciortino, S; Alpers, A; Royce, S; Lo, B			Detention of persistently nonadherent patients with tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Patients with tuberculosis (TB) who are persistently nonadherent to treatment present a public health risk. In 1993, California created a new civil detention process and allowed detention of noninfectious but persistently nonadherent patients. Objectives.-To determine (1) which patients TB controllers attempt to detain, (2) how often and where patients are detained, and (3) how many or these patients complete TB treatment. Design.-Case series with cross-sectional comparison to other adult TB patients in the study counties. Setting-Twelve California counties with the largest number of new TB cases reported in 1994. Subjects.-All patients whom TB controllers sought to detain during 1994 and 1995 because of persistent nonadherence to treatment. Data Sources.-Public health records, interviews with county TB officials, and Reports of Verified Cases of Tuberculosis to the California Tuberculosis Control Branch. Results.-Tuberculosis controllers sought the civil detention or arrest of 67 patients during the study period (1.3% of adult TB patients with the same disease sites). Forty-six percent of these patients were homeless, 81% had drug or alcohol abuse, and 28% had mental illness. Tuberculosis controllers sought civil detention of 15 patients. Fourteen patients were detained (median length of detention, 14.5 days). Tuberculosis controllers sought to arrest 62 patients during the study period. Fifty-three patients were arrested (median time in jail, 83 days). In 10 cases, both civil and criminal detention were attempted. We analyzed completion of therapy after excluding patients who were not detained or who died or moved. Overall, 41 (84%) of the remaining 49 detained patients completed therapy. Of the patients who completed therapy, only 17 were detained until treatment was completed. Compared with other TB patients in these counties, detained patients had 4 times the proportion lost to follow-up and half the proportion completing therapy within 12 months. Conclusion.-Further improvements in the care of persistently nonadherent patients may require more psychosocial services, appropriate facilities for civil detention, and detaining patients long enough to assure completion of treatment.	UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; CALIF DEPT HLTH SERV,BERKELEY,CA 94704	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Department of Health Care Services				Sciortino, Stanley/0000-0002-6191-8179	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [2 P50 MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ball C. A., 1994, YALE LAW POLICY REV, V12, P38; BAYER R, 1995, ANNU REV PUBL HEALTH, V16, P307; Bayer Ronald, 1992, TUBERCULOSIS REVIVAL; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GASNER R, 1996, TB TIMES, V10, P4; Gostin Lawrence O, 1995, MD Law Rev, V54, P1; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1	8	33	33	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					843	846		10.1001/jama.278.10.843	http://dx.doi.org/10.1001/jama.278.10.843			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU552	9293993				2022-12-28	WOS:A1997XU55200040
J	Irie, M; Hata, Y; Takeuchi, M; Ichtchenko, K; Toyoda, A; Hirao, K; Takai, Y; Rosahl, TW; Sudhof, TC				Irie, M; Hata, Y; Takeuchi, M; Ichtchenko, K; Toyoda, A; Hirao, K; Takai, Y; Rosahl, TW; Sudhof, TC			Binding of neuroligins to PSD-95	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; POSTSYNAPTIC DENSITY; SEPTATE JUNCTIONS; GUANYLATE KINASES; MEMBRANE PROTEIN; NEUREXINS; INTERACTS; HOMOLOG; FAMILY	PSD-95 is a component of postsynaptic densities in central synapses, It contains three PDZ domains that localize N-methyl-D-aspartate receptor subunit 2 (NMDA2 receptor) and K+ channels to synapses. In mouse forebrain, PSD-95 bound to the cytoplasmic COOH-termini of neuroligins, which are neuronal cell adhesion molecules that interact with beta-neurexins and form intercellular junctions. Neuroligins bind to the third PDZ domain of PSD-95, whereas NMDA2 receptors and K+ channels interact with the first and second PDZ domains. Thus different PDZ domains of PSD-95 are specialized for distinct functions. PSD-95 may recruit ion channels and neurotransmitter receptors to intercellular junctions formed between neurons by neuroligins and beta-neurexins.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; JAPAN SCI & TECHNOL CORP,ERATO,TAKAI BIOTIMER PROJECT,NISHI KU,KOBE,HYOGO 65122,JAPAN; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Japan Science & Technology Agency (JST); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Osaka University			Toyoda, Atsushi/AAA-5885-2020	Toyoda, Atsushi/0000-0002-0245-3244	NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Hata Y, 1996, J NEUROSCI, V16, P2488; Hunt CA, 1996, J NEUROSCI, V16, P1380; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOEHNSSON U, 1991, EIOTECHNIQUES, V11, P520; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NGUYEN T, IN PRESS J BIOL CHEM; Niethammer M, 1996, J NEUROSCI, V16, P2157; Rose MD., 1990, METHODS YEAST GENETI; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Russell AB, 1997, J NEUROSCI, V17, P4734; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Woods D F, 1993, J Cell Sci Suppl, V17, P171; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	30	570	591	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1511	1515		10.1126/science.277.5331.1511	http://dx.doi.org/10.1126/science.277.5331.1511			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278515				2022-12-28	WOS:A1997XV42900042
J	Stout, JE; Yu, VL				Stout, JE; Yu, VL			Legionellosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COMMUNITY-ACQUIRED PNEUMONIA; NOSOCOMIAL LEGIONNAIRES-DISEASE; PNEUMOPHILA SEROGROUP-1; RISK-FACTORS; POTABLE WATER; TAP WATER; TRANSMISSION; ASPIRATION; VIRULENCE; STRAINS		VET AFFAIRS MED CTR,INFECT DIS SECT,PITTSBURGH,PA 15240; UNIV PITTSBURGH,PITTSBURGH,PA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Allegheny County Health Department, 1997, APPR PREV CONTR LEG, P1; BABE KS, 1994, CLIN INFECT DIS, V19, P1164, DOI 10.1093/clinids/19.6.1164; BALTCH AL, 1995, ANTIMICROB AGENTS CH, V39, P1661, DOI 10.1128/AAC.39.8.1661; BANGSBORG JM, 1995, EUR J CLIN MICROBIOL, V14, P99, DOI 10.1007/BF02111866; BARKER J, 1995, J ANTIMICROB CHEMOTH, V36, P7, DOI 10.1093/jac/36.1.7; BARTLETT CLR, 1986, LEGIONELLA INFECT; BARTLETT JG, 1993, J CRIT ILLNESS, V8, P755; BERGER KH, 1993, MOL MICROBIOL, V7, P7, DOI 10.1111/j.1365-2958.1993.tb01092.x; BHOPAL R, 1995, J INFECTION, V30, P9, DOI 10.1016/S0163-4453(95)92665-8; BLATT SP, 1993, AM J MED, V95, P16, DOI 10.1016/0002-9343(93)90227-G; BLATT SP, 1994, CLIN INFECT DIS, V18, P227, DOI 10.1093/clinids/18.2.227; BRADY MT, 1989, J PEDIATR-US, V115, P46, DOI 10.1016/S0022-3476(89)80327-0; BREIMAN RF, 1993, LEGIONELLA, P30; *BRIT THOR SOC PUB, 1987, Q J MED, V62, P195; CARRATALA J, 1994, AM J RESP CRIT CARE, V149, P625, DOI 10.1164/ajrccm.149.3.8118629; CIRILLO JD, 1994, INFECT IMMUN, V62, P3254, DOI 10.1128/IAI.62.8.3254-3261.1994; Dominguez JA, 1996, J CLIN MICROBIOL, V34, P2334; DOURNON E, 1988, J INFECT DIS, V157, P496, DOI 10.1093/infdis/157.3.496; EBRIGHT JR, 1993, INFECT DIS CLIN PRAC, V2, P195; EDELSTEIN PH, 1993, CLIN INFECT DIS, V16, P741, DOI 10.1093/clind/16.6.741; EDELSTEIN PH, 1995, CLIN INFECT DIS S3, V21, P5265; ENGLEBERG NC, 1993, LEGIONELLA, P63; EWALD PW, 1993, SCI AM, V268, P86, DOI 10.1038/scientificamerican0493-86; FALCO V, 1991, CHEST, V100, P1007, DOI 10.1378/chest.100.4.1007; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FIELDS BS, 1993, LEGIONELLA, P129; Freije MR, 1996, LEGIONELLAE CONTROL; Green M, 1996, J CLIN MICROBIOL, V34, P175, DOI 10.1128/JCM.34.1.175-176.1996; Greene K A, 1990, J Perinatol, V10, P183; Heath CH, 1996, EUR J CLIN MICROBIOL, V15, P286, DOI 10.1007/BF01695659; HORIE H, 1992, ACTA PATHOL JAPON, V42, P427; HUTCHINSON DN, 1990, REV MED MICROBIOL, V1, P108; INGRAM JG, 1994, J CLIN MICROBIOL, V32, P209, DOI 10.1128/JCM.32.1.209-210.1994; JOHNSON JT, 1985, LANCET, V2, P298; JOLY JR, 1993, LEGIONELLA, P39; JOSEPH CA, 1994, EPIDEMIOL INFECT, V112, P329, DOI 10.1017/S0950268800057745; KESSLER HH, 1993, J CLIN MICROBIOL, V31, P3325, DOI 10.1128/JCM.31.12.3325-3328.1993; KOHLER RB, 1984, J CLIN MICROBIOL, V20, P605, DOI 10.1128/JCM.20.4.605-607.1984; KORVICK JA, 1987, ANN THORAC SURG, V43, P341, DOI 10.1016/S0003-4975(10)60633-9; KUZMAN I, 1995, SCAND J INFECT DIS, V27, P503, DOI 10.3109/00365549509047054; LEVERSTEINVANHALL MA, 1994, CLIN INFECT DIS, V19, P1147, DOI 10.1093/clinids/19.6.1147; LIN YE, IN PRESS SEMIN RESP; LINDSAY DSJ, 1994, J CLIN MICROBIOL, V32, P3068, DOI 10.1128/JCM.32.12.3068-3069.1994; LOWRY PW, 1993, AM J INFECT CONTROL, V21, P21, DOI 10.1016/0196-6553(93)90203-G; LOWRY PW, 1991, NEW ENGL J MED, V324, P109, DOI 10.1056/NEJM199101103240207; LUCK PC, 1994, EUR J CLIN MICROBIOL, V13, P565, DOI 10.1007/BF01971307; MAHONEY FJ, 1992, J INFECT DIS, V165, P736, DOI 10.1093/infdis/165.4.xxxx; MAIWALD M, 1995, EUR J CLIN MICROBIOL, V14, P25, DOI 10.1007/BF02112614; MARRA A, 1992, ANNU REV GENET, V26, P51, DOI 10.1146/annurev.ge.26.120192.000411; MARRIE TJ, 1991, EPIDEMIOL INFECT, V107, P591, DOI 10.1017/S0950268800049293; MARSTON BJ, 1993, LEGIONELLA, P36; MARSTON BJ, 1994, ARCH INTERN MED, V154, P2417, DOI 10.1001/archinte.154.21.2417; MATSIOTABERNARD P, 1994, J CLIN MICROBIOL, V32, P1503, DOI 10.1128/JCM.32.6.1503-1505.1994; MENSA J, 1993, J ANTIMICROB CHEMOTH, V31, P749, DOI 10.1093/jac/31.5.749; MORLEY JN, 1994, CLIN INFECT DIS, V19, P1130, DOI 10.1093/clinids/19.6.1130; Muder R R, 1989, Semin Respir Infect, V4, P32; MUDER RR, 1986, ARCH INTERN MED, V146, P1607, DOI 10.1001/archinte.146.8.1607; MURACA PW, 1988, AM IND HYG ASSOC J, V49, P584, DOI 10.1202/0002-8894(1988)049&lt;0584:LDITWE&gt;2.0.CO;2; NEIDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418; NELSON DP, 1985, ARCH INTERN MED, V145, P926, DOI 10.1001/archinte.145.5.926; OLIVERIO MJ, 1991, J CLIN MICROBIOL, V29, P2893, DOI 10.1128/JCM.29.12.2893-2894.1991; PASTORIS MC, 1988, SCAND J INFECT DIS, V20, P489, DOI 10.3109/00365548809032496; PLOUFFE JF, 1995, CLIN INFECT DIS, V20, P1286, DOI 10.1093/clinids/20.5.1286; PRODINGER WM, 1994, J HOSP INFECT, V26, P191, DOI 10.1016/0195-6701(94)90042-6; PRUCKLER J, 1995, 95 GEN M AM SOC MICR, P233; QUARESIMA T, 1992, RIV ITAL PED, V18, P125; REDA C, 1994, J ANTIMICROB CHEMOTH, V33, P757, DOI 10.1093/jac/33.4.757; RELLO J, 1993, CHEST, V103, P232, DOI 10.1378/chest.103.1.232; RIHS JD, 1985, J CLIN MICROBIOL, V22, P422, DOI 10.1128/JCM.22.3.422-424.1985; ROIG J, 1994, CHEST, V105, P1817, DOI 10.1378/chest.105.6.1817; ROIG J, 1991, CHEST, V99, P344, DOI 10.1378/chest.99.2.344; STOUT JE, 1992, NEW ENGL J MED, V326, P151, DOI 10.1056/NEJM199201163260302; STOUT JE, 1994, 32 INF DIS SOC AM AN, pA36; Straus WL, 1996, ARCH INTERN MED, V156, P1685, DOI 10.1001/archinte.156.15.1685; SWANSON DJ, 1992, AM J MED, V92, P61, DOI 10.1016/0002-9343(92)90016-5; TOMPKINS LS, 1988, NEW ENGL J MED, V318, P530, DOI 10.1056/NEJM198803033180902; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; VENEZIA RA, 1994, INFECT CONT HOSP EP, V15, P529; Womack S J, 1992, J Perinatol, V12, P303; WOO AH, 1992, CHEST, V102, P1586, DOI 10.1378/chest.102.5.1586; WRIGHT JB, 1989, J HOSP INFECT, V13, P187, DOI 10.1016/0195-6701(89)90026-1; YU VL, 1982, AM J MED, V73, P357, DOI 10.1016/0002-9343(82)90727-6; YU VL, 1987, AM J MED SCI, V294, P97, DOI 10.1097/00000441-198708000-00007; YU VL, 1993, INFECT CONT HOSP EP, V14, P567, DOI 10.1086/646638; YU VL, 1993, AM J MED, V95, P13, DOI 10.1016/0002-9343(93)90226-F; YU VL, 1993, NEW MACROLIDES AZALI, P141; 1995, MMWR-MORBID MORTAL W, V43, P968	87	380	404	0	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					682	687		10.1056/NEJM199709043371006	http://dx.doi.org/10.1056/NEJM199709043371006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU349	9278466				2022-12-28	WOS:A1997XU34900006
J	Giatras, I; Lau, J; Levey, AS				Giatras, I; Lau, J; Levey, AS			Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials	ANNALS OF INTERNAL MEDICINE			English	Article						angiotensin-converting enzyme inhibitors; kidney failure, chronic; meta-analysis; antihypertensive agents; blood pressure	BLOOD-PRESSURE CONTROL; ANTIHYPERTENSIVE THERAPY; DIABETIC NEPHROPATHY; ACE-INHIBITORS; INSUFFICIENCY; ENALAPRIL; CAPTOPRIL; FAILURE; DIET; MICROALBUMINURIA	Background: The effect of angiotensin-converting enzyme (ACE) inhibitors in slowing the decline in renal function in nondiabetic renal disease varies among studies. Purpose: To use meta-analysis to assess the effect of ACE inhibitors on the development of end-stage renal disease caused by factors other than diabetes. Data Sources: The English-language medical literature, identified by a MEDLINE search, and unpublished studies. Study Selection: All randomized studies that compared ACE inhibitors with other antihypertensive agents and had at least 1 year of planned follow-up were selected. Studies of diabetic renal disease and renal transplants were excluded. A total of 1594 patients in 10 studies was included. Data Extraction: Data on end-stage renal disease, death, drop out, and blood pressure were extracted. Study investigators confirmed results and provided additional data. Data Synthesis: Among 806 patients receiving ACE inhibitors, 52 (6.4%) developed end-stage renal disease and 17 (2.1%) died; in the 788 controls, the respective values were 72 (9.1%) and 12 (1.5%). The pooled relative risks were 0.70 (95% CI, 0.51 to 0.97) for end-stage renal disease and 1.24 (CI, 0.55 to 2.83) for death; the studies were not significantly heterogeneous. The decreases in weighted mean systolic and diastolic blood pressures during follow-up were 4.9 and 1.2 mm Hg greater, respectively, in the patients who received ACE inhibitors. Conclusions: Angiotensin-converting enzyme inhibitors are more effective than other antihypertensive agents in reducing the development of end-stage nondiabetic renal disease, and they do not increase mortality. It could not be determined whether this beneficial effect is due to the greater decline in blood pressure or to other effects of ACE inhibition.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV NEPHROL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University					AHRQ HHS [R01 HS08532, R01 HS07782] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; BANNISTER KM, 1995, CONTRIB NEPHROL, V111, P184; BECKER GJ, 1994, KIDNEY INT, V45, pS167; BERLIN JA, 1994, ONLINE J CURR CLIN T; BIANCHI S, 1991, AM J NEPHROL, V11, P131, DOI 10.1159/000168289; BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; BRUNNER HR, 1992, KIDNEY INT, V42, P463, DOI 10.1038/ki.1992.311; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; HANNEDOUCHE T, 1994, BRIT MED J, V309, P833, DOI 10.1136/bmj.309.6958.833; Himmelmann Anders, 1995, Blood Pressure, V4, P85, DOI 10.3109/08037059509077575; Hunsicker LG, 1997, KIDNEY INT, V51, P1908, DOI 10.1038/ki.1997.260; HUNSICKER LG, 1995, PRINCIPLES PRACTICE, P622; Ichikawa I, 1996, KIDNEY INT, V50, P684, DOI 10.1038/ki.1996.365; Ihle BU, 1996, AM J KIDNEY DIS, V27, P489, DOI 10.1016/S0272-6386(96)90158-4; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; KAMPER AL, 1992, AM J HYPERTENS, V5, P423, DOI 10.1093/ajh/5.7.423; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KEANE WF, 1989, ANN INTERN MED, V111, P503, DOI 10.7326/0003-4819-111-6-503; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LAFFEL LMB, 1995, AM J MED, V99, P497, DOI 10.1016/S0002-9343(99)80226-5; Levey AS, 1996, J AM SOC NEPHROL, V7, P556; Levey AS, 1996, J AM SOC NEPHROL, V7, P2097; LEVEY AS, 1990, KIDNEY INT, V38, P167, DOI 10.1038/ki.1990.182; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; OKAMURA M, 1991, CONTRIB NEPHROL, V90, P161; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; REMUZZI G, 1991, J NEPHROL, V3, P193; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; *US REN DAT SYST, 1995, NIH NAT I DIAB DIG K, pB1; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; ZUCCHELLI P, 1992, KIDNEY INT, V42, P452, DOI 10.1038/ki.1992.309; ZUCCHELLI P, 1995, NEPHROL DIAL TRANSPL, V10, P46	33	325	332	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					337	+		10.7326/0003-4819-127-5-199709010-00001	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273824				2022-12-28	WOS:A1997XU10000001
J	Hynes, DM; Stevenson, G; Nahmias, C				Hynes, DM; Stevenson, G; Nahmias, C			Towards filmless and distance radiology	LANCET			English	Article							COMMUNICATION-SYSTEMS; PACS; INFORMATION; ACCESS; IMPACT	To many people radiology is synonymous with films. For 20 years or so, however, it has been possible to capture digitally data traditionally displayed on film, and that was true from the beginning of computed tomography and magnetic resonance imaging too. There is more to picture archiving and communication systems (PACS) than the economies of filmlessness and the ability to modify images. To realise the full potential of PACS requires huge and expensively equipped networks linking the radiology department, hospital wards, outpatient clinics, laboratories, family doctors' clinics, and so on, permitting simultaneous consultations on different sites and almost instant reporting from specialist radiologists at a distance. The data sets that need to be transferred are huge but some of the technical obstacles are now being overcome and the past few years have seen some hospitals move to a filmless state. The more common pattern, though, will be a piecemeal approach. PACS and teleradiology certainly provide a quicker imaging service. How soon a total PACS will save money for a hospital operating budget is less clear.	MCMASTER UNIV,DEPT RADIOL,HAMILTON,ON L8N 3Z5,CANADA	McMaster University								[Anonymous], 1995, LANCET, V345, P73; BARNES GT, 1993, RADIOGRAPHICS, V13, P673, DOI 10.1148/radiographics.13.3.8316673; Bauman RA, 1996, J DIGIT IMAGING, V9, P172, DOI 10.1007/BF03168614; Berlin L, 1997, AM J ROENTGENOL, V168, P895, DOI 10.2214/ajr.168.4.9124135; BIDGOOD WD, 1992, RADIOGRAPHICS, V12, P345, DOI 10.1148/radiographics.12.2.1561424; DureSmith P, 1997, RADIOLOGY, V203, pA49, DOI 10.1148/radiology.203.3.49a; Grenier L E, 1995, Medinfo, V8 Pt 1, P440; GRIMES GJ, 1997, ADV IMAGING      JUL, P12; HARRISON RM, 1988, PHYS MED BIOL, V33, P750; HILSENRATH PE, 1991, AM J ROENTGENOL, V156, P177, DOI 10.2214/ajr.156.1.1898556; HONEYMAN JC, 1992, RADIOGRAPHICS, V12, P141, DOI 10.1148/radiographics.12.1.1734460; HYNES D, 1997, IN PRESS P SPIE; Ishigaki T, 1996, RADIOLOGY, V201, P51, DOI 10.1148/radiology.201.1.8816520; KENYON DB, 1996, COMPUTER APPL ASSIST, P224; Kundel HL, 1996, RADIOLOGY, V199, P143, DOI 10.1148/radiology.199.1.8633138; LANGLOTZ CP, 1995, J DIGIT IMAGING, V8, P95, DOI 10.1007/BF03168132; LEHMANN KJ, 1993, EUR J RADIOL, V17, P3, DOI 10.1016/0720-048X(93)90021-E; MATHEUS R, 1993, EURO J RADIOL, V17, P28; MURPHEY MD, 1991, INVEST RADIOL, V26, P590, DOI 10.1097/00004424-199106000-00017; Nishihara E, 1997, J DIGIT IMAGING, V10, P27, DOI 10.1007/BF03168547; Osteaux M, 1996, EUR J RADIOL, V22, P166, DOI 10.1016/0720-048X(96)00768-1; Pavone P, 1996, RADIOGRAPHICS, V16, P421, DOI 10.1148/radiographics.16.2.8966298; STRAUB WH, 1990, AM J ROENTGENOL, V155, P613, DOI 10.2214/ajr.155.3.2117364; Taira RK, 1996, J DIGIT IMAGING, V9, P1, DOI 10.1007/BF03168562; YU SK, 1996, COMPUTER APPL ASSIST, P454	25	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					657	660		10.1016/S0140-6736(97)08157-9	http://dx.doi.org/10.1016/S0140-6736(97)08157-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288061				2022-12-28	WOS:A1997XU28300043
J	Barger, SW; Harmon, AD				Barger, SW; Harmon, AD			Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E	NATURE			English	Article							CEREBROSPINAL-FLUID; SENILE PLAQUES; HEAD-INJURY; DISEASE; IMMUNOREACTIVITY; EXPRESSION; DOMAIN; CELLS; ONSET; BRAIN	A role for beta-amyloid precursor protein (beta-APP) in the development of Alzheimer's disease has been indicated by genetics', and many conditions in which beta-APP is raised have been associated with an increased risk of Alzheimer's disease or an Alzheimer's-like pathology(2-4). Inflammatory events may also contribute to Alzheimer's disease(5), Here we investigate whether a secreted derivative of beta-APP (sAPP-alpha) can induce inflammatory reactions in microglia, which are brain cells of monocytic lineage. We found that treatment with sAPP-alpha increased markers of activation in microglia and enhanced their production of neurotoxins. The ability of sAPP-alpha to activate microglia was blocked by prior incubation of the protein with apolipoprotein E3 but not apolipoprotein E4, a variant associated with an increased risk for Alzheimer's(6). A product of amyloidogenic beta-APP processing (sAPP-beta) also activated microglia. Because sAPP-beta is deficient in the neuroprotective activity shown by sAPP-alpha, our results indicate that increased amyloidogenic processing could adversely affect the balance of sAPP activities that determine neuronal viability.	UNIV ARKANSAS MED SCI,DEPT ANAT CELL BIOL & NEUROBIOL,LITTLE ROCK,AR 72205; JOHN L MCCLELLAN MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center	Barger, SW (corresponding author), UNIV ARKANSAS MED SCI,DONALD W REYNOLDS DEPT GERIATR,LITTLE ROCK,AR 72205, USA.			Barger, Steven/0000-0001-6049-6480				Barger SW, 1997, J NEUROCHEM, V69, P60; Barger SW, 1996, MOL BRAIN RES, V40, P116; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; CLAY MA, 1995, BIOCHEMISTRY-US, V34, P11142, DOI 10.1021/bi00035a020; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Hardy J, 1996, ANN MED, V28, P255, DOI 10.3109/07853899609033127; LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Rossi F, 1996, BIOCHEM BIOPH RES CO, V225, P474, DOI 10.1006/bbrc.1996.1197; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SHENG JG, 1994, J NEUROCHEM, V63, P1872; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	29	514	548	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					878	881		10.1038/42257	http://dx.doi.org/10.1038/42257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278049				2022-12-28	WOS:A1997XT75400050
J	Mark, EJ; Patalas, ED; Chang, HT; Evans, RJ; Kessler, SC				Mark, EJ; Patalas, ED; Chang, HT; Evans, RJ; Kessler, SC			Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; VASCULAR-DISEASE; ARTERIOPATHY; LESIONS		HARVARD UNIV,SCH MED,BOSTON,MA; COMMONWEALTH MASSACHUSETTS,OFF CHIEF MED EXAMINER,BOSTON,MA	Harvard University; Harvard Medical School	Mark, EJ (corresponding author), MASSACHUSETTS GEN HOSP,DEPT PATHOL,55 FRUIT ST,WARREN BLDG 219,BOSTON,MA 02114, USA.							Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; CASLIN AW, 1990, HISTOPATHOLOGY, V16, P9, DOI 10.1111/j.1365-2559.1990.tb01054.x; FOLLATH F, 1971, BMJ-BRIT MED J, V1, P265, DOI 10.1136/bmj.1.5743.265; GAHL K, 1970, Z KREISLAUFFORSCH, V59, P868; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GURTNER HP, 1985, COR VASA, V27, P160; GURTNER HP, 1968, SCHWEIZ MED WSCHR, V98, P1579; HEATH D, 1990, HISTOPATHOLOGY, V16, P21, DOI 10.1111/j.1365-2559.1990.tb01055.x; ISLER P, 1953, SCHWEIZ MED WSCHR, V83, P4; JACQUES C, 1992, HUM PATHOL, V23, P191, DOI 10.1016/0046-8177(92)90243-V; JAMISON BM, 1995, HUM PATHOL, V26, P987, DOI 10.1016/0046-8177(95)90088-8; Loyd JE, 1997, CHEST, V111, pS82, DOI 10.1378/chest.111.6_Supplement.82S; MARK EJ, 1984, LUNG BIOPSY INTERPRE, P132; *MASS GEN HOSP, 1992, NEW ENGL J MED, V326, P1682; *MASS GEN HOSP, 1976, NEW ENGL J MED, V294, P433; *MASS GEN HOSP, 1979, NEW ENGL J MED, V300, P909; MCMURRAY J, 1986, BRIT MED J, V293, P51, DOI 10.1136/bmj.293.6538.51-d; METTE SA, 1992, AM REV RESPIR DIS, V145, P1196, DOI 10.1164/ajrccm/145.5.1196; PETERSEN RC, 1983, HISTOPATHOLOGY, V7, P487, DOI 10.1111/j.1365-2559.1983.tb02262.x; PINDER RM, 1975, DRUGS, V10, P241, DOI 10.2165/00003495-197510040-00001; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; RUTTNER JR, 1980, THORAX, V35, P133, DOI 10.1136/thx.35.2.133; STRYDOM AJC, 1992, CLIN CHEM, V38, P323; WAGENVOORT CA, 1977, PATHOLOGY PULMONARY, P103; WAGENVOORT CA, 1989, BIOPSY PATHOLOGY PUL, P327; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68; WIDGREN S, 1970, Z KREISLAUFFORSCH, V59, P924; YAGINUMA G, 1990, THORAX, V45, P586, DOI 10.1136/thx.45.8.586	28	115	119	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					602	606		10.1056/NEJM199708283370904	http://dx.doi.org/10.1056/NEJM199708283370904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271482				2022-12-28	WOS:A1997XT39400004
J	Tsukamoto, Y; Kato, J; Ikeda, H				Tsukamoto, Y; Kato, J; Ikeda, H			Silencing factors participate in DNA repair and recombination in Saccharomyces cerevisiae	NATURE			English	Article							2-HYBRID SYSTEM; YEAST; PROTEINS; TELOMERES; RAP1	DNA double-strand breaks are repaired by homologous recombination or DNA end-joining, but the latter process often causes illegitimate recombination and chromosome rearrangements. One of the factors involved in the end-joining process is Hdf1, a yeast homologue of Ku protein(1-4). We used the yeast two-hybrid assay to show that Hdf1 interacts with Sir4, which is involved in transcriptional silencing at telomeres and HM loci(5,6). Analyses of sir4 mutants showed that Sir4 is required for deletion by illegitimate recombination and DNA end-joining in the pathway involving Hdf1. Sir2 and Sir3, but not Sir1, were also found to participate in these processes. Furthermore, mutations of the SIR2, SIR3 and SIR4 genes conferred increased sensitivity to gamma-radiation in a genetic background with a mutation of the RAD52 gene, which is essential for double-strand break repair mediated by homologous recombination. These results indicate that Sir proteins are involved in double-strand break repair mediated by end-joining. We propose that Sir proteins act with Hdf1 to alter broken DNA ends to create an inactivated chromatin structure that is essential for the rejoining of DNA ends.	UNIV TOKYO,INST MED SCI,DEPT MOL BIOL,TOKYO 108,JAPAN	University of Tokyo								APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lea D, 1948, J GENET, V49, P264; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Luria SE, 1943, GENETICS, V28, P491; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; PILUS L, 1989, CELL, V59, P637; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHORE D, 1995, TELOMERES, P139; Siede W, 1996, GENETICS, V142, P91; SIKORSKI RS, 1989, GENETICS, V122, P19; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TSKAMOTO Y, IN PRESS MOL GEN GEN; Tsukamoto Y, 1996, GENETICS, V142, P383; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0	30	293	304	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					900	903		10.1038/42288	http://dx.doi.org/10.1038/42288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278054	Bronze			2022-12-28	WOS:A1997XT75400055
J	Hurwitz, A; Brady, DA; Schaal, E; Samloff, IM; Dedon, J; Ruhl, CE				Hurwitz, A; Brady, DA; Schaal, E; Samloff, IM; Dedon, J; Ruhl, CE			Gastric acidity in older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUODENAL-ULCER PATIENTS; SERUM PEPSINOGEN-I; BACTERIAL OVERGROWTH; INTRAGASTRIC ACIDITY; ATROPHIC GASTRITIS; SMALL-INTESTINE; HEALTHY-MEN; SECRETION; AGE; PH	Context.-Early studies suggested that gastric acidity declines as people age. However, sequelae of achlorhydria are uncommon in older people, making this conventional wisdom unlikely. Objective.-To ascertain the prevalence of basal gastric acidity and atrophic gastritis (indicated by serum pepsinogen ratio) in older adults. Design.-Cross-sectional study in a volunteer sample. Setting.-Retirement communities in suburbs of Kansas City, Mo. Subjects.-A total of 248 white male and female volunteers aged 65 years or older living independently. Main Outcome Measures.-Presence of basal unstimulated gastric acid was evaluated noninvasively by having subjects swallow quininium resin. Gastric acid with a pH lower than 3.5 releases quinine, which is then absorbed and excreted into urine, Atrophic gastritis was defined as a ratio of serum pepsinogen I/pepsinogen II of less than 2.9. Results.-Basal unstimulated gastric content was acidic (pH <3.5) in 208 (84%) of 248 elderly subjects. On retesting 66 subjects (35 normals and 31 hyposecretors), 28 (80%) of 35 had pH less than 3.5 both times, and 22 (71%) of 31 had pH of 3.5 or higher twice; in the remaining 16 subjects, low vs high gastric pH changed between tests, Weighted population prevalence estimates in this sample were 67% for consistent acid secretion, 22% for intermittent secretion, and 11% for consistent gastric pH higher than 3.5. Whereas 14 (67%) of 21 consistent hyposecretors had serum pepsinogen ratios of less than 2.9, indicating atrophic gastritis, only 2 (5%) of 44 consistent or intermittent secretors of acid had ratios in this range (P<.001). Conclusions.-In contrast to what is commonly stated, nearly 90% of elderly people in this study were able to acidity gastric contents, even in the basal, unstimulated state. Of those who were consistent hyposecretors of acid, most had serum markers of atrophic gastritis.	UNIV KANSAS,MED CTR,CTR AGING,KANSAS CITY,KS 66160; VET AFFAIRS MED CTR,SEPULVEDA,CA; TRUMAN MED CTR,DEPT COMMUNITY MED & FAMILY PRACTICE,KANSAS CITY,MO	University of Kansas; University of Kansas Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hurwitz, A (corresponding author), UNIV KANSAS,MED CTR,DEPT MED,3901 RAINBOW BLVD,KANSAS CITY,KS 66160, USA.				NIA NIH HHS [R01AG02780] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREWS GR, 1967, AUSTRALAS ANN MED, V16, P230; BARON JH, 1963, GUT, V4, P136, DOI 10.1136/gut.4.2.136; BIEMOND I, 1994, SCAND J GASTROENTERO, V29, P238, DOI 10.3109/00365529409090470; BLAIR AJ, 1987, J CLIN INVEST, V79, P582, DOI 10.1172/JCI112850; BORCH K, 1989, SCAND J GASTROENTERO, V24, P870, DOI 10.3109/00365528909089228; COLLEN MJ, 1994, AM J GASTROENTEROL, V89, P712; CONNELL AM, 1973, CLIN TESTS GASTRIC F, P20; CORAZZA GR, 1990, GASTROENTEROLOGY, V98, P302, DOI 10.1016/0016-5085(90)90818-L; CRAMER G, 1963, SCAND J CLIN LAB INV, V15, P553, DOI 10.3109/00365516309079786; DRESSMAN JB, 1990, PHARMACEUT RES, V7, P756, DOI 10.1023/A:1015827908309; FELDMAN M, 1991, DIGEST DIS SCI, V36, P866, DOI 10.1007/BF01297133; Feldman M, 1996, GASTROENTEROLOGY, V110, P1043, DOI 10.1053/gast.1996.v110.pm8612992; GOLDSCHMIEDT M, 1991, GASTROENTEROLOGY, V101, P977, DOI 10.1016/0016-5085(91)90724-Y; GOLDSCHMIEDT M, 1993, CHRONIC GASTRITIS HY, P13; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; HIRSCHOWITZ BI, 1992, GASTROENTEROLOGY, V103, pA83; HOLT PR, 1989, DIGEST DIS SCI, V34, P933, DOI 10.1007/BF01540281; Holt PR, 1993, CHRONIC GASTRITIS HY; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; HUSEBYE E, 1992, GUT, V33, P1331, DOI 10.1136/gut.33.10.1331; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; KEKKI M, 1991, SCAND J GASTROENTERO, V26, P109, DOI 10.3109/00365529109103997; KERLIN P, 1988, GASTROENTEROLOGY, V95, P982, DOI 10.1016/0016-5085(88)90173-4; KING CE, 1986, GASTROENTEROLOGY, V91, P1447, DOI 10.1016/0016-5085(86)90199-X; KIRSNER JB, 1956, GASTROENTEROLOGY, V30, P779; KRASINSKI SD, 1986, J AM GERIATR SOC, V34, P800, DOI 10.1111/j.1532-5415.1986.tb03985.x; KUNA S., 1964, ARCH INT PHARMACODYN THERAP, V151, P79; MERKI HS, 1988, GASTROENTEROLOGY, V94, P887, DOI 10.1016/0016-5085(88)90543-4; MODLIN IM, 1994, AM J GASTROENTEROL, V89, P308; OCHS HR, 1978, AM J CARDIOL, V42, P481, DOI 10.1016/0002-9149(78)90944-X; POUNDER RE, 1993, BAILLIERE CLIN GASTR, V7, P55, DOI 10.1016/0950-3528(93)90031-M; RUSSELL TL, 1993, PHARMACEUT RES, V10, P187, DOI 10.1023/A:1018970323716; SALTZMAN JR, 1994, GASTROENTEROLOGY, V106, P615, DOI 10.1016/0016-5085(94)90693-9; SAMLOFF IM, 1982, GASTROENTEROLOGY, V83, P204; SAMLOFF IM, 1982, GASTROENTEROLOGY, V82, P26; SAVARINO V, 1988, DIGEST DIS SCI, V33, P1077, DOI 10.1007/BF01535781; SEGAL HL, 1953, ANN NY ACAD SCI, V57, P308, DOI 10.1111/j.1749-6632.1953.tb36405.x; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; ZAR JH, 1984, BIOSTAT ANAL, P380	40	113	122	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					659	662		10.1001/jama.278.8.659	http://dx.doi.org/10.1001/jama.278.8.659			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272898				2022-12-28	WOS:A1997XR54700039
J	Foster, GR; Goldin, RD; Main, J; MurrayLyon, I; Hargreaves, S; Thomas, HC				Foster, GR; Goldin, RD; Main, J; MurrayLyon, I; Hargreaves, S; Thomas, HC			Management of chronic hepatitis C: clinical audit of biopsy based management algorithm	BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT INTERFERON-ALFA; CONTROLLED TRIAL; VIRUS-INFECTION; ALPHA	Objective: To assess the attendance, outcome, compliance with treatment, and response to interferon alfa in patients with chronic hepatitis C who attended during 1995 and were treated according to a biopsy based algorithm. Design: Retrospective audit of all patients with chronic hepatitis C attending outpatient clinics over one year. Setting: The liver unit at a London teaching hospital. Subjects: 255 patients with chronic hepatitis C. Main outcome measures: Patient survival, attendance, and compliance with diagnostic and therapeutic regimens. Response to interferon alfa treatment, based on loss of viraemia three months after cessation of treatment. Results: A large proportion of patients (39%) with newly diagnosed chronic hepatitis C infection do not want to undergo further investigation. Of those patients who do attend for further treatment, a large proportion with severe hepatic fibrosis (42%) do not want to undergo currently available treatment. The response rate to interferon (21%) in treated patients was similar to that previously reported in a trial setting. There was no significant difference in response rates in patients with or without severe fibrosis not amounting to cirrhosis. In patients with cirrhosis there was a high incidence of hepatocellular carcinoma (18%) over a follow up period of 20 months. Conclusion: Current strategies aimed at investigating and treating patients with chronic hepatitis C are not acceptable to a large proportion of patients. Many patients with cirrhosis related to hepatitis C infection develop hepatic neoplasms, and management strategies to deal with this problem are urgently required.	ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT HISTOPATHOL,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT MED,LONDON W2 1PG,ENGLAND; CHELSEA & WESTMINSTER HOSP,LONDON SW10 9NH,ENGLAND; KENSINGTON & CHELSEA & WESTMINSTER HLTH AUTHOR,LONDON W2 6LX,ENGLAND	Imperial College London; Imperial College London; Imperial College London	Foster, GR (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,LIVER UNIT,PRAED ST,LONDON W2 1PG,ENGLAND.		Thomas, Howard C/A-3152-2009	Hargreaves, Sally/0000-0003-2974-4348; Foster, Graham/0000-0002-3704-386X; Goldin, Robert/0000-0001-5184-4519				BOOTH JCL, 1995, GUT, V36, P427, DOI 10.1136/gut.36.3.427; BOOTH JCL, 1995, GUT, V37, P449, DOI 10.1136/gut.37.4.449; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; Davis G L, 1994, J Viral Hepat, V1, P55, DOI 10.1111/j.1365-2893.1994.tb00062.x; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Dusheiko GM, 1996, BMJ-BRIT MED J, V312, P357, DOI 10.1136/bmj.312.7027.357; Fattovich G, 1996, J HEPATOL, V24, P38, DOI 10.1016/S0168-8278(96)80184-X; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; MALAGUARNERA M, 1995, CLIN DRUG INVEST, V9, P141, DOI 10.2165/00044011-199509030-00002; MUTIMER DJ, 1995, J VIRAL HEPATITIS, V2, P47, DOI 10.1111/j.1365-2893.1995.tb00071.x; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; SCHALM SW, 1996, DIGEST DIS SCI, V41, P1315; TIBBS CJ, 1995, J VIRAL HEPATITIS, V2, P113, DOI 10.1111/j.1365-2893.1995.tb00016.x; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607	16	72	75	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					453	458		10.1136/bmj.315.7106.453	http://dx.doi.org/10.1136/bmj.315.7106.453			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284661	Green Published			2022-12-28	WOS:A1997XT71400015
J	He, ZG; TessierLavigne, M				He, ZG; TessierLavigne, M			Neuropilin is a receptor for the axonal chemorepellent Semaphorin III	CELL			English	Article							GROWTH CONE GUIDANCE; NEURONAL RECOGNITION MOLECULE; CELL-SURFACE MOLECULE; CHICK NERVOUS-SYSTEM; SPINAL-CORD; C-ELEGANS; COLORECTAL-CANCER; NEURITE OUTGROWTH; VISUAL CENTERS; PROTEIN	Extending axons in the developing nervous system are guided to their targets through the coordinate actions of attractive and repulsive guidance cues. The semaphorin family of guidance cues comprises several members that can function as diffusible axonal chemorepellents. To begin to elucidate the mechanisms that mediate the repulsive actions of Collapsin-1/Semaphorin III/D (Sema III), we searched for Sema III-binding proteins in embryonic rat sensory neurons by expression cloning. We report that Sema III binds with high affinity to the transmembrane protein neuropilin, and that antibodies to neuropilin block the ability of Sema III to repel sensory axons and to induce collapse of their growth cones. These results provide evidence that neuropilin is a receptor or a component of a receptor complex that mediates the effects of Sema III on these axons.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	He, ZG (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.							Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJISAWA H, 1989, DEV BIOL, V135, P231, DOI 10.1016/0012-1606(89)90175-9; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; HIRATA T, 1993, NEUROSCI RES, V17, P159, DOI 10.1016/0168-0102(93)90092-5; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KINDT RM, 1995, NEURON, V15, P79, DOI 10.1016/0896-6273(95)90066-7; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI W, 1992, GENETICS, V132, P675; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; Shepherd IT, 1997, DEVELOPMENT, V124, P1377; Shirasaki R, 1996, NEURON, V17, P1079, DOI 10.1016/S0896-6273(00)80241-X; SNIDER WD, 1992, J NEUROSCI, V12, P3494; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	51	926	978	0	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					739	751		10.1016/S0092-8674(00)80534-6	http://dx.doi.org/10.1016/S0092-8674(00)80534-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288753	Bronze			2022-12-28	WOS:A1997XT06600017
J	Cella, M; Engering, A; Pinet, V; Pieters, J; Lanzavecchia, A				Cella, M; Engering, A; Pinet, V; Pieters, J; Lanzavecchia, A			Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells	NATURE			English	Article							ANTIGEN PROCESSING CAPACITY; EPIDERMAL LANGERHANS CELLS; TUMOR-NECROSIS-FACTOR; INVARIANT CHAIN; MOLECULES; COMPARTMENT; LYMPHOCYTES; EXPRESSION; PEPTIDES; CULTURE	Dendritic cells have the remarkable property of presenting any incoming antigen(1). To do so they must not only capture antigens with high efficiency and broad specificity, but must also maximize their capacity to load class II molecules of the major histocompatibility complex (MHC) with antigenic peptides in order to present a large array of epitopes from different proteins, each at a sufficient copy number. Here we show that formation of peptide-MHC class II complexes is boosted by inflammatory stimuli that induce maturation of dendritic cells. In immature dendritic cells, class II molecules are rapidly internalized and recycled, turning over with a half-life of about 10 hours. Inflammatory stimuli induce a rapid and transient boost of class II synthesis, while the half-life of dass II molecules increases to over 100 hours. These coordinated changes result in the rapid accumulation of a large number of long-lived peptide-loaded MHC dass II molecules capable of stimulating T cells even after several days, The capacity of dendritic cells to load many antigenic peptides over a short period of initial exposure to inflammatory stimuli could favour presentation of infectious antigens.	HOP ST ELOI,IMMUNOL LAB,INSERM,U291,F-34295 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Cella, M (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Cella, Marina/G-8850-2011; PINET, Valérie/G-6085-2012; Cella, Marina/ABA-8564-2020	PINET, Valérie/0000-0002-4044-6440; Cella, Marina/0000-0003-1230-1313; Pieters, Jean/0000-0002-5284-9757				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; KAMPGEN E, 1991, P NATL ACAD SCI USA, V88, P3014, DOI 10.1073/pnas.88.8.3014; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; PINET V, 1994, J IMMUNOL, V152, P4852; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROOSNEK E, 1988, J IMMUNOL, V140, P4079; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; STOSSEL H, 1990, J EXP MED, V172, P1471, DOI 10.1084/jem.172.5.1471; Zhong GM, 1997, J EXP MED, V185, P429, DOI 10.1084/jem.185.3.429	19	908	933	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					782	787		10.1038/42030	http://dx.doi.org/10.1038/42030			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285591	Bronze			2022-12-28	WOS:A1997XR66700053
J	Barquet, N; Domingo, P; Cayla, JA; Gonzalez, J; Rodrigo, C; FernandezViladrich, P; MoragaLlop, FA; Marco, F; Vazquez, J; SaezNieto, JA; Casal, J; Canela, J; Foz, M				Barquet, N; Domingo, P; Cayla, JA; Gonzalez, J; Rodrigo, C; FernandezViladrich, P; MoragaLlop, FA; Marco, F; Vazquez, J; SaezNieto, JA; Casal, J; Canela, J; Foz, M			Prognostic factors in meningococcal disease - Development of a bedside predictive model and scoring system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPTICEMIA; INFECTIONS; PENICILLIN; THERAPY; SCALE; COMA	Context.-Meningococcal disease is associated with significant morbidity and mortality. Development of a prognostic model based on clinical findings may be useful for identification and management of patients with meningococcal infection. Objectives.-To construct and validate a bedside model and scoring system for prognosis in meningococcal disease. Design.-Prospective, population-based study. Setting.-Twenty-four hospitals in the metropolitan area of Barcelona, Spain. Patients.-A total of 907 patients with microbiologically proven meningococcal disease. Patients diagnosed with meningococcal disease from 1987 through 1990 were used to develop the prognostic model, and those diagnosed in 1991. and 1992 were used to validate it. Outcome Measures.-Clinical independent prognostic factors for mortality in meningococcal disease. The association between outcome and independent prognostic factors was determined by logistic regression analysis. A scoring system was constructed and tested using receiver operating characteristic curves. Results.-Among 624 patients in the derivation set, 287 (46%) were male, the mean age was 12.4 years, and 34 patients (5.4%) died. Among 283 patients in the validation set, 124 (43.8%) were male, the mean age was 12.7 years, and 17 patients (6.0%) died. In multivariate analysis, independent predictors of death were hemorrhagic diathesis (odds ratio [OR], 101; 95% confidence interval [CI], 30-333), focal neurologic signs (OR, 25; 95% CI, 7-83), and age 60 years or older (OR, 10; 95% CI, 3-34), whereas receipt of adequate antibiotic therapy prior to admission was associated with reduced likelihood of death (OR, 0.09; 95% CI, 0.02-0.4). Hemorrhagic diathesis was scored with 2 points, presence of focal neurologic signs with 1 point, age of 60 years or older with 1 point, and preadmission antibiotic therapy was scored as -1. The clinical scores of -1, 0, 1, 2, and 3 or more points were associated with a probability of death of 0%, 2.3%, 27.3%, 73.3%, and 100%, respectively. Conclusions.-Hemorrhagic diathesis, focal neurologic signs, and age of 60 years or older were independent predictors of death in meningococcal disease, whereas receipt of adequate antibiotic therapy was associated with a more favorable prognosis. The scoring system presented is simple, is based on findings readily ;available at the bedside, and may be useful to help guide aggressive therapy.	INST CATALA SALUT, CAP GRACIA, BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, E-08025 BARCELONA, SPAIN; INST MUNICIPAL SALUT, BARCELONA, SPAIN; HOSP CLIN BARCELONA, BARCELONA, SPAIN; HOSP INFANTIL VALL HEBRON, BARCELONA, SPAIN; DEPT SALUT PUBL & LEGISLACIO SANITARIA, BARCELONA, SPAIN; HOSP GERMANS TRIAS & PUJOL, BADALONA, SPAIN; BELLVITGE HOSP, LHOSPITALET DE LLOBREGAT, SPAIN; CTR NACL MICROBIOL VIROL & INMUNOL SANITARIAS, LAB REFERENCIA MENINGOCOCOS, MADRID, SPAIN	University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari Vall d'Hebron; Hospital Germans Trias i Pujol; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital			Domingo, Pere/AAP-7571-2021; Domingo, Pere/CAF-3577-2022; Rodrigo, Carlos/F-7602-2017; Marco, Francesc D/K-2900-2017; Moraga Llop, Fernando/E-2316-2016	Domingo, Pere/0000-0003-1138-5770; Rodrigo, Carlos/0000-0003-1140-2585; Marco, Francesc D/0000-0002-1863-6379; Moraga Llop, Fernando/0000-0001-7449-2632; Vazquez, Julio A/0000-0003-3326-8831; Cayla, Joan A./0000-0003-3891-111X				BJORVATN B, 1984, BRIT MED J, V288, P439, DOI 10.1136/bmj.288.6415.439; BOHR V, 1983, J INFECTION, V7, P193, DOI 10.1016/S0163-4453(83)96980-3; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRANDTZEAG P, 1987, LANCET, V2, P862; BUSUND R, 1993, CRIT CARE MED, V21, P1699, DOI 10.1097/00003246-199311000-00019; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; DOMINGO P, 1995, LANCET, V345, P460, DOI 10.1016/S0140-6736(95)90446-8; DRAPER WH, 1864, AM MED TIMES, V9, P114; DRAPER WH, 1864, AM MED TIMES, V9, P99; DRAPER WH, 1864, AM MED TIMES, V9, P101; EMPARANZA JI, 1988, CRIT CARE MED, V16, P168, DOI 10.1097/00003246-198802000-00015; Flexner S, 1913, J EXP MED, V17, P553, DOI 10.1084/jem.17.5.553; GARDLUND B, 1986, INTENS CARE MED, V12, P302, DOI 10.1007/BF00261740; GEDDEDAHL TW, 1990, REV INFECT DIS, V12, P973; GIRAUD T, 1991, ARCH INTERN MED, V151, P310, DOI 10.1001/archinte.151.2.310; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; KAHN A, 1978, CLIN PEDIATR, V17, P680, DOI 10.1177/000992287801700902; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LEWIS LS, 1979, ARCH DIS CHILD, V54, P44, DOI 10.1136/adc.54.1.44; MORELLO JA, 1991, MANUAL CLIN MICROBIO, P258; NIKLASSON P-M, 1971, Scandinavian Journal of Infectious Diseases, V3, P17, DOI 10.3109/inf.1971.3.issue-1.03; Norusis M. J., 1986, SPSS PC IBM PC XT AT; SAUKKONEN K, 1988, J INFECT DIS, V158, P209, DOI 10.1093/infdis/158.1.209; SIMPSON D, 1982, LANCET, V2, P450; SINCLAIR JF, 1987, LANCET, V2, P38; *STAT EP RES CORP, 1990, EP GRAPH EST TEST PA; STIEHM ER, 1966, J PEDIATR-US, V68, P457, DOI 10.1016/S0022-3476(66)80250-0; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; STRONG N, 1811, MED PHILOS REG, V1, P12; STRONG N, 1811, MED PHILOS REG, V1, P57; STRONG N, 1811, MED PHILOS REG, V1, P96; TEASDALE G, 1974, LANCET, V2, P81; TESORO LJ, 1991, AM J DIS CHILD, V145, P218, DOI 10.1001/archpedi.1991.02160020112029; THOMSON APJ, 1991, CRIT CARE MED, V19, P26, DOI 10.1097/00003246-199101000-00010; THOMSON APJ, 1991, PEDIATRIC REV COMMUN, V5, P199; TUYSUZ B, 1993, ACTA PAEDIATR, V82, P1053, DOI 10.1111/j.1651-2227.1993.tb12809.x; Vieusseux G, 1806, J MED CHIR PHARMACOL, V11, P163; VIKMO H, 1978, SCAND J INFECT DIS, V10, P187, DOI 10.3109/inf.1978.10.issue-3.06; WONG VK, 1989, PEDIATR INFECT DIS J, V8, P224	42	62	63	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					491	496		10.1001/jama.278.6.491	http://dx.doi.org/10.1001/jama.278.6.491			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP243	9256224				2022-12-28	WOS:A1997XP24300031
J	Bannerman, E; Reilly, JJ; MacLennan, WJ; Kirk, T; Pender, F				Bannerman, E; Reilly, JJ; MacLennan, WJ; Kirk, T; Pender, F			Evaluation of validity of British anthropometric reference data for assessing nutritional state of elderly people in Edinburgh: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							SKELETAL SIZE; MALNUTRITION; INDEXES; VALUES	Objectives: To evaluate the appropriateness of two sets of commonly used anthropometric reference data for nutritional assessment of elderly people. Design: Cross sectional study. Setting: Two general practices in Edinburgh. Subjects: 200 independently living men and women aged 75 or over randomly recruited from the age and sex register of the practices. Main outcome measures: Weight (kg), knee height (cm), demispan (cm), mid-upper arm circumference (cm), triceps skinfold thickness (mm), arm muscle circumference (cm) body mass index (kg/m(2)), and demiquet (kg/m(2)) in men and minder (kg/m) in women. Results: Men and women in Edinburgh were significantly shorter than those in measured for the Nottingham reference data (demispan 0.79 v 0.80 (P < 0.05) for men and 0.72 v 0.73 (P < 0.01) for women). Comparison with data from South Wales showed that men and women from Edinburgh had significantly greater mid-upper arm circumference, triceps skinfold thickness, and arm muscle circumference. No one fell below the 10th centile of the South Wales data (the commonly used cut off point for determining malnutrition) for these measures. Conclusions: Both sets of reference data commonly used in Britain may be inappropriate for nutritional screening of elderly people in Edinburgh. Contemporary reference data appropriate for the whole of Britain need to be developed, and in the longer term biologically or clinically defined criteria for undernutrition should be established.	QUEEN MARGARET COLL,DEPT NUTR & DIETET,EDINBURGH EH12 8TS,MIDLOTHIAN,SCOTLAND; YORKHILL HOSP,DEPT HUMAN NUTR,GLASGOW G3 8SJ,LANARK,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,GERIATR MED UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Queen Margaret University; Royal Infirmary of Edinburgh; University of Edinburgh								[Anonymous], 1991, ANTHROPOMETRIC STAND; Bannerman E, 1997, P NUTR SOC, V55, p249A; BASSEY EJ, 1986, ANN HUM BIOL, V13, P499, DOI 10.1080/03014468600008661; BURR ML, 1984, BRIT J NUTR, V51, P165, DOI 10.1079/BJN19840020; CHUMLEA WC, 1985, J AM GERIATR SOC, V33, P116, DOI 10.1111/j.1532-5415.1985.tb02276.x; CHUMLEA WC, 1989, AM J CLIN NUTR, V50, P1158, DOI 10.1093/ajcn/50.5.1158; COCKRAM DB, 1990, AM J CLIN NUTR, V52, P397, DOI 10.1093/ajcn/52.2.397; DELARUE J, 1994, BRIT J NUTR, V71, P295, DOI 10.1079/BJN19940135; Department of Health, 1992, 43 DEP HLTH; FRIEDMAN PJ, 1985, AGE AGEING, V14, P149, DOI 10.1093/ageing/14.3.149; Gibson RS, 1990, Q REV BIOL; Gregory J., 1990, DIETARY NUTR SURVEY; LEHMANN AB, 1991, CLIN NUTR, V10, P18, DOI 10.1016/0261-5614(91)90076-O; Lennard-Jones J E, 1992, POSITIVE APPROACH NU; LOHMAN TG, 1993, ADV BODY COMPOSITION, V3; MCWHIRTER JP, 1994, BRIT MED J, V308, P945, DOI 10.1136/bmj.308.6934.945; MORGAN DB, 1986, AGE AGEING, V15, P65, DOI 10.1093/ageing/15.2.65; POTTER J, 1995, AGE AGEING, V24, P131, DOI 10.1093/ageing/24.2.131; SAVAGE SA, 1997, P NUTR SOC, V55, pA81; Thuluvath PJ, 1995, NUTRITION, V11, P731; Wright CM, 1996, BMJ-BRIT MED J, V313, P513, DOI 10.1136/bmj.313.7056.513	21	31	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					338	341						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270454	Green Published			2022-12-28	WOS:A1997XQ86400019
J	Young, JDH; MacEwen, CJ				Young, JDH; MacEwen, CJ			Managing congenital lacrimal obstruction in general practice	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NASOLACRIMAL DUCT OBSTRUCTION				Young, JDH (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT OPHTHALMOL, DUNDEE DD1 9SY, SCOTLAND.							ALHUSSAIN H, 1993, OPHTHALMIC PLAST REC, V9, P32, DOI 10.1097/00002341-199303000-00004; Becker BB, 1996, AM J OPHTHALMOL, V121, P304, DOI 10.1016/S0002-9394(14)70279-X; CASSADY JV, 1952, AMA ARCH OPHTHALMOL, V47, P141; CRIGLER LW, 1923, JAMA-J AM MED ASSOC, V51, P23; GRIN TR, 1991, OPHTHALMOLOGY, V98, P1238; GUERRY D, 1948, AM J OPHTHALMOL, V31, P773; KATOWITZ JA, 1987, OPHTHALMOLOGY, V94, P698; KUSHNER BJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P597; LYON DB, 1991, OPHTHALMIC SURG LAS, V22, P228; MacEwen C J, 1991, Eye (Lond), V5 ( Pt 5), P596; MACEWEN CJ, 1991, J PEDIATR OPHTHALMOL, V28, P302; MACEWEN CJ, 1994, J PEDIATR OPHTHALMOL, V31, P246; MANSOUR AM, 1991, OPHTHALMOLOGY, V98, P1744; NELSON LB, 1985, OPHTHALMOLOGY, V92, P1187; Nucci P, 1989, J Pediatr Ophthalmol Strabismus, V26, P39; PAUL TO, 1994, J PEDIATR OPHTHALMOL, V31, P362; PAUL TO, 1958, J PEDIATR, V22, P68; PETERSEN RA, 1978, J PEDIAT OPHTH STRAB, V15, P246; POLLARD ZF, 1991, J PEDIATR OPHTHALMOL, V28, P341; PRICE HW, 1947, J PEDIATR, V30, P302, DOI 10.1016/S0022-3476(47)80165-9; WEINSTEIN GS, 1982, AM J OPHTHALMOL, V94, P106, DOI 10.1016/0002-9394(82)90201-X; WESLEY RE, 1985, OPHTHALMIC SURG LAS, V16, P368; Young JDH, 1996, EYE, V10, P485, DOI 10.1038/eye.1996.107	23	43	49	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 2	1997	315	7103					293	296		10.1136/bmj.315.7103.293	http://dx.doi.org/10.1136/bmj.315.7103.293			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274552	Green Published			2022-12-28	WOS:A1997XP75000027
J	Philipp, T; Anlauf, M; Distler, A; Holzgreve, H; Michaelis, J; Wellek, S				Philipp, T; Anlauf, M; Distler, A; Holzgreve, H; Michaelis, J; Wellek, S			Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Results of the HANE study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; HYPERTENSION; PLACEBO; TRIAL	Objective: To compare the effectiveness and tolerability of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in patients with mild to moderate hypertension. Design: Randomised multicentre trial over 48 weeks with double blind comparison of treatments. Setting: 48 centres in four countries. Patients: 868 patients with essential hypertension (diastolic blood pressure 95-120 mm Hg). Interventions: Initial treatment (step 1) consisted of 12.5 mg hydrochlorothiazide (n=215), 25 mg atenolol (n=215), 10 mg nitrendipine (n=218), or 5 mg enalapril (n=220) once daily. If diastolic blood pressure was not reduced to < 90 mm Hg within four weeks, doses were increased to 25 mg, 50 mg, 20 mg, 10 mg, respectively, once daily (step 2) and after two more weeks to twice daily (step 3). The eight week titration phase was followed by an additional 40 weeks for patients who had reached the target diastolic pressure. Main outcome measure: Blood pressure by means of an automatic device with repeated measurements. Results: After eight weeks the response rate for atenolol (63.7%) was significantly higher than for enalapril (50.0%), hydrochlorothiazide (44.7%), or nitrendipine (44.5%). After one year atenolol was still more effective (48.0%) than hydrochlorothiazide (35.4%) and nitrendipine (32.9%), but not significantly better than enalapril (42.7%). The treatment related dropout rate was higher (P < 0.001) in the nitrendipine group (n=28). Conclusions: There is no evidence of superiority for antihypertensive effectiveness or tolerability of the ''new'' classes of antihypertensives (calcium channel blockers and angiotensin converting enzyme inhibitors). As these drugs are now widely used as treatment of first choice, our results further emphasise the need for studies confirming that they also reduce morbidity and mortality, as has been shown for diuretics and beta blockers.	ZENTRALKRANKENHAUS REINKENHEIDE, D-27574 BREMERHAVEN, GERMANY; FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, MED KLIN & POLIKLIN, D-12203 BERLIN, GERMANY; UNIV MUNICH, MED POLIKLIN, D-80336 MUNICH, GERMANY; ZI SEEL GESUNDHEIT, BIOSTAT ABT, D-68072 MANNHEIM, GERMANY; UNIV MAINZ, INST MED STAT, D-55131 MAINZ, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; Johannes Gutenberg University of Mainz	Philipp, T (corresponding author), UNIV ESSEN GESAMTHSCH KLINIKUM, ZENTRUM INNERE MED, HUFELANDSTR 55, D-45122 ESSEN, GERMANY.			Wellek, Stefan/0000-0001-8369-8122				*1993 GUID MAN MIL, 1993, J HYPERTENS, V11, P905; [Anonymous], 1980, LANCET, V1, P1261; BUHLER FR, 1983, HYPERTENSION, V5, P94; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DRAYER JIM, 1981, AM J MED SCI, V281, P135, DOI 10.1097/00000441-198105000-00003; *DTSCH LIG BEK HOH, 1904, EMPF HOCHDR PRAX BEH; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HOLM S, 1979, SCAND J STAT, V6, P65; HOLZGREVE H, 1989, BRIT MED J, V299, P881, DOI 10.1136/bmj.299.6704.881; *HYP DET FOLL UP P, 1979, JAMA-J AM MED ASSOC, V242, P2562; *HYP GUID COMM, 1991, GUID END HIGH BLOOD; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MUTTI E, 1991, J HYPERTENS, V9, P361, DOI 10.1097/00004872-199104000-00008; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; ROBERTSON JIS, 1990, J HYPERTENS       S4, V8, P559; SAUNDERS E, 1990, ARCH INTERN MED, V150, P1707, DOI 10.1001/archinte.150.8.1707; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; TVELD AJM, 1988, J CARDIOVASC PHAR S8, V12, P593; WASSERTHEILSMOLLER S, 1992, AM J HYPERTENS, V5, P37, DOI 10.1093/ajh/5.1.37; *WHO COLL CTR DRUG, 1993, AN THER CHEM ATC CLA	20	129	132	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	1997	315	7101					154	159		10.1136/bmj.315.7101.154	http://dx.doi.org/10.1136/bmj.315.7101.154			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251545	Green Published			2022-12-28	WOS:A1997XM32100019
J	Singleton, L; Turner, M; Haskal, R; Etkind, S; Tricarico, M; Nardell, E				Singleton, L; Turner, M; Haskal, R; Etkind, S; Tricarico, M; Nardell, E			Long-term hospitalization for tuberculosis control - Experience with a medical-psychosocial inpatient unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT; HEALTH; BABY	Context.-Patients with tuberculosis (TB) who are nonadherent to therapy or have complicated medical or social problems pose a threat to public health. In some cases, hospitalization may be a necessary component of a comprehensive TB control program. Objective.-To describe experience with a new inpatient program for TB control. Design.-Retrospective review. Setting.-Eighteen-bed, secure, TB treatment unit in a state public health hospital providing a spectrum of acute and chronic care services. Patients.-Patients with known or suspected TB who were unable to be treated as outpatients and were hospitalized from 1990 through 1995. Interventions.-voluntary or involuntary hospitalization, with medical, psychosocial, and legal services. Main Outcome Measures.-Admissions, treatment completion, and disposition. Results.-A total of 166 patients with a confirmed diagnosis of TB accounted for 214 hospitalizations for TB. The mean age was 42 years, 132 (79.5%) were men, 84 (50.6%) were nonwhite, and 45 (27.1%) were foreign born. At the time of admission, 58 patients (34.5%) were homeless, 116 (69.9%) had a history of abuse of alcohol or other drugs, and 46 (31.7%) were positive for human immunodeficiency virus. The mean length of stay was 119.7 days (median, 70 days; range, 7-656 days), and was higher among homeless patients than nonhomeless patients (168.8 vs 93.4 days). Of 48 patients (28.9%) who were admitted involuntarily, 21 required long-term confinement under court order. Admission indications (not mutually exclusive) changed over 5 years: nonadherence decreased (95% to 34%), medical complexity increased (14% to 77%), short-term isolation increased (19% to 39%), and involuntary admission decreased (54% to 13%). Of 157 patients with positive cultures for Mycobacterium tuberculosis, 36 (23.1%) were resistant to at least 1 drug, including 16 who were multidrug resistant. A total of 123 patients (74.7%) were discharged to an outpatient setting to complete therapy, 40 (24.1%) required inpatient care to complete therapy, and 3 died (1 from TB) before discharge. Conclusions.-A high proportion of patients with TB who failed outpatient therapy completed treatment in a combined medical and psychosocial inpatient unit. During the 5-year study period, involuntary admissions decreased and most patients completed therapy as outpatients. In Massachusetts, this program plays an important role in protecting public health and in providing specialized medical management for patients to complete therapy in a safe and supportive environment.	MASSACHUSETTS DEPT PUBL HLTH,LEMUEL SHATTUCK HOSP,BOSTON,MA 02130	Massachusetts Department of Public Health	Singleton, L (corresponding author), MASSACHUSETTS DEPT PUBL HLTH,DEPT PUBL HLTH,DIV TB PREVENT & CONTROL,305 S ST,BOSTON,MA 02130, USA.							ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; *AM LUNG ASS S CAR, 1989, US INC EN TUB CONTR; ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; Burman WJ, 1997, CHEST, V111, P1168, DOI 10.1378/chest.111.5.1168; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; EARNEST M, 1996, TUBERCULOSIS, P927; Etkind S, 1991, Semin Respir Infect, V6, P273; ETKIND SC, 1996, TUBERCULOSIS, P945; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; GUNDERSON JG, 1978, PSYCHIATRY, V41, P327, DOI 10.1080/00332747.1978.11023992; HARSCH HH, 1989, PSYCHOSOMATICS, V30, P313; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; POZIK CJ, 1993, MED CLIN N AM, V77, P1289; RUBEL AJ, 1992, PUBLIC HEALTH REP, V107, P626; SBARBARO JA, 1986, CHEST, V90, P754, DOI 10.1378/chest.90.5.754; STOUDEMIRE A, 1986, PSYCHOSOMATICS, V27, P341, DOI 10.1016/S0033-3182(86)72685-6; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; TURNER M, 1995, AM J RESP CRIT CAR 2, V151, pA554; TURNER M, 1994, AM J RESP CRIT CAR 2, V149, pA257; *US DEP HHS, 1994, IMPR PAT ADH TUB TRE; YEAGER H, 1986, CHEST, V90, P752, DOI 10.1378/chest.90.5.752	22	40	46	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					838	842		10.1001/jama.278.10.838	http://dx.doi.org/10.1001/jama.278.10.838			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU552	9293992				2022-12-28	WOS:A1997XU55200039
J	Ortmann, B; Copeman, J; Lehner, PJ; Sadasivan, B; Herberg, JA; Grandea, AG; Riddell, SR; Tampe, R; Spies, T; Trowsdale, J; Cresswell, P				Ortmann, B; Copeman, J; Lehner, PJ; Sadasivan, B; Herberg, JA; Grandea, AG; Riddell, SR; Tampe, R; Spies, T; Trowsdale, J; Cresswell, P			A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes	SCIENCE			English	Article							HLA CLASS-I; PEPTIDE-BINDING; ANTIGEN PRESENTATION; CELL LINE; MOLECULES; TRANSPORTERS; EXPRESSION; RETENTION; PATHWAY; CHARGE	Newly assembled major histocompatibility complex (MHC) class I molecules, together with the endoplasmic reticulum chaperone calreticulin, interact with the transporter associated with antigen processing (TAP) through a molecule called tapasin, The molecular cloning of tapasin revealed it to be a transmembrane glycoprotein encoded by an MHC-linked gene. It is a member of the immunoglobulin superfamily with a probable cytoplasmic endoplasmic reticulum retention signal. Up to four MHC class I-tapasin complexes were found to bind to each TAP molecule. Expression of tapasin in a negative mutant human cell line (220) restored class I-TAP association and normal class I cell surface expression. Tapasin expression also corrected the defective recognition of virus-infected 220 cells by class I-restricted cytotoxic T cells, establishing a critical functional role for tapasin in MHC class I-restricted antigen processing.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; IMPERIAL CANC RES FUND, HUMAN IMMUNOGENET LAB, LONDON WC2A 3PX, ENGLAND; FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Howard Hughes Medical Institute; Yale University; Cancer Research UK; Fred Hutchinson Cancer Center; Max Planck Society			Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160; Herberg, Jethro/0000-0001-6941-6491; Lehner, Paul Joseph/0000-0001-9383-1054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030581, R01AI030581] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30581] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BUSCH R, 1996, EMBO J, V15, P412; COLLINS JF, 1990, METHOD ENZYMOL, V183, P474; COLLINS JF, 1987, NUCLEIC ACID PROTEIN, P323; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; GRANDEA AG, IN PRESS IMMUNOGENET; GREEN NM, 1991, NATURE, V351, P349, DOI 10.1038/351349a0; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JONES T, 1997, GENOMICS, V40, P189; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Neisig A, 1996, J IMMUNOL, V156, P3196; Nelson K, 1989, IMMUNOBIOLOGY HLA, P292; Noessner Elfriede, 1995, Journal of Experimental Medicine, V181, P327; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; ORTMANN B, UNPUB; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SENGER G, 1993, CYTOGENET CELL GENET, V64, P49, DOI 10.1159/000133559; Solheim JC, 1997, J IMMUNOL, V158, P2236; Suh WK, 1996, J EXP MED, V184, P337, DOI 10.1084/jem.184.2.337; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLISON K, 1987, EMBO J, V6, P1967, DOI 10.1002/j.1460-2075.1987.tb02459.x	38	428	435	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	1997	277	5330					1306	1309		10.1126/science.277.5330.1306	http://dx.doi.org/10.1126/science.277.5330.1306			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271576				2022-12-28	WOS:A1997XT82700055
J	Goodrich, LV; Milenkovic, L; Higgins, KM; Scott, MP				Goodrich, LV; Milenkovic, L; Higgins, KM; Scott, MP			Altered neural cell fates and medulloblastoma in mouse patched mutants	SCIENCE			English	Article							SONIC-HEDGEHOG; FLOOR PLATE; INDUCTION; GENE; EXPRESSION; ECTODERM; MICE; CNS	The PATCHED (PTC) gene encodes a Sonic hedgehog (Shh) receptor and a tumor suppressor protein that is defective in basal cell nevus syndrome (BCNS). Functions of PTC were investigated by inactivating the mouse gene. Mice homozygous for the ptc mutation died during embryogenesis and were found to have open and overgrown neural tubes. Two Shh target genes, ptc itself and Gli, were derepressed in the ectoderm and mesoderm but not in the endoderm. Shh targets that are, under normal conditions, transcribed ventrally were aberrantly expressed in dorsal and lateral neural tube cells. Thus Ptc appears to be essential for repression of genes that are locally activated by Shh. Mice heterozygous for the ptc mutation were larger than normal, and a subset of them developed hindlimb defects or cerebellar medulloblastomas, abnormalities also seen in BCNS patients.	STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University								AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BONNEROT C, 1993, GUIDE TECHNIQUES MOU, P463; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Concordet JP, 1996, DEVELOPMENT, V122, P2835; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GREEN MARGARET C., 1952, OHIO JOUR SCI, V52, P31; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hepker J, 1997, DEVELOPMENT, V124, P549; HOGAN B, 1994, MANIPULATING MOUSE E, P196; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JOYNER AL, 1993, GENE TARGETING PRACT, P33; KADIN ME, 1970, J NEUROPATH EXP NEUR, V29, P583, DOI 10.1097/00005072-197010000-00005; LACOMBE D, 1990, Genetic Counseling, V1, P273; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marigo V, 1996, DEVELOPMENT, V122, P1225; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Provias JP, 1996, J NEURO-ONCOL, V29, P35, DOI 10.1007/BF00165516; Raffel C, 1997, CANCER RES, V57, P842; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RORKE LB, 1994, AM J PATHOL, V144, P444; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Stevenson L, 1934, ARCH NEURO PSYCHIATR, V31, P93, DOI 10.1001/archneurpsyc.1934.02250010105005; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Xie JW, 1997, CANCER RES, V57, P2369	45	1360	1407	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	1997	277	5329					1109	1113		10.1126/science.277.5329.1109	http://dx.doi.org/10.1126/science.277.5329.1109			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262482				2022-12-28	WOS:A1997XT03300039
J	Meyerson, M; Counter, CM; Eaton, EN; Ellisen, LW; Steiner, P; Caddle, SD; Ziaugra, L; Beijersbergen, RL; Davidoff, MJ; Liu, QY; Bacchetti, S; Haber, DA; Weinberg, RA				Meyerson, M; Counter, CM; Eaton, EN; Ellisen, LW; Steiner, P; Caddle, SD; Ziaugra, L; Beijersbergen, RL; Davidoff, MJ; Liu, QY; Bacchetti, S; Haber, DA; Weinberg, RA			hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization	CELL			English	Article							TETRAHYMENA-TELOMERASE; EPITHELIAL-CELLS; HUMAN GENOME; HUMAN FIBROBLASTS; RNA COMPONENT; MAP; IDENTIFICATION; LYMPHOCYTES; SENESCENCE; CARCINOMA	Telomerase, the ribonucleoprotein enzyme that elongates telomeres, is repressed in normal human somatic cells but is reactivated during tumor progression. We report the cloning of a human gene, hEST2, that shares significant sequence similarity with the telomerase catalytic subunit genes of lower eukaryotes. hEST2 is expressed at high levels in primary tumors, cancer cell lines, and telomerase-positive tissues but is undetectable in telomerase-negative cell lines and differentiated telomerase-negative tissues. Moreover, the message is up-regulated concomitant with the activation of telomerase during the immortalization of cultured cells and down-regulated during in vitro cellular differentiation. Taken together, these observations suggest that the induction of hEST2 mRNA expression is required for the telomerase activation that occurs during cellular immortalization and tumor progression.	MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CTR CANC,CHARLESTOWN,MA 02129; MERCK RES LABS,DEPT HUMAN GENET,W POINT,PA 19486; MCMASTER UNIV,DEPT PATHOL,CANC RES GRP,HAMILTON,ON L8N 3Z5,CANADA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Merck & Company; McMaster University	Meyerson, M (corresponding author), MIT,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142, USA.		Meyerson, Matthew L/E-7123-2012; Ellisen, Leif W/AAA-6572-2022	Ellisen, Leif W/0000-0003-0444-7910; Beijersbergen, Roderick/0000-0003-0116-4130; Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA058596, R35CA039826, R37CA058596] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39826, CA 58596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avilion AA, 1996, CANCER RES, V56, P645; Balsara BR, 1997, CANCER RES, V57, P2116; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; CHUMAKOV IM, 1995, NATURE, V377, P175; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Gollahon LS, 1996, ONCOGENE, V12, P715; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GREIDER CW, 1995, TELOMERES, P35; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Petersen I, 1997, CANCER RES, V57, P2331; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Wright WE, 1996, DEV GENET, V18, P173; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Xu D, 1996, LEUKEMIA, V10, P1354; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	65	1591	1803	1	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					785	795		10.1016/S0092-8674(00)80538-3	http://dx.doi.org/10.1016/S0092-8674(00)80538-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288757	Bronze			2022-12-28	WOS:A1997XT06600021
J	Tanksley, SD; McCouch, SR				Tanksley, SD; McCouch, SR			Seed banks and molecular maps: Unlocking genetic potential from the wild	SCIENCE			English	Article							PHYLOGENETIC-RELATIONSHIPS; LYCOPERSICON	Nearly a century has been spent collecting and preserving genetic diversity in plants. Germplasm banks-living seed collections that serve as repositories of genetic variation-have been established as a source of genes for improving agricultural crops. Genetic linkage maps have made it possible to study the chromosomal locations of genes for improving yield and other complex traits important to agriculture. The tools of genome research may finally unleash the genetic potential of our wild and cultivated germplasm resources for the benefit of society.			Tanksley, SD (corresponding author), CORNELL UNIV,DEPT PLANT BREEDING,252 EMERSON HALL,ITHACA,NY 14853, USA.							BERNACCHI D, UNPUB; Brown LR, 1994, STATE WORLD; Brown S. M., 1996, GENOME MAPPING PLANT, P85; DEVICENTE MC, 1993, GENETICS, V134, P585; DUVICK DN, 1977, ANN NY ACAD SCI, V287, P86, DOI 10.1111/j.1749-6632.1977.tb34233.x; ESHED Y, 1994, THEOR APPL GENET, V88, P891, DOI 10.1007/BF01254002; Falconer DS., 1993, INTRO QUANTITATIVE G; FULTON TF, IN PRESS THEOR APPL; GRANDILLO S, UNPUB; Harlan J. R., 1987, PLANT GENETIC RESOUR, P111; HARTAN JR, 1975, CROPS MAN; Karp A, 1997, NAT BIOTECHNOL, V15, P625, DOI 10.1038/nbt0797-625; MCCOUCH SR, COMMUNICATION; MILLER JC, 1990, THEOR APPL GENET, V80, P437, DOI 10.1007/BF00226743; National Academy of Sciences, 1972, GEN VULN MAJ CROPS; PATERSON A, 1996, GENOME MAPPING PLANT; Plunknett DL, 1987, GENE BANKS WORLDS FO; Smith S, 1996, GENOME MAPPING PLANT, P95; Tanksley SD, 1996, THEOR APPL GENET, V92, P213, DOI 10.1007/BF00223378; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; Tanksley SD, 1996, THEOR APPL GENET, V92, P191, DOI 10.1007/BF00223376; ULLSTROP AJ, 1978, AGR HDB, V199, P1; Vavilov NI, 1940, NEW SYSTEMATICS, P549; WANG ZY, 1992, THEOR APPL GENET, V83, P565, DOI 10.1007/BF00226900; Xiao JH, 1996, NATURE, V384, P223, DOI 10.1038/384223a0; [No title captured]	26	1502	1694	9	230	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1063	1066		10.1126/science.277.5329.1063	http://dx.doi.org/10.1126/science.277.5329.1063			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262467				2022-12-28	WOS:A1997XT03300024
J	Stella, N; Schweitzer, P; Piomelli, D				Stella, N; Schweitzer, P; Piomelli, D			A second endogenous cannabinoid that modulates long-term potentiation	NATURE			English	Article							ARACHIDONIC-ACID; BRAIN; ANANDAMIDE; RECEPTOR; NEURONS; IDENTIFICATION; INHIBITION; SLICES; BINDS	Cannabinoid receptors are molecular targets for marijuana and hashish, the widespread drugs of abuse. These receptors are expressed in areas of the central nervous system that contribute in important ways to the control of memory, cognition, movement and pain perception(1). Indeed, such functions can be strongly influenced by cannabinoid drugs, with consequences that include euphoria, analgesia, sedation and memory impairment(2). Although the pharmacology of cannabinoid drugs is now beginning to be understood, we still lack essential information on the endogenous signalling system(s) by which cannabinoid receptors are normally engaged. An endogenous ligand for cannabinoid receptors, anandamide, has been described(3). Here we report that sn-2 arachidonylglycerol (2-AG), a cannabinoid ligand isolated from intestinal tissue(4), is present in brain in amounts 170 times greater than anandamide. 2-AG is produced in hippocampal slices by stimulation of the Schaffer collaterals, an excitatory fibre tract that projects from CA3 to CA1 neurons. Formation of 2-AG is calcium dependent and is mediated by the enzymes phospholipase C and diacylglycerol lipase. 2-AG activates neuronal cannabinoid receptors as a full agonist, and prevents the induction of long-term potentiation at CA3-CA1 synapses. Our results indicate that 2-AG is a second endogenous cannabinoid ligand in the central nervous system.	INST NEUROSCI, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BELTRAMO M, IN PRESS SCIENCE; BRINDLEY DN, 1985, BIOCH LIPIDS MEMBRAN, P213; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; EVANS DM, 1994, J PHARMACOL EXP THER, V268, P1271; FAROOQUI AA, 1986, INT J BIOCHEM, V18, P991, DOI 10.1016/0020-711X(86)90244-2; Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014-5793(96)00891-5; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HEYSER CJ, 1993, J PHARMACOL EXP THER, V264, P294; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; Jung M, 1997, J NEUROCHEM, V68, P402; Mallet PE, 1996, BEHAV PHARMACOL, V7, P276; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; NOWICKY AV, 1987, BRAIN RES BULL, V19, P663, DOI 10.1016/0361-9230(87)90052-9; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; Schmid PC, 1996, FEBS LETT, V385, P125; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; STELLA N, 1995, J NEUROSCI, V15, P3307; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; TERRANOVA JP, 1995, N-S ARCH PHARMACOL, V352, P576, DOI 10.1007/BF00169393; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823; WEISS S, 1986, P NATL ACAD SCI USA, V83, P2238, DOI 10.1073/pnas.83.7.2238	30	1162	1192	0	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					773	778		10.1038/42015	http://dx.doi.org/10.1038/42015			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285589	Green Submitted, Bronze			2022-12-28	WOS:A1997XR66700051
J	Weinstein, LB; Jones, BCNM; Cosstick, R; Cech, TR				Weinstein, LB; Jones, BCNM; Cosstick, R; Cech, TR			A second catalytic metal ion in a group I ribozyme	NATURE			English	Article							TETRAHYMENA RIBOZYME; ENDORIBONUCLEASE ACTIVITY; GUANOSINE BINDING; RNA; SUBSTRATE; SITE; MECHANISM; COMPLEXES; CLEAVAGE; STEP	Although only a subset of protein enzymes depend on the presence of a metal ion for their catalytic function, all naturally occurring RNA enzymes require metal ions to stabilize their structure and for catalytic competence(1). In the self-splicing group I intron from Tetrahymena thermophila(2), several divalent metals can serve structural roles, but only Mg2+ and Mn2+ promote splice-site cleavage and exon ligation(3,4). A study of a ribozyme reaction analogous to 5'-splice-site cleavage by guanosine uncovered the first metal ion with a definitive role in catalysis. Substitution of the 3'-oxygen of the leaving group with sulphur resulted in a metal-specificity switch, indicating an interaction between the leaving group and the metal ion(5). Here we use 3'-(thioinosylyl)-(3' --> 5')-uridine(6), IspU, as a substrate in a reaction that emulates exon ligation. Activity requires the addition of a thiophilic metal ion (Cd2+ or Mn2+), providing evidence for stabilization of the leaving group by a metal ion in that step of splicing. Based on the principle of microscopic reversibility, this metal ion activates the nucleophilic 3'-hydroxyl of guanosine in the first step of splicing, supporting the model of a two-metal-ion active site(7).	UNIV COLORADO,DEPT CHEM & BIOCHEM,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV LIVERPOOL,DEPT CHEM,ROBERT ROBINSON LABS,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Liverpool								BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P648, DOI 10.1021/bi951962z; BHAT V, 1992, SYNTHETIC COMMUN, V22, P1481, DOI 10.1080/00397919208021616; Cech T.R., 1993, RA WELCH FDN C CHEM, VXXXVII, P91; CECH TR, 1996, NUCL ACIDS MOL BIOL, P1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1994, BIOCHEMISTRY-US, V33, P5291, DOI 10.1021/bi00183a036; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; Kuimelis RG, 1995, NUCLEIC ACIDS RES, V23, P4753, DOI 10.1093/nar/23.23.4753; MCCONNELL TS, 1995, BIOCHEMISTRY-US, V34, P4056, DOI 10.1021/bi00012a024; McConnell TS, 1997, BIOCHEMISTRY-US, V36, P8293, DOI 10.1021/bi9700678; MCCONNELL TS, 1994, THESIS U COLORADO; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; Pyle AM, 1996, MET IONS BIOL SYST, V32, P479; Sjogren AS, 1997, NUCLEIC ACIDS RES, V25, P648, DOI 10.1093/nar/25.3.648; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Thomson JB, 1996, J ORG CHEM, V61, P6273, DOI 10.1021/jo960795l; Weinstein LB, 1996, J AM CHEM SOC, V118, P10341, DOI 10.1021/ja9616903; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	26	153	157	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					805	808		10.1038/42076	http://dx.doi.org/10.1038/42076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285596	Bronze			2022-12-28	WOS:A1997XR66700058
J	Lo, YMD; Corbetta, N; Chamberlain, PF; Rai, V; Sargent, IL; Redman, CWG; Wainscoat, JS				Lo, YMD; Corbetta, N; Chamberlain, PF; Rai, V; Sargent, IL; Redman, CWG; Wainscoat, JS			Presence of fetal DNA in maternal plasma and serum	LANCET			English	Article							PRENATAL-DIAGNOSIS; PERIPHERAL-BLOOD; AMPLIFICATION; DISEASE; CELLS	Background The potential use of plasma and serum for molecular diagnosis has generated interest. Tumour DNA has been found in the plasma and serum of cancer patients, and molecular analysis has been done on this material. We investigated the equivalent condition in pregnancy-that is, whether fetal DNA is present in maternal plasma and serum. Methods We used a rapid-boiling method to extract DNA from plasma and serum. DNA from plasma, serum, and nucleated blood cells from 43 pregnant women underwent a sensitive Y-PCR assay to detect circulating male fetal DNA from women bearing male fetuses. Findings Fetus-derived Y sequences were detected in 24 (80%) of the 30 maternal plasma samples, and in 21 (70%) of the 30 maternal serum samples, from women bearing male fetuses. These results were obtained with only 10 mu L of the samples. When DNA from nucleated blood cells extracted from a similar volume of blood was used, only five (17%) of the 30 samples gave a positive Y signal. None of the 13 women bearing female fetuses, and none of the ten non-pregnant control women, had positive results for plasma, serum or nucleated blood cells. Interpretation Our finding of circulating fetal DNA in maternal plasma may have implications for non-invasive prenatal diagnosis, and for improving our understanding of the fetomaternal relationship.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT HAEMATOL,OXFORD OX3 9DU,ENGLAND; OSPED MAGGIORE,IRCCS,IST MED INTERNA & FISIOPATOL MED,MILAN,ITALY	University of Oxford; University of Oxford; University of Oxford; IRCCS Ca Granda Ospedale Maggiore Policlinico			Lo, Yuk Ming Dennis/D-4468-2011	Lo, Yuk Ming Dennis/0000-0001-8746-0293	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIANCHI DW, 1996, PEDIATR RES, V39, P142; CAMASCHELLA C, 1990, BLOOD, V75, P2102; Chen XQ, 1996, NAT MED, V2, P1033; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; EMANUEL SL, 1993, GENET ANAL-BIOMOL E, V10, P144, DOI 10.1016/1050-3862(93)90009-8; Lo YMD, 1996, BLOOD, V88, P4390; LO YMD, 1993, LANCET, V341, P1147, DOI 10.1016/0140-6736(93)93161-S; LO YMD, 1990, LANCET, V335, P1463, DOI 10.1016/0140-6736(90)91491-R; LO YMD, 1989, LANCET, V2, P1363; Mulcahy HE, 1996, LANCET, V348, P628, DOI 10.1016/S0140-6736(05)65067-2; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; REBELLO MT, 1991, PRENATAL DIAG, V11, P41, DOI 10.1002/pd.1970110108; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIMPSON JL, 1993, JAMA-J AM MED ASSOC, V270, P2357, DOI 10.1001/jama.270.19.2357; STROUN M, 1989, ONCOLOGY, V46, P318	15	1992	2417	11	191	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					485	487		10.1016/S0140-6736(97)02174-0	http://dx.doi.org/10.1016/S0140-6736(97)02174-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274585				2022-12-28	WOS:A1997XR13500011
J	Palda, VA; Detsky, AS				Palda, VA; Detsky, AS			Clinical guideline .2. Perioperative assessment and management of risk from coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Review							PERIPHERAL VASCULAR-SURGERY; ABDOMINAL AORTIC-SURGERY; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; SILENT-MYOCARDIAL-ISCHEMIA; DIPYRIDAMOLE-THALLIUM SCINTIGRAPHY; NON-CARDIAC SURGERY; ECG MONITORING PRIOR; NONCARDIAC SURGERY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION	Purpose: To summarize available evidence on preoperative cardiac risk stratification so that the internist may 1) use clinical and electrocardiographic findings to stratify a patient's perioperative risk for myocardial infarction and death; 2) decide which tests provide useful additional risk-related information; and 3) understand the benefits, risks, and evidence surrounding the decision to undertake coronary revascularization before elective noncardiac surgery. Data Sources: A MEDLINE search and review of the reference lists of identified articles. Sensitivities, specificities, and likelihood ratios for diagnostic tests were calculated, and a quality rating for study methods was applied. Data Extraction: Myocardial infarction and mortality were the major outcomes considered, and a quality rating for study methods was applied. Data Synthesis: Clinical and electrocardiographic findings, organized by multivariate prediction indices, accurately identify patients as having low, intermediate, or high risk for myocardial infarction or death. Pharmacologic stress imaging with thallium or echocardiography probably improves risk stratification for intermediate-risk patients having vascular surgery, These tests have not been shown to be effective prognostic indicators for patients having nonvascular surgery. No studies of angiography for risk prediction have been reported. Decision analyses and retrospective series suggest that the risks incurred by doing coronary angiography and revascularization before elective surgery outweigh the benefits. Prospective, controlled studies of coronary revascularization are lacking. Evidence from a randomized, controlled trial has shown a survival benefit with the perioperative use of beta-blockers in patients at risk for coronary artery disease. Conclusions: Evaluation of all surgical patients by use of clinical indices is recommended, Low-risk patients need no further evaluation before surgery. High-risk patients need optimal management of their high-risk problems, including (if appropriate) beta-blocker use, and may need to have their elective procedures canceled. Intermediate-risk patients probably benefit from further noninvasive stress testing, especially if they are having vascular surgery. Further clinical trials are needed for most areas of concern.	TORONTO HOSP, TORONTO, ON M5T 2S8, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Palda, VA (corresponding author), UNIV TORONTO, MT SINAI HOSP, ST MICHAELS HOSP, 30 BOND ST, 4-151, TORONTO, ON M5B 1W8, CANADA.							ALLEN JR, 1991, SURG GYNECOL OBSTET, V173, P285; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; BARON JF, 1991, ANESTHESIOLOGY, V75, P611, DOI 10.1097/00000542-199110000-00010; BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; BERTRAND M, 1990, Anesthesiology (Hagerstown), V73, pA86; BILLEBRAHE NE, 1980, ACTA ANAESTH SCAND, V24, P501, DOI 10.1111/j.1399-6576.1980.tb01593.x; Bodenheimer MM, 1996, ANN INTERN MED, V124, P763, DOI 10.7326/0003-4819-124-8-199604150-00010; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BOURASSA MG, 1976, CIRCULATION, V53, P106, DOI 10.1161/01.CIR.53.1.106; BREWSTER DC, 1985, J VASC SURG, V2, P504, DOI 10.1067/mva.1985.avs0020504; BROWN KA, 1993, J AM COLL CARDIOL, V21, P325, DOI 10.1016/0735-1097(93)90670-V; BROWNER WS, 1992, JAMA-J AM MED ASSOC, V268, P228, DOI 10.1001/jama.268.2.228; BRY JDL, 1994, J VASC SURG, V19, P112, DOI 10.1016/S0741-5214(94)70126-1; BUNT TJ, 1992, J VASC SURG, V15, P626, DOI 10.1016/0741-5214(92)90007-U; CALVIN JE, 1986, CAN J SURG, V29, P93; CAMBRIA RP, 1992, J VASC SURG, V15, P43, DOI 10.1016/0741-5214(92)70012-A; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CARLINER NH, 1985, AM J CARDIOL, V56, P51, DOI 10.1016/0002-9149(85)90565-X; CHADWICK L, 1991, BRIT J SURG, V78, P875, DOI 10.1002/bjs.1800780732; CHARLSON ME, 1987, ARCH INTERN MED, V147, P2155, DOI 10.1001/archinte.147.12.2155; CHRISTOPHERSON R, 1993, ANESTHESIOLOGY, V79, P422, DOI 10.1097/00000542-199309000-00004; CHUNG F, 1988, ANESTHESIOLOGY, V69, P343, DOI 10.1097/00000542-198809000-00010; COHEN MM, 1988, J CLIN EPIDEMIOL, V41, P83, DOI 10.1016/0895-4356(88)90012-1; COLEY CM, 1992, AM J CARDIOL, V69, P1280, DOI 10.1016/0002-9149(92)91221-O; CORIAT P, 1984, ANESTHESIOLOGY, V61, P193, DOI 10.1097/00000542-198408000-00013; CRAWFORD ES, 1978, ANN THORAC SURG, V26, P215, DOI 10.1016/S0003-4975(10)63673-9; CUTLER BS, 1987, J VASC SURG, V5, P91, DOI 10.1067/mva.1987.avs0050091; CUTLER BS, 1992, J VASC SURG, V15, P972, DOI 10.1016/0741-5214(92)90453-F; CUTLER BS, 1981, AM J SURG, V141, P501, DOI 10.1016/0002-9610(81)90148-3; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DAVILAROMAN VG, 1993, J AM COLL CARDIOL, V21, P957, DOI 10.1016/0735-1097(93)90353-3; DEBAKEY ME, 1984, J VASC SURG, V1, P605, DOI 10.1067/mva.1984.avs0010605; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; DODDS TM, 1993, ANESTH ANALG, V76, P705; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; EDWARDS ND, 1995, BRIT J ANAESTH, V74, P368, DOI 10.1093/bja/74.4.368; EICHELBERGER JP, 1993, AM J CARDIOL, V72, P602, DOI 10.1016/0002-9149(93)90359-K; EISENBERG MJ, 1992, JAMA-J AM MED ASSOC, V268, P210, DOI 10.1001/jama.268.2.210; ELLIOTT BM, 1991, CIRCULATION, V84, P54; ELMORE JR, 1993, MAYO CLIN PROC, V68, P637, DOI 10.1016/S0025-6196(12)60598-9; FLEISHER L A, 1990, Anesthesiology (Hagerstown), V73, pA75; FLEISHER LA, 1995, ANESTHESIOLOGY, V83, P906, DOI 10.1097/00000542-199511000-00003; FLEISHER LA, 1992, CAN J ANAESTH, V39, P179, DOI 10.1007/BF03008653; Fleisher LA, 1996, ANN INTERN MED, V124, P767, DOI 10.7326/0003-4819-124-8-199604150-00011; FLEISHER LA, 1994, ANESTH ANALG, V79, P661; FLEISHER LA, 1991, AM HEART J, V122, P980, DOI 10.1016/0002-8703(91)90461-P; FLETCHER JP, 1988, J CARDIOVASC SURG, V29, P666; FLETCHER JP, 1989, BRIT J SURG, V76, P26, DOI 10.1002/bjs.1800760109; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; FRANCO CD, 1989, J VASC SURG, V10, P656, DOI 10.1067/mva.1989.16173; GERSON MC, 1985, ANN INTERN MED, V103, P832, DOI 10.7326/0003-4819-103-6-832; GERSON MC, 1990, AM J MED, V88, P101, DOI 10.1016/0002-9343(90)90456-N; GESENSWAY DG, 1995, OBSERVER, V15, P28; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; GODET G, 1987, ANESTHESIOLOGY, V66, P241, DOI 10.1097/00000542-198702000-00027; GOLDMAN L, 1978, CHEST, V73, P450, DOI 10.1378/chest.73.4.450; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GRANT RP, 1990, CAN J ANAESTH, V37, P409, DOI 10.1007/BF03005616; Halm EA, 1996, ANN INTERN MED, V125, P433, DOI 10.7326/0003-4819-125-6-199609150-00001; HENDEL RC, 1995, CIRCULATION, V91, P1044, DOI 10.1161/01.CIR.91.4.1044; HENDEL RC, 1992, AM J CARDIOL, V70, P1243, DOI 10.1016/0002-9149(92)90756-O; HERTZER NR, 1979, ARCH SURG-CHICAGO, V114, P1336; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; HUBER KC, 1992, MAYO CLIN PROC, V67, P15, DOI 10.1016/S0025-6196(12)60271-7; JEFFREY CC, 1983, ANESTHESIOLOGY, V58, P462, DOI 10.1097/00000542-198305000-00013; JIVEGARD L, 1993, EUR J VASCULAR SURG, V7, P180, DOI 10.1016/S0950-821X(05)80760-1; JIVEGARD L, 1992, EUR J VASCULAR SURG, V6, P83, DOI 10.1016/S0950-821X(05)80100-8; JOSEPHSON MA, 1982, AM HEART J, V103, P1008, DOI 10.1016/0002-8703(82)90564-6; KAAJA R, 1993, ANGIOLOGY, V44, P11, DOI 10.1177/000331979304400102; Kazmers A, 1991, J Ky Med Assoc, V89, P279; KAZMERS A, 1988, J VASC SURG, V8, P128, DOI 10.1067/mva.1988.avs0080128; KETTUNEN J, 1995, HEPATO-GASTROENTEROL, V42, P106; KHURI SF, 1995, J AM COLL SURGEONS, V180, P519; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; Kirwin J D, 1993, Ann Vasc Surg, V7, P27, DOI 10.1007/BF02042656; KRESOWIK TF, 1993, ARCH SURG-CHICAGO, V128, P299; LALKA SG, 1992, J VASC SURG, V15, P831, DOI 10.1016/0741-5214(92)90718-N; LANDESBERG G, 1993, LANCET, V341, P715, DOI 10.1016/0140-6736(93)90486-Z; LANE RT, 1991, AM J CARDIOL, V68, P976, DOI 10.1016/0002-9149(91)90424-J; LANE SE, 1989, AM J CARDIOL, V64, P1275, DOI 10.1016/0002-9149(89)90567-5; LANGAN EM, 1993, J VASC SURG, V18, P905, DOI 10.1016/0741-5214(93)90544-V; LARSEN SF, 1987, EUR HEART J, V8, P179, DOI 10.1093/oxfordjournals.eurheartj.a062246; LAZOR L, 1988, SURG GYNECOL OBSTET, V167, P234; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; LETTE J, 1991, J VASC SURG, V14, P160; LETTE J, 1992, AM J CARDIOL, V69, P1553, DOI 10.1016/0002-9149(92)90702-Z; LETTE J, 1992, ANN SURG, V216, P192, DOI 10.1097/00000658-199208000-00010; LETTE J, 1992, AM J MED, V92, P615, DOI 10.1016/0002-9343(92)90779-B; LETTE J, 1989, AM J CARDIOL, V64, P276, DOI 10.1016/0002-9149(89)90519-5; LETTE J, 1990, ANN SURG, V211, P84, DOI 10.1097/00000658-199001000-00015; LEVINSON JR, 1990, AM J CARDIOL, V66, P406, DOI 10.1016/0002-9149(90)90694-V; LItalien GJ, 1996, J AM COLL CARDIOL, V27, P779, DOI 10.1016/0735-1097(95)00566-8; LUNDQVIST BW, 1989, ACTA CHIR SCAND, V155, P321; MADSEN PV, 1992, ANGIOLOGY, V43, P306; MAGNUSSON J, 1986, BRIT J ANAESTH, V58, P251, DOI 10.1093/bja/58.3.251; MAHAR LJ, 1978, J THORAC CARDIOV SUR, V76, P533; MAKAROUN MS, 1990, ARCH SURG-CHICAGO, V125, P1610; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; Mangano DT, 1995, NEW ENGL J MED, V333, P1750, DOI 10.1056/NEJM199512283332607; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MARSCH SCU, 1992, ANESTHESIOLOGY, V76, P518, DOI 10.1097/00000542-199204000-00006; MARSHALL ES, 1995, AM J CARDIOL, V76, P817, DOI 10.1016/S0002-9149(99)80234-3; MARWICK TH, 1990, CLIN CARDIOL, V13, P14, DOI 10.1002/clc.4960130105; MASON JJ, 1995, JAMA-J AM MED ASSOC, V273, P1919, DOI 10.1001/jama.273.24.1919; Matley P J, 1991, Eur J Vasc Surg, V5, P187, DOI 10.1016/S0950-821X(05)80686-3; MCCANN RL, 1989, J VASC SURG, V9, P583, DOI 10.1067/mva.1989.vs0090583; MCCANN RL, 1989, J VASC SURG, V10, P240; MCCOLLUM CH, 1977, SURGERY, V81, P302; MCENROE CS, 1990, J VASC SURG, V11, P497, DOI 10.1067/mva.1990.18756; MCFALLS EO, 1993, J AM COLL CARDIOL, V21, P1347, DOI 10.1016/0735-1097(93)90307-M; MCPHAIL N, 1988, J VASC SURG, V7, P60, DOI 10.1067/mva.1988.avs0070060; MCPHAIL N, 1985, CAN J SURG, V28, P404; MCPHAIL NV, 1993, EUR J VASCULAR SURG, V7, P151, DOI 10.1016/S0950-821X(05)80755-8; MCPHAIL NV, 1989, J VASC SURG, V10, P51, DOI 10.1067/mva.1989.vs0100051; MCPHAIL NV, 1990, CAN J SURG, V33, P224; MENKE H, 1993, INT SURG, V78, P266; MICHEL LA, 1990, J THORAC CARDIOV SUR, V100, P595; MILLER JI, 1992, ANN THORAC SURG, V54, P249, DOI 10.1016/0003-4975(92)91378-M; MILLER K, 1993, CLIN ORTHOP RELAT R, P148; MOSLEY JG, 1985, BRIT J SURG, V72, P886, DOI 10.1002/bjs.1800721113; NIELSEN JL, 1992, AM J SURG, V164, P423, DOI 10.1016/S0002-9610(05)81173-0; OUYANG P, 1989, AM J CARDIOL, V64, P1113, DOI 10.1016/0002-9149(89)90862-X; OWENS WD, 1975, SURGERY, V77, P586; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012; PASTERNACK PF, 1992, J VASC SURG, V16, P171, DOI 10.1016/0741-5214(92)90105-H; PASTERNACK PF, 1989, AM J SURG, V158, P113, DOI 10.1016/0002-9610(89)90357-7; PASTERNACK PF, 1987, CIRCULATION, V76, P1; PASTERNACK PF, 1984, J VASC SURG, V1, P320, DOI 10.1067/mva.1984.avs0010320; PASTERNACK PF, 1989, J VASC SURG, V10, P617, DOI 10.1067/mva.1989.15572; PASTERNACK PF, 1985, CIRCULATION, V72, P13; PAUL SD, 1994, J AM COLL CARDIOL, pA133; PEDERSEN T, 1990, ACTA ANAESTH SCAND, V34, P183, DOI 10.1111/j.1399-6576.1990.tb03067.x; PICANO E, 1991, J AM COLL CARDIOL, V17, P666, DOI 10.1016/S0735-1097(10)80182-2; POLDERMANS D, 1995, J AM COLL CARDIOL, V26, P648, DOI 10.1016/0735-1097(95)00240-5; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; PREZ RDD, 1995, CIRCULATION, V92, pS744; PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P122, DOI 10.1093/bja/43.2.122; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; RABY KE, 1990, NEW ENGL J MED, V323, P1781; REIFSNYDER T, 1992, J SURG RES, V52, P147, DOI 10.1016/0022-4804(92)90296-C; REUL GJ, 1986, J VASC SURG, V3, P788, DOI 10.1067/mva.1986.avs0030788; ROIZEN MF, 1993, ANESTHESIOLOGY, V78, P380; RUDDY T, 1989, Journal of the American College of Cardiology, V13, p149A; RYAN TJ, 1993, J AM COLL CARDIOL, V22, P2033, DOI 10.1016/0735-1097(93)90794-2; SACHS RN, 1988, SURGERY, V103, P584; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P119; SAUVE MD, 1989, CLIN RES, V37, pA325; SEEGER JM, 1994, ANN SURG, V219, P654, DOI 10.1097/00000658-199406000-00008; SHAW L, 1992, AM HEART J, V124, P861, DOI 10.1016/0002-8703(92)90965-X; STEEN PA, 1978, JAMA-J AM MED ASSOC, V239, P2566, DOI 10.1001/jama.239.24.2566; Steinberg J B, 1993, Cardiovasc Surg, V1, P552; STEYERBERG EW, 1995, ARCH INTERN MED, V155, P1998, DOI 10.1001/archinte.155.18.1998; STONE JG, 1988, BRIT J ANAESTH, V61, P675, DOI 10.1093/bja/61.6.675; STRATMANN HG, 1990, CLIN CARDIOL, V13, P611, DOI 10.1002/clc.4960130905; STRATMANN HG, 1989, J VASC SURG, V10, P385; STRAWN DJ, 1991, ARCH SURG-CHICAGO, V126, P880; STUHMEIER KD, 1992, BRIT J ANAESTH, V69, P602, DOI 10.1093/bja/69.6.602; SUGGS WD, 1993, J VASC SURG, V18, P349, DOI 10.1016/0741-5214(93)90251-G; TAKASE B, 1993, AM HEART J, V126, P1099, DOI 10.1016/0002-8703(93)90660-2; THOMPSON RC, 1985, JAMA-J AM MED ASSOC, V254, P2419, DOI 10.1001/jama.254.17.2419; TISCHLER MD, 1991, AM J CARDIOL, V68, P593, DOI 10.1016/0002-9149(91)90349-P; TOAL KW, 1984, AM J SURG, V148, P825, DOI 10.1016/0002-9610(84)90447-1; URBINATI S, 1994, STROKE, V25, P2022, DOI 10.1161/01.STR.25.10.2022; Vanzetto G, 1996, AM J CARDIOL, V77, P143, DOI 10.1016/S0002-9149(96)90585-8; VONKNORRING J, 1981, SURGERY, V90, P55; VONKNORRING J, 1995, EUR J VASC ENDOVASC, V9, P133, DOI 10.1016/S1078-5884(05)80081-4; WATTERS TA, 1991, J AM COLL CARDIOL, V18, P93, DOI 10.1016/S0735-1097(10)80224-4; WEBB GD, 1991, J AM COLL CARDIOL, V18, P323, DOI 10.1016/0735-1097(91)90574-S; WENGER NK, 1990, AM J CARDIOL, V66, P1375, DOI 10.1016/0002-9149(90)91172-3; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004; YOUNIS L, 1994, AM J CARDIOL, V74, P311, DOI 10.1016/0002-9149(94)90395-6; YOUNIS LT, 1990, AM HEART J, V119, P1287, DOI 10.1016/S0002-8703(05)80177-2; ZELDIN RA, 1984, CAN J SURG, V27, P402; Zellner J L, 1990, Ann Vasc Surg, V4, P238, DOI 10.1007/BF02009451; 1989, CLIN EFFICACY ASSESS; 1966, JAMA-J AM MED ASSOC, V197, P775	187	159	168	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					313	328		10.7326/0003-4819-127-4-199708150-00012	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00012			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265434				2022-12-28	WOS:A1997XR26600013
J	Perlmann, T; Evans, RM				Perlmann, T; Evans, RM			Nuclear receptors in Sicily: All in the famiglia	CELL			English	Review							THYROID-HORMONE RECEPTOR; BINDING DOMAIN; RETINOIC ACID; CO-REPRESSOR; LIGAND; GAMMA; J(2)		SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Howard Hughes Medical Institute; Salk Institute	Perlmann, T (corresponding author), LUDWIG INST CANC RES,STOCKHOLM BRANCH,S-17177 STOCKHOLM,SWEDEN.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	31	130	135	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					391	397		10.1016/S0092-8674(00)80498-5	http://dx.doi.org/10.1016/S0092-8674(00)80498-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267019	Bronze			2022-12-28	WOS:A1997XQ06300003
J	Chang, WP; Hwang, BF; Wang, D; Wang, JD				Chang, WP; Hwang, BF; Wang, D; Wang, JD			Cytogenetic effect of chronic low-dose, low-dose-rate gamma-radiation in residents of irradiated buildings	LANCET			English	Article							HUMAN-LYMPHOCYTES; RADIOLOGICAL ACCIDENT; X-IRRADIATION; MICRONUCLEI; BRAZIL; FREQUENCY	Background Many people in Taiwan have been living in buildings constructed with cobalt-60-contaminated steel rods. To study the biological effects of chronic low-dose ionising radiation on the residents of one such building, micronucleus formation in these individuals was compared with that in controls. Methods The 73 residents had 77 age-and-sex-matched controls: 31 had 31 close relatives as controls (group A controls); eight of the 31 had a second set of close relatives; and the other controls were 38 residents in neighbouring buildings. Two micronucleus assays were used-a cytochalasin B (CBMN) assay and another involving incubation cytarabine (CBMNA). Assay results are given as ''frequency'', or the number of binucleate cells containing one micronucleus per 1000 randomly examined binucleate cells. Findings The CBMN and CBMNA mean (SD) frequencies for 31 exposed individuals (0.016 [0.009] and 0.025 [0.013] respectively) were greater than those for their group A controls (0.009 [0.004] and 0.016 [0.009], respectively) (p=0.0006 and 0.0002, respectively). The mean CBMN and CBMNA frequencies for all the exposed individuals (0.017 [0.011] and 0.030 [0.014], respectively) were significantly greater than those for all controls (0.011 [0.008] and 0.019 [0.01]; p=0.0001 for both comparisons). The ranges of the differences in CBMN or CBMNA frequencies between 31 exposed individuals and their group A controls were 0.003 to 0.020 and 0.001 to 0.032, respectively. After adjustment for age, sex, and cigarette smoking, the adjusted relative risks of micronucleus formation from radiation exposure in all 73 residents was 1.56 (95% CI 1.42-1.71; p=0.0001) by the CBMN assay and 1.64 (1.53-1.77; p=0.0001) by the CBMNA assay. Interpretation These findings suggest that chronic low-dose and low-dose-rate gamma-ray environmental exposure may induce cytogenetic damage in human beings.	NATL TAIWAN UNIV, COLL PUBL HLTH, TAIPEI, TAIWAN	National Taiwan University	Chang, WP (corresponding author), NATL YANG MING UNIV, SCH MED, INST PUBL HLTH, 155 SECT 2, LIH LONG ST, TAIPEI, TAIWAN.		Hwang, Bing-Fang/O-2709-2015; Rascher, Uwe/D-5457-2009	Hwang, Bing-Fang/0000-0002-5951-9662; Pieruschka, Roland/0000-0002-9774-2670; Rascher, Uwe/0000-0002-9993-4588				BENDER MA, 1988, MUTAT RES, V196, P103, DOI 10.1016/0165-1110(88)90017-6; BILLEN D, 1990, RADIAT RES, V124, P242, DOI 10.2307/3577872; BONASSI S, 1994, MUTAT RES-ENVIR MUTA, V313, P69, DOI 10.1016/0165-1161(94)90034-5; Cardarelli J, 1997, HEALTH PHYS, V72, P351, DOI 10.1097/00004032-199703000-00002; Chang WP, 1996, ENVIRON MOL MUTAGEN, V27, P93; CHANG WP, 1993, LANCET, V342, P1544, DOI 10.1016/S0140-6736(05)80105-9; Chang WP, 1993, LANCET, V341, P750; CHANG WP, 1997, HEALTH PHYS, V73, P1; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; DACRUZ AD, 1994, MUTAT RES-ENVIR MUTA, V313, P57, DOI 10.1016/0165-1161(94)90033-7; FENECH M, 1986, MUTAT RES, V161, P193, DOI 10.1016/0027-5107(86)90010-2; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; FENECH M, 1992, ENVIRON MOL MUTAGEN, V19, P27, DOI 10.1002/em.2850190106; FRIEDBERG EC, 1987, J CELL SCI, P1; HOLMBERG K, 1995, INT J RADIAT BIOL, V68, P245, DOI 10.1080/09553009514551171; International Committee on Radiological Protection, 1991, ICRP PUBL; LITTLEFIELD LG, 1991, PROG CLIN BIOL RES, V372, P387; LUBENAU JO, 1995, HEALTH PHYS, V68, P440, DOI 10.1097/00004032-199504000-00001; PROSSER JS, 1988, MUTAT RES, V199, P37, DOI 10.1016/0027-5107(88)90228-X; RAMALHO AT, 1995, MUTAT RES-FUND MOL M, V331, P47, DOI 10.1016/0027-5107(95)00049-O; RAMALHO AT, 1991, MUTAT RES, V252, P157, DOI 10.1016/0165-1161(91)90016-2; SILVA MJ, 1994, MUTAT RES-GENET TOX, V322, P117, DOI 10.1016/0165-1218(94)00019-0; Wuttke K, 1996, INT J RADIAT BIOL, V69, P259, DOI 10.1080/095530096146101	24	70	73	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					330	333		10.1016/S0140-6736(97)11056-X	http://dx.doi.org/10.1016/S0140-6736(97)11056-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251638	Green Submitted			2022-12-28	WOS:A1997XP24200011
J	Greenhalgh, T				Greenhalgh, T			How to read a paper: Getting your bearings (deciding what the paper is about)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-PRACTICE GUIDELINES; MALE BRITISH DOCTORS; MEDICAL LITERATURE; USERS GUIDES; DECISION-ANALYSIS; HELP ME; DIAGNOSTIC-TEST; ARTICLE; WILL; RECOMMENDATIONS				Greenhalgh, T (corresponding author), UCL, SCH MED, ROYAL FREE HOSP SCH MED, DEPT PRIMARY CARE & POPULAT SCI, LONDON N19 5NF, ENGLAND.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				Altman DG, 1996, BRIT MED J, V313, P570; ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; [Anonymous], 1988, LANCET, V2, P349; Bero LA, 1996, INT J TECHNOL ASSESS, V12, P209, DOI 10.1017/S0266462300009582; Crombie I, 1996, POCKET GUIDE CRITICA, V1st; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1964, BMJ-BRIT MED J, V1, P1460, DOI 10.1136/bmj.1.5396.1460; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Dowie J, 1996, J Health Serv Res Policy, V1, P104; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; ESTERBROOK PJ, 1991, LANCET, V302, P1099; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; MACNAUGHTON J, 1995, BRIT J GEN PRACT, V45, P571; MCBRIDE WG, 1961, LANCET, V2, P1358; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; Popper K. R., 1963, CONJECTURES REFUTAT; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; ROSE G, 1993, EPIDEMIOLOGY UNINITI; Sackett D., 1996, EVIDENCE BASED MED P; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; TAYLOR CD, 1996, JAMA-J AM MED ASSOC, V275, P1435; THORNTON JG, 1995, BRIT MED J, V310, P791, DOI 10.1136/bmj.310.6982.791; THORNTON JG, 1992, BRIT MED J, V304, P1099, DOI 10.1136/bmj.304.6834.1099; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630	36	124	126	0	83	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 26	1997	315	7102					243	246		10.1136/bmj.315.7102.243	http://dx.doi.org/10.1136/bmj.315.7102.243			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	9253275	Green Published			2022-12-28	WOS:A1997XN51700031
J	Honour, JW				Honour, JW			Misuse of natural hormones in sport	LANCET			English	Editorial Material											Honour, JW (corresponding author), UCL, DEPT MOL PATHOL, MORTIMER ST, LONDON W1N 8AA, ENGLAND.							BILTON RF, 1995, LANCET, V345, P1186, DOI 10.1016/S0140-6736(95)91022-0; DONIKE M, 1996, RECENT ADV DOPING AN, V3, P95; DONIKE M, 1993, SPORT LEISTUNG GESUN, P293; Honour JW, 1996, LANCET, V348, P41, DOI 10.1016/S0140-6736(96)05336-6; KICMAN AT, 1992, BRIT MED BULL, V48, P496, DOI 10.1093/oxfordjournals.bmb.a072559; SCHANZER W, 1997, RECENT ADV DOPING AN, V4	6	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1786	1786		10.1016/S0140-6736(05)61689-3	http://dx.doi.org/10.1016/S0140-6736(05)61689-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269210				2022-12-28	WOS:A1997XF73500006
J	Bodenheimer, T				Bodenheimer, T			The Oregon Health Plan - Lessons for the nation .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MANAGED CARE; MENTAL-HEALTH; ILL		UNIV CALIF SAN FRANCISCO, SCH MED, DEPT FAMILY & COMMUNITY MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								BOODMAN SG, 1997, WASHINGTON POST 0506, P12; Grumbach K, 1996, J Am Board Fam Pract, V9, P360; HAWKINS D, IN PRESS FUTURE US H; *HLTH CAR FIN ADM, 1997, TENN MENT HLTH SIT V; Iglehart JK, 1996, NEW ENGL J MED, V334, P131, DOI 10.1056/NEJM199601113340221; JELLINEK MS, 1993, JAMA-J AM MED ASSOC, V270, P1737, DOI 10.1001/jama.270.14.1737; *KAIS COMM FUT MED, 1996, WHERE IS MED SPEND H; LURIE N, 1992, JAMA-J AM MED ASSOC, V267, P3300, DOI 10.1001/jama.267.24.3300; Nelson L, 1997, HEALTH AFFAIR, V16, P148, DOI 10.1377/hlthaff.16.2.148; PAGE L, 1997, AM MED NEWS     0616, P3; PAGE L, 1997, AM MED NEWS     0616, P24; RICHARDSON JD, 1997, COMMUNICATION   0113; Schauffler HH, 1996, J HEALTH POLIT POLIC, V21, P461, DOI 10.1215/03616878-21-3-461; SHARPE A, 1997, WALL STREET J   0124, pA1; SHARPE A, 1997, WALL STREET J   0124, pA11; Sparer MS, 1996, J HEALTH POLIT POLIC, V21, P433, DOI 10.1215/03616878-21-3-433; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; 1997, STATE HLTH WATCH, V4, P6; 1997, COMMERCIAL APPE 0101, pA1; 1997, OREGON HLTH FORUM, V7, P4; 1997, STATE HLTH WATCH, V4, P3	21	48	49	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					720	723		10.1056/NEJM199709043371021	http://dx.doi.org/10.1056/NEJM199709043371021			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU349	9278472				2022-12-28	WOS:A1997XU34900032
J	Christakis, DA; Feudtner, C				Christakis, DA; Feudtner, C			Temporary matters - The ethical consequences of transient social relationships in medical training	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS; DILEMMAS; STUDENTS; CARE	Medical students and resident physicians spend much of their training engaged in transient, time-limited relationships with patients, families, and other care providers. This article offers a partial catalog of the problems that the evanescent nature of trainees' relationships with others creates in their lives, the strategies they often use to address these problems, and the deleterious consequences these strategies may have on their behavior and ethical development.	UNIV WASHINGTON,CHILDRENS HOSP & MED CTR,DIV GEN PEDIAT,SEATTLE,WA; ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SEATTLE,WA	Seattle Children's Hospital; University of Washington; University of Washington Seattle			Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434	AHRQ HHS [T32 HS00009] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Annas GJ, 1995, HASTINGS CENT REP, V25, pS12, DOI 10.2307/3527850; Bellah R., 1991, GOOD SOC; Berwick DM, 1995, HASTINGS CENT REP, V25, pS21, DOI 10.2307/3527853; BOSK CL, 1979, FORGIVE REMEMBER; BRUNETTI LL, 1991, J GEN INTERN MED, V6, P323, DOI 10.1007/BF02597430; CHRISTAKIS DA, 1993, ACAD MED, V68, P249, DOI 10.1097/00001888-199304000-00003; Douglas M., 1986, I THINK; FEUDTNER C, 1994, HASTINGS CENT REP, V24, P6, DOI 10.2307/3562379; FEUDTNER C, 1994, ACAD MED, V69, P670, DOI 10.1097/00001888-199408000-00017; Feudtner C, 1996, JAMA, V276, P755, DOI 10.1001/jama.276.9.755; Fox R, 1988, ESSAYS MED SOCIOLOGY; FOX RC, 1959, EXPT PERILOUS PHYSIC; Goffman Erving, 1959, MISE SCENE VIE QUOTI; Hafferty F.W., 1991, VALLEY DEATH SOCIALI; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; Hughes Everett C., 1961, BOYS WHITE; KASS LR, 1990, HASTINGS CENT REP, V20, P5, DOI 10.2307/3562966; Lief H. I., 1963, PSYCHOL BASIS MED PR, P12; LIEF HI, 1957, STUDENT PHYSICIAN IN, P207; LO B, 1981, ARCH INTERN MED, V141, P1062, DOI 10.1001/archinte.141.8.1062; Lo B, 1995, HASTINGS CENT REP, V25, pS6, DOI 10.2307/3527848; Marshall PA, 1995, HASTINGS CENT REP, V25, pS9, DOI 10.2307/3527849; Merton R.K., 1957, STUDENT PHYS INTRO S; REISER SJ, 1994, HASTINGS CENT REP, V24, P28, DOI 10.2307/3563464; Rosenberg Charles E., 1987, CARE STRANGERS RISE; Strauss AL., 1985, SOCIAL ORG MED WORK; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; Wailoo Keith., 1997, DRAWING BLOOD TECHNO, P46; WINKENWERDER W, 1985, JAMA-J AM MED ASSOC, V254, P3454	29	81	81	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					739	743		10.1001/jama.278.9.739	http://dx.doi.org/10.1001/jama.278.9.739			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286834				2022-12-28	WOS:A1997XT70900027
J	Ganem, JL; Krakower, J				Ganem, JL; Krakower, J			Review of US medical school finances, 1995-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								For the 1995-1996 fiscal year, all 125 accredited US medical schools responded to the annual medical school questionnaire of the Liaison Committee on Medical Education, part I-A. Using data from the financial portion of the questionnaire, we identify patterns of financing medical education during the past 3 years and the practice plan arrangements adopted by medical schools, including their organizational and legal structures. This financial review details differences in how public and private medical schools are being funded and funding changes during the past 3 years. The reported data show that revenues supporting medical school programs and activities totaled more than $31 billion in 1995-1996, an increase of 5.4% in inflation-adjusted dollars during the previous year. Compared with the previous year, revenues, in current and constant dollars, increased in almost every category in 1995-1996.			Ganem, JL (corresponding author), ASSOC AMER MED COLL,SECT OPERAT STUDIES,2450 N ST NW,WASHINGTON,DC 20037, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					755	760						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286837				2022-12-28	WOS:A1997XT70900030
J	Aksentijevich, I; Centola, M; Deng, ZM; Sood, R; Balow, JE; Wood, G; Zaks, N; Mansfield, E; Chen, X; Eisenberg, S; Vedula, A; Shafran, N; Raben, N; Pras, E; Pras, M; Kastner, DL; Blake, T; Baxevanis, AD; Robbins, C; Krizman, D; Collins, FS; Liu, PP; Chen, XG; Shohat, M; Hamon, M; Kahan, T; Cercek, A; Rotter, JI; FischelGhodsian, N; Richards, N; Shelton, DA; Gumucio, D; Yokoyama, Y; Mangelsdorf, M; Orsborn, A; Richards, RI; Ricke, DO; Buckingham, JM; Moyzis, RK; Deaven, LL; Doggett, NA				Aksentijevich, I; Centola, M; Deng, ZM; Sood, R; Balow, JE; Wood, G; Zaks, N; Mansfield, E; Chen, X; Eisenberg, S; Vedula, A; Shafran, N; Raben, N; Pras, E; Pras, M; Kastner, DL; Blake, T; Baxevanis, AD; Robbins, C; Krizman, D; Collins, FS; Liu, PP; Chen, XG; Shohat, M; Hamon, M; Kahan, T; Cercek, A; Rotter, JI; FischelGhodsian, N; Richards, N; Shelton, DA; Gumucio, D; Yokoyama, Y; Mangelsdorf, M; Orsborn, A; Richards, RI; Ricke, DO; Buckingham, JM; Moyzis, RK; Deaven, LL; Doggett, NA			Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN SECONDARY STRUCTURE; SHORT ARM; EXPRESSION; CLONING; FINGER; IDENTIFICATION; CHROMOSOME-16; EVOLUTIONARY; AMYLOIDOSIS	Familial Mediterranean fever (FMF) is a recessively inherited disorder characterized by dramatic episodes of fever and serosal inflammation. This report describes the cloning of the gene likely to cause FMF from a 115-kb candidate interval on chromosome 16p. Three different missense mutations were identified in affected individuals, but not in normals. Haplotype and mutational analyses disclosed ancestral relationships among carrier chromosomes in populations that have been separated for centuries. The novel gene encodes a 3.7-kb transcript that is almost exclusively expressed in granulocytes. The predicted protein, pyrin, is a member of a family of nuclear factors homologous to the Ro52 autoantigen. The cloning of the FMF gene promises to shed light on the regulation of acute inflammatory responses.	NIAMSD, ARTHRIT & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA; CHAIM SHEBA MED CTR, HELLER INST MED RES, DEPT MED C, IL-52621 TEL HASHOMER, ISRAEL; NHGRI, CANC GENET LAB, BETHESDA, MD 20892 USA; NHGRI, LAB GENE TRANSFER, BETHESDA, MD 20892 USA; NHGRI, GENOME TECHNOL BRANCH, BETHESDA, MD 20892 USA; CEDARS SINAI MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90048 USA; CEDARS SINAI MED CTR, DEPT MED GENET, LOS ANGELES, CA 90048 USA; BEILINSON MED CTR, DEPT MED GENET, IL-49100 PETAH TIQWA, ISRAEL; UNIV MICHIGAN, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; ADELAIDE WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOL GENET, ADELAIDE, SA 5006, AUSTRALIA; LOS ALAMOS NATL LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Cedars Sinai Medical Center; Cedars Sinai Medical Center; Rabin Medical Center; University of Michigan System; University of Michigan; Womens & Childrens Hospital Australia; United States Department of Energy (DOE); Los Alamos National Laboratory			Richards, Robert/ABE-6423-2020; Hamon, Melanie/B-3501-2013; Aksentijevich, Ivona/AAF-1335-2019; Liu, Paul/A-7976-2012; Mangelsdorf, Marie E/A-2318-2013	Liu, Paul/0000-0002-6779-025X; Mangelsdorf, Marie E/0000-0002-7855-7701; Baxevanis, Andy/0000-0002-5370-0014; Hamon, Melanie/0000-0001-5078-4083; Richards, Robert Ian/0000-0002-5978-6453				AISEN PS, 1985, P NATL ACAD SCI USA, V82, P1232, DOI 10.1073/pnas.82.4.1232; AKSENTIJEVICH I, 1993, AM J HUM GENET, V53, P644; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BALOW JE, 1997, IN PRESS GENOMICS; BARAKAT MH, 1988, LANCET, V2, P1280; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; Dackowski WR, 1996, GENOME RES, V6, P515, DOI 10.1101/gr.6.6.515; DANIELS M, 1995, AM J MED GENET, V55, P311, DOI 10.1002/ajmg.1320550313; DOGGETT NA, 1995, NATURE, V377, P335; FRENCH FMF, 1996, AM J HUM GENET, V59, P603; GERTZ MA, 1987, MAYO CLIN PROC, V62, P1095, DOI 10.1016/S0025-6196(12)62502-6; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Henry J, 1997, BIOCHEM BIOPH RES CO, V235, P162, DOI 10.1006/bbrc.1997.6751; ITOH K, 1991, J CLIN INVEST, V87, P177, DOI 10.1172/JCI114968; JACK LJW, 1990, J BIOL CHEM, V265, P14481; KARENKO L, 1992, J INTERN MED, V232, P365, DOI 10.1111/j.1365-2796.1992.tb00600.x; KASTNER DL, 1996, RTHRITIS ALLIED COND, P1279; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Levy EN, 1996, AM J HUM GENET, V58, P523; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PRAS E, 1994, HUM GENET, V94, P576; PRAS E, 1992, NEW ENGL J MED, V326, P1509, DOI 10.1056/NEJM199206043262301; PRAS E, 1997, IN PRESS AM J MED GE; PRAS M, 1982, JOHNS HOPKINS MED J, V150, P22; PTACEK LJ, 1991, CELL, V67, P1021; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHOHAT M, 1992, AM J HUM GENET, V51, P1349; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; Sood R, 1996, CYTOGENET CELL GENET, V72, P21; Sood R, 1997, GENOMICS, V42, P83, DOI 10.1006/geno.1997.4629; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; VERNET C, 1993, J MOL EVOL, V37, P600; WEATHERALL DJ, 1995, METABOLIC MOL BASES, P3417; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; YUVAL Y, 1995, AM J MED GENET, V57, P455, DOI 10.1002/ajmg.1320570319	48	1137	1183	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					797	807						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288758				2022-12-28	WOS:A1997XT06600022
J	Kaghad, M; Bonnet, H; Yang, A; Creancier, L; Biscan, JC; Valent, A; Minty, A; Chalon, P; Lelias, JM; Dumont, X; Ferrara, P; McKeon, F; Caput, D				Kaghad, M; Bonnet, H; Yang, A; Creancier, L; Biscan, JC; Valent, A; Minty, A; Chalon, P; Lelias, JM; Dumont, X; Ferrara, P; McKeon, F; Caput, D			Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers	CELL			English	Article							TUMOR-SUPPRESSOR GENES; N-MYC AMPLIFICATION; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; PROTEIN; CARCINOMA; MUTATIONS; GROWTH; RETINOBLASTOMA	We describe a gene encoding p73, a protein that shares considerable homology with the tumor suppressor p53. p73 maps to 1p36, a region frequently deleted in neuroblastoma and other tumors and thought to contain multiple tumor suppressor genes. Our analysis of neuroblastoma cell lines with Ip and p73 loss of heterozygosity failed to detect coding sequence mutations in remaining p73 alleles. However, the demonstration that p73 is monoallelically expressed supports the notion that it is a candidate gene in neuroblastoma. p73 also has the potential to activate p53 target genes and to interact with p53. We propose that the disregulation of p73 contributes to tumorigenesis and that p53-related proteins operate in a network of developmental and cell cycle controls.	SANOFI RECH,F-31676 LABEGE,FRANCE; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; INST GUSTAVE ROUSSY,URA 1967 CNRS,LAB CYTOGENET & GENET ONCOL,VILLEJUIF,FRANCE	Sanofi-Aventis; Sanofi France; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								AMBROS PF, 1995, EUR J CANCER, V31A, P510, DOI 10.1016/0959-8049(95)00044-J; AMLER LC, 1995, EUR J CANCER, V31A, P527, DOI 10.1016/0959-8049(95)00064-P; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHENG NC, 1995, ONCOGENE, V10, P291; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; GENUARDI M, 1989, AM J HUM GENET, V45, P73; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huttner WB, 1997, CURR OPIN NEUROBIOL, V7, P29, DOI 10.1016/S0959-4388(97)80117-1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAUREYS G, 1995, EUR J CANCER, V31A, P523, DOI 10.1016/0959-8049(95)00012-8; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LIN J, 1994, COLD SPRING HARB SYM, V59, P215, DOI 10.1101/SQB.1994.059.01.026; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANIATIS T, 1992, MOL CLONING; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SOZZI G, 1988, CANCER GENET CYTOGEN, V30, P151, DOI 10.1016/0165-4608(88)90104-5; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEMESS BA, 1990, SCIENCE, V248, P76; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; YEH SH, 1994, CANCER RES, V54, P4188; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	59	1476	1614	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					809	819		10.1016/S0092-8674(00)80540-1	http://dx.doi.org/10.1016/S0092-8674(00)80540-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288759	Bronze			2022-12-28	WOS:A1997XT06600023
J	Katan, MB; Grundy, SM; Willett, WC				Katan, MB; Grundy, SM; Willett, WC			Beyond low-fat diets	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RANDOMIZED TRIAL; LIPOPROTEINS; ACIDS; WOMEN; CHOLESTEROL		UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard T.H. Chan School of Public Health	Katan, MB (corresponding author), AGR UNIV WAGENINGEN, DIV HUMAN NUTR & EPIDEMIOL, BOMENWEG 2, NL-6703 HD WAGENINGEN, NETHERLANDS.							BLACK HS, 1994, NEW ENGL J MED, V330, P1272, DOI 10.1056/NEJM199405053301804; ERNST N, 1980, CIRCULATION, V62, P41; GRUNDY SM, 1986, NEW ENGL J MED, V314, P745, DOI 10.1056/NEJM198603203141204; HYEWON LH, 1988, AM J CLIN NUTR, V48, P575, DOI 10.1093/ajcn/48.3.575; JEFFERY RW, 1995, INT J OBESITY, V19, P132; KASIM SE, 1993, AM J CLIN NUTR, V57, P146, DOI 10.1093/ajcn/57.2.146; KEYS A, 1957, LANCET, V2, P959; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; *NAT DIET HEART ST, 1968, CIRCULATION S1, V37, P170; SACKS RM, 1994, J CARDIOVASC RISK, V1, P3; SHEPPARD L, 1991, AM J CLIN NUTR, V54, P821, DOI 10.1093/ajcn/54.5.821; Vega GL, 1996, CURR OPIN LIPIDOL, V7, P209, DOI 10.1097/00041433-199608000-00007; Willett Walter C., 1997, P559; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; WILLETT WC, IN PRESS AM J CLIN N	16	206	209	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					563	566						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262504				2022-12-28	WOS:A1997XR54800012
J	Rye, HS; Burston, SG; Fenton, WA; Beechem, JM; Xu, ZH; Sigler, PB; Horwich, AL				Rye, HS; Burston, SG; Fenton, WA; Beechem, JM; Xu, ZH; Sigler, PB; Horwich, AL			Distinct actions of cis and trans ATP within the double ring of the chaperonin GroEL	NATURE			English	Article							PROTEIN; CYCLE; CARBOXYLASE; MECHANISM; INTENSITY; RELEASE; BINDING; DOMAIN	The chaperonin GroEL is a double-ring structure with a central cavity in each ring that provides an environment for the efficient folding of proteins(1-3) when capped by the co-chaperone GroES in the presence of adenine nucleotides(4-8). Productive folding of the substrate rhodanese has been observed in cis ternary complexes, where GroES and polypeptide are bound to the same ring, formed with either ATP, ADP or non-hydrolysable ATP analogues(2,9), suggesting that the specific requirement for ATP is confined to an action in the trans ring that evicts GroES and polypeptide from the cis side(9). We show here, however, that for the folding of malate dehydrogenase and Rubisco there is also an absolute requirement for ATP in the cis ring, as ADP and AMP-PNP are unable to promote folding. We investigated the specific roles of binding and hydrolysis of ATP in the cis and trans rings using mutant forms of GroEL that bind ATP but are defective in its hydrolysis. Binding of ATP and GroES in cis initiated productive folding inside a highly stable GroEL-ATP-GroES complex. To discharge GroES and polypeptide, ATP hydrolysis in the cis ring was required to form a GroEL-ADP-GroES complex with decreased stability, priming the cis complex for release by ATP binding (without hydrolysis) in the trans ring. These observations offer an explanation of why GroEL functions as a double-ring complex.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; VANDERBILT UNIV,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Vanderbilt University				Rye, Hays/0000-0002-9420-3137; Burston, Steven/0000-0003-1848-1853				BEECHEM JM, 1995, BIOCHEMISTRY-US, V34, P13943, DOI 10.1021/bi00042a028; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ETFINK MR, 1994, BIOPHYS J, V66, P482; Fenton WA, 1997, PROTEIN SCI, V6, P743; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; PIERCE J, 1986, ARCH BIOCHEM BIOPHYS, V245, P483, DOI 10.1016/0003-9861(86)90241-9; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	24	348	350	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					792	798		10.1038/42047	http://dx.doi.org/10.1038/42047			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285593	Bronze			2022-12-28	WOS:A1997XR66700055
J	Beller, M; Ellis, A; Lee, SH; Drebot, MA; Jenkerson, SA; Funk, E; Sobsey, MD; Simmons, OD; Monroe, SS; Ando, T; Noel, J; Petric, M; Middaugh, JP; Spika, JS				Beller, M; Ellis, A; Lee, SH; Drebot, MA; Jenkerson, SA; Funk, E; Sobsey, MD; Simmons, OD; Monroe, SS; Ando, T; Noel, J; Petric, M; Middaugh, JP; Spika, JS			Outbreak of viral gastroenteritis due to a contaminated well - International consequences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ROUND STRUCTURED VIRUS; REVERSE TRANSCRIPTION-PCR; NORWALK-LIKE VIRUSES; HOSPITAL OUTBREAK; AIRBORNE TRANSMISSION; SRSV GASTROENTERITIS; WATER-SYSTEM; CRUISE SHIP; ABOARD; EPIDEMIOLOGY	Context.-Small round-structured viruses (SRSVs) are known to cause viral gastroenteritis, but until now have not been confirmed in the implicated Vehicle in outbreaks. Objective.-Investigation of a gastroenteritis outbreak. Design.-After applying epidemiologic methods to locate the outbreak source, we conducted environmental and laboratory investigations to elucidate the cause. Setting.-Tourists traveling by bus through Alaska and the Yukon Territory of Canada. Participants.-Staff of a restaurant at a business complex implicated as the outbreak source, convenience sample of persons on buses that had stopped there, and bus employees. Main Outcome Measures.-Odds ratios (ORs) for illness associated with exposures. Water samples from the restaurant and stool specimens from tourists and restaurant staff were examined by nucleic acid amplification using reverse transcription polymerase chain reaction and sequencing of viral amplification products. Results.-The itineraries of groups of tourists manifesting vomiting or diarrhea were traced back to a restaurant where buses had stopped 33 to 36 hours previously, Water consumption was associated with illness (OR, 5.3; 95% confidence interval [CI], 2.3-12.6). Eighteen of 26 employees of the business complex were ill; although not the index case, an employee ill shortly before the outbreak lived in a building connected to a septic pit, which was found to contaminate the well supplying the restaurant's water, Genotype 2/P2B SRSV was identified in stool specimens of 2 tourists and 1 restaurant employee. Stools and water samples yielded identical amplification product sequences. Conclusions.-The investigation documented SRSVs in a vehicle epidemiologically linked to a gastroenteritis outbreak. The findings demonstrate the power of molecular detection and identification and underscore the importance of fundamental public health practices such as restaurant inspection, assurance of a safe water supply, and disease surveillance.	LAB CTR DIS CONTROL,BUR DIS SURVEILLANCE & FIELD EPIDEMIOL,OTTAWA,ON K1A 0L2,CANADA; NATL CTR ENTEROVIRUSES,HALIFAX,NS,CANADA; CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,NATL CTR INFECT DIS,ATLANTA,GA; UNIV N CAROLINA,SCH PUBL HLTH,DEPT ENVIRONM SCI & ENGN,CHAPEL HILL,NC 27599; HOSP SICK CHILDREN,DEPT MICROBIOL,VIROL LAB,TORONTO,ON M5G 1X8,CANADA; LAB CTR DIS CONTROL,BUR INFECT DIS,OTTAWA,ON K1A 0L2,CANADA	Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Beller, M (corresponding author), ALASKA DEPT HLTH & SOCIAL SERV,DIV PUBL HLTH,POB 240249,ANCHORAGE,AK 99524, USA.			Monroe, Stephan/0000-0002-5424-716X				ANDO T, 1995, J MED VIROL, V47, P145, DOI 10.1002/jmv.1890470207; ANDO T, 1995, J CLIN MICROBIOL, V33, P64, DOI 10.1128/JCM.33.1.64-71.1995; CANNON RO, 1991, J INFECT DIS, V164, P860, DOI 10.1093/infdis/164.5.860; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P446; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P37; CHADWICK PR, 1994, LANCET, V343, P171, DOI 10.1016/S0140-6736(94)90959-8; CHADWICK PR, 1994, J HOSP INFECT, V26, P251, DOI 10.1016/0195-6701(94)90015-9; CHALMERS JWT, 1995, EPIDEMIOL INFECT, V115, P163, DOI 10.1017/S0950268800058222; DINGLE KE, 1995, J GEN VIROL, V76, P2349, DOI 10.1099/0022-1317-76-9-2349; DREBOT MA, 1994, J MED VIROL, V44, P340, DOI 10.1002/jmv.1890440406; DREBOT MA, IN PRESS BIOTECHNIQU; FLEISSNER ML, 1989, AM J EPIDEMIOL, V129, P165, DOI 10.1093/oxfordjournals.aje.a115105; GELLERT GA, 1990, INFECT CONT HOSP EP, V11, P459; GOODMAN RA, 1982, ARCH ENVIRON HEALTH, V37, P358, DOI 10.1080/00039896.1982.10667591; HO MS, 1989, LANCET, V2, P961; KAPIKIAN AZ, 1996, FIELDS VIROLOGY, P783; KAPLAN JE, 1982, J INFECT DIS, V146, P190, DOI 10.1093/infdis/146.2.190; KHAN AS, 1994, J CLIN MICROBIOL, V32, P318, DOI 10.1128/JCM.32.2.318-322.1994; KOBAYASHI S, 1991, EPIDEMIOL INFECT, V107, P81, DOI 10.1017/S0950268800048706; KOHN MA, 1995, JAMA-J AM MED ASSOC, V273, P466, DOI 10.1001/jama.273.6.466; LAWSON HW, 1991, LANCET, V337, P1200, DOI 10.1016/0140-6736(91)92868-3; Levett PN, 1996, J CLIN MICROBIOL, V34, P1497, DOI 10.1128/JCM.34.6.1497-1501.1996; LO SV, 1994, EPIDEMIOL INFECT, V113, P513, DOI 10.1017/S0950268800068527; MCANULTY JM, 1993, AUST J PUBLIC HEALTH, V17, P86; Morgan D, 1994, Commun Dis Rep CDR Rev, V4, pR91; NELSON M, 1992, J ENVIRON HEALTH, V54, P50; PATTERSON T, 1993, EPIDEMIOL INFECT, V111, P157, DOI 10.1017/S0950268800056776; Perrett K, 1995, Commun Dis Rep CDR Rev, V5, pR153; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; SCHWAB KJ, 1995, APPL ENVIRON MICROB, V61, P531, DOI 10.1128/AEM.61.2.531-537.1995; SHARP TW, 1995, J MED VIROL, V45, P61, DOI 10.1002/jmv.1890450112; SOBSEY MD, 1979, APPL ENVIRON MICROB, V37, P588, DOI 10.1128/AEM.37.3.588-595.1979; SOBSEY MD, 1994, RAPID METHODS AND AUTOMATION IN MICROBIOLOGY AND IMMUNOLOGY, P387; STEVENSON P, 1994, J HOSP INFECT, V26, P261, DOI 10.1016/0195-6701(94)90016-7; TREANOR J, 1995, PRINCIPLES PRACTICE, P1666; WARNER RD, 1991, ARCH INTERN MED, V151, P2419, DOI 10.1001/archinte.151.12.2419; WILSON R, 1982, AM J PUBLIC HEALTH, V72, P72, DOI 10.2105/AJPH.72.1.72; 1994, COMMUN DIS REP CDR W, V4, P43	39	140	145	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					563	568		10.1001/jama.278.7.563	http://dx.doi.org/10.1001/jama.278.7.563			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268277				2022-12-28	WOS:A1997XQ98600030
J	Mouzin, E; Mascola, L; Tormey, MP; Dassey, DE				Mouzin, E; Mascola, L; Tormey, MP; Dassey, DE			Prevention of Vibrio vulnificus infections - Assessment of regulatory educational strategies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Vibrio vulnificus-related disease caused by eating contaminated raw oysters prompted California to implement regulatory educational initiatives in 1991. Objective.-To assess California guidelines and education efforts with regard to the prevention of V vulnificus infections in Los Angeles County and to evaluate compliance with state regulations mandating posting of warning signs concerning risks of eating raw oysters. Design.-Review of epidemiologic investigations of V vulnificus infections in Los Angeles County between 1993 and 1995; telephone interviews of patients or surrogates; and a survey of restaurants serving raw oysters in Los Angeles County. Setting-General community. Main Outcome Measures.-Prior warning of patients and posting of warning signs in restaurants. Results.-Recent cases of V vulnificus infections in Los Angeles County suggest that a unique, vulnerable group (uninsured Hispanic men with viral or alcoholic liver disease) has not been reached through education efforts. Of a total of 11 cases, information regarding being warned about the hazard of eating raw shellfish was available for 8; of these, only 1 case was reported as having been warned, but he had misunderstood the preventive message. Warning signs were not posted adequately in more than 50% of restaurants surveyed and one third of these establishments had signs in English only. Warnings were never located on dining tables and rarely included in menus. Conclusion.-A more effective strategy is required to prevent V vulnificus infections in Los Angeles County.			Mouzin, E (corresponding author), LOS ANGELES CTY DEPT HLTH SERV,ACUTE COMMUNICABLE DIS CONTROL UNIT,313 N FIGUEROA ST,ROOM 212,LOS ANGELES,CA 90012, USA.							BLAKE PA, 1979, NEW ENGL J MED, V300, P1, DOI 10.1056/NEJM197901043000101; *CA STAT DEP HLTH, 1993, CALIFORNIA MORBIDITY, V31; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P405; Center for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P621; DAYAL HH, 1993, AM J PREV MED, V9, P191, DOI 10.1016/S0749-3797(18)30737-2; FELIX CW, 1995, FOOD PROTECTION REP, V11, P1; JOHNSTON JM, 1985, JAMA-J AM MED ASSOC, V253, P2850, DOI 10.1001/jama.253.19.2850; KELLY MT, 1982, APPL ENVIRON MICROB, V44, P820, DOI 10.1128/AEM.44.4.820-824.1982; OLIVER JD, 1982, MAR TECHNOL SOC J, V25, P49; TACKET CO, 1984, J INFECT DIS, V149, P558, DOI 10.1093/infdis/149.4.558; TAMPLIN M, 1982, APPL ENVIRON MICROB, V44, P1466, DOI 10.1128/AEM.44.6.1466-1470.1982; TUTTLE J, 1994, J TRANSPLANT COORDIN, V4, P60	12	34	34	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					576	578		10.1001/jama.278.7.576	http://dx.doi.org/10.1001/jama.278.7.576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268279				2022-12-28	WOS:A1997XQ98600032
J	Carpentier, A				Carpentier, A			Does surgical reduction of heart size reduce heart failure?	LANCET			English	Editorial Material											Carpentier, A (corresponding author), HOP BROUSSAIS, DEPT CARDIOVASC SURG & ORGAN TRANSPLANTAT, F-75014 PARIS, FRANCE.							Batista RJV, 1996, J CARDIAC SURG, V11, P96, DOI 10.1111/j.1540-8191.1996.tb00019.x; BOLLING SF, 1995, J THORAC CARDIOVASC, V109, P678; Carpentier A, 1997, BAKKEN RES, V11, P3; CARPENTIER A, 1997, ANN M AM COLL CARD A; Kannel William B., 1997, P279; MCCARTHY PM, 1997, 77 ANN M AM ASS THOR	6	15	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					456	456		10.1016/S0140-6736(97)22033-7	http://dx.doi.org/10.1016/S0140-6736(97)22033-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274576				2022-12-28	WOS:A1997XR13500002
J	Hendry, BM; James, AF				Hendry, BM; James, AF			Endothelin antagonists in renal disease	LANCET			English	Editorial Material											Hendry, BM (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON SE5 9PJ,ENGLAND.							Benigni A, 1996, AM J KIDNEY DIS, V27, P416, DOI 10.1016/S0272-6386(96)90366-2; FIRTH JD, 1995, AM J PHYSIOL-RENAL, V269, pF522, DOI 10.1152/ajprenal.1995.269.4.F522; GELLAI M, 1995, J PHARMACOL EXP THER, V275, P200; Kaddoura S, 1996, LANCET, V348, P418, DOI 10.1016/S0140-6736(05)64531-X; Kohan DE, 1997, AM J KIDNEY DIS, V29, P2, DOI 10.1016/S0272-6386(97)90004-4; Nabokov A, 1996, NEPHROL DIAL TRANSPL, V11, P514; ONG ACM, 1995, KIDNEY INT, V48, P390, DOI 10.1038/ki.1995.307; Parkinson NA, 1996, NEPHROL DIAL TRANSPL, V11, P1532; Weber C, 1996, CLIN PHARMACOL THER, V60, P124, DOI 10.1016/S0009-9236(96)90127-7	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					381	382		10.1016/S0140-6736(05)64131-1	http://dx.doi.org/10.1016/S0140-6736(05)64131-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259650				2022-12-28	WOS:A1997XQ24800006
J	Umans, VA; Kloeg, PH; Bronzwaer, J				Umans, VA; Kloeg, PH; Bronzwaer, J			The CAPTURE trial	LANCET			English	Letter									VRIJE UNIV AMSTERDAM,DEPT CARDIOL,AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam	Umans, VA (corresponding author), MED CTR ALKMAAR,DEPT CARDIOL & PHARM,NL-1815 JD ALKMAAR,NETHERLANDS.		Bronzwaer, Jean/N-1267-2017					*CAPTURE INV, 1997, LANCET, V349, P1429; *EPIC INV, 1994, NEW ENGL J MED, V330, P956; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8	3	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					445	445		10.1016/S0140-6736(05)64172-4	http://dx.doi.org/10.1016/S0140-6736(05)64172-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259679	Bronze			2022-12-28	WOS:A1997XQ24800059
J	Whalen, CC; Johnson, JL; Okwera, A; Hom, DL; Huebner, R; Mogyenyi, P; Mugerwa, RD; Ellner, JJ				Whalen, CC; Johnson, JL; Okwera, A; Hom, DL; Huebner, R; Mogyenyi, P; Mugerwa, RD; Ellner, JJ			A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV-INFECTION; PULMONARY TUBERCULOSIS; ISONIAZID PROPHYLAXIS; DEVELOPING-COUNTRIES; ACTIVE TUBERCULOSIS; DRUG-REACTIONS; RISK; THERAPY; MALABSORPTION; MORTALITY	Background Infection with the human immunodeficiency virus (HIV) greatly increases the risk of reactivation tuberculosis. We evaluated the safety and efficacy of three preventive-therapy regimens in a setting where exposure to tuberculosis is common. Methods We performed a randomized, placebo-controlled trial in 2736 HIV-infected adults recruited in Kampala, Uganda. Subjects with positive tuberculin skin tests (induration, greater than or equal to 5 mm) with purified protein derivative (PPD) were randomly assigned to one of four regimens: placebo (464 subjects), isoniazid daily for six months (536), isoniazid and rifampin daily for three months (556), or isoniazid, rifampin, and pyrazinamide daily for three months (462). Subjects with anergy (0 mm induration in reaction to PPD and candida antigens) were randomly assigned to receive either placebo (323 subjects) or six months of isoniazid (395). The medications were dispensed monthly and were self-administered. Results Among the PPD-positive subjects, the incidence of tuberculosis in the three groups that received preventive therapy was lower than the rate in the placebo group (P = 0.002 by the log-rank test). The relative risk of tuberculosis with isoniazid alone, as compared with placebo, was 0.33 (95 percent confidence interval, 0.14 to 0.77); with isoniazid and rifampin, 0.40 (0.18 to 0.86); and with isoniazid, rifampin, and pyrazinamide, 0.51 (0.24 to 1.08). Among the subjects with anergy, the relative risk of tuberculosis was 0.83 (95 percent confidence interval, 0.34 to 2.04) with isoniazid as compared with placebo. Side effects were more common with the multidrug regimens, and particularly with the regimen containing pyrazinamide. Survival did not differ among the groups, but the subjects with anergy had a higher mortality rate than the PPD-positive subjects. Conclusions A six-month course of isoniazid confers short-term protection against tuberculosis among PPD-positive, HIV-infected adults. Multidrug regimens with isoniazid and rifampin taken for three months also reduce the risk of tuberculosis. (C) 1997, Massachusetts Medical Society.	UNIV HOSP CLEVELAND, DEPT MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; UGANDAN MINIST HLTH, NATL TB & LEPROSY PROGRAMME, KAMPALA, UGANDA; JOINT CLIN RES CTR, KAMPALA, UGANDA; MAKERERE UNIV, KAMPALA, UGANDA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	University Hospitals of Cleveland; Joint Clinic Research Center - United Arab Emirates; Makerere University; Centers for Disease Control & Prevention - USA	Whalen, CC (corresponding author), CASE WESTERN RESERVE UNIV, DEPT EPIDEMIOL & BIOSTAT, WG49, 10900 EUCLID BLVD, CLEVELAND, OH 44106 USA.			Ellner, Jerrold/0000-0001-6150-0082	FIC NIH HHS [TW-00011-08] Funding Source: Medline; PHS HHS [U78/CCU506716-04] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; *AIDS CLIN TRIAL G, 1993, TABL GRAD SEV AD ADV; ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; BASS JB, 1990, AM REV RESPIR DIS, V142, P1470; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BERNING SE, 1992, NEW ENGL J MED, V327, P1817, DOI 10.1056/NEJM199212173272514; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; COMSTOCK GW, 1979, AM REV RESPIR DIS, V119, P827; COMSTOCK GW, 1975, AM REV RESPIR DIS, V111, P573; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; Graham NMH, 1996, ARCH INTERN MED, V156, P889, DOI 10.1001/archinte.156.8.889; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; HALSEY N, 1994, 10 INT C AIDS INT C, P167; International Union Against Tuberculosis and Lung Disease, 1986, B INT UNION TUBER S2, V61, P1; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; OBRIEN RJ, 1995, AIDS, V9, P665, DOI 10.1097/00002030-199507000-00001; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PATEL KB, 1995, NEW ENGL J MED, V332, P336, DOI 10.1056/NEJM199502023320518; PELOQUIN CA, 1993, NEW ENGL J MED, V329, P1122, DOI 10.1056/NEJM199310073291513; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; POZNIAK AL, 1992, AIDS, V6, P809, DOI 10.1097/00002030-199208000-00007; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P3434; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; WADHAWAN D, 1991, 7 INT C AIDS FLOR IT, V2, P247; Whalen C, 1996, AM J RESP CRIT CARE, V153, P1977, DOI 10.1164/ajrccm.153.6.8665064; 1990, MMWR-MORBID MORTAL W, V39, P9	40	343	349	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					801	808		10.1056/NEJM199709183371201	http://dx.doi.org/10.1056/NEJM199709183371201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9295239				2022-12-28	WOS:A1997XW28300001
J	Bastida, JL; Mossialos, E				Bastida, JL; Mossialos, E			Spanish drug policy at the crossroads	LANCET			English	Editorial Material											Bastida, JL (corresponding author), UNIV LONDON LONDON SCH ECON & POLIT SCI, LSE HLTH, HOUGHTON ST, LONDON WC2A 2AE, ENGLAND.		Mossialos, Elias/ABE-1301-2021					BASTIDA JL, 1997, LSE HLTH; LOBO F, 1996, CREACION MERCADO MED; Rovira J, 1996, PHARMACOECONOMICS, V10, P4, DOI 10.2165/00019053-199600102-00004; 1996, SCRIP, V2140, P2	4	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	1997	350	9079					679	680		10.1016/S0140-6736(05)63509-X	http://dx.doi.org/10.1016/S0140-6736(05)63509-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291900				2022-12-28	WOS:A1997XU97700006
J	Blackstone, MO				Blackstone, MO			Fibrin glue for bleeding peptic ulcers	LANCET			English	Editorial Material							UPPER GASTROINTESTINAL HEMORRHAGE; INJECTION THERAPY; RANDOMIZED TRIAL				Blackstone, MO (corresponding author), UNIV CHICAGO,GASTROENTEROL SECT,CHICAGO,IL 60637, USA.							Brullet E, 1996, GASTROINTEST ENDOSC, V43, P111, DOI 10.1016/S0016-5107(06)80110-0; Hay JA, 1996, AM J MED, V100, P313, DOI 10.1016/S0002-9343(97)89490-9; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; Saeed ZA, 1996, ENDOSCOPY, V28, P288, DOI 10.1055/s-2007-1005455; VILLANUEVA C, 1994, GASTROINTEST ENDOSC, V40, P34, DOI 10.1016/S0016-5107(94)70006-0	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					679	679		10.1016/S0140-6736(05)63508-8	http://dx.doi.org/10.1016/S0140-6736(05)63508-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291899				2022-12-28	WOS:A1997XU97700005
J	Austin, E				Austin, E			Fanya kazi pamoja	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					697	697						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286818				2022-12-28	WOS:A1997XT70900002
J	Elders, MJ; Scott, CR; Frindik, JP; Kemp, SF				Elders, MJ; Scott, CR; Frindik, JP; Kemp, SF			Clinical workup for precocious puberty	LANCET			English	Editorial Material							ADULT				Elders, MJ (corresponding author), UNIV ARKANSAS MED SCI,ARKANSAS CHILDRENS HOSP,LITTLE ROCK,AR 72202, USA.							*A GUTTM I, 1994, SEX AM TEEN; CUTLER GB, 1992, MED PRACTICING PHYSI, P577; Eckert KL, 1996, PEDIATRICS, V97, P517; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; MALES MA, 1995, LANCET, V346, P64, DOI 10.1016/S0140-6736(95)92105-2; OERTER KE, 1991, J CLIN ENDOCR METAB, V73, P1235, DOI 10.1210/jcem-73-6-1235	6	13	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					457	458		10.1016/S0140-6736(05)63075-9	http://dx.doi.org/10.1016/S0140-6736(05)63075-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274578				2022-12-28	WOS:A1997XR13500004
J	Okamura, H; Oomori, N; Uchitomi, Y				Okamura, H; Oomori, N; Uchitomi, Y			An acutely confused 15-year-old girl	LANCET			English	Article									KURE NATL HOSP,DEPT PSYCHIAT,KURE,HIROSHIMA,JAPAN; NATL CANC CTR RES INST E,PSYCHOONCOL DIV,KASHIWA,CHIBA,JAPAN	National Cancer Center - Japan	Okamura, H (corresponding author), NATL CANC CTR,DEPT PSYCHIAT,TOKYO 104,JAPAN.		Uchitomi, Yosuke/E-1463-2015					Alamowitch S, 1997, BRAIN, V120, P923, DOI 10.1093/brain/120.6.923; Ashour AA, 1997, J CLIN ONCOL, V15, P1272, DOI 10.1200/JCO.1997.15.3.1272; POSNER JB, 1995, NEUROLOGIC COMPLICAT, P353	3	38	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					488	488		10.1016/S0140-6736(97)06208-9	http://dx.doi.org/10.1016/S0140-6736(97)06208-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274586				2022-12-28	WOS:A1997XR13500012
J	Kimura, KD; Tissenbaum, HA; Liu, YX; Ruvkun, G				Kimura, KD; Tissenbaum, HA; Liu, YX; Ruvkun, G			daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans	SCIENCE			English	Article							DAUER LARVA DEVELOPMENT; INTERMEDIARY METABOLISM; HORMONE; ENCODES; KINASE; MUTATIONS; PEPTIDE; FAMILY; CYCLE	A C. elegans neurosecretory signaling system regulates whether animals enter the reproductive life cycle or arrest development at the long-lived dauer diapause stage. daf-2, a key gene in the genetic pathway that mediates this endocrine signaling, encodes an insulin receptor family member. Decreases in DAF-2 signaling induce metabolic and developmental changes, as in mammalian metabolic control by the insulin receptor, Decreased DAF-2 signaling also causes an increase in life-span. Life-span regulation by insulin-like metabolic control is analogous to mammalian longevity enhancement induced by caloric restriction, suggesting a general link between metabolism, diapause, and longevity.	MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Kimura, Koutarou D./T-9645-2019	Kimura, Koutarou D./0000-0002-3359-1578	NIA NIH HHS [R01AG14161] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014161] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARPAGAUS M, 1987, ROUX ARCH DEV BIOL, V196, P527, DOI 10.1007/BF00399877; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; DORMAN JB, 1995, GENETICS, V141, P1399; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Finch CE, 1990, LONGEVITY SENESCENCE; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOTTLIEB S, 1994, GENETICS, V137, P107; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HETRU C, 1991, EUR J BIOCHEM, V201, P495, DOI 10.1111/j.1432-1033.1991.tb16308.x; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jonas EA, 1997, NATURE, V385, P343, DOI 10.1038/385343a0; Kahn CR, 1996, ANNU REV MED, V47, P509; KAHN CR, 1994, JOSLINS DIABETES MEI; KAWAKAMI A, 1989, P NATL ACAD SCI USA, V86, P6843, DOI 10.1073/pnas.86.18.6843; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KENYON C, 1997, C ELEGANS, V2, P791; KIM H, 1992, DIABETOLOGIA, V35, P261, DOI 10.1007/BF00400927; Krause M, 1995, METHOD CELL BIOL, V48, P483; LARSEN PL, 1995, GENETICS, V139, P1567; MALONE EA, 1994, GENETICS, V136, P879; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; NAGASAWA H, 1984, SCIENCE, V226, P1344, DOI 10.1126/science.226.4680.1344; ORIORDAN VB, 1989, COMP BIOCHEM PHYS B, V92, P233, DOI 10.1016/0305-0491(89)90271-X; ORIORDAN VB, 1990, COMP BIOCHEM PHYS B, V95, P125, DOI 10.1016/0305-0491(90)90258-U; PATTERSON GI, UNPUB; POPHAM JD, 1979, CAN J ZOOL, V57, P794, DOI 10.1139/z79-098; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle DL, 1997, C ELEGANS, P739; ROOVERS E, 1995, GENE, V162, P181, DOI 10.1016/0378-1119(95)00323-X; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; SHIER P, 1989, J BIOL CHEM, V264, P14605; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Tauber M.J., 1986, SEASONAL ADAPTATIONS; THOMAS JH, 1993, GENETICS, V134, P1105; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOWELS JJ, 1992, GENETICS, V130, P105; WADSWORTH WG, 1989, DEV BIOL, V132, P167, DOI 10.1016/0012-1606(89)90214-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	1637	1702	2	250	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	1997	277	5328					942	946		10.1126/science.277.5328.942	http://dx.doi.org/10.1126/science.277.5328.942			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252323				2022-12-28	WOS:A1997XQ98500038
J	Kleinman, LC; Boyd, EA; Heritage, JC				Kleinman, LC; Boyd, EA; Heritage, JC			Adherence to prescribed explicit criteria during utilization review - An analysis of communications between attending and reviewing physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; QUALITY	Context.-Utilization review (UR) seeks to improve quality and cost-efficiency of health care. However, how well the process works in practice has not been assessed. Objective.-To describe the outcomes of a sample of physician reviews in terms of the explicit criteria that the UR was designed to implement. Design.-Retrospective analysis of transcripts of precertification reviews. Participants and Setting.-California physicians employed by a UR firm conducted 96 interviews from April 1990 to July 1991 with attending physicians who had proposed to insert tympanostomy tubes on a patient younger than 16 years and whose proposals had been found to be inappropriate on an initial screen. Main Outcome Measures.-The appropriateness rating assigned to each case by the physician-reviewer and by the investigators using explicit criteria. Logistic regression identified factors associated with the reviewers' recommendations to perform surgery and with recommendations at variance from the criteria. Results.-The reviewers recommended 78% of cases for surgery, of which only 29% were supported by the criteria or had extenuating circumstances. The criteria. concurred with all 30 of the reviewers' recommendations against surgery. Two factors, female sex (odds ratio [OR], 8.2; 95% confidence interval [CI], 1.2-53.8) and previous tympanostomy tube insertion (OR, 30.9; 95% CI, 2.4-394.8) were associated with reviewer recommendations in favor of surgery that were at variance from the criteria, despite the lack of evidence for either as a mitigating circumstance. Conclusion.-Physician reviewers were more lenient than the explicit criteria that the reviews were designed to implement. In no cases did the reviewers depart from the criteria's recommendations in favor of surgery.	UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT SOCIOL,LOS ANGELES,CA 90024; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard Medical School			Kleinman, Lawrence/AAS-6934-2021					Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; *COMP RES CTR, 1987, STATA STAT DAT AN; Ellrodt A G, 1992, QRB Qual Rev Bull, V18, P456; FLEISS JL, 1986, STAT MEASURES RATES; HAYWARD RA, 1993, ANN INTERN MED, V118, P550, DOI 10.7326/0003-4819-118-7-199304010-00010; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; Maccoby E.E., 1974, PSYCHOL SEX DIFFEREN; PARADISE JL, 1978, NEW ENGL J MED, V298, P409, DOI 10.1056/NEJM197802232980801; ROSENBERG SN, 1995, NEW ENGL J MED, V333, P1326, DOI 10.1056/NEJM199511163332006; ROSENFELD RM, 1995, PEDIATR INFECT DIS J, V14, P731, DOI 10.1097/00006454-199509000-00001; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; *SAS I, 1992, SAS PROC GUID; SHAPIRO MF, 1995, NEW ENGL J MED, V333, P1353, DOI 10.1056/NEJM199511163332012; STOOL SE, 1994, AHCPR PUBLICATION; TANNEN D, 1987, SOC PSYCHOL QUART, V50, P205, DOI 10.2307/2786752; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WISE CG, 1995, JOINT COMM J QUAL IM, V21, P465, DOI 10.1016/S1070-3241(16)30173-0	19	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					497	501		10.1001/jama.278.6.497	http://dx.doi.org/10.1001/jama.278.6.497			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XP243	9256225				2022-12-28	WOS:A1997XP24300032
J	Lip, GYH; Beevers, DG				Lip, GYH; Beevers, DG			Can we treat coronary artery disease with antibiotics? Commentary	LANCET			English	Editorial Material									UNIV BIRMINGHAM,CITY HOSP,DEPT CARDIOL,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND	University of Birmingham	Lip, GYH (corresponding author), UNIV BIRMINGHAM,CITY HOSP,DEPT MED,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							Cook P. J., 1996, European Respiratory Journal Supplement, V9, p326S; Cook PJ, 1996, QJM-INT J MED, V89, P727, DOI 10.1093/qjmed/89.10.727; Gupta S, 1997, BRIT MED J, V314, P1778, DOI 10.1136/bmj.314.7097.1778; Gupta S, 1997, CIRCULATION, V96, P404; Gupta S., 1997, Journal of the American College of Cardiology, V29, p209A; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X	6	25	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					378	379		10.1016/S0140-6736(97)22032-5	http://dx.doi.org/10.1016/S0140-6736(97)22032-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259646				2022-12-28	WOS:A1997XQ24800002
J	Miles, P; Everett, J; Murphy, J; Kerr, D				Miles, P; Everett, J; Murphy, J; Kerr, D			Comparison of blood or urine testing by patients with newly diagnosed non-insulin dependent diabetes: patient survey after randomised crossover trial	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BOURNEMOUTH HOSP,BOURNEMOUTH DIABET & ENDOCRINE CTR,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND									BRADLEY C, 1995, HDB PSYCHOL DIABETES, P92; *DCGT RES GROUP, 1993, NEW ENGL J MED, V329, P977; TATTERSALL R, 1992, BRIT MED J, V305, P1171, DOI 10.1136/bmj.305.6863.1171; WATKINS PJ, 1993, J ROY COLL PHYS LOND, V27, P259; WING RR, 1986, AM J MED, V81, P830, DOI 10.1016/0002-9343(86)90354-2	5	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					348	349						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270457				2022-12-28	WOS:A1997XQ86400022
J	Wang, Y; Okamoto, M; Schmitz, F; Hofmann, K; Sudhof, TC				Wang, Y; Okamoto, M; Schmitz, F; Hofmann, K; Sudhof, TC			Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion	NATURE			English	Article							PROTEIN; EXOCYTOSIS; RABPHILIN-3A; CELLS	Rab3 is a neuronal GTP-binding protein that regulates fusion of synaptic vesicles and is essential for long-term potentiation of hippocampal messy fibre synapses(1-5). More than thirty Rab GTP-binding proteins are known to function in diverse membrane transport pathways, although their mechanisms of action are unclear. We have now identified a putative Rab3-effector protein called Rim. Rim is composed of an amino-terminal zinc-finger motif and carboxy-terminal PDZ and C-2 domains. It binds only to GTP (but not to GDP)-complexed Rab3, and interacts with no other Rab protein tested. There is enrichment of Rab3 and Rim in neurons, where they have complementary distributions. Rab3 is found only on synaptic vesicles, whereas Rim is localized to presynaptic active zones in conventional synapses, and to presynaptic ribbons in ribbon synapses. Transfection of PC12 cells with the amino-terminal domains of Rim greatly enhances regulated exocytosis in a Rab3-dependent manner. We propose that Rim serves as a Rab3-dependent regulator of synaptic-vesicle fusion by forming a GTP-dependent complex between synaptic plasma membranes and docked synaptic vesicles.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; MAX PLANCK INST EXPT MED,ABT 9,D-37075 GOTTINGEN,GERMANY; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society; Swiss Institute Experimental Cancer Research			Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083				Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Dowling J. E., 1987, RETINA APPROACHABLE; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITZ F, 1996, J NEUROSCI, V15, P7109; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	30	511	540	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					593	598		10.1038/41580	http://dx.doi.org/10.1038/41580			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252191	Bronze			2022-12-28	WOS:A1997XP72200052
J	Belizan, JM; Villar, J; Bergel, E; delPino, A; DiFulvio, S; Galliano, SV; Kattan, C				Belizan, JM; Villar, J; Bergel, E; delPino, A; DiFulvio, S; Galliano, SV; Kattan, C			Long term effect of calcium supplementation during pregnancy on the blood pressure of offspring: follow up of a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; HYPERTENSION; CHILDHOOD; PREVENTION; MOTHERS; LIFE	Objective: To explore the long term effect of calcium supplementation during p Design: Follow up of a population enrolled in a double blind, randomised, placebo controlled trial. Setting: Perinatal research unit, World Health Organisation's collaborative research centre. Subjects: 591 children at a mean age of 7 years whose mothers were randomly assigned during pregnancy to receive 2 g/day of elemental calcium (n = 298) or placebo (n = 293). Main outcome measures: Mean blood pressure and rate of high blood pressure of children, Results: Overall, systolic blood pressure was lower in the calcium group (mean difference - 1.4 mm Hg; 95% confidence interval - 3.2 to 0.5) than in the placebo group, The effect was found predominantly among children whose body mass index at assessment was above the median for this population (mean difference in systolic blood pressure -5.8 mm Hg (-9.8 mm Hg to -1.7 mm Hg) for children with an index > 17.5 and - 3.2 mm Hg (-6.3 mm Hg to -0.1 mm Hg) for those with an index of > 15.7 to 17.5). The risk of high systolic blood pressure was also lower in the calcium group than in the placebo group (relative risk 0.59; 0.39 to 0.90) and particularly among children in the highest fourth of body mass index (0.43; 0.26 to 0.71). Conclusion: Calcium supplementation during pregnancy is associated with lower systolic blood pressure in the offspring, particularly among overweight children.	WHO, UNFPA, UNDP, WORLD BANK SPECIAL PROGRAMME RES DEV & RES TRAINI, CH-1211 GENEVA 27, SWITZERLAND; CTR ROSARINO ESTUD PERINATALES, RA-2000 ROSARIO, SANTA FE, ARGENTINA	The World Bank; United Nations Population Fund; World Health Organization				Belizan, Jose/0000-0002-8412-3010				BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BELIZAN JM, 1984, ARCH LATINOAM NUTR, V34, P666; Campbell DM, 1996, BRIT J OBSTET GYNAEC, V103, P273, DOI 10.1111/j.1471-0528.1996.tb09718.x; deOnis M, 1996, AM J CLIN NUTR, V64, P650, DOI 10.1093/ajcn/64.4.650; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; Falkner B, 1996, PEDIATRICS, V98, P649; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; GILLMAN MW, 1995, J PEDIATR-US, V127, P186, DOI 10.1016/S0022-3476(95)70293-8; GILLMAN MW, 1992, JAMA-J AM MED ASSOC, V267, P2340, DOI 10.1001/jama.267.17.2340; GODFREY KM, 1994, BRIT J OBSTET GYNAEC, V101, P398, DOI 10.1111/j.1471-0528.1994.tb11911.x; HEMMINKI E, 1995, AM J OBSTET GYNECOL, V173, P205, DOI 10.1016/0002-9378(95)90191-4; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; LEVER AF, 1992, J HYPERTENS, V10, P101, DOI 10.1097/00004872-199202000-00001; LIN CM, 1994, AM J HYPERTENS, V7, P201, DOI 10.1093/ajh/7.2.201; MCGARVEY ST, 1991, HYPERTENSION, V17, P218, DOI 10.1161/01.HYP.17.2.218; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; ROSNER B, 1987, AM J EPIDEMIOL, V126, P1115, DOI 10.1093/oxfordjournals.aje.a114750; ROSNER B, 1977, AM J EPIDEMIOL, V106, P306, DOI 10.1093/oxfordjournals.aje.a112466; SANCHEZ RG, 1992, INT J EPIDEMIOL, V21, P478, DOI 10.1093/ije/21.3.478; SINAIKO AR, 1989, J PEDIATR-US, V114, P664, DOI 10.1016/S0022-3476(89)80718-8; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; WHINCUP PH, 1988, LANCET, V2, P890	26	123	128	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 2	1997	315	7103					281	285		10.1136/bmj.315.7103.281	http://dx.doi.org/10.1136/bmj.315.7103.281			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274547	Green Published			2022-12-28	WOS:A1997XP75000021
J	Ross, D; Rees, M; Godfree, V; Cooper, A; Hart, D; Kingsland, C; Whitehead, M				Ross, D; Rees, M; Godfree, V; Cooper, A; Hart, D; Kingsland, C; Whitehead, M			Randomised crossover comparison of skin irritation with two transdermal oestradiol patches	BRITISH MEDICAL JOURNAL			English	Article							ESTRADIOL		JOHN RADCLIFFE HOSP,MENOPAUSE CLIN,OXFORD OX3 9DU,ENGLAND; AMARANT CTR,LONDON SE1 7PW,ENGLAND; QUEEN CHARLOTTES & CHELSEA HOSP,MENOPAUSE CLIN,LONDON W6 0XG,ENGLAND; STOBHILL GEN HOSP,MENOPAUSE CLIN,GLASGOW G21 3UW,LANARK,SCOTLAND; LIVERPOOL WOMENS HOSP,MENOPAUSE CLIN,LIVERPOOL L8 7SS,MERSEYSIDE,ENGLAND	University of Oxford; Imperial College London; University of Liverpool	Ross, D (corresponding author), UNIV LONDON KINGS COLL HOSP,MENOPAUSE CLIN,DENMARK HILL,LONDON SE5 9RS,ENGLAND.							HILLARD TC, 1994, OSTEOPOROSIS INT, V4, P341, DOI 10.1007/BF01622195; HOWIE H, 1995, MENOPAUSE, V2, P43; PADWICK ML, 1985, AM J OBSTET GYNECOL, V152, P1085, DOI 10.1016/0002-9378(85)90567-8; STEVENSON JC, 1995, BRIT J CLIN PRACT, V49, P87; *TRANSD HRT INV GR, 1993, INT J FERTIL, V38, P5	5	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					288	288		10.1136/bmj.315.7103.288	http://dx.doi.org/10.1136/bmj.315.7103.288			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274549	Green Published			2022-12-28	WOS:A1997XP75000023
J	Gosden, T; Torgerson, DJ; Maynard, A				Gosden, T; Torgerson, DJ; Maynard, A			What is to be done about fundholding?	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE		UNIV YORK,NATL PRIMARY CARE RES & DEV CTR,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,NATL PRIMARY CARE RES & DEV CTR,DEPT HLTH SCI,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK; University of York - UK	Gosden, T (corresponding author), UNIV MANCHESTER,NATL PRIMARY CARE RES & DEV CTR,MANCHESTER M13 9PL,LANCS,ENGLAND.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				*AUD COMM, 1994, PRESCRIPTION IMPROVE; BURR A, 1992, PHARM J S, V249, pR8; DIXON J, 1995, BRIT MED J, V311, P727, DOI 10.1136/bmj.311.7007.727; FERBER I, 1982, SOCIAL EXPT EC POLIC; Gosden T, 1997, HEALTH POLICY, V40, P103, DOI 10.1016/S0168-8510(96)00888-3; Harris CM, 1996, BRIT MED J, V313, P1531, DOI 10.1136/bmj.313.7071.1531; PENNINGTON S, 1995, GP, V21, P21; PETTY R, 1995, LANCET, V346, P1139; *SECR STAT HLTH SC, 1996, PRIM CAR DEL FUT; *SECR STAT HLTH SC, 1996, CHOIC OPP PRIM CAR F; STEWARTBROWN S, 1995, BRIT MED J, V311, P1543, DOI 10.1136/bmj.311.7019.1543; WHYNES DK, 1995, J PUBLIC HEALTH MED, V17, P323; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347; 1994, HLTH NEWS BRIEFI MAR	14	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					170	171		10.1136/bmj.315.7101.170	http://dx.doi.org/10.1136/bmj.315.7101.170			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM321	9251549	Green Published			2022-12-28	WOS:A1997XM32100024
J	Black, N				Black, N			Health services research: Saviour or chimera?	LANCET			English	Article							MYOCARDIAL-INFARCTION; CORONARY; OUTCOMES; SURGERY; RATES; CARE; UK				Black, N (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 7HT, ENGLAND.							American Child Health Association Research Division, 1934, PHYS DEF PATHW CORR; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Black N, 1991, Int J Technol Assess Health Care, V7, P533; BLACK N, 1995, J EPIDEMIOL COMMUN H, V49, P408, DOI 10.1136/jech.49.4.408; BROOK RH, 1988, LANCET, V1, P750; Cleary P D, 1997, J Health Serv Res Policy, V2, P3; DOMENIGHETTI G, 1988, LANCET, V2, P1470; DONABEDIAN A, 1989, MILBANK Q, V67, P233, DOI 10.2307/3350139; EVANS T, 1986, STRATEGIC RESPONSE E; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; GROVES EW, 1908, BRIT MED J, V2, P1008; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; ILLICH I, 1976, LIMITS MED; LEE JA, 1961, LANCET, V2, P815; LEGORRETA AP, 1993, JAMA-J AM MED ASSOC, V270, P1429, DOI 10.1001/jama.270.12.1429; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; MCKEOWN T, 1976, ROLE MED; PFLANZ M, 1978, SOC SCI MED-MED ANTH, V12, P171, DOI 10.1016/0160-7987(78)90029-7; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; ULRICH RS, 1984, SCIENCE, V224, P420, DOI 10.1126/science.6143402; [No title captured]	25	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	1997	349	9068					1834	1836		10.1016/S0140-6736(96)12164-4	http://dx.doi.org/10.1016/S0140-6736(96)12164-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XF735	9269229				2022-12-28	WOS:A1997XF73500045
J	Rook, GAW; Zumla, A				Rook, GAW; Zumla, A			Gulf War syndrome: Is it due to a systemic shift in cytokine balance towards a Th2 profile?	LANCET			English	Article							MEASLES IMMUNIZATION; SUSCEPTIBLE MICE; IMMUNE-RESPONSE; T-CELLS; DEHYDROEPIANDROSTERONE; INTERLEUKIN-2; CORTICOTROPIN; INHIBITION; RESISTANT; CORTISOL	The symptoms of Gulf War syndrome are compatible with the hypothesis that the immune system of affected individuals is biased towards a Th2-cytokine pattern. Factors that could lead to a Th2 shift among Gulf War veterans include exposure to multiple Th2-inducing vaccinations under stressful circumstances and the way in which such vaccinations were administered, which would be expected to maximise Th2 immunogenicity. These factors may have led to a long-term systemic shift towards a Th2-cytokine balance and to mood changes related to the immunoendocrine state. Other vaccines that lead to similar long-term, non-specific shifts in cytokine balance are well-established. If our hypothesis is proven, treatment may be possible with regimens that induce a systemic Th1 bias.	UCL, SCH MED, DEPT MED, ACAD INFECT DIS UNIT, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School	Rook, GAW (corresponding author), UCL, SCH MED, DEPT BACTERIOL, LONDON W1P 6DB, ENGLAND.		ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735; Rook, Graham/0000-0002-8041-8110				AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; AABY P, 1995, SOC SCI MED, V41, P673, DOI 10.1016/0277-9536(95)00038-9; Bernton E, 1995, ANN NY ACAD SCI, V774, P217; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; BROWN DH, 1993, INFECT IMMUN, V61, P4793, DOI 10.1128/IAI.61.11.4793-4800.1993; CASALE GP, 1993, IMMUNOPHARM IMMUNOT, V15, P199, DOI 10.3109/08923979309025994; David A, 1997, BRIT MED J, V314, P239, DOI 10.1136/bmj.314.7076.239; DAYNES RA, 1990, J EXP MED, V171, P979, DOI 10.1084/jem.171.4.979; DAYNES RA, 1995, J INVEST DERMATOL, V105, pS14, DOI 10.1111/1523-1747.ep12315187; DAYNES RA, 1993, J IMMUNOL, V150, P5319; FISCHER A, 1991, IMMUNOLOGY, V74, P228; GARG M, 1993, INFECT IMMUN, V61, P2238, DOI 10.1128/IAI.61.5.2238-2241.1993; GLASER R, 1993, BEHAV NEUROSCI, V107, P525, DOI 10.1037/0735-7044.107.3.525; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; HOLSBOER F, 1984, NEW ENGL J MED, V311, P1127; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; MU HH, 1993, INFECT IMMUN, V61, P2834, DOI 10.1128/IAI.61.7.2834-2840.1993; Nilsson L, 1996, JAMA-J AM MED ASSOC, V275, P760, DOI 10.1001/jama.275.10.760; ODENT MR, 1994, JAMA-J AM MED ASSOC, V272, P592, DOI 10.1001/jama.1994.03520080034035; Padgett DA, 1995, ANN NY ACAD SCI, V774, P323; Ramirez F, 1996, J IMMUNOL, V156, P2406; Ramiya VK, 1996, J AUTOIMMUN, V9, P349, DOI 10.1006/jaut.1996.0047; RAVEN PW, 1995, CLIN ENDOCRINOL, V43, P637, DOI 10.1111/j.1365-2265.1995.tb02930.x; RAVEN PW, 1996, PSYCHONEUROENDOCRINO, V20, P543; Rook GAW, 1996, QJM-INT J MED, V89, P333; Rook GAW, 1996, ANNU REV MICROBIOL, V50, P259, DOI 10.1146/annurev.micro.50.1.259; RUPPRECHT M, 1995, PSYCHONEUROENDOCRINO, V20, P543, DOI 10.1016/0306-4530(94)00082-L; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Smit JA, 1996, TRANSPLANT P, V28, P665; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; STRAUS S, 1996, NIH PUBLICATION, P1; Suitters AJ, 1997, IMMUNOLOGY, V91, P314, DOI 10.1046/j.1365-2567.1997.00254.x; SUZUKI T, 1991, CLIN IMMUNOL IMMUNOP, V61, P202, DOI 10.1016/S0090-1229(05)80024-8; TOBACH E, 1956, AM J PHYSIOL, V187, P399, DOI 10.1152/ajplegacy.1956.187.2.399; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092; YOUNG MRI, 1995, CHRONOBIOL INT, V12, P19, DOI 10.3109/07420529509064496; Zwilling B, 1992, ASM NEWS, V58, P23; 1997, ECONOMIST       0111, P87	40	129	131	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1831	1833		10.1016/S0140-6736(97)01164-1	http://dx.doi.org/10.1016/S0140-6736(97)01164-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269228				2022-12-28	WOS:A1997XF73500044
J	Sharp, D				Sharp, D			Priorities in tropical medicine	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1786	1786		10.1016/S0140-6736(05)61690-X	http://dx.doi.org/10.1016/S0140-6736(05)61690-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269211				2022-12-28	WOS:A1997XF73500007
J	Yeh, KC; Wu, SH; Murphy, JT; Lagarias, JC				Yeh, KC; Wu, SH; Murphy, JT; Lagarias, JC			A cyanobacterial phytochrome two-component light sensory system	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; AVENA PHYTOCHROME; GENE; PROTEINS; SIMILARITY; MECHANISM; ETR1	The biliprotein phytochrome regulates plant growth and developmental responses to the ambient light environment through an unknown mechanism. Biochemical analyses demonstrate that phytochrome is an ancient molecule that evolved from a more compact light sensor in cyanobacteria. The cyanobacterial phytochrome Cph1 is a light-regulated histidine kinase that mediates red, far-red reversible phosphorylation of a small response regulator, Rcp1 (response regulator for cyanobacterial phytochrome), encoded by the adjacent gene, thus implicating protein phosphorylation-dephosphorylation in the initial step of light signal transduction by phytochrome.	UNIV CALIF DAVIS, SECT MOL & CELLULAR BIOL, DAVIS, CA 95616 USA	University of California System; University of California Davis			Lagarias, John Clark/L-3139-2013; Wu, Shu-Hsing/B-4317-2009; Yeh, Kuo-Chen/AAG-4485-2021	Lagarias, John Clark/0000-0002-2093-0403; Wu, Shu-Hsing/0000-0002-7179-3138; Yeh, Kuo-Chen/0000-0002-3791-3423	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NCRR NIH HHS [1 P41 RR06009] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Allen JF, 1997, TRENDS PLANT SCI, V2, P41, DOI 10.1016/S1360-1385(97)82554-X; BORTHWICK HA, 1960, SCIENCE, V132, P1223, DOI 10.1126/science.132.3435.1223; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jones Alan M., 1994, Seminars in Cell Biology, V5, P295, DOI 10.1006/scel.1994.1036; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; Kaneko T, 1996, DNA Res, V3, P109; Kehoe DM, 1997, J BACTERIOL, V179, P3914, DOI 10.1128/jb.179.12.3914-3921.1997; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; LI LM, 1992, J BIOL CHEM, V267, P19204; LINO M, 1997, PHOTOCHEM PHOTOBIOL, V65, P1032; LITTS JC, 1983, J BIOL CHEM, V258, P1025; Murphy JT, 1997, PHOTOCHEM PHOTOBIOL, V65, P750, DOI 10.1111/j.1751-1097.1997.tb01920.x; MUTCH N, 1986, J BACTERIOL, V165, P161; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; PRATT LH, 1995, PHOTOCHEM PHOTOBIOL, V61, P10, DOI 10.1111/j.1751-1097.1995.tb09238.x; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SCHMIDT TGM, 1994, J CHROMATOGR A, V676, P337, DOI 10.1016/0021-9673(94)80434-6; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; WONG YS, 1989, PLANT PHYSIOL, V91, P709, DOI 10.1104/pp.91.2.709; WONG YS, 1986, J BIOL CHEM, V261, P2089	33	437	463	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	1997	277	5331					1505	1508		10.1126/science.277.5331.1505	http://dx.doi.org/10.1126/science.277.5331.1505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278513				2022-12-28	WOS:A1997XV42900040
J	Gale, JE; Ashmore, JF				Gale, JE; Ashmore, JF			An intrinsic frequency limit to the cochlear amplifier	NATURE			English	Article							OUTER HAIR-CELLS; MEMBRANE CAPACITANCE; NA,K PUMP; CHANNEL; MOTILITY; TRANSITIONS	Hearing in mammals depends on a feedback process within the inner ear termed the 'cochlear amplifier'(1). The essential components of this amplifier are sensorimotor cells, the outer hair cells, which transduce motion of the basilar membrane induced by sound and generate forces to cancel the viscous damping of the cochlear partition(2,3). Outer hair cells alter the passive mechanics of the cochlea, enhancing both the sensitivity and the frequency selectivity of the auditory system. The molecular basis of the mechanism is thought to be a voltage-sensitive 'motor' protein, as yet unidentified, embedded in the basolateral membrane of the outer hair cell(4). The cochlear amplifier operates up to at least 22 kHz (ref. 5), but by measuring both the charge and mechanical movements associated with the motor(6,7) in isolated membrane patches under voltage damp, we show here that the limiting frequency at which the motor operates lies near 25 kHz. This value therefore sets an upper limit to the range of hearing in mammalian cochleas using this mechanism. The fast charge movement, arising from charge displacement within the presumed motor molecule, further suggests that the protein is more likely to be related to a transporter than to a modified ion channel.	UCL, DEPT PHYSIOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London	Gale, JE (corresponding author), UNIV BRISTOL, SCH MED SCI, DEPT PHYSIOL, UNIV WALK, BRISTOL BS8 1TD, AVON, ENGLAND.		Gale, Jonathan/AAG-6874-2019	Gale, Jonathan/0000-0003-4678-4878	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASHMORE JF, 1988, Q J EXP PHYSIOL CMS, V73, P143, DOI 10.1113/expphysiol.1988.sp003114; ASHMORE JF, 1990, NEUROSCI RES       S, V12, P39; CONTI F, 1989, EUR BIOPHYS J BIOPHY, V17, P53, DOI 10.1007/BF00257102; DALLOS P, 1995, SCIENCE, V267, P2006, DOI 10.1126/science.7701325; Dallos P., 1996, COCHLEA, P1; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; FORGE A, 1991, CELL TISSUE RES, V265, P473, DOI 10.1007/BF00340870; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GALE JE, 1997, EUR J PHYSL, V434, P267; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; IWASA KH, 1994, J ACOUST SOC AM, V96, P2216, DOI 10.1121/1.410094; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; MACONOCHIE DJ, 1995, BIOPHYS J, V68, P483, DOI 10.1016/S0006-3495(95)80209-2; MAMMANO F, 1993, J ACOUST SOC AM, V93, P3320, DOI 10.1121/1.405716; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; SANTOS-SACCHI J, 1989, J NEUROSCI, V9, P2954; SANTOS-SACCHI J, 1992, J NEUROSCI, V12, P1906; SIGG D, 1994, SCIENCE, V264, P578, DOI 10.1126/science.8160016; TUNSTALL MJ, 1995, J PHYSIOL-LONDON, V485, P739, DOI 10.1113/jphysiol.1995.sp020765; VATER M, 1992, J COMP NEUROL, V318, P367, DOI 10.1002/cne.903180403; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	24	107	107	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					63	66		10.1038/37968	http://dx.doi.org/10.1038/37968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288966				2022-12-28	WOS:A1997XU59600044
J	Uesugi, M; Nyanguile, O; Lu, H; Levine, AJ; Verdine, GL				Uesugi, M; Nyanguile, O; Lu, H; Levine, AJ; Verdine, GL			Induced alpha helix in the VP16 activation domain upon binding to a human TAF	SCIENCE			English	Article							TRANSCRIPTION FACTOR-TFIIB; TRANSACTIVATION DOMAIN; NMR-SPECTROSCOPY; PROTEINS; GAL4; C-13; H-1; EXPRESSION; TAF(II)40; SPECTRA	Activation domains are functional modules that enable sequence-specific DNA binding proteins to stimulate transcription. The structural basis for the function of activation domains is poorly understood. A combination of nuclear magnetic resonance (NMR) and biochemical experiments revealed that the minimal acidic activation domain of the herpes simplex virus VP16 protein undergoes an induced transition from random coil to or helix upon binding to its target protein, hTAF(parallel to)31 (a human TFIID TATA box-binding protein-associated factor). Identification of the two hydrophobic residues that make nonpolar contacts suggests a general recognition motif of acidic activation domains for hTAF(parallel to)31.	HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Harvard University; Princeton University			Uesugi, Motonari/AAM-9777-2020					BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; HAMPSEY M, 1997, CURR BIOL, V7, P44; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACFERRIN KD, 1993, METHOD ENZYMOL, V217, P79; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MORIUCHI H, 1995, P NATL ACAD SCI USA, V92, P9333, DOI 10.1073/pnas.92.20.9333; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4827; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016	38	272	278	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 29	1997	277	5330					1310	1313		10.1126/science.277.5330.1310	http://dx.doi.org/10.1126/science.277.5330.1310			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271577				2022-12-28	WOS:A1997XT82700056
J	Darling, GM; Johns, JA; McCloud, PI; Davis, SR				Darling, GM; Johns, JA; McCloud, PI; Davis, SR			Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; HORMONE-REPLACEMENT THERAPY; DENSITY LIPOPROTEIN CHOLESTEROL; RISK-FACTORS; FOLLOW-UP; CARDIOVASCULAR-DISEASE; PLASMA-LIPOPROTEINS; ARTERY DISEASE; LIPIDS; LP(A)	Background Postmenopausal estrogen therapy has favorable effects on serum lipoproteins in women with normal serum lipid levels, but the effect of combined estrogen and progestin therapy on lipoproteins in women with hypercholesterolemia has not been determined, nor has it been directly compared with the effect of conventional lipid-lowering therapy. Methods In a randomized crossover trial, we studied 58 postmenopausal women with fasting serum total cholesterol levels greater than 250 mg per deciliter. Each woman received simvastatin (10 mg dally) for eight weeks and postmenopausal hormone therapy (up to 1.25 mg of conjugated equine estrogens daily, along with 5 mg of medroxyprogesterone acetate daily) for eight weeks, with an eight-week washout period between the two treatment phases. Results At base line, the mean (+/-SD) cholesterol values were as follows: total cholesterol, 305+/-39 mg per deciliter; high-density lipoprotein (HDL) cholesterol, 62+/-19 mg per deciliter; and low-density lipoprotein (LDL) cholesterol, 217+/-39 mg per deciliter. For total cholesterol, the mean decrease with hormone therapy was 14 percent (95 percent confidence interval, 11 to 16 percent) and the mean decrease with simvastatin was 26 percent (95 percent confidence interval, 23 to 29 percent). For LDL cholesterol, the mean decrease was 24 percent (95 percent confidence interval, 20 to 28 percent) with hormone therapy and 36 percent (95 percent confidence interval, 32 to 40 percent) with simvastatin. The effect of simvastatin was significantly greater than that of hormone therapy (P<0.001). HDL cholesterol increased similarly with hormone therapy (mean increase, 7 percent; 95 percent confidence interval, 2 to 12 percent) and simvastatin (mean increase, 7 percent; 95 percent confidence interval, 4 to 10 percent). Triglyceride levels increased with hormone therapy (mean increase, 29 percent; 95 percent confidence interval, 15 to 42 percent) but decreased with simvastatin (mean decrease, 14 percent; 95 percent confidence interval, 8 to 20 percent). Lp(a) lipoprotein decreased with hormone therapy (mean decrease, 27 percent; 95 percent confidence interval, 20 to 34 percent), but not with simvastatin. Conclusions In postmenopausal women with hypercholesterolemia, therapy with estrogen plus progestin has beneficial effects on lipoprotein levels. Hormone therapy may be an effective alternative to treatment with simvastatin, especially in women with normal triglyceride levels. (C) 1997, Massachusetts Medical Society.	JEAN HAILES FDN, MELBOURNE, VIC, AUSTRALIA; AUSTIN & REPATRIAT MED CTR, DEPT CARDIOL, MELBOURNE, VIC, AUSTRALIA; MONASH UNIV, DEPT MATH, MELBOURNE, VIC 3004, AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University			Davis, Susan R/A-3111-2009; Davis, Susan D/GZL-2361-2022	Davis, Susan R/0000-0002-2955-0415; 				ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; BLOMQVIST N, 1977, J AM STAT ASSOC, V72, P746, DOI 10.2307/2286454; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COLEMAN MP, 1992, ATHEROSCLEROSIS, V92, P177, DOI 10.1016/0021-9150(92)90276-M; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; CUTTER GR, 1976, AM STAT, V30, P194, DOI 10.2307/2683763; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DAUBRESSE JC, 1993, AM J CARDIOL, V71, P1408; Davidson M. H., 1996, Journal of the American College of Cardiology, V27, p412A; DEEG R, 1983, CLIN CHEM, V29, P1798; DEMACKER PNM, 1980, CLIN CHEM, V26, P1775; DENKE MA, 1995, AM J MED, V99, P29, DOI 10.1016/S0002-9343(99)80101-6; FARISH E, 1991, BRIT MED J, V303, P694, DOI 10.1136/bmj.303.6804.694; FARISH E, 1989, BRIT J OBSTET GYNAEC, V96, P358, DOI 10.1111/j.1471-0528.1989.tb02398.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GRANFONE A, 1992, METABOLISM, V41, P1193, DOI 10.1016/0026-0495(92)90008-X; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAYES RJ, 1988, STAT MED, V7, P915, DOI 10.1002/sim.4780070903; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JENSEN J, 1990, MATURITAS, V12, P321, DOI 10.1016/0378-5122(90)90012-U; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KIM CJ, 1994, ARTERIOSCLER THROMB, V14, P275, DOI 10.1161/01.ATV.14.2.275; LEUS FR, 1994, CLIN BIOCHEM, V27, P449, DOI 10.1016/0009-9120(94)00052-W; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MENDOZA S, 1994, J LAB CLIN MED, V123, P837; NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165; PEDERSEN TR, 1994, LANCET, V344, P1383; SACKS FM, 1994, ARCH INTERN MED, V154, P1106, DOI 10.1001/archinte.154.10.1106; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SHRAPNEL WS, 1992, MED J AUSTRALIA, V156, pS9; SOMA MR, 1993, ARCH INTERN MED, V153, P1462, DOI 10.1001/archinte.153.12.1462; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; TONSTAD S, 1995, J INTERN MED, V238, P39, DOI 10.1111/j.1365-2796.1995.tb00897.x; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702	40	163	165	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					595	601		10.1056/NEJM199708283370903	http://dx.doi.org/10.1056/NEJM199708283370903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271481				2022-12-28	WOS:A1997XT39400003
J	Lindsay, R; Nieves, J; Formica, C; Henneman, E; Woelfert, L; Shen, V; Dempster, D; Cosman, F				Lindsay, R; Nieves, J; Formica, C; Henneman, E; Woelfert, L; Shen, V; Dempster, D; Cosman, F			Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis	LANCET			English	Article							SODIUM-FLUORIDE; CALCITONIN; RESORPTION; ESTROGEN; THERAPY	Background Small increases in bone mass are commonly seen with existing treatments for osteoporosis, which reduce bone remodelling and primarily prevent bone loss. Since these drugs reduce but do not eliminate risk of fractures, an anabolic agent that would increase bone mass and potentially cure the underlying skeletal problem is needed. Methods We did a 3-year randomised controlled trial to find out the effects of 1-34 human parathyroid hormone (hPTH [1-34], 400 U/25 mu g daily subcutaneously) in postmenopausal women with osteoporosis taking hormone-replacement therapy (n=17). The controls were women taking hormone-replacement therapy only (n=17). The primary outcome was bone-mineral density of the lumbar vertebrae, with bone-mineral density at other sites and vertebral fractures as secondary endpoints. Findings Patients taking hormone-replacement therapy and PTH (1-34) had continuous increase in vertebral bone-mineral density during the 3 years, whereas there was no significant change in the control group. The total increase in vertebral bone-mineral density was 13.0% (p<0.001); 2.7% at the hip (p=0.05); and 8.0% in total-body bone mineral (p=0.002). No loss of bone mass was found at any skeletal site. Increased bone mass was associated with a reduction in the rate of vertebral fractures, which was significant when fractures were taken as a 15% reduction in vertebral height (p=0.04). During the first 6 months of treatment, serum osteocalcin concentration, which reflects bone formation, increased by more than 55%, whereas excretion of crosslinked n-telopeptide, which reflects bone resorption, increased by only 20%, which suggests some uncoupling of bone formation and resorption. By 6 months, there were similar increases in gradually returned towards baseline progressed. Vertebral bone-mineral density increased most during the first year of PTH treatment. Interpretation We found that PTH has a pronouned anabolic effect on the central skeleton in patients on hormone- replacement therapy. PTH also Increases total-body bone mineral, with no detrimental effects at any skeletal site. The increased vertebral mass was associated with a reduced rate of vertebral fracture, despite increased bone turnover. Bone-mass changes may be consistent with a reduction in all osteoporotic fractures. If confirmed in larger studies, these data have important implications for the treatment of postmenopausal osteoporosis.	HELEN HAYES HOSP, REG BONE CTR, W HAVERSTRAW, NY 10993 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT EPIDEMIOL, NEW YORK, NY USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY USA	Columbia University; Columbia University; Columbia University	Lindsay, R (corresponding author), HELEN HAYES HOSP, CLIN RES CTR, ROUTE 9W, W HAVERSTRAW, NY 10993 USA.			Nieves, Jeri/0000-0001-8593-343X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042892] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39191] Funding Source: Medline; NIDDK NIH HHS [DK42892, DK4631] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COSMAN F, 1994, J CLIN ENDOCR METAB, V78, P939, DOI 10.1210/jc.78.4.939; Cosman F, 1997, J BONE MINER RES, V12, P958, DOI 10.1359/jbmr.1997.12.6.958; CUMMINGS SR, 1995, J BONE MINER RES, V10, P518; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; DEMPSTER DW, 1993, LANCET, V341, P797, DOI 10.1016/0140-6736(93)90570-7; FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404; Gallagher J. Christopher, 1996, P1191; HOCK JM, 1989, J BONE MINER RES, V4, P449; HODSMAN AB, 1991, BONE MINER, V14, P67, DOI 10.1016/0169-6009(91)90103-7; HODSMAN AB, 1993, J CLIN INVEST, V91, P1138, DOI 10.1172/JCI116273; JEROME CP, 1995, EFFECT TREATMENT 3 S, V17, P4158; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KLEEREKOPER M, 1984, OSTEOPOROSIS, V1, P103; KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x; Libanati Cesar, 1996, P1259; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Meng XW, 1996, J BONE MINER RES, V11, P421; NEER M, 1993, OSTEOPOROSIS INT, V3, pS204; OVERGAARD K, 1989, CLIN ENDOCRINOL, V30, P435, DOI 10.1111/j.1365-2265.1989.tb00443.x; PAK CYC, 1994, ANN INTERN MED, V120, P625, DOI 10.7326/0003-4819-120-8-199404150-00001; PARISIEN M, 1990, ENDOCRIN METAB CLIN, V19, P19, DOI 10.1016/S0889-8529(18)30337-2; REEVE J, 1990, BRIT MED J, V301, P314, DOI 10.1136/bmj.301.6747.314; Reeve J, 1991, Osteoporos Int, V1, P162, DOI 10.1007/BF01625448; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802; Salamone LM, 1996, J BONE MINER RES, V11, P1557, DOI 10.1002/jbmr.5650111024; SINGER FR, 1972, J CLIN INVEST, V51, P2331, DOI 10.1172/JCI107044	27	558	575	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	1997	350	9077					550	555		10.1016/S0140-6736(97)02342-8	http://dx.doi.org/10.1016/S0140-6736(97)02342-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284777	hybrid			2022-12-28	WOS:A1997XT22100010
J	Orme, S; daCosta, D				Orme, S; daCosta, D			Generalised pruritus associated with amlodipine	BRITISH MEDICAL JOURNAL			English	Article									ROYAL HALLAMSHIRE HOSP,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	Orme, S (corresponding author), NO GEN HOSP,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							BAKER BA, 1994, ANN PHARMACOTHER, V28, P118, DOI 10.1177/106002809402800125; BEWLEY AP, 1993, BRIT MED J, V307, P241, DOI 10.1136/bmj.307.6898.241-a; CROSS BW, 1993, BRIT J CLIN PRACT, V47, P237; HOSIE J, 1993, J CARDIOVASC PHAR SA, V29, pS9; ROOK GAW, 1992, TXB DERMATOLOGY, P527	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					463	463		10.1136/bmj.315.7106.463a	http://dx.doi.org/10.1136/bmj.315.7106.463a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284667	Green Published			2022-12-28	WOS:A1997XT71400022
J	Soutter, P				Soutter, P			Radical surgery or radiotherapy for stage Ib-IIa cervical cancer	LANCET			English	Editorial Material							CARCINOMA; HYSTERECTOMY				Soutter, P (corresponding author), HAMMERSMITH HOSP,INST OBSTET & GYNAECOL,LONDON W12 0HS,ENGLAND.							BISSETT D, 1994, BRIT J OBSTET GYNAEC, V101, P615, DOI 10.1111/j.1471-0528.1994.tb13653.x; FULLER AF, 1982, GYNECOL ONCOL, V13, P165, DOI 10.1016/0090-8258(82)90024-5; HACKER NF, 1995, INT J GYNECOL CANCER, V5, P250, DOI 10.1046/j.1525-1438.1995.05040250.x; HIMMELMANN A, 1985, GYNECOL ONCOL, V22, P73, DOI 10.1016/0090-8258(85)90010-1; KJORSTAD KE, 1983, GYNECOL ONCOL, V15, P42, DOI 10.1016/0090-8258(83)90115-4; NEWTON M, 1975, AM J OBSTET GYNECOL, V123, P535, DOI 10.1016/0002-9378(75)90041-1; REMY JC, 1990, GYNECOL ONCOL, V38, P161, DOI 10.1016/0090-8258(90)90033-H	7	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					532	532		10.1016/S0140-6736(05)63134-0	http://dx.doi.org/10.1016/S0140-6736(05)63134-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284771				2022-12-28	WOS:A1997XT22100004
J	Elghanian, R; Storhoff, JJ; Mucic, RC; Letsinger, RL; Mirkin, CA				Elghanian, R; Storhoff, JJ; Mucic, RC; Letsinger, RL; Mirkin, CA			Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles	SCIENCE			English	Article							PARTICLES; PROBES	A highly selective, colorimetric polynucleotide detection method based on mercaptoal-kyloligonucleotide-modified gold nanoparticle probes is reported. Introduction of a single-stranded target oligonucleotide (30 bases) into a solution containing the appropriate probes resulted in the formation of a polymeric network of nanoparticles with a concomitant red-to-pinkish/purple color change. Hybridization was facilitated by freezing and thawing of the solutions, and the denaturation of these hybrid materials showed transition temperatures over a narrow range that allowed differentiation of a variety of imperfect targets. Transfer of the hybridization mixture to a reverse-phase silica plate resulted in a blue color upon drying that could be detected visually. The unoptimized system can detect about 10 femtomoles of an oligonucleotide.	NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208	Northwestern University			Mirkin, Chad A/E-3911-2010	Mirkin, Chad/0000-0002-6634-7627	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM010265, R01GM010265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 10265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; BRUST M, 1995, ADV MATER, V7, P795, DOI 10.1002/adma.19950070907; DUSEMUND B, 1991, Z PHYS D ATOM MOL CL, V20, P305, DOI 10.1007/BF01543997; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; Grabar KC, 1996, J AM CHEM SOC, V118, P1148, DOI 10.1021/ja952233+; GRABAR KC, 1995, ANAL CHEM, V67, P735, DOI 10.1021/ac00100a008; GRYAZNOV SM, 1993, J AM CHEM SOC, V115, P3808, DOI 10.1021/ja00062a070; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HAMES BD, 1995, GENES PROBES, V1; KREIBIG U, 1985, SURF SCI, V156, P678, DOI 10.1016/0039-6028(85)90239-0; Kricka L. J., 1992, NONISOTOPIC DNA PROB; MANSFIELD ES, 1995, MOL CELL PROBE, V9, P145, DOI 10.1006/mcpr.1995.0023; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; RAZIN S, 1994, MOL CELL PROBE, V8, P497, DOI 10.1006/mcpr.1994.1071; Storhoff J. J., 1997, J CLUST SCI, V8, P179; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; URDEA MS, 1988, NUCLEIC ACIDS RES, V16, P4937, DOI 10.1093/nar/16.11.4937; Wang J, 1996, J AM CHEM SOC, V118, P7667, DOI 10.1021/ja9608050; Weisbecker CS, 1996, LANGMUIR, V12, P3763, DOI 10.1021/la950776r; YANG WH, 1995, J CHEM PHYS, V103, P869, DOI 10.1063/1.469787	20	3834	4155	26	1705	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1078	1081		10.1126/science.277.5329.1078	http://dx.doi.org/10.1126/science.277.5329.1078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262471				2022-12-28	WOS:A1997XT03300028
J	Gabay, L; Seger, R; Shilo, BZ				Gabay, L; Seger, R; Shilo, BZ			In situ activation pattern of Drosophila EGF receptor pathway during development	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; SIGNALING PATHWAY; RHOMBOID GENE; CELL FATE; ECTODERM; HOMOLOG; ENCODES; KINASE; ESTABLISHMENT; MELANOGASTER	Signaling cascades triggered by receptor tyrosine kinases (RTKs) participate in diverse developmental processes. The active state of these signaling pathways was monitored by examination of the in situ distribution of the active, dual phosphorylated form of mitogen-activated protein kinase (ERK) with a specific monoclonal antibody. Detection of the active state of the Drosophila epidermal growth factor receptor (DER) pathway allowed the visualization of gradients and boundaries of receptor activation, assessment of the distribution of activating ligands, and analysis of interplay with the inhibitory ligand Argos. This in situ approach can be used to monitor other receptor-triggered pathways in a wide range of organisms.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science				Shilo, Ben Zion/0000-0003-4903-8889				BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; DIAZBENJUMEA FJ, 1990, P ROY SOC B-BIOL SCI, V242, P36, DOI 10.1098/rspb.1990.0100; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gabay L, 1997, DEVELOPMENT, V124, P3535; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KOLODKIN AL, 1994, DEVELOPMENT, V120, P1731; NOLL R, 1994, DEVELOPMENT, V120, P2329; Okabe M, 1997, DEVELOPMENT, V124, P1045; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RAZ E, 1992, DEVELOPMENT, V114, P113; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Scholz H, 1997, MECH DEVELOP, V62, P79, DOI 10.1016/S0925-4773(96)00652-1; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Simcox AA, 1996, DEV BIOL, V177, P475, DOI 10.1006/dbio.1996.0179; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; Tio M, 1997, DEVELOPMENT, V124, P343; Xiao H, 1996, MECH DEVELOP, V58, P65, DOI 10.1016/S0925-4773(96)00559-X; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; zurLage P, 1997, CURR BIOL, V7, P166, DOI 10.1016/S0960-9822(97)70087-3	34	326	326	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1103	1106		10.1126/science.277.5329.1103	http://dx.doi.org/10.1126/science.277.5329.1103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262480				2022-12-28	WOS:A1997XT03300037
J	Jacobsen, SE; Meyerowitz, EM				Jacobsen, SE; Meyerowitz, EM			Hypermethylated SUPERMAN epigenetic alleles in Arabidopsis	SCIENCE			English	Article							HOMEOTIC GENES; THALIANA	Mutations in the SUPERMAN gene affect flower development in Arabidopsis. Seven heritable but unstable sup epi-alleles (the clark kent alleles) are associated with nearly identical patterns of excess cytosine methylation within the SUP gene and a decreased level of SUP RNA. Revertants of these alleles are largely demethylated at the SUP locus and have restored levels of SUP RNA. A transgenic Arabidopsis line carrying an antisense methyltransferase gene, which shows an overall decrease in genomic cytosine methylation, also contains a hypermethylated sup allele. Thus, disruption of methylation systems may yield more complex outcomes than expected and can result in methylation defects at known genes. The clark kent alleles differ from the antisense line because they do not show a general decrease in genomic methylation.	CALTECH,DIV BIOL 156 29,PASADENA,CA 91125	California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009					BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; GAISER JC, 1995, PLANT CELL, V7, P333, DOI 10.1105/tpc.7.3.333; Huang H, 1997, PLANT CELL, V9, P115; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KOORNNEEF M, 1982, MUTAT RES, V93, P109, DOI 10.1016/0027-5107(82)90129-4; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SAKAI H, COMMUNICATION; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832	17	348	370	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1100	1103		10.1126/science.277.5329.1100	http://dx.doi.org/10.1126/science.277.5329.1100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262479				2022-12-28	WOS:A1997XT03300036
J	RichEdwards, JW; Stampfer, MJ; Manson, JE; Rosner, B; Hankinson, SE; Colditz, GA; Willett, WC; Hennekens, CH				RichEdwards, JW; Stampfer, MJ; Manson, JE; Rosner, B; Hankinson, SE; Colditz, GA; Willett, WC; Hennekens, CH			Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; ADULT LIFE; BLOOD-PRESSURE; INFANT GROWTH; FETAL; DEATH; HYPERTENSION; CHILDHOOD; INUTERO	Objective: To examine the association between birth weight and non-fatal adult cardiovascular disease while controlling for potential confounders such as socioeconomic group and adult lifestyle. Design: Retrospective self report of birth weight in an ongoing longitudinal cohort of nurses followed up by postal questionnaire every two years. Setting: Nurses' health study, a cohort of 121 700 women followed up since 1976. Main outcome measures: Non-fatal cardiovascular disease, including myocardial infarction, coronary revascularisation, and stroke. Results: Among the 70 297 women free of cardiovascular disease at baseline who reported birth weight in the 1992 questionnaire there were 1309 first cases of non-fatal cardiovascular disease. Increasing birth weight was associated with decreasing risk of non-fatal cardiovascular disease. There were 1216 first cases of non-fatal cardiovascular disease among women who were singletons and had been born full term; their relative risks adjusted for several cardiovascular risk factors were 1.49 (95% confidence interval 1.05 to 2.10) for birth weight < 2268 g (< 5 lb 0 oz); 1.25 (0.98 to 1.61) for birth weight 2268-2495 g (5 lb 0 oz to 5 lb 8 oz); 1.12 (0.98 to 1.27) for birth weight > 2495-3175 g (> 5 lb 8 oz to 7 lb 0 oz); 1.00 (referent) for birth weight >3175-3856 g(>7 lb 0 oz to 8 lb 8 oz); 0.96 (0.80 to 1.15) for birth weight > 3856-4536 g (> 8 lb 8 oz to 10 lb 0 oz); and 0.68 (0.46 to 1.00) for birth weight > 4536 g (> 10 lb 0 oz) (P value for trend = 0.0004). The inverse trend was apparent for both coronary heart disease and stroke. Conclusions: These data Provide strong evidence of an association between birth weight and adult coronary heart disease and stroke.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02215; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594, HL-07575] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; COX DR, 1972, J R STAT SOC B, V34, P187; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; GABH Rose, 1982, WHO MONOGRAPH SERIES; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HENNEKENS CH, 1979, LANCET, V1, P1301; HOLLAND FJ, 1993, J EPIDEMIOL COMMUN H, V47, P432, DOI 10.1136/jech.47.6.432; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P336; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Rich-Edwards J. W., 1996, American Journal of Epidemiology, V143, pS39; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; US Census Bureau, 1994, STAT ABSTR US; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; Walker AE, 1981, STROKE S1, V12, P13	23	575	591	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					396	400		10.1136/bmj.315.7105.396	http://dx.doi.org/10.1136/bmj.315.7105.396			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277603	Green Published			2022-12-28	WOS:A1997XR54900019
J	King, RW; Lustig, KD; Stukenberg, PT; McGarry, TJ; Kirschner, MW				King, RW; Lustig, KD; Stukenberg, PT; McGarry, TJ; Kirschner, MW			Expression cloning in the test tube	SCIENCE			English	Article									TULARIK INC,DEPT BIOL,S SAN FRANCISCO,CA 94080		King, RW (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.			Stukenberg, Todd/0000-0002-6788-2111				CRYNS V, COMMUNICATION; KING RW, 1997, Patent No. 5654150; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; MCGARRY T, UNPUB; MEAD P, COMMUNICATION; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; XUE D, COMMUNICATION	7	41	45	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					973	974		10.1126/science.277.5328.973	http://dx.doi.org/10.1126/science.277.5328.973			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281074				2022-12-28	WOS:A1997XQ98500046
J	Dowling, B				Dowling, B			Effect of fundholding on waiting times: database study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To determine whether fundholding patients have shorter waiting times for surgery than non-fundholding patients and to establish if any such differences resulted from practices attaining fundholding status. Design: Comparison of waiting times of fundholding and non-fundholding patients for elective surgery covered by the fundholding scheme at four providers over four years. Comparison of the waiting times for patients of practices in their last par outside and first year inside the fundholding scheme with those for patients of practices remaining non-fundholding. Setting: West Sussex. Subjects: Over 57 000 patients on the elective waiting list who had operations purchased by a health authority or fundholding practice during 1992-6. Patients with booked or planned elective admissions were excluded. Main outcome measures: Waiting times for patients of fundholding and non-fundholding patients. Results: Patients of fundholding practices had significantly shorter waiting times than those of non-fundholders for all four providers and over all four years. Waiting times for patients did not fall until the year that the practices joined the fundholding scheme. Conclusions: Fundholding shortens waiting times. This may be because purchasing of elective surgery is best done at a practice level or because fundholding practices are funded overgenerously.			Dowling, B (corresponding author), UNIV LONDON LONDON SCH ECON & POLIT SCI,DEPT SOCIAL POLICY & ADM,HOUGHTON ST,LONDON WC2A 2AE,ENGLAND.							*AUD COMM, 1996, WHAT DOCT ORD STUD G; BARRY N, 1987, STATE MARKET POLITIC; DIXON J, 1994, BRIT MED J, V308, P772, DOI 10.1136/bmj.308.6931.772; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; GLENNERSTER H, 1996, WSP123 STICERD; MATSAGANIS M, 1994, J HEALTH ECON, V13, P31, DOI 10.1016/0167-6296(94)90003-5; *NHS EX, 1994, DAT MAN HOSP SERV MA	7	35	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					290	292		10.1136/bmj.315.7103.290	http://dx.doi.org/10.1136/bmj.315.7103.290			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274551	Green Published			2022-12-28	WOS:A1997XP75000025
